PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Richards, MA; Stockton, D; Babb, P; Coleman, MP				Richards, MA; Stockton, D; Babb, P; Coleman, MP			How many deaths have been avoided through improvements in cancer survival?	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER	Objective To estimate holy many deaths from cancer have been avoided in England and Wales because of recent improvements in survival. Design Analysis of national statistics. Setting England and Wales. Subjects 1.5 million adults with diagnosis of one of 47 different cancers during 1981-5 or 1986-90. Main outcome measures Reduction in number of cancer deaths within five years of diagnosis among patients with cancer diagnosed during 1986-90 compared with patients with cancer diagnosed during 1981-5, Results 17 041 deaths were avoided within five years of diagnosis among patients with cancer diagnosed during 1986-90. This represents 3.3% of the cancer deaths that would have been expected if survival had been the same as for patients with cancer diagnosed during 1981-5, Two thirds of the avoided deaths arose from improvements in survival for just five cancers: female br east cancer (4822), cancers of the colon (2560), rectum (1090), and bladder (1157), and melanoma of the skin (1098). The largest proportionate reductions in excess deaths were for melanoma of the skin (23%) and cancers of the testis (17%) and bone (17%). About 12 000 (70%) of the avoided deaths arose among adults aged under 75 at death. Improvements in survival from cancers of lung, prostate, stomach, ovary, and brain were small: the) accounted for 33% of all cancers but only 11% of avoided deaths. Conclusions Small gains in survival from common cancers save more lives than larger gains for uncommon cancers. If recent rates of improvement in cancer survival continue, about 24 000 deaths within five years of diagnosis would be avoided in patents aged under 75 by the year 2010, representing about a quarter of the government's overall target of 100 000 fewer cancer deaths.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England; St Thomas Hosp, Dept Palliat Med, London SE17 7EH, England; Informat & Stat Div, Scottish Canc Intelligence Unit, Canc Surveillance Grp, Edinburgh EH5 3SQ, Midlothian, Scotland; Off Natl Stat, Demog & Hlth Div, London SW1V 2QQ, England	University of London; London School of Hygiene & Tropical Medicine; Guy's & St Thomas' NHS Foundation Trust	Coleman, MP (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.		Coleman, Michel/AAA-9543-2020	Coleman, Michel/0000-0001-8940-3807				Abe O, 1998, LANCET, V352, P930; BERAL V, 1995, LANCET, V345, P1642, DOI 10.1016/S0140-6736(95)90151-5; Carstairs V., 1991, DEPRIVATION HLTH SCO; COLEMAN MP, 1999, SERIES SMPS, V61; *DEP HLTH, 1999, SAV LIV OUR HLTH NAT; ESTEVE J, 1990, STAT MED, V9, P529, DOI 10.1002/sim.4780090506; Expert Advisory Group on Cancer, 1995, POL FRAM COMM CANC S; *OFF NAT STAT, 1999, CANC 1971 1997 CD RO; Stockton D, 1997, BRIT MED J, V314, P472, DOI 10.1136/bmj.314.7079.472	9	63	63	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					895	898		10.1136/bmj.320.7239.895	http://dx.doi.org/10.1136/bmj.320.7239.895			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10741993	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000086337100020
J	Paice, E; Aitken, M; Cowan, G; Heard, S				Paice, E; Aitken, M; Cowan, G; Heard, S			Trainee satisfaction before and after the Calman reforms of specialist training: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							ATTITUDES; PROPOSALS	Objectives To evaluate the impact of the Calman reforms of higher specialist training on trainee satisfaction. Design Questionnaire surveys using portable electronic survey units, two years apart. Setting Postgraduate, teaching, district general, and community NHS trusts in North Thames. North Thames deanery includes London north of the Thames, Essex. and Hertfordshire. Participants Trainees in all grades and all specialties: 3078 took part in the first survey and 3517 in the second survey. Main outcome measures Trainees' satisfaction with training in their current post, including educational objectives, training agreements, induction, consultant feedback, hands on experience acquired use of log hooks, consultant supervision, and overall satisfaction with the post. Results In the second survey respondents were more likely to have discussed educational objectives with their consultant, used a log book, and had useful feedback fr-om their consultant. They were more likely to give high ratings to induction, consultant supervision, and hands on experience acquired in the post. Each of these elements was associated with increased satisfaction with the post overall. Improvements were most noticeable at the level of specialist registrar, but changes in the same direction were also seen in more junior grades. Conclusions After the reforms of specialist training, trainees in ail grades reported greater satisfaction with their current posts. The changes required extra training time and effort from consultants.	N Thames Dept Postgrad Med & Dent Educ, London WC1N 3EJ, England	University of London	Paice, E (corresponding author), N Thames Dept Postgrad Med & Dent Educ, London WC1N 3EJ, England.							ALLEN I, 1999, STRESS CONSULTANTS N; Anderson JM, 1999, ARCH DIS CHILD, V80, P485, DOI 10.1136/adc.80.5.485; Barber P, 1997, LANCET, V350, P974, DOI 10.1016/S0140-6736(05)64065-2; Bates T, 1996, Ann R Coll Surg Engl, V78, P61; Bayley TJ, 1995, MED EDUC, V29, P95, DOI 10.1111/j.1365-2923.1995.tb02903.x; CHARLTON BG, 1993, BRIT MED J, V307, P338, DOI 10.1136/bmj.307.6900.338; COLLINS M, 1994, J LARYNGOL OTOL, V108, P291, DOI 10.1017/S002221510012657X; DEMPSEY GA, 1997, ANAESTHESIA, V52, P181; *DEP HLTH, 1993, HOSP DOCT TRAIN FUT; *DEP HLTH, 1995, GUID SPEC REG TRAIN; General Medical Council, 1997, NEW DOCT; Hobbs KEF, 1997, LANCET, V350, P1851, DOI 10.1016/S0140-6736(05)63666-5; HUNTER S, 1993, BRIT MED J, V306, P1281, DOI 10.1136/bmj.306.6888.1281; JOHNSON JN, 1995, BRIT MED J, V311, P1298, DOI 10.1136/bmj.311.7015.1298; MATHER HM, 1995, BRIT MED J, V311, P1060, DOI 10.1136/bmj.311.7012.1060; Milligan DWA, 1996, ARCH DIS CHILD, V74, P260, DOI 10.1136/adc.74.3.260; *NHS MAN EX, 1991, JUN DOCT NEW DEAL; PAICE E, 1994, BRIT J HOSP MED, V51, P123; PAICE E, 1993, BRIT J HOSP MED, V50, P199; Paice E, 1997, BRIT MED J, V314, P719, DOI 10.1136/bmj.314.7082.719; TEMPLE JG, 1995, BRIT MED J, V311, P1574, DOI 10.1136/bmj.311.7019.1574	21	39	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					832	836		10.1136/bmj.320.7238.832	http://dx.doi.org/10.1136/bmj.320.7238.832			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731174	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086180300022
J	Clayton, DD				Clayton, DD			We have touched the dust from dying stars	NATURE			English	Letter									Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA	Clemson University	Clayton, DD (corresponding author), Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA.							Burrows A, 2000, NATURE, V403, P727, DOI 10.1038/35001501; Clayton DD, 1997, ASTROPHYS SPACE SCI, V251, P355, DOI 10.1023/A:1000799831553	2	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					329	329		10.1038/35006251	http://dx.doi.org/10.1038/35006251			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746697				2022-12-28	WOS:000086119000017
J	Gehrels, T				Gehrels, T			Brains, courage and integrity	NATURE			English	Editorial Material									Univ Arizona, Dept Planetary Sci, Tucson, AZ 85721 USA	University of Arizona	Gehrels, T (corresponding author), Univ Arizona, Dept Planetary Sci, Tucson, AZ 85721 USA.								0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					335	335		10.1038/35006261	http://dx.doi.org/10.1038/35006261			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746702	Bronze			2022-12-28	WOS:000086119000026
J	Thomas, EJ; Brennan, TA				Thomas, EJ; Brennan, TA			Incidence and types of preventable adverse events in elderly patients: population based review of medical records	BRITISH MEDICAL JOURNAL			English	Article							HOSPITALIZED-PATIENTS; DRUG EVENTS	Objective To determine the incidence and types of preventable adverse events in elderly patients. Design Review of random sample of medical records in two stage process by nurses and physicians to detect adverse events, Two study investigators then judged preventability. Setting Hospitals in US states of Utah and Colorado, excluding psychiatric and Veterans Administration hospitals. Subjects 15 000 hospitalised patients discharged in 1992. Main outcome measures Incidence of preventable adverse events (number of preventable events per 100 discharges) in elderly patients (greater than or equal to 65 years old) and non-elderly patients (16-64 years). Results When results were extrapolated to represent all discharges in 1992 in both states, non-elderly patients had 8901 adverse events (incidence 2.80% (SE 0.18%)) compared with 7419 (5.29% (0.37%)) among elderly patients (P = 0.001). Non-elderly patients had 5038 preventable adverse events (incidence 1.58% (0.14%)) compared with 4134 (2.95% (0.28%)) in elderly patients (P = 0.001). Elderly patients had a higher incidence of preventable events related to medical procedures (such as thoracentesis, cardiac catheterisation) (0.69% (0.14%) v 0.13% (0.04%)), preventable adverse drug events (0.63% (0.14%) v 0.17% (0.05%)), and preventable falls (0.10% (0.06%) v 0.01% (0.02%)). In multivariate analyses, adjusted for comorbid illnesses and case mix, age was not an independent predictor of preventable adverse events. Conclusions Preventable adverse events were more common among elderly patients, probably because of the clinical complexity of their care rather than age based discrimination. Preventable adverse drug events, events related to medical procedures, and falls were especially common in elderly patients and should be targets for efforts to prevent errors.	Univ Texas, Sch Med, Dept Med, Div Gen Internal Med, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Med, Clin Epidemiol Sect, Houston, TX 77030 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Div Gen Med, Boston, MA 02115 USA	University of Texas System; University of Texas System; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Thomas, EJ (corresponding author), Univ Texas, Sch Med, Dept Med, Div Gen Internal Med, 6431 Fannin MSB 1-122, Houston, TX 77030 USA.							BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BECKER PM, 1987, JAMA-J AM MED ASSOC, V257, P2313, DOI 10.1001/jama.257.17.2313; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Diggle PJ, 1995, J AM STAT ASSOC; Gray SL, 1998, J GERONTOL A-BIOL, V53, pM59, DOI 10.1093/gerona/53A.1.M59; JAHNIGEN D, 1982, J AM GERIATR SOC, V30, P387, DOI 10.1111/j.1532-5415.1982.tb02837.x; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; M Sowka, 1980, NATL ASS INSURANCE C; MORGAN VR, 1985, AM J PUBLIC HEALTH, V75, P775, DOI 10.2105/AJPH.75.7.775; Resnick NM, 1997, LANCET, V350, P1157, DOI 10.1016/S0140-6736(05)63817-2; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; THOMAS EJ, IN PRESS MED CARE	14	261	276	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					741	744		10.1136/bmj.320.7237.741	http://dx.doi.org/10.1136/bmj.320.7237.741			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296YQ	10720355	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000086054700020
J	Waller, AE; Daniels, JL; Weaver, NL; Robinson, P				Waller, AE; Daniels, JL; Weaver, NL; Robinson, P			Jockey injuries in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context: In the sport of horse racing, the position of the jockey and speed of the horse predispose the jockey to risk of injury. Objective To estimate rates of medically treated injuries among professional jockeys and identify patterns of injury events. Design Cross-sectional survey from data compiled by an insurance broker. Information on the cause of injury, location on the track, and body part injured was evaluated. Setting Official races at US professional racing facilities (n = 114) from January 1, 1993, through December 31, 1996. Participants A licensed jockey population of approximately 2700 persons. Main Outcome Measures Annual injury incidence rates per 1000 jockey-years, as well as injury type, cause, and location on the track. Results A total of 6545 injury events occurred during official races between 1993 and 1996 (606 per 1000 jockey-years). Nearly 1 in 5 injuries (18.8%) was to the jockey's head or neck. Other frequent sites included the leg (15.5%), foot/ankle (10.7%), back (10.7%), arm/hand (11.0%), and shoulder (9.6%). The most frequent location where injuries occurred was entering, within, or leaving the starting gate (35.1%), including 29.5% of head injuries, 39.8% of arm/hand injuries, and 52.0% of injuries to the leg/foot. Most head injuries resulted from being thrown from the horse (41.8%) or struck by the horse's head (23.2%), Being thrown from the horse was the cause of 55.1% of back and 49.6% of chest injuries. Conclusions Our data suggest that jockeys have a high injury rate. Efforts are needed to reduce the number of potential injury events on the track and to improve protective equipment so events do not lead to injury.	Univ N Carolina, Sch Med, Dept Emergency Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Waller, AE (corresponding author), Univ N Carolina, Sch Med, Dept Emergency Med, CB 7594, Chapel Hill, NC 27599 USA.				PHS HHS [R49/CCR402444] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARONE GW, 1989, J TRAUMA, V29, P245, DOI 10.1097/00005373-198902000-00019; BILES DB, 1996, BLOOD HORSE     0210, P730; BIXBYHAMMETT DM, 1987, AM FAM PHYSICIAN, V36, P206; Firth John L.., 1985, SPORTS INJURIES MECH, P431; INGEMARSON H, 1989, J TRAUMA, V29, P25, DOI 10.1097/00005373-198901000-00005; POUNDER DJ, 1984, MED J AUSTRALIA, V141, P632, DOI 10.5694/j.1326-5377.1984.tb113173.x; PRESS JM, 1995, CLIN J SPORT MED, V5, P236, DOI 10.1097/00042752-199510000-00005; Whitlock M R, 1987, Br J Sports Med, V21, P25	8	57	60	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2000	283	10					1326	1328		10.1001/jama.283.10.1326	http://dx.doi.org/10.1001/jama.283.10.1326			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289ND	10714733	Bronze			2022-12-28	WOS:000085628100030
J	Welsh, J				Welsh, J			Death penalty suspended in Illinois	LANCET			English	Editorial Material									Amnesty Int, Med Off, London WC1X 8DJ, England		Welsh, J (corresponding author), Amnesty Int, Med Off, Easton St, London WC1X 8DJ, England.							*AMN INT, 1989, WHEN STAT KILLS; *AMN INT, 1998, 516998 AMR AMN INT; ARMSTRONG K, 1999, CHICAGO TRIBUNE 0110; COLE W, 2000, TIME            0214; DIETER RC, 1997, INNOCENCE DEATH PENA; MILLS S, 1999, CHICAGO TRIBUNE 1114; *SUBC CIV CONST RI, 1993, INN DEATH PEN ASS DA	7	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					840	840		10.1016/S0140-6736(05)72450-8	http://dx.doi.org/10.1016/S0140-6736(05)72450-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711944				2022-12-28	WOS:000085766900041
J	McCabe, H				McCabe, H			Post-Cold War needs 'new forms of scientific linkage'	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					8	8		10.1038/35003731	http://dx.doi.org/10.1038/35003731			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716417	Bronze			2022-12-28	WOS:000085775100015
J	Peng, XG; Manna, L; Yang, WD; Wickham, J; Scher, E; Kadavanich, A; Alivisatos, AP				Peng, XG; Manna, L; Yang, WD; Wickham, J; Scher, E; Kadavanich, A; Alivisatos, AP			Shape control of CdSe nanocrystals	NATURE			English	Article							QUANTUM DOTS; EXCITON; GROWTH; SEMICONDUCTORS; CD(II); RESINS; DARK	Nanometre-size inorganic dots, tubes and wires exhibit a wide range of electrical and optical properties(1,2) that depend sensitively on both size and shape(3,4), and are of both fundamental and technological interest. In contrast to the syntheses of zero-dimensional systems, existing preparations of one-dimensional systems often yield networks of tubes or rods which are difficult to separate(5-12). And, in the case of optically active II-YI and III-V semiconductors, the resulting rod diameters are too large to exhibit quantum confinement effects(6,8-10). Thus, except for some metal nanocrystals(13), there are no methods of preparation that yield soluble and monodisperse particles that are quantum-confined in two of their dimensions. For semiconductors, a benchmark preparation is the growth of nearly spherical II-VI and III-V nanocrystals by injection of precursor molecules into a hot surfactant(14,15). Here we demonstrate that control of the growth kinetics of the II-VI semiconductor cadmium selenide can be used to vary the shapes of the resulting particles from a nearly spherical morphology to a rod-like one, with aspect ratios as large as ten to one. This method should be useful, not only for testing theories of quantum confinement, but also for obtaining particles with spectroscopic properties that could prove advantageous in biological labelling experiments(16,17) and as chromophores in light-emitting diodes(18,19).	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Peng, XG (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.		Alivisatos, Paul/N-8863-2015; Manna, Liberato/G-2339-2010; Han, Kyuhee/B-6201-2009; peng, xiaogang/R-6184-2016	Alivisatos, Paul/0000-0001-6895-9048; Manna, Liberato/0000-0003-4386-7985; peng, xiaogang/0000-0002-5606-8472				Ahmadi TS, 1996, SCIENCE, V272, P1924, DOI 10.1126/science.272.5270.1924; Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Cortina JL, 1996, HYDROMETALLURGY, V40, P195, DOI 10.1016/0304-386X(94)00078-H; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; Efros AL, 1996, PHYS REV B, V54, P4843, DOI 10.1103/PhysRevB.54.4843; Empedocles SA, 1999, NATURE, V399, P126, DOI 10.1038/20138; Han WQ, 1997, SCIENCE, V277, P1287, DOI 10.1126/science.277.5330.1287; HEATH JR, 1992, SCIENCE, V258, P1131, DOI 10.1126/science.258.5085.1131; HEATH JR, 1999, ACC CHEM RES, V32; Hu JT, 1999, NATURE, V399, P48, DOI 10.1038/19941; Huynh WU, 1999, ADV MATER, V11, P923, DOI 10.1002/(SICI)1521-4095(199908)11:11<923::AID-ADMA923>3.0.CO;2-T; Kabay N, 1998, IND ENG CHEM RES, V37, P2541, DOI 10.1021/ie970488l; KOLOSKY M, 1984, J CHROMATOGR, V299, P436, DOI 10.1016/S0021-9673(01)97861-6; Leung K, 1998, PHYS REV B, V57, P12291, DOI 10.1103/PhysRevB.57.12291; Lieber CM, 1998, SOLID STATE COMMUN, V107, P607, DOI 10.1016/S0038-1098(98)00209-9; Mattoussi H, 1998, J APPL PHYS, V83, P7965, DOI 10.1063/1.367978; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; NIRMAL M, 1995, PHYS REV LETT, V75, P3728, DOI 10.1103/PhysRevLett.75.3728; NISHIZAWA M, 1995, SCIENCE, V268, P700, DOI 10.1126/science.268.5211.700; Peng XG, 1998, J AM CHEM SOC, V120, P5343, DOI 10.1021/ja9805425; Peng XG, 1997, J AM CHEM SOC, V119, P7019, DOI 10.1021/ja970754m; Routkevitch D, 1996, J PHYS CHEM-US, V100, P14037, DOI 10.1021/jp952910m; Schlamp MC, 1997, J APPL PHYS, V82, P5837, DOI 10.1063/1.366452; Smalley RE, 1998, SOLID STATE COMMUN, V107, P597, DOI 10.1016/S0038-1098(98)00210-5; TRENTLER TJ, 1995, SCIENCE, V270, P1791, DOI 10.1126/science.270.5243.1791; Wang WZ, 1999, INORG CHEM COMMUN, V2, P83, DOI 10.1016/S1387-7003(99)00015-5; Zhu Y, 1998, J MATER SCI LETT, V17, P1897, DOI 10.1023/A:1006644023080; Zunger A, 1998, MRS BULL, V23, P35, DOI 10.1557/S0883769400031250	30	4088	4309	33	2358	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					59	61		10.1038/35003535	http://dx.doi.org/10.1038/35003535			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716439				2022-12-28	WOS:000085775100042
J	Reilly, JG; Ayis, SA; Ferrier, IN; Jones, SJ; Thomas, SHL				Reilly, JG; Ayis, SA; Ferrier, IN; Jones, SJ; Thomas, SHL			QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients	LANCET			English	Article							TORSADE-DE-POINTES; SUDDEN-DEATH; DISPERSION; THIORIDAZINE; NEUROLEPTICS; GUIDELINES; MEDICATION; DOSAGE; RISK	Background Sudden unexplained death in psychiatric patients may be due to drug-induced arrhythmia, of which lengthening of the rate-corrected QT interval (QTc) on the electrocardiogram is a predictive marker. We estimated the point prevalence of QTc lengthening in psychiatric patients and the effects of various psychotropic drugs. Methods Electrocardiograms were obtained from 101 healthy reference individuals and 495 psychiatric patients in various inpatient and community settings and were analysed with a previously validated digitiser technique. Patients with and without QTc lengthening, QTc dispersion, and T-wave abnormality were compared by logistic regression to calculate odds ratios for predictive variables. Findings Abnormal QTc was defined from the healthy reference group as more than 456 ms and was present in 8% (40 of 495) of patients. Age over 65 years (odds ratio 3.0 [95% CI 1.1-8.3]), use of tricyclic antidepressants (4.4 [1.6-12.1]), thioridazine (5.4 [2.0-13.7]), and droperidol (6.7 [1.8-24.8]) were robust predictors of QTc lengthening, as was antipsychotic dose (high dose 5.3 [1.2-24.4]; very high dose 8.2 [1.5-43.6]). Abnormal QT dispersion or T-wave abnormalities were not significantly associated with antipsychotic treatment, but were associated with lithium therapy. Interpretation Antipsychotic drugs cause QTc lengthening in a dose-related manner. Risks are substantially higher for thioridazine and droperidol. These drugs may therefore confer an increased risk of drug-induced arrhythmia.	Univ Newcastle Upon Tyne, Wolfson Unit Clin Pharmacol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Acad Dept Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Parkside Community Mental Hlth Ctr, Tees & NE Yorkshire NHS Trust, Middlesbrough, Cleveland, England	Newcastle University - UK; Newcastle University - UK	Thomas, SHL (corresponding author), Univ Newcastle Upon Tyne, Wolfson Unit Clin Pharmacol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Ayis, Salma/AAD-5336-2019	Ayis, Salma/0000-0002-0449-869X				ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; Atkins M., 1997, PSYCHIATR BULL, V21, P224, DOI DOI 10.1192/PB.21.4.224; Barnett AA, 1996, LANCET, V348, P256, DOI 10.1016/S0140-6736(05)65549-3; BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; DAY CP, 1990, BRIT HEART J, V63, P342; DONATINI B, 1992, CARDIOLOGY, V81, P340, DOI 10.1159/000175827; Drolet B, 1999, J PHARMACOL EXP THER, V288, P1261; FABER TS, 1994, DRUG SAFETY, V11, P463, DOI 10.2165/00002018-199411060-00007; GIARDINA EGV, 1979, CIRCULATION, V60, P1045, DOI 10.1161/01.CIR.60.5.1045; Hartigan-Go K., 1995, British Journal of Clinical Pharmacology, V39, p104P; HartiganGo K, 1996, CLIN PHARMACOL THER, V60, P543, DOI 10.1016/S0009-9236(96)90150-2; HENDERSON RA, 1991, HUM EXP TOXICOL, V10, P59, DOI 10.1177/096032719101000110; HII JTY, 1992, CIRCULATION, V86, P1376, DOI 10.1161/01.CIR.86.5.1376; Huston J R, 1966, JAMA, V198, P134, DOI 10.1001/jama.198.1.134; KAUTZNER J, 1994, PACE, V17, P928, DOI 10.1111/j.1540-8159.1994.tb01435.x; KIRCHNER V, 1998, COCHRANE LIB; Lawrence KR, 1997, PHARMACOTHERAPY, V17, P531; LIBERATORE MA, 1984, J CLIN PSYCHOPHARM, V4, P143; MITCHELL JE, 1982, J CLIN PSYCHIAT, V43, P47; NEWMAN SC, 1991, CAN J PSYCHIAT, V36, P239, DOI 10.1177/070674379103600401; REY MJ, 1989, INT CLIN PSYCHOPHARM, V4, P95, DOI 10.1097/00004850-198904000-00001; Royal College of psychiatrists, 1997, CR57 ROYAL COLL PSYC; SCHULZ P, 1989, INT CLIN PSYCHOPHARM, V4, P105, DOI 10.1097/00004850-198904000-00002; THOMAS SHL, 1994, ADVERSE DRUG REACT T, V13, P77; THOMPSON C, 1994, BRIT J PSYCHIAT, V164, P448, DOI 10.1192/bjp.164.4.448; Warner JP, 1996, ACTA PSYCHIAT SCAND, V93, P311, DOI 10.1111/j.1600-0447.1996.tb10653.x	26	445	464	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1048	1052		10.1016/S0140-6736(00)02035-3	http://dx.doi.org/10.1016/S0140-6736(00)02035-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	302TB	10744090				2022-12-28	WOS:000086380800011
J	Kornberg, TB; Krasnow, MA				Kornberg, TB; Krasnow, MA			The Drosophila genome sequence: Implications for biology and medicine	SCIENCE			English	Editorial Material								The 120-megabase euchromatic portion of the Drosophila melanogaster genome has been sequenced. Because the genome is compact and many genetic tools are available, and because fly cell biology and development have much in common with mammals, this sequence may be the Rosetta stone for deciphering the human genome.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University; Stanford University	Kornberg, TB (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.							Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BODMER R, 1999, HEART DEV, P65; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Gehring WJ, 1999, TRENDS GENET, V15, P371, DOI 10.1016/S0168-9525(99)01776-X; Hendricks JC, 2000, NEURON, V25, P129, DOI 10.1016/S0896-6273(00)80877-6; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoskins RA, 2000, SCIENCE, V287, P2271, DOI 10.1126/science.287.5461.2271; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; KERKUT GA, 1985, COMP INSECT PHYSIOL; McMahon AP, 2000, CELL, V100, P185, DOI 10.1016/S0092-8674(00)81555-X; Min KT, 1999, SCIENCE, V284, P1985, DOI 10.1126/science.284.5422.1985; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Riddle RD, 1999, SCI AM, V280, P74, DOI 10.1038/scientificamerican0299-74; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Rubin GM, 2000, SCIENCE, V287, P2216, DOI 10.1126/science.287.5461.2216; Spradling AC, 1999, GENETICS, V153, P135; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Wigglesworth, 1939, PRINCIPLES INSECT PH; XU T, 1993, DEVELOPMENT, V117, P1223	25	55	63	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2218	2220		10.1126/science.287.5461.2218	http://dx.doi.org/10.1126/science.287.5461.2218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731136				2022-12-28	WOS:000086049100037
J	Eagleman, DM; Sejnowski, TJ				Eagleman, DM; Sejnowski, TJ			Motion integration and postdiction in visual awareness	SCIENCE			English	Article							ATTENTION SHIFT; EXTRAPOLATION; CONSCIOUSNESS; SIGNALS; TIME	In the flash-lag illusion, a flash and a moving object in the same Location appear to be offset. A series of psychophysical experiments yields data inconsistent with two previously proposed explanations: motion extrapolation (a predictive model) and latency difference (an online model). We propose an alternative in which visual awareness is neither predictive nor online but is postdictive, so that the percept attributed to the time of the flash is a function of events that happen in the similar to 80 milliseconds after the flash. The results here show how interpolation of the past is the only framework of the three models that provides a unified explanation for the flash-lag phenomenon.	Salk Inst Biol Studies, Sloan Ctr Theoret Neurobiol, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Computat Neurobiol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Salk Institute; Salk Institute; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	Eagleman, DM (corresponding author), Salk Inst Biol Studies, Sloan Ctr Theoret Neurobiol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	eagleman@salk.edu	Sejnowski, Terrence/AAV-5558-2021					Bachmann T., 1994, PSYCHOPHYSIOLOGY VIS; BALDO MVC, 1995, NATURE, V378, P565, DOI 10.1038/378565a0; Berry MJ, 1999, NATURE, V398, P334, DOI 10.1038/18678; Dennet D. C., 1992, CONSCIOUSNESS EXPLAI; DENNETT DC, 1992, BEHAV BRAIN SCI, V15, P183, DOI 10.1017/S0140525X00068229; Frohlich FW., 1923, Z SINNESPHYSIOL, V54, P58; KHURANA B, 1995, NATURE, V378, P566, DOI 10.1038/378566a0; KINSBOURNE M, 1993, CIBA F SYMP, V174, P43; KOLERS PA, 1976, VISION RES, V16, P329, DOI 10.1016/0042-6989(76)90192-9; Krekelberg B, 1999, VISION RES, V39, P2669, DOI 10.1016/S0042-6989(98)00287-9; LIBET B, 1979, BRAIN, V102, P193, DOI 10.1093/brain/102.1.193; MACKAY DM, 1958, NATURE, V181, P507, DOI 10.1038/181507a0; Musseler J, 1998, PERCEPT PSYCHOPHYS, V60, P683, DOI 10.3758/BF03206055; NIJHAWAN R, 1994, NATURE, V370, P256, DOI 10.1038/370256b0; Pessoa L, 1998, BEHAV BRAIN SCI, V21, P723; RAO RS, UNPUB; Schlag J, 2000, NATURE, V403, P38, DOI 10.1038/47402; SNOWDEN RJ, 1989, VISION RES, V29, P1621, DOI 10.1016/0042-6989(89)90143-0; SNOWDEN RJ, 1991, VISION RES, V31, P907, DOI 10.1016/0042-6989(91)90156-Y; Watanabe K, 1998, PERCEPTION, V27, P1041, DOI 10.1068/p271041; WEICHSELGARTNER E, 1987, SCIENCE, V238, P778, DOI 10.1126/science.3672124; Whitney D, 2000, VISION RES, V40, P137, DOI 10.1016/S0042-6989(99)00166-2; Whitney D, 1998, NAT NEUROSCI, V1, P656, DOI 10.1038/3659; YANTIS S, 1984, J EXP PSYCHOL HUMAN, V10, P601, DOI 10.1037/0096-1523.10.5.601; Zeki S, 1998, P ROY SOC B-BIOL SCI, V265, P1583, DOI 10.1098/rspb.1998.0475	25	368	368	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2000	287	5460					2036	2038		10.1126/science.287.5460.2036	http://dx.doi.org/10.1126/science.287.5460.2036			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720334				2022-12-28	WOS:000085902800068
J	Matsuoka, T; Hirata, M; Tanaka, H; Takahashi, Y; Murata, T; Kabashima, K; Sugimoto, Y; Kobayashi, T; Ushikubi, F; Aze, Y; Eguchi, N; Urade, Y; Yoshida, N; Kimura, K; Mizoguchi, A; Honda, Y; Nagai, H; Narumiya, S				Matsuoka, T; Hirata, M; Tanaka, H; Takahashi, Y; Murata, T; Kabashima, K; Sugimoto, Y; Kobayashi, T; Ushikubi, F; Aze, Y; Eguchi, N; Urade, Y; Yoshida, N; Kimura, K; Mizoguchi, A; Honda, Y; Nagai, H; Narumiya, S			Prostaglandin D-2 as a mediator of allergic asthma	SCIENCE			English	Article							CELL-DEFICIENT; D RECEPTOR; AIRWAYS; HYPERREACTIVITY; ACCUMULATION; INFLAMMATION; EXPRESSION; CHALLENGE; RELEASE; POTENT	Allergic asthma is caused by the aberrant expansion in the lung of T helper cells that produce type 2 (T(H)2) cytokines and is characterized by infiltration of eosinophils and bronchial hyperreactivity. This disease is often triggered by mast cells activated by immunoglobulin E (IgE)-mediated allergic challenge. Activated mast cells release Various chemical mediators, including prostaglandin D-2 (PCD2), whose role in allergic asthma has now been investigated by the generation of mice deficient in the PCD receptor (DP). Sensitization and aerosol challenge of the homozygous mutant (DP-/-) mice with ovalbumin (OVA) induced increases in the serum concentration of IgE similar to those in wild-type mice subjected to this model of asthma. However, the concentrations of T(H)2 cytokines and the extent of lymphocyte accumulation in the lung of OVA-challenged DP-/- mice were greatly reduced compared with those in wild-type animals. Moreover, DP-/- mice showed only marginal infiltration of eosinophils and failed to develop airway hyperreactivity. Thus, PGD(2) functions as a mast cell-derived mediator to trigger asthmatic responses.	Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Fac Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Fac Med, Dept Anat, Sakyo Ku, Kyoto 6068501, Japan; Gifu Pharmaceut Univ, Dept Pharmacol, Gifu 5020003, Japan; Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Kyoto 6068501, Japan; Ono Pharmaceut Co, Fukui Safety Res Labs, Fukui 9138538, Japan; Osaka Biosci Inst, Osaka 5650874, Japan; Univ Tokyo, Inst Med Sci, Tokyo 1088639, Japan	Kyoto University; Kyoto University; Kyoto University; Gifu Pharmaceutical University; Kyoto University; Ono Pharmaceutical Co Ltd; University of Tokyo	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Kimura, Kazushi/ABB-4007-2020; Sugimoto, Yukihiko/AAV-6470-2021; Kabashima, Kenji/G-2521-2014	Sugimoto, Yukihiko/0000-0001-6973-932X; Murata, Takahiko/0000-0003-0132-5424; Kabashima, Kenji/0000-0002-0773-0554				AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; BARR RM, 1988, BRIT J PHARMACOL, V94, P773, DOI 10.1111/j.1476-5381.1988.tb11588.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; EMERY DL, 1989, J APPL PHYSIOL, V67, P959, DOI 10.1152/jappl.1989.67.3.959; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FUJITANI Y, UNPUB; GILES H, 1989, BRIT J PHARMACOL, V96, P291, DOI 10.1111/j.1476-5381.1989.tb11816.x; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; Holgate ST, 1998, CLIN EXP ALLERGY, V28, P97; Howarth PH, 1997, ALLERGY, V52, P12, DOI 10.1111/j.1398-9995.1997.tb04878.x; IKAI K, 1985, J INVEST DERMATOL, V85, P82, DOI 10.1111/1523-1747.ep12275365; Konzett H, 1940, N-S ARCH EX PATH PH, V195, P71, DOI 10.1007/BF01861842; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; MATSUOKA T, UNPUB; MIZOGUCHI A, IN PRESS P NATL ACAD; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; O'Sullivan S, 1999, ACTA PHYSIOL SCAND, V166, P1; Oida H, 1997, FEBS LETT, V417, P53, DOI 10.1016/S0014-5793(97)01253-2; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; Tanaka H, 1998, LIFE SCI, V62, pPL169, DOI 10.1016/S0024-3205(98)00047-2; Tsuri T, 1997, J MED CHEM, V40, P3504, DOI 10.1021/jm970343g; URADE Y, 1989, J IMMUNOL, V143, P2982; WALLS AF, 1991, LUNG, V169, P227, DOI 10.1007/BF02714157; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	28	603	642	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2000	287	5460					2013	2017		10.1126/science.287.5460.2013	http://dx.doi.org/10.1126/science.287.5460.2013			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720327	Green Submitted			2022-12-28	WOS:000085902800061
J	Hulka, BS; Kerkvliet, NL; Tugwell, P				Hulka, BS; Kerkvliet, NL; Tugwell, P			Experience of a scientific panel formed to advise the federal judiciary on silicone breast implants.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ N Carolina, Chapel Hill, NC 27599 USA; Oregon State Univ, Corvallis, OR 97331 USA; Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada	University of North Carolina; University of North Carolina Chapel Hill; Oregon State University; University of Ottawa; Ottawa Hospital Research Institute	Hulka, BS (corresponding author), Univ N Carolina, Chapel Hill, NC 27599 USA.		Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556				Angell M, 1996, NEW ENGL J MED, V334, P1513, DOI 10.1056/NEJM199606063342306; Bondurant S, 1999, SAFETY SILICONE BREA; Janowsky EC, 2000, NEW ENGL J MED, V342, P781, DOI 10.1056/NEJM200003163421105; Kaiser J, 1999, SCIENCE, V284, P1600; 1975, FED REG, P706	5	22	22	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2000	342	11					812	815		10.1056/NEJM200003163421111	http://dx.doi.org/10.1056/NEJM200003163421111			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293HW	10717019				2022-12-28	WOS:000085846900011
J	Brown, BE; Dunne, RP; Goodson, MS; Douglas, AE				Brown, BE; Dunne, RP; Goodson, MS; Douglas, AE			Marine ecology - Bleaching patterns in reef corals	NATURE			English	Article							EVENT		Univ Newcastle Upon Tyne, Dept Marine Sci & Coastal Management, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	Newcastle University - UK; University of York - UK	Brown, BE (corresponding author), Univ Newcastle Upon Tyne, Dept Marine Sci & Coastal Management, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.		Brown, Barbara E/N-2104-2015; Brown, Barbara/AAT-7991-2021	Goodson, Michael/0000-0002-5004-551X				ADACHI M, 1994, J PHYCOL, V30, P857, DOI 10.1111/j.0022-3646.1994.00857.x; Brown BE, 1996, CORAL REEFS, V15, P151, DOI 10.1007/BF01145885; BROWN BE, 1994, MAR ECOL PROG SER, V105, P219, DOI 10.3354/meps105219; BROWN BE, IN PRESS MAR ECOL PR; Brown BE, 1997, CORAL REEFS, V16, P129; FITT WK, 1993, CORAL REEFS, V12, P57, DOI 10.1007/BF00302102; GLYNN PW, 1993, CORAL REEFS, V12, P1, DOI 10.1007/BF00303779; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; HUGHES TP, 1985, ECOL MONOGR, V55, P141, DOI 10.2307/1942555; Jones RJ, 1997, MAR ECOL PROG SER, V158, P51, DOI 10.3354/meps158051; Rowan R, 1997, NATURE, V388, P265, DOI 10.1038/40843	11	142	148	5	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					142	143		10.1038/35004657	http://dx.doi.org/10.1038/35004657			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724156				2022-12-28	WOS:000085870900036
J	Schlossmann, J; Ammendola, A; Ashman, K; Zong, XG; Huber, A; Neubauer, G; Wang, GX; Allescher, HD; Korth, M; Wilm, M; Hofmann, F; Ruth, P				Schlossmann, J; Ammendola, A; Ashman, K; Zong, XG; Huber, A; Neubauer, G; Wang, GX; Allescher, HD; Korth, M; Wilm, M; Hofmann, F; Ruth, P			Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase I beta	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; VASCULAR SMOOTH-MUSCLE; MEMBRANE-PROTEIN; CA2+ RELEASE; ION; PHOSPHORYLATION; PURIFICATION; SUBSTRATE	Calcium release from the endoplasmic reticulum controls a number of cellular processes, including proliferation and contraction of smooth muscle and other cells(1,2). Calcium release from inositol 1,4,5-trisphosphate (IP3)-sensitive stores is negatively regulated by binding of calmodulin to the IP3 receptor (IP3R)(3,4) and the NO/cGMP/cGMP kinase I (cGKI) signalling pathways(5,6). Activation of cGKI decreases IP3-stimulated elevations in intracellular calcium(7), induces smooth muscle relaxation(8) and contributes to the antiproliferative(9) and pro-apoptotic effects of NO/cGMP(10). Here we show that, in microsomal smooth muscle membranes, cGKI beta phosphorylated the IP3R and cGKI beta, and a protein of relative molecular mass 125,000 which we now identify as the IP3R-associated cGMP kinase substrate (IRAG). These proteins were co-immunoprecipitated by antibodies directed against cGKI, IP3R or IRAG. IRAG was found in many tissues including aorta, trachea and uterus, and was localized perinuclearly after heterologous expression in COS-7 cells. Bradykinin-stimulated calcium release was not affected by the expression of either IRAG or cGKI beta, which we tested in the absence and presence of cGMP. However, calcium release was inhibited after co-expression of IRAG and cGKI beta in the presence of cGMP. These results identify IRAG as an essential NO/cGKI-dependent regulator of IP3-induced calcium release.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; European Mol Biol Lab, Prot & Peptide Grp, D-69117 Heidelberg, Germany; Univ Hamburg, Hosp Eppendorf, Abt Pharmakol Pharmazeuten, D-20246 Hamburg, Germany	Technical University of Munich; European Molecular Biology Laboratory (EMBL); University of Hamburg	Hofmann, F (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.		Ashman, Keith/G-2328-2011; Schlossmann, Jens/I-7743-2016	Schlossmann, Jens/0000-0002-2550-6839; Wilm, Matthias/0000-0002-5461-6834				BALTENSPERGER K, 1988, EUR J BIOCHEM, V172, P7, DOI 10.1111/j.1432-1033.1988.tb13848.x; BEHRENS TW, 1994, J IMMUNOL, V153, P682; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brenman JE, 1997, DEV NEUROSCI-BASEL, V19, P224, DOI 10.1159/000111211; Broad LM, 1999, J BIOL CHEM, V274, P32881, DOI 10.1074/jbc.274.46.32881; CASNELLI.JE, 1974, P NATL ACAD SCI USA, V71, P1891, DOI 10.1073/pnas.71.5.1891; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Eigenthaler M, 1999, Rev Physiol Biochem Pharmacol, V135, P173, DOI 10.1007/BFb0033673; Fujita S, 1999, J VASC RES, V36, P299, DOI 10.1159/000025658; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Missiaen L, 1999, J BIOL CHEM, V274, P13748, DOI 10.1074/jbc.274.20.13748; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; OROURKE F, 1994, BIOCHEM J, V300, P673, DOI 10.1042/bj3000673; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Rooney TA, 1996, J BIOL CHEM, V271, P19817, DOI 10.1074/jbc.271.33.19817; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; Shaughnessy JD, 1999, ONCOGENE, V18, P2069; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Tertyshnikova X, 1998, J PHYSIOL-LONDON, V512, P89, DOI 10.1111/j.1469-7793.1998.089bf.x; VONDERLEYEN H, 1994, P NATL ACAD SCI USA, V92, P1137; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+	29	352	372	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					197	201		10.1038/35004606	http://dx.doi.org/10.1038/35004606			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724174				2022-12-28	WOS:000085870900055
J	Orlov, T; Yakovlev, V; Hochstein, S; Zohary, E				Orlov, T; Yakovlev, V; Hochstein, S; Zohary, E			Macaque monkeys categorize images by their ordinal number	NATURE			English	Article							RHESUS-MONKEYS; CEBUS-APELLA; FRONTAL LESIONS; SERIAL-ORDER; TERM-MEMORY; WILD CARD; LIST; POSITION; ASSOCIATION; KNOWLEDGE	The recall of a list of items in a serial order is a basic cognitive skill(1). However, it is unknown whether a list of arbitrary items is remembered by associations between sequential items(2,3) or by associations between each item and its ordinal position(4). Here, to study the nonverbal strategies used for such memory tasks(5-9), we trained three macaque monkeys on a delayed sequence recall task. Thirty abstract images, divided into ten triplets, were presented repeatedly in fixed temporal order. On each trial the monkeys viewed three sequentially presented sample stimuli, followed by a test stimulus consisting of the same three images and a distracter image (chosen randomly from the remaining 27). The task was to touch the three images in their original order without touching the distracter. The most common error was touching the distractor when it had the same ordinal number (in its own triplet) as the correct image. Thus, the monkeys' natural tendency was to categorize images by their ordinal number. Additional, secondary strategies were used eventually to avoid the distracter images. These included memory of the sample images (working memory) and associations between sequence triplet members. Thus, monkeys use multiple mnemonic strategies according to their innate tendencies and the requirements of the task.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Neurobiol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Orlov, T (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Neurobiol, IL-91904 Jerusalem, Israel.	tanyao@apollo.ls.huji.ac.il						BUFFALO B, 1994, Q J EXP PSYCHOL-B, V47, P353; Chen SF, 1997, PSYCHOL SCI, V8, P80, DOI 10.1111/j.1467-9280.1997.tb00687.x; COLOMBO M, 1993, COGNITIVE BRAIN RES, V1, P211; DAMATO MR, 1989, J COMP PSYCHOL, V103, P252, DOI 10.1037/0735-7036.103.3.252; DAMATO MR, 1990, ANIM LEARN BEHAV, V18, P133, DOI 10.3758/BF03205250; DAMATO MR, 1988, J EXP PSYCHOL ANIM B, V14, P131, DOI 10.1037/0097-7403.14.2.131; EBBINGHAUS H, 1985, MEMORY CONTRIBUTION; Ebenholtz S. M., 1972, PSYCHOL LEARNING MOT, V5, P267; FARRER DN, 1967, PERCEPT MOTOR SKILL, V25, P305, DOI 10.2466/pms.1967.25.1.305; Fuster J., 1989, DISSERT ABSTRACTS IN, V60, P255; GOWER EC, 1992, BEHAV BRAIN RES, V52, P99, DOI 10.1016/S0166-4328(05)80329-8; MCGONIGLE B, 1992, Q J EXP PSYCHOL-B, V45, P189; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; MURRAY EA, 1993, J NEUROSCI, V13, P4549; Naya Y, 1996, P NATL ACAD SCI USA, V93, P2664, DOI 10.1073/pnas.93.7.2664; Parker A, 1998, NEUROPSYCHOLOGIA, V36, P259, DOI 10.1016/S0028-3932(97)00112-7; PETRIDES M, 1995, J NEUROSCI, V15, P359; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SANDS SF, 1980, J EXP PSYCHOL-ANIM B, V6, P386, DOI 10.1037/0097-7403.6.4.386; STRAUB RO, 1981, ANIM LEARN BEHAV, V9, P454, DOI 10.3758/BF03209775; SWARTZ KB, 1991, J EXP PSYCHOL ANIM B, V17, P396, DOI 10.1037/0097-7403.17.4.396; TERRACE HS, 1993, PSYCHOL SCI, V4, P162, DOI 10.1111/j.1467-9280.1993.tb00481.x; TERRACE HS, 1987, NATURE, V325, P149, DOI 10.1038/325149a0; TERRACE HS, 1995, J COMP PSYCHOL, V109, P162, DOI 10.1037/0735-7036.109.2.162; TERRACE HS, 1986, J EXP PSYCHOL ANIM B, V12, P203, DOI 10.1037/0097-7403.12.3.203; Treichler FR, 1996, J EXP PSYCHOL ANIM B, V22, P105, DOI 10.1037/0097-7403.22.1.105; YOUNG RK, 1961, AM J PSYCHOL, V74, P517, DOI 10.2307/1419662	27	72	74	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2000	404	6773					77	80		10.1038/35003571	http://dx.doi.org/10.1038/35003571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	292BW	10716445				2022-12-28	WOS:000085775100048
J	Smith, JL				Smith, JL			Commentary: Why do doctors overestimate?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Hospice Rochester, Rochester, NY 14607 USA		Smith, JL (corresponding author), Hospice Rochester, Rochester, NY 14607 USA.							Stuart B, 1996, MED GUIDELINES DETER	1	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					472	473						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10722294				2022-12-28	WOS:000085562200019
J	Quinn, TC; Wawer, MJ; Sewankambo, N; Serwadda, D; Li, CJ; Wabwire-Mangen, F; Meehan, MO; Lutalo, T; Gray, RH				Quinn, TC; Wawer, MJ; Sewankambo, N; Serwadda, D; Li, CJ; Wabwire-Mangen, F; Meehan, MO; Lutalo, T; Gray, RH		Rakai Project Study Grp	Viral load and heterosexual transmission of human immunodeficiency virus type 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HIV-1 RNA LEVELS; TRANSFUSION RECIPIENTS; SEXUAL TRANSMISSION; SEMEN; MEN; REDUCTION; BLOOD; RISK	Background and Methods: We examined the influence of viral load in relation to other risk factors for the heterosexual transmission of human immunodeficiency virus type 1 (HIV-1). In a community-based study of 15,127 persons in a rural district of Uganda, we identified 415 couples in which one partner was HIV-1-positive and one was initially HIV-1-negative and followed them prospectively for up to 30 months. The incidence of HIV-1 infection per 100 person-years among the initially seronegative partners was examined in relation to behavioral and biologic variables. Results: The male partner was HIV-1-positive in 228 couples, and the female partner was HIV-1-positive in 187 couples. Ninety of the 415 initially HIV-1-negative partners seroconverted (incidence, 11.8 per 100 person-years). The rate of male-to-female transmission was not significantly different from the rate of female-to-male transmission (12.0 per 100 person-years vs. 11.6 per 100 person-years). The incidence of seroconversion was highest among the partners who were 15 to 19 years of age (15.3 per 100 person-years). The incidence was 16.7 per 100 person-years among 137 uncircumcised male partners, whereas there were no seroconversions among the 50 circumcised male partners (P<0.001). The mean serum HIV-1 RNA level was significantly higher among HIV-1-positive subjects whose partners seroconverted than among those whose partners did not seroconvert (90,254 copies per milliliter vs. 38,029 copies per milliliter, P=0.01). There were no instances of transmission among the 51 subjects with serum HIV-1 RNA levels of less than 1500 copies per milliliter; there was a significant dose-response relation of increased transmission with increasing viral load. In multivariate analyses of log-transformed HIV-1 RNA levels, each log increment in the viral load was associated with a rate ratio of 2.45 for seroconversion (95 percent confidence interval, 1.85 to 3.26). Conclusions: The viral load is the chief predictor of the risk of heterosexual transmission of HIV-1, and transmission is rare among persons with levels of less than 1500 copies of HIV-1 RNA per milliliter. (N Engl J Med 2000;342:921-9.) (C) 2000, Massachusetts Medical Society.	Johns Hopkins Univ, Div Infect Dis, Baltimore, MD 21205 USA; NIAID, Bethesda, MD 20892 USA; Columbia Univ, New York, NY USA; Makerere Univ, Fac Med, Kampala, Uganda	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Columbia University; Makerere University	Quinn, TC (corresponding author), Johns Hopkins Univ, Div Infect Dis, 720 Rutland Ave,Ross 1159, Baltimore, MD 21205 USA.		Quinn, Thomas/A-2494-2010	Sewankambo, Nelson/0000-0001-9362-053X	NIAID NIH HHS [R01 AI34826S, R01 AI34826B] Funding Source: Medline; NICHD NIH HHS [5P30HD06826] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000361, R01AI034826, Z01AI000361, ZIAAI000358, Z01AI000358] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*AIDS CONTR PROGR, 1992, HIV TEST POL, P1; ARMITAGE P, 1977, STAT METHODS MED RES; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CAMERON DW, 1989, LANCET, V2, P403; *CDCP, 1998, HIV AIDS SURV REP, V10; Cohen MS, 1998, LANCET, V351, P5, DOI 10.1016/S0140-6736(98)90002-2; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Coombs RW, 1998, J INFECT DIS, V177, P320, DOI 10.1086/514213; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; Downs AM, 1996, J ACQ IMMUN DEF SYND, V11, P388, DOI 10.1097/00042560-199604010-00010; Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1; Fiscus SA, 1998, AIDS RES HUM RETROV, V14, pS27; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; Haase AT, 1998, NEW ENGL J MED, V339, P1846, DOI 10.1056/NEJM199812173392510; Halperin DT, 1999, LANCET, V354, P1813, DOI 10.1016/S0140-6736(99)03421-2; Hart CE, 1999, J INFECT DIS, V179, P871, DOI 10.1086/314656; Hoffman TL, 1997, J INFECT DIS, V176, P1093, DOI 10.1086/516519; Iversen AKN, 1998, J INFECT DIS, V177, P1214, DOI 10.1086/515266; Lavreys L, 1999, J INFECT DIS, V180, P330, DOI 10.1086/314884; Lee TH, 1996, J ACQ IMMUN DEF SYND, V12, P427, DOI 10.1097/00042560-199608010-00015; Mayaux MJ, 1997, J INFECT DIS, V175, P172, DOI 10.1093/infdis/175.1.172; Michael NL, 1999, J CLIN MICROBIOL, V37, P2557, DOI 10.1128/JCM.37.8.2557-2563.1999; Mock PA, 1999, AIDS, V13, P407, DOI 10.1097/00002030-199902250-00014; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Moses S, 1998, SEX TRANSM INFECT, V74, P368, DOI 10.1136/sti.74.5.368; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; Nelson KE, 1999, J INFECT DIS, V180, P337, DOI 10.1086/314882; Nelson KE, 1999, J INFECT DIS, V180, P1756; Operskalski EA, 1997, AM J EPIDEMIOL, V146, P655, DOI 10.1093/oxfordjournals.aje.a009331; Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276; Pedraza MA, 1999, J ACQ IMMUN DEF SYND, V21, P120; Quinn, 1996, LANCET, V348, P276; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; Ragni MV, 1998, J ACQ IMMUN DEF SYND, V17, P42, DOI 10.1097/00042560-199801010-00006; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Royce RA, 1997, NEW ENGL J MED, V337, P799; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SHIBOSKI SC, 1999, J ACQ IMMUN DEF SYND, V19, P527; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; *STAT DEP, 1996, UG DEM HLTH SURV 199, P48; Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967; *UNAIDS JOINT UN P, 1999, AIDS EP UPD; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006; Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3; *WHO, 1985, WEEKL EP REC, V60, P342; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502	50	2267	2312	1	104	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	2000	342	13					921	929		10.1056/NEJM200003303421303	http://dx.doi.org/10.1056/NEJM200003303421303			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DC	10738050				2022-12-28	WOS:000086179700003
J	Frieden, TR; Lerner, BH; Rutherford, BR				Frieden, TR; Lerner, BH; Rutherford, BR			Lessons from the 1800s: tuberculosis control in the new millennium	LANCET			English	Review							NEW-YORK-CITY; CONTROL PROGRAM; HEALTH		Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA; Columbia Univ, Dept Med, New York, NY 10032 USA	Centers for Disease Control & Prevention - USA; Columbia University	Frieden, TR (corresponding author), WHO, Reg Off SE Asia, Indraprastha Estate,Ring Rd, New Delhi 110002, India.	friedent@whosea.org		Frieden, Thomas/0000-0002-4759-2256				Abel EK, 1997, AM J PUBLIC HEALTH, V87, P1808, DOI 10.2105/AJPH.87.11.1808; [Anonymous], 1993, WORLD DEV REP 1993; [Anonymous], 1999, WORLD HLTH REPORT 19; Arif K, 1998, INT J TUBERC LUNG D, V2, P225; BIGGS HM, 1997, BRIT MED J, V1, P629; BISHOP P J, 1970, Tubercle, V51, P196; BRANDT L, 1903, HDB PREVENTION TUBER, P36; BUNYAN J, 1929, LIFE DEATH BADMAN 16; Caldwell M., 1988, LAST CRUSADE WAR CON; Cantwell MF, 1996, TUBERCLE LUNG DIS, V77, P220, DOI 10.1016/S0962-8479(96)90004-0; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; Davies RPO, 1999, INT J TUBERC LUNG D, V3, P1051; DUFFY J, 1974, HIST PUBLIC HLEHT NE; Fairchild AL, 1998, AM J PUBLIC HEALTH, V88, P1105, DOI 10.2105/AJPH.88.7.1105; FEE E, 1995, HIVES SICKNESS PUBLI, P155; Fox D M, 1975, Bull Hist Med, V49, P169; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Gasner MR, 1999, NEW ENGL J MED, V340, P359, DOI 10.1056/NEJM199902043400506; *HLTH BOARD COMP R, 1997, MED REC, V51, P126; KNOPF SA, 1909, TUBERULOSIS PREVENTA; Kochi A, 1997, WORLD HEALTH FORUM, V18, P225; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; La Motte Ellen N, 1915, TUBERCULOSIS NURSE H; LERNER B, 1998, CONTAGION CONFINEMEN; LERNER BH, 1993, AM J PUBLIC HEALTH, V83, P758, DOI 10.2105/AJPH.83.5.758; Marrero A, 2000, THORAX, V55, P39, DOI 10.1136/thorax.55.1.39; McKeown T., 1979, MED HIST, DOI DOI 10.1515/9781400854622; *NY CIT DEP HLTH, 1999, TUB INF SUMM 1999; Prabhakar R, 1996, INDIAN J MED RES, V103, P19; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; STYBLO K, 1993, ETHIOPIAN MED J, V21, P101; Tomes Nancy, 1998, GOSPEL GERMS MEN WOM; *WHO, 1999, WHOTB99259; Winslow CEA, 1929, LIFE HERMANN BIGGS; World Health Organization, 1994, WHOTB94179; World Health Organization Geneva, 1993, WHO31; ZHANG LX, 1992, TUBERCLE LUNG DIS, V73, P162, DOI 10.1016/0962-8479(92)90150-I; 1997, MED REC, V51, P461	39	27	27	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	2000	355	9209					1088	1092		10.1016/S0140-6736(00)02048-1	http://dx.doi.org/10.1016/S0140-6736(00)02048-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744106				2022-12-28	WOS:000086380800041
J	Korinek, WS; Copeland, MJ; Chaudhuri, A; Chant, J				Korinek, WS; Copeland, MJ; Chaudhuri, A; Chant, J			Molecular linkage underlying microtubule orientation toward cortical sites in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR MIGRATION; MITOTIC SPINDLE; PROTEIN; IDENTIFICATION; TUBULIN; BINDING; KINESIN; GENE	Selective microtubule orientation-toward spatially defined cortical sites is critical to polarized cellular processes as diverse as axon outgrowth and T cell cytotoxicity. In yeast, oriented cytoplasmic microtubules align the mitotic spindle between mother and bud. The cortical marker protein Kar9 Localizes to the bud tip and is required for the orientation of microtubules toward this region. Here, we show that Kar9 directs microtubule orientation by acting through Bim1, a conserved microtubule-binding protein. Bim1 homolog EB1 was originally identified through its interaction with adenomatous polyposis coil (APC) tumor suppressor, raising the possibility that an APC-EB1 linkage orients microtubules in higher cells.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Chant, J (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	chant@fas.harvard.edu		Korinek, William/0000-0002-6293-1623	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049782] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07620-19, GM49782, GM07620-20] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; James P, 1996, GENETICS, V144, P1425; Kaiser C., 1994, METHODS YEAST GENETI; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KORINEK WS, UNPUB; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Miller J. H, 1972, EXPT MOL GENETICS; Miller RK, 1998, J CELL BIOL, V140, P377, DOI 10.1083/jcb.140.2.377; Miller RK, 1998, MOL BIOL CELL, V9, P2051, DOI 10.1091/mbc.9.8.2051; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; Shaw SL, 1997, J CELL BIOL, V139, P985, DOI 10.1083/jcb.139.4.985; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; SNYDER M, 1991, J CELL BIOL, V114, P515, DOI 10.1083/jcb.114.3.515; Stearns T, 1997, J CELL BIOL, V138, P957, DOI 10.1083/jcb.138.5.957; SU LK, 1995, CANCER RES, V55, P2972; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993	26	179	180	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2257	2259		10.1126/science.287.5461.2257	http://dx.doi.org/10.1126/science.287.5461.2257			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731146				2022-12-28	WOS:000086049100049
J	Misura, KMS; Scheller, RH; Weis, WI				Misura, KMS; Scheller, RH; Weis, WI			Three-dimensional structure of the neuronal-Sec1-syntaxin 1a complex	NATURE			English	Article							PROTEIN-PROTEIN INTERACTIONS; SYNAPTIC VESICLE DOCKING; N-TERMINAL DOMAIN; SNARE COMPLEX; NEUROTRANSMITTER RELEASE; SEC1 HOMOLOG; SYNTAXIN; FUSION; ROP; SPECIFICITY	Syntaxin 1a and neuronal Sec1 (nSec1) form an evolutionarily conserved heterodimer that is essential for vesicle trafficking and membrane fusion. The crystal structure of the nSec1-syntaxin la complex, determined at 2.6 Angstrom resolution, reveals that major conformational rearrangements occur in syntaxin relative to both the core SNARE complex and isolated syntaxin. We identify regions of the two proteins that seem to determine the binding specificity of particular Sec1 proteins for syntaxin isoforms, which is likely to be important for the fidelity of membrane trafficking. The structure also indicates mechanisms that might couple the action of upstream effector proteins to conformational changes in syntaxin la and nSec1 that lead to core complex formation and membrane fusion.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Bldg,299 Campus Dr W, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Rowe J, 1999, J CELL SCI, V112, P1865; Sassa T, 1999, J NEUROSCI, V19, P4772; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TERWILLIGER TC, 1997, SOLVE AUTOMATED CRYS; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Webb GC, 1997, GENETICS, V147, P467; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	49	587	606	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					355	362		10.1038/35006120	http://dx.doi.org/10.1038/35006120			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746715				2022-12-28	WOS:000086119000040
J	Berger, A				Berger, A			Transplanted pancreatic stem cells can reverse diabetes in mice	BRITISH MEDICAL JOURNAL			English	News Item																		Ramiya VK, 2000, NAT MED, V6, P278	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					736	736						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720353				2022-12-28	WOS:000086054700018
J	Stevens, DA; Schwartz, HJ; Lee, JY; Moskovitz, BL; Jerome, DC; Catanzaro, A; Bamberger, DM; Weinmann, AJ; Tuazon, CU; Judson, MA; Platts-Mills, TAE; DeGraff, AC; Grossman, J; Slavin, RG; Reuman, P				Stevens, DA; Schwartz, HJ; Lee, JY; Moskovitz, BL; Jerome, DC; Catanzaro, A; Bamberger, DM; Weinmann, AJ; Tuazon, CU; Judson, MA; Platts-Mills, TAE; DeGraff, AC; Grossman, J; Slavin, RG; Reuman, P			A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 26-MAR 03, 1999	ORLANDO, FLORIDA	Amer Acad Allergy Asthma & Immunol			INVASIVE ASPERGILLOSIS; THERAPY; CRITERIA; KETOCONAZOLE; FLUCONAZOLE; INVITRO	Background: Allergic bronchopulmonary aspergillosis is a hypersensitivity disorder that can progress from an acute phase to chronic disease. The main treatment is systemic corticosteroids, but data from uncontrolled studies suggest that itraconazole, an orally administered antifungal agent, may be an effective adjunctive therapy. Methods: We conducted a randomized, double-blind trial of treatment with either 200 mg of itraconazole twice daily or placebo for 16 weeks in patients who met immunologic and pulmonary-function criteria for corticosteroid-dependent allergic bronchopulmonary aspergillosis. A response was defined as a reduction of at least 50 percent in the corticosteroid dose, a decrease of at least 25 percent in the serum IgE concentration, and one of the following: an improvement of at least 25 percent in exercise tolerance or pulmonary-function tests or resolution or absence of pulmonary infiltrates. In a second, open-label part of the trial, all the patients received 200 mg of itraconazole per day for 16 weeks. Results: There were responses in 13 of 28 patients in the itraconazole group (46 percent), as compared with 5 of 27 patients in the placebo group (19 percent, P=0.04). The rate of adverse events was similar in the two groups. In the subsequent open-label phase, 12 of the 33 patients who had not had a response during the double-blind phase (36 percent) had responses, and none of the patients who had a response in the double-blind phase of the trial had a relapse. Conclusions: For patients with corticosteroid-dependent allergic bronchopulmonary aspergillosis, the addition of itraconazole can lead to improvement in the condition without added toxicity. (N Engl J Med 2000;342:756-62.) (C)2000, Massachusetts Medical Society.	Santa Clara Valley Med Ctr, Dept Med, San Jose, CA 95128 USA; Stanford Univ, Sch Med, Dept Med, Div Infect Dis & Geog Med, Stanford, CA USA; NIAID, Mycoses Study Grp, NIH, Bethesda, MD USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Alabama, Birmingham, AL USA; Janssen Pharmaceut, Titusville, NJ USA; Vet Affairs Med Ctr, Long Beach, CA USA; Univ Missouri, Sch Med, Dept Med, Kansas City, MO 64108 USA; Wayne State Univ, Div Infect Dis, Detroit, MI USA; George Washington Univ, Med Ctr, Washington, DC 20037 USA; Med Univ S Carolina, Div Pulm & Crit Care, Charleston, SC USA; Univ Virginia, Dept Med, Charlottesville, VA USA; Univ Connecticut, Dept Med, Hartford, CT 06112 USA; Vivra Res, Tucson, AZ USA; St Louis Univ, Sch Med, St Louis, MO USA; NIAID, Mycoses Study Grp, NIH, Bethesda, MD USA	Santa Clara Valley Medical Center; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Case Western Reserve University; University Hospitals of Cleveland; University of Alabama System; University of Alabama Birmingham; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson USA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of Missouri System; University of Missouri Kansas City; Wayne State University; George Washington University; Medical University of South Carolina; University of Virginia; University of Connecticut; Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Stevens, DA (corresponding author), Santa Clara Valley Med Ctr, Dept Med, 751 S Bascom Ave, San Jose, CA 95128 USA.		Judson, Marc/I-7140-2019; Bamberger, David/GYV-3403-2022	Judson, Marc/0000-0002-4663-7985; Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI065296, N01AI015082, R01AI030840] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI-30840, N0-AI-15082, N0-AI-65296] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1987, FED REG, V52, P19466; BASICH JE, 1981, J ALLERGY CLIN IMMUN, V68, P98, DOI 10.1016/0091-6749(81)90165-2; BERLINGER FG, 1974, POSTGRAD MED, V5, P153; CAPEWELL S, 1989, THORAX, V44, P925, DOI 10.1136/thx.44.11.925; CROMPTON G K, 1973, British Journal of Diseases of the Chest, V67, P301, DOI 10.1016/S0007-0971(73)80002-6; CURRIE DC, 1990, THORAX, V45, P447, DOI 10.1136/thx.45.6.447; DEBUELE K, 1988, MYCOSES, V31, P476; DENNING DW, 1989, AM J MED, V86, P791, DOI 10.1016/0002-9343(89)90475-0; DENNING DW, 1992, DIAGN MICR INFEC DIS, V15, P21, DOI 10.1016/0732-8893(92)90053-V; DENNING DW, 1994, AM J MED, V97, P135, DOI 10.1016/0002-9343(94)90023-X; DENNING DW, 1991, CHEST, V100, P813, DOI 10.1378/chest.100.3.813; DENNING DW, 1994, AM J MED, V97, P497; FOURNIER EC, 1987, THORAX, V42, P831, DOI 10.1136/thx.42.10.831; GANER A, 1987, REV INFECTIOUS DI S1, V9, P77; GREENBERGER PA, 1987, CHEST, V91, pS165, DOI 10.1378/chest.91.6.165S; HENDERSON AH, 1968, THORAX, V23, P519, DOI 10.1136/thx.23.5.519; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEBRUNVIGNES B, 1996, EXP CLIN PHARM SB, V18, P207; LEBRUNVIGNES B, 1997, ANN DERM VENEREOL S1, V124, pS53; LEWISTON NJ, 1973, CYSTIC FIBROSIS Q S, P47; MCCARTHY D S, 1970, Clinical Radiology, V21, P366, DOI 10.1016/S0009-9260(70)80070-8; MIDDLETON WG, 1977, BRIT J DIS CHEST, V71, P115, DOI 10.1016/0007-0971(77)90092-4; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MROUEH S, 1994, CHEST, V105, P32, DOI 10.1378/chest.105.1.32; Nepomuceno IB, 1999, CHEST, V115, P364, DOI 10.1378/chest.115.2.364; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; RAFFERTY P, 1983, THORAX, V38, P579, DOI 10.1136/thx.38.8.579; RILEY DJ, 1975, AM REV RESPIR DIS, V111, P232; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; Salez F, 1999, CHEST, V116, P1665, DOI 10.1378/chest.116.6.1665; SCHWARTZ HJ, 1991, J LAB CLIN MED, V117, P138; SHALE DJ, 1987, THORAX, V42, P26, DOI 10.1136/thx.42.1.26; SLAVIN RG, 1970, J ALLERGY, V46, P150, DOI 10.1016/0021-8707(70)90093-6; STARK JE, 1967, DIS CHEST, V51, P96; Stevens DA, 1996, DIAGN MICR INFEC DIS, V26, P145, DOI 10.1016/S0732-8893(96)00199-X; Stevens DA, 1997, DIAGN MICR INFEC DIS, V29, P103, DOI 10.1016/S0732-8893(97)00104-1; Stevens DA, 1997, ARCH INTERN MED, V157, P1857, DOI 10.1001/archinte.157.16.1857; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TUCKER RM, 1990, J ANTIMICROB CHEMOTH, V26, P561, DOI 10.1093/jac/26.4.561; TUCKER RM, 1992, CLIN INFECT DIS, V14, P165, DOI 10.1093/clinids/14.1.165; Varis T, 1998, CLIN PHARMACOL THER, V64, P363, DOI 10.1016/S0009-9236(98)90066-2	45	329	360	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2000	342	11					756	762		10.1056/NEJM200003163421102	http://dx.doi.org/10.1056/NEJM200003163421102			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293HW	10717010	Bronze			2022-12-28	WOS:000085846900002
J	Lee, JS; Collins, KM; Brown, AL; Lee, CH; Chung, JH				Lee, JS; Collins, KM; Brown, AL; Lee, CH; Chung, JH			hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response	NATURE			English	Article							CELL-CYCLE; OVARIAN-CANCER; S-PHASE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; GENE; TRANSCRIPTION; BREAST; YEAST; ATM	Mutations in the BRCA1 (ref. 1) tumour suppressor gene are found in almost all of the families with inherited breast and ovarian cancers and about half of the families with only breast cancer(2,3). Although the biochemical function of BRCA1 is not well understood, it is important for DNA damage repair(4-7) and cell-cycle checkpoints(8-10). BRCA1 exists in nuclear foci but is hyperphosphorylated and disperses after DNA damage(11,12). It is not known whether BRCA1 phosphorylation and dispersion and its function in DNA damage response are related. In yeast the DNA damage response and the replication-block checkpoint are mediated partly through the Cds1 kinase family(13-20). Here we report that the human Cds1 kinase (hCds1/Chk2)(21-23) regulates BRCA1 function after DNA damage by phosphorylating serine 988 of BRCA1. We show that hCds1 and BRCA1 interact and colocalize within discrete nuclear foci but separate after gamma irradiation. Phosphorylation of BRCA1 at serine 988 is required for the release of BRCA1 from hCds1. This phosphorylation is also important for the ability of BRCA1 to restore survival after DNA damage in the BRCA1-mutated cell line HCC1937.	NHLBI, Lab Mol Hematol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Chung, JH (corresponding author), NHLBI, Lab Mol Hematol, NIH, Bldg 10, Bethesda, MD 20892 USA.							Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; BODDY MN, 1998, NATURE, V395, P507; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; EASTON DF, 1993, AM J HUM GENET, V52, P678; Feunteun J, 1996, BBA-REV CANCER, V1242, P177, DOI 10.1016/0304-419X(95)00016-9; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Larson JS, 1997, CANCER RES, V57, P3351; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Sidorova JM, 1997, GENE DEV, V11, P3032, DOI 10.1101/gad.11.22.3032; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	29	439	457	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					201	204		10.1038/35004614	http://dx.doi.org/10.1038/35004614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724175				2022-12-28	WOS:000085870900056
J	Duddridge, M; West, KP; Wales, J; Browning, MJ				Duddridge, M; West, KP; Wales, J; Browning, MJ			A coughing policeman	LANCET			English	Article							COMMON VARIABLE IMMUNODEFICIENCY; GRANULOMATOUS-DISEASE; SARCOIDOSIS		Leicester Royal Infirm NHS Trust, Dept Immunol, Leicester LE1 5WW, Leics, England; Leicester Royal Infirm NHS Trust, Dept Pathol, Leicester LE1 5WW, Leics, England; Glenfield Hosp NHS Trust, Div Resp Med, Leicester, Leics, England		Browning, MJ (corresponding author), Leicester Royal Infirm NHS Trust, Dept Immunol, Leicester LE1 5WW, Leics, England.							Fasano MB, 1996, MEDICINE, V75, P251, DOI 10.1097/00005792-199609000-00002; Mechanic LJ, 1997, ANN INTERN MED, V127, P613, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00005; Mullighan CG, 1997, J IMMUNOL, V159, P6236; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; WRIGHT JJ, 1990, BLOOD, V76, P2046	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					804	804		10.1016/S0140-6736(99)11450-8	http://dx.doi.org/10.1016/S0140-6736(99)11450-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711929				2022-12-28	WOS:000085766900013
J	Abe, Y; Shodai, T; Muto, T; Mihara, K; Torii, H; Nishikawa, S; Endo, T; Kohda, D				Abe, Y; Shodai, T; Muto, T; Mihara, K; Torii, H; Nishikawa, S; Endo, T; Kohda, D			Structural basis of presequence recognition by the mitochondrial protein import receptor Tom20	CELL			English	Article							NUCLEAR MAGNETIC-RESONANCE; OUTER-MEMBRANE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; C-13/N-15-ENRICHED PROTEINS; PREPROTEIN TRANSLOCASE; C-13 MAGNETIZATION; BINDING DOMAIN; ACID CHAIN; NMR	Most mitochondrial proteins are synthesized in the cytosol as precursor proteins with a cleavable N-terminal presequence and are imported into mitochondria. We report here the NMR structure of a general import receptor, rat Tom20, in a complex with a presenquence peptide derived from rat aldehyde dehydrogenase, The cytosolic domain of Tom20 forms an all alpha-helical structure with a groove to accommodate the presequence peptide. The bound presequence forms an amphiphilic helical structure with hydrophobic leucines aligned on one side to interact with a hydrophobic patch in the Tom20 groove. Although the positive charges of the presequence are essential for import ability, presequence binding to Tom20 is mediated mainly by hydrophobic rather than ionic interactions.	Nagoya Univ, Fac Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Biomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128512, Japan	Nagoya University; Kyushu University	Kohda, D (corresponding author), Nagoya Univ, Fac Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Abe, Yoshito/D-8370-2012; Kohda, Daisuke/I-4990-2019; Abe, Yoshito/AAH-6141-2021	Abe, Yoshito/0000-0002-0016-8490; Kohda, Daisuke/0000-0001-8234-3776; Abe, Yoshito/0000-0002-0016-8490				BAKER A, 1987, P NATL ACAD SCI USA, V84, P3117, DOI 10.1073/pnas.84.10.3117; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOPING IS, 1995, FEBS LETT, V373, P45; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; Kanamori T, 1997, P NATL ACAD SCI USA, V94, P485, DOI 10.1073/pnas.94.2.485; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NAKAI T, 1993, J BIOMOL NMR, V3, P19; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Ogura K, 1996, J BIOMOL NMR, V8, P492, DOI 10.1007/BF00228150; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; Schleiff E, 1998, BIOCHEMISTRY-US, V37, P13052, DOI 10.1021/bi980746y; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Yano M, 1998, J BIOL CHEM, V273, P26844, DOI 10.1074/jbc.273.41.26844; [No title captured]	52	415	424	2	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 3	2000	100	5					551	560		10.1016/S0092-8674(00)80691-1	http://dx.doi.org/10.1016/S0092-8674(00)80691-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721992	Bronze			2022-12-28	WOS:000085700000008
J	Duchovnay, B; Joyce, C				Duchovnay, B; Joyce, C			The spirit of discovery	SCIENCE			English	Article									Eastern Res Grp, Lexington, MA 02421 USA; Univ Wisconsin, Milwaukee, WI 53213 USA	University of Wisconsin System; University of Wisconsin Milwaukee	Duchovnay, B (corresponding author), Eastern Res Grp, Lexington, MA 02421 USA.								0	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2000	287	5458					1595	+		10.1126/science.287.5458.1595	http://dx.doi.org/10.1126/science.287.5458.1595			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10733427				2022-12-28	WOS:000085628200020
J	Hayward, RC; Saville, DA; Aksay, IA				Hayward, RC; Saville, DA; Aksay, IA			Electrophoretic assembly of colloidal crystals with optically tunable micropatterns	NATURE			English	Article							PHOTONIC-CRYSTAL; DEPOSITION; CRYSTALLIZATION; SPHERES; OXIDE	The production of materials with micrometre- and submicrometre-scale patterns is of importance in a range of applications, such as photonic materials(1,2), high-density magnetic data storage devices: microchip reactors(4) and biosensors(5). One method of preparing such structures is through the assembly of colloidal particles(5-10). Micropatterned colloidal assemblies Have been produced with lithographically patterned electrodes(5,11) or micromoulds(12). Here we describe a different method that combines the well-known photochemical sensitivity of semiconductors(13,14) with electric-field-induced assembly(15,16) to create ordered arrays of micrometre-sized colloidal particles with tunable patterns. We show that light affects the assembly processes, and demonstrate how to produce patterns using electrophoretic deposition in the presence of an ultraviolet (UV) illumination moth. The distribution of current across an indium tin oxide (ITO) electrode can be altered by varying the illumination intensity: during the deposition process, this causes colloidal particles to be swept from darkened areas into lighted regions. Illumination also assists in immobilizing the particles on the electrode surface. Although the details of these processes are not well understood, the patterning effects of the UV light are discussed in terms of alterations in the current density(15,17) that affects particle assembly on an ITO electrode.	Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA	Princeton University; Princeton University	Aksay, IA (corresponding author), Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA.		Aksay, Ilhan A/B-9281-2008; Hayward, Ryan C/P-4745-2016; Han, Kyuhee/B-6201-2009	Hayward, Ryan C/0000-0001-6483-2234; 				ANDRES RP, 1989, J MATER RES, V4, P704, DOI 10.1557/JMR.1989.0704; Asher SA, 1998, MRS BULL, V23, P44, DOI 10.1557/S0883769400029596; BENKHELIFA F, 1993, THIN SOLID FILMS, V232, P83, DOI 10.1016/0040-6090(93)90766-I; Bertone JF, 1999, PHYS REV LETT, V83, P300, DOI 10.1103/PhysRevLett.83.300; Bocarsly A.B., 1996, LAB TECHNIQUES ELECT, V2nd, p[855, Heineman]; Bohmer M, 1996, LANGMUIR, V12, P5747; Gau H, 1999, SCIENCE, V283, P46, DOI 10.1126/science.283.5398.46; GIERSIG M, 1993, LANGMUIR, V9, P3408, DOI 10.1021/la00036a014; GIERSIG M, 1993, J PHYS CHEM-US, V97, P6334, DOI 10.1021/j100126a003; Haginoya C, 1997, APPL PHYS LETT, V71, P2934, DOI 10.1063/1.120220; INANC I, 1996, PHYS REV LETT, V76, P315; Kim E, 1996, ADV MATER, V8, P245, DOI 10.1002/adma.19960080313; Lin SY, 1998, SCIENCE, V282, P274, DOI 10.1126/science.282.5387.274; Morrison S.R., 1980, ELECTROCHEMISTRY SEM; MURAT I, 1988, CAN J ANAESTH, V35, P20, DOI 10.1007/BF03010539; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; RICHETTI P, 1984, J PHYS LETT-PARIS, V45, P1137, DOI 10.1051/jphyslet:0198400450230113700; RICHETTI P, 1987, PHYS COMPLEX SUPERMO, P387; RUSSEL WB, 1989, COLLOIDAL DISPERSION; Solomentsev Y, 1997, LANGMUIR, V13, P6058, DOI 10.1021/la970294a; Trau M, 1996, SCIENCE, V272, P706, DOI 10.1126/science.272.5262.706; Trau M, 1997, LANGMUIR, V13, P6375, DOI 10.1021/la970568u; VANDENMEERAKKER JEAM, 1993, J APPL PHYS, V74, P3282, DOI 10.1063/1.354549; Velev OD, 1999, LANGMUIR, V15, P3693, DOI 10.1021/la981729c; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; Yeh SR, 1997, NATURE, V386, P57, DOI 10.1038/386057a0	26	503	524	4	225	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					56	59		10.1038/35003530	http://dx.doi.org/10.1038/35003530			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716438				2022-12-28	WOS:000085775100041
J	Whitmore, D; Foulkes, NS; Sassone-Corsi, P				Whitmore, D; Foulkes, NS; Sassone-Corsi, P			Light acts directly on organs and cells in culture to set the vertebrate circadian clock	NATURE			English	Article							DROSOPHILA; ZEBRAFISH; GENE; ENTRAINMENT; EXPRESSION	The expression of dock genes in vertebrates is widespread and not restricted to classical dock structures(1,2). The expression of the Clock gene in zebrafish shows a strong circadian oscillation in many tissues in vivo and in culture, showing that endogenous oscillators exist in peripheral organs(3). A defining feature of circadian clocks is that they can be set or entrained to local time, usually by the environmental light-dark cycle(4,5). An important question is whether peripheral oscillators are entrained to local time by signals from central pacemakers such as the eyes or are themselves directly light-responsive. Here we show that the peripheral organ docks of zebrafish are set by light-dark cycles in culture. We also show that a zebrafish-derived cell line contains a circadian oscillator, which is also directly light entrained.	Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbour, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Sassone-Corsi, P (corresponding author), Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.	paolosc@titus.u-strasbg.fr	Foulkes, Nicholas S/K-7003-2013; Sassone-Corsi, Paolo/H-6182-2011	Foulkes, Nicholas S/0000-0002-1794-9891; Whitmore, David/0000-0003-2420-8220				Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; ASCHOFF J, 1986, Journal of Biological Rhythms, V1, P91, DOI 10.1177/074873048600100201; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BARRETT RK, 1995, J NEUROSCI, V15, P5681; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; CERMAKIAN N, IN PRESS P NATL ACAD, V97; Earnest DJ, 1999, SCIENCE, V283, P693, DOI 10.1126/science.283.5402.693; Earnest DJ, 1999, J NEUROBIOL, V39, P1, DOI 10.1002/(SICI)1097-4695(199904)39:1<1::AID-NEU1>3.0.CO;2-F; Gothilf Y, 1999, ENDOCRINOLOGY, V140, P4895, DOI 10.1210/en.140.10.4895; Ishikawa T, 1999, GENES CELLS, V4, P57, DOI 10.1046/j.1365-2443.1999.00237.x; Kazimi N, 1999, DEV BRAIN RES, V117, P47, DOI 10.1016/S0165-3806(99)00096-6; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Koike N, 1998, FEBS LETT, V441, P427, DOI 10.1016/S0014-5793(98)01597-X; LIN S, 1994, SCIENCE, V265, P666, DOI 10.1126/science.8036514; Liu Y, 1998, SCIENCE, V281, P825, DOI 10.1126/science.281.5378.825; MCARTHUR AJ, 1991, BRAIN RES, V565, P158, DOI 10.1016/0006-8993(91)91748-P; PEPPELENBOSCH MP, 1995, EXP CELL RES, V218, P183, DOI 10.1006/excr.1995.1146; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Shearman LP, 1999, NEUROSCIENCE, V89, P387, DOI 10.1016/S0306-4522(98)00325-X; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Whitmore D, 1998, NAT NEUROSCI, V1, P701, DOI 10.1038/3703; Whitmore D, 1998, CURR OPIN NEUROBIOL, V8, P635, DOI 10.1016/S0959-4388(98)80092-5; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZIMMERMAN WF, 1968, J INSECT PHYSIOL, V14, P669, DOI 10.1016/0022-1910(68)90226-6; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	29	346	351	3	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2000	404	6773					87	91		10.1038/35003589	http://dx.doi.org/10.1038/35003589			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716448				2022-12-28	WOS:000085775100051
J	Hayashi, Y; Shi, SH; Esteban, JA; Piccini, A; Poncer, JC; Malinow, R				Hayashi, Y; Shi, SH; Esteban, JA; Piccini, A; Poncer, JC; Malinow, R			Driving AMPA receptors into synapses by LTP and CaMKII: Requirement for GluR1 and PDZ domain interaction	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; SYNAPTIC TRANSMISSION; GLUTAMATE RECEPTORS; IN-VIVO; CALMODULIN; NEURONS; PHOSPHORYLATION; MECHANISMS; COMPONENT	To elucidate mechanisms that control and execute activity-dependent synaptic plasticity, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptors (AMPA-Rs) with an electrophysiological tag were expressed in rat hippocampal neurons. Long-term potentiation (LTP) or increased activity of the calcium/calmodulin-dependent protein kinase II (CaMKII) induced delivery of tagged AMPA-Rs into synapses. This effect was not diminished by mutating the CaMKII phosphorylation site on the GLuR1 AMPA-R subunit, but was blocked by mutating a predicted PDZ domain interaction site. These results show that LTP and CaMKII activity drive AMPA-Rs to synapses by a mechanism that requires the association between GluR1 and a PDZ domain protein.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Malinow, R (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	malinow@cshl.org	Hayashi, Yasunori/C-2249-2008; Esteban, Jose/L-4944-2014; Hayashi, Yasunori/AAF-1408-2019; Poncer, Jean Christophe/R-6362-2016	Hayashi, Yasunori/0000-0002-7560-3004; Esteban, Jose/0000-0002-3759-3300; Hayashi, Yasunori/0000-0002-7560-3004; Poncer, Jean Christophe/0000-0001-5729-3009				Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BARRIA A, 1998, THESIS VOLLUM I PORT; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; BLACKSTONE C, 1994, J NEUROSCI, V14, P7585; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; HAYASHI Y, UNPUB; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; Kim JH, 1999, CURR OPIN CELL BIOL, V11, P248, DOI 10.1016/S0955-0674(99)80033-7; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Li P, 1999, NAT NEUROSCI, V2, P972, DOI 10.1038/14771; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MALINOW R, 1999, IMAGING LIVING CELLS; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MILLER SG, 1985, J BIOL CHEM, V260, P9039; Nagano T, 1998, J BIOCHEM-TOKYO, V124, P869, DOI 10.1093/oxfordjournals.jbchem.a022200; Neve RL, 1997, NEUROSCIENCE, V79, P435, DOI 10.1016/S0306-4522(96)00645-8; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Saras J, 1997, J BIOL CHEM, V272, P20979, DOI 10.1074/jbc.272.34.20979; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Shirke AM, 1997, J NEUROPHYSIOL, V78, P2682, DOI 10.1152/jn.1997.78.5.2682; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222; Wyszynski M, 1999, Methods Enzymol, V294, P371	40	1169	1206	1	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2262	2267		10.1126/science.287.5461.2262	http://dx.doi.org/10.1126/science.287.5461.2262			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731148				2022-12-28	WOS:000086049100051
J	Filatov, DA; Moneger, F; Negrutiu, I; Charlesworth, D				Filatov, DA; Moneger, F; Negrutiu, I; Charlesworth, D			Low variability in a Y-linked plant gene and its implications for Y-chromosome evolution	NATURE			English	Article							SEX-DETERMINING LOCUS; DIOECIOUS PLANT; MELANDRIUM-ALBUM; DNA-SEQUENCES; POLYMORPHISM; HITCHHIKING; HYPOTHESIS; MICE; SRY	Sex chromosomes have evolved independently in several different groups of organisms, but they share common features, including genetic degeneration of the Y chromosome(1,2). Suppression of recombination between ancestral proto-X and proto-Y chromosomes is thought to have led to their gradual divergence, and to degeneration of the Y chromosome(2), but the evolutionary forces responsible are unknown. In non-recombining Y chromosomes, deleterious mutations may be carried to fixation by linked advantageous mutations ("selective sweeps")(3). Occurrence of deleterious mutations may drive "Muller's ratchet" (stochastic loss of chromosomes with the fewest mutations)(2,4). Selective elimination of deleterious mutations, causing "background selection"(5,6) may accelerate stochastic fixation of mildly detrimental mutations(2). All these processes lower effective population sizes, and therefore reduce variability of genes in evolving Y chromosomes. We have studied DNA diversity and divergence in a recently described X- and Y-linked gene pair(7) (SLX-1 and SLY-1) of the plant Silene latifolia to obtain evidence about the early stages of Y degeneration. Here we show that DNA polymorphism in SLY-1 is 20-fold lower than in SLX-1, but the pattern of polymorphism does not suggest a selective sweep.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Ecole Normale Super Lyon, ENS Lyon 1, INRA, CNRS,UMR 5667, F-69364 Lyon, France	University of Edinburgh; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON)	Charlesworth, D (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	Deborah.Charlesworth@ed.ac.uk	Charlesworth, Deborah/F-3071-2011	Filatov, Dmitry/0000-0001-8077-5452; Moneger, Francoise/0000-0003-2107-5696				Anagnostopoulos T, 1999, AM J HUM GENET, V64, P508, DOI 10.1086/302250; BRAVERMAN JM, 1995, GENETICS, V140, P783, DOI 10.1093/genetics/140.2.783; BULL JJ, 1993, EVOLUTION SEX DETERM; Burrows W, 1997, NATURE, V385, P125, DOI 10.1038/385125a0; Buzek J, 1997, CHROMOSOME RES, V5, P57, DOI 10.1023/A:1011693603279; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; CHARLESWORTH D, 1995, GENETICS, V141, P1619; Delichere C, 1999, EMBO J, V18, P4169, DOI 10.1093/emboj/18.15.4169; Desfeux C, 1996, P ROY SOC B-BIOL SCI, V263, P409, DOI 10.1098/rspb.1996.0062; Filatov DA, 1999, GENETICS, V153, P1423; FU YX, 1993, GENETICS, V133, P693; Gaut BS, 1998, EVOL BIOL, V30, P93; GRANT S, 1994, DEV GENET, V15, P214, DOI 10.1002/dvg.1020150304; Guttman DS, 1998, NATURE, V393, P263, DOI 10.1038/30492; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1987, GENET RES, V50, P245, DOI 10.1017/S0016672300023776; HUDSON RR, 1985, GENETICS, V111, P147; KUMAR S, 1993, MEGA MOL EVOLUTION G; LUNDRIGAN BL, 1994, MOL BIOL EVOL, V11, P483; MANNING JT, 1984, ACTA BIOTHEOR, V33, P219, DOI 10.1007/BF00048429; McAllister BF, 1999, GENETICS, V153, P221; NACHMAN MW, 1994, MOL BIOL EVOL, V11, P539; Nei M., 1987, MOL EVOLUTIONARY GEN; Orr HA, 1998, GENETICS, V150, P1693; RICE WR, 1987, GENETICS, V116, P161; TAJIMA F, 1989, GENETICS, V123, P585; VAGERA J, 1994, ANN BOT-LONDON, V73, P455, DOI 10.1006/anbo.1994.1056; WESTERGAARD M, 1958, ADV GENET, V9, P217, DOI 10.1016/S0065-2660(08)60163-7; YE D, 1990, SEX PLANT REPROD, V3, P179, DOI 10.1007/BF00205227; Zurovcova M, 1999, GENETICS, V153, P1709	30	147	151	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					388	390		10.1038/35006057	http://dx.doi.org/10.1038/35006057			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746725				2022-12-28	WOS:000086119000050
J	Grenier, IA				Grenier, IA			Gamma-ray astronomy - A needle in a cosmic haystack	NATURE			English	Editorial Material									Ctr Etud Saclay, CEA Saclay, Serv Astrophys, F-91191 Gif Sur Yvette, France; Univ Paris 07, F-75221 Paris 05, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Grenier, IA (corresponding author), Univ Paris 07, F-75221 Paris 05, France.	isabelle.grenier@cea.fr						Gehrels N, 2000, NATURE, V404, P363, DOI 10.1038/35006001; GRENIER IA, P 6MAJ ATM CHER DET; GRENIER IA, 1999, P 26 INT COSM RAY C, V3, P476; Mukherjee R, 1997, AIP CONF PROC, P394, DOI 10.1063/1.54037; Poppel W., 1997, FUNDAM COSMIC PHYS, V18, P1; Romero GE, 1999, ASTRON ASTROPHYS, V348, P868; Thompson DJ, 1997, AIP CONF PROC, P39, DOI 10.1063/1.54038; Yadigaroglu IA, 1997, ASTROPHYS J, V476, P347, DOI 10.1086/303601	8	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					344	345		10.1038/35006191	http://dx.doi.org/10.1038/35006191			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746707				2022-12-28	WOS:000086119000031
J	Knill, E; Laflamme, R; Martinez, R; Tseng, CH				Knill, E; Laflamme, R; Martinez, R; Tseng, CH			An algorithmic benchmark for quantum information processing	NATURE			English	Article							COMPUTATION; NMR; RESONANCE; COMPUTER	Quantum information processing offers potentially great advantages over classical information processing, both for efficient algorithms(1,2) and for secure communication(3,4). Therefore, it is important to establish that scalable control of a large number of quantum bits (qubits) can be achieved in practice. There are a rapidly growing number of proposed device technologies(5-11) for quantum information processing. Of these technologies, those exploiting nuclear magnetic resonance (NMR) have been the first to demonstrate non-trivial quantum algorithms with small numbers of qubits(12-16). To compare different physical realizations of quantum information processors, it is necessary to establish benchmark experiments that are independent of the underlying physical system, and that demonstrate reliable and coherent control of a reasonable number of qubits. Here we report an experimental realization of an algorithmic benchmark using an NMR technique that involves coherent manipulation of seven qubits. Moreover, our experimental procedure can be used as a reliable and efficient method for creating a standard pseudopure state, the first step for implementing traditional quantum algorithms in liquid state NMR systems. The benchmark and the techniques can be adapted for use with other proposed quantum devices.	Los Alamos Natl Lab, Los Alamos, NM 87545 USA; MIT, Dept Nucl Engn, Cambridge, MA 02139 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Massachusetts Institute of Technology (MIT)	Knill, E (corresponding author), Los Alamos Natl Lab, MS B265, Los Alamos, NM 87545 USA.	knill@lanl.gov						AHARONOV D, 1996, P 29 ANN ACM S THEOR, P176; BARENCO A, 1995, PHYS REV A, V52, P3457, DOI 10.1103/PhysRevA.52.3457; Bennett C. H., 1992, Journal of Cryptology, V5, P3, DOI 10.1007/BF00191318; Bocko MF, 1997, IEEE T APPL SUPERCON, V7, P3638, DOI 10.1109/77.622206; Chuang IL, 1998, NATURE, V393, P143, DOI 10.1038/30181; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; Cory DG, 1998, PHYS REV LETT, V81, P2152, DOI 10.1103/PhysRevLett.81.2152; Cory DG, 1997, P NATL ACAD SCI USA, V94, P1634, DOI 10.1073/pnas.94.5.1634; Dur W, 1999, PHYS REV A, V59, P169, DOI 10.1103/PhysRevA.59.169; EMSLEY L, 1994, P INT SCH PHYS, V123, P123; Freeman R., 1998, SPIN CHOREOGRAPHY; Gershenfeld NA, 1997, SCIENCE, V275, P350, DOI 10.1126/science.275.5298.350; Jones JA, 1998, NATURE, V393, P344, DOI 10.1038/30687; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Knill E, 1998, PHYS REV A, V57, P3348, DOI 10.1103/PhysRevA.57.3348; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; MAFFEI P, 1991, J MAGN RESON, V95, P382, DOI 10.1016/0022-2364(91)90227-K; MARX R, 1999, QUANTPH9905087; Nielsen MA, 1998, NATURE, V396, P52, DOI 10.1038/23891; Shnirman A, 1997, PHYS REV LETT, V79, P2371, DOI 10.1103/PhysRevLett.79.2371; Shor PW, 1997, SIAM J COMPUT, V26, P1484, DOI [10.1137/S0097539795293172, 10.1137/S0036144598347011]; Simon DR, 1997, SIAM J COMPUT, V26, P1474, DOI 10.1137/S0097539796298637; SORENSEN OW, 1983, PROG NUCL MAGN RESON, V16; Vandersypen LMK, 1999, PHYS REV LETT, V83, P3085, DOI 10.1103/PhysRevLett.83.3085; WEITEKAMP DP, 1982, J CHEM PHYS, V77, P2870, DOI 10.1063/1.444180	30	215	226	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					368	370		10.1038/35006012	http://dx.doi.org/10.1038/35006012			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746718				2022-12-28	WOS:000086119000043
J	Barach, P; Small, SD				Barach, P; Small, SD			Reporting and preventing medical mishaps: lessons from non-medical near miss reporting systems	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ADVERSE DRUG EVENTS; INTENSIVE-CARE; INCIDENTS; ERROR; QUALITY; UNIT		Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Barach, P (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA.	pbarach@etherdome.mgh.harvard.edu	Barach, paul/B-9915-2016; Barach, Paul/AAX-5315-2020	Barach, paul/0000-0002-7906-698X; Barach, Paul/0000-0002-7906-698X				[Anonymous], 1994, HOSTAGES EACH OTHER; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; Barach Paul, 1999, Anesthesiology (Hagerstown), V91, pA1209; Battles JB, 1998, ARCH PATHOL LAB MED, V122, P231; Beckman U, 1996, ANAESTH INTENS CARE, V24, P315; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Billings CE, 1998, ARCH PATHOL LAB MED, V122, P214; BILLINGS CE, 1984, AVIAT SPACE ENVIR MD, V55, P960; Bogner MS, 1994, HUMAN ERROR MED; Bosk CL, 1979, FORGIVE REMEMBER MAN, DOI DOI 10.7208/CHICAGO/9780226924687.001.0001; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Campling EA, 1995, REPORT NATL CONFIDEN; Carroll J.S., 1995, IND ENV CRISIS Q, V9, P175; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COHEN MR, 1998, J HEALTHCARE RISK MA, V2, P16; COOPER JB, 1978, ANESTHESIOLOGY, V49, P399, DOI 10.1097/00000542-197812000-00004; CORCORAN WR, 1998, PHOENIX HDB ULTIMATE; CULLEN DJ, 1995, JOINT COMM J QUAL IM, V21, P541, DOI 10.1016/S1070-3241(16)30180-8; deLaval MR, 1996, PAEDIATR ANAESTH, V6, P349; Derman H, 1997, ARCH PATHOL LAB MED, V121, P287; DONCHIN Y, 1995, CRIT CARE MED, V23, P294, DOI 10.1097/00003246-199502000-00015; Emanuel L, 1997, JAMA-J AM MED ASSOC, V278, P21, DOI 10.1001/jama.1997.03550010035025; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Fiesta J, 1994, Nurs Manage, V25, P17, DOI 10.1097/00006247-199407000-00003; FISCHHOFF B, 1975, J EXP PSYCHOL HUMAN, V1, P288, DOI 10.1037/0096-1523.1.3.288; GAMBINO R, 1991, LAB REPORT, V13, P41; Geiduschek JM, 1998, ASA NEWSLETTER, V62, P16; GLIESSON RM, 1997, THESIS EINDHOVEN U T; GRIFFITH S, 1998, AVIATION WEEK S 0713; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; HART GK, 1994, ANAESTH INTENS CARE, V22, P556, DOI 10.1177/0310057X9402200509; *I MED, 1999, ERR IS HUM BUILD SAF; *I NUCL POW OP, 1990, 90005 INPO; IVES G, 1991, NEAR MISS REPORTING; Kaplan HS, 1998, TRANSFUSION, V38, P1071, DOI 10.1046/j.1537-2995.1998.38111299056319.x; Kletz, 1994, LEARNING ACCIDENTS; Langley GJ, 1996, IMPROVEMENT GUIDE; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LUCAS DA, 1987, HUMAN RELIABILITY NU; March JG, 1991, ORGAN SCI, V2, P1, DOI 10.1287/orsc.2.1.1; McArthur JH, 1997, JAMA-J AM MED ASSOC, V277, P985, DOI 10.1001/jama.277.12.985; Millenson ML., 1997, DEMANDING MED EXCELL; MORAY N, 1904, HUMAN ERROR MED, P67; *NASA AV REP SYST, 1986, AV SAF REP SYST PROG; *NAT RES COUNC, 1980, IMPR AIRCR SAF FAA C; O'Leary M, 1996, ICAO J, V51, P11; O'Leary M., 1995, FLIGHT DECK, V16, P11; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; PIDGEON NF, 1991, J CROSS CULT PSYCHOL, V22, P129, DOI 10.1177/0022022191221009; RASMUSSEN J, 1990, ERGONOMICS, V33, P1185, DOI 10.1080/00140139008925325; RASON J, 1997, MANAGING RISKS ORG A; REYNARD WD, 1986, 1114 NASA SCI TECHN; RICHTER ED, 1995, MT SINAI J MED, V62, P390; RICHTER ED, 1992, PREHOSP DISASTER MED, V7, P389; ROBERTS KH, 1989, IEEE T ENG MANAGE, V36, P132, DOI 10.1109/17.18830; ROBERTSON L, 1998, INQUIRY EPIDEMIOLOGY; RUNCIMAN WB, 1993, ANAESTH INTENS CARE, V21, P506, DOI 10.1177/0310057X9302100506; RUNCIMAN WB, 2000, IATROGENIC INJURY AU; SAGAN S, 1994, LIMITS SAFETY ORG AC; SENDERS J, 1994, HUMAN ERROR CAUSE PR; SERIG D, 1996, P EX ERR HLTH CAR DE; Shappell SA, 1997, INT J AVIAT PSYCHOL, V7, P269, DOI 10.1207/s15327108ijap0704_2; SHEA CE, 1996, THESIS U MANCHESTER; STAENDER S, 1999, HUMAN RECOVERIES MAN; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TAMUZ M, 1988, THESIS STANFORD U ST; TAMUZ M, 1994, P PHYS SCI ANN M 2 S; TAMUZ M, 1987, P PHYS SCI ANN M 3, V2, P7; Thomas EJ, 1999, INQUIRY-J HEALTH CAR, V36, P255; Turner Barry A., 1997, MAN MADE DISASTERS; *US NUCL REG COMM, 1998, NUREGBR0240; VANDERSCHAFF TW, 1991, NEAR MISS REPORTING; VANDERSCHAFF TW, 1998, P ENH PAT SAF RED ER, P190; VANVUUREN W, 1998, THESIS EINDHOVEN U T; Vincent C, 1999, J EVAL CLIN PRACT, V5, P1; VINCENT C, 1993, MED ACCIDENTS; WAGENAR WA, 1993, RELIABILITY SAFETT H; Westrum R., 1992, VERIFICATION VALIDAT, P401; WIENER E, 1989, HUMAN FACTORS AVIATI; WRIGHT D, 1991, LANCET, V338, P676, DOI 10.1016/0140-6736(91)91243-N; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089	82	613	631	0	51	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2000	320	7237					759	763		10.1136/bmj.320.7237.759	http://dx.doi.org/10.1136/bmj.320.7237.759			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296YQ	10720361	Green Published			2022-12-28	WOS:000086054700026
J	Wiebe, S				Wiebe, S			Epilepsy: A comprehensive textbook on CD-ROM	BRITISH MEDICAL JOURNAL			English	Software Review									Univ Western Ontario, London, ON, Canada	Western University (University of Western Ontario)	Wiebe, S (corresponding author), Univ Western Ontario, London, ON, Canada.								0	1	2	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					810	810						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720392				2022-12-28	WOS:000086054700080
J	Chen, HY; Schlecht, S; Semple, TC; Hartwig, JF				Chen, HY; Schlecht, S; Semple, TC; Hartwig, JF			Thermal, catalytic, regiospecific functionalization of alkanes	SCIENCE			English	Article							BOND-DISSOCIATION ENERGIES; CARBON HYDROGEN-BONDS; C-H ACTIVATION; SATURATED-HYDROCARBONS; COMPLEXES; DEHYDROGENATION	The formation of a single product from terminal functionalization of linear alkanes from a transition metal-catalyzed reaction is reported. The rhodium complex Cp*Rh(eta(4)-C6Me6) (Cp*, C5Me5; Me, methyl) catalyzes the high-yield formation of linear alkylboranes from commercially available borane reagents under thermal conditions. These reactions now allow catalytic, regiospecific functionalization of alkanes under thermal conditions. The organoborane products are among the most versatile synthetic intermediates in chemistry and serve as convenient precursors to alcohols, amines, and other common classes of functionalized molecules.	Yale Univ, Dept Chem, New Haven, CT 06520 USA; Shell Chem, Westhollow Technol Ctr, Houston, TX 77251 USA	Yale University; Royal Dutch Shell	Hartwig, JF (corresponding author), Yale Univ, Dept Chem, POB 208107, New Haven, CT 06520 USA.							BAUNDRY D, 1983, J CHEM SOC CHEM COMM, P788; BOWYER WJ, 1989, ORGANOMETALLICS, V8, P191, DOI 10.1021/om00103a025; BROWN HC, 1975, ORGANIC SYNTHESIS BO; BURK MJ, 1987, J AM CHEM SOC, V109, P8025, DOI 10.1021/ja00260a013; Chen HY, 1999, ANGEW CHEM INT EDIT, V38, P3391, DOI 10.1002/(SICI)1521-3773(19991115)38:22<3391::AID-ANIE3391>3.0.CO;2-N; CHENIER PJ, 1992, SURVEY IND CHEM, P194; CRABTREE RH, 1985, J CHEM SOC CHEM COMM, P1651; GILBERT TM, 1985, J AM CHEM SOC, V107, P3508, DOI 10.1021/ja00298a018; HOYANO JK, 1982, J AM CHEM SOC, V104, P3723, DOI 10.1021/ja00377a032; Irvine GJ, 1998, CHEM REV, V98, P2685, DOI 10.1021/cr9500085; Iverson CN, 1999, J AM CHEM SOC, V121, P7696, DOI 10.1021/ja991258w; JANOWICZ AH, 1982, J AM CHEM SOC, V104, P352, DOI 10.1021/ja00365a091; JANOWICZ AH, 1983, J AM CHEM SOC, V105, P3929, DOI 10.1021/ja00350a031; JONES WD, 1984, J AM CHEM SOC, V106, P1650, DOI 10.1021/ja00318a018; JONES WD, 1983, ORGANOMETALLICS, V2, P562, DOI 10.1021/om00076a020; Lenges CP, 1999, J AM CHEM SOC, V121, P4385, DOI 10.1021/ja984409o; Liu FC, 1999, J AM CHEM SOC, V121, P4086, DOI 10.1021/ja983460p; MARKS TJ, 1972, J AM CHEM SOC, V94, P1542, DOI 10.1021/ja00760a018; MCMILLEN DF, 1982, ANNU REV PHYS CHEM, V33, P493, DOI 10.1146/annurev.pc.33.100182.002425; MOSELEY K, 1970, J CHEM SOC A, P2875, DOI 10.1039/j19700002875; ONAK T, 1975, ORGANOBORANE CHEM, P111; Pelter A., 1988, BORANE REAGENTS; Rablen PR, 1996, J AM CHEM SOC, V118, P4648, DOI 10.1021/ja9542451; ROSENBLUM L, 1955, J AM CHEM SOC, V77, P5016, DOI 10.1021/ja01624a023; RUIZ J, 1987, J CHEM SOC DALTON, P1963, DOI 10.1039/dt9870001963; Sakaki S, 1997, INORG CHEM, V36, P226, DOI 10.1021/ic951504e; SAKAKURA T, 1987, J CHEM SOC CHEM COMM, P758, DOI 10.1039/c39870000758; Waltz KM, 1999, ORGANOMETALLICS, V18, P3383, DOI 10.1021/om990113v; Waltz KM, 1997, SCIENCE, V277, P211, DOI 10.1126/science.277.5323.211; WENZEL TT, 1986, J AM CHEM SOC, V108, P4856, DOI 10.1021/ja00276a025; Xu WW, 1997, CHEM COMMUN, P2273, DOI 10.1039/a705105k	31	730	743	2	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1995	1997		10.1126/science.287.5460.1995	http://dx.doi.org/10.1126/science.287.5460.1995			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720320				2022-12-28	WOS:000085902800054
J	Ostermann, ME; Keenan, SP; Seiferling, RA; Sibbald, WJ				Ostermann, ME; Keenan, SP; Seiferling, RA; Sibbald, WJ			Sedation in the intensive care unit - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CRITICALLY-ILL PATIENTS; LONG-TERM SEDATION; OPEN-HEART-SURGERY; CARDIAC-SURGERY; MECHANICAL VENTILATION; COST-EFFECTIVENESS; MYOCARDIAL-ISCHEMIA; PROLONGED SEDATION; MIDAZOLAM; PROPOFOL	Context Sedation has become an integral part of critical care practice in minimizing patient discomfort; however, sedatives have adverse effects and the potential to prolong mechanical ventilation, which may increase health care costs. Objective To determine which form of sedation is associated with optimal sedation, the shortest time to extubation, and length of intensive care unit (ICU) stay. Data Sources A key word search of MEDLINE, EMBASE, and the Cochrane Collaboration databases and hand searches of 6 anesthesiology journals from 1980 to June 1998. Experts and industry representatives were contacted, personal files were searched, and reference lists of relevant primary and review articles were reviewed. Study Selection Studies included were randomized controlled trials enrolling adult patients receiving mechanical ventilation and requiring short-term or long-term sedation. At least 2 sedative agents had to be compared and the quality of sedation, time to extubation, or length of ICU stay analyzed. Data Extraction Data on population, intervention, outcome, and methodological quality were extracted in duplicate by 2 of 3 investigators using 8 validity criteria. Data Synthesis Of 49 identified randomized controlled trials, 32 met our selection criteria; 20 studied short-term sedation and 14, long-term sedation. Of these, 20 compared propofol with midazolam. Most trials were not double-blind and did not report or standardize important cointerventions. Propofol provides at least as effective sedation as midazolam and results in a faster time to extubation, with an increased risk of hypotension and higher cost. Insufficient data exist to determine effect on length of stay in the ICU. Isoflurane demonstrated some advantages over midazolam, and ketamine had a more favorable hemodynamic profile than fentanyl in patients with head injuries. Conclusion Considering the widespread use of sedation for critically ill patients, more large, high-quality, randomized controlled trials of the effectiveness of different agents for short-term and long-term sedation are warranted.	St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6M 2N8, Canada; Univ Western Ontario, Dept Med, Div Crit Care, London, ON, Canada; London Hlth Sci Ctr, Richard Ivey Crit Care Trauma Ctr, London, ON, Canada; London Hlth Sci Ctr, Dept Pharm, London, ON, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	St. Paul's Hospital; University of Saskatchewan; Western University (University of Western Ontario); London Health Sciences Centre; London Health Sciences Centre; University of British Columbia	Keenan, SP (corresponding author), St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, 620B-1081 Burrard, Vancouver, BC V6M 2N8, Canada.		Ostermann, Marlies/AAH-8160-2021; Ostermann, Marlies/B-8777-2015	Ostermann, Marlies/0000-0001-9500-9080				ADAMS HA, 1991, ANAESTHESIST, V40, P238; ADAMS HA, 1988, ANAESTHESIST, V37, P268; AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009; BERGER I, 1995, AM FAM PHYSICIAN, V51, P166; BEYER R, 1992, ANAESTHESIST, V41, P335; BOYD O, 1993, CAN J ANAESTH, V40, P1142, DOI 10.1007/BF03009603; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Carrasco G, 1998, CRIT CARE MED, V26, P844, DOI 10.1097/00003246-199805000-00015; Cernaianu AC, 1996, CRIT CARE MED, V24, P222, DOI 10.1097/00003246-199602000-00007; Chamorro C, 1996, CRIT CARE MED, V24, P932, DOI 10.1097/00003246-199606000-00010; CHAUDHRI S, 1992, BRIT J ANAESTH, V68, P98, DOI 10.1093/bja/68.1.98; COOK S, 1989, J DRUG DEV S2, V4, P65; Costa J, 1994, Clin Intensive Care, V5, P17; CRIPPEN DW, 1990, CRIT CARE CLIN, V6, P369; CRIPPEN DW, 1994, CRIT CARE CLIN, V10, P733, DOI 10.1016/S0749-0704(18)30103-9; DASTA JF, 1994, CRIT CARE MED, V22, P974, DOI 10.1097/00003246-199406000-00016; DEJONGHE B, IN PRESS INTENSIVE C; Durbin C G Jr, 1994, New Horiz, V2, P64; ENGELMAN RM, 1994, ANN THORAC SURG, V58, P1742, DOI 10.1016/0003-4975(94)91674-8; EWART MC, 1992, ANAESTHESIA, V47, P146, DOI 10.1111/j.1365-2044.1992.tb02015.x; GROUNDS RM, 1987, BRIT MED J, V294, P397, DOI 10.1136/bmj.294.6569.397; Hall RI, 1997, ANESTH ANALG, V85, P971, DOI 10.1097/00000539-199711000-00004; Hall S, 1996, CULT STUD, V10, P12, DOI 10.1080/09502389600490431; HANSENFLASCHEN JH, 1991, JAMA-J AM MED ASSOC, V266, P2870, DOI 10.1001/jama.266.20.2870; HARDING J, 1994, CHEST, V106, P194, DOI 10.1378/chest.106.1.194; HARPER SJ, 1991, EUR J ANAESTH, V8, P157; HARRIS CE, 1990, ANAESTHESIA, V45, P366, DOI 10.1111/j.1365-2044.1990.tb14777.x; Heinrichs W, 1992, Anaesthesiol Reanim, V17, P77; HEINRICHS W, 1992, ANAESTHESIOL REANIM, V17, P82; HIGGINS TL, 1994, CRIT CARE MED, V22, P1415, DOI 10.1097/00003246-199409000-00011; HILLMAN AL, 1995, ANN INTERN MED, V123, P61; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; KONG KL, 1989, BRIT MED J, V298, P1277, DOI 10.1136/bmj.298.6683.1277; KONG KL, 1990, BRIT J ANAESTH, V64, P159, DOI 10.1093/bja/64.2.159; KOVARIK WD, 1996, CLIN INTENSIVE CARE, V7, P248; Kress JP, 1996, AM J RESP CRIT CARE, V153, P1012, DOI 10.1164/ajrccm.153.3.8630539; KRESS JP, 1997, J CRIT ILLNESS, V12, P287; LEDINGHAM I M, 1988, Resuscitation, V16, pS69, DOI 10.1016/0300-9572(88)90008-1; Louvelle J M, 1995, Can J Hosp Pharm, V48, P344; Manley NM, 1997, PHARMACOECONOMICS, V12, P247, DOI 10.2165/00019053-199712020-00015; MATHEWS HML, 1987, BRIT J ANAESTH, V59, P557, DOI 10.1093/bja/59.5.557; MAZZEO AJ, 1995, CRIT CARE CLIN, V11, P937, DOI 10.1016/S0749-0704(18)30047-2; McLeod G, 1997, INTENS CARE MED, V23, P428, DOI 10.1007/s001340050352; MCMURRAY TJ, 1990, ANAESTHESIA, V45, P322, DOI 10.1111/j.1365-2044.1990.tb14743.x; MENDEL PR, 1993, INT ANESTHESIOL CLIN, V31, P185, DOI 10.1097/00004311-199331020-00012; MILLER DR, 1994, CAN J ANAESTH, V41, P782, DOI 10.1007/BF03011584; O'Connor M, 1992, Acta Anaesthesiol Belg, V43, P235; Plunkett JJ, 1997, ANESTHESIOLOGY, V86, P785, DOI 10.1097/00000542-199704000-00008; POHLMAN AS, 1994, CRIT CARE MED, V22, P1241, DOI 10.1097/00003246-199408000-00007; POLSTER MR, 1993, BRIT J ANAESTH, V70, P612, DOI 10.1093/bja/70.6.612; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; REEVE WG, 1991, CARE CRIT ILL, V7, P238; REVES JG, 1994, DRUG INFUSION SEDATI; RHONEY DH, 1998, CRIT CARE MED, V26, pA24; Roekaerts P M, 1993, J Cardiothorac Vasc Anesth, V7, P142, DOI 10.1016/1053-0770(93)90206-Z; RONAN KP, 1995, CRIT CARE MED, V23, P286, DOI 10.1097/00003246-199502000-00014; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; Searle NR, 1997, CAN J ANAESTH, V44, P629, DOI 10.1007/BF03015447; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; Sherry KM, 1996, ANAESTHESIA, V51, P312, DOI 10.1111/j.1365-2044.1996.tb07738.x; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; SNELLEN F, 1990, INTENS CARE MED, V16, P312, DOI 10.1007/BF01706356; SPENCER EM, 1992, INTENS CARE MED, V18, P415, DOI 10.1007/BF01694344; STOLTZFUS DP, 1995, CRIT CARE CLIN, V11, P903, DOI 10.1016/S0749-0704(18)30045-9; TreggiariVenzi M, 1996, INTENS CARE MED, V22, P1186, DOI 10.1007/BF01709334; TUNG A, 1995, CRIT CARE CLIN, V11, P791, DOI 10.1016/S0749-0704(18)30039-3; VINIK H R, 1991, Intensive Care Medicine, V17, pS20, DOI 10.1007/BF01731150; Wahr JA, 1996, ANESTHESIOLOGY, V84, P1350, DOI 10.1097/00000542-199606000-00011; Weinbroum AA, 1997, INTENS CARE MED, V23, P1258, DOI 10.1007/s001340050495; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WESTPHAL LM, 1987, ANESTHESIOLOGY, V67, P257, DOI 10.1097/00000542-198708000-00020; WEYLAND W, 1993, ANAESTHESIST, V42, P391; WHEELER AP, 1993, CHEST, V104, P566, DOI 10.1378/chest.104.2.566; YATE PM, 1986, BRIT J ANAESTH, V58, P1091, DOI 10.1093/bja/58.10.1091	76	255	267	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2000	283	11					1451	1459		10.1001/jama.283.11.1451	http://dx.doi.org/10.1001/jama.283.11.1451			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290UR	10732935	Bronze			2022-12-28	WOS:000085696700030
J	Chen, IW; Wang, XH				Chen, IW; Wang, XH			Sintering dense nanocrystalline ceramics without final-stage grain growth	NATURE			English	Article							OXIDE POWDERS; ALUMINA	Sintering is the process whereby interparticle pores in a granular material are eliminated by atomic diffusion driven by capillary forces. It is the preferred manufacturing method for industrial ceramics. The observation of Burke and Coble(1,2) that certain crystalline granular solids could gain full density and translucency by solid-state sintering was an important milestone for modern technical ceramics. But these final-stage sintering processes are always accompanied by rapid grain growth(3,6), because the capillary driving forces for sintering (involving surfaces) and grain growth (involving grain boundaries) are comparable in magnitude, both being proportional to the reciprocal grain size. This has greatly hampered efforts to produce dense materials with nanometre-scale structure (grain size less than 100 nm)(4,8), leading many researchers to resort to the 'brute force' approach of high-pressure consolidation at elevated temperatures(7-9). Here we show that fully dense cubic Y2O3 (melting point, 2,439 degrees C) with a grain size of 60 nm can be prepared by a simple two-step sintering method, at temperatures of about 1,000 degrees C without applied pressure. The suppression of the final-stage grain growth is achieved by exploiting the difference in kinetics between grain-boundary diffusion and grain-boundary migration. Such a process should facilitate the cost-effective preparation of other nanocrystalline materials for practical applications.	Univ Penn, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA	University of Pennsylvania	Chen, IW (corresponding author), Univ Penn, Dept Mat Sci & Engn, 3231 Walnut St, Philadelphia, PA 19104 USA.			Chen, I-Wei/0000-0002-4045-4467				ARZT E, 1983, ACTA METALL MATER, V31, P1977, DOI 10.1016/0001-6160(83)90015-9; Brook R. J., 1976, TREATISE MATERIALS S, P331; CAMERON CP, 1988, J AM CERAM SOC, V71, P1031, DOI 10.1111/j.1151-2916.1988.tb05787.x; CANNON RM, 1980, J AM CERAM SOC, V63, P48; CHEN IW, 1990, J AM CERAM SOC, V73, P2585, DOI 10.1111/j.1151-2916.1990.tb06734.x; Chen PL, 1996, J AM CERAM SOC, V79, P1801, DOI 10.1111/j.1151-2916.1996.tb07998.x; Chen PL, 1996, J AM CERAM SOC, V79, P3129, DOI 10.1111/j.1151-2916.1996.tb08087.x; Chen PL, 1997, J AM CERAM SOC, V80, P637, DOI 10.1111/j.1151-2916.1997.tb02879.x; Coble R. L., 1984, ADV CERAM, V10, P839; COBLE RL, 1961, J APPL PHYS, V32, P787, DOI 10.1063/1.1736107; COBLE RL, 1963, PROGR CERAMIC SCI, V3, P197; COBLE RL, 1978, MATER SCI RES, V11, P151; Czubayko U, 1998, ACTA MATER, V46, P5863, DOI 10.1016/S1359-6454(98)00241-9; GLEITER H, 1989, PROG MATER SCI, V33, P223, DOI 10.1016/0921-5093(89)90083-X; HANSEN JD, 1992, J AM CERAM SOC, V75, P1129, DOI 10.1111/j.1151-2916.1992.tb05549.x; HERRING C, 1950, J APPL PHYS, V21, P301, DOI 10.1063/1.1699658; KINGERY WD, 1967, SINTERING RELATED PH, P471; Klein S, 1998, CHEM VAPOR DEPOS, V4, P143, DOI 10.1002/(SICI)1521-3862(199807)04:04<143::AID-CVDE143>3.0.CO;2-Z; KUMAR KNP, 1992, NATURE, V358, P48, DOI 10.1038/358048a0; Land TA, 1999, NATURE, V399, P442, DOI 10.1038/20886; Liao SC, 1998, NANOSTRUCT MATER, V10, P1063, DOI 10.1016/S0965-9773(98)00125-1; Mayo MJ, 1996, INT MATER REV, V41, P85, DOI 10.1179/095066096790326039; McFadden SX, 1999, NATURE, V398, P684, DOI 10.1038/19486; WAKAI F, 1990, NATURE, V344, P421, DOI 10.1038/344421a0; ZHAO J, 1987, J AM CERAM SOC, V70, P860, DOI 10.1111/j.1151-2916.1987.tb04906.x	25	1120	1180	32	892	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					168	171		10.1038/35004548	http://dx.doi.org/10.1038/35004548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724165				2022-12-28	WOS:000085870900046
J	Reichhardt, T				Reichhardt, T			Funding woes spell doom for US radio dish	NATURE			English	News Item																		Macilwain C, 1996, NATURE, V384, P505, DOI 10.1038/384505a0	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					7	7		10.1038/35003724	http://dx.doi.org/10.1038/35003724			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716416	Bronze			2022-12-28	WOS:000085775100012
J	Roy, D; Talajic, M; Dorian, P; Connolly, S; Eisenberg, MJ; Green, M; Kus, T; Lambert, J; Dubuc, M; Gagne, P; Nattel, S; Thibault, B				Roy, D; Talajic, M; Dorian, P; Connolly, S; Eisenberg, MJ; Green, M; Kus, T; Lambert, J; Dubuc, M; Gagne, P; Nattel, S; Thibault, B		Canadian Trial Atrial Fibrillation	Amiodarone to prevent recurrence of atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE AMIODARONE; ANTIARRHYTHMIC DRUG-THERAPY; SINUS RHYTHM; ELECTRICAL CARDIOVERSION; FLUTTER; MAINTENANCE; PROPAFENONE; FLECAINIDE; SUPPRESSION; QUINIDINE	Background: The restoration and maintenance of sinus rhythm is a desirable goal in patients with atrial fibrillation, because the prevention of recurrences can improve cardiac function and relieve symptoms. Uncontrolled studies have suggested that amiodarone in low doses may be more effective and safer than other agents in preventing recurrence, but this agent has not been tested in a large, randomized trial. Methods: We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone. We randomly assigned patients who had had at least one episode of atrial fibrillation within the previous six months to amiodarone or to sotalol or propafenone, given in an open-label fashion. The patients in the group assigned to sotalol or propafenone underwent a second randomization to determine whether they would receive sotalol or propafenone first; if the first drug was unsuccessful the second agent was prescribed. Loading doses of the drugs were administered and electrical cardioversion was performed (if necessary) within 21 days after randomization for all patients in both groups. The follow-up period began 21 days after randomization. The primary end point was the length of time to a first recurrence of atrial fibrillation. Results: Of the 403 patients in the study, 201 were assigned to amiodarone and 202 to either sotalol (101 patients) or propafenone (101 patients). After a mean of 16 months of follow-up, 71 of the patients who were assigned to amiodarone (35 percent) and 127 of those who were assigned to sotalol or propafenone (63 percent) had a recurrence of atrial fibrillation (P<0.001). Adverse events requiring the discontinuation of drug therapy occurred in 18 percent of the patients receiving amiodarone, as compared with 11 percent of those treated with sotalol or propafenone (P=0.06). Conclusions: Amiodarone is more effective than sotalol or propafenone for the prevention of recurrences of atrial fibrillation. (N Engl J Med 2000;342:913-20.) (C) 2000, Massachusetts Medical Society.	Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; McMaster Univ, Hamilton, ON, Canada; Hamilton Gen Hosp, Hamilton, ON, Canada; Univ Ottawa, Inst Heart, Ottawa, ON, Canada; Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada	Universite de Montreal; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster University; McMaster University; University of Ottawa; University of Ottawa Heart Institute; Universite de Montreal	Roy, D (corresponding author), Montreal Heart Inst, 5000 Belanger St E, Montreal, PQ H1T 1C8, Canada.	roy@icm.umontreal.ca		Nattel, Stanley/0000-0002-5565-3311; Talajic, Mario/0000-0001-8469-4748				ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; [Anonymous], 1994, ARCH INTERN MED, V154, P2254; ANTMAN EM, 1988, J AM COLL CARDIOL, V12, P1005, DOI 10.1016/0735-1097(88)90468-8; ANTMAN EM, 1989, J AM COLL CARDIOL, V13, P264; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; CHUN SH, 1995, AM J CARDIOL, V76, P47, DOI 10.1016/S0002-9149(99)80799-1; Collaborative Group for Amiodarone Evaluation, 1984, AM J CARDIOL, V53, P1564; Connolly SJ, 1997, LANCET, V350, P1417; CONNOLLY SJ, 1989, AM J CARDIOL, V63, P817, DOI 10.1016/0002-9149(89)90049-0; COPLEN SE, 1991, CIRCULATION, V83, P714; COX DR, 1972, J R STAT SOC B, V34, P187; DETHY M, 1988, AM J CARDIOL, V62, P723, DOI 10.1016/0002-9149(88)91210-6; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; GOSSELINK ATM, 1994, BRIT HEART J, V72, P161; GOSSELINK ATM, 1992, JAMA-J AM MED ASSOC, V267, P3289, DOI 10.1001/jama.267.24.3289; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; Kochiadakis GE, 1998, AM J CARDIOL, V81, P995, DOI 10.1016/S0002-9149(98)00078-2; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEWIS RV, 1988, EUR HEART J, V9, P777, DOI 10.1093/eurheartj/9.7.777; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASON JW, 1987, NEW ENGL J MED, V316, P455; MIDDLEKAUFF HR, 1993, AM J CARDIOL, V72, pF75, DOI 10.1016/0002-9149(93)90967-H; MORRIS JJ, 1965, CIRCULATION, V31, P670, DOI 10.1161/01.CIR.31.5.670; Naccarelli GV, 1996, AM J CARDIOL, V77, pA53, DOI 10.1016/S0002-9149(97)89118-7; NATTEL S, 1994, DRUGS, V48, P345, DOI 10.2165/00003495-199448030-00003; PRITCHETT ELC, 1991, ANN INTERN MED, V114, P539, DOI 10.7326/0003-4819-114-7-539; PRITCHETT ELC, 1992, NEW ENGL J MED, V326, P1264; RAEDER EA, 1985, AM HEART J, V109, P975, DOI 10.1016/0002-8703(85)90238-8; REIMOLD SC, 1993, AM J CARDIOL, V71, P558, DOI 10.1016/0002-9149(93)90511-A; Roy D, 1997, AM J CARDIOL, V80, P464, DOI 10.1016/S0002-9149(97)00396-2; SHAPIRO W, 1968, CIRCULATION, V38, P1074, DOI 10.1161/01.CIR.38.6.1074; Talajic M, 1996, Can J Cardiol, V12 Suppl A, p29A; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; VANGELDER IC, 1991, AM J CARDIOL, V68, P41, DOI 10.1016/0002-9149(91)90707-R; VANGELDER IC, 1989, AM J CARDIOL, V64, P1317, DOI 10.1016/0002-9149(89)90574-2; VITOLO E, 1981, ACTA CARDIOL, V36, P431; Vorperian VR, 1997, J AM COLL CARDIOL, V30, P791, DOI 10.1016/S0735-1097(97)00220-9; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; ZAREMBSKI DG, 1995, ARCH INTERN MED, V155, P1885, DOI 10.1001/archinte.155.17.1885	42	801	852	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	2000	342	13					913	920		10.1056/NEJM200003303421302	http://dx.doi.org/10.1056/NEJM200003303421302			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DC	10738049				2022-12-28	WOS:000086179700002
J	Brenner, S				Brenner, S			Genomics - The end of the beginning	SCIENCE			English	Editorial Material									Inst Mol Sci, Berkeley, CA 94704 USA	The Molecular Sciences Institute	Brenner, S (corresponding author), Inst Mol Sci, Berkeley, CA 94704 USA.	brenner@molsci.org						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204	3	34	34	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2173	2174		10.1126/science.287.5461.2173	http://dx.doi.org/10.1126/science.287.5461.2173			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10744539				2022-12-28	WOS:000086049100028
J	Buchthal, SD; den Hollander, JA; Merz, CNB; Rogers, WJ; Pepine, CJ; Reichek, N; Sharaf, BL; Reis, S; Kelsey, SF; Pohost, GM				Buchthal, SD; den Hollander, JA; Merz, CNB; Rogers, WJ; Pepine, CJ; Reichek, N; Sharaf, BL; Reis, S; Kelsey, SF; Pohost, GM			Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GRADED REGIONAL ISCHEMIA; ARTERY DISEASE; PHOSPHATE-METABOLISM; ANGINA-PECTORIS; SYNDROME-X; EXERCISE; INVIVO	Background: After hospitalization for chest pain, women are more likely than men to have normal coronary angiograms. In such women, myocardial ischemia in the absence of clinically significant coronary-artery obstruction has long been suspected. Most methods for the detection of the metabolic effects of myocardial ischemia are highly invasive. Phosphorus-31 nuclear magnetic resonance (P-31-NMR) spectroscopy is a noninvasive technique that can directly measure high-energy phosphates in the myocardium and identify metabolic evidence of ischemia. Methods: We enrolled 35 women who were hospitalized for chest pain but who had no angiographically significant coronary-artery obstructions and 12 age- and weight-matched control women with no evidence of heart disease. Myocardial high-energy phosphates were measured with P-31-NMR spectroscopy at 1.5 tesla before, during, and after isometric handgrip exercise at a level that was 30 percent of the maximal voluntary grip strength. We measured the change in the ratio of phosphocreatine to ATP during exercise. Results: Seven (20 percent) of the 35 women with chest pain and no angiographically significant stenosis had decreases in the phosphocreatine:ATP ratio during handgrip that were more than 2 SD below the mean value in the control subjects without chest pain. There were no significant differences between the two groups with respect to hemodynamic variables at rest and during handgrip, risk factors for ischemic heart disease, findings on magnetic resonance imaging and radionuclide perfusion studies of the heart, or changes in brachial flow during the infusion of acetylcholine. Conclusions: Our results provide direct evidence of an abnormal metabolic response to handgrip exercise in at least some women with chest pain consistent with the occurrence of myocardial ischemia but no angiographically significant coronary stenoses. (N Engl J Med 2000;342:829-35.) (C)2000, Massachusetts Medical Society.	Univ Alabama, Ctr Nucl Magnet Resonance Res & Dev, Birmingham, AL 35294 USA; Univ Alabama, Div Cardiovasc Dis, Dept Med, Birmingham, AL 35294 USA; Cedars Sinai Med Ctr, Cedars Sinai Res Inst, Dept Med, Div Cardiol, Los Angeles, CA 90048 USA; Univ Florida, Dept Med, Div Cardiol, Gainesville, FL USA; Allegheny Univ Hlth Sci, Dept Med, Div Cardiol, Pittsburgh, PA USA; Rhode Isl Hosp, Div Cardiol, Providence, RI USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Med, Div Cardiol, Pittsburgh, PA USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Cedars Sinai Medical Center; State University System of Florida; University of Florida; Lifespan Health Rhode Island; Rhode Island Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pohost, GM (corresponding author), Univ Alabama, Ctr Nucl Magnet Resonance Res & Dev, 828 8th Ct S, Birmingham, AL 35294 USA.			Reis, Steven/0000-0001-8023-0102	NHLBI NIH HHS [N01-HV-68163, N01-HV-68161, N01-HV-68162] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV068161, N01HV068163, N01HV068162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOTTOMLEY PA, 1987, RADIOLOGY, V165, P703, DOI 10.1148/radiology.165.3.2961004; CAMICI P, 1991, CIRCULATION, V83, P8; CRAKE T, 1988, BRIT HEART J, V59, P31; DAVIS KB, 1995, J AM COLL CARDIOL, V25, P1000, DOI 10.1016/0735-1097(94)00518-U; EGASHIRA K, 1993, NEW ENGL J MED, V328, P1659, DOI 10.1056/NEJM199306103282302; EGASHIRA K, 1993, J CLIN INVEST, V91, P29, DOI 10.1172/JCI116183; FLAHERTY JT, 1982, CIRCULATION, V65, P561, DOI 10.1161/01.CIR.65.3.561; GREENBERG MA, 1987, J AM COLL CARDIOL, V9, P743, DOI 10.1016/S0735-1097(87)80227-9; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hasdai D, 1997, CIRCULATION, V96, P3390; KASKI JC, 1995, J AM COLL CARDIOL, V25, P807, DOI 10.1016/0735-1097(94)00507-M; Kemp H G, 1967, Trans Assoc Am Physicians, V80, P59; LIKOFF W, 1967, NEW ENGL J MED, V276, P1063, DOI 10.1056/NEJM196705112761904; Merz CNB, 1999, J AM COLL CARDIOL, V33, P1453; NEUBAUER S, 1992, CIRCULATION, V86, P1810, DOI 10.1161/01.CIR.86.6.1810; NUNNALLY RL, 1981, SCIENCE, V211, P177, DOI 10.1126/science.7444460; OUYYUMI AA, 1992, CIRCULATION, V86, P1864; PAPANICOLAOU MN, 1986, AM J CARDIOL, V58, P1181, DOI 10.1016/0002-9149(86)90378-4; SCHAEFER S, 1989, CIRC RES, V64, P968, DOI 10.1161/01.RES.64.5.968; SCHAEFER S, 1990, J CLIN INVEST, V85, P706, DOI 10.1172/JCI114495; VANDEBOS A, 1982, HDB MEASUREMENT SCI, V1; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; YABE T, 1994, CIRCULATION, V89, P1709, DOI 10.1161/01.CIR.89.4.1709	23	278	292	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	2000	342	12					829	835		10.1056/NEJM200003233421201	http://dx.doi.org/10.1056/NEJM200003233421201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296FU	10727587				2022-12-28	WOS:000086014100001
J	Loder, N				Loder, N			Northern lobby attacks UK synchrotron siting	NATURE			English	News Item																		2000, NATURE, V404, P221	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					323	323		10.1038/35006234	http://dx.doi.org/10.1038/35006234			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746693	Bronze			2022-12-28	WOS:000086119000011
J	Robinson, RG				Robinson, RG			An 82-year-old woman with mood changes following a stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENERALIZED ANXIETY DISORDER; POSTSTROKE DEPRESSION; CEREBROVASCULAR LESIONS; LOCATION; RECOVERY; CITALOPRAM; PREVALENCE; VALIDATION; MORTALITY; FREQUENCY		Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA	University of Iowa	Robinson, RG (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA.		Robinson, Robert/AAF-6191-2021		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053592, R01MH052879, R01MH040355] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-52879, MH53592, MH-40355] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSEN G, 1994, STROKE, V25, P1099, DOI 10.1161/01.STR.25.6.1099; ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; Astrom M, 1996, STROKE, V27, P270, DOI 10.1161/01.STR.27.2.270; ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; BURVILL PW, 1995, BRIT J PSYCHIAT, V166, P320, DOI 10.1192/bjp.166.3.320; CASTILLO CS, 1993, J NERV MENT DIS, V181, P100, DOI 10.1097/00005053-199302000-00005; COHENCOLE SA, 1993, DEPRESSION, V2, P281; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DAM H, 1989, ACTA PSYCHIAT SCAND, V80, P118, DOI 10.1111/j.1600-0447.1989.tb01312.x; EASTWOOD MR, 1989, BRIT J PSYCHIAT, V154, P195, DOI 10.1192/bjp.154.2.195; EYSENDE HJ, 1964, MANUAL EYSENCK PERSO; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; Gainotti G, 1999, BRIT J PSYCHIAT, V175, P163, DOI 10.1192/bjp.175.2.163; HERRMANN M, 1993, J NEUROL NEUROSUR PS, V56, P672, DOI 10.1136/jnnp.56.6.672; HIBBARD MR, 1990, BEHAV THERAPIST, V13, P15; HOUSE A, 1990, BRAIN, V113, P1113, DOI 10.1093/brain/113.4.1113; LIPSEY JR, 1984, LANCET, V1, P297; LIPSEY JR, 1983, BRIT J PSYCHIAT, V143, P266, DOI 10.1192/bjp.143.3.266; MAYBERG HS, 1988, AM J PSYCHIAT, V145, P937; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; MORRIS PLP, 1992, MED J AUSTRALIA, V157, P239, DOI 10.5694/j.1326-5377.1992.tb137126.x; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P601, DOI 10.3109/00048679309075822; Morris PLP, 1996, J NEUROPSYCH CLIN N, V8, P399; MORRIS PLP, 1993, AM J PSYCHIAT, V150, P124; MORRIS PLP, 1990, INT J PSYCHIAT MED, V20, P349, DOI 10.2190/N8VU-6LWU-FLJN-XQKV; MORRIS PLP, 1992, AUST NZ J PSYCHIAT, V26, P208, DOI 10.3109/00048679209072029; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P443, DOI 10.3109/00048679309075801; ORADEI DM, 1974, AM J ORTHOPSYCHIAT, V44, P386, DOI 10.1111/j.1939-0025.1974.tb00891.x; Paradiso S, 1997, INT J PSYCHIAT MED, V27, P137, DOI 10.2190/BWJA-KQP3-7VUY-D06T; Paradiso S, 1999, AM J GERIAT PSYCHIAT, V7, P244, DOI 10.1097/00019442-199908000-00009; PARIKH RM, 1990, ARCH NEUROL-CHICAGO, V47, P785, DOI 10.1001/archneur.1990.00530070083014; Pohjasvaara T, 1998, STROKE, V29, P2311, DOI 10.1161/01.STR.29.11.2311; Rabins P V, 1991, J Neuropsychiatry Clin Neurosci, V3, P6; REDING MJ, 1986, ARCH NEUROL-CHICAGO, V43, P763, DOI 10.1001/archneur.1986.00520080011011; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; ROBINSON RG, 1979, SCIENCE, V205, P707, DOI 10.1126/science.462179; Robinson RG, 1999, J GERIATR PSYCH NEUR, V12, P128, DOI 10.1177/089198879901200306; Robinson RG., 1998, CLIN NEUROPSYCHIATRY; ROBINSON RG, IN PRESS AM J PSYCHI; SCHWEIZER E, 1990, J CLIN PSYCHIAT, V51, P8; Shimoda K, 1999, BIOL PSYCHIAT, V45, P187, DOI 10.1016/S0006-3223(98)00178-4; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STARKSTEIN SE, 1993, J NEUROPSYCH CLIN N, V5, P189	47	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2000	283	12					1607	1614		10.1001/jama.283.12.1607	http://dx.doi.org/10.1001/jama.283.12.1607			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293MV	10735399				2022-12-28	WOS:000085857300039
J	Espinosa, JA; Nolan, TW				Espinosa, JA; Nolan, TW			Reducing errors made by emergency physicians in interpreting radiographs: longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							RADIOLOGISTS	Objectives To reduce errors made in the interpretation of radiographs in an emergency department. Design Longitudinal study. Setting Hospital emergency department. Interventions All staff reviewed all clinically significant discrepancies at monthly meetings. A file of clinically significant errors was created; the file was used for teaching. Later a team redesigned the process. A system was developed for interpreting radiographs that would be followed regardless of the day of the week or time of day. All standard radiographs were brought directly to the emergency physician for immediate interpretation. Radiologists reviewed the films within 12 hours as a quality control measure, and if a significant misinterpretation was found patients were asked to return. Main outcome measures Reduction in number of clinically significant errors (such as missed fractures or foreign bodies) on radiographs read in the emergency department. Data on the error rate for radiologists and the effect of the recall procedure were not available so reliability modelling was used to assess the effect of these on overall safety. Results After the initial improvements the rate of false negative errors fell from 3% (95% confidence interval 2.8% to 3.2%)to 1.2% (1.03% to 1.37%). After the processes were redesigned it fell further to 0.3% (0.26% to 0.34%). Reliability modelling showed that die number of potential adverse effects per 1000 cases fell from 19 before the improvements to-3 afterwards and unmitigated adverse effects fell from 2.2/1000 before to 0.16/1000 afterwards, assuming 95% success in calling patients back. Conclusion Systems of radiograph interpretation that optimise the skills of an clinicians involved and contain reliable processes for mitigating errors can reduce error rates substantially.	Atlantic Hlth Syst, Overlook Hosp, Dept Emergency Med, Summit, NJ 07902 USA; Associates Proc Improvement, Silver Spring, MD 20910 USA	Atlantic Health System	Espinosa, JA (corresponding author), Atlantic Hlth Syst, Overlook Hosp, Dept Emergency Med, 99 Beauvoir Ave, Summit, NJ 07902 USA.							Berwick DM, 1996, BRIT MED J, V312, P619, DOI 10.1136/bmj.312.7031.619; FASTOW JS, 1986, AM COLL EMERGENCY PH; FLEISHER G, 1983, ANN EMERG MED, V12, P153, DOI 10.1016/S0196-0644(83)80557-5; George J E, 1992, Emerg Med Clin North Am, V10, P179; Lufkin KC, 1998, ANN EMERG MED, V31, P202, DOI 10.1016/S0196-0644(98)70307-5; Nolan TW, 2000, BMJ-BRIT MED J, V320, P771, DOI 10.1136/bmj.320.7237.771; OLEARY MR, 1988, ANN EMERG MED, V17, P1019, DOI 10.1016/S0196-0644(88)80438-4; Preston CA, 1998, AM J EMERG MED, V16, P160, DOI 10.1016/S0735-6757(98)90036-5; RHEA JT, 1979, RADIOLOGY, V132, P277, DOI 10.1148/132.2.277; Robinson PJA, 1999, BRIT J RADIOL, V72, P323, DOI 10.1259/bjr.72.856.10474490; SCOTT WW, 1995, RADIOLOGY, V195, P223, DOI 10.1148/radiology.195.1.7892474; TRAUTLEIN JJ, 1984, ANN EMERG MED, V13, P709, DOI 10.1016/S0196-0644(84)80733-7; Ushakov IA, 1994, HDB RELIABILITY ENG	13	116	117	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					737	740		10.1136/bmj.320.7237.737	http://dx.doi.org/10.1136/bmj.320.7237.737			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720354	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000086054700019
J	Gibbs, JB				Gibbs, JB			Mechanism-based target identification and drug discovery in cancer research	SCIENCE			English	Review							ANTICANCER DRUGS; PACLITAXEL; APOPTOSIS	Cancer as a disease in the human population is becoming a Larger health problem, and the medicines used as treatments have clear Limitations. In the past 20 years, there has been a tremendous increase in our knowledge of the molecular mechanisms and pathophysiology of human cancer. Many of these mechanisms have been exploited as new targets for drug development in the hope that they will have greater antitumor activity with Less toxicity to the patient than is seen with currently used medicines. The fruition of these efforts in the clinic is just now being realized with a few encouraging results.	Merck Res Labs, Dept Canc Res, West Point, PA 19486 USA	Merck & Company	Gibbs, JB (corresponding author), Merck Res Labs, Dept Canc Res, West Point, PA 19486 USA.	jay_gibbs@merck.com						Baselga J, 1998, CANCER RES, V58, P2825; Beckett RP, 1998, EXPERT OPIN THER PAT, V8, P259, DOI 10.1517/13543776.8.3.259; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Boschelli Diane H., 1999, Drugs of the Future, V24, P515, DOI 10.1358/dof.1999.024.05.858622; Chabner BA, 1996, GOODMAN GILMANS PHAR, P1233; Cotter Finbarr E., 1999, Seminars in Hematology, V36, P9; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Ewer MS, 1999, SEMIN ONCOL, V26, P96; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gescher A, 1998, GEN PHARMACOL, V31, P721, DOI 10.1016/S0306-3623(98)00069-X; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Goldenberg MM, 1999, CLIN THER, V21, P309, DOI 10.1016/S0149-2918(00)88288-0; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hamby JM, 1999, PHARMACOL THERAPEUT, V82, P169, DOI 10.1016/S0163-7258(98)00053-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Heimbrook David C., 1997, P35; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Holmlund JT, 1999, CURR OPIN MOL THER, V1, P372; Jordan VC, 1999, TRENDS ENDOCRIN MET, V10, P312, DOI 10.1016/S1043-2760(99)00181-2; Kaelin WG, 1999, J CLIN INVEST, V104, P1503, DOI 10.1172/JCI8888; Kelloff GJ, 1999, EUR J CANCER, V35, P1755, DOI 10.1016/S0959-8049(99)00164-1; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Leonard Daniele M., 1999, Drugs of the Future, V24, P1099, DOI 10.1358/dof.1999.024.10.858630; Levenson AS, 1999, EUR J CANCER, V35, P1628, DOI 10.1016/S0959-8049(99)00183-5; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; McCormick F, 1999, CANCER J SCI AM, V5, P139; McDonnell DP, 1999, TRENDS ENDOCRIN MET, V10, P301, DOI 10.1016/S1043-2760(99)00177-0; Moyer JD, 1997, CANCER RES, V57, P4838; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OATES JA, 1996, GOODMAN GILMANS PHAR, P780; Ojima I, 1999, P NATL ACAD SCI USA, V96, P4256, DOI 10.1073/pnas.96.8.4256; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Perkins Archibald S., 1997, P79; Sawyer TK, 1998, BIOPOLYMERS, V47, P243, DOI 10.1002/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Shak S, 1999, SEMIN ONCOL, V26, P71; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; Vogel C L, 1999, Oncologist, V4, P17; Williams TM, 1999, EXPERT OPIN THER PAT, V9, P1263, DOI 10.1517/13543776.9.9.1263	52	380	413	0	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2000	287	5460					1969	1973		10.1126/science.287.5460.1969	http://dx.doi.org/10.1126/science.287.5460.1969			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720316				2022-12-28	WOS:000085902800048
J	Alsdorf, DE; Melack, JM; Dunne, T; Mertes, LAK; Hess, LL; Smith, LC				Alsdorf, DE; Melack, JM; Dunne, T; Mertes, LAK; Hess, LL; Smith, LC			Interferometric radar measurements of water level changes on the Amazon flood plain	NATURE			English	Article							SYNTHETIC-APERTURE RADAR; ICE-SHEET MOTION; LANDERS EARTHQUAKE; INUNDATION AREA; RIVER; SAR; CALIFORNIA; VEGETATION; HYDROLOGY; BRAZIL	Measurements of water levels in the main channels of rivers, upland tributaries and floodplain lakes are necessary for understanding flooding hazards, methane production, sediment transport and nutrient exchange. But most remote river basins have only a few gauging stations and these tend to be restricted to large river channels. Although radar remote sensing techniques using interferometric phase measurements have the potential to greatly improve spatial sampling, the phase is temporally incoherent over open water and has therefore not been used to determine water levels. Here we use interferometric synthetic aperture radar (SAR) data(1-3), acquired over the central Amazon by the Space Shuttle imaging radar mission(4), to measure subtle water level changes in an area of flooded vegetation on the Amazon flood plain. The technique makes use of the fact that flooded forests and floodplain lakes with emergent shrubs permit radar double-bounce returns from water and vegetation surfaces(5,6), thus allowing coherence to be maintained. Our interferometric phase observations show decreases in water levels of 7-11 cm per day for tributaries and lakes within similar to 20 km of a main channel and 2-5 cm per day at distances of similar to 80 km. Proximal floodplain observations are in close agreement with main-channel gauge records, indicating a rapid response of the flood plain to decreases in river stage. With additional data from future satellite missions, the technique described here should provide direct observations important for understanding flood dynamics and hydrologic exchange between rivers and flood plains.	Univ Calif Santa Barbara, Inst Computat Earth Syst Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Donald Bren Sch Environm Sci & Management, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Geog, Santa Barbara, CA 93106 USA; Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Los Angeles	Alsdorf, DE (corresponding author), Univ Calif Santa Barbara, Inst Computat Earth Syst Sci, Santa Barbara, CA 93106 USA.		Dunne, Thomas/B-6374-2014; Smith, Laurence C./E-7785-2012	Dunne, Thomas/0000-0002-5281-6517; Smith, Laurence C./0000-0001-6866-5904				Birkett CM, 1995, J GEOPHYS RES-OCEANS, V100, P25179, DOI 10.1029/95JC02125; Birkett CM, 1998, WATER RESOUR RES, V34, P1223, DOI 10.1029/98WR00124; Burgmann R, 1998, GEOLOGY, V26, P559, DOI 10.1130/0091-7613(1998)026<0559:SATHFC>2.3.CO;2; Dunne T, 1998, GEOL SOC AM BULL, V110, P450, DOI 10.1130/0016-7606(1998)110<0450:EOSBTF>2.3.CO;2; GOLDSTEIN RM, 1993, SCIENCE, V262, P1525, DOI 10.1126/science.262.5139.1525; HESS LL, 1995, IEEE T GEOSCI REMOTE, V33, P896, DOI 10.1109/36.406675; Joughin I, 1996, J GLACIOL, V42, P564, DOI 10.3189/S0022143000003543; LESACK LFW, 1995, WATER RESOUR RES, V31, P329, DOI 10.1029/94WR02271; LI FK, 1990, IEEE T GEOSCI REMOTE, V28, P88, DOI 10.1109/36.45749; MASSONNET D, 1993, IEEE T GEOSCI REMOTE, V31, P455, DOI 10.1109/36.214922; MASSONNET D, 1993, NATURE, V364, P138, DOI 10.1038/364138a0; MELACK IM, IN PRESS BIOGEOCHEMI; MERTES LAK, 1995, GEOMORPHOLOGY, V13, P215, DOI 10.1016/0169-555X(95)00038-7; Mertes LAK, 1997, WATER RESOUR RES, V33, P1749, DOI 10.1029/97WR00658; PELTZER G, 1995, SCIENCE, V268, P1333, DOI 10.1126/science.268.5215.1333; RICHEY JE, 1989, CYCLES, V3, P191, DOI DOI 10.1029/GB003I003P00191; Rignot E, 1996, GEOPHYS RES LETT, V23, P993, DOI 10.1029/96GL00456; Rignot EJ, 1997, SCIENCE, V276, P934, DOI 10.1126/science.276.5314.934; ROSEN PA, 1996, J GEOPHYS RES, V101, P2309; Sippel SJ, 1998, INT J REMOTE SENS, V19, P3055, DOI 10.1080/014311698214181; Smith LC, 1997, HYDROL PROCESS, V11, P1427, DOI 10.1002/(SICI)1099-1085(199708)11:10&lt;1427::AID-HYP473&gt;3.0.CO;2-S; STOFAN ER, 1995, IEEE T GEOSCI REMOTE, V33, P817, DOI 10.1109/36.406668; Wang Y, 1995, REMOTE SENS ENVIRON, V54, P324, DOI 10.1016/0034-4257(95)00140-9; Wicks C, 1998, SCIENCE, V282, P458, DOI 10.1126/science.282.5388.458; Zebker HA, 1996, GEOLOGY, V24, P495, DOI 10.1130/0091-7613(1996)024<0495:AOALFO>2.3.CO;2; ZEBKER HA, 1992, IEEE T GEOSCI REMOTE, V30, P950, DOI 10.1109/36.175330; ZEBKER HA, 1994, J GEOPHYS RES-SOL EA, V99, P19617, DOI 10.1029/94JB01179	27	227	240	6	86	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					174	177		10.1038/35004560	http://dx.doi.org/10.1038/35004560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724167				2022-12-28	WOS:000085870900048
J	Feikema, SM; Klevens, RM; Washington, ML; Barker, L				Feikema, SM; Klevens, RM; Washington, ML; Barker, L			Extraimmunization among US children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD IMMUNIZATION; IMPACT	Context Little is known about the extent of extraimmunization, ie, vaccine doses given in excess of the recommended, schedule, and whether it should be a public health concern. Objectives To determine the extent and cost of extraimmunization in children and to identify its associated factors. Design, Setting, and Participants United States 1997 National Immunization Survey, in which telephone interviews were conducted with parents of 32 742 19- to 35-month-old children and vaccination histories were collected from health care providers for 22 806 of these children (overall response rate, 68.5%). Estimates were weighted to represent the full sample. Main outcome Measures Frequency of extraimmunization compared by vaccine type as well as with adequate immunization; factors associated with extraimmunization; and vaccine and visit costs associated with extraimmunization. Results Frequency of extraimmunization was less than 5% for each vaccine considered except poliovirus (14.1%). Overall, 21 % of children were extraimmunized for at least 1 vaccine vs 31 % underimmunized for at least 1 vaccine. in a multivariate model, the strongest contributors to extraimmunization were having more than 1 immunization provider (odds ratio [OR], 2.8; 95% confidence interval [CI], 2.4-3.2) and having multiple types of providers (eg, private and public health department, OR, 2.0; 95% CI, 1.6-2.4). Children seen only in public health department clinics were significantly less likely to be extraimmunized (OR, 0.3; 95% CI, 0.2-0.3). Annual costs associated with extraimmunization for this cohort of children were estimated conservatively at $26.5 million. Conclusions These data indicate that extraimmunization can be costly, The challenge is to reduce extraimmunization without interfering with more important efforts to combat underimmunization. Improvements in immunization record keeping and sharing practices may help reduce extraimmunization.	Ctr Dis Control & Prevent, Med Management Dept, Childrens Healthcare Atlanta, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Assessment Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Stat Anal Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Data Management Div, Natl Immunizat Program, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Children's Healthcare of Atlanta (CHOA); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Klevens, RM (corresponding author), Ctr Dis Control & Prevent, Med Management Dept, Childrens Healthcare Atlanta, Mailstop E-62,1600 Clifton Rd, Atlanta, GA 30333 USA.	rmk2@cdc.gov						*ADV COMM IMM PRAC, 1996, MMWR-MORBID MORTAL W, V45, P1; *ADV COMM IMM PRAC, 1994, MMWR-MORBID MORTAL W, V43, P29; Advisory Committee on Immunization Practices, 1991, MMWR-MORBID MORTAL W, V40, P1; Advisory Committee on Immunization Practices, 1997, MMWR-MORBID MORTAL W, V46, P1; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P1; BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BERNIER RH, 1993, JAMA-J AM MED ASSOC, V269, P1817, DOI 10.1001/jama.1993.03500140069038; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P57; CUTTS FT, 1992, ANNU REV PUBL HEALTH, V13, P385, DOI 10.1146/annurev.publhealth.13.1.385; Haddix A, 1996, PREVENTION EFFECTIVE; Hamlin JS, 1996, AM J PUBLIC HEALTH, V86, P1812, DOI 10.2105/AJPH.86.12.1812; Hatziandreu EJ, 1994, COST BENEFIT ANAL OP; Immunization Practices Advisory Committee, 1991, MMWR-MORBID MORTAL W, V40, P1; Linkins RW, 1998, PEDIATR ANN, V27, P349, DOI 10.3928/0090-4481-19980601-09; MASSEY JT, 1988, WILEY S PRO, P143; Murphy TV, 1997, PEDIATR INFECT DIS J, V16, P47, DOI 10.1097/00006454-199701000-00011; *NAT ADV COMM IMM, 1990, CAN DIS WKLY REP, V16, P11; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; Pierce Carol, 1996, JAMA (Journal of the American Medical Association), V276, P626, DOI 10.1001/jama.276.8.626; STATTON KR, 1994, ADVERSE EVENTS ASS C; Trinca J C, 1976, Aust Fam Physician, V5, P734; Yawn BP, 1998, AM J MANAG CARE, V4, P185; ZELL E, 1995, P SECT SURV RES METH, P684; 1996, MMWR MORB MORTAL WKL, V45, P635; 1996, MMWR MORB MORTAL WKL, V44, P940; 1998, MMWR MORB MORTAL WKL, V47, P547	27	61	61	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2000	283	10					1311	1317		10.1001/jama.283.10.1311	http://dx.doi.org/10.1001/jama.283.10.1311			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289ND	10714730				2022-12-28	WOS:000085628100027
J	Yang, A; Walker, N; Bronson, R; Kaghad, M; Oosterwegel, M; Bonnin, J; Vagner, C; Bonnet, H; Dikkes, P; Sharpe, A; McKeon, F; Caput, D				Yang, A; Walker, N; Bronson, R; Kaghad, M; Oosterwegel, M; Bonnin, J; Vagner, C; Bonnet, H; Dikkes, P; Sharpe, A; McKeon, F; Caput, D			p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours	NATURE			English	Article							DENTATE GYRUS; P53; REELER; RECEPTORS; MAMMALS; MOUSE; ORGANIZATION; FAMILY; CELLS; DEATH	p73 (ref. 1) has high homology with the tumour suppressor p53 (refs 2-4), as well as with p63, a gene implicated in the maintenance of epithelial stem cells(5-7). Despite the localization of the p73 gene to chromosome 1p36.3, a region of frequent aberration in a wide range of human cancers(1), and the ability of p73 to transactivate p53 target genes(1), it is unclear whether p73 functions as a tumour suppressor. Here we show that mice functionally deficient for all p73 isoforms exhibit profound defects, including hippocampal dysgenesis, hydrocephalus, chronic infections and inflammation, as well as abnormalities in pheromone sensory pathways. In contrast to p53-deficient mice, however, those lacking p73 show no increased susceptibility to spontaneous tumorigenesis. We report the mechanistic basis of the hippocampal dysgenesis and the loss of pheromone responses, and show that new,potentially dominant-negative, p73 variants are the predominant expression products of this gene hi developing and adult tissues. Our data suggest that there is a marked divergence in the physiological functions of the p53 family members, and reveal unique roles for p73 in neurogenesis, sensory pathways and homeostatic control.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Sanofi Rech, F-31676 Labege, France; Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Dept Pathol, Boston, MA 02111 USA; Brigham & Womens Hosp, Dept Pathol, Div Immunol Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Sanofi-Aventis; Sanofi France; Tufts University; United States Department of Agriculture (USDA); Tufts University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	McKeon, F (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	fmckeon@hms.harvard.edu; daniel.caput@wanadoo.fr						Alcantara S, 1998, J NEUROSCI, V18, P7779; Bargmann CI, 1997, CELL, V90, P585, DOI 10.1016/S0092-8674(00)80518-8; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Cressman VL, 1998, AM J RESP CELL MOL, V19, P853, DOI 10.1165/ajrcmb.19.6.3194; D'Arcangelo G, 1998, BIOESSAYS, V20, P235, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;235::AID-BIES7&gt;3.0.CO;2-Q; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Frotscher M, 1998, CURR OPIN NEUROBIOL, V8, P570, DOI 10.1016/S0959-4388(98)80082-2; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Go K G, 1997, Adv Tech Stand Neurosurg, V23, P47; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim KC, 1997, EUR RESPIR J, V10, P2644, DOI 10.1183/09031936.97.10112644; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; STANFIELD BB, 1979, J COMP NEUROL, V185, P393, DOI 10.1002/cne.901850302; Tirindelli R, 1998, TRENDS NEUROSCI, V21, P482, DOI 10.1016/S0166-2236(98)01274-0; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	30	832	863	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2000	404	6773					99	103		10.1038/35003607	http://dx.doi.org/10.1038/35003607			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716451				2022-12-28	WOS:000085775100054
J	LeVier, K; Phillips, RW; Grippe, VK; Roop, RM; Walker, GC				LeVier, K; Phillips, RW; Grippe, VK; Roop, RM; Walker, GC			Similar requirements of a plant symbiont and a mammalian pathogen for prolonged intracellular survival	SCIENCE			English	Article							BRUCELLA-ABORTUS; SYSTEM; MUTAGENESIS; VIRULENCE; SBMA; GENE	Brucella abortus, a mammalian pathogen, and Rhizobium meliloti, a phylogenetically related plant symbiont, establish chronic infections in their respective hosts. Here a highly conserved B, abortus homolog of the R, meliloti bacA gene, which encodes a putative cytoplasmic membrane transport protein required for symbiosis, was identified. An isogenic B, abortus bacA mutant exhibited decreased survival in macrophages and greatly accelerated clearance from experimentally infected mice compared to the virulent parental strain. Thus, the bacA gene product is critical for the maintenance of two very diverse host-bacterial relationships.	MIT, Dept Biol, Cambridge, MA 02139 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Shreveport, LA 71130 USA	Massachusetts Institute of Technology (MIT); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Walker, GC (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	gwalker@mit.edu		/0000-0001-7243-8261	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031030] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31030] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin C.L., 2002, INFEC AGENT, P255; Corbel MJ, 1997, EMERG INFECT DIS, V3, P213, DOI 10.3201/eid0302.970219; DELEY J, 1987, INT J SYST BACTERIOL, V37, P35, DOI 10.1099/00207713-37-1-35; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; Elzer PH, 1996, INFECT IMMUN, V64, P4838, DOI 10.1128/IAI.64.11.4838-4841.1996; *GENB, X73522 GENB; GLAZEBROOK J, 1993, GENE DEV, V7, P1485, DOI 10.1101/gad.7.8.1485; GRIPPE VK, UNPUB; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Ichige A, 1997, J BACTERIOL, V179, P209, DOI 10.1128/jb.179.1.209-216.1997; LONG S, 1988, J BACTERIOL, V170, P4257, DOI 10.1128/jb.170.9.4257-4265.1988; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; MELLOR RB, 1989, J EXP BOT, V40, P831, DOI 10.1093/jxb/40.8.831; MONTARAZ JA, 1986, INFECT IMMUN, V53, P245, DOI 10.1128/IAI.53.2.245-251.1986; Niner BM, 1998, SYMBIOSIS, V24, P51; PHILLIPS RA, UNPUB; Porte F, 1999, INFECT IMMUN, V67, P4041, DOI 10.1128/IAI.67.8.4041-4047.1999; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; SCHWEIZER HP, 1995, GENE, V158, P15, DOI 10.1016/0378-1119(95)00055-B; Sola-Landa A, 1998, MOL MICROBIOL, V29, P125, DOI 10.1046/j.1365-2958.1998.00913.x	20	139	147	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2000	287	5462					2492	2493		10.1126/science.287.5462.2492	http://dx.doi.org/10.1126/science.287.5462.2492			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741969				2022-12-28	WOS:000086202200046
J	Pietro, DA; Shyavitz, LJ; Smith, RA; Auerbach, BS				Pietro, DA; Shyavitz, LJ; Smith, RA; Auerbach, BS			Detecting and reporting medical errors: why the dilemma?	BRITISH MEDICAL JOURNAL			English	Article									Sturdy Mem Hosp, Ambulatory Serv, Attleboro, MA 02703 USA; Sturdy Mem Hosp, Emergency Serv, Attleboro, MA 02703 USA		Pietro, DA (corresponding author), Sturdy Mem Hosp, Ambulatory Serv, 211 Pk St,POB 2963, Attleboro, MA 02703 USA.								0	32	33	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					794	796		10.1136/bmj.320.7237.794	http://dx.doi.org/10.1136/bmj.320.7237.794			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720371	Green Published			2022-12-28	WOS:000086054700036
J	Drews, J				Drews, J			Drug discovery: A historical perspective	SCIENCE			English	Review							RECEPTOR; ANTIBODY; INNOVATION; BINDING; LIBRARY	Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium. Genome sciences, combined with bioinformatic tools, allow us to dissect the genetic basis of multifactorial diseases and to determine the most suitable points of attack for future medicines, thereby increasing the number of treatment options. The dramatic increase in the complexity of drug research is enforcing changes in the institutional basis of this interdisciplinary endeavor. The biotech industry is establishing itself as the discovery arm of the pharmaceutical industry. In bridging the gap between academia and Large pharmaceutical companies, the biotech firms have been effective instruments of technology transfer.	Int Biomed Management Partners, Basel, Switzerland; Orbimed Advisors LLC, New York, NY 10017 USA		Drews, J (corresponding author), Int Biomed Management Partners, Basel, Switzerland.							AHLQUIST RP, 1948, AM J PHYSIOL, V1, P100; ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Bacq ZM, 1983, DISCOVERIES PHARM, V1, P49; Black J. W., 1967, DRUG RESPONSES MAN, P111; Brenner SE, 1997, CURR OPIN STRUC BIOL, V7, P369, DOI 10.1016/S0959-440X(97)80054-1; Bruggemann M, 1996, IMMUNOL TODAY, V17, P391, DOI 10.1016/0167-5699(96)10025-6; Burley SK, 1999, NAT GENET, V23, P151, DOI 10.1038/13783; Buske C, 1999, EUR J CANCER, V35, P549, DOI 10.1016/S0959-8049(98)00420-1; Chain E, 1940, LANCET, V2, P226; Chouchane L, 1999, INT ARCH ALLERGY IMM, V120, P50, DOI 10.1159/000024219; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cragg MS, 1999, CURR OPIN IMMUNOL, V11, P541, DOI 10.1016/S0952-7915(99)00010-2; Dixon SL, 1998, J CHEM INF COMP SCI, V38, P1192, DOI 10.1021/ci980105+; Drews J, 1997, DRUG DISCOV TODAY, V2, P365, DOI 10.1016/S1359-6446(97)01086-6; Drews J, 1998, DRUG DISCOV TODAY, V3, P491, DOI 10.1016/S1359-6446(98)01252-5; DREWS J, 1997, HUMAN DIS GENETIC CA, P5; DREWS J, 1999, QUEST TOMORROWS MED, P51; DREWS J, 1997, SPECIAL PULLOUT NATU, V15; Drews Jurgen, 1996, DRUG INF J, V30, P97; Ehrlich P., 1957, GESAMMELTE ARBEITEN; FARBER E, 1952, EVOLUTION CHEM HIST, P173; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Guillausseau PJ, 1997, DIABETES METAB, V23, P14; Haffner SM, 1998, INT J OBESITY, V22, P695, DOI 10.1038/sj.ijo.0800619; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; KAUVAR LM, 1995, CHEM BIOL, V2, P107, DOI 10.1016/1074-5521(95)90283-X; KOCHWESER J, 1978, LIFE SCI, V22, P1361, DOI 10.1016/0024-3205(78)90099-1; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; Lahana R, 1999, DRUG DISCOV TODAY, V4, P447, DOI 10.1016/S1359-6446(99)01393-8; Langley JN, 1905, J PHYSIOL-LONDON, V33, P374; Limbird, 1996, GOODMAN GILMANS PHAR; Lindley PF, 1999, ACTA CRYSTALLOGR D, V55, P1654, DOI 10.1107/S0907444999008288; Maxwell R., 1990, DRUG DISCOVERY CASEB; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; MELDRUM N. IT., 1933, JOUR PHYSIOL, V80, P113; MOORE FJ, 1918, HIST CHEM, P212; Peyer Hans Conrad, 1996, ROCHE GESCH UNTERNEH; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; ROBERTS AM, 1989, SERENDIPITY, P66; Rodi DJ, 1999, CURR OPIN BIOTECH, V10, P87, DOI 10.1016/S0958-1669(99)80016-0; Sakiniene E, 1999, SCAND J IMMUNOL, V50, P250; SCHWARTZ WB, 1949, NEW ENGL J MED, V240, P173, DOI 10.1056/NEJM194902032400503; SERTURNER FW, 1917, GILBERTS ANN PHYSIK, V25, P56; Shimkets R A, 1996, Curr Opin Nephrol Hypertens, V5, P162, DOI 10.1097/00041552-199603000-00011; SILLS M, COMMUNICATION; SNEADER W, 1985, DRUG DISCOVERY; Stigers KD, 1999, CURR OPIN CHEM BIOL, V3, P714, DOI 10.1016/S1367-5931(99)00030-7; STLIGGET, UNPUB; Tanaka H, 1997, YAKUGAKU ZASSHI, V117, P542, DOI 10.1248/yakushi1947.117.8_542; TAYLOR HR, 1987, INT OPHTHALMOL, V2, P83; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; WHITE DJG, 1982, P INT C CYCL A, P5; WINTER G, 1993, TRENDS PHARMACOL SCI, V14, P139, DOI 10.1016/0165-6147(93)90197-R; Wright S., 1984, EVOLUTION GENETICS P; ZIPKIN I, 1999, BIOCENTURY, V7, P1	61	1948	2070	10	453	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1960	1964		10.1126/science.287.5460.1960	http://dx.doi.org/10.1126/science.287.5460.1960			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720314				2022-12-28	WOS:000085902800046
J	Weinrich, M; Stuart, M				Weinrich, M; Stuart, M			Provision of methadone treatment in primary care medical practices - Review of the Scottish experience and implications for US policy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GENERAL-PRACTITIONERS; MAINTENANCE TREATMENT; OUTCOMES	Context Under new proposed regulations, US physicians outside of traditional methadone clinics could prescribe methadone to patients with opioid dependence. No large-scale evaluations of US programs in which methadone maintenance is provided by primary care physicians are available, but primary care physicians in Scotland have participated in such programs on a large scale. Objective To review the history, operation, and outcome data on the efficacy and safety of 2 Scottish primary care-based opioid agonist treatment programs to derive lessons for the US context. Design and Setting Naturalistic study of programs in Edinburgh and Glasgow, Scotland, with data obtained through site visits and interviews conducted in 1996 and 1998, as well as from published reports and retrospective analysis of electronic databases. Main Outcome Measures Proportions of injection drug users who were enrolled in the methadone maintenance programs, average methadone doses in the pro grams, and methadone-related deaths. Results A total of 60% to 80% of injection drug users in Edinburgh and 41% to 73% of those in Glasgow were enrolled in methadone maintenance in 1998-1999, Dose levels are consistent with US recommendations (for Edinburgh in 1998, 61 mg; for Glasgow in 1994-1996, 54 mg). The Glasgow program required supervised consumption of methadone in community pharmacies for the first year and experienced significantly fewer methadone-related deaths than Edinburgh in 1997 (17 vs 30 deaths; P<.0001). Programs in both Edinburgh and Glasgow provided support to primary care physicians and achieved levels of general practitioner participation of 59% (1998) and 30% (1999), respectively. Conclusions The Scottish experience indicates that prescription of methadone in office-based settings can expand access to an important treatment modality. Primary care physicians safely prescribed methadone for maintenance treatment when provided with adequate support. Diversion of methadone was minimized by requiring supervised consumption in community pharmacies.	Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA; Univ Maryland Baltimore Cty, Dept Sociol & Anthropol, Baltimore, MD 21228 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore County	Weinrich, M (corresponding author), NICHHD, Natl Ctr Med Rehabil Res, NIH, 6100 Execut Blvd,Room 2A03,MSC 7510, Bethesda, MD 20892 USA.	mw287k@nih.gov						[Anonymous], 1995, FEDERAL REGULATION M; Bach PB, 1999, AM J PUBLIC HEALTH, V89, P662, DOI 10.2105/AJPH.89.5.662; Blendon RJ, 1998, JAMA-J AM MED ASSOC, V279, P827, DOI 10.1001/jama.279.11.827; BURY J, 1998, SUPPORTING PRACTICES; BURY J, 1995, INT J DRUG POLICY, V6, P267; Christian J, 1999, DRUG ALCOHOL DEPEN, V55, P265, DOI 10.1016/S0376-8716(99)00021-6; COLE SK, 1998, DRUG RELATED DEATHS; *COMM DRUG PROBL S, 1998, AUD DAT APR 1997 MAR; Conrad DA, 1998, JAMA-J AM MED ASSOC, V279, P853, DOI 10.1001/jama.279.11.853; Cooper GAA, 1999, MED SCI LAW, V39, P233, DOI 10.1177/002580249903900308; DAUNNO T, 1992, JAMA-J AM MED ASSOC, V267, P253, DOI 10.1001/jama.267.2.253; Deehan A, 1997, BRIT J GEN PRACT, V47, P705; DEMARIA PA, 1995, POSTGRAD MED, V97, P83, DOI 10.1080/00325481.1995.11945971; *DEP HLTH, 1995, TACKL DRUGS STRAT EN; *DEP HLTH, 1998, TACKL DRUGS BUILD BR; *DEP HLTH SCOTT OF, 1999, DRUG MIS DEP GUID CL; DESMOND DP, 1997, EFFECTIVE MED TREATM; DuPont RL, 1996, SUBST USE MISUSE, V31, P1929, DOI 10.3109/10826089609066439; EGERTSON JA, 1997, TREATING DRUG USERS; ETHERIDGE RM, 1997, EFFECTIVE MED TREATM; Gerada C, 1999, BRIT J GEN PRACT, V49, P125; GLANZ A, 1986, BRIT MED J, V293, P486, DOI 10.1136/bmj.293.6545.486; *GREAT GLASG DRUG, 1998, GETT GRIPS DRUGS GRE; *GREAT GLASG HLTH, 1999, GUID GREAT GLASG GP; GREENWOOD J, 1992, BRIT J ADDICT, V87, P567; GREENWOOD J, 1990, BRIT MED J, V300, P587, DOI 10.1136/bmj.300.6724.587; GREENWOOD J, 1996, PSYCHIAT B, V20, P8; GREENWOOD J, 1994, LOTHIAN COMMUNITY DR; Gruer L, 1997, BMJ-BRIT MED J, V314, P1730, DOI 10.1136/bmj.314.7096.1730; JAFFE JH, 1997, EFFECTIVE MED TREATM; Lewis DC, 1996, J ADDICT DIS, V15, P1, DOI 10.1300/J069v15n01_01; LEWIS DC, 1997, EFFECTIVE MED TREATM; MacGowan RJ, 1996, J PSYCHOACTIVE DRUGS, V28, P259, DOI 10.1080/02791072.1996.10472487; Martin E, 1998, BRIT J GEN PRACT, V48, P1679; Massing M., 1998, THE FIX; McCarty D, 1999, MILBANK Q, V77, P341, DOI 10.1111/1468-0009.00139; MCCLELLAN AT, 1997, TREATING DRUG USERS, P7; McLellan AT, 1996, MILBANK Q, V74, P51, DOI 10.2307/3350433; NELSON H, 1996, TREATING DRUG USERS; NOVICK DM, 1994, J GEN INTERN MED, V9, P127, DOI 10.1007/BF02600025; OCONNOR PG, 1995, J GEN INTERN MED, V10, P255, DOI 10.1007/BF02599882; *OFF NAT DRUG AB P, 1999, ROAD AHEA CONS DOC O; PAYTE JY, 1997, EFFECTIVE MED TREATM; PETERS A, 1994, AUDIT EVALUATION COM; *PRIM CAR FACT TEA, 1996, MAN DRUG US GEN PRAC; Reinhardt UE, 1999, JAMA-J AM MED ASSOC, V281, P462, DOI 10.1001/jama.281.5.462; ROSENBAUM M, 1995, J PSYCHOACTIVE DRUGS, V27, P145, DOI 10.1080/02791072.1995.10471683; SIMON D, 1997, CORNER; Stuart ME, 1998, MILBANK Q, V76, P251, DOI 10.1111/1468-0009.00088; UMBRICHTSCHNEITER A, 1994, AM J PUBLIC HEALTH, V84, P207, DOI 10.2105/AJPH.84.2.207; *US DHHS, 1999, DRUG ABU WARN NETW; *US DHHS, 1999, FED REG         0722, V64, P39810; WILSON P, 1994, BRIT MED J, V309, P641, DOI 10.1136/bmj.309.6955.641; 1998, JAMA, V280, P1936, DOI DOI 10.1001/JAMA.280.22.1936	54	52	53	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2000	283	10					1343	1348		10.1001/jama.283.10.1343	http://dx.doi.org/10.1001/jama.283.10.1343			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	289ND	10714738				2022-12-28	WOS:000085628100035
J	Farr, GW; Furtak, K; Rowland, MB; Ranson, NA; Saibil, HR; Kirchhausen, T; Horwich, AL				Farr, GW; Furtak, K; Rowland, MB; Ranson, NA; Saibil, HR; Kirchhausen, T; Horwich, AL			Multivalent binding of nonnative substrate proteins by the chaperonin GroEL	CELL			English	Article							CRYSTAL-STRUCTURE; FOLDING REACTION; MECHANISM; POLYPEPTIDE; RELEASE; ATP	The chaperonin GroEL binds nonnative substrate protein in the central cavity of an open ring through exposed hydrophobic residues at the inside aspect of the apical domains and then mediates productive folding upon binding ATP and the cochaperonin GroES. Whether nonnative proteins bind to more than one of the seven apical domains of a GroEL ring is unknown. We have addressed this using rings with various combinations of wild-type and binding-defective mutant apical domains, enabled by their production as single polypeptides. A wild-type extent of binary complex formation with two stringent substrate proteins, malate dehydrogenase or Rubisco, required a minimum of three consecutive binding-proficient apical domains. Rhodanese, a less-stringent substrate, required only two wild-type domains and was insensitive to their arrangement. As a physical correlate, multivalent binding of Rubisco was directly observed in an oxidative cross-linking experiment.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Howard Hughes Medical Institute; Yale University; Yale University; University of London; Birkbeck University London; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Horwich, AL (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.			Ranson, Neil/0000-0002-3640-5275				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURNETT BP, 1994, J BACTERIOL, V176, P6980, DOI 10.1128/JB.176.22.6980-6985.1994; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Sparrer H, 1997, J BIOL CHEM, V272, P14080, DOI 10.1074/jbc.272.22.14080; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642	28	153	158	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 3	2000	100	5					561	573		10.1016/S0092-8674(00)80692-3	http://dx.doi.org/10.1016/S0092-8674(00)80692-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721993	Bronze			2022-12-28	WOS:000085700000009
J	Cole, CR; Foody, JM; Blackstone, EH; Lauer, MS				Cole, CR; Foody, JM; Blackstone, EH; Lauer, MS			Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Abnormal heart rate recovery after symptom-limited exercise predicts death. It is unknown whether this is also true among patients undergoing submaximal testing. Objective: To test the prognostic implications of heart rate recovery in cardiovascularly healthy adults undergoing submaximal exercise testing. Design: Population-based cohort study. Setting: 10 primary care sites. Participants: 5234 adults without evidence of cardiovascular disease who were enrolled in the Lipid Research Clinics Prevalence Study. Measurements: Heart rate recovery was defined as the change from peak heart rate to that measured 2 minutes later (heart rate recovery was defined as less than or equal to 42 beats/min). Results: During 12 years of follow-up, 312 participants died. Abnormal heart rate recovery predicted death (relative risk, 2.58 [CI, 2.06 to 3.20]). After adjustment for standard risk factors, fitness, and resting and exercise heart rates, abnormal heart rate recovery remained predictive (adjusted relative risk, 1.55 [CI, 1.22 to 1.98]) (P < 0.001). Conclusion: Even after submaximal exercise, abnormal heart rate recovery predicts death.	Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplantat Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplantat Med, 9500 Euclid Ave,Desk F25, Cleveland, OH 44195 USA.	lauerm@ccf.org	Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177				[Anonymous], 1999, HLTH AGING CHARTBOOK; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; CRIQUI MH, 1983, CIRCULATION, V68, P225, DOI 10.1161/01.CIR.68.2.225; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; IMAI K, 1994, J AM COLL CARDIOL, V24, P1529, DOI 10.1016/0735-1097(94)90150-3; Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8; Lauer MS, 1996, CIRCULATION, V93, P1520, DOI 10.1161/01.CIR.93.8.1520; Lauer MS, 1999, JAMA-J AM MED ASSOC, V281, P524, DOI 10.1001/jama.281.6.524; LEBLANC M, 1992, BIOMETRICS, V48, P411, DOI 10.2307/2532300; RIFKIND BM, 1979, CIRCULATION, V60, P427; Wilkoff Bruce L., 1992, Cardiology Clinics, V10, P705; WILLIAMS OD, 1980, CIRCULATION, V62, P18	12	378	406	0	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					552	555		10.7326/0003-4819-132-7-200004040-00007	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744592				2022-12-28	WOS:000086129300006
J	Singh, SC; Taylor, MAJ; Montagner, JP				Singh, SC; Taylor, MAJ; Montagner, JP			On the presence of liquid in Earth's inner core	SCIENCE			English	Article							TRAVEL-TIMES; FREE OSCILLATIONS; ANISOTROPY; ATTENUATION; IRON; ELASTICITY; CONVECTION; CRACKS; PKIKP; PKP	Seismological studies indicate that the inner core of Earth is anisotropic for compressional waves (P waves), and has Low shear wave (S wave) velocity, and high seismic attenuation. Using an effective medium theory for composite materials, we show that the presence of a volume fraction of 3 to 10% liquid in the form of oblate spheroidal inclusions aligned in the equatorial plane between iron crystals is sufficient to explain the aforementioned seismic phenomena. Variation of S-wave velocity between the polar axis and equatorial plane is more sensitive to the addition of Liquid than that of P waves. The Liquid could arise from the presence of dendrites or a mixture of elements other than iron that exist in Liquid form under inner-core conditions.	Inst Phys Globe, Dept Sismol, F-75252 Paris 05, France; Univ Cambridge, Bullard Labs, Cambridge CB3 0EZ, England	UDICE-French Research Universities; Universite Paris Cite; University of Cambridge	Singh, SC (corresponding author), Inst Phys Globe, Dept Sismol, 4 Pl Jussieu, F-75252 Paris 05, France.		Montagner, Jean-Paul/A-8733-2011	Montagner, Jean-Paul/0000-0001-9958-3012				Bergman MI, 1997, NATURE, V389, P60, DOI 10.1038/37962; BHATTACHARYYA J, 1993, GEOPHYS J INT, V114, P1, DOI 10.1111/j.1365-246X.1993.tb01461.x; BIRCH F, 1952, J GEOPHYS RES, V57, P227, DOI 10.1029/JZ057i002p00227; Breger L, 2000, EARTH PLANET SC LETT, V175, P133, DOI 10.1016/S0012-821X(99)00286-1; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; BULLEN KE, 1953, ANN GEOFIS, V6, P1; Cormier VF, 1998, GEOPHYS RES LETT, V25, P4019, DOI 10.1029/1998GL900074; CREAGER KC, 1992, NATURE, V356, P309, DOI 10.1038/356309a0; DOORNBOS DJ, 1974, GEOPHYS J ROY ASTR S, V38, P397, DOI 10.1111/j.1365-246X.1974.tb04131.x; DZIEWONSKI AM, 1971, NATURE, V234, P465, DOI 10.1038/234465a0; ESHELBY JD, 1957, PROC R SOC LON SER-A, V241, P376, DOI 10.1098/rspa.1957.0133; FEARN DR, 1981, NATURE, V292, P232, DOI 10.1038/292232a0; Glatzmaier GA, 1998, INT J ENG SCI, V36, P1325, DOI 10.1016/S0020-7225(98)00035-4; GUBBINS D, 1977, J GEOPHYS-Z GEOPHYS, V43, P453; HORNBY BE, 1994, GEOPHYSICS, V59, P1570, DOI 10.1190/1.1443546; Hudson JA, 1996, GEOPHYS J INT, V124, P105, DOI 10.1111/j.1365-246X.1996.tb06355.x; Jakobsen M, 2000, J GEOPHYS RES-SOL EA, V105, P561, DOI 10.1029/1999JB900190; JEANLOZ R, 1988, GEOPHYS RES LETT, V15, P72, DOI 10.1029/GL015i001p00072; Jeffreys H., 1929, EARTH, P265; JEPHCOAT A, 1987, NATURE, V325, P332, DOI 10.1038/325332a0; JULIAN BR, 1972, NATURE, V235, P317, DOI 10.1038/235317a0; KENNETT BLN, 1995, GEOPHYS J INT, V122, P108, DOI 10.1111/j.1365-246X.1995.tb03540.x; Lehmann I., 1936, BUR CENT SEISMOL INT, V14, P3; Mao HK, 1998, NATURE, V396, P741, DOI 10.1038/25506; Mao HK, 1999, NATURE, V399, P280, DOI 10.1038/20472; MAO HK, 1990, J GEOPHYS RES-SOLID, V95, P21737, DOI 10.1029/JB095iB13p21737; MORELLI A, 1986, GEOPHYS RES LETT, V13, P1545, DOI 10.1029/GL013i013p01545; NISHIZAWA O, 1982, J PHYS EARTH, V30, P331, DOI 10.4294/jpe1952.30.331; Okal EA, 1998, EARTH PLANET SC LETT, V164, P23, DOI 10.1016/S0012-821X(98)00210-6; Romanowicz B, 1996, SCIENCE, V274, P963, DOI 10.1126/science.274.5289.963; SECCO RA, 1995, MINERAL PHYSICS CRYS, P218; SHEARER PM, 1988, NATURE, V333, P228, DOI 10.1038/333228a0; SHENG P, 1990, PHYS REV B, V41, P4507, DOI 10.1103/PhysRevB.41.4507; Singh SC, 1999, NATURE, V400, P629, DOI 10.1038/23171; SOURIAU A, 1995, GEOPHYS J INT, V123, P572, DOI 10.1111/j.1365-246X.1995.tb06872.x; Souriau A, 1996, GEOPHYS RES LETT, V23, P1, DOI 10.1029/95GL03583; Stixrude L, 1997, J GEOPHYS RES-SOL EA, V102, P24729, DOI 10.1029/97JB02125; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; TROMP J, 1993, NATURE, V366, P678, DOI 10.1038/366678a0; WIDMER R, 1991, GEOPHYS J INT, V104, P541, DOI 10.1111/j.1365-246X.1991.tb05700.x; WOODHOUSE JH, 1986, GEOPHYS RES LETT, V13, P1549, DOI 10.1029/GL013i013p01549	41	107	110	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2471	2474		10.1126/science.287.5462.2471	http://dx.doi.org/10.1126/science.287.5462.2471			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741963				2022-12-28	WOS:000086202200040
J	Beard, JD				Beard, JD			ABC of arterial and venous disease - Chronic lower limb ischaemia	BRITISH MEDICAL JOURNAL			English	Review									No Gen Hosp, Sheffield Vasc Inst, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital	Beard, JD (corresponding author), No Gen Hosp, Sheffield Vasc Inst, Sheffield S5 7AU, S Yorkshire, England.							DAVIES AH, 1999, ESSENTIAL VASCULAR S; LENG GC, 1999, COCHRANE LIB; *SCOTT INT GUID NE, 1998, SIGN, P27; 1998, HEART S, V80, pS1	4	33	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					854	+		10.1136/bmj.320.7238.854	http://dx.doi.org/10.1136/bmj.320.7238.854			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731185	Green Published			2022-12-28	WOS:000086180300030
J	Sanders, DS; Carter, MJ				Sanders, DS; Carter, MJ			Antibiotic prophylaxis after percutaneous endoscopic gastrostomy insertion - All encompassing study is needed	BRITISH MEDICAL JOURNAL			English	Letter									Royal Hallamshire Hosp, Gastroenterol & Liver Unit, Sheffield S10 2JE, S Yorkshire, England	University of Sheffield	Sanders, DS (corresponding author), Royal Hallamshire Hosp, Gastroenterol & Liver Unit, Sheffield S10 2JE, S Yorkshire, England.							*BRIT SOC GASTR, 1996, GUT S            SEP; JAIN NK, 1987, ANN INTERN MED, V107, P824, DOI 10.7326/0003-4819-107-6-824; JONAS SK, 1985, AM J GASTROENTEROL, V80, P438; Preclik G, 1999, BRIT MED J, V319, P881, DOI 10.1136/bmj.319.7214.881; Sturgis TM, 1996, AM J GASTROENTEROL, V91, P2301	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					870	870						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731192				2022-12-28	WOS:000086180300045
J	Snyder, L; Caplan, AL				Snyder, L; Caplan, AL			Assisted suicide: Finding common ground	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA	University of Pennsylvania	Snyder, L (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.	lsnyder@mail.acponline.org						Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Doerflinger RM, 1999, HASTINGS CENT REP, V29, P52	2	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					468	469		10.7326/0003-4819-132-6-200003210-00007	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293CV	10733446				2022-12-28	WOS:000085834700006
J	Gwiazda, J; Ong, E; Held, R; Thorn, F				Gwiazda, J; Ong, E; Held, R; Thorn, F			Vision - Myopia and ambient night-time lighting	NATURE			English	Article									New England Coll Optometry, Boston, MA 02115 USA		Gwiazda, J (corresponding author), New England Coll Optometry, 424 Beacon St, Boston, MA 02115 USA.							GWIAZDA J, 1993, CLIN VISION SCI, V8, P337; Pacella R, 1999, OPTOMETRY VISION SCI, V76, P381, DOI 10.1097/00006324-199906000-00017; Quinn GE, 1999, NATURE, V399, P113, DOI 10.1038/20094	3	48	50	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					144	144		10.1038/35004663	http://dx.doi.org/10.1038/35004663			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724158	Bronze			2022-12-28	WOS:000085870900038
J	Yankner, BA				Yankner, BA			A century of cognitive decline	NATURE			English	Editorial Material									Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Yankner, BA (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.								0	20	22	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					125	125		10.1038/35004673	http://dx.doi.org/10.1038/35004673			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724145	Bronze			2022-12-28	WOS:000085870900023
J	Cohen, A				Cohen, A			Paediatrician Flora Brovina remains imprisoned in Kosovo	LANCET			English	Editorial Material									Physicians Human Rights, Boston, MA 02116 USA		Cohen, A (corresponding author), Physicians Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.							*PHYS HUM RIGHTS, 1999, WAR CRIM KOS POP BAS	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					839	839		10.1016/S0140-6736(05)72449-1	http://dx.doi.org/10.1016/S0140-6736(05)72449-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711943				2022-12-28	WOS:000085766900040
J	Engel, JD; Tanimoto, K				Engel, JD; Tanimoto, K			Looping, linking, and chromatin activity: New insights into beta-globin locus regulation	CELL			English	Review							CHROMOSOME TRANSGENIC MICE; CONTROL REGION; DEVELOPMENTAL REGULATION; GENE-EXPRESSION; ERYTHROID-CELLS; EPSILON-GLOBIN; TRANSCRIPTION; DELETION; HS3		Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Engel, JD (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.		Tanimoto, Keiji/B-2600-2014	Tanimoto, Keiji/0000-0003-1971-6546				Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hardison R, 1998, GENOMICS, V47, P429, DOI 10.1006/geno.1997.5147; Li QL, 1998, J BIOL CHEM, V273, P17361, DOI 10.1074/jbc.273.28.17361; Liu QH, 1997, P NATL ACAD SCI USA, V94, P169, DOI 10.1073/pnas.94.1.169; Navas PA, 1998, MOL CELL BIOL, V18, P4188, DOI 10.1128/MCB.18.7.4188; Peterson KR, 1996, P NATL ACAD SCI USA, V93, P6605, DOI 10.1073/pnas.93.13.6605; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	20	158	162	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 3	2000	100	5					499	502		10.1016/S0092-8674(00)80686-8	http://dx.doi.org/10.1016/S0092-8674(00)80686-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721987	Bronze			2022-12-28	WOS:000085700000003
J	Holt, IJ; Lorimer, HE; Jacobs, HT				Holt, IJ; Lorimer, HE; Jacobs, HT			Coupled leading- and lagging-strand synthesis of mammalian mitochondrial DNA	CELL			English	Article							REPLICATION ORIGINS; ETHIDIUM-BROMIDE; GEL-ELECTROPHORESIS; 2-DIMENSIONAL GELS; YEAST; SEQUENCE; ORGANIZATION	Analysis of mammalian mtDNA by two-dimensional agarose gel electrophoresis revealed two classes of replication intermediate. One was resistant to single-strand nuclease digestion and displayed the mobility properties of coupled leading- and lagging- strand replication products, Intermediates of coupled, unidirectional mtDNA replication were found in mouse liver and human placenta and were the predominant species in cultured cells recovering from transient mtDNA replication. Replication intermediates sensitive to single-strand nuclease were most abundant in untreated cultured cells, These are presumed to derive from the orthodox, strand-asynchronous mode of mtDNA replication. These findings indicate that two modes of mtDNA replication operate in mammalian cells and that changes in mtDNA copy number involve an alteration in the mode of mtDNA replication.	Univ Dundee, Ninewells Med Sch, Dept Mol Pathol, Dundee DD1 9SY, Scotland; Youngstown State Univ, Dept Biol Sci, Youngstown, OH 44555 USA; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Univ Tampere, Tampere Univ Hosp, FIN-33101 Tampere, Finland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Dundee; University System of Ohio; Youngstown State University; Tampere University; Tampere University; Tampere University Hospital; University of Glasgow	Holt, IJ (corresponding author), Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Jacobs, Howard T/G-2434-2011	holt, ian/0000-0001-5468-0193; Jacobs, Howard/0000-0003-1895-6003	Medical Research Council [MC_U105663140] Funding Source: Medline; MRC [MC_U105663140] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BRUN C, 1995, CHROMOSOMA, V104, P92; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; CREWS S, 1979, NATURE, V277, P192, DOI 10.1038/277192a0; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717; GOLDRING ES, 1970, J MOL BIOL, V52, P323, DOI 10.1016/0022-2836(70)90033-1; HAN ZY, 1994, CHROMOSOMA, V103, P162, DOI 10.1007/BF00368008; IKEDA S, 1994, CELL MOL BIOL, V40, P489; Kalejta RF, 1996, MOL CELL BIOL, V16, P4915; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KOIKE K, 1974, J CELL BIOL, V61, P14, DOI 10.1083/jcb.61.1.14; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LOCKSHON D, 1995, CELL, V81, P947, DOI 10.1016/0092-8674(95)90014-4; MAYHOOK AG, 1992, P ROY SOC B-BIOL SCI, V248, P85, DOI 10.1098/rspb.1992.0046; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAWOTKA KA, 1988, MOL CELL BIOL, V8, P1408, DOI 10.1128/MCB.8.4.1408; Preiser PR, 1996, EMBO J, V15, P684, DOI 10.1002/j.1460-2075.1996.tb00401.x; Sambrook J., 2002, MOL CLONING LAB MANU; SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1; WISEMAN A, 1978, MOL GEN GENET, V167, P51, DOI 10.1007/BF00270321; Wolstenholme D R, 1974, Cold Spring Harb Symp Quant Biol, V38, P267	28	284	292	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 3	2000	100	5					515	524		10.1016/S0092-8674(00)80688-1	http://dx.doi.org/10.1016/S0092-8674(00)80688-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721989	Bronze			2022-12-28	WOS:000085700000005
J	Smaglik, P				Smaglik, P			Gene therapy institute denies that errors led to trial death	NATURE			English	News Item																			0	7	7	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					820	820		10.1038/35002758	http://dx.doi.org/10.1038/35002758			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10733385	Bronze			2022-12-28	WOS:000085559200013
J	Smoger, SH; Felice, TL; Kloecker, GH				Smoger, SH; Felice, TL; Kloecker, GH			Urinary incontinence among male veterans receiving care in primary care clinics	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; PREVALENCE; COMMUNITY; HEALTH; SEEKING; ADULTS; WOMEN	Background: Male urinary incontinence is not a well-investigated subject. Objective: To determine the prevalence and consequences of incontinence in men. Design: Cross-sectional survey. Setting: 3 primary care clinics in a Kentucky Veterans Affairs facility. Patients: 840 men with a mean age of 59.8 years (range, 25 to 93 years). Measurements: Written survey on patient demographic information and continence, including the Incontinence Impact Questionnaire. Results: Among all study patients, 32.3% reported incontinence within the past 12 months and 13.8% (43% of those who were incontinent) reported at least weekly episodes. Age did not correlate with frequency or amount of urine loss. Frequency correlated with emotional health, social relationships, physical activity, and travel. Greater amounts of lost urine had a stronger effect on emotional health, social relationships, and travel. Among men with incontinence, only 32% had discussed incontinence with their medical provider but 75% desired evaluation and treatment. Conclusions: Urinary incontinence is common among male veterans and affects all age groups. Although incontinence often has unfavorable consequences on quality of life and although men with incontinence desired treatment, they seldom discussed the problem with medical providers. Systematic screening of men for urinary incontinence may be necessary.	Univ Louisville, Div Gen Internal Med, Louisville, KY 40292 USA; Vet Affairs Med Ctr, Louisville, KY USA	University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Smoger, SH (corresponding author), Univ Louisville, Div Gen Internal Med, 530 S Jackson St, Louisville, KY 40292 USA.	shsmog01@med.louisville.edu						*AG HLTH CAR POL R, 1996, AHCPR PUBL; ARMSTRONG EP, 1998, VET HLTH SYST J  OCT, P37; BURGIO KL, 1994, J AM GERIATR SOC, V42, P208, DOI 10.1111/j.1532-5415.1994.tb04954.x; DIOKNO AC, 1986, J UROLOGY, V136, P1022; DuBeau CE, 1998, J AM GERIATR SOC, V46, P683, DOI 10.1111/j.1532-5415.1998.tb03801.x; HERR HW, 1994, J UROLOGY, V151, P652, DOI 10.1016/S0022-5347(17)35038-3; HERZOG AR, 1990, J AM GERIATR SOC, V38, P273, DOI 10.1111/j.1532-5415.1990.tb03504.x; Hunskaar Steinar, 1993, Scandinavian Journal of Primary Health Care, V11, P193, DOI 10.3109/02813439308994829; Johnson TM, 1998, J AM GERIATR SOC, V46, P693, DOI 10.1111/j.1532-5415.1998.tb03802.x; LAGACE EA, 1993, J FAM PRACTICE, V36, P610; NIH, 1990, J AM GERIATR SOC, V38, P265; Nygaard IE, 1996, J AM GERIATR SOC, V44, P1049, DOI 10.1111/j.1532-5415.1996.tb02936.x; OUSLANDER JG, 1990, GERONTOLOGIST, V30, P369, DOI 10.1093/geront/30.3.369; OUSLANDER JG, 1982, JAMA-J AM MED ASSOC, V248, P1194, DOI 10.1001/jama.248.10.1194; Payne CK, 1998, UROLOGY, V51, P3, DOI 10.1016/S0090-4295(98)90001-2; Roberts RO, 1998, J AM GERIATR SOC, V46, P467, DOI 10.1111/j.1532-5415.1998.tb02468.x; SHUMAKER SA, 1994, QUAL LIFE RES, V3, P291, DOI 10.1007/BF00451721; Thom D, 1998, J AM GERIATR SOC, V46, P473, DOI 10.1111/j.1532-5415.1998.tb02469.x; THOMAS TM, 1980, BRIT MED J, V281, P1243, DOI 10.1136/bmj.281.6250.1243; WETLE T, 1995, J AM GERIATR SOC, V43, P349, DOI 10.1111/j.1532-5415.1995.tb05806.x	20	17	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					547	551		10.7326/0003-4819-132-7-200004040-00006	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	298FU	10744591				2022-12-28	WOS:000086129300005
J	Goodman, NW				Goodman, NW			Survey of active verbs in the titles of clinical trial reports	BRITISH MEDICAL JOURNAL			English	Article									Southmead Hosp, Bristol BS10 5NB, Avon, England	Southmead Hospital	Goodman, NW (corresponding author), Southmead Hosp, Bristol BS10 5NB, Avon, England.							HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; HUTH EJ, 1990, WRITE PUBLISH PAPERS, P89; ROSNER JL, 1990, NATURE, V345, P108, DOI 10.1038/345108a0; WEISS GB, 1995, J CLIN ONCOL, V13, P1829, DOI 10.1200/JCO.1995.13.7.1829	4	21	22	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					914	915		10.1136/bmj.320.7239.914	http://dx.doi.org/10.1136/bmj.320.7239.914			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10742001	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000086337100029
J	Grishok, A; Tabara, H; Mello, CC				Grishok, A; Tabara, H; Mello, CC			Genetic requirements for inheritance of RNAi in C-elegans	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; PLANTS; MUTANTS	In Caenorhabditis elegans, the introduction of double-stranded RNA Triggers sequence-specific generic interference (RNAi) that is transmitted to offspring. The inheritance properties associated with this phenomenon were examined. Transmission of the interference effect occurred through a dominant extragenic agent. The wild-type activities of the RNAi pathway genes rde-1 and rde-4 were required for the formation of this interfering agent but were not needed for interference thereafter. In contrast, the rde-2 and mut-7 genes were required downstream for interference. These findings provide evidence for germ line transmission of an extragenic sequence-specific silencing factor and implicate rde-1 and rde-4 in the formation of the inherited agent.	Univ Massachusetts, Ctr Canc, Dept Cell Biol, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Mello, CC (corresponding author), Univ Massachusetts, Ctr Canc, Dept Cell Biol, Program Mol Med, 2 Biotech Suite 213,373 Plantat St, Worcester, MA 01605 USA.	craig.mello@ummed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058800] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58800] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Baulcombe DC, 1996, PLANT MOL BIOL, V32, P79, DOI 10.1007/BF00039378; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Henikoff S, 1998, CELL, V93, P329, DOI 10.1016/S0092-8674(00)81161-7; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Ratcliff FG, 1999, PLANT CELL, V11, P1207, DOI 10.1105/tpc.11.7.1207; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Schmidt A, 1999, GENETICS, V151, P749; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 1999, DEVELOPMENT, V126, P1; VANDERKEYL H, 1994, DEV DYNAM, V201, P86, DOI 10.1002/aja.1002010109; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959	23	339	404	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2000	287	5462					2494	2497		10.1126/science.287.5462.2494	http://dx.doi.org/10.1126/science.287.5462.2494			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741970				2022-12-28	WOS:000086202200047
J	Wimmer, EA; Carleton, A; Harjes, P; Turner, T; Desplan, C				Wimmer, EA; Carleton, A; Harjes, P; Turner, T; Desplan, C			bicoid-independent formation of thoracic segments in Drosophila	SCIENCE			English	Article							GENE HUNCHBACK; BODY PATTERN; DIFFERENTIAL REGULATION; RNA-BINDING; EMBRYO; EXPRESSION; GRADIENT; PROTEIN; ANTERIOR; MORPHOGEN	The maternal determinant Bicoid (Bcd) represents the paradigm of a morphogen that provides positional information for pattern formation. However, as bicoid seems to be a recently acquired gene in flies, the question was raised as to how embryonic patterning is achieved in organisms with more ancestral modes of development. Because the phylogenetically conserved Hunchback (Hb) protein had previously been shown to act as a morphogen in abdominal patterning, we asked which functions of Bcd could be performed by Hb. By reestablishing a proposed ancient regulatory circuitry in which maternal Hb controls zygotic hunchback expression, we show that Hb is able to form thoracic segments in the absence of Bcd.	NYU, Dept Biol, New York, NY 10003 USA; Univ Bayreuth, Lehrstuhl Genet, D-95447 Bayreuth, Germany	New York University; University of Bayreuth	Desplan, C (corresponding author), NYU, Dept Biol, 100 Washington Sq E, New York, NY 10003 USA.		Carleton, Alan/C-9721-2010	Carleton, Alan/0000-0001-5633-9159; Desplan, Claude/0000-0002-6914-1413; Wimmer, Ernst A./0000-0002-2480-2804				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; CURTIS D, 1995, DEVELOPMENT, V121, P1899; DRAPER B, 1996, CELL, V82, P205; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Gao Q, 1998, DEVELOPMENT, V125, P4185; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; HULSKAMP M, 1994, GENETICS, V138, P125; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; Isaacs HV, 1999, EVOL DEV, V1, P143, DOI 10.1046/j.1525-142x.1999.99020.x; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Janody F, 2000, DEVELOPMENT, V127, P1573; Kosman D, 1997, DEVELOPMENT, V124, P1343; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LUKOWITZ W, 1994, MECH DEVELOP, V45, P105, DOI 10.1016/0925-4773(94)90024-8; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MARGOLIS JS, 1995, DEVELOPMENT, V121, P3067; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; Niessing D, 2000, MOL CELL, V5, P395, DOI 10.1016/S1097-2765(00)80434-7; PATEL NH, COMMUNICATION; Raff R.A., 1996, SHAPE LIFE; RiveraPomar R, 1996, TRENDS GENET, V12, P478, DOI 10.1016/0168-9525(96)10044-5; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; ROTHE M, 1992, NATURE, V359, P156, DOI 10.1038/359156a0; SANDER K, 1994, DEVELOPMENT S, V120, P187; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SCHRODER R, 1993, ROUX ARCH DEV BIOL, V203, P34, DOI 10.1007/BF00539888; SCHULZ C, 1994, DEVELOPMENT, V120, P3043; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SOMMER R, 1991, DEVELOPMENT, V113, P419; SOMMER RJ, 1992, P NATL ACAD SCI USA, V89, P10782, DOI 10.1073/pnas.89.22.10782; Stauber M, 1999, P NATL ACAD SCI USA, V96, P3786, DOI 10.1073/pnas.96.7.3786; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; WIMMER E, UNPUB; Wimmer EA, 1997, DEVELOPMENT, V124, P1509; Wolff C, 1995, DEVELOPMENT, V121, P4227; Wolff C, 1998, DEVELOPMENT, V125, P3645; XU X, 1994, DEVELOPMENT, V120, P277	49	67	67	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2476	2479		10.1126/science.287.5462.2476	http://dx.doi.org/10.1126/science.287.5462.2476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741965				2022-12-28	WOS:000086202200042
J	Berlyne, G; Barnes, N				Berlyne, G; Barnes, N			No role for NO in asthma?	LANCET			English	Editorial Material							EXHALED NITRIC-OXIDE; INHIBITION; AIR		London Chest Hosp, Dept Resp Med, London E2 9JX, England	University of London; Queen Mary University London	Berlyne, G (corresponding author), London Chest Hosp, Dept Resp Med, London E2 9JX, England.							de Gouw HWFM, 1999, THORAX, V54, P1033, DOI 10.1136/thx.54.11.1033; Hamad AM, 1999, EUR RESPIR J, V14, P702, DOI 10.1034/j.1399-3003.1999.14c34.x; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Silkoff PE, 1999, AM J RESP CRIT CARE, V159, P940, DOI 10.1164/ajrccm.159.3.9805044; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260, DOI 10.1164/ajrccm.155.1.9001322; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99, DOI 10.1164/ajrccm.158.1.9709091; Taylor DA, 1998, THORAX, V53, P483, DOI 10.1136/thx.53.6.483; van Rensen ELJ, 1999, THORAX, V54, P403, DOI 10.1136/thx.54.5.403; Yates DH, 1996, EUR RESPIR J, V9, P1130, DOI 10.1183/09031936.96.09061130	13	16	19	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1029	1030		10.1016/S0140-6736(00)02027-4	http://dx.doi.org/10.1016/S0140-6736(00)02027-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744082				2022-12-28	WOS:000086380800003
J	Foley, PA				Foley, PA			Recent advances - Dermatology	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PHOTODYNAMIC THERAPY; ANDROGENETIC ALOPECIA; KAPOSI-SARCOMA; LASER; HUMAN-HERPESVIRUS-8; TATTOOS; MEN		Univ Melbourne, St Vincents Hosp, Dept Med Dermatol, Fitzroy, Vic 3065, Australia	St Vincent's Hospital Melbourne; University of Melbourne	Foley, PA (corresponding author), Univ Melbourne, St Vincents Hosp, Dept Med Dermatol, Fitzroy, Vic 3065, Australia.	FOLEYP@svhm.org.au						Alaiti S, 1998, J AM ACAD DERMATOL, V38, P69, DOI 10.1016/S0190-9622(98)70541-9; ALORA MBT, 1999, MED SURG DERMATOL, V6, P51; Bissonnette R, 1997, DERMATOL CLIN, V15, P507, DOI 10.1016/S0733-8635(05)70458-7; Cattani P, 1998, ARCH DERMATOL, V134, P695, DOI 10.1001/archderm.134.6.695; Dierickx CC, 1998, ARCH DERMATOL, V134, P837, DOI 10.1001/archderm.134.7.837; Edwards L, 1998, ARCH DERMATOL, V134, P25, DOI 10.1001/archderm.134.1.25; Ferguson J, 1999, ARCH DERMATOL, V135, P589, DOI 10.1001/archderm.135.5.589; Ferguson JE, 1996, BRIT J DERMATOL, V135, P586, DOI 10.1111/j.1365-2133.1996.tb03836.x; Frazier CC, 1996, INT J DERMATOL, V35, P312, DOI 10.1111/j.1365-4362.1996.tb03629.x; Fritsch C, 1998, ARCH DERMATOL, V134, P207, DOI 10.1001/archderm.134.2.207; GERONEMUS RG, 1995, DERMATOL SURG, V21, P399, DOI 10.1111/j.1524-4725.1995.tb00204.x; Goyal S, 1997, J AM ACAD DERMATOL, V36, P122, DOI 10.1016/S0190-9622(97)70346-3; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Kaufman KD, 1998, J AM ACAD DERMATOL, V39, P578, DOI 10.1016/S0190-9622(98)70007-6; Kitchin JES, 1997, J AM ACAD DERMATOL, V37, P445, DOI 10.1016/S0190-9622(18)30747-3; Lebbe C, 1998, ARCH DERMATOL, V134, P736, DOI 10.1001/archderm.134.6.736; MAN I, 1998, CURR MED LIT DERMATO, V3, P59; Nousari HC, 1998, ARCH DERMATOL, V134, P1509, DOI 10.1001/archderm.134.12.1509; ORT RJ, 1999, MED SURG DERMATOL, V6, P1; Ruzicka T, 1999, ARCH DERMATOL, V135, P574, DOI 10.1001/archderm.135.5.574; Sawaya ME, 1997, J INVEST DERMATOL, V109, P296, DOI 10.1111/1523-1747.ep12335779; Sinclair R, 1998, BRIT MED J, V317, P865, DOI 10.1136/bmj.317.7162.865; Spicer MS, 1996, J AM ACAD DERMATOL, V34, P1, DOI 10.1016/S0190-9622(96)90827-0; Sullivan J R, 1999, Australas J Dermatol, V40, P61, DOI 10.1046/j.1440-0960.1999.00323.x; Syed Tanweer A., 1998, Journal of Dermatology (Tokyo), V25, P309; Tanew A, 1999, ARCH DERMATOL, V135, P519, DOI 10.1001/archderm.135.5.519; Tong D W, 1999, Australas J Dermatol, V40, P135, DOI 10.1046/j.1440-0960.1999.00343.x; Tope WD, 1998, ARCH DERMATOL, V134, P867, DOI 10.1001/archderm.134.7.867; Vinciullo C, 1999, DERMATOLOGY AT THE MILLENNIUM, P89; Weiss R A, 1998, J Natl Cancer Inst Monogr, P51	30	3	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	2000	320	7238					850	+		10.1136/bmj.320.7238.850	http://dx.doi.org/10.1136/bmj.320.7238.850			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731184	Green Published			2022-12-28	WOS:000086180300029
J	Hakala, M; Niemela, RK				Hakala, M; Niemela, RK			Does autonomic nervous impairment have a role in pathophysiology of Sjogren's syndrome	LANCET			English	Editorial Material							AUTOANTIBODIES; PROGRESSION		Univ Oulu, Dept Internal Med, Div Rheumatol, FIN-90220 Oulu, Finland	University of Oulu	Hakala, M (corresponding author), Univ Oulu, Dept Internal Med, Div Rheumatol, FIN-90220 Oulu, Finland.							Andonopoulos AP, 1998, J RHEUMATOL, V25, P2385; Bacman S, 1998, INVEST OPHTH VIS SCI, V39, P151; Barendregt PJ, 1999, ANN RHEUM DIS, V58, P746, DOI 10.1136/ard.58.12.746; Fox R I, 1999, Curr Opin Rheumatol, V11, P364, DOI 10.1097/00002281-199909000-00007; JONSSON R, 1993, BRIT J RHEUMATOL, V32, P578; KAUTZNER J, 1995, HEART RATE VARIABILI, P165; Kovacs L, 2000, ANN RHEUM DIS, V59, P48, DOI 10.1136/ard.59.1.48; Mandl T, 1997, SCAND J RHEUMATOL, V26, P253, DOI 10.3109/03009749709105312; Robinson CP, 1998, P NATL ACAD SCI USA, V95, P7538, DOI 10.1073/pnas.95.13.7538; Tenovuo J, 1994, TXB CLIN CARIOLOGY, P17; Tornwall J, 1997, LANCET, V349, P1814, DOI 10.1016/S0140-6736(05)61694-7; Zoukhri D, 1998, CLIN IMMUNOL IMMUNOP, V89, P126, DOI 10.1006/clin.1998.4597	12	13	14	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1032	1033		10.1016/S0140-6736(00)02030-4	http://dx.doi.org/10.1016/S0140-6736(00)02030-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744085				2022-12-28	WOS:000086380800006
J	Ward, CD				Ward, CD			Bordeaux mixture	NATURE			English	Editorial Material																			0	0	0	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					337	337		10.1038/35006178	http://dx.doi.org/10.1038/35006178			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746703	Bronze			2022-12-28	WOS:000086119000027
J	Yanovski, JA; Yanovski, SZ; Sovik, KN; Nguyen, TT; O'Neil, PM; Sebring, NG				Yanovski, JA; Yanovski, SZ; Sovik, KN; Nguyen, TT; O'Neil, PM; Sebring, NG			A prospective study of holiday weight gain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-MASS INDEX; SEASONAL AFFECTIVE-DISORDER; UNITED-STATES; SMOKING CESSATION; US ADULTS; WOMEN; OVERWEIGHT; PREVALENCE; AGE; OBESITY	Background: It is commonly asserted that the average American gains 5 lb (2.3 kg) or more over the holiday period between Thanksgiving and New Year's Day, yet few data support this statement. Methods: To estimate actual holiday-related weight variation, we measured body weight in a convenience sample of 195 adults. The subjects were weighed four times at intervals of six to eight weeks, so that weight change was determined for three periods: preholiday (from late September or early October to mid-November), holiday (from mid-November to early or mid-January), and postholiday (from early or mid-January to late February or early March). A final measurement of body weight was obtained in 165 subjects the following September or October. Data on other vital signs and self-reported health measures were obtained from the patients in order to mask the main outcome of interest. Results: The mean (+/-SD) weight increased significantly during the holiday period (gain, 0.37+/-1.52 kg; P<0.001), but not during the preholiday period (gain, 0.18+/-1.49 kg; P=0.09) or the postholiday period (loss, 0.07+/-1.14 kg; P=0.36). As compared with their weight in late September or early October, the study subjects had an average net weight gain of 0.48+/-2.22 kg in late February or March (P=0.003). Between February or March and the next September or early October, there was no significant additional change in weight (gain, 0.21 kg+/-2.3 kg; P=0.13) for the 165 participants who returned for follow-up. Conclusions: The average holiday weight gain is less than commonly asserted. Since this gain is not reversed during the spring or summer months, the net 0.48-kg weight gain in the fall and winter probably contributes to the increase in body weight that frequently occurs during adulthood. (N Engl J Med 2000;342:861-7.) (C)2000, Massachusetts Medical Society.	NICHHD, Unit Growth & Obes, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Div Digest Dis & Nutr, NIH, Bethesda, MD 20892 USA; NIDDKD, Div Nutr Res Coordinat, NIH, Bethesda, MD 20892 USA; NIH, Warren G Magnuson Clin Ctr, Dept Nutr, Bethesda, MD 20892 USA; Med Univ S Carolina, Charleston, SC 29425 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; Medical University of South Carolina	Yanovski, JA (corresponding author), NICHHD, Unit Growth & Obes, Dev Endocrinol Branch, NIH, Bldg 10,Rm 10N262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.			O'Neil, Patrick/0000-0002-0388-4046; Yanovski, Jack/0000-0001-8542-1637	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000641] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 HD000641, ZIA HD000641-14] Funding Source: Medline; NICHD NIH HHS [Z01 HD-00641] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON I, 1992, INT J OBESITY, V16, P1013; Baker RC, 1998, HEALTH PSYCHOL, V17, P367, DOI 10.1037/0278-6133.17.4.367; BALLARDBARBASH R, 1990, CANCER RES, V50, P2152; Boutelle KN, 1999, HEALTH PSYCHOL, V18, P364, DOI 10.1037/0278-6133.18.4.364; CARLEY T, 1997, EXERCISE TIPS REDUCE; *CNN INT, 1995, AV AM GAINS 7 10 POU; COLDITZ GA, 1990, AM J CLIN NUTR, V51, P1100, DOI 10.1093/ajcn/51.6.1100; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FLEGAL KM, 1995, NEW ENGL J MED, V333, P1165, DOI 10.1056/NEJM199511023331801; GOLDBOURT U, 1991, ISRAEL J MED SCI, V27, P264; Hollingshead A.B., 1975, 4 FACTOR INDEX SOCIA; Jeffery RW, 1997, INT J OBESITY, V21, P457, DOI 10.1038/sj.ijo.0800431; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MOE K, 1996, KEEPING HOLIDAY POUN; NAJJAR M, 1987, VITAL HLTH STAT, V11; NASH W, 1997, RICH HOLIDAY FOOD LE, P3; Nurse G T, 1968, Cent Afr J Med, V14, P122; *OH U, 1997, PART HEART RIGHT APP; PANTERBRICK C, 1995, J BIOSOC SCI, V27, P215, DOI 10.1017/S0021932000022719; PAWSON IG, 1982, SOC SCI MED, V16, P183, DOI 10.1016/0277-9536(82)90021-1; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; ROOKUS MA, 1987, HUM BIOL, V59, P599; ROSENTHAL NE, 1987, ANN NY ACAD SCI, V499, P216, DOI 10.1111/j.1749-6632.1987.tb36213.x; Sahyoun NR, 1999, AM J PUBLIC HEALTH, V89, P391, DOI 10.2105/AJPH.89.3.391; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; SHAH M, 1991, INT J OBESITY, V15, P499; Shimamoto H, 1998, JPN J PHYS FIT SPORT, V47, P509, DOI 10.7600/jspfsm1949.47.509; SILVERSTEIN LJ, 1996, J AM DIET ASSOC, V96, pA30; SMITH N, 1999, HOLIDAY WEIGHT GAIN; SOBAL J, 1992, SOC SCI MED, V35, P915, DOI 10.1016/0277-9536(92)90106-Z; *TEX MED ASS, 1998, HOL EAT; THOMPSON C, 1988, J AFFECT DISORDERS, V14, P257, DOI 10.1016/0165-0327(88)90043-2; VANLIERE MJ, 1994, BRIT J NUTR, V72, P479, DOI 10.1079/BJN19940049; VANSTAVEREN WA, 1986, INT J OBESITY, V10, P133; WESCOTT WL, 1998, SURVIVAL STRATEGIES; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WILLIAMSON DF, 1994, INT J OBESITY, V18, P561; WILLIAMSON DF, 1993, ANN INTERN MED, V119, P646, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00004; WING RR, 1991, ARCH INTERN MED, V151, P97, DOI 10.1001/archinte.151.1.97; Wolfe WS, 1997, INT J OBESITY, V21, P802, DOI 10.1038/sj.ijo.0800478; ZAHORSKAMARKIEWICZ B, 1980, INT J OBESITY, V4, P139; 1998, OBES RES, V6, P464	45	227	231	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 23	2000	342	12					861	867		10.1056/NEJM200003233421206	http://dx.doi.org/10.1056/NEJM200003233421206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296FU	10727591	Green Accepted			2022-12-28	WOS:000086014100006
J	Zoller, P				Zoller, P			Quantum optics - Tricks with a single photon	NATURE			English	Editorial Material									Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria	University of Innsbruck	Zoller, P (corresponding author), Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria.	peter.zoller@uibk.ac.at	Zoller, Peter/O-1639-2014	Zoller, Peter/0000-0003-4014-1505				Cirac JI, 1997, PHYS REV LETT, V78, P3221, DOI 10.1103/PhysRevLett.78.3221; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; Nogues G, 1999, NATURE, V400, P239, DOI 10.1038/22275; PINS, 2000, PINSKE PWH, V404, P365; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Varcoe BTH, 2000, NATURE, V403, P743, DOI 10.1038/35001526; Ye J, 1999, PHYS REV LETT, V83, P4987, DOI 10.1103/PhysRevLett.83.4987	7	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					340	341		10.1038/35006185	http://dx.doi.org/10.1038/35006185			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746705				2022-12-28	WOS:000086119000029
J	Vincent, C; Taylor-Adams, S; Chapman, EJ; Hewett, D; Prior, S; Strange, P; Tizzard, A				Vincent, C; Taylor-Adams, S; Chapman, EJ; Hewett, D; Prior, S; Strange, P; Tizzard, A			How to investigate and analyse clinical incidents: Clinical risk unit and association of litigation and risk management protocol	BRITISH MEDICAL JOURNAL			English	Article							MEDICINE		UCL, Dept Psychol, Clin Risk Unit, London WC1E 6BT, England; Aston Univ, Sch Life & Hlth Sci, Dept Psychol, Birmingham B4 7ET, W Midlands, England; NW London Hosp NHS Trust, Harrow HA1 3UJ, Middx, England; Winchester & Eastleigh Healthcare NHS Trust, Family Serv, Winchester SO22 5DG, Hants, England; Bromley Hosp NHS Trust, Orpington BR6 8ND, England; United Bristol Healthcare NHS Trust, St Michaels Hosp, Bristol BS2 8EG, Avon, England	University of London; University College London; Aston University	Vincent, C (corresponding author), UCL, Dept Psychol, Clin Risk Unit, Mortimer St, London WC1E 6BT, England.	c.vincent@ucl.ac.uk	Vincent, Charles/D-1134-2010	Vincent, Charles/0000-0003-0270-0222				Cook RI, 1994, HUMAN ERROR MED, P255; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; Cullen Lord, 1990, PUBLIC INQUIRY PIPER; EAGLE CJ, 1992, CAN J ANAESTH, V39, P118, DOI 10.1007/BF03008640; FERROW M, 1991, PETROLEUM REV    JAN, P9; HUGHES H, 1991, PETROLEUM REV    JAN, P5; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; REASON JT, 1995, CLIN RISK MANAGEMENT, P31; Stanhope N, 1997, BRIT J OBSTET GYNAEC, V104, P1225, DOI 10.1111/j.1471-0528.1997.tb10967.x; Taylor-Adams S, 1999, SAFETY SCI, V31, P143, DOI 10.1016/S0925-7535(98)00062-9; Vincent C, 1998, BRIT MED J, V316, P1154, DOI 10.1136/bmj.316.7138.1154; Vincent C., 1995, CLIN RISK MANAGEMENT, P391; VINCENT C, 2000, J MENTAL HLTH, V9, P89; VINCENT CA, 1999, PROTOCOL INVESTIGATI	14	276	291	1	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					777	781		10.1136/bmj.320.7237.777	http://dx.doi.org/10.1136/bmj.320.7237.777			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720366	Green Published			2022-12-28	WOS:000086054700031
J	Janowsky, EC; Kupper, LL; Hulka, BS				Janowsky, EC; Kupper, LL; Hulka, BS			Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; COSMETIC SURGERY; ALLEGHENY COUNTY; WOMEN; EPIDEMIOLOGY; SCLERODERMA; POPULATION; AUGMENTATION; POLYMYOSITIS	Background: The postulated relation between silicone breast implants and the risk of connective-tissue and autoimmune diseases has generated intense medical and legal interest during the past decade. The salience of the issue persists, despite the fact that a great deal of research has been conducted on this subject. To provide a stronger quantitative basis for addressing the postulated relation, we applied several techniques of meta-analysis that combine, compare, and summarize the results of existing relevant studies. Methods: We searched data bases and reviewed citations in relevant articles to identify studies that met prestated inclusion criteria. Nine cohort studies, nine case-control studies, and two cross-sectional studies were included in our meta-analyses. We conducted meta-analyses of the results of these studies, both with and without adjustment for confounding factors, and a separate analysis restricted to studies of silicone-gel-filled breast implants. Finally, we estimated the annual number of new cases of connective-tissue disease that could be attributed to breast implants. Results: There was no evidence that breast implants were associated with a significant increase in the summary adjusted relative risk of individual connective-tissue diseases (rheumatoid arthritis, 1.04 [95 percent confidence interval, 0.72 to 1.51]; systemic lupus erythematosus, 0.65 [95 percent confidence interval, 0.35 to 1.23]; scleroderma or systemic sclerosis, 1.01 [95 percent confidence interval, 0.59 to 1.73]; and Sjogren's syndrome, 1.42 [95 percent confidence interval, 0.65 to 3.11]); all definite connective-tissue diseases combined (0.80; 95 percent confidence interval, 0.62 to 1.04); or other autoimmune or rheumatic conditions (0.96; 95 percent confidence interval, 0.74 to 1.25). Nor was there evidence of significantly increased risk in the unadjusted analyses or in the analysis restricted to silicone-gel-filled implants. Conclusions: On the basis of our meta-analyses, there was no evidence of an association between breast implants in general, or silicone-gel-filled breast implants specifically, and any of the individual connective-tissue diseases, all definite connective-tissue diseases combined, or other autoimmune or rheumatic conditions. From a public health perspective, breast implants appear to have a minimal effect on the number of women in whom connective-tissue diseases develop, and the elimination of implants would not be likely to reduce the incidence of connective-tissue diseases. (N Engl J Med 2000;342:781-90.) (C)2000, Massachusetts Medical Society.	Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Janowsky, EC (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, CB 7400, Chapel Hill, NC 27599 USA.	esther_janowsky@unc.edu						ALBANI S, 1997, ARTHRITIS ALLIED CON, V1, P979; ANAYA JM, 1997, ARTHRITIS ALLIED CON, V2, P1561; Angell M, 1996, NEW ENGL J MED, V334, P1513, DOI 10.1056/NEJM199606063342306; BENBASSAT J, 1980, ISRAEL J MED SCI, V16, P197; Burns CJ, 1996, J RHEUMATOL, V23, P1904; Cook LS, 1997, JAMA-J AM MED ASSOC, V277, P1612, DOI 10.1001/jama.277.20.1612; Cooper C, 1998, BMJ-BRIT MED J, V316, P403, DOI 10.1136/bmj.316.7129.403; DIAMOND BA, 1998, SILICON BREAST IMPLA; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; DUGOWSON CE, 1991, ARTHRITIS RHEUM-US, V34, P1502; Edworthy SM, 1998, J RHEUMATOL, V25, P254; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Englert H, 1996, AUST NZ J MED, V26, P349, DOI 10.1111/j.1445-5994.1996.tb01921.x; FELSON DT, 1997, ARTHRITIS ALLIED CON, V1, P3; FOX RI, 1986, SCAND J RHEUMATOL, P28; Friis S, 1997, ANN PLAS SURG, V39, P1, DOI 10.1097/00000637-199707000-00001; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; GOLDMAN JA, 1995, J CLIN EPIDEMIOL, V48, P571, DOI 10.1016/0895-4356(94)00215-C; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; GUDMUNDSSON S, 1990, J RHEUMATOL, V17, P1162; Hennekens CH, 1998, JAMA-J AM MED ASSOC, V279, P198; Hochberg MC, 1996, CURR TOP MICROBIOL, V210, P411; HOCHBERG MC, 1985, ARTHRITIS RHEUM-US, V28, P80, DOI 10.1002/art.1780280113; Hochberg MC, 1996, ARTHRITIS RHEUM, V39, P1125, DOI 10.1002/art.1780390708; HOPKINSON ND, 1993, BRIT J RHEUMATOL, V32, P110; JOHNSON AE, 1995, ARTHRITIS RHEUM, V38, P551, DOI 10.1002/art.1780380415; JONSSON H, 1990, BRIT J RHEUMATOL, V29, P185; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; Lacey JV, 1997, J RHEUMATOL, V24, P1854; Laing Timothy J., 1996, Arthritis and Rheumatism, V39, pS150; Lewin SL, 1997, PLAST RECONSTR SURG, V100, P1309, DOI 10.1097/00006534-199710000-00038; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; Mayes MD, 1996, RHEUM DIS CLIN N AM, V22, P751, DOI 10.1016/S0889-857X(05)70299-4; MEDSGER TA, 1970, AM J MED, V48, P715, DOI 10.1016/S0002-9343(70)80006-7; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; NORTHRIDGE ME, 1995, AM J PUBLIC HEALTH, V85, P1202, DOI 10.2105/AJPH.85.9.1202; NOSSENT JC, 1992, ANN RHEUM DIS, V51, P1197, DOI 10.1136/ard.51.11.1197; Nyren O, 1998, BRIT MED J, V316, P417, DOI 10.1136/bmj.316.7129.417; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; Park AJ, 1998, PLAST RECONSTR SURG, V101, P261, DOI 10.1097/00006534-199802000-00001; Perkins LL, 1995, ANN PLAS SURG, V35, P561, DOI 10.1097/00000637-199512000-00001; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Rosenbaum JT, 1997, SCIENCE, V276, P1524, DOI 10.1126/science.276.5318.1524; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SCHUSTERMAN MA, 1993, ANN PLAS SURG, V31, P1; STAR VL, 1993, ARTHRITIS RHEUM, V36, pS100; Steen VD, 1997, ARTHRITIS RHEUM-US, V40, P441, DOI 10.1002/art.1780400309; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; SYMMONS DPM, 1992, ARTHRITIS RHEUM, V35, pS126; TEEL WB, 1997, THESIS U WASHINGTON; TEICHALASIA S, 1993, INT CONF PLAST REC S; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; WELLS KE, 1994, PLAST RECONSTR SURG, V93, P907, DOI 10.1097/00006534-199404001-00002; WOLFE P, 1995, ARTHRITIS RHEUM S, V38, pS265; Wong O, 1996, REGUL TOXICOL PHARM, V23, P74, DOI 10.1006/rtph.1996.0011	57	268	276	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2000	342	11					781	790		10.1056/NEJM200003163421105	http://dx.doi.org/10.1056/NEJM200003163421105			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293HW	10717013	Green Published			2022-12-28	WOS:000085846900005
J	Tanaka, H; Arakawa, H; Yamaguchi, T; Shiraishi, K; Fukuda, S; Matsui, K; Takei, Y; Nakamura, Y				Tanaka, H; Arakawa, H; Yamaguchi, T; Shiraishi, K; Fukuda, S; Matsui, K; Takei, Y; Nakamura, Y			A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage	NATURE			English	Article							WILD-TYPE P53; SMALL-SUBUNIT; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; UV IRRADIATION; PROTEIN; EXPRESSION; REPAIR; SENSITIVITY; AGENTS	The p53 gene is frequently inactivated in human cancers. Here we have isolated a p53-inducible gene, p53R2,by using differential display to examine messenger RNAs in a cancer-derived human cell line carrying a highly regulated wild-type p53 expression system. p53R2 contains a p53-binding sequence in intron 1 and encodes a 351-amino-acid peptide with striking similarity to the ribonucleotide reductase small subunit(R2), which is important in DNA synthesis during cell division. Expression of p53R2, but not R2, was induced by ultraviolet and gamma-irradiation and adriamycin treatment in a wild-type p53-dependent manner. Induction of p53R2 in p53-deficient cells caused G2/M arrest and prevented cells from death in response to adriamycin, Inhibition of endogenous p53R2 expression in cells that have an intact p53-dependent DNA damage checkpoint reduced ribonucleotide reductase activity, DNA repair and cell survival after exposure to various genotoxins. Our results indicate that p53R2 encodes a ribonucleotide reductase that is directly involved in the p53 checkpoint for repair of damaged DNA, The discovery of p53R2 clarifies a relationship between a ribonucleotide reductase activity involved in repair of damaged DNA and tumour suppression by p53.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Ceraline J, 1998, INT J CANCER, V75, P432, DOI 10.1002/(SICI)1097-0215(19980130)75:3<432::AID-IJC17>3.3.CO;2-J; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; ERIKSSON S, 1981, J BIOL CHEM, V256, P9436; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Furuhata T, 1996, ONCOGENE, V13, P1965; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; HARPER JW, 1993, CELL, V75, P805; Hawkins DS, 1996, CANCER RES, V56, P892; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Ng CC, 1999, GENE CHROMOSOME CANC, V26, P329, DOI 10.1002/(SICI)1098-2264(199912)26:4<329::AID-GCC7>3.0.CO;2-C; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; REDDY GPV, 1982, J BIOL CHEM, V257, P2526; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Takei Y, 1998, GENE CHROMOSOME CANC, V23, P1; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Urano T, 1997, CANCER RES, V57, P3281; Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	41	725	746	2	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					42	49		10.1038/35003506	http://dx.doi.org/10.1038/35003506			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716435				2022-12-28	WOS:000085775100038
J	Diamond, J				Diamond, J			Archaeology - Blitzkrieg against the moas	SCIENCE			English	Editorial Material									Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Diamond, J (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.	jdiamond@mednet.ucla.edu						ANDERSON A, 1991, ANTIQUITY, V65, P767, DOI 10.1017/S0003598X00080510; ANDERSON A, 1996, SHAG RIVER MOUTH; [Anonymous], 1989, PRODIGIOUS BIRDS; Holdaway RN, 2000, SCIENCE, V287, P2250, DOI 10.1126/science.287.5461.2250; Martin PS, 1984, QUATERNARY EXTINCTIO; MOSIMANN JE, 1975, AM SCI, V63, P304	6	10	10	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2170	2171		10.1126/science.287.5461.2170	http://dx.doi.org/10.1126/science.287.5461.2170			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10744538				2022-12-28	WOS:000086049100025
J	Hoskins, RA; Nelson, CR; Berman, BP; Laverty, TR; George, RA; Ciesiolka, L; Naeemuddin, M; Arenson, AD; Durbin, J; David, RG; Tabor, PE; Bailey, MR; DeShazo, DR; Catanese, J; Mammoser, A; Osoegawa, K; de Jong, PJ; Celniker, SE; Gibbs, RA; Rubin, GM; Scherer, SE				Hoskins, RA; Nelson, CR; Berman, BP; Laverty, TR; George, RA; Ciesiolka, L; Naeemuddin, M; Arenson, AD; Durbin, J; David, RG; Tabor, PE; Bailey, MR; DeShazo, DR; Catanese, J; Mammoser, A; Osoegawa, K; de Jong, PJ; Celniker, SE; Gibbs, RA; Rubin, GM; Scherer, SE			A BAC-based physical map of the major autosomes of Drosophila melanogaster	SCIENCE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; GENOME; CLONES; CONTIGS	We constructed a bacterial artificial chromosome (BAC)-based physical map of chromosomes 2 and 3 of Drosophila melanogaster, which constitute 81% of the genome. Sequence tagged site (STS) content, restriction fingerprinting, and polytene chromosome in situ hybridization approaches were integrated to produce a map spanning the euchromatin. Three of five remaining gaps are in repeat-rich regions near the centromeres. A tiling path of clones spanning this map and STS maps of chromosomes X and 4 was sequenced to low coverage; the maps and tiling path sequence were used to support and verify the whole-genome sequence assembly, and tiling path BACs were used as templates in sequence finishing.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA; Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Baylor College of Medicine; Roswell Park Cancer Institute	Hoskins, RA (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA.	hoskins@bdgp.lbl.gov	Berman, Benjamin P/D-5942-2014; BERMAN, BENJAMIN/AAT-3720-2021	Berman, Benjamin P/0000-0002-2099-9005; BERMAN, BENJAMIN/0000-0002-2099-9005; Rubin, Gerald/0000-0001-8762-8703	NHGRI NIH HHS [HG00750] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000750] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; AJIOKA JW, 1991, CHROMOSOMA, V100, P495, DOI 10.1007/BF00352200; Ashburner M, 1999, GENETICS, V153, P179; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; BRIZUELA BJ, 1994, GENETICS, V137, P803; CAI HN, 1994, GENETICS, V136, P1385; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; Green E D, 1991, PCR Methods Appl, V1, P77; Kimmerly W, 1996, GENOME RES, V6, P414, DOI 10.1101/gr.6.5.414; LOCKE J, IN PRESS GENETICS; MADUENO E, 1995, GENETICS, V139, P1631; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Mozo T, 1999, NAT GENET, V22, P271, DOI 10.1038/10334; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; PETERS AHF, UNPUB; RIETHMAN H, 1997, GENOME ANAL LAB MANU, V1, P106; Ross M.T., 1999, CURRENT PROTOCOLS HU; SIDENKIAMOS I, 1990, NUCLEIC ACIDS RES, V18, P6261, DOI 10.1093/nar/18.21.6261; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; SULSTON J, 1988, COMPUT APPL BIOSCI, V4, P125; [No title captured]	24	106	112	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2271	2274		10.1126/science.287.5461.2271	http://dx.doi.org/10.1126/science.287.5461.2271			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731150				2022-12-28	WOS:000086049100053
J	Sahn, SA; Heffner, JE				Sahn, SA; Heffner, JE			Spontaneous pneumothorax	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ASSISTED THORACIC-SURGERY; SECONDARY SPONTANEOUS PNEUMOTHORAX; RECURRENT SPONTANEOUS PNEUMOTHORAX; LIMITED AXILLARY THORACOTOMY; SURGICAL-TREATMENT; THORACOSCOPIC SURGERY; COMPUTED-TOMOGRAPHY; TETRACYCLINE PLEURODESIS; TALC PLEURODESIS; CLINICAL COURSE		Med Univ S Carolina, Div Pulm & Crit Care Med Allergy & Clin Immunol, Charleston, SC 29425 USA	Medical University of South Carolina	Sahn, SA (corresponding author), Med Univ S Carolina, Div Pulm & Crit Care Med Allergy & Clin Immunol, 96 Honathan Lucas St,Suite 812,POB 250623, Charleston, SC 29425 USA.		Hug, Balthasar L./G-1568-2010					ALFAGEME I, 1994, CHEST, V106, P347, DOI 10.1378/chest.106.2.347; ALMIND M, 1989, THORAX, V44, P627, DOI 10.1136/thx.44.8.627; Andres B, 1998, SURG LAPAROSC ENDOSC, V8, P108, DOI 10.1097/00019509-199804000-00005; BARONOFSKY ID, 1957, J THORAC SURG, V34, P310; BENSE L, 1987, EUR J RESPIR DIS, V71, P181; BENSE L, 1987, CHEST, V92, P1009, DOI 10.1378/chest.92.6.1009; BENSE L, 1993, CHEST, V103, P433, DOI 10.1378/chest.103.2.433; Bertrand PC, 1996, ANN THORAC SURG, V61, P1641, DOI 10.1016/0003-4975(96)00190-7; BOURGOUIN P, 1985, J CAN ASSOC RADIOL, V36, P341; BOUTIN C, 1995, CLIN CHEST MED, V16, P497; BRADLEY M, 1991, ARCH EMERG MED, V8, P115; British Thoracic Society Research Committee, 1993, THORAX, V48, P430; BYRNES TA, 1989, J THORAC CARDIOV SUR, V98, P546; Campos JRM, 1997, LANCET, V349, P251, DOI 10.1016/S0140-6736(05)64860-X; CASOLA G, 1988, RADIOLOGY, V166, P89, DOI 10.1148/radiology.166.1.3336707; Chee CBE, 1998, RESP MED, V92, P757, DOI 10.1016/S0954-6111(98)90008-7; CONCES DJ, 1988, CHEST, V94, P55, DOI 10.1378/chest.94.1.55; Crisci R, 1996, EUR J CARDIO-THORAC, V10, P556, DOI 10.1016/S1010-7940(96)80424-6; DEGIACOMO T, 1995, EUR J SURG, V161, P227; DINES DE, 1970, MAYO CLIN PROC, V45, P481; DONAHUE DM, 1993, CHEST, V104, P1767, DOI 10.1378/chest.104.6.1767; Dumont P, 1997, EUR J CARDIO-THORAC, V11, P27, DOI 10.1016/S1010-7940(96)01021-4; Freixinet J, 1997, EUR RESPIR J, V10, P409, DOI 10.1183/09031936.97.10020409; Fukuda Y, 1994, AM J RESP CRIT CARE, V149, pA1022; GEORGE RB, 1975, JAMA-J AM MED ASSOC, V234, P389, DOI 10.1001/jama.234.4.389; GOBBEL WG, 1963, J THORAC CARDIOV SUR, V46, P331, DOI 10.1016/S0022-5223(19)33666-9; HAGEN RH, 1987, SCAND J THORAC CARD, V21, P183, DOI 10.3109/14017438709106521; HAZELRIGG SR, 1993, J THORAC CARDIOV SUR, V105, P389; Horio H, 1998, SURG ENDOSC-ULTRAS, V12, P1155, DOI 10.1007/s004649900805; IKEDA M, 1988, J THORAC CARDIOV SUR, V96, P615; INDERBITZI RGC, 1994, J THORAC CARDIOV SUR, V107, P1410, DOI 10.1016/S0022-5223(94)70415-5; Ingram RJH, 1996, CLIN INFECT DIS, V23, P624, DOI 10.1093/clinids/23.3.624; Jain SK, 1998, J CARDIOVASC SURG, V39, P107; JANSSEN JP, 1995, CHEST, V108, P330, DOI 10.1378/chest.108.2.330; JANSSEN JP, 1994, EUR RESPIR J, V7, P1281, DOI 10.1183/09031936.94.07071281; Jordan KG, 1997, CHEST, V111, P280, DOI 10.1378/chest.111.2.280; Joseph J, 1996, AM J MED, V100, P164, DOI 10.1016/S0002-9343(97)89454-5; Kim J, 1998, SURG ENDOSC-ULTRAS, V12, P1290, DOI 10.1007/s004649900842; Kim KH, 1996, ANN THORAC SURG, V61, P1510; KIRBY TJ, 1992, CLIN CHEST MED, V13, P97; KONDO T, 1994, AM J RESP CRIT CARE, V149, P178, DOI 10.1164/ajrccm.149.1.8111579; Korner H, 1996, EUR J CARDIO-THORAC, V10, P656, DOI 10.1016/S1010-7940(96)80381-2; LESUR O, 1990, CHEST, V98, P341, DOI 10.1378/chest.98.2.341; LEWIS JG, 1964, Q J MED, V33, P337; LIGHT RW, 1990, JAMA-J AM MED ASSOC, V264, P2224, DOI 10.1001/jama.264.17.2224; LIPPERT HL, 1991, EUR RESPIR J, V4, P324; Macklin MT, 1944, MEDICINE, V23, P281, DOI 10.1097/00005792-194412000-00001; Martin T, 1996, CHEST, V110, P1169, DOI 10.1378/chest.110.5.1169; Massard G, 1998, ANN THORAC SURG, V66, P592, DOI 10.1016/S0003-4975(98)00621-3; MCCLELLAN MD, 1991, CHEST, V100, P1224, DOI 10.1378/chest.100.5.1224; MELTON LJ, 1979, AM REV RESPIR DIS, V120, P1379; METERSKY ML, 1995, CHEST, V108, P946, DOI 10.1378/chest.108.4.946; MILANEZ JRC, 1994, CHEST, V106, P1162, DOI 10.1378/chest.106.4.1162; MINAMI H, 1992, AM J MED SCI, V304, P345, DOI 10.1097/00000441-199212000-00002; MITLEHNER W, 1992, RESPIRATION, V59, P221; Mouroux J, 1996, J THORAC CARDIOV SUR, V112, P385, DOI 10.1016/S0022-5223(96)70266-0; Mukaida T, 1998, ANN THORAC SURG, V65, P924, DOI 10.1016/S0003-4975(98)00108-8; MURRAY KD, 1993, CHEST, V103, P137, DOI 10.1378/chest.103.1.137; Nasreen N, 1998, AM J RESP CRIT CARE, V158, P971, DOI 10.1164/ajrccm.158.3.9801097; NKERE UU, 1991, THORAX, V46, P596, DOI 10.1136/thx.46.8.596; NORTHFIELD TC, 1971, BMJ-BRIT MED J, V4, P86, DOI 10.1136/bmj.4.5779.86; OHATA M, 1980, CHEST, V77, P771, DOI 10.1378/chest.77.6.771; Passlick B, 1998, ANN THORAC SURG, V65, P324, DOI 10.1016/S0003-4975(97)01128-4; PAVLIN DJ, 1986, CHEST, V89, P70, DOI 10.1378/chest.89.1.70; Ponn RB, 1997, ANN THORAC SURG, V64, P1437, DOI 10.1016/S0003-4975(97)00853-9; PRIMROSE WR, 1984, SCOT MED J, V29, P15, DOI 10.1177/003693308402900105; Rozenman J, 1996, RESP MED, V90, P235, DOI 10.1016/S0954-6111(96)90293-0; RUCKLEY CV, 1966, THORAX, V21, P139, DOI 10.1136/thx.21.2.139; SCHOENENBERGER RA, 1991, ARCH SURG-CHICAGO, V126, P764; Schramel FMNH, 1997, EUR RESPIR J, V10, P1372, DOI 10.1183/09031936.97.10061372; SEPKOWITZ KA, 1991, ANN INTERN MED, V114, P455, DOI 10.7326/0003-4819-114-6-455; SEREMETIS MG, 1970, CHEST, V57, P65, DOI 10.1378/chest.57.1.65; Shields T W, 1966, Ann Thorac Surg, V2, P377; SO SY, 1982, THORAX, V37, P46, DOI 10.1136/thx.37.1.46; Soulsby T, 1998, J ACCID EMERG MED, V15, P317; Spivak H, 1996, AM SURGEON, V62, P753; TANAKA F, 1993, ANN THORAC SURG, V55, P372, DOI 10.1016/0003-4975(93)91001-4; TAYLOR JR, 1990, NEW ENGL J MED, V323, P1254, DOI 10.1056/NEJM199011013231807; Trachiotis GD, 1996, ANN THORAC SURG, V62, P1608, DOI 10.1016/S0003-4975(96)00756-4; Tschopp JM, 1997, THORAX, V52, P329, DOI 10.1136/thx.52.4.329; VIDEM V, 1987, EUR J RESPIR DIS, V71, P365; WALLAERT B, 1993, AM REV RESPIR DIS, V147, P1537, DOI 10.1164/ajrccm/147.6_Pt_1.1537; YIM APC, 1995, SURG ENDOSC-ULTRAS, V9, P332; Yim APC, 1997, SURG LAPAROSC ENDOSC, V7, P236, DOI 10.1097/00019509-199706000-00012; [No title captured]	85	447	471	1	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	2000	342	12					868	874		10.1056/NEJM200003233421207	http://dx.doi.org/10.1056/NEJM200003233421207			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296FU	10727592				2022-12-28	WOS:000086014100007
J	Dignam, JJ; Fisher, B				Dignam, JJ; Fisher, B			Occurrence of stroke with tamoxifen in NSABP B-24	LANCET			English	Letter							BREAST-CANCER; ADJUVANT		NASBP Biostat Ctr, Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project	Fisher, B (corresponding author), NASBP Biostat Ctr, Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA 15213 USA.							Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; SAPHNER T, 1991, J CLIN ONCOL, V9, P286, DOI 10.1200/JCO.1991.9.2.286	3	25	26	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					848	849		10.1016/S0140-6736(05)72466-1	http://dx.doi.org/10.1016/S0140-6736(05)72466-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711957				2022-12-28	WOS:000085766900058
J	Gauntlett, J				Gauntlett, J			Physics - Brane new worlds	NATURE			English	Editorial Material							DIMENSIONS; MILLIMETER		Univ London Queen Mary & Westfield Coll, Dept Phys, London E1 4NS, England	University of London; Queen Mary University London	Gauntlett, J (corresponding author), Univ London Queen Mary & Westfield Coll, Dept Phys, Mile End Rd, London E1 4NS, England.			Gauntlett, Jerome/0000-0001-6622-7812				Antoniadis I, 1998, PHYS LETT B, V436, P257, DOI 10.1016/S0370-2693(98)00860-0; Arkani-Hamed N, 1998, PHYS LETT B, V429, P263, DOI 10.1016/S0370-2693(98)00466-3; Horava P, 1996, NUCL PHYS B, V475, P94, DOI 10.1016/0550-3213(96)00308-2; Randall L, 1999, PHYS REV LETT, V83, P4690, DOI 10.1103/PhysRevLett.83.4690; Randall L, 1999, PHYS REV LETT, V83, P3370, DOI 10.1103/PhysRevLett.83.3370	5	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					28	29		10.1038/35003679	http://dx.doi.org/10.1038/35003679			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716427				2022-12-28	WOS:000085775100027
J	Gregory, R				Gregory, R			Reversing Rorschach - Ink-blot tests might be able to tell us more about creativity than personality.	NATURE			English	Editorial Material									Univ Bristol, Dept Expt Psychol, Bristol BS8 1TN, Avon, England	University of Bristol	Gregory, R (corresponding author), Univ Bristol, Dept Expt Psychol, 8 Woodland Rd, Bristol BS8 1TN, Avon, England.							RORSCHACH, 1921, PSYCHODIAGNOSTICS DI	1	8	9	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					19	19		10.1038/35003661	http://dx.doi.org/10.1038/35003661			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716422				2022-12-28	WOS:000085775100022
J	McAuley, P				McAuley, P			Danger - hard hack area - "Sequence your genome at home, and set science free!" cry the biopunks.	NATURE			English	Editorial Material									Univ St Andrews, St Andrews KY16 9AJ, Fife, Scotland	University of St Andrews	McAuley, P (corresponding author), Univ St Andrews, St Andrews KY16 9AJ, Fife, Scotland.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					21	21		10.1038/35003664	http://dx.doi.org/10.1038/35003664			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716423	Bronze			2022-12-28	WOS:000085775100023
J	Pertea, M; Salzberg, SL; Gardner, MJ				Pertea, M; Salzberg, SL; Gardner, MJ			Bioinformatics - Finding genes in Plasmodium falciparum	NATURE			English	Article									Inst Genom Res, Rockville, MD 20850 USA	J. Craig Venter Institute	Pertea, M (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.		Salzberg, Steven/Q-6514-2019; Salzberg, Steven L/F-6162-2011; Pertea, Mihaela/AAT-2705-2021	Salzberg, Steven/0000-0002-8859-7432; Salzberg, Steven L/0000-0002-8859-7432; Pertea, Mihaela/0000-0003-0762-8637				Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Salzberg SL, 1999, GENOMICS, V59, P24, DOI 10.1006/geno.1999.5854	3	18	18	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					34	34		10.1038/35003643	http://dx.doi.org/10.1038/35003643			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716431	Bronze			2022-12-28	WOS:000085775100032
J	Bloom, DE; Canning, D				Bloom, DE; Canning, D			Public health - The health and wealth of nations	SCIENCE			English	Article									Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA; Queens Univ Belfast, Belfast BT7 1NN, Antrim, North Ireland	Harvard University; Harvard T.H. Chan School of Public Health; Queens University Belfast	Bloom, DE (corresponding author), Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.		Canning, David/A-1917-2008					[Anonymous], 1999, WORLD HLTH REPORT 19; [Anonymous], 1997, CONFR AIDS PUBL PRIO; Becker C, 1998, WORLD DEV, V26, P1913, DOI 10.1016/S0305-750X(98)00097-7; Bloom DE, 1998, WORLD BANK ECON REV, V12, P419, DOI 10.1093/wber/12.3.419; BLOOM DE, IN PRESS POPULATION; BLOOM DE, IN PRESS POPUL DEV R; BLOOM DE, 1998, MACROECON, V2, P207; BLOOM DE, 1999, MOMENT TIME AIDS BUS; BLOOM DE, IN PRES QUALITY LIFE; EASTERLIN RA, 1998, UNPUB; Steckel R.H., 1997, HLTH WELFARE IND; Strauss J, 1998, J ECON LIT, V36, P766; *WORLD BANK, 1999, WORLD DEV IND 1999	13	377	389	4	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1207	+		10.1126/science.287.5456.1207	http://dx.doi.org/10.1126/science.287.5456.1207			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	286KG	10712155				2022-12-28	WOS:000085444700029
J	EHRHARDT, DW; ATKINSON, EM; LONG, SR				EHRHARDT, DW; ATKINSON, EM; LONG, SR			DEPOLARIZATION OF ALFALFA ROOT HAIR MEMBRANE-POTENTIAL BY RHIZOBIUM-MELILOTI NOD FACTORS	SCIENCE			English	Article							ELONGATION; SIGNAL; CELLS; AUXIN	Although much is known about the bacterial genetics of early nodulation, little is known about the plant cell response. Alfalfa root hair cells were impaled with intracellular micro-electrodes to measure a membrane potential depolarizing activity in Rhizobium meliloti cell-free filtrates, a plant response dependent on the bacterial nodulation genes. The depolarization was desensitized by repeated exposure to factors and was not observed in a representative nonlegume. A purified extracellular Nod factor, NodRm-IV(S), caused membrane potential depolarization at nanomolar concentrations. This rapid single-cell assay provides a tool for dissecting the mechanisms of host cell response in early nodulation.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University								BATES GW, 1982, J MEMBRANE BIOL, V66, P15, DOI 10.1007/BF01868478; BISSELING T, COMMUNICATION; CLARKSON DT, 1988, J CELL SCI, V91, P71; CLELAND RE, 1977, PLANT PHYSIOL, V60, P709, DOI 10.1104/pp.60.5.709; DJORDJEVIC MA, 1987, ANNU REV PHYTOPATHOL, V25, P145, DOI 10.1146/annurev.py.25.090187.001045; DUDLEY ME, 1987, PLANTA, V171, P289, DOI 10.1007/BF00398674; DUDLEY ME, 1989, PLANT CELL, V1, P65, DOI 10.1105/tpc.1.1.65; EHRHARDT DW, UNPUB; FAUCHER C, 1988, J BACTERIOL, V170, P5489, DOI 10.1128/jb.170.12.5489-5499.1988; HAGER A, 1971, PLANTA, V100, P47, DOI 10.1007/BF00386886; HOPE AB, 1978, PHYSL GIANT ALGAL CE; LEROUGE P, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P177; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LICHTNER FT, 1981, PLANT PHYSIOL, V67, P869, DOI 10.1104/pp.67.4.869; Long S. R., 1984, Plant-microbe interactions. Molecular and genetic perspectives. Volume I., P265; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; MAYER MG, 1988, PHYSIOL MOL PLANT P, V33, P397, DOI 10.1016/0885-5765(88)90006-9; PAVLOVKIN J, 1986, PHYSIOL MOL PLANT P, V28, P125, DOI 10.1016/S0048-4059(86)80014-5; RAYLE D, 1970, PLANT PHYSIOL, V46, P250, DOI 10.1104/pp.46.2.250; RYAN CA, 1987, ANNU REV CELL BIOL, V3, P295, DOI 10.1146/annurev.cellbio.3.1.295; SCHROEDER JI, 1989, TRENDS BIOCH SCI, V14; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SPAINK H, COMMUNICATION; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0	25	317	326	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					998	1000		10.1126/science.10744524	http://dx.doi.org/10.1126/science.10744524			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	10744524				2022-12-28	WOS:A1992HU22400030
J	Karcher, AM; Zaman, A; Brewis, C; Fahmy, T				Karcher, AM; Zaman, A; Brewis, C; Fahmy, T			Neck lumps: expect the unexpected	LANCET			English	Article							MELIOIDOSIS		St Bartholomews Hosp, Dept Microbiol, London EC1A 7BE, England; St Bartholomews Hosp, Dept ENT, London EC1A 7BE, England; Norfolk & Norwich Hosp, Dept ENT, Norwich, Norfolk, England	University of London; Queen Mary University London; University of London; Queen Mary University London; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Karcher, AM (corresponding author), Homerton Hosp, Dept Med Microbiol, London E9 6SR, England.	AnneMarieKarcher@cs.com						CHAOWAGUL W, 1989, J INFECT DIS, V159, P890, DOI 10.1093/infdis/159.5.890; Hoque SN, 1999, RHEUMATOLOGY, V38, P1029, DOI 10.1093/rheumatology/38.10.1029a; KIBBLER CC, 1991, POSTGRAD MED J, V67, P764, DOI 10.1136/pgmj.67.790.764; Minassian MA, 1999, INT J ANTIMICROB AG, V12, P263, DOI 10.1016/S0924-8579(99)00071-0; RAJCHANUVONG A, 1995, T ROY SOC TROP MED H, V89, P546, DOI 10.1016/0035-9203(95)90104-3	5	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	2000	355	9209					1070	1070		10.1016/S0140-6736(00)02040-7	http://dx.doi.org/10.1016/S0140-6736(00)02040-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744094				2022-12-28	WOS:000086380800015
J	Stenius-Aarniala, B; Poussa, T; Kvarnstrom, J; Gronlund, EL; Ylikahri, M; Mustajoki, P				Stenius-Aarniala, B; Poussa, T; Kvarnstrom, J; Gronlund, EL; Ylikahri, M; Mustajoki, P			Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study	BRITISH MEDICAL JOURNAL			English	Article							MORBID-OBESITY; BEHAVIOR; THERAPY	Objective To investigate the influence of weight reduction on obese patients with asthma. Design Open study two randomised parallel groups. Setting Private outpatients centre, Helsinki, Finland. Participants Two groups of 19 obese patients with asthma (body mass index (kg/m(2)) 30 to 42) recruited through newspaper advertisements. Intervention Supervised weight reduction programme including 8 week very low energy diet. Main outcome measures Body weight morning peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory volume in one second (FEV1); and also asthma symptoms, number of acute episodes, courses of oral steroids, health status (quality of life). Results At the end of the weight reducing programme, the participants in the treatment group had lost a mean of 14.5% of their pretreatment weight, the controls 0.3%. The corresponding figures after one) ear were 11.3% and a weight gain of 2.2%. After the 8 week dieting period the difference in changes in percentage of predicted FEV1 from baseline in the treatment and control groups was 7.2% (95% confidence interval 1.9% to 12.5%, P = 0.009). The corresponding difference in the changes in FVC was 8.6% (4.8% to 12.5%, P < 0.0001). After one lear the differences in the changes in the two groups were still significant: 7.6% for FEV1 (1.5% to 13.8%, P = 0.02) and 7.6% for FVC (3.5% to 11.8%, P = 0.001). By the end of the weight reduction programme, reduction in dyspnoea was 13 mm (on a visual analogue scale 0 mm to 100 mm) in the treatment group and 1 mm in the control group (P = 0.02). The reduction of rescue medication was 1.2 and 0.1 doses respectively (P = 0.03). After one year the differences in the changes between the two groups were - 12 for symptom scores (range - 1 to - 22, P = 0.04) and - 10 for total scores (- 18 to - 1, P = 0.02). The median number of exacerbations in the treatment group was 1 (0-4) and in the controls 4 (0-7), P = 0.001. Conclusion Weight reduction in obese patients with asthma improves lung function, symptoms, morbidity and health status.	Univ Helsinki, Cent Hosp, Dept Med, Div Pulm Med & Allergol, FIN-00029 Hyks, Finland; STAT Consulting, FIN-33540 Tampere, Finland; Peijas Hosp, FIN-01400 Vantaa, Finland	University of Helsinki; Helsinki University Central Hospital	Stenius-Aarniala, B (corresponding author), Univ Helsinki, Cent Hosp, Dept Med, Div Pulm Med & Allergol, PL 340, FIN-00029 Hyks, Finland.							CAREY OJ, 1993, THORAX, V48, P714, DOI 10.1136/thx.48.7.714; GALL H, 1990, ALLERGOLOGIE, V13, P352; Glenny AM, 1997, INT J OBESITY, V21, P715, DOI 10.1038/sj.ijo.0800495; HAKALA K, 1995, INT J OBESITY, V19, P343; Harding SM, 1997, CHEST, V111, P1389, DOI 10.1378/chest.111.5.1389; Hill J, 1997, EUR RESPIR J, V10, P2225, DOI 10.1183/09031936.97.10102225; JONES PW, 1994, EUR RESPIR J, V7, P55, DOI 10.1183/09031936.94.07010055; MUSTAJOKI P, 1998, DIS MANAGEMENT HLTH, V4, P267; NUNN JA, 1989, BRIT MED J, V289, P1068; Pekkarinen T, 1996, INT J OBESITY, V20, P332; Pekkarinen T, 1997, ARCH INTERN MED, V157, P1581, DOI 10.1001/archinte.157.14.1581; POCOCK SJ, 1988, CLIN TRIALS PRACTICA, P124; Santanello NC, 1999, EUR RESPIR J, V14, P23, DOI 10.1034/j.1399-3003.1999.14a06.x; Seidell JC, 1997, BRIT MED BULL, V53, P238, DOI 10.1093/oxfordjournals.bmb.a011611; Viljanen A, 1982, SCAND J CLIN LA S159, V42, P1; Wing R. R., 1998, HDB OBESITY, P855	16	384	399	1	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					827	832		10.1136/bmj.320.7238.827	http://dx.doi.org/10.1136/bmj.320.7238.827			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731173	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086180300021
J	Faure, S; Meyer, L; Costagliola, D; Vaneensberghe, C; Genin, E; Autran, B; Delfraissy, JF; McDermott, DH; Murphy, PM; Debre, P; Theodorou, I; Combadiere, C				Faure, S; Meyer, L; Costagliola, D; Vaneensberghe, C; Genin, E; Autran, B; Delfraissy, JF; McDermott, DH; Murphy, PM; Debre, P; Theodorou, I; Combadiere, C		French ALT IMMUNOCO Study Grp; SEROCO Study Grp	Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX(3)CR1	SCIENCE			English	Article							DISEASE PROGRESSION; GENETIC RESTRICTION; INFECTION; CCR5; FRACTALKINE; IDENTIFICATION; PATHOGENESIS; TRANSMISSION; RESISTANCE; MICROGLIA	Human immunodeficiency virus (HIV) enters cells in vitro via CD4 and a coreceptor. Which of 15 known coreceptors are important in vivo is poorly defined but may be inferred from disease-modifying mutations, as for CCR5, Here two single nucleotide polymorphisms are described in Caucasians in CX(3)CR1, an HIV coreceptor and leukocyte chemotactic/adhesion receptor for the chemokine fractalkine. HIV-infected patients homozygous for CX(3)CR1-1249 M280, a variant haplotype affecting two amino acids (isoleucine-249 and methionine-280), progressed to AIDS more rapidly than those with other haplotypes. Functional CX(3)CR1 analysis showed that fractalkine binding is reduced among patients homozygous for this particular haplotype. Thus, CX(3)CR1-1249 M280 is a recessive genetic risk factor in HIV/AIDS.	Hop La Pitie Salpetriere, Lab Immunol Cellulaire & Tissulaire, CNRS, UMR 7627, Paris, France; Hop Bicetre, Fac Med, Dept Epidemiol, INSERM,U292, Le Kremlin Bicetre, France; Univ Paris 06, INSERM SC4, Paris, France; Hop Bicetre, INSERM, U155, Le Kremlin Bicetre, France; Hop Bicetre, Serv Med Interne, Le Kremlin Bicetre, France; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; CHU Bichat, INSERM, U479, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Theodorou, I (corresponding author), Hop La Pitie Salpetriere, Lab Immunol Cellulaire & Tissulaire, CNRS, UMR 7627, Paris, France.	ioannis.theodorou@psl.ap-hop-paris.fr	Combadiere, Christophe/I-5639-2013; McDermott, David/AAP-2459-2021; Costagliola, Dominique/H-5849-2011; Genin, Emmanuelle/C-4974-2013	Combadiere, Christophe/0000-0002-1755-4531; McDermott, David/0000-0001-6978-0867; Costagliola, Dominique/0000-0003-0765-0869; Genin, Emmanuelle/0000-0003-4117-2813	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000615, ZIAAI000615] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Cairns JS, 1998, NAT MED, V4, P563, DOI 10.1038/nm0598-563; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Horuk R, 1999, IMMUNOL TODAY, V20, P89, DOI 10.1016/S0167-5699(98)01396-6; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; Magierowska M, 1999, BLOOD, V93, P936, DOI 10.1182/blood.V93.3.936.403k08_936_941; Magierowska M, 1999, MICROBES INFECT, V1, P123, DOI 10.1016/S1286-4579(99)80002-1; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Meyer L, 1997, AIDS, V11, pF73, DOI 10.1097/00002030-199711000-00001; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Michael NL, 1999, CURR OPIN IMMUNOL, V11, P466, DOI 10.1016/S0952-7915(99)80078-8; Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786; Nguyen GT, 1999, J ACQ IMMUN DEF SYND, V22, P75, DOI 10.1097/00042560-199909010-00010; PARMENTIER M, COMMUNICATION; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Theodorou I, 1997, LANCET, V349, P1219; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; XIE X, 1993, AM J HUM GENET, V53, P1107; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	33	259	269	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2274	2277		10.1126/science.287.5461.2274	http://dx.doi.org/10.1126/science.287.5461.2274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731151				2022-12-28	WOS:000086049100054
J	Holdaway, RN; Jacomb, C				Holdaway, RN; Jacomb, C			Rapid extinction of the moas (Aves : Dinorinthiformes): Model, test, and implications	SCIENCE			English	Article							NEW-ZEALAND; DIOMEDEA-EXULANS; WANDERING ALBATROSS; SOUTH-GEORGIA; OVERKILL	A Leslie matrix population model supported by carbon-14 dating of early occupation Layers Lacking moa remains suggests that human hunting and habitat destruction drove the 11 species of moa to extinction Less than 100 years after Polynesian settlement of New Zealand. The rapid extinction contrasts with models that envisage several centuries of exploitation.	Palaecol Res, Christchurch 8004, New Zealand; Canterbury Museum, Christchurch, New Zealand		Holdaway, RN (corresponding author), Palaecol Res, 167 Springs Rd, Christchurch 8004, New Zealand.	piopio@netaccess.co.nz						ANDERSON A, 1989, J ARCHAEOL SCI, V16, P137, DOI 10.1016/0305-4403(89)90062-9; ANDERSON A, 1991, ANTIQUITY, V65, P767, DOI 10.1017/S0003598X00080510; Anderson A., 1984, P728; Anderson A, 1996, WORLD ARCHAEOL, V27, P359, DOI 10.1080/00438243.1996.9980314; Anderson A.J., 1989, PRODIGIOUS BIRDS MOA; ANDERSON AJ, 1996, ANH PUBLICATIONS; ANDERSON AJ, 1996, ARCHAEOLOGY NATURAL, pCH20; Cassels R., 1984, P741; CROSALL JP, 1991, BRD POPULATION STUDI, P272; CROXALL JP, 1990, J ANIM ECOL, V59, P775, DOI 10.2307/4895; CROXALL JP, 1979, ARDEA, V67, P15; Davidson J.M., 1984, PREHISTORY NZ; DUFF RS, 1950, CANTERBURY MUSEUM B, V1; ENRIGHT NJ, 1988, NZ J ARCHAEOLOGY, V10, P139; FALLA RA, 1964, NEW DICT BIRDS, P477; FERSON S, 1991, RAMAS AGE MODELLING; FORBES HO, 1891, T P NZ I, V23, P373; Golson J., 1959, ANTHR S SEAS, P29; HARNEL GE, 1979, BRIT ARCHAEOLOGICAL, V62, P61; Hartree W. H. Jr., 1999, Notornis, V46, P457; HIGHAM T, 1994, QUATERNARY SCI REV, V13, P163, DOI 10.1016/0277-3791(94)90043-4; Higham TFG, 1995, RADIOCARBON, V37, P409, DOI 10.1017/S0033822200030885; Holdaway Richard N., 1999, P189; JACOMB C, 1995, THESIS OTAGO U DUNED; Lebreton J.-D., 1991, BIRD POPULATION STUD, P105; McGlone MS, 1999, QUATERN INT, V59, P5, DOI 10.1016/S1040-6182(98)00067-6; MCGLONE MS, 1989, NEW ZEAL J ECOL, V12, P115; MCGLONE MS, 1994, ORIGINS 1 NZ; MOSIMANN JE, 1975, AM SCI, V63, P304; Murray-McIntosh RP, 1998, P NATL ACAD SCI USA, V95, P9047, DOI 10.1073/pnas.95.15.9047; PERRINS CM, 1991, BIRD POPULATION STUD, P190; Ramsey CB, 1995, RADIOCARBON, V37, P425, DOI 10.1017/S0033822200030903; SCHMIDT M, 1993, PA EXCAVATION RADIOC; Skinner H.D., 1924, RECORDS CANTERBURY M, V2, P151; Stuiver M, 1998, RADIOCARBON, V40, P1127, DOI 10.1017/S0033822200019172; SUTTON DG, 1987, NZ J ARCHAEOLOGY, V9, P135; Taylor RE, 1996, QUATERNARY SCI REV, V15, P655, DOI 10.1016/0277-3791(96)00024-8; WEIMERSKIRCH H, 1987, OIKOS, V49, P315, DOI 10.2307/3565767	38	191	201	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2250	2254		10.1126/science.287.5461.2250	http://dx.doi.org/10.1126/science.287.5461.2250			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731144				2022-12-28	WOS:000086049100047
J	Kirchner, JW; Weil, A				Kirchner, JW; Weil, A			Delayed biological recovery from extinctions throughout the fossil record	NATURE			English	Article							TIME-SERIES ANALYSIS; UNEVENLY SPACED DATA; SPECTRAL-ANALYSIS; END	How quickly does biodiversity rebound after extinctions? Palaeobiologists have examined the temporal, taxonomic and geographic patterns of recovery following individual mass extinctions in detail(1-5), but have not analysed recoveries from extinctions throughout the fossil record as a whole. Here, we measure how fast biodiversity rebounds after extinctions in general, rather than after individual mass extinctions, by calculating the cross-correlation between extinction and origination rates across the entire Phanerozoic marine fossil record. Our results show that extinction rates are not significantly correlated with contemporaneous origination rates, but instead are correlated with origination rates roughly 10 million years later. This lagged correlation persists when we remove the 'Big Five' major mass extinctions, indicating that recovery times following mass extinctions and background extinctions are similar. Our results suggest that there are intrinsic limits to how quickly global biodiversity can recover after extinction events, regardless of their magnitude. They also imply that today's anthropogenic extinctions will diminish biodiversity for millions of years to come.	Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA; Duke Univ, Dept Biol Anthropol & Anat, Durham, NC 27708 USA	University of California System; University of California Berkeley; Duke University	Kirchner, JW (corresponding author), Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA.		Kirchner, James W/B-6126-2009; Kirchner, James/AAC-4707-2019	Kirchner, James W/0000-0001-6577-3619; Kirchner, James/0000-0001-6577-3619				Agterberg F P, 1970, GEOSTATISTICS, P113; Bracewell RN, 2000, FOURIER TRANSFORM IT; CLEVELAND WS, 1984, J AM STAT ASSOC, V79, P807, DOI 10.2307/2288711; Erwin DH, 1998, TRENDS ECOL EVOL, V13, P344, DOI 10.1016/S0169-5347(98)01436-0; GILINSKY NL, 1991, ANAL PALEOBIOLOGY, P157; Hallam A., 1991, Historical Biology, V5, P257; Jablonski D, 1998, SCIENCE, V279, P1327, DOI 10.1126/science.279.5355.1327; Jablonski David, 1995, P25; Kirchner JW, 1998, NATURE, V395, P337, DOI 10.1038/26384; LOMB NR, 1976, ASTROPHYS SPACE SCI, V39, P447, DOI 10.1007/BF00648343; Press W. H., 1988, Computers in Physics, V2, p77, 80; SCARGLE JD, 1982, ASTROPHYS J, V263, P835, DOI 10.1086/160554; SCARGLE JD, 1989, ASTROPHYS J, V343, P874, DOI 10.1086/167757; Schultz, 1982, GEOLOGICAL SOC AM SP, V190, P291, DOI DOI 10.1130/SPE190-P291; Schulz M, 1997, COMPUT GEOSCI, V23, P929, DOI 10.1016/S0098-3004(97)00087-3; Sepkoski J.J., 1996, GLOBAL EVENT STRATIG, P35, DOI [10.1007/978-3-642-79634-0_4, DOI 10.1007/978-3-642-79634-0_4]; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; Sepkoski JJ, 1998, PHILOS T R SOC B, V353, P315, DOI 10.1098/rstb.1998.0212; Walliser O.H., 1996, GLOBAL EVENTS EVENT, P7, DOI DOI 10.1007/978-3-642-79634-0_2	19	120	125	0	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					177	180		10.1038/35004564	http://dx.doi.org/10.1038/35004564			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724168				2022-12-28	WOS:000085870900049
J	Geijtenbeek, TBH; Torensma, R; van Vliet, SJ; van Duijnhoven, GCF; Adema, GJ; van Kooyk, Y; Figdor, CG				Geijtenbeek, TBH; Torensma, R; van Vliet, SJ; van Duijnhoven, GCF; Adema, GJ; van Kooyk, Y; Figdor, CG			Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses	CELL			English	Article							INTERCELLULAR-ADHESION MOLECULE-3; PERIPHERAL LYMPHOID ORGANS; CLASS-II COMPARTMENT; C-TYPE LECTIN; MANNOSE RECEPTOR; LYMPHOCYTES-T; HUMAN BLOOD; ANTIGEN; ACTIVATION; LFA-1	Contact between dendritic cells (DC) and resting T cells is essential to initiate a primary immune response. Here, we demonstrate that ICAM-3 expressed by resting T cells is important in this first contact with DC. We discovered that instead of the common ICAM-3 receptors LFA-1 and alpha D beta 2, a novel DC-specific C-type lectin, DC-SIGN, binds ICAM-3 with high affinity. DC-SIGN, which is abundantly expressed by DC both in vitro and in vivo, mediates transient adhesion with T cells. Since antibodies against DC-SIGN inhibit DC-induced proliferation of resting T cells, our findings predict that DC-SIGN enables T cell receptor engagement by stabilization of the DC-T cell contact zone.	Radboud Univ Nijmegen Med Ctr, Dept Tumor Immunol, NL-6525 EX Nijmegen, Netherlands	Radboud University Nijmegen	van Kooyk, Y (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Tumor Immunol, Philips van Leydenlaan 25, NL-6525 EX Nijmegen, Netherlands.	y.vankooyk@dent.kun.nl	Adema, G.J./H-8007-2014; Geijtenbeek, Teunis/C-2229-2009; Torensma, Ruurd/C-2853-2009; Figdor, Carl G/A-4232-2010	Torensma, Ruurd/0000-0002-0555-7903; Figdor, Carl G/0000-0002-2366-9212; Van Kooyk, Yvette/0000-0001-5997-3665; van Vliet, Sandra/0000-0003-1811-2687				Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; ALBEROLAILA J, 1991, J IMMUNOL, V146, P1085; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Binnerts ME, 1999, IMMUNOL TODAY, V20, P240, DOI 10.1016/S0167-5699(99)01467-X; BINNERTS ME, 1994, EUR J IMMUNOL, V24, P2155, DOI 10.1002/eji.1830240933; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; David LR, 1996, J CRANIOFAC SURG, V7, P177, DOI 10.1097/00001665-199605000-00003; de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DELPOZO MA, 1994, CELL ADHES COMMUN, V2, P211, DOI 10.3109/15419069409004439; DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Geijtenbeek TBH, 1999, BLOOD, V94, P754, DOI 10.1182/blood.V94.2.754.414k11_754_764; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HAUSS P, 1995, EUR J IMMUNOL, V25, P2285, DOI 10.1002/eji.1830250826; HERNANDEZCASELLES T, 1993, EUR J IMMUNOL, V23, P2799, DOI 10.1002/eji.1830231112; HOCK BD, 1994, IMMUNOLOGY, V83, P573; INABA K, 1984, J EXP MED, V160, P858, DOI 10.1084/jem.160.3.858; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; JUAN M, 1994, J EXP MED, V179, P1747, DOI 10.1084/jem.179.6.1747; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Mullin NP, 1997, J BIOL CHEM, V272, P5668, DOI 10.1074/jbc.272.9.5668; PARRA E, 1993, SCAND J IMMUNOL, V38, P508, DOI 10.1111/j.1365-3083.1993.tb03233.x; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STARLING GC, 1995, EUR J IMMUNOL, V25, P2528, DOI 10.1002/eji.1830250918; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; STEINMAN RM, 1974, J EXP MED, V139, P380, DOI 10.1084/jem.139.2.380; Tan MCAA, 1997, EUR J IMMUNOL, V27, P2426, DOI 10.1002/eji.1830270942; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VILELLA R, 1990, TISSUE ANTIGENS, V36, P203, DOI 10.1111/j.1399-0039.1990.tb01830.x; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wild MK, 1999, J EXP MED, V190, P31, DOI 10.1084/jem.190.1.31; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	47	1361	1497	4	86	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 3	2000	100	5					575	585		10.1016/S0092-8674(00)80693-5	http://dx.doi.org/10.1016/S0092-8674(00)80693-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721994	Bronze			2022-12-28	WOS:000085700000010
J	Michael, BD; O'Neill, P				Michael, BD; O'Neill, P			Molecular biology - A sting in the tail of electron tracks	SCIENCE			English	Editorial Material							DNA-DAMAGE; STRAND		Mt Vernon Hosp, Gray Lab Canc Res Trust, Cell & Mol Biophys Grp, Northwood HA6 2JR, Middx, England; MRC, Radiat & Genome Stabil Unit, DNA Damage Grp, Didcot OX11 0RD, Oxon, England	University of Oxford; MRC Harwell	Michael, BD (corresponding author), Mt Vernon Hosp, Gray Lab Canc Res Trust, Cell & Mol Biophys Grp, Northwood HA6 2JR, Middx, England.		Michael, Barry D/C-7126-2008					Boudaiffa B, 2000, SCIENCE, V287, P1658, DOI 10.1126/science.287.5458.1658; Box HC, 1997, FREE RADICAL BIO MED, V23, P1021, DOI 10.1016/S0891-5849(97)00166-4; DELARA CM, 1995, RADIAT RES, V144, P43, DOI 10.2307/3579234; FOLKARD M, 1993, INT J RADIAT BIOL, V64, P651, DOI 10.1080/09553009314551891; GOODHEAD DT, 1988, HEALTH PHYS, V55, P231, DOI 10.1097/00004032-198808000-00015; HIEDA K, 1994, INT J RADIAT BIOL, V66, P561, DOI 10.1080/09553009414551631; Nikjoo H, 1997, INT J RADIAT BIOL, V71, P467, DOI 10.1080/095530097143798; ONEILL P, 1993, ADV RADIAT BIOL, V17, P53; PRISE KM, IN PRESS INT J RAD B; SIDDIQI MA, 1987, RADIAT RES, V112, P449, DOI 10.2307/3577098; WARD JF, 1985, RADIAT RES, V104, pS103, DOI 10.2307/3576637	11	186	192	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2000	287	5458					1603	1604		10.1126/science.287.5458.1603	http://dx.doi.org/10.1126/science.287.5458.1603			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10733428				2022-12-28	WOS:000085628200025
J	Peifer, M; Polakis, P				Peifer, M; Polakis, P			Cancer - Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus	SCIENCE			English	Review							BETA-CATENIN; NEGATIVE REGULATOR; AXIN; PATHWAYS; APC; GSK3-BETA; POLARITY; PROTEIN	The Wnt cell-cell signaling pathway plays a critical and evolutionarily conserved role in directing cell fates during embryogenesis. In addition, inappropriate activation of the Wnt signal transduction pathway plays a role in a variety of human cancers. Many recent studies of Wnt signaling have provided mechanistic insight into these dual roles. Here we focus on two areas of rapid advance: (i) the machinery that regulates the stability of the key signal transducer, beta-catenin, and (ii) the effect of Wnt signaling on cellular targets outside the nucleus, the actin and microtubule cytoskeletons.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Genentech Inc, S San Francisco, CA 94080 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Roche Holding; Genentech	Peifer, M (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.		Peifer, Mark/A-1152-2010	Peifer, Mark/0000-0003-1412-3987				Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Bowerman B, 1999, CURR OPIN GENET DEV, V9, P390, DOI 10.1016/S0959-437X(99)80059-8; Chae J, 1999, DEVELOPMENT, V126, P5421; Chen CM, 1999, DEVELOPMENT, V126, P5441; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; Gubb D, 1999, GENE DEV, V13, P2315, DOI 10.1101/gad.13.17.2315; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; LISUI T, 1999, CELL, V98, P585; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Lu BW, 1999, CURR BIOL, V9, P1247, DOI 10.1016/S0960-9822(99)80505-3; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rocheleau CE, 1999, CELL, V97, P717, DOI 10.1016/S0092-8674(00)80784-9; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Schlesinger A, 1999, GENE DEV, V13, P2028, DOI 10.1101/gad.13.15.2028; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shin TH, 1999, MOL CELL, V4, P275, DOI 10.1016/S1097-2765(00)80375-5; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WILELRT K, 1999, GENE DEV, V13, P1768; Willert K, 1999, DEVELOPMENT, V126, P4165; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yu X, 1999, NAT CELL BIOL, V1, P144, DOI 10.1038/11064; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247	49	1100	1164	3	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	2000	287	5458					1606	1609		10.1126/science.287.5458.1606	http://dx.doi.org/10.1126/science.287.5458.1606			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10733430				2022-12-28	WOS:000085628200027
J	Steinman, RM				Steinman, RM			DC-SIGN: A guide to some mysteries of dendritic cells	CELL			English	Review							T-CELLS; SKIN; HIV-1		Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA	Rockefeller University	Steinman, RM (corresponding author), Rockefeller Univ, Cellular Physiol & Immunol Lab, 1230 York Ave, New York, NY 10021 USA.	steinma@rockvax.rockefeller.edu	Steinman, Ralph/F-7729-2012					Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; BHARDWAJ N, 1993, J EXP MED, V178, P633, DOI 10.1084/jem.178.2.633; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; DHODAPKAR MV, 2000, IN PRESS J CLIN IMMU; Fayette J, 1997, J EXP MED, V185, P1909, DOI 10.1084/jem.185.11.1909; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; INABA K, 2000, IN PRESS J EXP MED; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Reece JC, 1998, J EXP MED, V187, P1623, DOI 10.1084/jem.187.10.1623; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261	20	142	155	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 3	2000	100	5					491	494		10.1016/S0092-8674(00)80684-4	http://dx.doi.org/10.1016/S0092-8674(00)80684-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721985	Bronze			2022-12-28	WOS:000085700000001
J	Baker, D; Pryce, G; Croxford, JL; Brown, P; Pertwee, RG; Huffman, JW; Layward, L				Baker, D; Pryce, G; Croxford, JL; Brown, P; Pertwee, RG; Huffman, JW; Layward, L			Cannabinoids control spasticity and tremor in a multiple sclerosis model	NATURE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CB1	Chronic relapsing experimental allergic encephalomyelitis (CREAE) is an autoimmune model of multiple sclerosis(1). Although both these diseases are typified by relapsing-remitting paralytic episodes, after CREAE induction by sensitization to myelin antigens(1) Biozzi ABH mice also develop spasticity and tremor. These symptoms also occur during multiple sclerosis and are difficult to control. This has prompted some patients to find alternative medicines, and to perceive benefit from cannabis use(2), Although this benefit has been backed up by small clinical studies, mainly With non-quantifiable outcomes(3-7) the value of cannabis use in multiple sclerosis remains anecdotal. Here we show that cannabinoid (CB) receptor agonism using R(+)-WIN 55,212, Delta(9)-tetrahydrocannabinol, methanandamide and JWH-133 (ref. 8) quantitatively ameliorated both tremor and spasticity in diseased mice. The exacerbation Of these signs after antagonism of the CB(1) and CB(2) receptors, notably the CB(1) receptor, using SR141716A and SR144528 (ref. 8) indicative that the endogenous cannabinoid system may be tonically active in the control of tremor and spasticity. This provides a rationale for patients' indications of the therapeutic potential of cannabis in the control of the symptoms of multiple sclerosis(2), and provides a means of evaluating more selective cannabinoids in the future.	UCL, Inst Neurol, Dept Neurochem, Neuroinflammat Grp, London WC1N 1PJ, England; UCL, Inst Ophthalmol, London EC1V 9EL, England; Natl Hosp Neurol & Neurosurg, MRC, Human Movement & Balance Unit, London WC1N 3BG, England; Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland; Clemson Univ, Dept Chem, Clemson, SC 29634 USA; Multiple Sclerosis Soc Great Britain & No Ireland, London SW6 1EE, England	University of London; King's College London; University College London; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Aberdeen; Clemson University	Baker, D (corresponding author), UCL, Inst Neurol, Dept Neurochem, Neuroinflammat Grp, 1 Wakefield St, London WC1N 1PJ, England.	D.Baker@ion.ucl.ac.uk	Brown, Peter/J-4307-2016; Pertwee, Roger Guy/E-1312-2011	Brown, Peter/0000-0002-5201-3044; Pertwee, Roger/0000-0003-3227-2783	Multiple Sclerosis Society [541] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)		BAKER D, 1990, J NEUROIMMUNOL, V28, P261, DOI 10.1016/0165-5728(90)90019-J; Breivogel CS, 1998, NEUROBIOL DIS, V5, P417, DOI 10.1006/nbdi.1998.0229; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; CHAI CK, 1961, J HERED, V52, P241, DOI 10.1093/oxfordjournals.jhered.a107083; CLIFFORD DB, 1983, ANN NEUROL, V13, P669, DOI 10.1002/ana.410130616; Consroe P, 1998, NEUROBIOL DIS, V5, P534, DOI 10.1006/nbdi.1998.0220; Consroe P, 1997, EUR NEUROL, V38, P44, DOI 10.1159/000112901; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; HELLER AH, 1982, BRAIN RES, V234, P299, DOI 10.1016/0006-8993(82)90870-8; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6; LYMAN WD, 1989, J NEUROIMMUNOL, V23, P73, DOI 10.1016/0165-5728(89)90075-1; MARTYN CN, 1995, LANCET, V345, P579, DOI 10.1016/S0140-6736(95)90485-9; NOTH J, 1991, J NEUROL, V238, P131, DOI 10.1007/BF00319679; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Pertwee RG, 1999, CURR MED CHEM, V6, P635; Petro D. J., 1981, J CLIN PHARMACOL, P413; Portier M, 1999, J PHARMACOL EXP THER, V288, P582; UNDERLEIDER JT, 1987, ADV ALCOHOL SUBSTANC, V7, P39; WIRGUIN I, 1994, IMMUNOPHARMACOLOGY, V28, P209, DOI 10.1016/0162-3109(94)90056-6	20	410	477	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					84	87		10.1038/35003583	http://dx.doi.org/10.1038/35003583			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716447				2022-12-28	WOS:000085775100050
J	Fernandes, PG; Brierley, AS; Simmonds, EJ; Millard, NW; McPhail, SD; Armstrong, F; Stevenson, P; Squiress, M				Fernandes, PG; Brierley, AS; Simmonds, EJ; Millard, NW; McPhail, SD; Armstrong, F; Stevenson, P; Squiress, M			Oceanography - Fish do not avoid survey vessels	NATURE			English	Article									FRS Marine Lab Aberdeen, Aberdeen AB11 9DB, Scotland; British Antarctic Survey, Cambridge CB3 0ET, England; Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; NERC National Oceanography Centre; University of Southampton	Fernandes, PG (corresponding author), FRS Marine Lab Aberdeen, POB 101,Victoria Rd, Aberdeen AB11 9DB, Scotland.		Brierley, Andrew S/G-8019-2011; Fernandes, Paul/H-2972-2013	Brierley, Andrew S/0000-0002-6438-6892; Fernandes, Paul/0000-0003-4135-115X				Brierley AS, 1998, DEEP-SEA RES PT II, V45, P1155, DOI 10.1016/S0967-0645(98)00025-3; Ferng W. R., 1991, Numerical Algorithms, V1, P1, DOI 10.1007/BF02145580; FOOTE KG, 1983, J ACOUST SOC AM, V73, P1932, DOI 10.1121/1.389583; FREON P, 1992, FISH RES, V15, P45, DOI 10.1016/0165-7836(92)90004-D; HOLLIDAY DV, 1995, ICES J MAR SCI, V52, P279, DOI 10.1016/1054-3139(95)80044-1; MacLennan D.N., 1992, SPRINGER SCI BUS MED; MAGURRAN AE, 1999, DYNAMICS PELAGIC FIS, pR9; Millard NW, 1998, UNDERWATER TECHNOL, V23, P7, DOI 10.3723/175605498783259894; MILLARD NW, 1999, P INT C REM TECHN HA, P19; Mitson R.B., 1995, ICES Cooperative Research Report, V209, P1; Rose GA, 1999, CAN J FISH AQUAT SCI, V56, P118, DOI 10.1139/cjfas-56-S1-118; Simmonds EJ, 1996, ICES J MAR SCI, V53, P189; WALTERS CJ, 1996, W FISHERIES      JAN, P41	13	90	92	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					35	36		10.1038/35003648	http://dx.doi.org/10.1038/35003648			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716432				2022-12-28	WOS:000085775100034
J	Woydt, P				Woydt, P			Biomedical centre memorial to victims of Nazi research	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	2000	403	6772					816	816						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10733384				2022-12-28	WOS:000085559200004
J	Tutt, A; Ross, G				Tutt, A; Ross, G			Commentary: much still to learn about relations between tumour biology, prognosis, and treatment outcome in early breast cancer	BRITISH MEDICAL JOURNAL			English	Editorial Material							EXPRESSION; C-ERBB-2; P53		Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ross, G (corresponding author), Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England.							ALBAIN KS, 1994, MONOGR NATL CANC I, V16, P35; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Bertheau P, 1998, HUM PATHOL, V29, P323, DOI 10.1016/S0046-8177(98)90111-3; Daidone MG, 1999, INT J CANCER, V84, P580, DOI 10.1002/(SICI)1097-0215(19991222)84:6<580::AID-IJC7>3.0.CO;2-W; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Phillips KA, 1999, J CLIN ONCOL, V17, P3653, DOI 10.1200/JCO.1999.17.11.3653	7	2	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					478	479						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10722296				2022-12-28	WOS:000085562200022
J	Shiratori, Y; Imazeki, F; Moriyama, M; Yano, M; Arakawa, Y; Yokosuka, O; Kuroki, T; Nishiguchi, S; Sata, M; Yamada, G; Fujiyama, S; Yoshida, H; Omata, M				Shiratori, Y; Imazeki, F; Moriyama, M; Yano, M; Arakawa, Y; Yokosuka, O; Kuroki, T; Nishiguchi, S; Sata, M; Yamada, G; Fujiyama, S; Yoshida, H; Omata, M			Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC ACTIVE HEPATITIS; HEPATOCELLULAR-CARCINOMA; FOLLOW-UP; VIRUS-INFECTION; LIVER-DISEASE; ALPHA THERAPY; HCV-RNA; CIRRHOSIS; EFFICACY; ALFA-2B	Background: Short-term histologic improvement in hepatitis C-related hepatic fibrosis has been noted in studies with more than 2 years of follow-up, but the long-term effects of interferon therapy on hepatic fibrosis remain unclear. Objective: To assess changes in hepatic fibrosis after interferon therapy in patients with chronic hepatitis C. Design: Retrospective cohort study. Setting: 7 university hospitals and 1 national hospital in Japan. Patients: 593 patients with chronic hepatitis C who underwent a paired liver biopsy from 1987 to 1997. Of these, 487 patients received interferon therapy and 106 patients were untreated. Intervention: Patients in the treatment group received a 2- to 6-month course of interferon within 6 months after the initial biopsy. Measurements: Fibrosis and inflammatory activity in paired biopsy samples obtained a median of 3.7 years apart (range, 1 to 10 years) were graded by using the criteria of Desmet and colleagues (F0 to F4) and those of the French METAVIR Cooperative Study Group (A0 to A3), respectively. Changes in fibrosis staging and activity scores and yearly rates of fibrosis progression and regression were calculated. Results: 183 of the 487 interferon-treated patients showed a sustained virologic response. Activity grade was unchanged in most of the untreated patients and improved in 89% (CI, 83% to 93%) of patients with a sustained virologic response. A sustained response to interferon was associated with a mean (ISE) reduction in fibrosis score of -0.60 +/- 0.07 at less than 3 years of follow-up and -0.88 +/- 0.08 at 3 years or more of follow-up. The rate of fibrosis progression was -0.28 +/- 0.03 unit/y (regression) in patients with sustained response, 0.02 +/- 0.02 unit/y in patients with nonsustained response (P < 0.001), and 0.10 +/- 0.02 unit/y in untreated patients. Conclusion: Although the time between biopsies partly affected the patient's clinical course, the differences observed here suggest that in patients with chronic hepatitis C, regression of fibrosis is associated with sustained virologic response to interferon therapy.	Univ Tokyo, Dept Internal Med, Div Gastroenterol Hepatol, Bunkyo Ku, Tokyo 1138655, Japan; Nihon Univ, Sch Med, Tokyo, Japan; Chiba Univ, Sch Med, Chiba 280, Japan; Natl Nagasaki Cent Hosp, Nagasaki, Japan; Osaka City Univ, Sch Med, Osaka 545, Japan; Kurume Univ, Sch Med, Fukuoka, Japan; Kawasaki Med Sch, Sch Med, Okayama, Japan; Kumamoto Univ, Sch Med, Kumamoto 860, Japan	University of Tokyo; Nihon University; Chiba University; Osaka Metropolitan University; Kurume University; Kawasaki Medical School; Kumamoto University	Shiratori, Y (corresponding author), Univ Tokyo, Dept Internal Med, Div Gastroenterol Hepatol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Bonis PAL, 1997, HEPATOLOGY, V26, P1035, DOI 10.1053/jhep.1997.v26.pm0009328332; Chemello L, 1996, ANN INTERN MED, V124, P1058, DOI 10.7326/0003-4819-124-12-199606150-00005; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; IINO S, 1993, DIGEST DIS SCI, V38, P612, DOI 10.1007/BF01316789; KATO N, 1993, HEPATOLOGY, V18, P16, DOI 10.1002/hep.1840180104; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lau DTY, 1998, HEPATOLOGY, V28, P1121, DOI 10.1002/hep.510280430; Manesis EK, 1997, HEPATOLOGY, V26, P734, DOI 10.1002/hep.510260327; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; OMATA M, 1989, DIGEST DIS SCI, V34, P330, DOI 10.1007/BF01536251; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SARACCO G, 1993, HEPATOLOGY, V18, P1300, DOI 10.1002/hep.1840180603; Shiffman ML, 1997, HEPATOLOGY, V26, P780, DOI 10.1002/hep.510260335; Shiratori Y, 1997, GASTROENTEROLOGY, V113, P558, DOI 10.1053/gast.1997.v113.pm9247476; Shiratori Y, 1996, J GASTROEN HEPATOL, V11, P705, DOI 10.1111/j.1440-1746.1996.tb00318.x; TAKANO S, 1995, HEPATOLOGY, V21, P650; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1002/hep.1840220502; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607; Yoshida H, 1999, ANN INTERN MED, V131, P174, DOI 10.7326/0003-4819-131-3-199908030-00003; Ziol M, 1996, J HEPATOL, V25, P833, DOI 10.1016/S0168-8278(96)80286-8	30	593	625	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					517	524		10.7326/0003-4819-132-7-200004040-00002	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744587				2022-12-28	WOS:000086129300001
J	Poiesz, B; Dube, D; Dube, S; Love, J; Papsidero, L; Uner, A; Hutchinson, R				Poiesz, B; Dube, D; Dube, S; Love, J; Papsidero, L; Uner, A; Hutchinson, R			Brief report: HTLV-II-associated cutaneous T-cell lymphoma in a patient with HIV-1 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS TYPE-II; HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS-DRUG-USERS; LYMPHOTROPIC VIRUS; MYCOSIS-FUNGOIDES; DNA-SEQUENCES; LEUKEMIA; DISEASE; IDENTIFICATION; PROTEIN		SUNY Syracuse, Upstate Med Ctr, Dept Med, Syracuse, NY USA; SUNY Syracuse, Upstate Med Ctr, Dept Pathol, Syracuse, NY USA; Cellular Prod, Buffalo, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Poiesz, B (corresponding author), SUNY Hlth Sci Ctr, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.		Üner, Ayşegül/A-9028-2011	Üner, Ayşegül/0000-0002-2522-1606	DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB067021] Funding Source: NIH RePORTER; NHLBI NIH HHS [HB 67021] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cimarelli A, 1996, VIROLOGY, V223, P362, DOI 10.1006/viro.1996.0487; DYSTER LM, 1994, J CLIN MICROBIOL, V32, P547, DOI 10.1128/JCM.32.2.547-550.1994; EHRLICH GD, 1989, BLOOD, V74, P1658; EHRLICH GD, 1989, AM J HEMATOL, V30, P128, DOI 10.1002/ajh.2830300304; Ferrer JF, 1996, J INFECT DIS, V174, P944, DOI 10.1093/infdis/174.5.944; Gentile TC, 1998, BRIT J HAEMATOL, V101, P507, DOI 10.1046/j.1365-2141.1998.00712.x; HARPER ME, 1986, NEW ENGL J MED, V315, P1073, DOI 10.1056/NEJM198610233151707; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KAPLAN MH, 1991, AM J MED, V91, P300, DOI 10.1016/0002-9343(91)90132-H; KUZEL TM, 2000, HEMATOLOGY BASIC PRI, P1372; LaDuca JR, 1998, J INFECT DIS, V178, P1610, DOI 10.1086/314514; LAL RB, 1995, VIROLOGY, V210, P441, DOI 10.1006/viro.1995.1360; LONGO DL, 1984, NATURE, V310, P505, DOI 10.1038/310505a0; LOUGHRAN TP, 1992, BLOOD, V80, P1116; Love JL, 1998, J ACQ IMMUN DEF SYND, V18, P178, DOI 10.1097/00042560-199806010-00010; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PAPSIDERO L, 1990, J CLIN MICROBIOL, V28, P949, DOI 10.1128/JCM.28.5.949-955.1990; PAPSIDERO LD, 1992, J CLIN MICROBIOL, V30, P351, DOI 10.1128/JCM.30.2.351-358.1992; Poeschla Eric Murnane, 1997, P153; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POIESZ BJ, 1995, NEOPLASTIC DIS BLOOD, V159, P75; ROSENBLATT JD, 1988, BLOOD, V71, P363; SCHAFER A, 1991, AM J OBSTET GYNECOL, V164, P593, DOI 10.1016/S0002-9378(11)80029-3; SHERMAN MP, 1995, ARTHRITIS RHEUM, V38, P690, DOI 10.1002/art.1780380518; TENDLER CL, 1991, J CELL BIOCHEM, V46, P302, DOI 10.1002/jcb.240460405; THOMAS JA, 1993, BLOOD, V81, P3350; VISCONTI A, 1993, J ACQ IMMUN DEF SYND, V6, P1228; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZUCKERFRANKLIN D, 1994, AIDS RES HUM RETROV, V10, P1173, DOI 10.1089/aid.1994.10.1173; ZUCKERFRANKLIN D, 1992, BLOOD, V80, P1537	33	47	47	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	2000	342	13					930	936		10.1056/NEJM200003303421304	http://dx.doi.org/10.1056/NEJM200003303421304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DC	10738051				2022-12-28	WOS:000086179700004
J	Camilleri, M; Northcutt, AR; Kong, S; Dukes, GE; McSorley, D; Mangel, AW				Camilleri, M; Northcutt, AR; Kong, S; Dukes, GE; McSorley, D; Mangel, AW			Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial	LANCET			English	Article							QUALITY-OF-LIFE; ANTAGONISM; SENSITIVITY; ONDANSETRON; DISTENSION; RESPONSES; TRANSIT; PAIN	Background Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with symptoms of abdominal pain, discomfort, and altered bowel function. Antagonists of the type 3 serotonin receptor (5-HT3) have shown promising results in the relief of IBS-associated symptoms. We aimed to confirm these findings by doing a randomised, placebo-controlled trial. Methods We studied 647 female IBS patients with diarrhoea-predominant or alternating bowel patterns (diarrhoea and constipation). 324 patients were assigned 1 mg alosetron and 323 placebo orally twice daily for 12 weeks, followed by a 4-week post-treatment period. Adequate relief of abdominal pain and discomfort was the primary endpoint; secondary endpoints included improvements in urgency, stool frequency, and stool consistency. Analysis was by intention to treat. Findings 79 (24%) of patients in the alosetron group and 53 (16%) in the placebo group dropped out. The difference in the drop-out rate between groups was mainly due to a greater occurrence of constipation in the alosetron group. A greater proportion of alosetron-treated patients than placebo-treated patients (133 [41%] vs 94 [29%], respectively) reported adequate relief for all 3 months of treatment (difference 12% [4.7-19.2]). Alosetron also significantly decreased urgency and stool frequency, and increased stool firmness. Constipation occurred in 30% and 346 of patients in the alosetron and placebo groups, respectively. Interpretation Alosetron was well tolerated and clinically effective in alleviating pain and bowel-related symptoms in this population of women with IBS.	Glaxo Wellcome Inc, Gastroenterol Clin Dev, Res Triangle Pk, NC 27709 USA; Mayo Clin, Gastrointestinal Res Unit, Rochester, MN USA; Glaxo Wellcome Inc, Clin Stat, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; Mayo Clinic; GlaxoSmithKline	Mangel, AW (corresponding author), Glaxo Wellcome Inc, Gastroenterol Clin Dev, Res Triangle Pk, NC 27709 USA.			mangel, allen/0000-0002-5430-1402; McSorley, David/0000-0002-6122-2083				[Anonymous], 1992, GASTROENTEROL INT; Bardhan KD, 2000, ALIMENT PHARM THERAP, V14, P23; Camilleri M, 1999, ALIMENT PHARM THERAP, V13, P1149; COOK N, 1998, DIGESTION S3, V59, P282; Degen LP, 1996, GUT, V39, P299, DOI 10.1136/gut.39.2.299; Delvaux M, 1998, ALIMENT PHARM THER, V12, P849, DOI 10.1046/j.1365-2036.1998.00375.x; Drossman DA, 1997, GASTROENTEROLOGY, V112, P2120, DOI 10.1053/gast.1997.v112.agast972120; EVERHART JE, 1991, GASTROENTEROLOGY, V100, P998, DOI 10.1016/0016-5085(91)90275-P; FORSTER JM, 1997, GASTROENTEROLOGY, V112, pA732; Goldberg PA, 1996, DIGESTION, V57, P478, DOI 10.1159/000201377; GORE S, 1990, ALIMENT PHARM THERAP, V4, P139; Hahn BA, 1999, DIGESTION, V60, P77, DOI 10.1159/000007593; Harding JP, 1997, ALIMENT PHARM THERAP, V11, P1073, DOI 10.1046/j.1365-2036.1997.00256.x; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; Mangel AW, 1998, J INT MED RES, V26, P76, DOI 10.1177/030006059802600203; Mangel AW, 1999, GASTROENTEROLOGY, V116, pA1035; Maxton DG, 1996, ALIMENT PHARM THERAP, V10, P595, DOI 10.1046/j.1365-2036.1996.30172000.x; Miura M, 1999, DIGEST DIS SCI, V44, P20, DOI 10.1023/A:1026633629141; NGUYEN P, 1995, AM J GASTROENTEROL, V90, P901; Northcutt AR, 1999, GASTROENTEROLOGY, V116, pA1036; Patrick DL, 1998, DIGEST DIS SCI, V43, P400, DOI 10.1023/A:1018831127942; PRIOR A, 1993, ALIMENT PHARM THERAP, V7, P175; SILVERMAN D, 1997, J NUCL MED, V38, pP237; Wells NEJ, 1997, ALIMENT PHARM THER, V11, P1019, DOI 10.1046/j.1365-2036.1997.00262.x; Whitehead WE, 1996, DIGEST DIS SCI, V41, P2248, DOI 10.1007/BF02071408; ZIGHELBOIM J, 1995, DIGEST DIS SCI, V40, P819, DOI 10.1007/BF02064986	27	431	447	1	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1035	1040		10.1016/S0140-6736(00)02033-X	http://dx.doi.org/10.1016/S0140-6736(00)02033-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744088				2022-12-28	WOS:000086380800009
J	Brook, BW; O'Grady, JJ; Chapman, AP; Burgman, MA; Akcakaya, HR; Frankham, R				Brook, BW; O'Grady, JJ; Chapman, AP; Burgman, MA; Akcakaya, HR; Frankham, R			Predictive accuracy of population viability analysis in conservation biology	NATURE			English	Article							MODELS; VALIDATION; ECOLOGY; RISK	Population viability analysis (PVA) is widely applied in conservation biology to predict extinction risks for threatened species and to compare alternative options for their mangement(1-4). It can also be used as a basis for listing species as endangered under World Conservation Union criteria(5), However, there is considerable scepticism regarding the predictive accuracy of PVA, mainly because of a lack of validation in real systems(2,6-8). Here we conducted a retrospective test of PVA based on 21 long-term ecological studies-the first comprehensive and replicated evaluation of the predictive powers of PVA. Parameters were estimated from the first half of each data set and the second half was used to evaluate the performance of the model. Contrary to recent criticisms, we found that PVA predictions were surprisingly accurate. The risk of population decline closely matched observed outcomes, there was no significant bias, and population size projections did not differ significantly from reality. Furthermore, the predictions of the five PVA software packages were highly concordant. We conclude that PVA is a valid and sufficiently accurate tool for categorizing and managing endangered species.	Univ Melbourne, Sch Bot, Parkville, Vic 3052, Australia; Appl Biomath, Setauket, NY 11733 USA; Macquarie Univ, Dept Biol Sci, Key Ctr Biodivers & Bioresources, N Ryde, NSW 2109, Australia	University of Melbourne; Macquarie University	Brook, BW (corresponding author), No Terr Univ, Key Ctr Trop Wildlife Management, Darwin, NT 0909, Australia.		Brook, Barry W./G-2686-2011; Akcakaya, H. Resit/A-7830-2008	Brook, Barry W./0000-0002-2491-1517; Akcakaya, H. Resit/0000-0002-8679-5929; Burgman, Mark/0000-0003-0435-4829				Akû║akaya H.R., 1999, APPL POPULATION ECOL; ARNQVIST G, 1995, TRENDS ECOL EVOL, V10, P236, DOI 10.1016/S0169-5347(00)89073-4; Beissinger SR, 1998, J WILDLIFE MANAGE, V62, P821, DOI 10.2307/3802534; BELOVSKY GE, 1994, OECOLOGIA, V100, P475, DOI 10.1007/BF00317870; BOYCE MS, 1992, ANNU REV ECOL SYST, V23, P481, DOI 10.1146/annurev.es.23.110192.002405; Brook BW, 1999, ANIM CONSERV, V2, P23, DOI 10.1111/j.1469-1795.1999.tb00045.x; Brook BW, 1997, BIOL CONSERV, V82, P119, DOI 10.1016/S0006-3207(97)00026-8; Burgman MA, 1993, RISK ASSESSMENT CONS; CAUGHLEY G, 1994, J ANIM ECOL, V63, P215, DOI 10.2307/5542; Ginzburg LR, 1982, RISK ANAL, V2, P171, DOI 10.1111/j.1539-6924.1982.tb01379.x; GRENFELL BT, 1992, NATURE, V355, P823, DOI 10.1038/355823a0; GROEEM MJ, 1998, CONSERV BIOL, P4; HUGGARD DJ, 1994, OECOLOGIA, V100, P470, DOI 10.1007/BF00317869; International Union for the Conservation of Nature, 1994, IUCN RED LIST CAT; Ludwig D, 1999, ECOLOGY, V80, P298, DOI 10.1890/0012-9658(1999)080[0298:IIMTEA]2.0.CO;2; Mills LS, 1996, CONSERV BIOL, V10, P863, DOI 10.1046/j.1523-1739.1996.10030863.x; NORTON TW, 1995, BIOL CONSERV, V73, P91, DOI 10.1016/0006-3207(95)90027-6; ORESKES N, 1994, SCIENCE, V263, P641, DOI 10.1126/science.263.5147.641; POSSINGHAM HP, 1993, PAC CONSEV BIOL, V1, P38; Ralls Katherine, 1997, P228; Ramanathan R., 1995, INTRO ECONOMETRICS; REYNOLDS MR, 1981, FOREST SCI, V27, P349; Sokal RR, 1995, BIOMETRY; Soule ME, 1989, RES PRIORITIES CONSE; TAYLOR BL, 1995, CONSERV BIOL, V9, P551, DOI 10.1046/j.1523-1739.1995.09030551.x; Wahlberg N, 1996, SCIENCE, V273, P1536, DOI 10.1126/science.273.5281.1536; WIGLEY TML, 1995, NATURE, V376, P463, DOI 10.1038/376463a0; ZECKHAUSER RJ, 1990, SCIENCE, V248, P559, DOI 10.1126/science.2333509	28	393	432	4	237	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					385	387		10.1038/35006050	http://dx.doi.org/10.1038/35006050			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746724				2022-12-28	WOS:000086119000049
J	Richmond, BG; Strait, DS				Richmond, BG; Strait, DS			Evidence that humans evolved from a knuckle-walking ancestor	NATURE			English	Article							HOMINID; QUADRUPEDALISM; MORPHOLOGY; HOMINOIDS; PLIOCENE; ETHIOPIA; RADIUS; ORIGIN; KENYA; HAND	Bipedalism has traditionally been regarded as the fundamental adaptation that sets hominids apart from other primates. Fossil I evidence demonstrates that by 4.1 million years ago(1), and perhaps earlier(2), hominids exhibited adaptations to bipedal walking. At present, however, the fossil record offers little information about the origin of bipedalism, and despite nearly a century of research on existing fossils and comparative anatomy, there is still no consensus concerning the mode of locomotion that preceded bipedalism(3-10). Here we present evidence that fossils attributed to Australopithecus anamensis (KNM-ER 20419)(11) and A. afarensis (AL 288-1)(12) retain specialized wrist morphology associated with knuckle-walking. This distal radial morphology differs from that of later hominids and non-knuckle-walking anthropoid primates, suggesting that knuckle-walking is a derived feature of the African ape and human clads. This removes key morphological evidence for a Pan-Gorilla clade, and suggests that bipedal hominids evolved from a knuckle-walking ancestor that was already partly terrestrial.	George Washington Univ, Dept Anthropol, Washington, DC 20052 USA	George Washington University	Richmond, BG (corresponding author), George Washington Univ, Dept Anthropol, 2110 G St NW, Washington, DC 20052 USA.	brich@gwu.edu						ANDREWS P, 1987, J HUM EVOL, V16, P101, DOI 10.1016/0047-2484(87)90062-5; BEGUN DR, 1992, SCIENCE, V257, P1929, DOI 10.1126/science.1411507; BEGUN DR, 1993, SCIENCE, V259, P294; Dainton M, 1999, J HUM EVOL, V36, P171, DOI 10.1006/jhev.1998.0265; FLEAGLE JG, 1981, S ZOOLOGICAL SOC LON, V48, P359; Gebo DL, 1996, AM J PHYS ANTHROPOL, V101, P55, DOI 10.1002/(SICI)1096-8644(199609)101:1<55::AID-AJPA5>3.0.CO;2-C; GRINE FE, 1991, AM J PHYS ANTHROPOL, V84, P229, DOI 10.1002/ajpa.1330840302; HEINRICH RE, 1993, AM J PHYS ANTHROPOL, V92, P139, DOI 10.1002/ajpa.1330920203; HEWES GW, 1961, AM ANTHROPOL, V63, P687, DOI 10.1525/aa.1961.63.4.02a00020; Hunt KD, 1996, S AFR J SCI, V92, P77; Jenkins F.A. Jr., 1975, P213; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P403, DOI 10.1002/ajpa.1330570403; Keith A, 1923, BMJ-BRIT MED J, V1923, P669, DOI 10.1136/bmj.1.3251.669; Keith A, 1923, BRIT MED J, V1923, P624; Keith A, 1923, BRIT MED J, V1923, P587; Keith A, 1923, BRIT MED J, V1923, P545; Keith A, 1923, BRIT MED J, V1923, P499; Keith A, 1923, BMJ-BRIT MED J, V1923, P451, DOI 10.1136/bmj.1.3246.451; LEAKEY MG, 1995, NATURE, V376, P565, DOI 10.1038/376565a0; LOVEJOY CO, 1981, SCIENCE, V211, P341, DOI 10.1126/science.211.4480.341; MARZKE MW, 1971, AM J PHYS ANTHROPOL, V34, P61, DOI 10.1002/ajpa.1330340106; Napier J. R., 1959, Fossil Mammals of Africa, V16, P1; Richmond BG, 1998, THESIS STATE U NEW Y; Rose M.D., 1991, P37; Ruvolo M, 1997, MOL BIOL EVOL, V14, P248, DOI 10.1093/oxfordjournals.molbev.a025761; SCHMITT D, 1994, J HUM EVOL, V26, P441, DOI 10.1006/jhev.1994.1027; Stern J., 1975, YEARB PHYS ANTHROPOL, V19, P59; STERN JT, 1983, AM J PHYS ANTHROPOL, V60, P279, DOI 10.1002/ajpa.1330600302; SUSMAN RL, 1979, AM J PHYS ANTHROPOL, V50, P565, DOI 10.1002/ajpa.1330500408; SUSMAN RL, 1979, AM J PHYS ANTHROPOL, V50, P215, DOI 10.1002/ajpa.1330500211; TUTTLE R, 1974, CURR ANTHROPOL, V15, P389, DOI 10.1086/201494; TUTTLE RH, 1967, AM J PHYS ANTHROPOL, V26, P171, DOI 10.1002/ajpa.1330260207; TUTTLE RH, 1969, J MORPHOL, V128, P309, DOI 10.1002/jmor.1051280304; Washburn SL, 1967, P ROYAL ANTHR I GREA, V3, P21; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0	35	178	181	0	116	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					382	385		10.1038/35006045	http://dx.doi.org/10.1038/35006045			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	298BG	10746723				2022-12-28	WOS:000086119000048
J	Faber-Langendoen, K; Karlawish, JHT				Faber-Langendoen, K; Karlawish, JHT		Univ Pennsylvania	Should assisted suicide be only physician assisted?	ANNALS OF INTERNAL MEDICINE			English	Article							ATTITUDES; EUTHANASIA; DEATH; ONCOLOGISTS; RELIGION; CANCER	Discussions in the media, courts, legislatures, and professional societies generally assume assistance with suicide to be a-physician's task; in these venues it is commonly referred to as "physician-assisted suicide." This paper defines both the necessity and the limits of the physician's role in assisted suicide by asking the question: Should assisted suicide be only physician assisted? Although physician involvement is necessary, we argue that it is not sufficient to ensure that patients requesting assisted suicide receive the best care. Assisted suicide requires physician involvement, but physicians' limited competence in performing the full range of tasks, the competencies of other professions, and the possibility that other professions could expand their authority in this area suggest that physician-assisted suicide is a far too narrow construct of the task. The willingness of other professionals-including nurses, social workers, and clergy-to participate and even take the lead in assisting suicides is critical to meet society's interest that assisted suicide should be humane, effective, and confined to appropriate cases. As long as legislation and guidelines focus exclusively on the physician's role, our laws and regulations will fall short of meeting societal expectations.	Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA	University of Pennsylvania; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Faber-Langendoen, K (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE ON AGING [K01AG000931] Funding Source: NIH RePORTER; NIA NIH HHS [1K01-AG00931] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Admiraal P V, 1995, Ned Tijdschr Geneeskd, V139, P265; *AM MED ASS COUNC, 1932, JAMA-J AM MED ASSOC, V270, P365; *AM NURS ASS, 1994, POS STAT ASS SUIC, P1; Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATTIN MP, 1996, DRUG USE ASSISTED SU, P267; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BRODY H, 1997, PHYSICIAN ASSISTED S, P136; BYOCK I, 1997, PHYSICIAN ASSISTED S, P107; CALLAHAN D, 1997, PHYSICIAN ASSISTED S, P69; CAPLAN AL, 2000, ANN INTERN MED, V132, P482; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; FIELD MJ, 1997, APPROACHING DEATH IM, P363; GILLESPIE M, 1999, KEVORKIAN FACE MURDE; Goldfarb LM, 1996, AM J DRUG ALCOHOL AB, V22, P549, DOI 10.3109/00952999609001680; Humphry Derek, 1991, FINAL EXIT PRACTICAL; JAMISON S, 1995, FINAL ACTS LOVE FAMI; Koenig H G, 1991, J Pastoral Care, V45, P254; Loewy E H, 1992, J Clin Ethics, V3, P29; MAUGANS TA, 1991, J FAM PRACTICE, V32, P210; MILES SH, 1995, HASTINGS CENT REP, V25, P17, DOI 10.2307/3562108; Miller FG, 1998, ANN INTERN MED, V128, P559, DOI 10.7326/0003-4819-128-7-199804010-00007; *N CUMM FDN FETZ I, 1997, SPIR BEL DYING PROC; *NAT ASS BOARDS PH, 1997, 1997 98 SURV PHARM L, P65; *NAT ASS SOC WORK, 1994, CLIENT SELF DET END, P58; NEELEMAN J, 1993, ACTA PSYCHIAT SCAND, V88, P420, DOI 10.1111/j.1600-0447.1993.tb03484.x; *ONC NURS SOC, 1995, ONC NURS SOC END AM; RUPP MT, 1994, AM J HOSP PHARM, V51, P69, DOI 10.1093/ajhp/51.1.69; SuarezAlmazor ME, 1997, J CLIN ONCOL, V15, P418, DOI 10.1200/JCO.1997.15.2.418; Tulsky JA, 2000, ANN INTERN MED, V132, P494, DOI 10.7326/0003-4819-132-6-200003210-00012; van der Wal G, 1992, Ned Tijdschr Geneeskd, V136, P1299; 1997, OREG NURSE, V62, P5	36	22	22	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					482	487		10.7326/0003-4819-132-6-200003210-00010	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293CV	10733449				2022-12-28	WOS:000085834700009
J	Saxon, E; Bertozzi, CR				Saxon, E; Bertozzi, CR			Cell surface engineering by a modified Staudinger reaction	SCIENCE			English	Article								Selective chemical reactions enacted within a cellular environment can be powerful tools for elucidating biological processes or engineering novel interactions. A chemical transformation that permits the selective formation of covalent adducts among richly functionalized biopolymers within a cellular context is presented. A ligation modeled after the Staudinger reaction forms an amide bond by coupling of an azide and a specifically engineered triarylphosphine. Both reactive partners are abiotic and chemically orthogonal to native cellular components. Azides installed within cell surface glycoconjugates by metabolism of a synthetic azidosugar were reacted with a biotinylated triarylphosphine to produce stable cell-surface adducts. The tremendous selectivity of the transformation should permit its execution within a cell's interior, offering new possibilities for probing intracellular interactions.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.				NIGMS NIH HHS [GM58867-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM058867, R01GM058867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARTWRIGHT IL, 1976, NUCLEIC ACIDS RES, V3, P2331, DOI 10.1093/nar/3.9.2331; GOLOLOBOV YG, 1992, TETRAHEDRON, V48, P1353, DOI 10.1016/S0040-4020(01)92229-X; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; JACOBS AK, 1995, P NATL ACAD SCI USA, V92, P3323; Lee JH, 1999, J BIOL CHEM, V274, P21878, DOI 10.1074/jbc.274.31.21878; Lemieux GA, 1999, J AM CHEM SOC, V121, P4278, DOI 10.1021/ja984228m; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; Staudinger H, 1919, HELV CHIM ACTA, V2, P635, DOI 10.1002/hlca.19190020164; van Hest JCM, 1998, FEBS LETT, V428, P68, DOI 10.1016/S0014-5793(98)00489-X; Winans KA, 1998, CHEM BIOL, V5, pR313, DOI 10.1016/S1074-5521(98)90658-5; Yarema KJ, 1998, J BIOL CHEM, V273, P31168, DOI 10.1074/jbc.273.47.31168	12	1760	1954	74	652	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2007	2010		10.1126/science.287.5460.2007	http://dx.doi.org/10.1126/science.287.5460.2007			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720325				2022-12-28	WOS:000085902800059
J	Kim, AS; Kakalis, LT; Abdul-Manan, M; Liu, GA; Rosen, MK				Kim, AS; Kakalis, LT; Abdul-Manan, M; Liu, GA; Rosen, MK			Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein	NATURE			English	Article							X-LINKED THROMBOCYTOPENIA; TYROSINE PHOSPHORYLATION; WASP GENE; NMR; CDC42; BINDING; MUTATIONS; DOMAIN; C-13; IDENTIFICATION	The Rho-family GTPase, Cdc42, can regulate the actin cytoskeleton through activation of Wiskott-Aldrich syndrome protein (WASP) family members. Activation relieves an autoinhibitory contact between the GTPase-binding domain and the carboxyterminal region of WASP proteins. Here we report the autoinhibited structure of the GTPase-binding domain of WASP, which can be induced by the C-terminal region or by organic co-solvents, In the autoinhibited complex, intramolecular interactions with the GTPase-binding domain occlude residues of the C terminus that regulate the Arp2/3 actin-nucleating complex. Binding of Cdc42 to the GTPase-binding domain causes a dramatic conformational change, resulting in disruption of the hydrophobic core and release of the C terminus, enabling its interaction with the actin regulatory machinery. These data show that 'intrinsically unstructured' peptides such as the GTPase-binding domain of WASP can be induced into distinct structural and functional states depending on context.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Rosen, MK (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	rosen@mrnmrl.ski.mskcc.org						Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1993, XPLOR MANUAL; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DERRY JMJ, 1995, HUM MOL GENET, V4, P1127, DOI 10.1093/hmg/4.7.1127; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KOLLURI R, 1995, HUM MOL GENET, V4, P1119, DOI 10.1093/hmg/4.7.1119; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KWAN SP, 1995, HUM MOL GENET, V4, P1995, DOI 10.1093/hmg/4.10.1995; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Oda A, 1998, BLOOD, V92, P1852, DOI 10.1182/blood.V92.6.1852.418k36_1852_1858; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohl CA, 1996, PROTEIN SCI, V5, P2623, DOI 10.1002/pro.5560051225; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Scherbina A, 1999, J IMMUNOL, V163, P6314; Sharman GJ, 1998, J AM CHEM SOC, V120, P5291, DOI 10.1021/ja9705405; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	44	590	601	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2000	404	6774					151	158		10.1038/35004513	http://dx.doi.org/10.1038/35004513			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724160				2022-12-28	WOS:000085870900041
J	Gallant, JE				Gallant, JE			Strategies for long-term success in the treatment of HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SAQUINAVIR; RESISTANCE; THERAPY	Highly active antiretroviral therapy has revolutionized the treatment of human immunodeficiency virus (HIV) infection, which can now be viewed as a chronic and manageable disease. However, HIV infection differs from other chronic diseases in that early treatment decisions can irrevocably alter the patient's response to future therapy. Despite the large number of approved antiretroviral agents, the number of sequential treatment regimens that will be effective for an individual patient is sharply limited by cross-resistance within the 3 drug classes. Because of the complexity of antiretroviral therapy, clinicians prescribing it require considerable expertise. Treatment should be deferred until the patient has been educated about the importance of strict adherence and has demonstrated willingness and motivation to begin therapy. Drug regimens should be chosen that the patient can tolerate and adhere to, and the consequences of resistance should be considered before therapy is begun. When treatment fails, the timing and choice of subsequent therapy can be critical in determining the magnitude and durability of response. Resistance testing can help guide the clinician in the choice of therapy. In patients who have been treated with numerous antiretroviral agents, it may be impossible to achieve significant viral suppression. Therapy may still be beneficial for such patients, but it should be tolerable and should not increase resistance to drugs that may become available::in the near future. Drug resistance and-treatment failure are not random events, but are the result of factors over which clinicians and their patients have some control. The treatment of drug-resistant patients is challenging; the best way to deal with resistance is to prevent it.	Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21287 USA	Johns Hopkins University	Gallant, JE (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, 1830 E Monument St,Room 443, Baltimore, MD 21287 USA.							BARTLETT JG, 1998, 12 AIDS C JUN 28 JUL; BAXTER JD, 1999, 6 C RETR OPP INF JAN; BECKER S, 1999, 39 INT C ANT AG CHEM; Boden D, 1999, JAMA-J AM MED ASSOC, V282, P1135, DOI 10.1001/jama.282.12.1135; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carroll DS, 1998, PALLIATIVE MED, V12, P51, DOI 10.1191/026921698666041220; Deeks SG, 1998, AIDS, V12, pF97, DOI 10.1097/00002030-199810000-00002; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; *DHHS PAN CLIN PRA, 1999, GUID US ANT AG HIV I; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; FEDERICI ME, 1998, 12 WORLD AIDS C JUN; Hall CS, 1999, AIDS, V13, P1207, DOI 10.1097/00002030-199907090-00009; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142; MILLER V, 1999, 2 INT WORKSH SALV TH; MONTANER JS, 1999, 39 INT C ANT AG CHEM; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Peters R, 1998, JAMA, V280, P2037, DOI 10.1001/jama.280.23.2037; PIKETTY C, 1999, 39 INT C ANT AG CHEM; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Roberts NA, 1998, AIDS, V12, P453, DOI 10.1097/00002030-199805000-00005; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; STASZEWSKI S, 1999, 39 INT C ANT AG CHEM; Tebas P, 1999, AIDS, V13, pF23, DOI 10.1097/00002030-199902040-00002; ZOLOPA A, 1999, 39 INT C ANT AG CHEM; Zolopa AR, 1999, ANN INTERN MED, V131, P813, DOI 10.7326/0003-4819-131-11-199912070-00003	32	84	86	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2000	283	10					1329	1334		10.1001/jama.283.10.1329	http://dx.doi.org/10.1001/jama.283.10.1329			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289ND	10714734				2022-12-28	WOS:000085628100031
J	Pomeroy, VM; Tallis, RC				Pomeroy, VM; Tallis, RC			Need to focus research in stroke rehabilitation	LANCET			English	Editorial Material							CENTRALLY PARETIC HAND; MOTOR CORTEX; SUPPORT		Univ Manchester, Sch Med, Stroke Assoc Therapy Res Unit, Manchester M13 9PL, Lancs, England; Univ Manchester, Sch Med, Dept Geriatr Med, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester	Pomeroy, VM (corresponding author), Hope Hosp, Clin Sci Bldg,Eccles Old Rd, Salford M6 8HD, Lancs, England.	vpomeroy@fs1.ho.man.ac.uk		Pomeroy, Valerie/0000-0003-4487-823X				Ada L, 1998, J NEUROL NEUROSUR PS, V64, P628, DOI 10.1136/jnnp.64.5.628; Bonn D, 1998, LANCET, V352, P119, DOI 10.1016/S0140-6736(98)85026-5; Boult C, 1997, J AM GERIATR SOC, V45, P881, DOI 10.1111/j.1532-5415.1997.tb01519.x; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; DICKSTEIN R, 1986, PHYS THER, V66, P1233, DOI 10.1093/ptj/66.8.1233; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; Hallett M, 1998, NEUROREHABILITATION, V10, P131, DOI 10.3233/NRE-1998-10205; Hamdy S, 1998, NAT NEUROSCI, V1, P64, DOI 10.1038/264; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HUMMELSHEIM H, 1995, ELECTROMYOGR MOTOR C, V97, P18, DOI 10.1016/0924-980X(94)00279-G; Indredavik B, 1997, STROKE, V28, P1861, DOI 10.1161/01.STR.28.10.1861; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; Langhorne P, 1996, Physiother Res Int, V1, P75; Nudo RJ, 1996, J NEUROSCI, V16, P785; Oudega M, 1999, BRAIN RES, V818, P431, DOI 10.1016/S0006-8993(98)01314-6; POMEROY VM, IN PRESS CLIN REHABI; Tyson SF, 1998, CLIN REHABIL, V12, P395, DOI 10.1191/026921598669871795; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5; Young J, 1996, BRIT MED J, V313, P677	20	34	34	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2000	355	9206					836	837		10.1016/S0140-6736(99)08143-X	http://dx.doi.org/10.1016/S0140-6736(99)08143-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711941				2022-12-28	WOS:000085766900038
J	Cox, MM; Goodman, MF; Kreuzer, KN; Sherratt, DJ; Sandler, SJ; Marians, KJ				Cox, MM; Goodman, MF; Kreuzer, KN; Sherratt, DJ; Sandler, SJ; Marians, KJ			The importance of repairing stalled replication forks	NATURE			English	Article							STRAND-BREAK REPAIR; INDUCED DNA-REPLICATION; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; RECA PROTEIN; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; SOS RESPONSE; PRIA; BACTERIOPHAGE-T4	The bacterial SOS response to unusual levels of DNA damage has been recognized and studied for several decades. Pathways for re-establishing inactivated replication forks under normal growth conditions have received far less attention. In bacteria growing aerobically in the absence of SOS-inducing conditions, many replication forks encounter DNA damage, leading to inactivation. The pathways for fork reactivation involve the homologous recombination systems, are nonmutagenic, and integrate almost every aspect of DNA metabolism. On a frequency-of-use basis, these pathways represent the main function of bacterial DNA recombination systems, as well as the main function of a number of other enzymatic systems that are associated with replication and site-specific recombination.	Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Univ Oxford, Dept Biochem, Div Mol Genet, Oxford OX1 3QU, England; Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	University of Southern California; University of Wisconsin System; University of Wisconsin Madison; University of Southern California; Duke University; University of Oxford; University of Massachusetts System; University of Massachusetts Amherst; Memorial Sloan Kettering Cancer Center	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM034557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Arai K, 1981, Prog Nucleic Acid Res Mol Biol, V26, P9, DOI 10.1016/S0079-6603(08)60392-X; Bidnenko V, 1999, MOL MICROBIOL, V33, P846, DOI 10.1046/j.1365-2958.1999.01532.x; Bosco G, 1998, GENETICS, V150, P1037; Chen C, 1998, MOL CELL, V2, P9, DOI 10.1016/S1097-2765(00)80109-4; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; Cox MM, 1997, P NATL ACAD SCI USA, V94, P11764, DOI 10.1073/pnas.94.22.11764; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; COX MM, 1999, PROG NUCL ACID RES M, V63, P310; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; Galitski T, 1997, GENETICS, V146, P751; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Hanawalt P C, 1966, Photochem Photobiol, V5, P1, DOI 10.1111/j.1751-1097.1966.tb05756.x; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; KUZMINOV A, 1995, BIOESSAYS, V17, P733, DOI 10.1002/bies.950170810; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; Kuzminov A, 1999, GENE DEV, V13, P345, DOI 10.1101/gad.13.3.345; Le S, 1999, GENETICS, V152, P143; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; Marians KJ, 2000, PROG NUCLEIC ACID RE, V63, P39; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Morrow DM, 1997, GENETICS, V147, P371; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Neilson L, 1999, MOL MICROBIOL, V31, P915, DOI 10.1046/j.1365-2958.1999.01231.x; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; Opperman T, 1999, P NATL ACAD SCI USA, V96, P9218, DOI 10.1073/pnas.96.16.9218; Rangarajan S, 1999, P NATL ACAD SCI USA, V96, P9224, DOI 10.1073/pnas.96.16.9224; Recchia GD, 1999, EMBO J, V18, P5724, DOI 10.1093/emboj/18.20.5724; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sandler SJ, 1999, MOL MICROBIOL, V34, P91, DOI 10.1046/j.1365-2958.1999.01576.x; Sandler SJ, 1996, GENETICS, V143, P5; Saveson CJ, 1999, GENETICS, V152, P5; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Shinagawa H, 1996, EXS, V77, P221; Skalka A., 1974, MECH RECOMBINATION, P421, DOI [10.1007/978-1-4684-2133-0_37, DOI 10.1007/978-1-4684-2133-0_37]; SKARSTAD K, 1993, J BACTERIOL, V175, P5505, DOI 10.1128/JB.175.17.5505-5509.1993; Steiner W, 1999, MOL MICROBIOL, V31, P579, DOI 10.1046/j.1365-2958.1999.01198.x; Steiner WW, 1998, MOL MICROBIOL, V27, P257, DOI 10.1046/j.1365-2958.1998.00651.x; Steiner WW, 1998, J BACTERIOL, V180, P6269; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WOODGATE R, 1991, MOL GEN GENET, V229, P10, DOI 10.1007/BF00264207; ZAVITZ KH, 1991, MOL MICROBIOL, V5, P2869, DOI 10.1111/j.1365-2958.1991.tb01846.x	62	846	874	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2000	404	6773					37	41		10.1038/35003501	http://dx.doi.org/10.1038/35003501			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716434				2022-12-28	WOS:000085775100037
J	Dickson, D				Dickson, D			... amid calls for international biotech panel	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	2000	403	6772					821	821		10.1038/35002766	http://dx.doi.org/10.1038/35002766			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	288JG	10733386	Bronze			2022-12-28	WOS:000085559200015
J	Ker, J				Ker, J			Commentary: Applying the BMJ's guidelines on educational interventions	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Dundee, Ninewells Hosp & Med Sch, Clin Skills Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Ker, J (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Clin Skills Ctr, Dundee DD1 9SY, Scotland.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	2000	320	7229					230	230						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279DR	10712017				2022-12-28	WOS:000085029600028
J	Post, SG; Puchalski, CM; Larson, DB				Post, SG; Puchalski, CM; Larson, DB			Physicians and patient spirituality: Professional boundaries, competency, and ethics	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							NONDISABLED PERSONS; RELIGIOUS SERVICES; CARDIAC-SURGERY; HEALTH; ATTENDANCE; MEDICINE; DISEASE; BELIEFS; DEPRESSION; HISTORY	Clinical studies are beginning to clarify how spirituality and religion can contribute to the coping strategies of many patients with severe, chronic, and terminal conditions. The ethical aspects of physician attention to the spiritual and religious dimensions of patients' experiences of illness require review and discussion. Should the physician discuss spiritual issues with his or her patients? What are the boundaries between the physician and patient regarding these issues? What are the professional boundaries between the physician and the chaplain? This article examines the physician-patient relationship and medical ethics at a time when researchers are beginning to appreciate the spiritual aspects of coping with illness.	Case Western Reserve Univ, Sch Med, Ctr Biomed Eth, Cleveland, OH 44106 USA; George Washington Univ, Sch Med, Washington, DC USA; Duke Univ, Med Ctr, Chapel Hill, NC USA	Case Western Reserve University; George Washington University; Duke University	Post, SG (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Biomed Eth, Cleveland, OH 44106 USA.							ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003; ANDERSON JM, 1993, ARCH PHYS MED REHAB, V74, P574, DOI 10.1016/0003-9993(93)90154-3; *ASS AM MED COLL, 1998, 1 ASS AM MED COLL; Asser SM, 1998, PEDIATRICS, V101, P625, DOI 10.1542/peds.101.4.625; AZHAR MZ, 1995, ACTA PSYCHIAT SCAND, V91, P233, DOI 10.1111/j.1600-0447.1995.tb09774.x; Baider L, 1999, PSYCHO-ONCOL, V8, P27, DOI 10.1002/(SICI)1099-1611(199901/02)8:1<27::AID-PON334>3.3.CO;2-M; BARNARD D, 1995, ACAD MED, V70, P806, DOI 10.1097/00001888-199509000-00016; BARSKY AJ, 1988, NEW ENGL J MED, V318, P414, DOI 10.1056/NEJM198802183180705; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Benson Herbert, 1996, TIMELESS HEALING POW; BRODY H, 1992, HEALERS POWER; CARROLL S, 1993, J STUD ALCOHOL, V54, P297, DOI 10.15288/jsa.1993.54.297; DAALEMAN TP, 1994, J FAM PRACTICE, V39, P564; DAGI TF, 1995, J CLIN ETHIC, V6, P274; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; Ehman JW, 1999, ARCH INTERN MED, V159, P1803, DOI 10.1001/archinte.159.15.1803; Emmons R. A., 1999, PSYCHOL ULTIMATE CON; FEE E, 1997, EMOTIONS DIS; FOGLIO JP, 1988, J FAM PRACTICE, V27, P473; GALLOP G, 1985, RELIGION AM 50 YEARS; Gorsuch RL, 1995, J SOC ISSUES, V51, P65, DOI 10.1111/j.1540-4560.1995.tb01324.x; Hatch RL, 1998, J FAM PRACTICE, V46, P476; Holland JC, 1999, PSYCHO-ONCOLOGY, V8, P14, DOI 10.1002/(SICI)1099-1611(199901/02)8:1<14::AID-PON321>3.0.CO;2-E; Idler EL, 1997, J GERONTOL B-PSYCHOL, V52, pS306, DOI 10.1093/geronb/52B.6.S306; Idler EL, 1997, J GERONTOL B-PSYCHOL, V52, pS294, DOI 10.1093/geronb/52B.6.S294; Jakobovits Immanuel, 1959, JEWISH MEDICAL ETHIC; JOHNSON SC, 1991, J RELIG HEALTH, V30, P21, DOI 10.1007/BF00986676; KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519; KIECOLTGLASER JK, 1995, PSYCHOSOM MED, V57, P269, DOI 10.1097/00006842-199505000-00008; KING DE, 1994, J FAM PRACTICE, V39, P349; Koenig H. G., 1999, HEALING POWER FAITH; Koenig HG, 1999, INT J PSYCHIAT MED, V29, P123, DOI 10.2190/C2FB-95VW-FKYD-C8RV; Koenig HG, 1999, J GERONTOL A-BIOL, V54, pM370, DOI 10.1093/gerona/54.7.M370; KOENIG HG, 1995, PSYCHOSOMATICS, V36, P369, DOI 10.1016/S0033-3182(95)71646-2; Koenig HG, 1998, SOUTHERN MED J, V91, P925, DOI 10.1097/00007611-199810000-00006; KOENIG HG, 1992, AM J PSYCHIAT, V149, P1693; KRAUSE N, 1989, J GERONTOL, V44, pS4, DOI 10.1093/geronj/44.1.S4; LARSON DB, 1988, HOSP COMMUNITY PSYCH, V39, P1064; Larson DB, 1998, SCI RES SPIRITUALITY; LESERMAN J, 1989, BEHAV MED, V15, P111, DOI 10.1080/08964289.1989.9934573; Levin J S, 1997, JAMA, V278, P792, DOI 10.1001/jama.278.9.792; Levin JS, 1996, SOC SCI MED, V43, P849, DOI 10.1016/0277-9536(96)00150-5; LEVIN JS, 1994, SOC SCI MED, V38, P1475, DOI 10.1016/0277-9536(94)90109-0; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Maugans TA, 1996, ARCH FAM MED, V5, P11, DOI 10.1001/archfami.5.1.11; MAUGANS TA, 1991, J FAM PRACTICE, V32, P210; McBride J L, 1998, Fam Med, V30, P122; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MUYSKENS JL, 1979, SUFFICIENCY HOPE CON; OLIVE KE, 1995, SOUTHERN MED J, V88, P1249, DOI 10.1097/00007611-199512000-00012; OSLER W, 1951, WAY LIFE SELECTED WR, P237; OXMAN TE, 1995, PSYCHOSOM MED, V57, P5, DOI 10.1097/00006842-199501000-00002; Pargament K.I., 1997, PSYCHOL RELIG COPING; PECK M. S., 1997, DENIAL SOUL SPIRITUA; Pellegrino E., 1988, PATIENTS GOOD RESTOR; POST SG, 1993, CULT MED PSYCHIAT, V17, P363, DOI 10.1007/BF01380010; POST SG, 1995, J LAW MED ETHICS, V23, P20, DOI 10.1111/j.1748-720X.1995.tb01326.x; POST SG, 1995, HARPERCOLLINS DICT R, P690; Post Stephen G, 1995, IRB, V17, P8, DOI 10.2307/3564567; Puchalski CM, 1998, ACAD MED, V73, P970, DOI 10.1097/00001888-199809000-00015; PUCHALSKI CM, 1999, SPIRITUALITY MED CON, V3, P1; Roberts JA, 1997, AM J OBSTET GYNECOL, V176, P166, DOI 10.1016/S0002-9378(97)80030-0; SELWAY DA, 1997, DISABILITY REHABILIT, P19; Sloan RP, 1999, LANCET, V353, P664, DOI 10.1016/S0140-6736(98)07376-0; Sternberg EM, 1997, NAT MED, V3, P264, DOI 10.1038/nm0397-264; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; Strawbridge WJ, 1997, AM J PUBLIC HEALTH, V87, P957, DOI 10.2105/AJPH.87.6.957; Thiel MM, 1997, J CLIN ETHIC, V8, P94; WILLIAMS DR, 1991, SOC SCI MED, V32, P1257, DOI 10.1016/0277-9536(91)90040-J; 1997, J CLIN BEHAV MED, P2	70	257	260	0	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					578	583		10.7326/0003-4819-132-7-200004040-00010	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744595				2022-12-28	WOS:000086129300009
J	Leydon, GM; Boulton, M; Moynihan, C; Jones, A; Mossman, J; Boudioni, M; McPherson, K				Leydon, GM; Boulton, M; Moynihan, C; Jones, A; Mossman, J; Boudioni, M; McPherson, K			Cancer patients' information needs and information seeking behaviour: in depth interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREFERENCES	Objectives To explore why cancer patients do riot want or seek information about their condition beyond that volunteered by their physicians at times during their illness. Design Qualitative study based on in-depth interviews. Setting Outpatient oncology clinics at a London cancer centre. Participants 17 patients with cancer diagnosed in previous 6 months. Main outcome measures Analysis of patients narratives to identify key themes and categories. Results While all patients wanted basic information on diagnosis and treatment, not all wanted further information at all stages of their illness. Three overarching attitudes to their management of cancel limited patients' desire for and subsequent efforts to obtain further information: faith, hope, and charity: Faith in their doctor's medical expertise precluded the need for patients to seek further information themselves. Hope was essential for patients to carry on with life as normal and could be maintained through silence and avoiding information, especially too detailed or "unsafe" information. Charity to fellow patients, especially those seen as more needy than themselves, was expressed in the recognition that scarce resources-including information and explanations-had to be shared and meant that limited Information was accepted as inevitable. Conclusions Cancer patients' attitudes to cancer. and their strategies for coping with their illness can constrain their wish for information and their, efforts to obtain it. In developing recommendations, the government's cancer information strategy should attend to variations in patients' desires for information and the reasons for them.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Canc & Publ Hlth Unit, London WC1E 7HT, England; Oxford Brookes Univ, Sch Social Sci & Law, Oxford OX3 0BP, England; Inst Canc Res, Sutton SM2 5PT, Surrey, England; Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England; Royal Free Hosp, Sch Med, London NW3 2QG, England; CancerBACUP, London EC2A 3JR, England	University of London; London School of Hygiene & Tropical Medicine; Oxford Brookes University; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Leydon, GM (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Canc & Publ Hlth Unit, London WC1E 7HT, England.	g.leydon@Ishtm.ac.uk	Leydon, Geraldine M/C-4968-2011; BOULTON, Mary/X-9056-2019	BOULTON, Mary/0000-0002-2247-8318; Leydon, Geraldine Marie/0000-0001-5986-3300				Boudioni M, 1999, BRIT J CANCER, V79, P138, DOI 10.1038/sj.bjc.6690023; Boudioni M, 1998, BRIT MED J, V317, P1016, DOI 10.1136/bmj.317.7164.1016; BUTOW P, 1994, BRIT J CANCER, V71, P1115; Byrne P.S., 1976, DOCTORS TALKING PATI; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; Coulter A, 1998, BMJ-BRIT MED J, V317, P225, DOI 10.1136/bmj.317.7153.225; FALLOWFIELD L, 1995, PSYCHO-ONCOLOGY, V4, P197, DOI 10.1002/pon.2960040305; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; FORD S, 1995, SOC SCI MED, P1; HARRISON J, 1995, SOC SCI MED, V41, P1255, DOI 10.1016/0277-9536(94)00411-L; HOUTS P, 1991, J CANCER EDUC, V6, P225; INGELFINGER FJ, 1980, NEW ENGL J MED, V303, P1507, DOI 10.1056/NEJM198012253032604; LUPTON D, 1996, HLTH SOCIOLOGY EMOTI, P157; Meredith C, 1996, BMJ-BRIT MED J, V313, P724; National Cancer Alliance, 1996, PAT CTR CANC SERV WH; Orne M T, 1968, Int J Psychiatry, V5, P403; Parsons T., 1951, SOCIAL SYSTEM; Pinder R., 1990, MANAGEMENT CHRONIC I; RITCHIE J, 1994, ANAL QUALITATIVE DAT, P172; Silverman D., 2015, INTERPRETING QUALITA; Slevin ML, 1996, BRIT J CANCER, V74, P1275, DOI 10.1038/bjc.1996.529; The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995, POL FRAM COMM CANC S; WongWylie G, 1997, QUAL HEALTH RES, V7, P32, DOI 10.1177/104973239700700103	23	571	578	5	86	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2000	320	7239					909	913		10.1136/bmj.320.7239.909	http://dx.doi.org/10.1136/bmj.320.7239.909			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	301YA	10742000	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086337100025
J	Williams, B; Whatmough, P; McGill, J; Rushton, L				Williams, B; Whatmough, P; McGill, J; Rushton, L			Private funding of elective hospital treatment in England and Wales, 1997-8: national survey	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham, Queens Med Ctr, Sch Community Hlth Sci, Nottingham NG7 2UH, England; Univ Leicester, MRC, Inst Environm & Hlth, Leicester LE1 7DD, Leics, England	University of Nottingham; University of Leicester	Williams, B (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Community Hlth Sci, Nottingham NG7 2UH, England.							Dawson J, 1999, LANCET, V353, P2161, DOI 10.1016/S0140-6736(05)75602-6; *IND HEALTHC ASS, 1996, DIR IND HOSP HLTH SE; NICHOLL JP, 1989, BRIT MED J, V298, P243, DOI 10.1136/bmj.298.6668.243; Plomp J, 1999, HEART, V81, P593, DOI 10.1136/hrt.81.6.593; WILLIAMS BT, 1994, BRIT MED J, V308, P1699, DOI 10.1136/bmj.308.6945.1699	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					904	905		10.1136/bmj.320.7239.904	http://dx.doi.org/10.1136/bmj.320.7239.904			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10741997	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000086337100023
J	Chapman, B				Chapman, B			Necessity for afferent activity to maintain eye-specific segregation in ferret lateral geniculate nucleus	SCIENCE			English	Article							TETRODOTOXIN; INFUSION	In the adult mammal, retinal ganglion cell axon arbors are restricted to eye-specific Layers in the lateral geniculate nucleus. Blocking neuronal activity early in development prevents this segregation from occurring. To test whether activity is also required to maintain eye-specific segregation, ganglion cell activity was blocked after segregation was established. This caused desegregation, so that both eyes' axons became concentrated in lumina A, normally occupied only by contralateral afferents. These results show that an activity-dependent process is necessary for maintaining eye-specific segregation and suggest that activity-independent cues may favor Lamina A as the target for arborization of afferents from both eyes.	Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA	University of California System; University of California Davis	Chapman, B (corresponding author), Univ Calif Davis, Ctr Neurosci, 1544 Newton Court, Davis, CA 95616 USA.				NATIONAL EYE INSTITUTE [R01EY011369] Funding Source: NIH RePORTER; NEI NIH HHS [EY-11369, R01 EY011369-11, R01 EY011369] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Chapman B, 2000, J NEUROSCI, V20, P1922; Cook PM, 1999, VISUAL NEUROSCI, V16, P491, DOI 10.1017/S0952523899163107; GUILLERY RW, 1985, J NEUROSCI, V5, P1370; HUTCHINS JB, 1990, J COMP NEUROL, V298, P113, DOI 10.1002/cne.902980109; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; MORGAN J, 1993, VISUAL NEUROSCI, V10, P303, DOI 10.1017/S0952523800003709; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; RAKIC P, 1976, NATURE, V261, P467, DOI 10.1038/261467a0; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHIELLS RA, 1981, NATURE, V294, P592, DOI 10.1038/294592a0; SLAUGHTER MM, 1981, SCIENCE, V211, P182, DOI 10.1126/science.6255566; SRETAVAN DW, 1986, J NEUROSCI, V6, P990; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; WONG WC, COMMUNICATION; Wong WT, 2000, J NEUROSCI, V20, P351, DOI 10.1523/JNEUROSCI.20-01-00351.2000	15	90	97	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2479	2482		10.1126/science.287.5462.2479	http://dx.doi.org/10.1126/science.287.5462.2479			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741966	Green Accepted			2022-12-28	WOS:000086202200043
J	Appleby, J; Boyle, S				Appleby, J; Boyle, S			Blair's billions: where will he find the money for the NHS?	BRITISH MEDICAL JOURNAL			English	Article									Kings Fund, Hlth Syst Programme, London W1M 0AN, England; London Sch Econ, Dept Operat Res, London WC2A 2AE, England	University of London; London School Economics & Political Science	Appleby, J (corresponding author), Kings Fund, Hlth Syst Programme, 11-13 Cavendish Sq, London W1M 0AN, England.							*DEP HLTH, 1999, REV BOD DOCT DENT RE; Ferriman A, 2000, BRIT MED J, V320, P205, DOI 10.1136/bmj.320.7229.205; *I FISC STUD, 2000, IFS GREEN BUDG 2000; MARSDEN K, 2000, 5 PER CENT SOLUTION; *ORG EC COOP DEV, 1999, OECD HLTH DAT 99 COM; Towse A, 2000, BRIT MED J, V320, P640, DOI 10.1136/bmj.320.7235.640; *TREAS, 1999, CM4479	7	12	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					865	867		10.1136/bmj.320.7238.865	http://dx.doi.org/10.1136/bmj.320.7238.865			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731188	Green Published			2022-12-28	WOS:000086180300034
J	Berger, A				Berger, A			Saliva test could diagnose cancers	BRITISH MEDICAL JOURNAL			English	News Item																		Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					825	825		10.1136/bmj.320.7238.825	http://dx.doi.org/10.1136/bmj.320.7238.825			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731167	Green Published			2022-12-28	WOS:000086180300015
J	Ridker, PM; Hennekens, CH; Buring, JE; Rifai, N				Ridker, PM; Hennekens, CH; Buring, JE; Rifai, N			C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; AVERAGE CHOLESTEROL LEVELS; SEVERE UNSTABLE ANGINA; APPARENTLY HEALTHY-MEN; MYOCARDIAL-INFARCTION; RISK; EVENTS; ATHEROSCLEROSIS; PRAVASTATIN; PREVENTION	Background: Since inflammation is believed to have a role in the pathogenesis of cardiovascular events, measurement of markers of inflammation has been proposed as a method to improve the prediction of the risk of these events. Methods: We conducted a prospective, nested case-control study among 28,263 apparently healthy postmenopausal women over a mean follow-up period of three years to assess the risk of cardiovascular events associated with base-line levels of markers of inflammation. The markers included high-sensitivity C-reactive protein (hs-CRP), serum amyloid A, interleukin-6, and soluble intercellular adhesion molecule type 1 (sICAM-1). We also studied homocysteine and several lipid and lipoprotein measurements. Cardiovascular events were defined as death from coronary heart disease, nonfatal myocardial infarction or stroke, or the need for coronary-revascularization procedures. Results: Of the 12 markers measured, hs-CRP was the strongest univariate predictor of the risk of cardiovascular events; the relative risk of events for women in the highest as compared with the lowest quartile for this marker was 4.4 (95 percent confidence interval, 2.2 to 8.9). Other markers significantly associated with the risk of cardiovascular events were serum amyloid A (relative risk for the highest as compared with the lowest quartile, 3.0), sICAM-1 (2.6), interleukin-6 (2.2), homocysteine (2.0), total cholesterol (2.4), low-density lipoprotein (LDL) cholesterol (2.4), apolipoprotein B-100 (3.4), high-density lipoprotein (HDL) cholesterol (0.3), and the ratio of total cholesterol to HDL cholesterol (3.4). Prediction models that incorporated markers of inflammation in addition to lipids were significantly better at predicting risk than models based on lipid levels alone (P<0.001). The levels of hs-CRP and serum amyloid A were significant predictors of risk even in the subgroup of women with LDL cholesterol levels below 130 mg per deciliter (3.4 mmol per liter), the target for primary prevention established by the National Cholesterol Education Program. In multivariate analyses, the only plasma markers that independently predicted risk were hs-CRP (relative risk for the highest as compared with the lowest quartile, 1.5; 95 percent confidence interval, 1.1 to 2.1) and the ratio of total cholesterol to HDL cholesterol (relative risk, 1.4; 95 percent confidence interval, 1.1 to 1.9). Conclusions: The addition of the measurement of C-reactive protein to screening based on lipid levels may provide an improved method of identifying women at risk for cardiovascular events. (N Engl J Med 2000;342:836-43.) (C)2000, Massachusetts Medical Society.	Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Childrens Hosp, Med Ctr, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Ridker, PM (corresponding author), Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, 75 Francis St, Boston, MA 02115 USA.				NCI NIH HHS [CA47988] Funding Source: Medline; NHLBI NIH HHS [HL43851, HL58755] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851, R01HL058755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Biasucci LM, 1999, CIRCULATION, V99, P2079, DOI 10.1161/01.CIR.99.16.2079; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Hwang SJ, 1997, CIRCULATION, V96, P4219; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Liuzzo G, 1998, CIRCULATION, V98, P2370, DOI 10.1161/01.CIR.98.22.2370; Macy EM, 1997, CLIN CHEM, V43, P52; Maseri A, 1997, NEW ENGL J MED, V336, P1014, DOI 10.1056/NEJM199704033361409; Morrow DA, 1998, J AM COLL CARDIOL, V31, P1460, DOI 10.1016/S0735-1097(98)00136-3; Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007; Ridker PM, 1997, NEW ENGL J MED, V337, P356; Ridker PM, 1999, ANN INTERN MED, V131, P573, DOI 10.7326/0003-4819-131-8-199910190-00004; Ridker PM, 1999, JAMA-J AM MED ASSOC, V281, P1817, DOI 10.1001/jama.281.19.1817; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Ridker PM, 1999, ANN INTERN MED, V130, P933, DOI 10.7326/0003-4819-130-11-199906010-00018; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; RIDKER PM, IN PRESS CIRCULATION; Rifai N, 1999, CLIN CHEM, V45, P2136; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Toss H, 1997, CIRCULATION, V96, P4204; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; *WHO, 1971, ISCH HEART DIS REG R	33	4453	4729	2	387	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	2000	342	12					836	843		10.1056/NEJM200003233421202	http://dx.doi.org/10.1056/NEJM200003233421202			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296FU	10733371				2022-12-28	WOS:000086014100002
J	Olschewski, H; Ghofrani, HA; Schmehl, T; Winkler, J; Wilkens, H; Hoper, MM; Behr, J; Kleber, FX; Seeger, W				Olschewski, H; Ghofrani, HA; Schmehl, T; Winkler, J; Wilkens, H; Hoper, MM; Behr, J; Kleber, FX; Seeger, W		German PPH Study Grp	Inhaled iloprost to treat severe pulmonary hypertension - An uncontrolled trial	ANNALS OF INTERNAL MEDICINE			English	Article						iloprost; hypertension; hemodynamics; pulmonary heart disease; administration, inhalation	RESPIRATORY-DISTRESS-SYNDROME; HEART-LUNG TRANSPLANTATION; NITRIC-OXIDE; AEROSOLIZED PROSTACYCLIN; EPOPROSTENOL PROSTACYCLIN; SURVIVAL; THERAPY; SHOCK; AGENT	Background: Inhaled aerosolized iloprost, a stable prostacyclin analogue, has been considered a selective pulmonary vasodilator in the management of pulmonary hypertension. Objective: To assess the efficacy of inhaled iloprost in the treatment of life-threatening pulmonary hypertension. Design: Open, uncontrolled, multicenter study. Setting: Intensive care units and pulmonary hypertension clinics at six university hospitals in Germany. Patients: 19 patients who had progressive right-heart failure despite receiving maximum conventional therapy (12 with primary pulmonary hypertension, 3 with pulmonary hypertension related to collagen vascular disease without lung fibrosis, and 4 with secondary pulmonary hypertension). Intervention: Inhaled iloprost, 6 to 12 times daily (50 to 200 mu g/d). Measurements: Right-heart catheterization and distance walked in 6 minutes at baseline and after 3 months of therapy. Results: During the first 3 months of therapy, New York Heart Association functional class improved in 8 patients and was unchanged in 7 patients. Four patients died, 3 of right-heartfailure and 1 of sepsis. The acute hemodynamic response to inhaled iloprost was predominant pulmonary vasodilatation with little systemic effect at baseline and at 3 months (data available for 12 patients). Hemodynamic variables were improved at 3 months, and the distance walked in 6 minutes improved by 148 m (95% CI, 4.5 to 282 m; P = 0.048). Of the 15 patients who continued to use inhaled iloprost, 8 stopped: Four had lung transplantation, 1 switched to intravenous prostacyclin therapy, and 3 died. Seven patients are still receiving inhaled iloprost (mean +/-SD) duration of therapy, 536 +/- 309 days; mean dosage, 164 +/- 38 mu g/d). Conclusions: Inhaled iloprost may offer a new therapeutic option for improvement of hemodynamics and physical function in patients with life-threatening pulmonary hypertension and progressive right-heart failure that is refractory to conventional therapy.	Univ Giessen, Dept Internal Med 2, D-35392 Giessen, Germany; Univ Clin, Leipzig, Germany; Univ Clin Saarland, Homburg, Germany; Hannover Med Sch, D-3000 Hannover, Germany; Univ Clin Grosshadern, Munich, Germany; Accid Clin, Berlin, Germany	Justus Liebig University Giessen; Leipzig University; Universitatsklinikum des Saarlandes; Hannover Medical School; University of Munich	Seeger, W (corresponding author), Univ Giessen, Dept Internal Med 2, Klin Str 36, D-35392 Giessen, Germany.	werner.seeger@innere.med.uni-giessen.de	Ghofrani, Hossein Ardeschir/AAD-2856-2022; Ghofrani, Ardeschir/AAD-5293-2020; Olschewski, Horst/L-3547-2019	Ghofrani, Ardeschir/0000-0002-2029-4419; Olschewski, Horst/0000-0002-2834-7466; Seeger, Werner/0000-0003-1946-0894				AGUSTI AGN, 1993, EUR RESPIR J, V6, P1371; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BARST RJ, 1994, ANN INTERN MED, V121, P409, DOI 10.7326/0003-4819-121-6-199409150-00003; Channick RN, 1996, CHEST, V109, P1545, DOI 10.1378/chest.109.6.1545; Cueto E, 1997, ACTA PAEDIATR, V86, P1337, DOI 10.1111/j.1651-2227.1997.tb14909.x; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; De Jaegere APMC, 1998, EUR RESPIR J, V12, P932, DOI 10.1183/09031936.98.12040932; Eichelbronner O, 1996, INTENS CARE MED, V22, P880; Higenbottam T, 1998, HEART, V80, P151, DOI 10.1136/hrt.80.2.151; HIGENBOTTAM TW, 1993, BRIT HEART J, V70, P366; HOPER MM, IN PRESS J AM COLL C; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; Mikhail G, 1997, EUR HEART J, V18, P1499; MILLER OI, 1995, LANCET, V346, P51, DOI 10.1016/S0140-6736(95)92681-X; Olschewski H, 1999, AM J RESP CRIT CARE, V160, P600, DOI 10.1164/ajrccm.160.2.9810008; Olschewski H, 1998, INTENS CARE MED, V24, P631, DOI 10.1007/s001340050628; Olschewski H, 1996, ANN INTERN MED, V124, P820, DOI 10.7326/0003-4819-124-9-199605010-00006; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; Putensen C, 1998, AM J RESP CRIT CARE, V157, P1743, DOI 10.1164/ajrccm.157.6.9609017; Ricciardi MJ, 1998, J AM COLL CARDIOL, V32, P1068, DOI 10.1016/S0735-1097(98)00361-1; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; SANDOVAL J, 1994, CIRCULATION, V89, P1733, DOI 10.1161/01.CIR.89.4.1733; SITBON O, 1995, AM J RESP CRIT CARE, V151, P384, DOI 10.1164/ajrccm.151.2.7842196; SNELL GI, 1995, AM J RESP CRIT CARE, V151, P1263; Walmrath D, 1996, AM J RESP CRIT CARE, V153, P991, DOI 10.1164/ajrccm.153.3.8630585; WALMRATH D, 1995, AM J RESP CRIT CARE, V151, P724; WALMRATH D, 1993, LANCET, V342, P961, DOI 10.1016/0140-6736(93)92004-D; Warren JB, 1996, LANCET, V348, P629, DOI 10.1016/S0140-6736(05)65068-4; Williamson DJ, 1996, CIRCULATION, V94, P477, DOI 10.1161/01.CIR.94.3.477	29	210	224	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					435	+		10.7326/0003-4819-132-6-200003210-00003	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293CV	10733442				2022-12-28	WOS:000085834700002
J	Lieu, TA; Ray, GT; Black, SB; Butler, JC; Klein, JO; Breiman, RF; Miller, MA; Shinefield, HR				Lieu, TA; Ray, GT; Black, SB; Butler, JC; Klein, JO; Breiman, RF; Miller, MA; Shinefield, HR			Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE OTITIS-MEDIA; UNITED-STATES; BACTERIAL-MENINGITIS; IMMUNIZATION; INFECTIONS; EPIDEMIOLOGY; PREVENTION; EFFICACY; PROGRAM	Context Pneumococcal conjugate vaccine for infants has recently been found effective against meningitis, bacteremia, pneumonia, and otitis media. Objective Tc,evaluate the projected health and economic impact: of pneumococcal conjugate vaccination of healthy US infants and young children. Design Cost-effectiveness analysis based on data from the Northern California Kaiser Permanente randomized trial and other published and unpublished sources. Setting and Patients A hypothetical US birth cohort of 3.8 million infants, Interventions Hypothetical comparisons of routine vaccination of healthy infants, requiring 4 doses of pneumococcal conjugate vaccine (at 2, 4, 6, and 12-15 months), and catch-up vaccination of children aged 2 to 4.9 years requiring 1 dose, with children receiving no intervention. Main Outcome Measures Cost per life-year saved and cost per-episode of meningitis, bacteremia, pneumonia, and otitis media prevented. Results Vaccination of healthy infants would prevent more than 12 000 cases of meningitis and bacteremia, 53 000 cases of pneumonia, 1 million episodes of otitis media, and 116 deaths due to pneumococcal infection. Before accounting for vaccine costs, the vaccination program would save $342 million in medical and $415 million in work-loss and other costs from averted pneumococcal disease. Vaccination of healthy infants would result in net savings for society if the vaccine cost less than $46 per dose, and net savings for the health care payer if the vaccine cost less than $18 pet dose. At the manufacturer's list price of $58 per dose, infant vaccination would cost society $80 000 per life-year saved or $160 per otitis media episode prevented (other estimated costs would be $3200 per pneumonia case prevented, $15 000 for bacteremia, and $280 000 for meningitis). The cost-effectiveness of an additional program to administer 1 dose of vaccine to children aged 2 to 4.9 years would vary depending on the children's ages, relative risks of pneumococcal disease, and vaccine cost Conclusions Pneumococcal conjugate vaccination of healthy US infants has the potential to be cost-effective, To achieve cost savings, its cost would need to be lower than the manufacturer's list price. In addition to tangible costs, the vaccine should be appraised based on the less tangible value of preventing mortality and morbidity from pneumococcal disease.	Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Kaiser Permanente, Div Res, Vaccine Study Ctr, Oakland, CA USA; Boston Univ, Med Ctr, Boston City Hosp, Dept Pediat, Boston, MA USA; Natl Ctr Infect Dis, Arctic Invest Program, Anchorage, AK USA; Ctr Dis Control & Prevent, Natl Vaccine Program Off, Atlanta, GA USA; Childrens Vaccine Initiat, Geneva, Switzerland	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Kaiser Permanente; Boston Medical Center; Boston University; Centers for Disease Control & Prevention - USA	Lieu, TA (corresponding author), Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 200, Boston, MA 02215 USA.	tracy_lieu@hphc.org						Alsarraf R, 1998, ANN OTO RHINOL LARYN, V107, P120, DOI 10.1177/000348949810700207; *AM MED ASS, 1998, PHYS MED GUID; Black S, 1999, PEDIATR RES, V45, p157A, DOI 10.1203/00006450-199904020-00932; BLACK S, 1998, CONT PEDIAT S    NOV, P12; BLACK S, IN PRESS PEDIAT INFE; BLUESTONE CD, 1995, OTITIS MEDIA INFANTS, P229; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; *BUR LAB STAT, 1999, CONS PRIC IND ALL UR; BUTLER JC, 1995, J INFECT DIS, V171, P885, DOI 10.1093/infdis/171.4.885; BYMS PJ, 1997, ARCH PEDIAT ADOLESC, V151, P407; CAPRA AM, IN PRESS PEDIAT INFE; CASPER LM, 1999, WHOS MINDING OUR PRE; *CDCP, 1997, VITAL HLTH STAT, V23, P69; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P829; Centers for Disease Control and Prevention, 2000, ACT BACT COR SURV AB; COCHI SL, 1988, AM J DIS CHILD, V142, P499, DOI 10.1001/archpedi.1988.02150050037025; Eskola J, 1999, PEDIATR INFECT DIS J, V18, P543, DOI 10.1097/00006454-199906000-00015; Fiore AE, 1999, EMERG INFECT DIS, V5, P828, DOI 10.3201/eid0506.990616; Freed GL, 1996, ARCH PEDIAT ADOL MED, V150, P421, DOI 10.1001/archpedi.1996.02170290087014; Gold MR, 1996, COST EFFECTIVENESS H; GRABOWSKY M, 1991, J INFECT DIS, V164, P1237, DOI 10.1093/infdis/164.6.1237; HADDIX A, 1994, PRACTICAL GUIDE PREV; HALL MJ, 1998, ADV DATA VITAL HLTH, V300, P8; HALLORAN ME, 1991, AM J EPIDEMIOL, V133, P323, DOI 10.1093/oxfordjournals.aje.a115884; HARDY AM, 1991, VITAL HLTH STAT, V10, P10; Joffe S, 1999, PEDIATRICS, V104, P419, DOI 10.1542/peds.104.3.419; Kaplan SL, 1998, PEDIATRICS, V102, P538, DOI 10.1542/peds.102.3.538; KLEIN JO, 1994, CLIN INFECT DIS, V19, P823, DOI 10.1093/clinids/19.5.823; Levine OS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e28; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; LIEU TA, 1994, JAMA-J AM MED ASSOC, V217, P375; Lipsitch M, 1999, EMERG INFECT DIS, V5, P336, DOI 10.3201/eid0503.990304; MAKELA PH, 1981, REV INFECT DIS, V3, pS124; MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; McIntyre PB, 1997, JAMA-J AM MED ASSOC, V278, P925, DOI 10.1001/jama.278.11.925; Miller MA, 1996, JAMA-J AM MED ASSOC, V276, P967, DOI 10.1001/jama.276.12.967; Mulholland K, 1999, PEDIATR INFECT DIS J, V18, pS17; Nieminen T, 1999, PEDIATR INFECT DIS J, V18, P764, DOI 10.1097/00006454-199909000-00005; Obaro S, 1998, LANCET, V351, P1284, DOI 10.1016/S0140-6736(05)79345-4; Oh PI, 1996, CLIN THER, V18, P160, DOI 10.1016/S0149-2918(96)80188-3; POMEROY SL, 1990, NEW ENGL J MED, V323, P1651, DOI 10.1056/NEJM199012133232402; *PRACT MAN INF COR, 1999, MED FEES US; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; Severens JL, 1997, AM J OTOL, V18, P714; Shinefield HR, 1999, PEDIATR INFECT DIS J, V18, P757, DOI 10.1097/00006454-199909000-00004; Sorum PC, 1999, MED DECIS MAKING, V19, P27, DOI 10.1177/0272989X9901900104; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; Thompson D, 1999, PEDIATR INFECT DIS J, V18, P239, DOI 10.1097/00006454-199903000-00006; Tucker AW, 1998, JAMA-J AM MED ASSOC, V279, P1371, DOI 10.1001/jama.279.17.1371; WAITZMAN NJ, 1996, COST BIRTH DEFECTS; Zangwill KM, 1996, J INFECT DIS, V174, P752, DOI 10.1093/infdis/174.4.752; 1998, FED REG, V63, P40954	54	202	204	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2000	283	11					1460	1468		10.1001/jama.283.11.1460	http://dx.doi.org/10.1001/jama.283.11.1460			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290UR	10732936				2022-12-28	WOS:000085696700031
J	Ratner, M				Ratner, M			Molecular electronics - Pushing electrons around	NATURE			English	Editorial Material							CONDUCTANCE		Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University	Ratner, M (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.							Bumm LA, 1999, J PHYS CHEM B, V103, P8122, DOI 10.1021/jp9921699; Campbell IH, 1997, APPL PHYS LETT, V71, P3528, DOI 10.1063/1.120381; Cohen R, 1999, J AM CHEM SOC, V121, P10545, DOI 10.1021/ja9906150; Dai HJ, 1996, SCIENCE, V272, P523, DOI 10.1126/science.272.5261.523; DEKKER C, 1999, PHYS TODAY      0522; Emberly E, 1999, NANOTECHNOLOGY, V10, P285, DOI 10.1088/0957-4484/10/3/311; Hall LE, 2000, J CHEM PHYS, V112, P1510, DOI 10.1063/1.480696; Joachim C, 1996, EUROPHYS LETT, V33, P635, DOI 10.1209/epl/i1996-00391-2; JORTNER JR, 1997, MOL ELECT; KRUGER J, IN PRESS ADV MAT; MUJICA V, IN PRESS J PHYS CHEM; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Tian WD, 1998, J CHEM PHYS, V109, P2874, DOI 10.1063/1.476841; Vilan A, 2000, NATURE, V404, P166, DOI 10.1038/35004539; Vondrak T, 1999, J PHYS CHEM B, V103, P8915, DOI 10.1021/jp9916337	15	56	56	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					137	138		10.1038/35004697	http://dx.doi.org/10.1038/35004697			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724152				2022-12-28	WOS:000085870900031
J	Blackwood, D				Blackwood, D			P300, a state and a trait marker in schizophrenia	LANCET			English	Editorial Material							SUBCOMPONENT ABNORMALITIES		Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh	Blackwood, D (corresponding author), Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland.							Adler LE, 1999, BIOL PSYCHIAT, V46, P8, DOI 10.1016/S0006-3223(99)00085-2; Almasy L, 1999, AM J MED GENET, V88, P383; Bauer LO, 1999, BIOL PSYCHIAT, V46, P263, DOI 10.1016/S0006-3223(98)00335-7; Blackwood DHR, 1999, BRIT J PSYCHIAT, V175, P357, DOI 10.1192/bjp.175.4.357; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, pP357; Ford JM, 1999, BIOL PSYCHIAT, V46, P94, DOI 10.1016/S0006-3223(98)00290-X; Frodl-Bauch T, 1999, BIOL PSYCHIAT, V45, P116, DOI 10.1016/S0006-3223(98)00108-5; Higashima M, 1998, BIOL PSYCHIAT, V44, P115, DOI 10.1016/S0006-3223(97)00359-4; O'Donnell BF, 1999, PSYCHOPHYSIOLOGY, V36, P388, DOI 10.1017/S0048577299971688; ROTH WT, 1972, ARCH GEN PSYCHIAT, V27, P466; Salisbury DF, 1998, ARCH GEN PSYCHIAT, V55, P173, DOI 10.1001/archpsyc.55.2.173; Turetsky B, 1998, BIOL PSYCHIAT, V43, P31, DOI 10.1016/S0006-3223(97)00261-8; Turetsky BI, 1998, BIOL PSYCHIAT, V43, P84, DOI 10.1016/S0006-3223(97)00258-8; Umbricht D, 1998, BIOL PSYCHIAT, V44, P716, DOI 10.1016/S0006-3223(97)00524-6; Weir N, 1998, SCHIZOPHR RES, V31, P151, DOI 10.1016/S0920-9964(98)00017-6; Weisbrod M, 1999, BIOL PSYCHIAT, V46, P721, DOI 10.1016/S0006-3223(99)00022-0	16	50	52	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					771	772		10.1016/S0140-6736(99)00261-5	http://dx.doi.org/10.1016/S0140-6736(99)00261-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711922				2022-12-28	WOS:000085766900006
J	Chen, JL; Blasco, MA; Greider, CW				Chen, JL; Blasco, MA; Greider, CW			Secondary structure of vertebrate telomerase RNA	CELL			English	Article							SMALL NUCLEOLAR RNAS; RIBONUCLEASE-P RNA; ACTIVITY IN-VITRO; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; RIBOSOMAL-RNA; RIBONUCLEOPROTEIN ENZYME; PHYLOGENETIC ANALYSIS; TERMINAL TRANSFERASE; TETRAHYMENA	Telomerase is a ribonucleoprotein enzyme that maintains telomere length by adding telomeric sequence repeats onto chromosome ends. The essential RNA component of telomerase provides the template for telomeric repeat synthesis. To determine the secondary structure of vertebrate telomerase RNA, 32 new telomerase RNA genes were cloned and sequenced from a variety of vertebrate species including 18 mammals, 2 birds, 1 reptile, 7 amphibians, and 4 fishes. Using phylogenetic comparative analysis, we propose a secondary structure that contains four structural domains conserved in all vertebrates. Ten helical regions of the RNA are universally conserved while other regions vary significantly in length and sequence between different classes of vertebrates. The proposed vertebrate telomerase RNA structure displays a strikingly similar topology to the previously determined ciliate telomerase RNA structure, implying an evolutionary conservation of the global architecture of telomerase RNA.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University	Greider, CW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	cgreider@jhmi.edu	Blasco, Maria A./M-1694-2014; Chen, Julian J.-L./D-6488-2014	Blasco, Maria A./0000-0002-4211-233X; Chen, Julian J.-L./0000-0002-7253-2722; Greider, Carol/0000-0002-5494-8126	NIA NIH HHS [AG09838] Funding Source: Medline; NINDS NIH HHS [NS R01 35429] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035429] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Autexier C, 1998, NUCLEIC ACIDS RES, V26, P787, DOI 10.1093/nar/26.3.787; AUTEXIER C, 1995, GENE DEV, V9, P2227, DOI 10.1101/gad.9.18.2227; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; AVILION AA, 1995, GRADUATE PROGRAM CEL, P234; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BLACKBURN EH, 1991, TRENDS BIOCHEM SCI, V16, P378, DOI 10.1016/0968-0004(91)90155-O; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BROWN JW, 1991, J BACTERIOL, V173, P3855, DOI 10.1128/JB.173.12.3855-3863.1991; Brown JW, 1996, P NATL ACAD SCI USA, V93, P3001, DOI 10.1073/pnas.93.7.3001; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; Chen JL, 1998, EMBO J, V17, P1515, DOI 10.1093/emboj/17.5.1515; Collins K, 1999, ANNU REV BIOCHEM, V68, P187, DOI 10.1146/annurev.biochem.68.1.187; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; CZELUSNIAK J, 1990, METHOD ENZYMOL, V183, P601; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; GAUTHERET D, 1994, J MOL BIOL, V242, P1, DOI 10.1006/jmbi.1994.1552; Gilley D, 1999, P NATL ACAD SCI USA, V96, P6621, DOI 10.1073/pnas.96.12.6621; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; Gilley D, 1996, MOL CELL BIOL, V16, P66; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUTELL RR, 1994, MICROBIOL REV, V58, P10, DOI 10.1128/MMBR.58.1.10-26.1994; Hinkley CS, 1998, NUCLEIC ACIDS RES, V26, P532, DOI 10.1093/nar/26.2.532; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; Licht JD, 1999, GENE DEV, V13, P1116, DOI 10.1101/gad.13.9.1116; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MCCORMICKGRAHAM M, 1995, NUCLEIC ACIDS RES, V23, P1091, DOI 10.1093/nar/23.7.1091; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Narayanan A, 1999, EMBO J, V18, P5120, DOI 10.1093/emboj/18.18.5120; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; Ofengand J, 1995, BIOCHEM CELL BIOL, V73, P915, DOI 10.1139/o95-099; Oguchi K, 1999, FEBS LETT, V457, P465, DOI 10.1016/S0014-5793(99)01083-2; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PLEIJ CWA, 1989, METHOD ENZYMOL, V180, P289; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; SINGH D, 1994, INDIAN J CHEM TECHN, V1, P266; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; TENDAM E, 1991, NUCLEIC ACIDS RES, V19, P6951; TENDAM E, 1992, BIOCHEMISTRY-US, V31, P11665, DOI 10.1021/bi00162a001; Tesmer VM, 1999, MOL CELL BIOL, V19, P6207; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; Tsao DA, 1998, GENE, V221, P51, DOI 10.1016/S0378-1119(98)00432-6; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Williams KP, 1996, RNA, V2, P1306; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141; Zaug AJ, 1996, NUCLEIC ACIDS RES, V24, P532, DOI 10.1093/nar/24.3.532	67	465	501	1	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 3	2000	100	5					503	514		10.1016/S0092-8674(00)80687-X	http://dx.doi.org/10.1016/S0092-8674(00)80687-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721988	Bronze			2022-12-28	WOS:000085700000004
J	Vielle-Calzada, JP; Baskar, R; Grossniklaus, U				Vielle-Calzada, JP; Baskar, R; Grossniklaus, U			Delayed activation of the paternal genome during seed development	NATURE			English	Article							ARABIDOPSIS-THALIANA; PATTERN-FORMATION; GENE; EMBRYO; EMBRYOGENESIS; PROTEIN; GNOM; TRAP	Little is known about the timing of the maternal-to-zygotic transition during seed development in flowering plants. Because plant embryos can develop from somatic cells or microspores(1), maternal contributions are not considered to be crucial in early embryogensis(2). Early-acting embryo-lethal mutants in Arabidopsis, including emb30/gnom which affects the first zygotic division(3,4) have fuelled the perception that both maternal and paternal genomes are active immediately after fertilization. Here we show that none of the paternally inherited alleles of 20 loci that we tested is expressed during early seed development in Arabidopsis. For genes that are expressed at later stages, the paternally inherited allele becomes active three to four days after fertilization. The genes that we tested are involved in various processes and distributed throughout the genome, indicating that most, if not all, of the paternal genome may be initially silenced. Our findings are corroborated by genetic studies showing that emb30/gnom has a maternal-effect phenotype that is paternally rescuable in addition to its zygotic lethality. Thus, contrary to previous interpretations, early embryo and endosperm development are mainly under maternal control.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Grossniklaus, U (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Vielle-Calzada, Jean-Philippe/AAG-4036-2019; Grossniklaus, Ueli/A-2736-2012; Grossniklaus, Ueli/E-9995-2016	Grossniklaus, Ueli/0000-0002-0522-8974; Ramamurthy, Baskar/0000-0001-5705-9976; Vielle-Calzada, Jean-Philippe/0000-0002-3017-2490				BENSAUDE O, 1983, NATURE, V305, P331, DOI 10.1038/305331a0; Berger F, 1999, CURR OPIN PLANT BIOL, V2, P28, DOI 10.1016/S1369-5266(99)80006-5; BOWMAN JL, 1994, ARABIDOPSIS ATLAS MO, P351; Buglia G, 1999, CHROMOSOME RES, V7, P71, DOI 10.1023/A:1009231529635; Busch M, 1996, MOL GEN GENET, V250, P681, DOI 10.1007/BF02172979; Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998; Grossniklaus U, 1998, SCIENCE, V280, P446, DOI 10.1126/science.280.5362.446; HOWELL SH, 1999, MOL GENETICS PLANT D; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; MAYER U, 1993, DEVELOPMENT, V117, P149; MEINKE DW, 1985, THEOR APPL GENET, V69, P543, DOI 10.1007/BF00251102; Meinke DW, 1994, ARABIDOPSIS THALIANA, P253; Moore JM, 1997, COLD SPRING HARB SYM, V62, P35, DOI 10.1101/SQB.1997.062.01.007; Mordhorst AP, 1997, CRIT REV PLANT SCI, V16, P535, DOI 10.1080/713608156; Newman-Smith ED, 1998, CURR OPIN GENET DEV, V8, P472, DOI 10.1016/S0959-437X(98)80120-2; NUR U, 1990, DEVELOPMENT S, V1, P29; Oakeley EJ, 1997, P NATL ACAD SCI USA, V94, P11721, DOI 10.1073/pnas.94.21.11721; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; Steinmann T, 1999, SCIENCE, V286, P316, DOI 10.1126/science.286.5438.316; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Torii KU, 1999, J BIOL CHEM, V274, P27674, DOI 10.1074/jbc.274.39.27674; UEDA K, 1995, DEV BIOL, V169, P210, DOI 10.1006/dbio.1995.1138; VAN WENT J. L., 1984, EMBRYOLOGY ANGIOSPER, P273, DOI [10.1007/978-3-642-69302-1_6, DOI 10.1007/978-3-642-69302-1_6]; Vielle-Calzada JP, 1999, GENE DEV, V13, P2971, DOI 10.1101/gad.13.22.2971; Walbot V, 1996, TRENDS PLANT SCI, V1, P27, DOI 10.1016/S1360-1385(96)80020-3; Xu HL, 1999, PLANT MOL BIOL, V39, P607, DOI 10.1023/A:1006162120037; ZALOKAR M, 1976, DEV BIOL, V49, P425, DOI 10.1016/0012-1606(76)90185-8; ZIMMERMAN JL, 1991, NEW BIOL, V3, P641	29	239	257	2	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					91	94		10.1038/35003595	http://dx.doi.org/10.1038/35003595			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716449				2022-12-28	WOS:000085775100052
J	Esmail, S; May, C				Esmail, S; May, C			Commentary: Oral exams - get them right or don't bother	BRITISH MEDICAL JOURNAL			English	Editorial Material							MRCGP		Univ Manchester, Rusholme Hlth Ctr, Sch Primary Care, Manchester M14 5NP, Lancs, England	University of Manchester	Esmail, S (corresponding author), Univ Manchester, Rusholme Hlth Ctr, Sch Primary Care, Manchester M14 5NP, Lancs, England.		May, Carl/A-8502-2011	May, Carl/0000-0002-0451-2690				WAKEFORD R, 1992, BRIT MED J, V305, P92, DOI 10.1136/bmj.305.6845.92; WAKEFORD R, 1995, BRIT MED J, V311, P931	2	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					375	375						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10712026				2022-12-28	WOS:000085211400038
J	Walker, RG; Willingham, AT; Zuker, CS				Walker, RG; Willingham, AT; Zuker, CS			A Drosophila mechanosensory transduction channel	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; HAIR-CELLS; MECHANOELECTRICAL TRANSDUCTION; ADAPTATION; MUTATIONS; RECEPTOR; GENETICS; NEURONS; EAR	Mechanosensory transduction underlies a wide range of senses, including proprioception, touch, balance, and hearing. The pivotal element of these senses is a mechanically gated ion channel that transduces sound, pressure, or movement into changes in excitability of specialized sensory cells. Despite the prevalence of mechanosensory systems, Little is known about the molecular nature of the transduction channels. To identify such a channel, we analyzed Drosophila melanogaster mechanoreceptive mutants for defects in mechanosensory physiology, Loss-of-function mutations in the no mechanoreceptor potential C (nompC) gene virtually abolished mechanosensory signaling. nompC encodes a new ion channel that is essential for mechanosensory transduction. As expected for a transduction channel, D, melanogaster NOMPC and a Caenorhabditis elegans homolog were selectively expressed in mechanosensory organs.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Zuker, CS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	charles@flyeye.ucsd.edu			NIGMS NIH HHS [5T32GM08107] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008107] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; Colbert HA, 1997, J NEUROSCI, V17, P8259; COREY DP, 1979, BIOPHYS J, V26, P499, DOI 10.1016/S0006-3495(79)85267-4; CORFAS G, 1990, J NEUROSCI, V10, P491; CRAWFORD AC, 1989, J PHYSIOL-LONDON, V419, P405, DOI 10.1113/jphysiol.1989.sp017878; EATOCK RA, 1987, J NEUROSCI, V7, P2821; Eberl DF, 1997, P NATL ACAD SCI USA, V94, P14837, DOI 10.1073/pnas.94.26.14837; Fekete DM, 1999, TRENDS NEUROSCI, V22, P263, DOI 10.1016/S0166-2236(98)01366-6; GarciaAnoveros J, 1997, ANNU REV NEUROSCI, V20, P567, DOI 10.1146/annurev.neuro.20.1.567; George H, 1997, GENETICS, V146, P1345; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Keil TA, 1997, MICROSC RES TECHNIQ, V39, P506, DOI 10.1002/(SICI)1097-0029(19971215)39:6<506::AID-JEMT5>3.0.CO;2-B; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; KERNAN M, 1995, CURR OPIN NEUROBIOL, V5, P443, DOI 10.1016/0959-4388(95)80003-4; KERNAN M, UNPUB; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; MARKIN VS, 1995, ANNU REV BIOPH BIOM, V24, P59, DOI 10.1146/annurev.bb.24.060195.000423; Morrison A, 1999, MECH DEVELOP, V84, P169, DOI 10.1016/S0925-4773(99)00066-0; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; SAIMI Y, 1987, ANNU REV GENET, V21, P47, DOI 10.1146/annurev.genet.21.1.47; Sawin E.R., 1996, SELECTED WORKS MAO T, V151, P135; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; THURM U, 1965, COLD SPRING HARB SYM, V30, P75, DOI 10.1101/SQB.1965.030.01.011; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; WALKER RB, UNPUB; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Whitfield TT, 1996, DEVELOPMENT, V123, P241; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0	35	489	529	2	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2229	2234		10.1126/science.287.5461.2229	http://dx.doi.org/10.1126/science.287.5461.2229			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10744543				2022-12-28	WOS:000086049100041
J	Zeder, MA; Hesse, B				Zeder, MA; Hesse, B			The initial domestication of goats (Capra hircus) in the Zagros mountains 10,000 years ago	SCIENCE			English	Article								Initial goat domestication is documented in the highlands of western Iran at 10,000 calibrated calendar years ago. Metrical analyses of patterns of sexual dimorphism in modern wild goat skeletons (Capra hircus aegagrus) allow sex-specific age curves to be computed for archaeofaunal assemblages, A distinct shift to selective harvesting of subadult males marks initial human management and the transition from hunting to herding of the species. Direct accelerator mass spectrometry radiocarbon dates on skeletal elements provide a tight temporal context for the transition.	Natl Museum Nat Hist, Dept Anthropol, Archaeobiol Program, Smithsonian Inst, Washington, DC 20560 USA; Univ Alabama, Dept Anthropol, Birmingham, AL 35294 USA	Smithsonian Institution; Smithsonian National Museum of Natural History; University of Alabama System; University of Alabama Birmingham	Zeder, MA (corresponding author), Natl Museum Nat Hist, Dept Anthropol, Archaeobiol Program, Smithsonian Inst, Washington, DC 20560 USA.	zeder.melinda@nmnh.si.edu						[Anonymous], 1987, BAR INT SERIES; BarYosef O, 1995, SCH AM RES, V354, P39; HEDGES REM, 1990, ARCHAEOMETRY, V32, P231; HESSE B, 1982, MAN, V17, P403, DOI 10.2307/2801705; Hesse B., 1984, ANIMALS ARCHAEOLOGY, P243; Hesse BC., 1978, EVIDENCE HUSBANDRY E; HOLE F, 1969, MEMOIR MUSEUM ANTHR, V1; Hole FA., 1998, TNE ORIGINS SPREAD A, P263; Meadow R.H, 1989, WALKING LARDER PATTE, P80; PAYNE S, 1973, ANATOLIAN STUD, V23, P781; Pringle H, 1998, SCIENCE, V282, P1446, DOI 10.1126/science.282.5393.1446; Redding, 1981, THESIS U MICHIGAN; REDDING RW, 1963, SCI ARCHAEOL, P250; Smith B. D., 1998, EMERGENCE AGR; Uerpmann H.-P., 1979, PROBLEME NEOLITHISIE; ZEDER MA, IN PRESS PALEORIENT; ZEDER MA, IN PRESS J ARCHAEOL; [No title captured]	18	380	410	0	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2254	2257		10.1126/science.287.5461.2254	http://dx.doi.org/10.1126/science.287.5461.2254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731145				2022-12-28	WOS:000086049100048
J	Raber, J; Wong, D; Yu, GQ; Buttini, M; Mahley, RW; Pitas, RE; Mucke, L				Raber, J; Wong, D; Yu, GQ; Buttini, M; Mahley, RW; Pitas, RE; Mucke, L			Alzheimer's disease - Apolipoprotein E and cognitive performance	NATURE			English	Article									Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Neurol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Program Neurosci, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Raber, J (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA.			Buttini, Manuel/0000-0003-1805-0279				Buttini M, 1999, J NEUROSCI, V19, P4867; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Holcomb LA, 1999, BEHAV GENET, V29, P177, DOI 10.1023/A:1021691918517; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Jensen M, 1999, ANN NEUROL, V45, P504, DOI 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Wilson CA, 1999, J NEUROPATH EXP NEUR, V58, P787, DOI 10.1097/00005072-199908000-00001	13	189	199	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					352	354		10.1038/35006165	http://dx.doi.org/10.1038/35006165			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746713				2022-12-28	WOS:000086119000038
J	Rosier, RN; Rosenberg, AE; Hornicek, FJ				Rosier, RN; Rosenberg, AE; Hornicek, FJ			A 41-year-old man with multiple bony lesions and adjacent soft-tissue masses - Erdheim-Chester disease involving multiple bones, with pathologic fractures and soft-tissue masses.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RECURRENT MULTIFOCAL OSTEOMYELITIS; LANGERHANS-CELL HISTIOCYTOSIS; POEMS-SYNDROME; GAUCHERS-DISEASE; MANIFESTATIONS; INVOLVEMENT; DISTINCT; SPECTRUM; ENTITY		Univ Rochester, Med Ctr, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Rosier, RN (corresponding author), Univ Rochester, Med Ctr, Rochester, NY 14642 USA.							Amstalden EMI, 1996, MEDICINE, V75, P212, DOI 10.1097/00005792-199607000-00004; Avila NA, 1998, SKELETAL RADIOL, V27, P119, DOI 10.1007/s002560050350; BASSETT FH, 1972, SOUTH MED J, V65, P547, DOI 10.1097/00007611-197205000-00009; Baumgartner I, 1997, MED PEDIATR ONCOL, V28, P9, DOI 10.1002/(SICI)1096-911X(199701)28:1<9::AID-MPO3>3.0.CO;2-P; BONAKDARPOUR A, 1983, ORTHOP CLIN N AM, V14, P21; BOOZ MY, 1993, CLIN RADIOL, V47, P265, DOI 10.1016/S0009-9260(05)81136-5; BROWER AC, 1984, RADIOLOGY, V151, P35, DOI 10.1148/radiology.151.1.6608118; CARLSON DWA, 1994, CLIN ORTHOP RELAT R, P187; CHAN YF, 1990, J BONE JOINT SURG BR, V72, P500, DOI 10.1302/0301-620X.72B3.2341456; Chetritt J, 1999, HUM PATHOL, V30, P1093, DOI 10.1016/S0046-8177(99)90228-9; Delsignore J L, 1996, Iowa Orthop J, V16, P126; Egan AJM, 1999, AM J SURG PATHOL, V23, P17, DOI 10.1097/00000478-199901000-00002; Elstein D, 1997, BAILLIERE CLIN HAEM, V10, P793, DOI 10.1016/S0950-3536(97)80041-8; EVANS S, 1986, CLIN RADIOL, V37, P93, DOI 10.1016/S0009-9260(86)80184-2; GIEDION A, 1972, ANN RADIOL, V15, P292; GOVENDER S, 1990, J BONE JOINT SURG BR, V72, P504, DOI 10.1302/0301-620X.72B3.2341457; HIMMELFARB E, 1974, J BONE JOINT SURG AM, VA 56, P1723, DOI 10.2106/00004623-197456080-00027; Hindman BW, 1998, SKELETAL RADIOL, V27, P177, DOI 10.1007/s002560050361; Jaffe H, 1972, METABOLIC INFLAMMATO, P535; JAMES D G, 1976, Seminars in Arthritis and Rheumatism, V6, P53, DOI 10.1016/S0049-0172(76)80005-4; Kambouchner M, 1997, HISTOPATHOLOGY, V30, P353, DOI 10.1046/j.1365-2559.1997.d01-614.x; KOLAR J, 1984, FORTSCHR RONTG NEUEN, V141, P698, DOI 10.1055/s-2008-1053217; LACHIEWICZ PF, 1984, ORTHOP CLIN N AM, V15, P765; Lacy MQ, 1997, AM J HEMATOL, V56, P288, DOI 10.1002/(SICI)1096-8652(199712)56:4<288::AID-AJH16>3.0.CO;2-5; *MA GEN HOSP, 1995, NEW ENGL J MED, V333, P507; MARINO C, 1992, NEW YORK STATE J MED, V92, P360; Merkle EM, 1997, SKELETAL RADIOL, V26, P289, DOI 10.1007/s002560050237; MIRALLES GD, 1992, NEW ENGL J MED, V327, P1919, DOI 10.1056/NEJM199212313272705; MOLNAR CP, 1988, CLIN NUCL MED, V13, P736, DOI 10.1097/00003072-198810000-00012; Ono K, 1996, HUM PATHOL, V27, P91, DOI 10.1016/S0046-8177(96)90145-8; PROSE NS, 1994, J AM ACAD DERMATOL, V31, P376, DOI 10.1016/S0190-9622(94)70176-8; SCHAJOWICZ F, 1978, J BONE JOINT SURG BR, V60, P100, DOI 10.1302/0301-620X.60B1.627569; SCHWARZ J, 1984, PATHOL RES PRACT, V178, P617, DOI 10.1016/S0344-0338(84)80096-5; SIMPSON FG, 1979, BRIT J RADIOL, V52, P232, DOI 10.1259/0007-1285-52-615-232; SOUBRIER MJ, 1994, AM J MED, V97, P543, DOI 10.1016/0002-9343(94)90350-6; STULL MA, 1992, RADIOGRAPHICS, V12, P801, DOI 10.1148/radiographics.12.4.1636041; SUEI Y, 1995, ORAL SURG ORAL MED O, V80, P401, DOI 10.1016/S1079-2104(05)80332-4; UNNI KK, 1971, CANCER-AM CANCER SOC, V27, P1403, DOI 10.1002/1097-0142(197106)27:6<1403::AID-CNCR2820270621>3.0.CO;2-6; VeyssierBelot C, 1996, MEDICINE, V75, P157, DOI 10.1097/00005792-199605000-00005; WAITE RJ, 1988, AM J ROENTGENOL, V150, P869, DOI 10.2214/ajr.150.4.869; WU PC, 1985, AM J SURG PATHOL, V9, P531, DOI 10.1097/00000478-198507000-00008; Zeppa MA, 1996, SKELETAL RADIOL, V25, P337, DOI 10.1007/s002560050092	42	12	12	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 23	2000	342	12					875	883		10.1056/NEJM200003233421208	http://dx.doi.org/10.1056/NEJM200003233421208			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296FU	10727593				2022-12-28	WOS:000086014100008
J	Chen, LH; Baker, SP; Braver, ER; Li, GH				Chen, LH; Baker, SP; Braver, ER; Li, GH			Carrying passengers as a risk factor for crashes fatal to 16-and 17-year-old drivers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Injuries from motor vehicle crashes are the leading cause of death among teenagers. Carrying passengers has been identified as a possible risk factor for these crashes. Objective To determine whether the presence of passengers is associated with an increased risk of crashes fatal to 16- and 17-year-old drivers and whether the risk varies by time of day and age and sex of drivers and passengers. Design and Setting Incidence study of data from the Fatality Analysis Reporting System and General Estimates System (1992-1997), as well as the Nationwide Personal Transportation Survey (1995). Subjects Driver; aged 16 and 17 years who drove passenger cars, vans, or pickup trucks. Main Outcome Measure Driver deaths per 20 million trips by number of passengers, driver age and sex, and time of day; and driver deaths per 1000 crashes by passenger age and sex. Results Compared with drivers of the same age without passengers, the relative risk of death per 10 million trips was 1.39 (95% confidence interval [CI], 1.24-1.55) for 16-year-old drivers with 1 passenger, 1.86 (95% CI, 1.56-2.20) for those with 2 passengers, and 2.82 (95% CI, 2.27-3.50) for those with 3 or more passengers. The relative risk of death was 1.48 (95% CI, 1.35-1.62) for 17-year-old drivers with 1 passenger, 2.58 (95% CI, 2.24-2.95) for those with 2 passengers, and 3.07 (95% CI, 2.50-3.77) for those with 3 or more passengers. The risk of death increased significantly for drivers transporting passengers irrespective of the time of day or sex of the driver, although male drivers were at greater risk. Driver deaths per 1000 crashes increased for 16- and 17-year-olds transporting male passengers or passengers younger than 30 years. Conclusion Our data indicate that the risk of fatal injury for a 16- or 17-year-old driver increases with the number of passengers. This result supports inclusion of restrictions on carrying passengers in graduated licensing systems for young drivers.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA; Insurance Inst Highway Safety, Arlington, VA USA	Johns Hopkins University; Johns Hopkins University	Chen, LH (corresponding author), Johns Hopkins Sch Publ Hlth, Ctr Injury Res & Policy, 624 N Broadway, Baltimore, MD 21205 USA.		Braver, Elisa/AAT-4631-2020		PHS HHS [R49CCR302486] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Daly LE, 1998, AM J EPIDEMIOL, V147, P783; Doherty ST, 1998, ACCIDENT ANAL PREV, V30, P45, DOI 10.1016/S0001-4575(97)00060-2; FARROW JA, 1987, INT J ADDICT, V22, P1255, DOI 10.3109/10826088709027485; *FED HIGH ADM, 1997, 1995 NAT PERS TRANSP; FOLDVARY LA, 1969, P 13 ANN ASS ADV AUT; Langley JD, 1996, ACCIDENT ANAL PREV, V28, P139, DOI 10.1016/0001-4575(95)00040-2; Mayhew D.R., 1981, YOUNG DRIVER ACCIDEN; McKenna F.P., 1998, MALE FEMALE DRIVERS; *NA HIGHW TRAFF SA, 1997, GEN EST SYST 1992 19; *NAT HIGHW TRAFF S, 1997, FAT AN REP SYST 1992; Preusser DF, 1998, ACCIDENT ANAL PREV, V30, P217, DOI 10.1016/S0001-4575(97)00081-X; *RES TRIANG I, 1998, SUDAAN COMP PROGR VE; Rothman K., 1998, MODERN EPIDEMIOLOGY; *SAS I INC, 1997, SAS COMP PROGR VERS; *SPSS INC, 1997, STAT PACK SOC SCI; ULMER RG, IN PRESS ACCID ANAL; WILLIAMS AF, 1995, J SAFETY RES, V26, P161, DOI 10.1016/0022-4375(95)00012-F	17	308	310	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2000	283	12					1578	1582		10.1001/jama.283.12.1578	http://dx.doi.org/10.1001/jama.283.12.1578			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293MV	10735394	Bronze			2022-12-28	WOS:000085857300034
J	Weingart, SN; Wilson, RM; Gibberd, RW; Harrison, B				Weingart, SN; Wilson, RM; Gibberd, RW; Harrison, B			Epidemiology of medical error	BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG EVENTS; INTENSIVE-CARE UNIT; HOSPITALIZED-PATIENTS; QUALITY; PREVENTION; MORTALITY; MISTAKES; COSTS		Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Royal N Shore Hosp, Qual Assurance Royal N Shore, St Leonards, NSW 2065, Australia; Univ Newcastle, Dept Stat, Newcastle, NSW 2308, Australia	Harvard University; Beth Israel Deaconess Medical Center; Royal North Shore Hospital; University of Newcastle	Weingart, SN (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave, Boston, MA 02215 USA.							Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; Bates DW, 1999, ARCH INTERN MED, V159, P2553, DOI 10.1001/archinte.159.21.2553; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Bhasale AL, 1998, MED J AUSTRALIA, V169, P73, DOI 10.5694/j.1326-5377.1998.tb140186.x; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 1996, NEW ENGL J MED, V335, P1963, DOI 10.1056/NEJM199612263352606; BURNUM JF, 1976, ANN INTERN MED, V85, P80, DOI 10.7326/0003-4819-85-1-80; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; COOK RI, 1998, TALE I STORIES CONTR; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; Darchy B, 1999, ARCH INTERN MED, V159, P71, DOI 10.1001/archinte.159.1.71; DONCHIN Y, 1995, CRIT CARE MED, V23, P294, DOI 10.1097/00003246-199502000-00015; GANDHI TK, IN PRESS J GEN INTER; Garcia-Martin M, 1997, J CLIN EPIDEMIOL, V50, P1319, DOI 10.1016/S0895-4356(97)00219-9; Gawande AA, 1999, SURGERY, V126, P66, DOI 10.1067/msy.1999.98664; Johnson JA, 1997, AM J HEALTH-SYST PH, V54, P554, DOI 10.1093/ajhp/54.5.554; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; LANSHMANAN MC, 1986, ARCH INTERN MED, V146, P1931; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; Lundberg GD, 1998, JAMA-J AM MED ASSOC, V280, P1273, DOI 10.1001/jama.280.14.1273; Macklis RM, 1998, J CLIN ONCOL, V16, P551, DOI 10.1200/JCO.1998.16.2.551; MARTINEZ JVB, 1998, AN MED INTERNA, V15, P179; MITCHELL H, 1990, BRIT MED J, V300, P1622, DOI 10.1136/bmj.300.6740.1622; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; Plebani M, 1997, CLIN CHEM, V43, P1348; SHIMMEL EM, 1964, ANN INTERN MED, V60, P100; Stambouly JJ, 1996, INTENS CARE MED, V22, P1098, DOI 10.1007/BF01699236; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TRUNET P, 1980, JAMA-J AM MED ASSOC, V244, P2617, DOI 10.1001/jama.244.23.2617; Wilson DG, 1998, EUR J PEDIATR, V157, P769, DOI 10.1007/s004310050932; Wilson RM, 1999, MED J AUSTRALIA, V170, P411, DOI 10.5694/j.1326-5377.1999.tb127814.x; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x; Windsor JA, 1998, AUST NZ J SURG, V68, P186, DOI 10.1111/j.1445-2197.1998.tb04742.x; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089	39	351	376	0	32	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					774	777		10.1136/bmj.320.7237.774	http://dx.doi.org/10.1136/bmj.320.7237.774			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720365	Green Published			2022-12-28	WOS:000086054700030
J	Jia, CG; Piao, DG; Oyamada, JZ; Lu, WJ; Kitamura, T; Fujiwara, Y				Jia, CG; Piao, DG; Oyamada, JZ; Lu, WJ; Kitamura, T; Fujiwara, Y			Efficient activation of aromatic C-H bonds for addition to C-C multiple bonds	SCIENCE			English	Article							COMPLEXES; ACID; ACETYLENES	Efficient electrophilic metalation of aromatic C-H bonds Leading to new C-C bond formation through regio- and stereoselective addition to alkynes and alkenes has been realized by a catalytic amount (0.02 to 5 mole percent) of palladium(II) or platinum(II) compounds in a mixed solvent containing trifluoroacetic acid at room temperature. Various arenes undergo unexpected selective trans hydroarylation to terminal or internal C=C bonds inter- and intramolecularly with high efficiency (up to a turnover number of 4500 for palladium), especially for electron-rich arenes, giving thermodynamically unfavorable cis-alkenes, and the oxygen- and nitrogen-containing heterocycles. The simplicity, generality, and efficiency of this process should be very attractive to the possible industrial application for the functionalization of arenes.	Kyushu Univ, Grad Sch Engn, Dept Chem & Biochem, Fukuoka 8128581, Japan	Kyushu University	Fujiwara, Y (corresponding author), Kyushu Univ, Grad Sch Engn, Dept Chem & Biochem, Fukuoka 8128581, Japan.	yfujitcf@mbox.nc.kyushu-u.ac.jp	Lu, Wenjun/A-9960-2008	Lu, Wenjun/0000-0001-8077-7060				BOESE WT, 1991, ORGANOMETALLICS, V10, P782, DOI 10.1021/om00049a045; BRAINARD RL, 1988, ORGANOMETALLICS, V7, P2379, DOI 10.1021/om00101a019; Bruneau C, 1999, ACCOUNTS CHEM RES, V32, P311, DOI 10.1021/ar980016i; Chen JT, 1998, J AM CHEM SOC, V120, P3243, DOI 10.1021/ja973926o; Christian P.L., 1999, J AM CHEM SOC, V121, P6616; CLARK FRS, 1974, J CHEM SOC PERK T 1, P1289, DOI 10.1039/p19740001289; FUJIWARA Y, 1982, J ORGANOMET CHEM, V226, pC36, DOI 10.1016/S0022-328X(00)87439-2; FUJIWARA Y, 1969, J AM CHEM SOC, V91, P7166, DOI 10.1021/ja01053a047; Fujiwara Y, 1996, SYNLETT, P591, DOI 10.1055/s-1996-5541; Hill C. L., 1989, ACTIVATION FUNCTIONA; HONG P, 1980, CHEM LETT, P507, DOI 10.1246/cl.1980.507; Jia CG, 1999, ORG LETT, V1, P2097, DOI 10.1021/ol991148u; KAKIUCHI F, 1995, CHEM LETT, P681, DOI 10.1246/cl.1995.681; KAKLUCHI F, 1993, NATURE, V366, P529; Littke AF, 1999, J ORG CHEM, V64, P10, DOI 10.1021/jo9820059; LU XY, 1992, TETRAHEDRON LETT, V33, P7205, DOI 10.1016/S0040-4039(00)60873-0; MORITANI I, 1967, TETRAHEDRON LETT, P1119; MURAI S, 1999, TOPICS ORGANOMETALLI, V3; Patai S., 1978, CHEM CARBON CARBON T; Shilov AE, 1997, CHEM REV, V97, P2879, DOI 10.1021/cr9411886; Swang O, 1996, J PHYS CHEM-US, V100, P17334, DOI 10.1021/jp9621944; Tsuji J., 1995, PALLADIUM REAGENTS C; White S, 1999, ORGANOMETALLICS, V18, P2536, DOI 10.1021/om990179q; ZARGARIAN D, 1993, ORGANOMETALLICS, V12, P712, DOI 10.1021/om00027a022; ZEIJDEN A, 1992, ORGANOMETALLICS, V11, P563	25	657	661	2	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2000	287	5460					1992	1995		10.1126/science.287.5460.1992	http://dx.doi.org/10.1126/science.287.5460.1992			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720319				2022-12-28	WOS:000085902800053
J	Bida, TA; Killen, RM; Morgan, TH				Bida, TA; Killen, RM; Morgan, TH			Discovery of calcium in Mercury's atmosphere	NATURE			English	Article							SURFACE; SODIUM; MOON	The composition and evolutionary history of Mercury's crust are not well determined(1,2). The planet as a whole has been predicted(3) to have a refractory, anhydrous composition: rich in Ca, Al, Mg and Fe, but poor in Na, K, OH, and S. Its atmosphere is believed to be derived in large part from the surface materials. A combination of effects that include impact vaporization (from infalling material), volatile evaporation, photon-stimulated desorption and sputtering releases material from the surface to form the atmosphere. Sodium and potassium have already been observed in Mercury's atmosphere(4-6), with abundances that require a volatile-rich crust(7). The sodium probably results from photon-stimulated desorption(8,9), and has a temperature of 1,500 K (ref. 10). Here we report the discovery of calcium in the atmosphere near Mercury's poles. The column density is very low and the temperature is apparently very high (12,000 K). The localized distribution and high temperature, if confirmed, suggest that the atmospheric calcium may arise from surface sputtering by ions, which enter Mercury's auroral zone. The low abundance of atmospheric Ca may indicate that the regolith is rarefied in calcium.	CARA, WM Keck Observ, Kamuela, HI 96743 USA; SW Res Inst, San Antonio, TX 78228 USA; NASA Headquarters, Washington, DC 20546 USA	Southwest Research Institute; National Aeronautics & Space Administration (NASA)	Bida, TA (corresponding author), CARA, WM Keck Observ, 65-1120 Mamalahoa Highway, Kamuela, HI 96743 USA.		Killen, Rosemary M/E-7127-2012; Morgan, Thomas/I-5943-2013					CHAMBERLAIN J.W., 1987, THEORY PLANETARY ATM; CHAMBERLAIN JW, 1976, J GEOPHYS RES-SPACE, V81, P1774, DOI 10.1029/JA081i010p01774; CHENG AF, 1987, ICARUS, V71, P430, DOI 10.1016/0019-1035(87)90038-8; ELPHIC RC, 1991, GEOPHYS RES LETT, V18, P2165, DOI 10.1029/91GL02669; Goettel K.A., 1988, MERCURY, P613; JEANLOZ R, 1995, SCIENCE, V268, P1455, DOI 10.1126/science.7770770; KIILEN RM, 1993, ICARUS, V101, P293; Killen RM, 1999, PLANET SPACE SCI, V47, P1449, DOI 10.1016/S0032-0633(99)00071-9; Kurucz R. L., 1984, Solar flux atlas from 296 to 1300 nm; Lewis J.S., 1988, MERCURY, P651; LEWIS JS, 1972, EARTH PLANET SC LETT, V15, P286, DOI 10.1016/0012-821X(72)90174-4; Madey TE, 1998, J GEOPHYS RES-PLANET, V103, P5873, DOI 10.1029/98JE00230; MCGRATH MA, 1986, NATURE, V323, P694, DOI 10.1038/323694a0; Morgan TH, 1997, PLANET SPACE SCI, V45, P81, DOI 10.1016/S0032-0633(96)00099-2; POTTER A, 1985, SCIENCE, V229, P651, DOI 10.1126/science.229.4714.651; POTTER AE, 1986, ICARUS, V67, P336, DOI 10.1016/0019-1035(86)90113-2; Sprague AL, 1998, ICARUS, V136, P60, DOI 10.1006/icar.1998.6009; Sprague AL, 1997, ICARUS, V129, P506, DOI 10.1006/icar.1997.5784; Sprague AL, 1997, ADV SPACE RES-SERIES, V19, P1507, DOI 10.1016/S0273-1177(97)00363-3; SPRAGUE AL, 1993, ICARUS, V104, P33, DOI 10.1006/icar.1993.1080; SUGITA S, 1997, P LUNAR PLANET SCI C, V28, P1393; VOGT S, 1994, P SOC PHOTO-OPT INS, V2198, P362, DOI 10.1117/12.176725; Yakshinskiy BV, 1999, NATURE, V400, P642, DOI 10.1038/23204	23	135	135	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					159	161		10.1038/35004521	http://dx.doi.org/10.1038/35004521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724161				2022-12-28	WOS:000085870900042
J	Cocheo, V; Sacco, P; Boaretto, C; De Saeger, E; Ballesta, PP; Skov, H; Goelen, E; Gonzalez, N; Caracena, AB				Cocheo, V; Sacco, P; Boaretto, C; De Saeger, E; Ballesta, PP; Skov, H; Goelen, E; Gonzalez, N; Caracena, AB			Urban benzene and population exposure	NATURE			English	Article									IRCCS, Fdn Salvatore Maugeri, I-35127 Padua, Italy; Commiss European Communities, Joint Res Ctr, I-21020 Ispra, Italy; Natl Environm Res Inst, DK-4000 Roskilde, Denmark; Vlaamse Instelling Technol Onderzoek, B-2400 Mol, Belgium; Inst Natl Environm Ind & Risques, F-60550 Verneuil En Halatte, France; Univ Murcia, Dept Ingn Quim Murcia, E-30071 Murcia, Spain	Istituti Clinici Scientifici Maugeri IRCCS; European Commission Joint Research Centre; EC JRC ISPRA Site; Aarhus University; VITO; Institut National de l'Environnement Industriel et des Risques (INERIS); University of Murcia	Cocheo, V (corresponding author), IRCCS, Fdn Salvatore Maugeri, Via Svizzera 16, I-35127 Padua, Italy.		Caracena, Antonia Baeza/L-7529-2014	Caracena, Antonia Baeza/0000-0002-8207-0453; Skov, Henrik/0000-0003-1167-8696				BOND GG, 1986, BRIT J IND MED, V43, P685; Cocheo V, 1996, AM IND HYG ASSOC J, V57, P897, DOI 10.1202/0002-8894(1996)057<0897:HURRDS>2.0.CO;2; Kumar N, 1996, ATMOS ENVIRON, V30, P1099, DOI 10.1016/1352-2310(95)00317-7; Rinsky R A, 1981, Am J Ind Med, V2, P217, DOI 10.1002/ajim.4700020305; SNYDER R, 1993, ENVIRON HEALTH PERSP, V100, P293, DOI 10.2307/3431535; VIGLIANI EC, 1964, NEW ENGL J MED, V271, P872, DOI 10.1056/NEJM196410222711703; WARD JB, 1992, MUTAT RES, V268, P49, DOI 10.1016/0027-5107(92)90082-D; *WHO, 1996, EURICPEHAZ9405MT12 R	8	99	101	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					141	142		10.1038/35004651	http://dx.doi.org/10.1038/35004651			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724154				2022-12-28	WOS:000085870900034
J	Steinmetz, PN; Roy, A; Fitzgerald, PJ; Hsiao, SS; Johnson, KO; Niebur, E				Steinmetz, PN; Roy, A; Fitzgerald, PJ; Hsiao, SS; Johnson, KO; Niebur, E			Attention modulates synchronized neuronal firing in primate somatosensory cortex	NATURE			English	Article							CORTICAL ACTIVITY; MONKEYS; OSCILLATIONS; PATTERNS	A potentially powerful information processing strategy in the brain is to take advantage of the;temporal structure of neuronal spike trains. An increase in synchrony within the neural representation of an object or location increases the efficacy of that neural representation at the next synaptic stage in the brain; thus, increasing synchrony is a candidate for the neural correlate of attentional selection(1). We investigated the synchronous firing of pairs of neurons in the secondary somatosensory cortex (SII) of three monkeys trained to switch attention between a visual task and a tactile discrimination task. We found that most neuron pairs in SII cortex fired synchronously and, furthermore, that the degree of synchrony was affected by the monkey's attentional state. In the monkey performing the most difficult task, 35% of neuron pairs that fired synchronously changed their degree of synchrony when the monkey switched attention between the tactile and visual tasks. Synchrony increased in 80% and decreased in 20% of neuron pairs affected by attention.	Johns Hopkins Univ, Zanvyl Krieger Mind Brain Inst, Baltimore, MD 21218 USA	Johns Hopkins University	Niebur, E (corresponding author), Johns Hopkins Univ, Zanvyl Krieger Mind Brain Inst, Baltimore, MD 21218 USA.	niebur@jhu.edu	Steinmetz, Peter/H-3151-2011					ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Abeles M., 1982, LOCAL CORTICAL CIRCU; Brody CD, 1998, J NEUROPHYSIOL, V80, P3345, DOI 10.1152/jn.1998.80.6.3345; Burton H, 1997, SOMATOSENS MOT RES, V14, P237, DOI 10.1080/08990229770971; Craig JC, 1996, SOMATOSENS MOT RES, V13, P199, DOI 10.3109/08990229609052576; Crick F., 1990, Seminars in the Neurosciences, V2, P263; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; DiCarlo JJ, 1996, J NEUROSCI METH, V64, P75, DOI 10.1016/0165-0270(95)00113-1; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; Efron B., 1994, MONOGRAPHS STAT APPL; Haalman I, 1998, Z NATURFORSCH C, V53, P657; HSIAO SS, 1993, J NEUROPHYSIOL, V70, P444, DOI 10.1152/jn.1993.70.1.444; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; Murthy VN, 1996, J NEUROPHYSIOL, V76, P3968, DOI 10.1152/jn.1996.76.6.3968; Niebur E, 1994, J Comput Neurosci, V1, P141, DOI 10.1007/BF00962722; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; POGGIO GF, 1964, J NEUROPHYSIOL, V27, P517, DOI 10.1152/jn.1964.27.4.517; PORANEN A, 1982, ELECTROEN CLIN NEURO, V53, P525, DOI 10.1016/0013-4694(82)90065-7; Prut Y, 1998, J NEUROPHYSIOL, V79, P2857, DOI 10.1152/jn.1998.79.6.2857; ROY A, IN PRESS NEUROCOMPUT; Roy S, 1999, J NEUROPHYSIOL, V81, P999, DOI 10.1152/jn.1999.81.3.999; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0	25	556	576	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2000	404	6774					187	190		10.1038/35004588	http://dx.doi.org/10.1038/35004588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724171				2022-12-28	WOS:000085870900052
J	Thompson, PM; Giedd, JN; Woods, RP; MacDonald, D; Evans, AC; Toga, AW				Thompson, PM; Giedd, JN; Woods, RP; MacDonald, D; Evans, AC; Toga, AW			Growth patterns in the developing brain detected by using continuum mechanical tensor maps	NATURE			English	Article							ALZHEIMERS-DISEASE; IMAGES	The dynamic nature of growth and degenerative disease processes requires the design of sensitive strategies to detect, track and quantify structural change in the brain in its full spatial and temporal complexity(1). Although volumes of brain substructures are known to change during development(2), detailed maps of these dynamic growth processes have been unavailable. Here we report the creation of spatially complex, four-dimensional quantitative maps of growth patterns in the developing human brain, detected using a tensor mapping strategy with greater spatial detail and sensitivity than previously obtainable. By repeatedly scanning children (aged 3-15 years) across time spans of up to four years, a rostro-caudal wave of growth was detected at the corpus callosum, a fibre system that relays information between brain hemispheres. Peak growth rates, in fibres innervating association and language cortices, were attenuated after puberty, and contrasted sharply with a severe, spatially localized loss of subcortical grey matter. Conversely, at ages 3-6 years, the fastest growth rates occurred in frontal networks that regulate the planning of new actions. Local rates, profiles, and principal directions of growth were visualized in each individual child.	Univ Calif Los Angeles, Sch Med, Div Brain Mapping, Dept Neurol,Lab Neuroimaging, Los Angeles, CA 90095 USA; NIMH, Child Psychiat Branch, NIH, Bethesda, MD 20892 USA; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); McGill University	Thompson, PM (corresponding author), Univ Calif Los Angeles, Sch Med, Div Brain Mapping, Dept Neurol,Lab Neuroimaging, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	thompson@loni.ucla.edu	Giedd, Jay N/B-7302-2012; Giedd, Jay N./A-3080-2008; Thompson, Paul M/C-4194-2018; Giedd, Jay/J-9644-2015	Giedd, Jay N/0000-0003-0827-3460; Thompson, Paul M/0000-0002-4720-8867; Giedd, Jay/0000-0003-2002-8978				CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Davatzikos C, 1996, J COMPUT ASSIST TOMO, V20, P656, DOI 10.1097/00004728-199607000-00031; Fox NC, 1996, LANCET, V348, P94, DOI 10.1016/S0140-6736(96)05228-2; Freeborough PA, 1996, J COMPUT ASSIST TOMO, V20, P1012, DOI 10.1097/00004728-199611000-00030; Giedd JN, 1996, CEREB CORTEX, V6, P551, DOI 10.1093/cercor/6.4.551; Grimshaw GM, 1998, BRAIN LANG, V63, P237, DOI 10.1006/brln.1997.1943; MacDonald D, 1994, P SOC PHOTO-OPT INS, V2359, P160; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Thomas HC, 1996, J VIRAL HEPATITIS, V3, P1; Thompson JS, 1996, IEEE PERS COMMUN, V3, P16, DOI 10.1109/98.542234; Thompson P M, 1997, Med Image Anal, V1, P271; Thompson PM, 1997, J COMPUT ASSIST TOMO, V21, P567, DOI 10.1097/00004728-199707000-00008; Thompson PM, 1998, CEREB CORTEX, V8, P492, DOI 10.1093/cercor/8.6.492; THOMPSON PM, 1998, BRAIN WARPING, P311; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; Yakovlev P. I., 1967, REGIONAL DEV BRAIN E, P3; Zijdenbos Alex P., 1994, Critical Reviews in Biomedical Engineering, V22, P401	18	647	650	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2000	404	6774					190	193		10.1038/35004593	http://dx.doi.org/10.1038/35004593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724172				2022-12-28	WOS:000085870900053
J	Chadwick, D				Chadwick, D			Waveguide: an EEG atlas on CD-ROM	BRITISH MEDICAL JOURNAL			English	Software Review									Walton Ctr Neurol & Neurosci, Liverpool, Merseyside, England	Walton Centre	Chadwick, D (corresponding author), Walton Ctr Neurol & Neurosci, Liverpool, Merseyside, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					947	947		10.1136/bmj.320.7239.947	http://dx.doi.org/10.1136/bmj.320.7239.947			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10742026	Green Published			2022-12-28	WOS:000086337100070
J	Gress, TW; Nieto, FJ; Shahar, E; Wofford, MR; Brancati, FL				Gress, TW; Nieto, FJ; Shahar, E; Wofford, MR; Brancati, FL		Atherosclerosis Risk Communities S	Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPAIRED GLUCOSE-TOLERANCE; HIGH-BLOOD-PRESSURE; FOLLOW-UP; MILD HYPERTENSION; PREVENTION TRIAL; LONG-TERM; MEN; DIURETICS; HEALTH; AGENTS	Background: Previous research has suggested that thiazide diuretics and beta-blockers may promote the development of type 2 diabetes mellitus. However, the results of these studies have been inconsistent, and many studies have been limited by inadequate data on outcomes and by potential confounding. Methods: We conducted a prospective study of 12,550 adults 45 to 64 years old who did not have diabetes. An extensive health evaluation conducted at base line included assessment of medication use and measurement of blood pressure with a random-zero sphygmomanometer. The incidence of new cases of diabetes was assessed after three years and after six years by measurement of serum glucose concentrations while the subjects were fasting. Results: After simultaneous adjustment for age, sex, race, education, adiposity, family history with respect to diabetes, physical-activity level, other health-related behavior, and coexisting illnesses, subjects with hypertension who were taking thiazide diuretics were not at greater risk for the subsequent development of diabetes than were subjects with hypertension who were not receiving any antihypertensive therapy (relative hazard, 0.91; 95 percent confidence interval, 0.73 to 1.13). Likewise, subjects who were taking angiotensin-converting-enzyme inhibitors and calcium-channel antagonists were not at greater risk than those not taking any medication. In contrast, subjects with hypertension who were taking beta-blockers had a 28 percent higher risk of subsequent diabetes (relative hazard, 1.28; 95 percent confidence interval, 1.04 to 1.57). Conclusions: Concern about the risk of diabetes should not discourage physicians from prescribing thiazide diuretics to nondiabetic adults who have hypertension. The use of beta-blockers appears to increase the risk of diabetes, but this adverse effect must be weighed against the proven benefits of beta-blockers in reducing the risk of cardiovascular events. (N Engl J Med 2000;342:905-12.) (C) 2000, Massachusetts Medical Society.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Univ Mississippi, Med Ctr, Div Hypertens, Jackson, MS USA	Johns Hopkins University; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; University of Mississippi; University of Mississippi Medical Center	Brancati, FL (corresponding author), Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA.	fbrancat@welch.jhu.edu			DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016, N01HC055018, N01HC055015] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55016, N01-HC-55015, N01-HC-55018] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, DIABETES AM; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; *ATH RISK COMM STU, 1987, OP MAN; AUBERT RE, 1995, NIH PUBLICATION, P553; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BENGTSSON C, 1984, BMJ-BRIT MED J, V289, P1495, DOI 10.1136/bmj.289.6457.1495; BERGLUND G, 1986, ACTA MED SCAND, V220, P419; Black HR, 1998, ARCH INTERN MED, V158, P573; Bray GA, 1999, DIABETES CARE, V22, P623; BRECKENR.A, 1967, LANCET, V1, P61; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CHIANG CL, 1961, VITAL STAT SPECIAL R, V47; FLETCHER AE, 1991, AM J MED, V90, pS42, DOI 10.1016/0002-9343(91)90435-Z; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; GURWITZ JH, 1993, ANN INTERN MED, V118, P273, DOI 10.7326/0003-4819-118-4-199302150-00005; GURWITZ JH, 1994, J AM GERIATR SOC, V42, P1235, DOI 10.1111/j.1532-5415.1994.tb06503.x; Hammersley MS, 1997, METABOLISM, V46, P44, DOI 10.1016/S0026-0495(97)90317-6; HARDMAN JG, 1996, GOODMAN GILMANS PHAR, P1465; HELGELAND A, 1984, AM J MED, V76, P802, DOI 10.1016/0002-9343(84)90990-2; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; Jacob S, 1998, AM J HYPERTENS, V11, P1258, DOI 10.1016/S0895-7061(98)00141-1; JAVITT JC, 1995, DIABETES AM, P601; Kenny S.J., 1995, NIH PUBLICATION, P47; KOHNER EM, 1971, LANCET, V1, P986; LUSTGARTEN JA, 1972, CLIN CHEM, V18, P1419; MORALES PA, 1993, DIABETES, V42, P154, DOI 10.2337/diabetes.42.1.154; MURPHY MB, 1982, LANCET, V2, P1293; MYKKANEN L, 1994, J HYPERTENS, V12, P1425; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; NEESE JW, 1976, DEHW PUBLICATION; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; RAMIREZ EA, 1985, HYPERTENSION, V7, P1008; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; SAMUELSSON O, 1994, J HUM HYPERTENS, V8, P257; SARTOR G, 1980, DIABETES, V29, P41, DOI 10.2337/diabetes.29.1.41; Savage PJ, 1998, ARCH INTERN MED, V158, P741, DOI 10.1001/archinte.158.7.741; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHAPIRO AP, 1961, NEW ENGL J MED, V265, P1028, DOI 10.1056/NEJM196111232652102; SIEDEL J, 1983, CLIN CHEM, V29, P1075; SKARFORS ET, 1989, BRIT MED J, V298, P1147, DOI 10.1136/bmj.298.6681.1147; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; *STAT, 1997, STAT STAT SOFTW; STOLK RP, 1993, EUR J EPIDEMIOL, V9, P134, DOI 10.1007/BF00158782; STRUTHERS AD, 1985, HYPERTENSION, V7, P95; Teuscher AU, 1997, J HYPERTENS, V15, pS67, DOI 10.1097/00004872-199715022-00006; TURNER R, 1999, EARLY DIABETES INTER; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; WOLFF FW, 1963, JAMA-J AM MED ASSOC, V185, P568, DOI 10.1001/jama.1963.03060070036019; [No title captured]	50	795	852	2	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	2000	342	13					905	912		10.1056/NEJM200003303421301	http://dx.doi.org/10.1056/NEJM200003303421301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DC	10738048				2022-12-28	WOS:000086179700001
J	Crayford, TJB; Campbell, S; Bourne, TH; Rawson, HJ; Collins, WP				Crayford, TJB; Campbell, S; Bourne, TH; Rawson, HJ; Collins, WP			Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening	LANCET			English	Article							TUMORS; WOMEN; ULTRASONOGRAPHY; STRATEGIES; MASSES	Background Whether some benign ovarian cysts can develop into cancerous cysts is not known. If a large proportion of ovarian cancers arose in this way, it might be possible to remove the benign cysts in a screening programme before they became malignant. We used follow-up data from a cohort of 5479 self-referred women without symptoms, who participated in a ultrasonographic-screening trial for early ovarian cancer between June, 1981, and August, 1987. We assessed whether the removal of persistent ovarian cysts from these women was associated with a reduction in the expected number of deaths from ovarian cancer in the cohort as a whole. Methods The expected number of deaths from all causes, all cancers, and ovarian. breast. and colorectal cancers were calculated for the study cohort by the standard life-table method. The actual number of deaths and each cause were obtained and the proportional mortality ratio was calculated for each cause of death. Findings 5135 (95%) of the participants in the original trial were traced. During the screening, five of these women were found to have stage I epithelial ovarian cancer and 88 had benign epithelial ovarian tumours. The number of reported deaths from all causes (387 [50% of expected]), ail cancers (221 [71%]), and ovarian cancer (22 [90%]) was lower than expected because of the "healthy-volunteer effect". Proportional mortality ratios were 100% (by definition) for all cancers. 141% for breast cancer, 128% for ovarian cancer (95% CI 87.7-187.6, p=0.19), 84% for colorectal cancer, and 48% for lung cancer. Interpretation The removal of persistent ovarian cysts was not associated with a decrease in the proportion of expected deaths from ovarian cancer relative to other cancers during follow-up. For population-based screening of healthy women without a family history of ovarian cancer, a screening test is required that is specific and sensitive to early malignant disease. and inexpensive.	Kings Coll Hosp London, Guys Kings & St Thomas Sch Med, Dept Epidemiol & Publ Hlth, London SE5 9PJ, England; Univ London St Georges Hosp, Sch Med, Dept Obstet & Gynaecol, London SW17 0RE, England; Kings Coll Hosp London, Guys Kings & St Thomas Sch Med, Acad Dept Obstet & Gynaecol, London SE5 9PJ, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; St Georges University London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Crayford, TJB (corresponding author), Kings Coll Hosp London, Guys Kings & St Thomas Sch Med, Dept Epidemiol & Publ Hlth, London SE5 9PJ, England.	tim@crayford.net	Bourne, Tom/I-6478-2012	Bourne, Tom/0000-0003-1421-6059				Anderson MC, 1990, OVARIAN CANCER BIOL, P187; Bailey CL, 1998, GYNECOL ONCOL, V69, P3, DOI 10.1006/gyno.1998.4965; BELL DA, 1994, CANCER, V73, P1859, DOI 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L; BHAN V, 1989, BRIT J OBSTET GYNAEC, V96, P1384, DOI 10.1111/j.1471-0528.1989.tb06299.x; BOUME TH, 1991, GYNECOL ONCOL, V43, P92; Breslow NE., 1987, STAT METHODS CANC RE, P81; CAMPBELL S, 1982, LANCET, V1, P425; CAMPBELL S, 1990, BRIT J OBSTET GYNAEC, V97, P304, DOI 10.1111/j.1471-0528.1990.tb01806.x; Collins WP, 1998, CURR OPIN OBSTET GYN, V10, P33, DOI 10.1097/00001703-199802000-00007; GOSWAMY RK, 1983, CLIN OBSTET GYNAECOL, V10, P621; Hoskins WJ, 1996, J NATL CANCER I, V88, P1790, DOI 10.1093/jnci/88.24.1790; *OFF NAT STAT, 1998, 20 CENT MORT CD ROM; Parker S. L., 1996, CA CANC J CLIN, V65, P5; PETTERSON F, 1995, ANN FIGO REPORT RESU, V22, P83; POELS LE, 1992, GYNECOL ONCOL, V47, P53; POWELL DE, 1992, HUM PATHOL, V23, P846, DOI 10.1016/0046-8177(92)90393-H; Salazar H, 1996, JNCI-J NATL CANCER I, V88, P1810, DOI 10.1093/jnci/88.24.1810; SCULLY R, 1995, OVARIAN CANC, V3, P139; SCULLY RE, 1995, INT J GYNECOL OBSTET, V49, pS9, DOI 10.1016/0020-7292(95)02404-Z; Scully RE, 1995, J CELL BIOCHEM, P208; SCULLY RE, 1992, OVARIAN CANCER, V2, P199; Tailor A, 1997, ULTRASOUND OBST GYN, V10, P41, DOI 10.1046/j.1469-0705.1997.10010041.x; Timmerman D, 1999, ULTRASOUND OBST GYN, V13, P17, DOI 10.1046/j.1469-0705.1999.13010017.x; WESTHOFF C, 1992, BRIT J OBSTET GYNAEC, V99, P329, DOI 10.1111/j.1471-0528.1992.tb13733.x; ZHENG JP, 1993, CANCER RES, V53, P4138; 1982, HLTH SURVEY ENGLAND	26	64	65	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	2000	355	9209					1060	1063		10.1016/S0140-6736(00)02038-9	http://dx.doi.org/10.1016/S0140-6736(00)02038-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744092				2022-12-28	WOS:000086380800013
J	Watson, R				Watson, R			EU advisers to declare their interests	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					824	824						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731165				2022-12-28	WOS:000086180300013
J	Gehrels, N; Macomb, DJ; Bertsch, DL; Thompson, DJ; Hartman, RC				Gehrels, N; Macomb, DJ; Bertsch, DL; Thompson, DJ; Hartman, RC			Discovery of a new population of high-energy gamma-ray sources in the Milky Way	NATURE			English	Article							EGRET SOURCES; SUPERNOVA-REMNANTS; GALACTIC PLANE; GOULD BELT; EMISSION; PULSARS	One of the great mysteries of the high-energy gamma-ray sky is the group of similar to 170 unidentified point sources(1,2) found along the Galactic plane. They are more numerous than all other high-energy gamma-ray sources combined and, despite 20 years of effort, no clear counterparts have been found at other wavelengths. Here we report a new population of such objects. A cluster of similar to 20 faint sources appears north of the Galactic Centre, which is part of a broader class of faint objects at mid-latitudes. In addition, we show in a model-independent way that the mid-latitude sources are distinct from the population of bright unidentified sources along the Galactic plane. The distribution on the sky indicates that the faint mid-latitude sources are associated with the Gould belt(3,4) of massive stars and gas clouds at similar to 600 light years distance, as has been previously suggested(5).	NASA, Goddard Space Flight Ctr, High Energy Astrophys Lab, Greenbelt, MD 20771 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Gehrels, N (corresponding author), NASA, Goddard Space Flight Ctr, High Energy Astrophys Lab, Greenbelt, MD 20771 USA.		Thompson, David J/D-2939-2012; Gehrels, Neil/D-2971-2012	Thompson, David J/0000-0001-5217-9135; 				Dixon DD, 1998, NEW ASTRON, V3, P539, DOI 10.1016/S1384-1076(98)00024-4; Esposito JA, 1996, ASTROPHYS J, V461, P820, DOI 10.1086/177104; Gehrels N, 1999, ASTROPART PHYS, V11, P277, DOI 10.1016/S0927-6505(99)00066-3; Gould B.A., 1879, BRILLANTEZ POSICION, P354; GRENIER IA, 1995, ADV SPACE RES, V15, P73, DOI 10.1016/0273-1177(94)00039-4; GRENIER IA, 1999, P 26 INT COSM RAY C, V3, P476; Guillout P, 1998, ASTRON ASTROPHYS, V337, P113; Hartman RC, 1999, ASTROPHYS J SUPPL S, V123, P79, DOI 10.1086/313231; HOUSTON BP, 1983, ASTRON ASTROPHYS, V126, P22; Hunter SD, 1997, ASTROPHYS J, V481, P205, DOI 10.1086/304012; Kaaret P, 1996, ASTROPHYS J, V462, pL35, DOI 10.1088/1538-4357/462/1/L35; Lamb RC, 1997, ASTROPHYS J, V488, P872, DOI 10.1086/304736; LINDBLAD PO, 1973, ASTRON ASTROPHYS, V24, pL309; Mattox JR, 1996, ASTROPHYS J, V461, P396, DOI 10.1086/177068; MONTMERLE T, 1979, ASTROPHYS J, V231, P95, DOI 10.1086/157166; OLANO CA, 1982, ASTRON ASTROPHYS, V112, P195; Ozel ME, 1996, ASTROPHYS J, V463, P105, DOI 10.1086/177226; ROMANI RW, 1995, ASTROPHYS J, V438, P314, DOI 10.1086/175076; Romero GE, 1999, ASTRON ASTROPHYS, V348, P868; STOTHERS R, 1974, ASTRON J, V79, P456, DOI 10.1086/111565; STURNER SJ, 1995, ASTRON ASTROPHYS, V293, pL17; SWANENBURG BN, 1981, ASTROPHYS J, V243, pL69, DOI 10.1086/183445; TAYLOR DK, 1987, ASTROPHYS J, V315, P104, DOI 10.1086/165117; THOMPSON DJ, 1993, ASTROPHYS J SUPPL S, V86, P629, DOI 10.1086/191793; THOMPSON DJ, 1994, ASTROPHYS J, V436, P229, DOI 10.1086/174895	25	119	120	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					363	365		10.1038/35006001	http://dx.doi.org/10.1038/35006001			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746716				2022-12-28	WOS:000086119000041
J	Winker, MA; Flanagin, B; Chi-Lum, B; White, J; Andrews, K; Kennett, RL; DeAngelis, CD; Musacchio, RA				Winker, MA; Flanagin, B; Chi-Lum, B; White, J; Andrews, K; Kennett, RL; DeAngelis, CD; Musacchio, RA			Guidelines for medical and health information sites on the Internet - Principles governing AMA Web sites	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY	Access to medical information via the Internet has the potential to speed the transformation of the patient-physician relationship from that of physician authority ministering advice and treatment to that of shared decision making between patient and physician. However, barriers impeding this transformation include wide variations in quality of content on the Web, potential for commercial interests to influence online content, and uncertain preservation of personal privacy. To address these issues, the American Medical Association (AMA) has developed principles to guide development and posting of Web site content, govern acquisition and posting of online advertising and sponsorship, ensure site visitors' and patients' rights to privacy and confidentiality, and provide effective and secure means of e-commerce. While these guidelines were developed for the AMA Web sites and visitors to these sites, they also may be useful to other providers and users of medical information on the Web. These principles have been developed with the understanding that they will require frequent revision to keep pace with evolving technology and practices on the Internet, The AMA encourages review and feedback from readers, Web site visitors, policymakers, and all others interested in providing reliable quality information via the Web.	Amer Med Assoc, Chicago, IL 60610 USA	American Medical Association	Winker, MA (corresponding author), JAMA, 515 N State St, Chicago, IL 60610 USA.			Winker, Margaret/0000-0002-4708-5641				Eysenbach G, 1998, BRIT MED J, V317, P1496, DOI 10.1136/bmj.317.7171.1496; GOLDMAN J, 2000, REPORT PRIVACY POLIC; Jadad AR, 1999, BMJ-BRIT MED J, V319, P761, DOI 10.1136/bmj.319.7212.761; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P611, DOI 10.1001/jama.279.8.611; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244	5	289	296	1	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2000	283	12					1600	1606		10.1001/jama.283.12.1600	http://dx.doi.org/10.1001/jama.283.12.1600			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MV	10735398	Bronze			2022-12-28	WOS:000085857300038
J	Callum, K; Bradbury, A				Callum, K; Bradbury, A			ABC of arterial and venous disease - Acute limb ischaemia	BRITISH MEDICAL JOURNAL			English	Article									Derbyshire Royal Infirm, Derby DE1 2QY, England; Univ Birmingham, Birmingham Heartlands Hosp, Birmingham, W Midlands, England	Heart of England NHS Foundation Trust; University of Birmingham	Callum, K (corresponding author), Derbyshire Royal Infirm, Derby DE1 2QY, England.								0	59	63	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					764	767		10.1136/bmj.320.7237.764	http://dx.doi.org/10.1136/bmj.320.7237.764			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720362	Green Published			2022-12-28	WOS:000086054700027
J	Reason, J				Reason, J			Human error: models and management	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Dept Psychol, Manchester M13 9PL, Lancs, England	University of Manchester	Reason, J (corresponding author), Univ Manchester, Dept Psychol, Manchester M13 9PL, Lancs, England.	reason@psy.man.ac.uk	Fitall, Eleanor/AAP-2930-2020					Lerner MJ, 1970, ALTRUISM HELPING BEH; MARX D, 1992, MAINTENANCE ERROR CA; Marx D., 1997, GROUND EFF, V2, P1; MEDVEDEV G, 1991, TRUTH CHERNOBYL; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; Reason J., 1997, MANAGING RISK ORG AC; WEICK KE, 1987, CALIF MANAGE REV, V29, P112, DOI 10.2307/41165243; Weick KE, 1999, RES ORGAN BEHAV, V21, P81	8	2793	2890	13	365	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2000	320	7237					768	770		10.1136/bmj.320.7237.768	http://dx.doi.org/10.1136/bmj.320.7237.768			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296YQ	10720363	Green Published			2022-12-28	WOS:000086054700028
J	Rosamond, L; Allsop, A				Rosamond, L; Allsop, A			Harnessing the power of the genome in the search for new antibiotics	SCIENCE			English	Review							YEAST GENOME; GENE; RESISTANCE; INHIBITORS; INFECTION	Over the past 40 years, the search for new antibiotics has been Largely restricted to well-known compound classes active against a standard set of drug targets. Although many effective compounds have been discovered, insufficient chemical variability has been generated to prevent a serious escalation in clinical resistance. Recent advances in genomics have provided an opportunity to expand the range of potential drug targets and have facilitated a fundamental shift from direct antimicrobial screening programs toward rational target-based strategies. The application of genome-based technologies such as expression profiling and proteomics will Lead to further changes in the drug discovery paradigm by combining the strengths and advantages of both screening strategies in a single program.	AstraZeneca, Macclesfield SK10 4TG, Cheshire, England	AstraZeneca	Allsop, A (corresponding author), AstraZeneca, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.							BASSET EB, 1996, CURR OPIN GENE DEV, V6, P736; Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Brown S, 1998, LANCET, V351, P186, DOI 10.1016/S0140-6736(05)78210-6; BROWNE MJ, 1995, MOL MED TODAY, V1, P373, DOI 10.1016/S1357-4310(95)93853-2; Burley SK, 1999, NAT GENET, V23, P151, DOI 10.1038/13783; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Dixon G, 1997, J STEROID BIOCHEM, V62, P165, DOI 10.1016/S0960-0760(97)00032-0; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; File TM, 1999, CHEST, V115, p3S, DOI 10.1378/chest.115.suppl_1.3S; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; GRAY CP, 1998, EXPERT OPIN INVEST D, V7, P147; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; HAWKEY PM, 1998, BRIT MED J, V317; Heithoff DM, 1997, TRENDS MICROBIOL, V5, P509, DOI 10.1016/S0966-842X(97)01153-0; ILLINGWORTH R, UNPUB; Jones RN, 1998, DIAGN MICR INFEC DIS, V31, P379, DOI 10.1016/S0732-8893(98)00037-6; Koonin EV, 1998, CURR OPIN STRUC BIOL, V8, P355, DOI 10.1016/S0959-440X(98)80070-5; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; MARTON MJ, 1998, NAT MED, V4, P11; Oliver SG, 1997, CURR OPIN GENET DEV, V7, P405, DOI 10.1016/S0959-437X(97)80156-6; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Strauss EJ, 1997, SCIENCE, V276, P707, DOI 10.1126/science.276.5313.707; Thomas K, 1996, FEBS LETT, V396, P1, DOI 10.1016/0014-5793(96)01063-0; Thomas SM, 1998, EXPERT OPIN THER PAT, V8, P503, DOI 10.1517/13543776.8.5.503; *UN WHO, 1996, WHO WORLD HLTH REP; VanBogelen RA, 1997, ELECTROPHORESIS, V18, P1243, DOI 10.1002/elps.1150180805; WHITE AC, UNPUB; Winzeler EA, 1997, CURR OPIN GENET DEV, V7, P771, DOI 10.1016/S0959-437X(97)80039-1; WISON M, 1999, P NATL ACAD SCI USA, V96, P12833	35	136	155	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1973	1976		10.1126/science.287.5460.1973	http://dx.doi.org/10.1126/science.287.5460.1973			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720317				2022-12-28	WOS:000085902800049
J	O'Brien, CM; Fox, CJ; Planque, B; Casey, J				O'Brien, CM; Fox, CJ; Planque, B; Casey, J			Fisheries - Climate variability and North Sea cod	NATURE			English	Article									Ctr Environm Fisheries & Aquaculture Sci, Lowestoft Lab, Lowestoft NR33 0HT, Suffolk, England	Centre for Environment Fisheries & Aquaculture Science	O'Brien, CM (corresponding author), Ctr Environm Fisheries & Aquaculture Sci, Lowestoft Lab, Pakefield Rd, Lowestoft NR33 0HT, Suffolk, England.		Planque, Benjamin/D-2729-2013; Fox, Clive/C-5935-2012	Planque, Benjamin/0000-0002-0557-7410; 				Cook RM, 1997, NATURE, V385, P521, DOI 10.1038/385521a0; COUTANT CC, 1987, ENVIRON BIOL FISH, V18, P161, DOI 10.1007/BF00000356; CUSHING DH, 1996, EXCELLENCE ECOLOGY, V7; *ICES COOP RES REP, 1999, REP ICES ADV COMM FI; Longhurst A, 1998, FISH RES, V38, P101, DOI 10.1016/S0165-7836(98)00152-0; Planque B, 1999, CAN J FISH AQUAT SCI, V56, P2069, DOI 10.1139/cjfas-56-11-2069	6	222	229	0	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					142	142		10.1038/35004654	http://dx.doi.org/10.1038/35004654			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724155	Bronze			2022-12-28	WOS:000085870900035
J	de Gruchy, J; Rubenstein, LS				de Gruchy, J; Rubenstein, LS			Will South African physicians build a culture of human rights?	LANCET			English	Editorial Material									Physicians Human Rights, Washington, DC 20005 USA		de Gruchy, J (corresponding author), Physicians Human Rights, 1156 15th St,NW Suite 1001, Washington, DC 20005 USA.							Baldwin- Ragavan l., 1999, AMBULANCE WRONG COLO; CHAPMAN AR, 1998, HLTH HUMAN RIGHTS LE; de Gruchy J, 1998, S AFR MED J, V88, P975; *TRC, 1998, TRC REP, V4, P126; *TRC, 1998, TRC REP, V2, P250; *TRC, 1998, TRC REP, V2, P510	6	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					838	838		10.1016/S0140-6736(00)01336-2	http://dx.doi.org/10.1016/S0140-6736(00)01336-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711942				2022-12-28	WOS:000085766900039
J	Cunningham, EJA; Russell, AF				Cunningham, EJA; Russell, AF			Egg investment is influenced by male attractiveness in the mallard	NATURE			English	Article							DIFFERENTIAL-ALLOCATION HYPOTHESIS; EXTRA-PAIR PATERNITY; REPRODUCTIVE EFFORT; BLUE TIT; SURVIVAL; SIZE; QUALITY; VIABILITY; PEACOCKS; TRAINS	Why females prefer to copulate with particular males is a contentious issue. Attention is currently focused on whether females choose males on the basis of their genetic quality, in order to produce more viable offspring(1). Support for this hypothesis in birds has come from studies showing that preferred males tend to father offspring of better condition or with increased survivorship(2-8). Before attributing greater offspring viability to a male's heritable genetic quality, however, it is important: to discount effects arising from confounding sources, including maternal effects. This has generally been addressed by comparing offspring viability from two different breeding attempts by the same female: one when offspring; are sired by a preferred male, and one when offspring are sired by a less preferred male, However, here we show that individual female mallard (Anas platyrhynchos) lay larger eggs after copulating: with preferred males and smaller eggs after copulating with less preferred males. As a result, females produced offspring of better body condition when paired with preferred males. After controlling: for these differences in maternal investment, we found no effect: of paternity on offspring condition. This shows that differences between half-sibs cannot always be attributed to paternal or maternal genetic effects.	Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Cunningham, EJA (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	ejac3@hermes.cam.ac.uk	Cunningham, Emma/I-9190-2012	Russell, Andy/0000-0002-1299-8555				Andersson Malte, 1994; Balzer AL, 1998, BEHAVIOUR, V135, P297, DOI 10.1163/156853998793066230; BERGER J, 1983, NATURE, V303, P59, DOI 10.1038/303059a0; BOLTON M, 1991, J ANIM ECOL, V60, P949, DOI 10.2307/5424; BURLEY N, 1988, AM NAT, V132, P611, DOI 10.1086/284877; CluttonBrock T, 1997, BEHAV ECOL, V8, P392, DOI 10.1093/beheco/8.4.392; CUNNINGHAM EJA, 1997, FORCED COPULATION SP; DELOPE F, 1993, EVOLUTION, V47, P1152, DOI 10.1111/j.1558-5646.1993.tb02142.x; ELDER WH, 1954, J WILDLIFE MANAGE, V18, P495, DOI 10.2307/3797084; Gil D, 1999, SCIENCE, V286, P126, DOI 10.1126/science.286.5437.126; Griffith SC, 1999, NATURE, V400, P358, DOI 10.1038/22536; Hasselquist D, 1996, NATURE, V381, P229, DOI 10.1038/381229a0; HOYT DF, 1979, AUK, V96, P73; Kempenaers B, 1997, BEHAV ECOL, V8, P481, DOI 10.1093/beheco/8.5.481; KEMPENAERS B, 1992, NATURE, V357, P494, DOI 10.1038/357494a0; Lorenz K., 1951, Avicultural Magazine, V57, P157; Mjelstad Hermund, 1990, Wildfowl, V41, P150; MOLLER AP, 1994, P NATL ACAD SCI USA, V91, P6929, DOI 10.1073/pnas.91.15.6929; NORRIS K, 1993, NATURE, V362, P537, DOI 10.1038/362537a0; Omland KE, 1996, BEHAV ECOL SOCIOBIOL, V39, P353, DOI 10.1007/s002650050300; PETRIE M, 1993, P ROY SOC B-BIOL SCI, V251, P127, DOI 10.1098/rspb.1993.0018; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; RHYMER JM, 1988, OECOLOGIA, V75, P20, DOI 10.1007/BF00378809; Schwabl H, 1997, NATURE, V386, P231, DOI 10.1038/386231a0; Sheldon BC, 1997, P ROY SOC B-BIOL SCI, V264, P297, DOI 10.1098/rspb.1997.0042; SORENSON LG, 1994, BEHAV ECOL SOCIOBIOL, V35, P389, DOI 10.1007/s002650050111; WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461; WILLIAMS TD, 1994, BIOL REV, V69, P35, DOI 10.1111/j.1469-185X.1994.tb01485.x; Witte K, 1995, EVOLUTION, V49, P1289, DOI 10.1111/j.1558-5646.1995.tb04458.x	29	288	292	3	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2000	404	6773					74	77		10.1038/35003565	http://dx.doi.org/10.1038/35003565			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716444				2022-12-28	WOS:000085775100047
J	da Silva, JMC; Tabarelli, M				da Silva, JMC; Tabarelli, M			Tree species impoverishment and the future flora of the Atlantic forest of northeast Brazil	NATURE			English	Article								Estimates of species extinction due to human impact on tropical forests have previously been based on the relationship between species number and area(1). Here we use a different approach to estimate loss of tree species in the Atlantic forest of northeast Brazil. We evaluate the characteristics of plant species, their avian dispersers and the distribution of the forest remnants on the landscape to estimate that about 33.9% of tree species in this region will become extinct on a regional scale. Because northeast Brazil is the most threatened sector of South American Atlantic forest(2), our results highlight the need. to change the current conservation paradigm for this region. Rather than focus on the creation of isolated reserves in any medium-to-large forest remnant, a bioregional planning approach is urgently required to rescue this unique biota from extinction.	Univ Fed Pernambuco, Ctr Ciencias Biol, Dept Zool, BR-50670020 Recife, PE, Brazil; Univ Fed Pernambuco, Ctr Ciencias Biol, Dept Bot, BR-50670020 Recife, PE, Brazil	Universidade Federal de Pernambuco; Universidade Federal de Pernambuco	da Silva, JMC (corresponding author), Univ Fed Pernambuco, Ctr Ciencias Biol, Dept Zool, Av Prof Moraes Rego 1235, BR-50670020 Recife, PE, Brazil.		Tabarelli, Marcelo/F-1088-2010; da Silva, José Maria Cardoso/K-3479-2016	Tabarelli, Marcelo/0000-0001-7573-7216; da Silva, José Maria Cardoso/0000-0002-7229-6694				Almeida Roberval T., 1995, Neotropical Primates, V3, P174; Bierregaard Richard O. Jr., 1996, P187; Brooks T, 1996, NATURE, V380, P115, DOI 10.1038/380115a0; BUCKLEY P. A., 1985, ORNITHOL MONOGR, V36, P865, DOI [10.2307/40168322, DOI 10.2307/40168322]; Caro TM, 1999, CONSERV BIOL, V13, P805, DOI 10.1046/j.1523-1739.1999.98338.x; Corlett Richard T., 1997, P333; DIAS IS, 1990, WORKSH MAT ATL PROBL; Galetti M, 1997, BIOL CONSERV, V82, P31, DOI 10.1016/S0006-3207(97)00004-9; GUIDON FC, 1996, FOREST PATCHES TROPI, P163; Laurance WF, 1997, TROPICAL FOREST REMN, P275; LIMA D, 1997, RAIN REV, V4, P1; MORAES P. L. R., 1992, REV I FLORESTAL, V4, P1206; Muller P, 1973, DISPERSAL CTR TERRES; Murcia Carolina, 1996, P19; Offerman Holly L., 1995, Environmental Reviews, V3, P191, DOI 10.1139/a95-009; Parker TA III, 1996, NEOTROPICAL BIRDS EC; Pijl L., 1982, PRINCIPLES DISPERSAL; Prance G.T., 1982, BIOL DIVERSIFICATION, P137; Ranta P, 1998, BIODIVERS CONSERV, V7, P385, DOI 10.1023/A:1008885813543; REDFORD KH, 1992, BIOSCIENCE, V42, P412, DOI 10.2307/1311860; Robinson John G., 1996, P111; Sick H., 1985, ORNITOLOGIA BRASILEI; Silva Jose Maria Cardoso Da, 1996, Conservation Biology, V10, P491; Soule Michael E., 1999, P1; Tabarelli M, 1999, BIOL CONSERV, V91, P119, DOI 10.1016/S0006-3207(99)00085-3; Viana Virgilio M., 1997, P351; WILLIS E O, 1979, Papeis Avulsos de Zoologia (Sao Paulo), V33, P1; WUNDERLEE JM, 1997, FOREST ECOL MANAGMT, V9, P223	28	284	308	1	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					72	74		10.1038/35003563	http://dx.doi.org/10.1038/35003563			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716443				2022-12-28	WOS:000085775100046
J	Gottlieb, S				Gottlieb, S			Supreme Court rules that FDA cannot regulate tobacco industry	BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					894	894		10.1136/bmj.320.7239.894	http://dx.doi.org/10.1136/bmj.320.7239.894			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10741991	Green Published			2022-12-28	WOS:000086337100018
J	Hacker, BR; Gnos, E; Ratschbacher, L; Grove, M; McWilliams, M; Sobolev, SV; Wan, J; Wu, ZH				Hacker, BR; Gnos, E; Ratschbacher, L; Grove, M; McWilliams, M; Sobolev, SV; Wan, J; Wu, ZH			Hot and dry deep crustal xenoliths from Tibet	SCIENCE			English	Article							PLAGIOCLASE-QUARTZ GEOBAROMETERS; ORTHO-PYROXENE; VOLCANIC-ROCKS; PLATEAU; GARNET; GEOCHEMISTRY; LITHOSPHERE; VELOCITIES; EVOLUTION; COLLISION	Anhydrous metasedimentary and mafic xenoliths entrained in 3-million-year-old shoshonitic Lavas of the central Tibetan Plateau record a thermal gradient reaching about 800 degrees to 1000 degrees C at a depth of 30 to 50 kilometers; just before extraction, these same xenoliths were heated as much as 200 degrees C, Although these rocks show that the central Tibetan crust is hot enough to cause even dehydration melting of mica, the absence of hydrous minerals, and the match of our calculated P-wave speeds and Poisson's ratios with seismological observations, argue against the presence of widespread crustal melting.	Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA; Univ Bern, Mineral Petrog Inst, CH-3012 Bern, Switzerland; Tech Univ Bergakad Freiberg, Inst Geol, D-9596 Freiberg, Germany; Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Stanford Univ, Stanford, CA 94305 USA; Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; Chinese Acad Geol Sci, Inst Geomech, Beijing 100081, Peoples R China	University of California System; University of California Santa Barbara; University of Bern; Technical University Freiberg; Stanford University; Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Chinese Academy of Geological Sciences	Hacker, BR (corresponding author), Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA.		Sobolev, Stephan V/G-3813-2011; McWilliams, Michael O/A-9548-2011; Gnos, Edwin/AAI-7477-2020	Sobolev, Stephan V/0000-0002-3382-4028; McWilliams, Michael O/0000-0002-4107-7069; Gnos, Edwin/0000-0003-0940-8435; Ratschbacher, Lothar/0000-0001-9960-2084				Alsdorf D, 1999, GEOLOGY, V27, P943, DOI 10.1130/0091-7613(1999)027<0943:TSMLEF>2.3.CO;2; Aranovich LY, 1997, AM MINERAL, V82, P345; ARGAND E, 1924, P 13 INT GEOL C BRUS, P171; ARNAUD NO, 1992, EARTH PLANET SC LETT, V111, P351, DOI 10.1016/0012-821X(92)90189-3; BARAZANGI M, 1982, GEOLOGY, V10, P179, DOI 10.1130/0091-7613(1982)10<179:VAPCOP>2.0.CO;2; BREY GP, 1990, J PETROL, V31, P1353, DOI 10.1093/petrology/31.6.1353; Carswell D. A., 1990, ECLOGITE FACIES ROCK, P83; Chung SL, 1998, NATURE, V394, P769, DOI 10.1038/29511; COULON C, 1986, EARTH PLANET SC LETT, V79, P281, DOI 10.1016/0012-821X(86)90186-X; DENG W, 1991, CHIN J GEOCHEM, V10, P140; Deng W M, 1996, ACTA PETROLOGICA MIN, V15, P289; DEWEY JF, 1988, PHILOS T R SOC A, V327, P379, DOI 10.1098/rsta.1988.0135; Dooley DF, 1996, AM MINERAL, V81, P202; ECKERT JO, 1991, AM MINERAL, V76, P148; ECKERT JO, 1998, GEOL SOC AM ABSTR PR, V30; Edwards MA, 1997, GEOLOGY, V25, P543, DOI 10.1130/0091-7613(1997)025<0543:WDTRCL>2.3.CO;2; Ganguly J, 1999, EARTH PLANET SC LETT, V170, P131, DOI 10.1016/S0012-821X(99)00089-8; Hacker BR, 1996, TECTONICS, V15, P1230, DOI 10.1029/96TC01973; HARLEY SL, 1982, NATURE, V300, P697, DOI 10.1038/300697a0; HARLEY SL, 1984, CONTRIB MINERAL PETR, V86, P359, DOI 10.1007/BF01187140; HARLEY SL, 1999, DRIVES METAMORPHISM, V138, P81; Harrison TM, 1997, EARTH PLANET SC LETT, V146, pE1, DOI 10.1016/S0012-821X(96)00215-4; Holland TJB, 1998, J METAMORPH GEOL, V16, P309, DOI 10.1111/j.1525-1314.1998.00140.x; HOLLOWAY JR, 1975, EARTH PLANET SC LETT, V25, P44, DOI 10.1016/0012-821X(75)90208-3; Johannes W., 1996, PETROGENESIS EXPT PE, DOI 10.1007/978-3-642-61049-3_2; Kapp P, 2000, GEOLOGY, V28, P19; KOZIOL AM, 1989, CONTRIB MINERAL PETR, V103, P423, DOI 10.1007/BF01041750; LENARDIC A, 1995, J GEOPHYS RES-SOL EA, V100, P15193, DOI 10.1029/95JB01289; MCKENNA LW, 1990, J GEOPHYS RES-SOLID, V95, P21483, DOI 10.1029/JB095iB13p21483; McNamara DE, 1997, J GEOPHYS RES-SOL EA, V102, P493, DOI 10.1029/96JB02112; MECHIE J, 1999, EOS, V80, pF951; Meyer B, 1998, GEOPHYS J INT, V135, P1, DOI 10.1046/j.1365-246X.1998.00567.x; Miller C, 1999, J PETROL, V40, P1399, DOI 10.1093/petrology/40.9.1399; Mock C, 1999, EARTH PLANET SC LETT, V171, P107, DOI 10.1016/S0012-821X(99)00133-8; MOECHER DP, 1988, CONTRIB MINERAL PETR, V100, P92, DOI 10.1007/BF00399441; Murphy MA, 1997, GEOLOGY, V25, P719, DOI 10.1130/0091-7613(1997)025<0719:DTIACA>2.3.CO;2; Owens TJ, 1997, NATURE, V387, P37, DOI 10.1038/387037a0; Patino Douce A.E., 1998, CONTINENTS COLLIDES, P27, DOI DOI 10.1007/978-94-015-9050-1_2; RICHTER FM, 1991, EARTH PLANET SC LETT, V105, P266, DOI 10.1016/0012-821X(91)90136-6; Rodgers AJ, 1998, J GEOPHYS RES-SOL EA, V103, P7137, DOI 10.1029/97JB03535; Smith HA, 1997, GEOCHIM COSMOCHIM AC, V61, P1047, DOI 10.1016/S0016-7037(96)00396-1; SOBOLEV SV, 1994, SURV GEOPHYS, V15, P515, DOI 10.1007/BF00690173; Turner S, 1996, J PETROL, V37, P45, DOI 10.1093/petrology/37.1.45; TURNER S, 1993, NATURE, V364, P50, DOI 10.1038/364050a0; WESTAWAY R, 1995, J GEOPHYS RES-SOL EA, V100, P15173, DOI 10.1029/95JB01310; ZHAO WL, 1985, TECTONICS, V4, P359, DOI 10.1029/TC004i004p00359; 1997, P 30 INT GEOL C, V15, P3	47	264	300	4	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2463	2466		10.1126/science.287.5462.2463	http://dx.doi.org/10.1126/science.287.5462.2463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741961				2022-12-28	WOS:000086202200038
J	Assmann, SF; Pocock, SJ; Enos, LE; Kasten, LE				Assmann, SF; Pocock, SJ; Enos, LE; Kasten, LE			Subgroup analysis and other (mis)uses of baseline data in clinical trials	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; RANDOMIZED TRIAL; JOURNALS; QUALITY; RISK	Background Baseline data collected on each patient at randomisation in controlled clinical trials can be used to describe the population of patients, to assess comparability of treatment groups, to achieve balanced randomisation. to adjust treatment comparisons for prognostic factors, and to undertake subgroup analyses. We assessed the extent and quality of such practices in major clinical trial reports. Methods A sample of 50 consecutive clinical-trial reports was obtained from four major medical journals during July to September, 1997. We tabulated the detailed information on uses of baseline data by use of a standard form. Findings Most trials presented baseline comparability in a table. These tables were often unduly large, and about half the trials inappropriately used significance tests for baseline comparison. Methods of randomisation, including possible stratification, were often poorly described. There was little consistency over whether to use covariate adjustment and the criteria for selecting baseline factors for which to adjust were often unclear. Most trials emphasised the simple unadjusted results and covariate adjustment usually made negligible difference. Two-thirds of the reports presented subgroup findings, but mostly without appropriate statistical tests for interaction. Many reports put too much emphasis on subgroup analyses that commonly lacked statistical power. Interpretation Clinical trials need a predefined statistical analysis plan for uses of baseline data, especially covariate-adjusted analyses and subgroup analyses. Investigators and journals need to adopt improved standards of statistical reporting, and exercise caution when drawing conclusions from subgroup findings.	Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HT, England; New England Res Inst, Watertown, MA 02172 USA	University of London; London School of Hygiene & Tropical Medicine; HealthCore, Inc	Pocock, SJ (corresponding author), Univ London London Sch Hyg & Trop Med, Med Stat Unit, Keppel St, London WC1E 7HT, England.							Alderman EL, 1996, NEW ENGL J MED, V335, P217; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ALTMAN DG, 1985, STATISTICIAN, V34, P125; Altman DG, 1998, ENCY BIOSTATISTICS, P1000; BEACH ML, 1989, CONTROL CLIN TRIALS, V10, pS161; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BIRKETT JJ, 1985, CONTROL CLIN TRIALS, V6, P146; Chamberlain DA, 1997, LANCET, V350, P461; CHRISTENSEN E, 1985, GASTROENTEROLOGY, V89, P1084, DOI 10.1016/0016-5085(85)90213-6; FORD I, 1995, STAT MED, V14, P735, DOI 10.1002/sim.4780140804; FrasureSmith N, 1997, LANCET, V350, P473, DOI 10.1016/S0140-6736(97)02142-9; FREEDMAN LS, 1976, BIOMETRICS, V32, P691, DOI 10.2307/2529759; FRIEDMAN LM, 1998, FUNDAMENTALS CLIN TR, P61; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; Gordin FM, 1997, NEW ENGL J MED, V337, P315, DOI 10.1056/NEJM199707313370505; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; POCOCK SJ, 1982, BRIT J CANCER, V46, P368, DOI 10.1038/bjc.1982.212; Pocock SJ., 2013, CLIN TRIALS PRACTICA; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Rolfs RT, 1997, NEW ENGL J MED, V337, P307, DOI 10.1056/NEJM199707313370504; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SENN S, 1994, STAT MED, V13, P1715, DOI 10.1002/sim.4780131703; SENN SJ, 1989, STAT MED, V8, P467, DOI 10.1002/sim.4780080410; SNEDECOR GW, 1989, STAT METHODS, P419; Sundberg K, 1997, LANCET, V350, P697, DOI 10.1016/S0140-6736(97)02449-5; tenCate JW, 1997, NEW ENGL J MED, V337, P657; vanderHorst CM, 1997, NEW ENGL J MED, V337, P15, DOI 10.1056/NEJM199707033370103; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	30	798	812	2	49	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1064	1069		10.1016/S0140-6736(00)02039-0	http://dx.doi.org/10.1016/S0140-6736(00)02039-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744093				2022-12-28	WOS:000086380800014
J	de Matteis, A; Nuzzo, F; Rossi, E; Landi, G; Perrone, F				de Matteis, A; Nuzzo, F; Rossi, E; Landi, G; Perrone, F			Intestinal side-effects of docetaxel/vinorelbine combination	LANCET			English	Letter									Natl Canc Inst, Div Med Oncol Endocrinol C, I-80131 Naples, Italy; Natl Canc Inst, Clin Trials Off, I-80131 Naples, Italy	IRCCS Fondazione Pascale; IRCCS Fondazione Pascale	Perrone, F (corresponding author), Natl Canc Inst, Div Med Oncol Endocrinol C, I-80131 Naples, Italy.		Perrone, Francesco/AAB-8283-2022	Perrone, Francesco/0000-0002-9738-0526				Fumoleau P, 1997, Oncology (Williston Park), V11, P29; Ibrahim NK, 2000, LANCET, V355, P281, DOI 10.1016/S0140-6736(99)06195-4; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9	4	8	8	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1098	1099		10.1016/S0140-6736(05)72219-4	http://dx.doi.org/10.1016/S0140-6736(05)72219-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744113				2022-12-28	WOS:000086380800049
J	Pinkse, PWH; Fischer, T; Maunz, P; Rempe, G				Pinkse, PWH; Fischer, T; Maunz, P; Rempe, G			Trapping an atom with single photons	NATURE			English	Article							OPTICAL CAVITY; NEUTRAL ATOMS; FIELD; ION	The creation of a photon-atom bound state was first envisaged for the case of an atom in a long-lived excited state inside a high-quality microwave cavity(1,2). In practice, however, light forces in the microwave domain are insufficient to support an atom against gravity. Although optical photons can provide forces of the required magnitude, atomic decay rates and cavity losses are larger too, and so the atom-cavity system must be continually excited by an external laser(3,4). Such an approach also permits continuous observation of the atom's position, by monitoring the light transmitted through the cavity(5-9). The dual role of photons in this system distinguishes it from other single-atom experiments such as those using magneto-optical traps(10-12), ion traps(13,14) or a far-off-resonance optical trap(15). Here we report high-finesse optical cavity experiments in which the change in transmission induced by a single slow atom approaching the cavity triggers an external feedback switch which traps the atom in a light field containing about one photon on average. The oscillatory motion of the trapped atom induces oscillations in the transmitted light intensity; we attribute periodic structure in intensity-correlation-function data to 'long-distance' flights of the atom between different anti-nodes of the standing-wave in the cavity. The system should facilitate investigations of the dynamics of single quantum objects and may find future applications in quantum information processing.	Max Planck Inst Quantum Opt, D-85748 Garching, Germany	Max Planck Society	Rempe, G (corresponding author), Max Planck Inst Quantum Opt, Hans Kopfermann Str 1, D-85748 Garching, Germany.	Gerhard.Rempe@mpq.mpg.de						Berman P., 1994, CAVITY QUANTUM ELECT; Carmichael H, 1993, OPEN SYSTEMS APPROAC; Cirac JI, 1997, PHYS REV LETT, V78, P3221, DOI 10.1103/PhysRevLett.78.3221; ENGLERT BG, 1991, EUROPHYS LETT, V14, P25, DOI 10.1209/0295-5075/14/1/005; HAROCHE S, 1991, EUROPHYS LETT, V14, P19, DOI 10.1209/0295-5075/14/1/004; Haubrich D, 1996, EUROPHYS LETT, V34, P663, DOI 10.1209/epl/i1996-00512-5; Hechenblaikner G, 1998, PHYS REV A, V58, P3030, DOI 10.1103/PhysRevA.58.3030; Hood CJ, 1998, PHYS REV LETT, V80, P4157, DOI 10.1103/PhysRevLett.80.4157; Horak P, 1997, PHYS REV LETT, V79, P4974, DOI 10.1103/PhysRevLett.79.4974; HU Z, 1994, OPT LETT, V19, P1888, DOI 10.1364/OL.19.001888; Kuhn A, 1999, APPL PHYS B-LASERS O, V69, P373, DOI 10.1007/s003400050822; Law CK, 1997, J MOD OPTIC, V44, P2067, DOI 10.1080/095003497152357; Law CK, 1996, PHYS REV LETT, V76, P1055, DOI 10.1103/PhysRevLett.76.1055; Mabuchi H, 1999, APPL PHYS B-LASERS O, V68, P1095, DOI 10.1007/s003400050751; Mabuchi H, 1996, OPT LETT, V21, P1393, DOI 10.1364/OL.21.001393; MANCINI S, IN PRESS PHYS REV A; MOLMER K, 1993, J OPT SOC AM B, V10, P524, DOI 10.1364/JOSAB.10.000524; Munstermann P, 1999, OPT COMMUN, V159, P63, DOI 10.1016/S0030-4018(98)00596-3; Munstermann P, 1999, PHYS REV LETT, V82, P3791, DOI 10.1103/PhysRevLett.82.3791; NEUHAUSER W, 1980, PHYS REV A, V22, P1137, DOI 10.1103/PhysRevA.22.1137; QUADT R, 1995, PHYS REV LETT, V74, P351, DOI 10.1103/PhysRevLett.74.351; REMPE G, 1995, APPL PHYS B-LASERS O, V60, P233, DOI 10.1007/BF01135867; Ruschewitz F, 1996, EUROPHYS LETT, V34, P651, DOI 10.1209/epl/i1996-00510-7; WINELAND DJ, 1981, PHYS LETT A, V82, P75, DOI 10.1016/0375-9601(81)90942-7; Ye J, 1999, PHYS REV LETT, V83, P4987, DOI 10.1103/PhysRevLett.83.4987	25	383	390	3	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					365	368		10.1038/35006006	http://dx.doi.org/10.1038/35006006			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746717				2022-12-28	WOS:000086119000042
J	Tulsky, JA; Ciampa, R; Rosen, EJ				Tulsky, JA; Ciampa, R; Rosen, EJ		Univ Pennsylvania	Responding to legal requests for physician-assisted suicide	ANNALS OF INTERNAL MEDICINE			English	Article							WASHINGTON-STATE; PATIENT REQUESTS; EUTHANASIA; ATTITUDES; CARE; AUTONOMY; PERSPECTIVE; CHOICE; WILL; DIE	In 1998, 15 terminally ill Oregon residents ended their lives with overdoses of medications supplied legally by their physicians. Many more people consider this possibility. This paper examines the ways in which the physician's response to requests for assisted suicide may change in an era of legalization, articulates some of the resulting conceptual challenges, and provides practical advice to physicians facing such requests. In areas where it is legal, assisted dying becomes one of the many options that can be freely considered for terminally ill patients with extreme suffering. Some patients even view assisted death as a right that can be expected on demand. We consider the ethical implications of disclosing assisted dying to patients as an option of last resort: and suggest that physicians working in environments where assisted dying is legal are obliged to do so. However, we conclude that physicians should not encourage patients to hasten death even when practicing in jurisdictions that allow assisted dying. Furthermore, without abandoning the model, we suggest that strict informed consent does not fully address patients' needs at this time. Physicians must also focus on patients' broader biopsychosocial concerns and help them identify solutions through empathic listening and emotional support. We provide a framework and vocabulary for physicians to use when responding to requests for assisted suicide. Physicians should clarify the request, explore and address the patient's concerns, achieve a shared understanding of the goals of treatment, search for less harmful alternatives, express to the patient what they are willing to do, discuss the relevant legal issues, and share their decision making with colleagues.	Vet Affairs Med Ctr, Durham, NC 27705 USA; Duke Univ, Med Ctr, Durham, NC USA; Hosp Univ Penn, Philadelphia, PA 19104 USA; Family Inst Westchester, Scarsdale, NY USA; Phelps Mem Hospice, Scarsdale, NY USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; University of Pennsylvania; Northwell Health	Tulsky, JA (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.							APPELBAUM P, 1987, INFORMED CONSENT LEG; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; BRODY H, 1992, HEALERS POWER; Byock I, 1997, DYING WELL PROSPECT; CAPLAN AL, 1993, PRESCRIBING OUR FUTU, P149; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826, DOI 10.1001/jama.274.10.826; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; Cole Roger M., 1993, Palliative Medicine, V7, P139, DOI 10.1177/026921639300700208; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; Dunn PM, 1996, J GEN INTERN MED, V11, P689, DOI 10.1007/BF02600161; EDWARDS MJ, 1992, ANN INTERN MED, V117, P254, DOI 10.7326/0003-4819-117-3-254; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL L, 1999, ED PHYSICIANS END OF; Emanuel LL, 1998, JAMA-J AM MED ASSOC, V280, P643, DOI 10.1001/jama.280.7.643; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; Maguire P, 1996, EUR J CANCER, V32A, P78, DOI 10.1016/0959-8049(95)00527-7; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Rose PG, 1998, J CLIN ONCOL, V16, P405, DOI 10.1200/JCO.1998.16.2.405; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Teno JM, 1996, J CLIN ETHIC, V7, P205; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683	34	18	18	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					494	499		10.7326/0003-4819-132-6-200003210-00012	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293CV	10733451				2022-12-28	WOS:000085834700011
J	Merz, CNB; Paul-Labrador, M; Vongvanich, P				Merz, CNB; Paul-Labrador, M; Vongvanich, P			Time to reevaluate risk stratification guidelines for medically supervised exercise training in patients with coronary artery disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; MULTIFACTORIAL INTERVENTION PROGRAM; CARDIAC REHABILITATION; SUDDEN DEATHS; REDUCTION; TRIALS		Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Prevent & Rehabil Cardiac Ctr, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Merz, CNB (corresponding author), Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Prevent & Rehabil Cardiac Ctr, 444 S San Vicente Blvd,Suite 901, Los Angeles, CA 90048 USA.	merz@cshs.org						*AG HLTH CAR POL R, 1995, CARD REH GUID; *AM ASS CARD PULM, 1995, GUID CARD REH PROGR; *ANT TRIAL COLL, 1983, BMJ-BRIT MED J, V296, P320; BONDESTAM E, 1995, AM J CARDIOL, V75, P767, DOI 10.1016/S0002-9149(99)80408-1; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; Dorn J, 1999, CIRCULATION, V100, P1764, DOI 10.1161/01.CIR.100.17.1764; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; Gordon NF, 1997, AM J CARDIOL, V80, pH69, DOI 10.1016/S0002-9149(97)00825-4; HAMALAINEN H, 1989, EUR HEART J, V10, P55; Hambrecht R, 1993, J AM COLL CARDIOL, V22, P468, DOI 10.1016/0735-1097(93)90051-2; KALLIO V, 1979, LANCET, V2, P1091; LEIZOROVICZ A, 1988, EUR HEART J, V9, P8; LEVIN LA, 1991, J INTERN MED, V230, P427, DOI 10.1111/j.1365-2796.1991.tb00468.x; Merz CNB, 1996, AM HEART J, V132, P418; MILLER NH, 1984, CIRCULATION, V70, P645, DOI 10.1161/01.CIR.70.4.645; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE N, 1993, AM J CARDIOL, V72, P154, DOI 10.1016/0002-9149(93)90152-3; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; PASHKOW FJ, 1993, J AM COLL CARDIOL, V21, P822, DOI 10.1016/0735-1097(93)90116-I; Paul-Labrador M, 1999, J Cardiopulm Rehabil, V19, P118, DOI 10.1097/00008483-199903000-00006; PAULLABRADOR M, 1994, J CARDIOPULM REHABIL, V14, P328; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; SCHULER G, 1988, CIRCULATION, V77, P172, DOI 10.1161/01.CIR.77.1.172; THOMPSON PD, 1982, JAMA-J AM MED ASSOC, V247, P2535, DOI 10.1001/jama.247.18.2535; VANCAMP SP, 1986, JAMA-J AM MED ASSOC, V256, P1160, DOI 10.1001/jama.256.9.1160; Vongvanich P, 1996, AM J CARDIOL, V77, P1383, DOI 10.1016/S0002-9149(96)00215-9; Vongvanich P, 1996, J Cardiopulm Rehabil, V16, P233, DOI 10.1097/00008483-199607000-00004; Wenger N K, 1992, Ann Acad Med Singap, V21, P141; WHITE LJ, 1988, ANN INTERN MED, V109, P671, DOI 10.7326/0003-4819-109-8-671; [No title captured]	31	2	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2000	283	11					1476	1478						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290UR	10732938				2022-12-28	WOS:000085696700033
J	Gordon, RG				Gordon, RG			Plate tectonics - The Antarctic connection	NATURE			English	Editorial Material							HOTSPOTS; PACIFIC; MOTION; OCEANS		Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Gordon, RG (corresponding author), Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA.	rgg@rice.edu						ACTON GD, 1994, SCIENCE, V263, P1246, DOI 10.1126/science.263.5151.1246; ATWATER T, 1973, STANFORD U PUBL GEOL, V13, P136; BERCOVICI D, IN PRESS HIST DYNAMI; Cande SC, 2000, NATURE, V404, P145, DOI 10.1038/35004501; DUNCAN RA, 1981, TECTONOPHYSICS, V74, P29, DOI 10.1016/0040-1951(81)90126-8; Engebretson D.C., 1985, 206 GEOL SOC AM; JURDY DM, 1979, J GEOPHYS RES, V84, P6796, DOI 10.1029/JB084iB12p06796; Luyendyk B, 1996, TECTONICS, V15, P122, DOI 10.1029/95TC02524; MOLNAR P, 1975, GEOPHYS J ROY ASTR S, V40, P383, DOI 10.1111/j.1365-246X.1975.tb04139.x; MOLNAR P, 1987, NATURE, V327, P587, DOI 10.1038/327587a0; Morgan W.J., 1981, SEA VOLUME 7 OCEANIC, V7, P443; RAYMOND CA, IN PRESS HIST DYNAMI	12	5	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2000	404	6774					139	140		10.1038/35004703	http://dx.doi.org/10.1038/35004703			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724153				2022-12-28	WOS:000085870900033
J	Gabashvili, IS; Agrawal, RK; Spahn, CMT; Grassucci, RA; Svergun, DI; Frank, J; Penczek, P				Gabashvili, IS; Agrawal, RK; Spahn, CMT; Grassucci, RA; Svergun, DI; Frank, J; Penczek, P			Solution structure of the E. coli 70S ribosome at 11.5 angstrom resolution	CELL			English	Article							CONTRAST TRANSFER-FUNCTION; ELONGATION-FACTOR-G; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CRYOELECTRON MICROSCOPY; TRANSFER-RNA; 3-DIMENSIONAL RECONSTRUCTION; ELECTRON CRYOMICROSCOPY; THERMUS-THERMOPHILUS; PROTEIN S7	Over 73,000 projections of the E. coli ribosome bound with formyl-methionyl initiator tRNA(f)(Met) were used to obtain an 11.5 Angstrom cryo-electron microscopy map of the complex. This map allows identification of RNA helices, peripheral proteins, and intersubunit bridges. Comparison of double-stranded RNA regions and positions of proteins identified in both cryo-EM and X-ray maps indicates good overall agreement but points to rearrangements of ribosomal components required for the subunit association. Fitting of known components of the 50S stalk base region into the map defines the architecture of the GTPase-associated center and reveals a major change in the orientation of the alpha-sarcin-ricin loop. Analysis of the bridging connections between the subunits provides insight into the dynamic signaling mechanism between the ribosomal subunits.	Hlth Res Inc, Howard Hughes Med Inst, Albany, NY 12201 USA; Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA; DESY, European Mol Biol Lab, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	Health Research Inc; Howard Hughes Medical Institute; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Frank, J (corresponding author), Hlth Res Inc, Howard Hughes Med Inst, Empire State Plaza, Albany, NY 12201 USA.	joachim@wadsworth.org	Gabashvili, Irene/S-8737-2019	Gabashvili, Irene/0000-0002-0097-1478; Svergun, Dmitri/0000-0003-0830-5696	NIGMS NIH HHS [R01 GM55440, R37 GM29169, R37 GM029169] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029169, R01GM055440] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P53; Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Agrawal RK, 1999, INT J BIOCHEM CELL B, V31, P243, DOI 10.1016/S1357-2725(98)00149-6; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Clemons WM, 1998, STRUCT FOLD DES, V6, P429, DOI 10.1016/S0969-2126(98)00045-8; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Correll CC, 1999, J MOL BIOL, V292, P275, DOI 10.1006/jmbi.1999.3072; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; Culver GM, 1999, SCIENCE, V285, P2133, DOI 10.1126/science.285.5436.2133; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; FANNING TG, 1978, NUCLEIC ACIDS RES, V5, P933, DOI 10.1093/nar/5.3.933; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; Frank J, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P45; FRANK J, 1995, OPTIK, V98, P125; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Frank J, 2000, METHOD ENZYMOL, V317, P276; Gabashvili IS, 1999, EMBO J, V18, P6501, DOI 10.1093/emboj/18.22.6501; Gabashvili IS, 1999, J MOL BIOL, V286, P1285, DOI 10.1006/jmbi.1999.2538; GLAESER RM, 1992, ULTRAMICROSCOPY, V47, P256, DOI 10.1016/0304-3991(92)90201-T; Harms J, 1999, STRUCTURE, V7, P931, DOI 10.1016/S0969-2126(99)80120-8; Hosaka H, 1997, STRUCTURE, V5, P1199, DOI 10.1016/S0969-2126(97)00270-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; LAMBERT JM, 1981, J MOL BIOL, V149, P451, DOI 10.1016/0022-2836(81)90481-2; LATA KR, 1995, ULTRAMICROSCOPY, V58, P381, DOI 10.1016/0304-3991(95)00002-I; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; Li YH, 1997, J STRUCT BIOL, V120, P266, DOI 10.1006/jsbi.1997.3917; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Nikonov S, 1996, EMBO J, V15, P1350, DOI 10.1002/j.1460-2075.1996.tb00477.x; Orlova EV, 1997, J MOL BIOL, V271, P417, DOI 10.1006/jmbi.1997.1182; OSSWALD M, 1995, NUCLEIC ACIDS RES, V23, P4635, DOI 10.1093/nar/23.22.4635; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; Peltz SW, 1999, MOL CELL BIOL, V19, P384; Penczek P, 1999, J STRUCT BIOL, V128, P44, DOI 10.1006/jsbi.1999.4157; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; Schlunzen F, 1999, J SYNCHROTRON RADIAT, V6, P928, DOI 10.1107/S0909049599006664; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; Spahn CMT, 1999, STRUCT FOLD DES, V7, P1567, DOI 10.1016/S0969-2126(00)88347-1; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; Stemmer C, 1997, J MOL BIOL, V273, P52, DOI 10.1006/jmbi.1997.1270; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; VANHEEL M, 1986, OPTIK, V73, P83; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 1997, STRUCTURE, V5, P1187, DOI 10.1016/S0969-2126(97)00269-4; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; WITTMANN HG, 1982, FEBS LETT, V146, P217, DOI 10.1016/0014-5793(82)80739-4; WittmannLiebold B, 1995, BIOCHEM CELL BIOL, V73, P1187, DOI 10.1139/o95-128; Zhu J, 1997, J STRUCT BIOL, V118, P197, DOI 10.1006/jsbi.1997.3845	63	336	352	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 3	2000	100	5					537	549		10.1016/S0092-8674(00)80690-X	http://dx.doi.org/10.1016/S0092-8674(00)80690-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721991	Bronze			2022-12-28	WOS:000085700000007
J	Bendick, R; Bilham, R; Freymueller, J; Larson, K; Yin, GH				Bendick, R; Bilham, R; Freymueller, J; Larson, K; Yin, GH			Geodetic evidence for a low slip rate in the Altyn Tagh fault system	NATURE			English	Article							CONTINENTAL COLLISION; ACTIVE DEFORMATION; GPS MEASUREMENTS; CENTRAL-ASIA; TIBET; CONSTRAINTS; EARTHQUAKES; KINEMATICS; NEPAL; CHINA	The collision between India and Asia has been simulated with a variety of computational models that describe or predict the motions of the main faults of east Asia. Geological slip-rate estimates of 20-30 mm yr(-1) suggest that the largest of these faults, the 2,000-km-long Altyn Tagh fault system on the northern edge of the Tibetan plateau, absorbs as much of the Indo-Asian convergence signal as do the Himalayas(1,2)-partly by oblique slip and partly by contraction and mountain growth(3-5). However, the predictions of dynamic models for Asian deformation(6) and the lower bounds of some geological slip-rates estimates (3-9 mm yr(-1); refs 7, 8) suggest that the Altyn Tagh system is less active. Here, we report geodetic data from 89-91 degrees E that indicate left-lateral shear of 9 +/- 5 mm yr(-1) and contraction of 3 +/- 1 mm yr(-1) across the Altyn Tagh system, This result-combined with our finding that, at 98 degrees E, Tibet contracts north-south at 9 1 mm yr(-1)-supports the predictions of dynamic models of Asian deformation.	Univ Colorado, CIRES, Boulder, CO 80309 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Univ Oxford, Oxford OX1 3PR, England; Univ Alaska, Inst Geophys, Fairbanks, AK 99775 USA; Univ Colorado, Dept Aerosp Engn Sci, Boulder, CO 80309 USA; Xinjiang Seism Bur, Urumqi, Xinjiang, Peoples R China	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Oxford; University of Alaska System; University of Alaska Fairbanks; University of Colorado System; University of Colorado Boulder	Bendick, R (corresponding author), Univ Colorado, CIRES, Boulder, CO 80309 USA.		Larson, Kristine M/J-7623-2018	Larson, Kristine M/0000-0003-4666-8885; Bilham, Roger/0000-0002-5547-4102; Freymueller, Jeffrey/0000-0003-0614-0306; Bendick, Rebecca/0000-0003-4204-3546				Abdrakhmatov KY, 1996, NATURE, V384, P450, DOI 10.1038/384450a0; AVOUAC JP, 1993, GEOPHYS RES LETT, V20, P895, DOI 10.1029/93GL00128; Bilham R, 1997, NATURE, V386, P61, DOI 10.1038/386061a0; Bilham R, 1998, CURR SCI INDIA, V74, P213; ENGLAND P, 1990, NATURE, V344, P140, DOI 10.1038/344140a0; England P, 1997, SCIENCE, V278, P647, DOI 10.1126/science.278.5338.647; HOUSEMAN G, 1986, J GEOPHYS RES-SOLID, V91, P3651, DOI 10.1029/JB091iB03p03651; HOUSEMAN G, 1993, J GEOPHYS RES-SOL EA, V98, P12233, DOI 10.1029/93JB00443; JACKSON M, 1994, J GEOPHYS RES-SOL EA, V99, P13897, DOI 10.1029/94JB00714; JONES CH, 1992, SCIENCE, V256, P83, DOI 10.1126/science.256.5053.83; King RW, 1997, GEOLOGY, V25, P179, DOI 10.1130/0091-7613(1997)025<0179:GMOCMI>2.3.CO;2; KONG X, 1996, TECTONIC EVOLUTION A, P18; LAMB S, 1994, GEOPHYS J INT, V119, P313, DOI 10.1111/j.1365-246X.1994.tb00930.x; LARSON K, 1999, J GEOPHYS RES, V104, P1111; Larson KM, 1997, J GEOPHYS RES-SOL EA, V102, P9961, DOI 10.1029/97JB00514; LONGIUM Y, 1999, GEOLOGY, V27, P227; McCaffrey R., 1996, GEOL SOC LOND SPEC P, P3, DOI DOI 10.1144/GSL.SP.1996.106.01.02; MERIAUX A, 1998, EOS FALL M S, V79, P400; Meyer B, 1996, GEOPHYS J INT, V124, P29, DOI 10.1111/j.1365-246X.1996.tb06350.x; MOLNAR P, 1975, SCIENCE, V189, P419, DOI 10.1126/science.189.4201.419; MOLNAR P, 1984, J GEOPHYS RES, V89, P6203, DOI 10.1029/JB089iB07p06203; PELTZER G, 1989, SCIENCE, V246, P1285, DOI 10.1126/science.246.4935.1285; Peltzer G, 1996, J GEOPHYS RES-SOL EA, V101, P27943, DOI 10.1029/96JB02698; Savage JC, 1998, J GEOPHYS RES-SOL EA, V103, P2439, DOI 10.1029/97JB02562; *SEISM BUR CHIN, 1992, ALT TAGH FAULT, P1; VILOTTE JP, 1982, J GEOPHYS RES, V87, P709, DOI 10.1029/JB087iB13p10709	26	229	268	4	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					69	72		10.1038/35003555	http://dx.doi.org/10.1038/35003555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716442				2022-12-28	WOS:000085775100045
J	Patel, AD; Balaban, E				Patel, AD; Balaban, E			Temporal patterns of human cortical activity reflect tone sequence structure	NATURE			English	Article							STEADY-STATE RESPONSES; TONOTOPIC ORGANIZATION; MUSIC; PERCEPTION; PITCH	Despite growing interest in temporal aspects of auditory neural processing(1,2), little is known about large-scale timing patterns of brain activity during the perception of auditory sequences(3). This is partly because it has not been possible ro distinguish stimulus-related activity from other, endogenous brain signals recorded by electrical or magnetic sensors. Here we use amplitude modulation of unfamiliar, unfamiliar, similar to 1-minute-long tone sequences to label stimulus-related magnetoencephalographic neural activity in human subjects(4-9). We show that temporal patterns of activity recorded over particular brain regions track the pitch contour of tone sequences, with the accuracy of tracking increasing as tone sequences become more predictable in structure. In contrast, temporal synchronization between recording locations, particularly between sites over the left posterior hemisphere and the rest of the brain, is greatest when sequences have melody-like statistical properties(10,11) which may reflect the perceptual integration of local ant; global pitch patterns in melody-like sequences(12). This method is particularly well suited to studying temporal neural correlates of complex auditory sequences (such as speech or music) which engage multiple brain areas as perception unfolds in time.	Inst Neurosci, San Diego, CA 92121 USA		Patel, AD (corresponding author), Inst Neurosci, 10640 John Jay Hopkins Dr, San Diego, CA 92121 USA.	apatel@nsi.edu; evan@nsi.edu	Balaban, Evan/AAV-2353-2020	Balaban, Evan/0000-0002-0391-3433				[Anonymous], 1993, ENG APPL CORRELATION; BOON JP, 1995, CHAOS, V5, P501, DOI 10.1063/1.166145; Cariani PA, 1996, J NEUROPHYSIOL, V76, P1698, DOI 10.1152/jn.1996.76.3.1698; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; GREENBERG S, **NON-TRADITIONAL**; Gutschalk A, 1999, CLIN NEUROPHYSIOL, V110, P856, DOI 10.1016/S1388-2457(99)00019-X; HARI R, 1989, J ACOUST SOC AM, V86, P1033, DOI 10.1121/1.398093; Ligeois-Chauvel C, 1998, BRAIN, V121, P1853, DOI 10.1093/brain/121.10.1853; Makeig S, 1997, P NATL ACAD SCI USA, V94, P10979, DOI 10.1073/pnas.94.20.10979; NETTHEIM N, 1992, INTERFACE-J NEW MUS, V21, P135, DOI 10.1080/09298219208570604; PANTEV C, 1993, ELECTROEN CLIN NEURO, V88, P389, DOI 10.1016/0168-5597(93)90015-H; Pantev C, 1996, HEARING RES, V101, P62, DOI 10.1016/S0378-5955(96)00133-5; Patel AD, 1998, BRAIN LANG, V61, P123, DOI 10.1006/brln.1997.1862; PETSCHE H, 1993, MUSIC PERCEPT, V11, P117; RIBARY U, 1991, P NATL ACAD SCI USA, V88, P11037, DOI 10.1073/pnas.88.24.11037; ROMANI GL, 1982, SCIENCE, V216, P1339, DOI 10.1126/science.7079770; SCHMUCKLER MA, 1993, J EXP PSYCHOL HUMAN, V19, P641; SIEGEL S, 1988, MONPARAMETRIC STAT B; Srinivasan R, 1999, J NEUROSCI, V19, P5435; VOSS RF, 1978, J ACOUST SOC AM, V63, P258, DOI 10.1121/1.381721; VOSS RF, 1975, NATURE, V258, P317, DOI 10.1038/258317a0; ZATORRE RJ, 1994, J NEUROSCI, V14, P1908, DOI 10.1523/jneurosci.14-04-01908.1994; [No title captured]	23	82	83	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2000	404	6773					80	84		10.1038/35003577	http://dx.doi.org/10.1038/35003577			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716446				2022-12-28	WOS:000085775100049
J	Solomon, T; Dung, NM; Vaughn, DW; Kneen, R; Thao, LTT; Raengsakulrach, B; Loan, HT; Day, NPJ; Farrar, J; Myint, KSA; Warrell, MJ; James, WS; Nisalak, A; White, NJ				Solomon, T; Dung, NM; Vaughn, DW; Kneen, R; Thao, LTT; Raengsakulrach, B; Loan, HT; Day, NPJ; Farrar, J; Myint, KSA; Warrell, MJ; James, WS; Nisalak, A; White, NJ			Neurological manifestations of dengue infection	LANCET			English	Article							JAPANESE ENCEPHALITIS; VIRUSES; FEVER; IDENTIFICATION; CHILDREN; ANTIGEN; TYPE-2; LIVER; PCR	Background Severe forms of dengue, the most important arboviral infection of man, are associated with haemorrhagic disease and a generalised Vascular leak syndrome. The importance of dengue as a cause of neurological disease is uncertain. Methods During 1995, all patients with suspected CNS infections admitted to a referral hospital in southern Vietnam were investigated by culture, PCR, and antibody measurement in serum and CSF for dengue and other viruses. Findings Of 378 patients, 16 (4.2%) were infected with dengue viruses, compared with four (1.4%) of 286 hospital controls (odds ratio [95% CI] 3.1[1.7-5.8]). Five additional dengue positive patients with CNS abnormalities were studied subsequently. No other cause of CNS infection was identified. Seven infections were primary dengue, 13 secondary, and one was not classified. Ten patients had dengue viruses isolated or detected by PCR, and three had dengue antibody in the CSF. 12 of the 21 had no characteristic features of dengue on admission. The most frequent neurological manifestations were reduced consciousness and convulsions. Nine patients had encephalitis. No patient died, but six had neurological sequelae at discharge. Phylogenetic analysis of the four DEN-2 strains isolated mapped them with a DEN-2 strain isolated from a patient with dengue haemorhagic fever, and with other strains previously isolated in southern Vietnam. Interpretation In dengue endemic areas patients with encephalitis and encephalopathy should be investigated for this infection, whether or not they have other features of the disease.	Cho Quan Hosp, Wellcome Trust Clin Res Unit, Ho Chi Minh City, Vietnam; Cho Quan Hosp, Ctr Trop Dis, Ho Chi Minh City, Vietnam; Armed Forces Res Inst Med Sci, USA, Med Component, Dept Virol, Bangkok 10400, Thailand; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 2JD, England; John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med & Infect Dis, Oxford OX3 9DU, England	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); University of Oxford; University of Oxford	Solomon, T (corresponding author), Univ Liverpool, Walton Ctr Neurol & Neurosurg, Dept Neurol Sci, Lower Lane, Liverpool L9 7LJ, Merseyside, England.		james, william/H-4289-2013; Myint, Khin/HHS-2027-2022; White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019	james, william/0000-0002-2506-1198; Myint, Khin/0000-0002-2087-7331; White, Nick/0000-0002-1897-1978; Solomon, Tom/0000-0001-7266-6547				BHAMARAP.N, 1967, ANN TROP MED PARASIT, V61, P500, DOI 10.1080/00034983.1967.11686519; BURKE DS, 1985, AM J TROP MED HYG, V34, P1203, DOI 10.4269/ajtmh.1985.34.1203; BURKE T, 1968, T ROY SOC TROP MED H, V62, P682, DOI 10.1016/0035-9203(68)90120-X; CHEN W-J, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P659; CHIMELLI L, 1990, CLIN NEUROPATHOL, V9, P157; COYLE PK, 1999, NEUROBASE; DAVIS LE, 1987, INFECTIONS NERVOUS S, P156; Fong MY, 1998, RES VIROLOGY, V149, P457, DOI 10.1016/S0923-2516(99)80014-4; GUBLER DJ, 1985, AM J TROP MED HYG, V34, P170, DOI 10.4269/ajtmh.1985.34.170; Halstead Scott B., 1992, World Health Statistics Quarterly, V45, P292; Innis B. L., 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P695; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; IYNGKARAN N, 1992, LANCET, V340, P1466, DOI 10.1016/0140-6736(92)92653-W; KHO LK, 1981, SE ASIAN J TROP MED, V12, P583; KUBERSKI TT, 1977, AM J TROP MED HYG, V26, P533, DOI 10.4269/ajtmh.1977.26.533; KUNO G, 1985, J VIROL METHODS, V12, P93, DOI 10.1016/0166-0934(85)90011-4; KUO CH, 1992, AM J TROP MED HYG, V47, P265, DOI 10.4269/ajtmh.1992.47.265; LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992; Letocart M, 1997, J CLIN MICROBIOL, V35, P248, DOI 10.1128/JCM.35.1.248-253.1997; Lum LCS, 1996, AM J TROP MED HYG, V54, P256, DOI 10.4269/ajtmh.1996.54.256; MOLYNEUX ME, 1989, Q J MED, V71, P441; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; NIMMANNITA S, 1987, T R SOC TROP MED HYG, V18, P292; NIMMANNITYA S, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P398; PATEY O, 1993, AM J TROP MED HYG, V48, P793, DOI 10.4269/ajtmh.1993.48.793; Plum F, 1982, DIAGNOSIS STUPOR COM, P177; Read SJ, 1997, J CLIN MICROBIOL, V35, P691, DOI 10.1128/JCM.35.3.691-696.1997; RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; ROSEN L, 1989, RES VIROLOGY, V140, P351, DOI 10.1016/S0923-2516(89)80115-3; Row D, 1996, AM J TROP MED HYG, V54, P253, DOI 10.4269/ajtmh.1996.54.253; Solomon T, 1998, J CLIN MICROBIOL, V36, P2030, DOI 10.1128/JCM.36.7.2030-2034.1998; Solomon T, 1998, LANCET, V351, P1094, DOI 10.1016/S0140-6736(97)07509-0; Solomon T, 1996, 7 INT C INF DIS, P132; Solomon T, 1997, NEUROL INFECT EPIDEM, V2, P191; THANH ND, 1994, TROP MED, V36, P177; WHO, 1997, DENG HAEM FEV DIAGN; World Health Organization, 1975, TECHN GUID DIAGN TRE; WULUR HS, 1978, LANCET, V1, P449	39	394	421	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1053	1059		10.1016/S0140-6736(00)02036-5	http://dx.doi.org/10.1016/S0140-6736(00)02036-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744091				2022-12-28	WOS:000086380800012
J	Sexton, JB; Thomas, EJ; Helmreich, RL				Sexton, JB; Thomas, EJ; Helmreich, RL			Error, stress,and teamwork in medicine and aviation: cross sectional surveys	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COCKPIT MANAGEMENT ATTITUDES; RESOURCE-MANAGEMENT; PERFORMANCE; RATINGS	Objectives: To survey operating theatre and intensive care unit staff about altitudes concerning error, stress, and teamwork and to compare these attitudes with those of airline cockpit crew. Design: Cross sectional surveys. Setting: Urban teaching and non-teaching hospitals in the United States, Israel, Germany, Switzerland, and Italy. Major air-lines around the world. Participants: 1033 doctors, nurses, fellows, and residents working in operating theatres and intensive care units and over 30 000 cockpit crew members (captains, first officers, and second officers). Main outcome measures: Perceptions of error; stress, and teamwork. Results: Pilots were least likely to deny die effects of fatigue on performance (26% v 70% of consultant surgeons and 47% of consultant anaesthetists). Most pilots (97%) and intensive care staff (94%) rejected steep hierarchies (in which senior team members are not open to input from junior members), but only 55% of consultant surgeons rejected such hierarchies. High levels of teamwork with consultant surgeons were reported by 73% of surgical residents, 64% of consultant surgeons, 39% of anaesthesia consultants, 28% of surgical nurses, 25% of anaesthetic nurses, and 10% of anaesthetic residents. Only a third of staff reported that errors are handled appropriately at their hospital. A third of intensive care staff did not acknowledge that they make errors. Over half of intensive care staff reported that they find it difficult to discuss mistakes. Conclusions: Medical staff reported that error is important but difficult to discuss and not handled well in their hospital. Barriers to discussing error are more important since medical staff seem to deny the effect of stress and fatigue on performance. Further problems include differing perceptions of teamwork among team members and reluctance of senior theatre staff to accept input from junior members.	Univ Texas, Human Factors Res Project, Austin, TX 78701 USA; Univ Texas, Houston Med Sch, Dept Med, Div Gen Internal Med, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Dept Med, Clin Epidemiol Sect, Houston, TX 77030 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Sexton, JB (corresponding author), Univ Texas, Human Factors Res Project, 1609 Shoal Creek Blvd, Austin, TX 78701 USA.	sexton@psy.utexas.edu						COMBS AW, 1952, J ABNORM SOC PSYCH, V47, P420, DOI 10.1037/h0057196; deLeval MR, 1997, LANCET, V349, P723, DOI 10.1016/S0140-6736(96)11327-1; DONCHIN Y, 1995, CRIT CARE MED, V23, P294, DOI 10.1097/00003246-199502000-00015; EASTERBROOK JA, 1959, PSYCHOL REV, V66, P183, DOI 10.1037/h0047707; FOUSHEE HC, 1984, AM PSYCHOL, V39, P885, DOI 10.1037/0003-066X.39.8.885; Gaba DM, 1998, ANESTHESIOLOGY, V89, P8, DOI 10.1097/00000542-199807000-00005; GREGORICH SE, 1990, J APPL PSYCHOL, V75, P682, DOI 10.1037/0021-9010.75.6.682; Helmreich R L, 1991, Int J Aviat Psychol, V1, P287, DOI 10.1207/s15327108ijap0104_3; Helmreich R.L., 1998, CULTURE WORK AVIATIO; HELMREICH RL, 1984, HUM FACTORS, V26, P583, DOI 10.1177/001872088402600510; HELMREICH RL, 1986, AVIAT SPACE ENVIR MD, V57, P1198; HELMREICH RL, 1990, AVIAT SPACE ENVIR MD, V61, P576; Helmreich RL, 1999, INT J AVIAT PSYCHOL, V9, P19, DOI 10.1207/s15327108ijap0901_2; Helmreich RL, 2000, BRIT MED J, V320, P781, DOI 10.1136/bmj.320.7237.781; HELMREICH RL, 1993, 934 NASAUTFAA; HELMREICH RL, 1994, HUMAN ERROR MED; Irwin C. M., 1991, P 6 INT S AV PSYCH C, P344; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Marsch SCU, 1998, SIMULATORS IN ANESTHESIOLOGY EDUCATION, P51; MAURINO DE, 1995, AVIATION HUMAN FACTO; MERRITT AC, 1997, P OR AIRL ASS AIR SA, P123; Michaelson M, 1997, Eur J Emerg Med, V4, P94, DOI 10.1097/00063110-199706000-00007; SANDAL GM, 1999, INT J LIFE SUPPORT B, V5, P226; Santora TA, 1996, AM J EMERG MED, V14, P564, DOI 10.1016/S0735-6757(96)90100-X; Sexton B, 1998, SIMULATORS IN ANESTHESIOLOGY EDUCATION, P107; SEXTON JB, 1999, 998 U TEX; SEXTON JB, 1999, THESIS U TEXAS AUSTI; Small SD, 1999, ACAD EMERG MED, V6, P312, DOI 10.1111/j.1553-2712.1999.tb00395.x; Thomas EJ, 1999, INQUIRY-J HEALTH CAR, V36, P255; THOMAS EJ, IN PRESS MED CARE; WIENER EL, 1993, COCKPIT RESOURCE MAN	32	956	977	2	153	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2000	320	7237					745	749		10.1136/bmj.320.7237.745	http://dx.doi.org/10.1136/bmj.320.7237.745			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296YQ	10720356	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000086054700021
J	Siegel-Itzkovich, J				Siegel-Itzkovich, J			Doctors develop new treatment for cystic fibrosis	BRITISH MEDICAL JOURNAL			English	News Item																		Wilschanski M, 2000, AM J RESP CRIT CARE, V161, P860, DOI 10.1164/ajrccm.161.3.9904116	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					734	734						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720348				2022-12-28	WOS:000086054700013
J	Tchernov, E; Rieppel, O; Zaher, H; Polcyn, MJ; Jacobs, LL				Tchernov, E; Rieppel, O; Zaher, H; Polcyn, MJ; Jacobs, LL			A fossil snake with limbs	SCIENCE			English	Article							PACHYRHACHIS	A 95-million-year-old fossil snake from the Middle East documents the most extreme hindlimb development of any known member of that group, as it preserves the tibia, fibula, tarsals, metatarsals, and phalanges. It is more complete than Pachyrhachis, a second fossil snake with hindlimbs that was recently portrayed to be basal to all other snakes. Phylogenetic analysis of the relationships of the new taxon, as well as reanalysis of Pachyrhachis, shows both to be related to macrostomatans, a group that includes relatively advanced snakes such as pythons, boas, and colubroids to the exclusion of more primitive snakes such as blindsnakes and pipesnakes.	Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA; Hebrew Univ Jerusalem, Dept Evolut Syst & Ecol, IL-91904 Jerusalem, Israel; Univ Sao Paulo, Dept Zool, Inst Biociencias, BR-05508900 Sao Paulo, Brazil; So Methodist Univ, Shuler Museum Paleontol, Dallas, TX 75275 USA	Field Museum of Natural History (Chicago); Hebrew University of Jerusalem; Universidade de Sao Paulo; Southern Methodist University	Rieppel, O (corresponding author), Field Museum Nat Hist, Dept Geol, 1400 S Lake Shore Dr, Chicago, IL 60605 USA.	rieppel@fmnh.org	Zaher, Hussam/ABC-1701-2021; Zaher, Hussam/D-4000-2012	Zaher, Hussam/0000-0002-6994-489X; Zaher, Hussam/0000-0002-6994-489X				BARRIE DJ, 1990, MEMOIRS QUEENSLAND M, V28, P139; Caldwell MW, 1997, NATURE, V386, P705, DOI 10.1038/386705a0; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; Greene HW., 1997, SNAKES; GREER AE, 1991, J HERPETOL, V25, P166, DOI 10.2307/1564644; Haas G., 1980, P177; HAAS G, 1980, Bulletin du Museum National d'Histoire Naturelle Section C Sciences de la Terre Paleontologie Geologie Mineralogie, V2, P87; HAAS G, 1979, Bulletin du Museum National d'Histoire Naturelle Section C Sciences de la Terre Paleontologie Geologie Mineralogie, V1, P51; Kluge A.G., 1991, MISCELLANEOUS PUBLIC, V178, P1; Lee MSY, 1999, NATURE, V400, P655, DOI 10.1038/23236; Lee MSY, 1999, J ZOOL, V248, P509, DOI 10.1017/S0952836999008109; Lee MSY, 1998, BIOL J LINN SOC, V65, P369, DOI 10.1111/j.1095-8312.1998.tb01148.x; Lee MSY, 1998, PHILOS T ROY SOC B, V353, P1521, DOI 10.1098/rstb.1998.0308; Nopcsa, 1923, PALAEONTOGRAPHICA, V65, P99; Polcyn Michael J., 1999, National Science Museum Monographs, V15, P259; Rage J.C., 1984, ENCY PALEOHERPETOLOG, P1; RAGE JC, 1982, CR ACAD SCI II, V294, P563; RIEPPEL O, IN PRESS ZOOL J LINN; RIEPPEL O, 2000, FIELDIANA GEOL, V43, P1, DOI DOI 10.5962/BHL.TITLE.3584; Scanlon J.D., 1999, Historical Biology, V13, P127; Scanlon JD, 2000, NATURE, V403, P416, DOI 10.1038/35000188; Zaher H, 1998, J VERTEBR PALEONTOL, V18, P1, DOI 10.1080/02724634.1998.10011029; Zaher H, 1999, CR ACAD SCI II A, V329, P831, DOI 10.1016/S1251-8050(00)88639-5; Zaher Hussam, 1999, American Museum Novitates, V3271, P1	24	172	176	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2010	2012		10.1126/science.287.5460.2010	http://dx.doi.org/10.1126/science.287.5460.2010			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720326				2022-12-28	WOS:000085902800060
J	Zhu, XK; O'Nions, RK; Guo, YL; Reynolds, BC				Zhu, XK; O'Nions, RK; Guo, YL; Reynolds, BC			Secular variation of iron isotopes in North Atlantic Deep Water	SCIENCE			English	Article							EQUATORIAL PACIFIC-OCEAN; PHYTOPLANKTON; CRUSTS	A high-precision iron isotope time series for a ferromanganese crust demonstrates that the iron isotope composition in North Atlantic Deep Water has changed substantially over the past 6 million years and that iron isotope variations in the crust are closely correlated to those of Lead isotopes. The close correlation between the two isotope series indicates that the observed iron isotope variations predominantly reflect those of iron input from terrigenous sources and provides no evidence for biologically induced mass fractionation within North Atlantic Deep Water.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	University of Oxford	Zhu, XK (corresponding author), Univ Oxford, Dept Earth Sci, Parks Rd, Oxford OX1 3PR, England.							Abouchami W, 1999, GEOCHIM COSMOCHIM AC, V63, P1489, DOI 10.1016/S0016-7037(99)00068-X; Beard BL, 1999, SCIENCE, V285, P1889, DOI 10.1126/science.285.5435.1889; Beard BL, 1999, GEOCHIM COSMOCHIM AC, V63, P1653, DOI 10.1016/S0016-7037(99)00089-7; Belshaw NS, 2000, INT J MASS SPECTROM, V197, P191, DOI 10.1016/S1387-3806(99)00245-6; BEWERS JM, 1977, NATURE, V268, P595, DOI 10.1038/268595a0; Burton KW, 1997, NATURE, V386, P382, DOI 10.1038/386382a0; Christensen JN, 1997, SCIENCE, V277, P913, DOI 10.1126/science.277.5328.913; Cooper DJ, 1996, NATURE, V383, P511, DOI 10.1038/383511a0; DEBAAR HJW, 1995, NATURE, V373, P412, DOI 10.1038/373412a0; DUCE RA, 1991, LIMNOL OCEANOGR, V36, P1715, DOI 10.4319/lo.1991.36.8.1715; Johnson KS, 1997, MAR CHEM, V57, P137, DOI 10.1016/S0304-4203(97)00043-1; KOLBER ZS, 1994, NATURE, V371, P145, DOI 10.1038/371145a0; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; O'Nions RK, 1998, EARTH PLANET SC LETT, V155, P15, DOI 10.1016/S0012-821X(97)00207-0; PIEPGRAS DJ, 1979, EARTH PLANET SC LETT, V45, P223, DOI 10.1016/0012-821X(79)90125-0; Polyakov VB, 1997, GEOCHIM COSMOCHIM AC, V61, P4213, DOI 10.1016/S0016-7037(97)00204-4; Price NM, 1998, MET IONS BIOL SYST, V35, P1; Reynolds BC, 1999, EARTH PLANET SC LETT, V173, P381, DOI 10.1016/S0012-821X(99)00243-5; von Blanckenburg F, 1996, EARTH PLANET SC LETT, V141, P213, DOI 10.1016/0012-821X(96)00059-3; WELLS ML, 1995, MAR CHEM, V48, P157, DOI 10.1016/0304-4203(94)00055-I; WU J, 1997, ANAL CHIM ACTA, V367, P183; Zhu XK, 2000, CHEM GEOL, V163, P139, DOI 10.1016/S0009-2541(99)00076-5	23	137	180	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2000	2002		10.1126/science.287.5460.2000	http://dx.doi.org/10.1126/science.287.5460.2000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720322				2022-12-28	WOS:000085902800056
J	Dalakas, MC; Park, KY; Semino-Mora, C; Lee, HS; Sivakumar, K; Goldfarb, LG				Dalakas, MC; Park, KY; Semino-Mora, C; Lee, HS; Sivakumar, K; Goldfarb, LG			Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MICE LACKING DESMIN; ALPHA-B-CRYSTALLIN; MYOFIBRILLAR MYOPATHY; INTERMEDIATE FILAMENTS; NULL MUTATION; MUSCLE; POSITIVITY; EXPRESSION; PROTEINS; VACUOLES	Background: Myofibrillar myopathies are a heterogeneous group of inherited or sporadic skeletal myopathies associated with cardiomyopathy. Among the myofibrillar proteins that accumulate within the muscle fibers of affected patients, the one found most consistently is desmin, an intermediate-filament protein responsible for the structural integrity of the myofibrils. Skeletal and cardiac myopathy develops in mice that lack desmin, suggesting that mutations in the desmin gene may be pathogenic. Methods: We examined 22 patients from 8 families with dominantly inherited myofibrillar or desmin-related myopathy and 2 patients with sporadic disease and analyzed the desmin gene for mutations, using complementary DNA (cDNA) amplified from muscle-biopsy specimens and genomic DNA extracted from blood lymphocytes. Restriction-enzyme analysis was used to confirm the mutations. Expression vectors containing normal or mutant desmin cDNA were introduced into cultured cells to determine whether the mutant desmin formed intermediate filaments. Results: Six missense mutations in the coding region of the desmin gene that cause the substitution of an amino acid were identified in 11 patients (10 members of 4 families and 1 patient with sporadic disease); a splicing defect that resulted in the deletion of exon 3 was identified in the other patient with sporadic disease. Mutations were clustered in the carboxy-terminal part of the rod domain, which is critical for filament assembly. In transfected cells, the mutant desmin was unable to form a filamentous network. Seven of the 12 patients with mutations in the desmin gene had cardiomyopathy. Conclusions: Mutations in the desmin gene affecting intermediate filaments cause a distinct myopathy that is often associated with cardiomyopathy and is termed "desmin myopathy.'' The mutant desmin interferes with the normal assembly of intermediate filaments, resulting in fragility of the myofibrils and severe dysfunction of skeletal and cardiac muscles. (N Engl J Med 2000;342:770-80.) (C)2000, Massachusetts Medical Society.	NINDS, Neuromuscular Dis Sect, NIH, Bethesda, MD 20892 USA; NINDS, Clin Neurogenet Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Dalakas, MC (corresponding author), NINDS, Neuromuscular Dis Sect, NIH, Bldg 10,Rm 4N248,10 Ctr Dr,MSC 1382, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002038, ZIANS002973, Z01NS002973] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amato AA, 1998, NEUROLOGY, V51, P1646, DOI 10.1212/WNL.51.6.1646; Banwell BL, 1999, J NEUROPATH EXP NEUR, V58, P832, DOI 10.1097/00005072-199908000-00006; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; Capetanaki Y, 1997, CELL STRUCT FUNCT, V22, P103, DOI 10.1247/csf.22.103; DALAKAS MC, 1997, SCI AM MED, V3; DeBleecker JL, 1996, J NEUROPATH EXP NEUR, V55, P563, DOI 10.1097/00005072-199605000-00009; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Goebel HH, 1997, CURR OPIN NEUROL, V10, P426, DOI 10.1097/00019052-199710000-00012; Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300; Hijikata T, 1999, J CELL SCI, V112, P867; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Munoz-Marmol AM, 1998, P NATL ACAD SCI USA, V95, P11312, DOI 10.1073/pnas.95.19.11312; Nakano S, 1997, J NEUROPATH EXP NEUR, V56, P850, DOI 10.1097/00005072-199708000-00002; Nakano S, 1996, J NEUROPATH EXP NEUR, V55, P549, DOI 10.1097/00005072-199605000-00008; RAATS JMH, 1991, EUR J CELL BIOL, V56, P84; Raats JMH, 1996, EUR J CELL BIOL, V71, P221; Semino-Mora C, 1998, HUM PATHOL, V29, P1128, DOI 10.1016/S0046-8177(98)90425-7; Sivakumar K, 1996, NEUROLOGY, V46, P1337, DOI 10.1212/WNL.46.5.1337; Sjoberg G, 1999, HUM MOL GENET, V8, P2191, DOI 10.1093/hmg/8.12.2191; Sjuve R, 1998, J MUSCLE RES CELL M, V19, P415, DOI 10.1023/A:1005353805699; Thornell LE, 1997, J MOL CELL CARDIOL, V29, P2107, DOI 10.1006/jmcc.1997.0446; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Vicart P, 1996, HUM GENET, V98, P422, DOI 10.1007/s004390050233; Watson PA, 1996, AM J PHYSIOL-CELL PH, V270, pC1228, DOI 10.1152/ajpcell.1996.270.4.C1228; Weitzer G, 1995, DEV BIOL, V172, P422, DOI 10.1006/dbio.1995.8070; YU KR, 1994, P NATL ACAD SCI USA, V91, P2497, DOI 10.1073/pnas.91.7.2497	31	322	337	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2000	342	11					770	780		10.1056/NEJM200003163421104	http://dx.doi.org/10.1056/NEJM200003163421104			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293HW	10717012				2022-12-28	WOS:000085846900004
J	Fagiolini, M; Hensch, TK				Fagiolini, M; Hensch, TK			Inhibitory threshold for critical-period activation in primary visual cortex	NATURE			English	Article							EXPERIENCE-DEPENDENT PLASTICITY; OCULAR DOMINANCE PLASTICITY; LONG-TERM POTENTIATION; ORIENTATION SELECTIVITY; MONOCULAR DEPRIVATION; RAT; MATURATION; DEFICIENT; SYNAPSES; SYSTEM	Neuronal circuits across several systems display remarkable plasticity to sensory input during postnatal development(1-10) Experience-dependent refinements are often restricted to well-defined critical periods in early life, but how these are established remains mostly unknown. A representative example is the loss of responsiveness in neocortex to an eye deprived of vision(2-6). Here we show that the potential for plasticity is retained throughout life until an inhibitory threshold is attained. In mice of all ages lacking an isoform of GABA (gamma-aminobutyric acid) synthetic enzyme (GAD65), as well as in immature wild-type animals before the onset of their natural critical period, benzodiazepines selectively reduced a prolonged discharge phenotype to unmask plasticity. Enhancing GABA-mediated transmission early in life rendered mutant animals insensitive to monocular deprivation as adults, similar to normal wild-type mice. Short-term presynaptic dynamics reflected a synaptic reorganization in GAD65 knockout mice after chronic diazepam treatment. A threshold level of inhibition within the visual cortex may thus trigger, once in life, an experience-dependent critical period for circuit consolidation, which may otherwise lie dormant.	RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dev, Wako, Saitama 3510198, Japan	RIKEN	Hensch, TK (corresponding author), RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dev, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Hensch, Takao/L-4182-2019	fagiolini, michela/0000-0003-2807-803X				Bear M F, 1993, Curr Opin Neurobiol, V3, P197, DOI 10.1016/0959-4388(93)90210-P; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DAW N, 1995, VISUAL DEV; DELCERRO S, 1992, NEUROSCIENCE, V49, P1, DOI 10.1016/0306-4522(92)90071-9; Doupe AJ, 1999, ANNU REV NEUROSCI, V22, P567, DOI 10.1146/annurev.neuro.22.1.567; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Feldman DE, 1998, NEURON, V20, P1067, DOI 10.1016/S0896-6273(00)80488-2; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; Finnerty GT, 1999, NATURE, V400, P367, DOI 10.1038/22553; FOX K, 1992, J NEUROSCI, V12, P1826; Gordon JA, 1996, J NEUROSCI, V16, P3274; GU Q, 1994, P NATL ACAD SCI USA, V91, P8408, DOI 10.1073/pnas.91.18.8408; Hensch TK, 1998, J NEUROSCI, V18, P2108; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; Kash SF, 1997, P NATL ACAD SCI USA, V94, P14060, DOI 10.1073/pnas.94.25.14060; Knudsen EI, 1998, SCIENCE, V279, P1531, DOI 10.1126/science.279.5356.1531; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247, DOI 10.1152/jn.1991.65.2.247; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MATAGA N, 1992, NEUROSCI LETT, V142, P115, DOI 10.1016/0304-3940(92)90352-8; Maurer D, 1999, SCIENCE, V286, P108, DOI 10.1126/science.286.5437.108; MOWER GD, 1985, J NEUROPHYSIOL, V53, P572, DOI 10.1152/jn.1985.53.2.572; MULLER CM, 1989, NATURE, V342, P427, DOI 10.1038/342427a0; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; PETTIGREW JD, 1978, NATURE, V271, P761, DOI 10.1038/271761a0; SCOTT JP, 1962, SCIENCE, V138, P949, DOI 10.1126/science.138.3544.949; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1	30	478	489	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					183	186		10.1038/35004582	http://dx.doi.org/10.1038/35004582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724170				2022-12-28	WOS:000085870900051
J	Stephens, BB; Keeling, RF				Stephens, BB; Keeling, RF			The influence of Antarctic sea ice on glacial-interglacial CO2 variations	NATURE			English	Article							ATMOSPHERIC CO2; SOUTHERN-OCEAN; WATER; PRESERVATION; TEMPERATURE; CIRCULATION; CADMIUM	Ice-core measurements indicate that atmospheric CO2 concentrations during glacial periods were consistently about 80 parts per million lower than during interglacial periods(1). Previous explanations for this observation(2-9) have typically had difficulty accounting for either the estimated glacial O-2 concentrations in the deep sea, C-13/C-12 ratios in Antarctic surface waters, or the depth of calcite saturation; also lacking is an explanation for the strong link between atmospheric CO2 and Antarctic air temperature(1). There is growing evidence that the amount of deep water upwelling at low latitudes is significantly overestimated in most ocean general circulation models(10,11) and simpler box models previously used to investigate this problem. Here we use a box model with deep-water upwelling confined to south of 55 degrees S to investigate the glacial-interglacial linkages between Antarctic air temperature and atmospheric CO2 variations. We suggest that low glacial atmospheric CO2 levels might result from reduced deep-water ventilation associated with either year-round Antarctic sea-ice coverage, or wintertime coverage combined with ice-induced stratification during the summer. The model presented here reproduces 67 parts per million of the observed glacial-interglacial CO2 difference, as a result of reduced air-sea gas exchange in the Antarctic region, and is generally consistent with the additional observational constraints.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Stephens, BB (corresponding author), Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA.		Stephens, Britton B/B-7962-2008	Stephens, Britton B/0000-0002-1966-6182				ARCHER D, 1994, NATURE, V367, P260, DOI 10.1038/367260a0; BERGER WH, 1977, NATURE, V269, P301, DOI 10.1038/269301a0; BOYLE EA, 1992, ANNU REV EARTH PL SC, V20, P245, DOI 10.1146/annurev.ea.20.050192.001333; BOYLE EA, 1988, J GEOPHYS RES-OCEANS, V93, P15701, DOI 10.1029/JC093iC12p15701; Broecker W. S, 1998, GREENHOUSE PUZZLES; BROECKER WS, 1993, PALEOCEANOGRAPHY, V8, P137, DOI 10.1029/93PA00262; BROECKER WS, 1985, J GEOPHYS RES-OCEANS, V90, P6925, DOI 10.1029/JC090iC04p06925; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P352, DOI 10.1029/98PA00920; Broecker WS, 1998, J GEOPHYS RES-OCEANS, V103, P15833, DOI 10.1029/98JC00248; CHARLES CD, 1990, NATO ADV SCI I C-MAT, V308, P519; Cooke D. W., 1982, ANTARCT GEOSCI, P1017; Crosta X., 1999, GEOPHYS RES LETT, V26, P1865; Francois R, 1997, NATURE, V389, P929, DOI 10.1038/40073; Gnanadesikan A, 1999, GEOPHYS RES LETT, V26, P1865, DOI 10.1029/1999GL900379; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; KNOX F, 1984, J GEOPHYS RES-ATMOS, V89, P4629, DOI 10.1029/JD089iD03p04629; MARINO BD, 1992, NATURE, V357, P461, DOI 10.1038/357461a0; MARTIN J, 1990, ORGAN SCI, V1, P1; McCartney M. S., 1979, VOYAGE DISCOVERY G D, P103; MOLINELLI EJ, 1981, J MAR RES, V39, P267; OPDYKE BN, 1992, GEOLOGY, V20, P733, DOI 10.1130/0091-7613(1992)020<0733:ROTCRH>2.3.CO;2; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Robbins PE, 1997, DEEP-SEA RES PT I, V44, P879, DOI 10.1016/S0967-0637(96)00126-4; SARMIENTO JL, 1984, NATURE, V308, P621, DOI 10.1038/308621a0; SIEGENTHALER U, 1984, NATURE, V308, P624, DOI 10.1038/308624a0; Smith HJ, 1999, NATURE, V400, P248, DOI 10.1038/22291; Toggweiler JR, 1999, PALEOCEANOGRAPHY, V14, P571, DOI 10.1029/1999PA900033; TOGGWEILER JR, 1985, CARBON CYCLE ATMOSPH, P163; TOGGWEILER JR, 1993, GLOBAL CARBON CYCLE, P333; Tomczak M., 1994, REGIONAL OCEANOGRAPH, P67, DOI [10.1016/B978-0-08-041021-0.50010-2, DOI 10.1016/B978-0-08-041021-0.50010-2]	30	355	364	1	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					171	174		10.1038/35004556	http://dx.doi.org/10.1038/35004556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724166				2022-12-28	WOS:000085870900047
J	Tiedemann, MW				Tiedemann, MW			The song of the Neanderthal	NATURE			English	Editorial Material																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					127	127		10.1038/35004676	http://dx.doi.org/10.1038/35004676			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724146	Bronze			2022-12-28	WOS:000085870900024
J	Sees, KL; Delucchi, KL; Masson, C; Rosen, A; Clark, HW; Robillard, H; Banys, P; Hall, SM				Sees, KL; Delucchi, KL; Masson, C; Rosen, A; Clark, HW; Robillard, H; Banys, P; Hall, SM			Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSTIC INTERVIEW SCHEDULE; SUBSTANCE-ABUSE TREATMENT; ADDICTION SEVERITY INDEX; FOLLOW-UP; COCAINE ABUSERS; VALIDITY; PHARMACOTHERAPY; PSYCHOTHERAPY; RELIABILITY; SERVICES	Context Despite evidence that methadone maintenance treatment (MMT) is effective for opioid dependence, it remains a controversial therapy because of its indefinite provision of a dependence-producing medication. Objective To compare outcomes of patients with opioid dependence treated with MMT vs an alternative treatment, psychosocially enriched 180-day methadone-assisted detoxification. Design Randomized controlled trial conducted from May 1995 to April 1999. Setting Research clinic In an established drug treatment service. Patients Of 858 volunteers screened, 179 adults with diagnosed opioid depen dence were randomized into the study, 154 completed 12 weeks of follow-up. Interventions Patients were randomized to MMT (n = 91), which required 2 hours of psychosocial therapy per week during the first 6 months; or detoxification (n = 88), which required 3 hours of psychosocial therapy per week, 14 education sessions, and 1 hour of cocaine group therapy, if appropriate, for 6 months, and 6 months of (non-methadone) aftercare services. Main Outcome Measures Treatment retention, heroin and cocaine abstinence (by self-report and monthly urinalysis), human immunodeficiency virus (HIV) risk behaviors (Risk of AIDS Behavior scale store), and function in 5 problem areas: employment, family, psychiatric, legal,:and alcohol use (Addiction Severity Index), compared by intervention group. Results Methadone maintenance therapy resulted in greater treatment retention (median, 438.5 vs 174.0 days) and lower heroin use rates than did detoxification, Cocaine use was more closely related to study dropout in detoxification than in MMT, Methadone maintenance therapy resulted in a lower rate of drug-related (mean [SD] at 12 months, 2.17 [3.88] vs 3.73 [6.86]) but not sex-related HIV risk behaviors and in a lower severity score for legal status (mean [SD] at 12 months, 0.05 [0.13] vs 0.13 [0.19]). There were no differences between groups in employment or family functioning or alcohol use. In both groups, monthly heroin use rates were 50% or greater, but days of use per month dropped markedly from baseline. Conclusions Our results confirm the usefulness of MMT in reducing heroin use and HIV risk behaviors. Illicit opioid use continued in both groups, but frequency was reduced. Results do not provide support for diverting resources from MMT into longterm detoxification.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; San Francisco Vet Affairs Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Hall, SM (corresponding author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave,Box 0984-TRC, San Francisco, CA 94143 USA.				NIDA NIH HHS [2P50 DA09253] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA009253] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BALL JC, 1988, J HEALTH SOC BEHAV, V29, P214, DOI 10.2307/2137033; BURNAM MA, 1983, ARCH GEN PSYCHIAT, V40, P1189; CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P989; CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P177; Crits-Christoph P, 1999, ARCH GEN PSYCHIAT, V56, P493, DOI 10.1001/archpsyc.56.6.493; Diggle PJ, 1994, ANAL LONGITUDINAL DA; ERDMAN HP, 1992, J PSYCHIAT RES, V26, P85, DOI 10.1016/0022-3956(92)90019-K; HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218; HUBBARD RL, 1984, TREATMENT OUTCOME PR, P42; KOSTEN TR, 1986, AM J DRUG ALCOHOL AB, V12, P1, DOI 10.3109/00952998609083739; LEVITAN RD, 1991, CAN J PSYCHIAT, V36, P728; MANN AR, 1982, AM J DRUG ALCOHOL AB, V19, P289; Maude-Griffin PM, 1998, J CONSULT CLIN PSYCH, V66, P832, DOI 10.1037/0022-006X.66.5.832; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; MCLELLAN AT, 1992, J NERV MENT DIS, V180, P101, DOI 10.1097/00005053-199202000-00007; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; METZGER D, 1991, AM J PSYCHIAT, V148, P636; RESNICK R, 1983, RES TREATMENT NARCOT, P160; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SIMPSON DD, 1982, ARCH GEN PSYCHIAT, V39, P1318; SIMPSON DD, 1979, ARCH GEN PSYCHIAT, V36, P772; SORENSEN JL, 1982, ARCH GEN PSYCHIAT, V39, P167; *US DHHS, 1999, NEW DAT SHOWS OP TAK; Wasserman DA, 1998, DRUG ALCOHOL DEPEN, V52, P183, DOI 10.1016/S0376-8716(98)00092-1; WOODY GE, 1983, ARCH GEN PSYCHIAT, V40, P25; ZANIS DA, 1994, J SUBST ABUSE TREAT, V11, P541, DOI 10.1016/0740-5472(94)90005-1; 1989, FED REG, V54, P8954	27	291	297	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2000	283	10					1303	1310		10.1001/jama.283.10.1303	http://dx.doi.org/10.1001/jama.283.10.1303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	289ND	10714729	Bronze			2022-12-28	WOS:000085628100026
J	de Silva, S; Fisher, CA; Premawardhena, A; Lamabadusuriya, SP; Peto, TEA; Perera, G; Old, JM; Clegg, JB; Olivieri, NF; Weatherall, DJ				de Silva, S; Fisher, CA; Premawardhena, A; Lamabadusuriya, SP; Peto, TEA; Perera, G; Old, JM; Clegg, JB; Olivieri, NF; Weatherall, DJ		Sri Lanka Thalassaemia Study Grp	Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations	LANCET			English	Article							THALASSEMIA	Background Thalassaemias pose an increasing problem for the Indian subcontinent and many Asian countries. We analysed the different types of thalassaemia in the Sri Lankan population, surveyed gene frequencies in schoolchildren. and estimated the burden of disease and requirements for its control. Methods We analysed blood samples from patients attending clinics in nine hospitals and defined the different types of beta thalassaemia by high-performance liquid chromatography (HPLC) and DNA analysis. The range of mutations was obtained by analysis of beta-globin genes. Capillary blood was obtained from schoolchildren from different parts of the island and analysed by HPLC to provide an approximate assessment of the carrier frequency of beta thalassaemia and haemoglobin E (HbE). To estimate the frequency of or thalassaemia the cr-globin genotypes were also analysed when it was possible. Findings Blood samples were obtained from 703 patients with beta thalassaemia and from 1600 schoolchildren. The thalassaemia mutations were unevenly spread. Although 23 different beta-thalassaemia mutations were found, three accounted for the thalassaemia phenotype in about 70% of the patients, most whom are homozygotes or compound heterozygotes for IVS1-5 (G-->C) or IVS1-1 (G-->A). The third common mutation, codon 26 (G-->A), which produces HbE, interacts with one or other of these mutations to produce HbE/beta thalassaemia; this comprises 13.0-30.9% of cases in the main centres. Samples from 472 patients were analysed to determine the alpha-globin genotype. Overall, 15.5% patients were carriers for deletion forms of alpha(+) thalassaemia. Average gene frequencies showed that there will be more than 2000 patients requiring treatment at any one time, in the future, of whom those with HbE/beta thalassaemia will account for about 40%. Interpretation In Sri Lanka, interactions of the two common beta-thalassaemia alleles will nearly always result in a transfusion-dependent disorder. However, about 40% of patients will have HbE/beta thalassaemia, which has a variable course. The management of these disorders could require about 5% of the total health budget. We need to learn more about the natural history and appropriate management of HbE/beta thalassaemia if resources are to be used effectively.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; Gen Hosp, Thalassaemia Unit, Kurunegala, Sri Lanka; John Radcliffe Hosp, Natl Haemoglobin Reference Lab, Oxford OX3 9DU, England; John Radcliffe Hosp, MRC, Mol Haematol Unit, Oxford OX3 9DU, England; Univ Colombo, Dept Paediat, Colombo, Sri Lanka; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Toronto Gen Hosp, Toronto, ON, Canada	University of Oxford; University of Oxford; University of Oxford; University of Colombo; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Weatherall, DJ (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.		Premawardhena, Anuja/GLN-5388-2022; Olivieri, Nancy/AAI-2250-2020	Premawardhena, Anuja/0000-0003-0605-9081; 				[Anonymous], 1993, WORLD DEV REPORT; BLACKWELL RQ, 1974, TROP GEOGR MED, V26, P214; Bodmer W. F., 1976, GENETICS EVOLUTION M; DESILVA CC, 1951, ARCH DIS CHILD, V26, P99; DESILVA CC, 1959, ABNORMAL HAEMOGLOBIN, P340; *EEC, 1999, PREV GEN VAR THAL IN; Ellepola S B, 1980, Ceylon Med J, V25, P29; HIGGS DR, 1993, BAILLIERE CLIN HAEM, V6, P117, DOI 10.1016/S0950-3536(05)80068-X; HUISMAN THJ, 1997, SYLLABUS THALASSAEMI; *MIN HLTH SRI LANK, 1996, ANN HLTH B; NAGARATNAM N, 1989, HEMOGLOBIN, V13, P201, DOI 10.3109/03630268908998074; Old J. M, 1983, METHODS HAEMATOLOGY, P74; OLD JM, 1990, LANCET, V336, P834, DOI 10.1016/0140-6736(90)92338-I; Rees DC, 1998, ANN NY ACAD SCI, V850, P334, DOI 10.1111/j.1749-6632.1998.tb10490.x; Weatherall DJ, 1996, NAT MED, V2, P847, DOI 10.1038/nm0896-847; WEATHERALL DJ, IN PRESS THALASSAEMI; WICKREMASINGHE RL, 1963, J R ANTHR I, V93, P117; World Health Organization, 1994, GUID CONTR HAEM DIS	18	109	110	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					786	791		10.1016/S0140-6736(99)08246-X	http://dx.doi.org/10.1016/S0140-6736(99)08246-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711926				2022-12-28	WOS:000085766900010
J	Rowsell, M; Bello, M; Hemingway, DM				Rowsell, M; Bello, M; Hemingway, DM			Circumferential mucosectomy (stapled haemorrhoidectomy) versus conventional haemorrhoidectomy: randomised controlled trial	LANCET			English	Article							DIATHERMY HEMORRHOIDECTOMY; PAIN	Background Haemorrhoidectomy is commonly an inpatient procedure because it is frequently associated with postoperative pain. Day case haemorrhoidectomy is a similar operation to that used on inpatients but with different strategies for managing postoperative pain. Circumferential mucosectomy (stapled haemorrhoidectomy) may be associated with less postoperative pain than conventional haemorrhoidectomy. We compared stapled haemorrhoidectomy with conventional haemorrhoidectomy in patients with third degree haemorrhoids, Methods We randomly assigned 22 patients to conventional haemorrhoidectomy by the diathermy dissection or to stapled haemorrhoidectomy with the use of an intraluminal stapling device, Patients were discharged when free of pain, took cocodamol as required, completed visual analogue charts each day, and were assessed at 1 and 6 weeks postoperatively for symptom control. Findings All patients received the assigned treatment. Mean inpatient slay was lower in the group assigned to stapled as opposed to conventional haemorrhoidectomy (1.09 [0.3] vs 2.82 [0.09] nights, p<0.001), experienced less pain overall (p=0.003), and returned to normal activities sooner (8.1[1.53] vs 16.9 [2.33] days, p<0.005). Stapled haemorrhoidectomy controlled symptoms of prolapse, discharge and bleeding in all patients. Interpretation Stapled haemorrhoidectomy is an effective treatment for third degree haemorrhoids with significant advantages for patients compared with conventional haemorrhoidectomy.	Leicester Royal Infirm, Dept Gastroenterol & Gen Surg, Leicester LE1 5WW, Leics, England	University of Leicester	Hemingway, DM (corresponding author), Leicester Royal Infirm, Dept Gastroenterol & Gen Surg, Infirm Sq, Leicester LE1 5WW, Leics, England.							ANDREWS BT, 1993, DIS COLON RECTUM, V36, P580, DOI 10.1007/BF02049865; Carapeti EA, 1998, LANCET, V351, P169, DOI 10.1016/S0140-6736(97)09003-X; Hunt L, 1999, BRIT J SURG, V86, P255, DOI 10.1046/j.1365-2168.1999.01024.x; LEICESTER RJ, 1981, DIS COLON RECTUM, V24, P602, DOI 10.1007/BF02605755; LEWIS AM, 1983, BRIT J SURG, V70, P45; Longo A, 1998, 6TH WORLD CONGRESS OF ENDOSCOPIC SURGERY, PTS 1 AND 2, P777; Milligan ETC, 1937, LANCET, V2, P1119; MURIE JA, 1982, BRIT J SURG, V69, P536, DOI 10.1002/bjs.1800690913; Patel N, 1996, AUST NZ J SURG, V66, P830, DOI 10.1111/j.1445-2197.1996.tb00760.x; Pescatori M, 1997, TECH COLOPROCTOL, V1, P96; ROE AM, 1987, BRIT J SURG, V74, P948, DOI 10.1002/bjs.1800741022; SENAGORE A, 1993, DIS COLON RECTUM, V36, P1042, DOI 10.1007/BF02047297; SHARIF HI, 1991, INT J COLORECTAL DIS, V6, P217, DOI 10.1007/BF00341395; SMITH LE, 1979, DIS COLON RECTUM, V22, P10, DOI 10.1007/BF02586749; THOMSON WHF, 1975, BRIT J SURG, V62, P542, DOI 10.1002/bjs.1800620710	15	267	285	1	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					779	781		10.1016/S0140-6736(99)06122-X	http://dx.doi.org/10.1016/S0140-6736(99)06122-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711924				2022-12-28	WOS:000085766900008
J	Turney, JH				Turney, JH			Renal conservation for gas-forming infections	LANCET			English	Editorial Material							EMPHYSEMATOUS PYELONEPHRITIS		Gen Infirm, Dept Renal Med, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Turney, JH (corresponding author), Gen Infirm, Dept Renal Med, Leeds LS1 3EX, W Yorkshire, England.							Best CD, 1999, J UROLOGY, V162, P1273, DOI 10.1016/S0022-5347(05)68263-8; Chen MT, 1997, J UROLOGY, V157, P1569, DOI 10.1016/S0022-5347(01)64797-9; EVANOFF GV, 1987, AM J MED, V83, P149, DOI 10.1016/0002-9343(87)90511-0; Kelly HA, 1898, JAMA-J AM MED ASSOC, V31, P375, DOI [10.1001/jama.1898.92450080001001, DOI 10.1001/JAMA.1898.92450080001001]; MICHAELI J, 1984, J UROLOGY, V131, P203, DOI 10.1016/S0022-5347(17)50309-2; Patterson JE, 1997, INFECT DIS CLIN N AM, V11, P735, DOI 10.1016/S0891-5520(05)70383-4; Wan YL, 1998, J UROLOGY, V159, P369, DOI 10.1016/S0022-5347(01)63919-3; Wan YL, 1996, RADIOLOGY, V198, P433, DOI 10.1148/radiology.198.2.8596845	8	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					770	771		10.1016/S0140-6736(99)00351-7	http://dx.doi.org/10.1016/S0140-6736(99)00351-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711921				2022-12-28	WOS:000085766900005
J	Campbell, M; Sharp, DN; Harrison, MT; Denning, RG; Turberfield, AJ				Campbell, M; Sharp, DN; Harrison, MT; Denning, RG; Turberfield, AJ			Fabrication of photonic crystals for the visible spectrum by holographic lithography	NATURE			English	Article							BAND-STRUCTURE; SPONTANEOUS EMISSION; GAP; ARRAYS; ATOMS; LIGHT	The term 'photonics' describes a technology whereby data transmission and processing occurs largely or entirely by means of photons. photonic crystals are microstructured materials in which the dielectric constant is periodically modulated on a length scale comparable to the desired wavelength of operation. Multiple interference between waves scattered fr om each unit cell of the structure may open a 'photonic bandgap'-a range of frequencies, analogous to the electronic bandgap of a semiconductor, within which no propagating electromagnetic modes exist(1-3). Numerous device principles that exploit this property have been identified(4-8). Considerable progress has now been made in constructing two-dimensional structures using conventional lithography(3), but the fabrication of three-dimensional photonic crystal structures for the visible spectrum remains a considerable challenge. Here we describe a technique-three-dimensional holographic lithography-that is well suited to the production of three-dimensional structures with sub-micrometre periodicity. With this technique we have made microperiodic polymeric structures, and we have used these as templates to create complementary structures with higher refractive-index contrast.	Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England; Univ Oxford, Inorgan Chem Lab, Dept Chem, Oxford OX1 3QR, England	University of Oxford; University of Oxford	Turberfield, AJ (corresponding author), Univ Oxford, Dept Phys, Clarendon Lab, Parks Rd, Oxford OX1 3PU, England.		Turberfield, Andrew J/O-2135-2017	Turberfield, Andrew J/0000-0002-3876-0190				Berger V, 1997, J APPL PHYS, V82, P60, DOI 10.1063/1.365849; Cheng CC, 1997, J VAC SCI TECHNOL B, V15, P2764, DOI 10.1116/1.589723; Cumpston BH, 1999, NATURE, V398, P51, DOI 10.1038/17989; Fan SH, 1997, PHYS REV LETT, V78, P3294, DOI 10.1103/PhysRevLett.78.3294; Fleming JG, 1999, OPT LETT, V24, P49, DOI 10.1364/OL.24.000049; Foresi JS, 1997, NATURE, V390, P143, DOI 10.1038/36514; GRYNBERG G, 1993, PHYS REV LETT, V70, P2249, DOI 10.1103/PhysRevLett.70.2249; HO KM, 1990, PHYS REV LETT, V65, P3152, DOI 10.1103/PhysRevLett.65.3152; Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; JOHN S, 1991, PHYS REV B, V43, P12772, DOI 10.1103/PhysRevB.43.12772; Kapitonov AM, 1998, PHYS STATUS SOLIDI A, V165, P119, DOI 10.1002/(SICI)1521-396X(199801)165:1<119::AID-PSSA119>3.0.CO;2-Y; KLEIN JD, 1993, CHEM MATER, V5, P902, DOI 10.1021/cm00031a002; Krauss TF, 1999, PROG QUANT ELECTRON, V23, P51, DOI 10.1016/S0079-6727(99)00004-X; Lee KY, 1995, J VAC SCI TECHNOL B, V13, P3012, DOI 10.1116/1.588297; Lin SY, 1998, SCIENCE, V282, P274, DOI 10.1126/science.282.5387.274; Mayo MJ, 1996, INT MATER REV, V41, P85, DOI 10.1179/095066096790326039; NODA S, 1996, JPN J APPL PHYS, V35, P909; Subramanian G, 1999, ADV MATER, V11, P1261, DOI 10.1002/(SICI)1521-4095(199910)11:15<1261::AID-ADMA1261>3.0.CO;2-A; Tarhan II, 1996, PHYS REV LETT, V76, P315, DOI 10.1103/PhysRevLett.76.315; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; Velev OD, 1999, NATURE, V401, P548, DOI 10.1038/44065; Vlasov YA, 1999, ADV MATER, V11, P165, DOI 10.1002/(SICI)1521-4095(199902)11:2<165::AID-ADMA165>3.0.CO;2-3; Wanke MC, 1997, SCIENCE, V275, P1284, DOI 10.1126/science.275.5304.1284; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; YABLONOVITCH E, 1991, PHYS REV LETT, V67, P3380, DOI 10.1103/PhysRevLett.67.3380; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; YABLONOVITCH E, 1991, PHYS REV LETT, V67, P2295, DOI 10.1103/PhysRevLett.67.2295; Zakhidov AA, 1998, SCIENCE, V282, P897, DOI 10.1126/science.282.5390.897	30	1579	1733	14	594	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					53	56		10.1038/35003523	http://dx.doi.org/10.1038/35003523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716437				2022-12-28	WOS:000085775100040
J	Wuite, GJL; Smith, SB; Young, M; Keller, D; Bustamante, C				Wuite, GJL; Smith, SB; Young, M; Keller, D; Bustamante, C			Single-molecule studies of the effect of template tension on T7 DNA polymerase activity	NATURE			English	Article							BACTERIOPHAGE-T7; EXONUCLEASE; FIDELITY; ENZYME	T7 DNA polymerase(1,2) catalyses DNA replication in vitro at rates of more than 100 bases per second and has a 3'--> 5' exonuclease (nucleotide removing) activity at a separate active site. This enzyme possesses a 'right hand' shape which is common to most polymerases with fingers, palm and thumb domains(3,4). The rate-limiting step for replication is thought to involve a conformational change between an 'open fingers' state in which the active site samples nucleotides, and a 'closed' state in which nucleotide incorporation occurs(3,5). DNA polymerase must function as a molecular motor converting chemical energy into mechanical force as it moves over the template. Here we show, using a single-molecule assay based on the differential elasticity of single-stranded and double-stranded DNA, that mechanical force is generated during the rate-limiting step and that the motor can work against a maximum template tension of similar to 34 pN. Estimates of the mechanical and entropic work done by the enzyme show that T7 DNA polymerase organizes two template bases in the polymerization site during each catalytic cycle. We also find a force-induced 100-fold increase in exonucleolysis above 40pN.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Oregon; University of New Mexico	Bustamante, C (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.			wuite, gijs/0000-0002-5706-043X; Bustamante, Carlos/0000-0002-2970-0073				BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Cluzel P, 1996, SCIENCE, V271, P792, DOI 10.1126/science.271.5250.792; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; EssevazRoulet B, 1997, P NATL ACAD SCI USA, V94, P11935, DOI 10.1073/pnas.94.22.11935; Gurrieri S, 1999, P NATL ACAD SCI USA, V96, P453, DOI 10.1073/pnas.96.2.453; Hegner M, 1999, P NATL ACAD SCI USA, V96, P10109, DOI 10.1073/pnas.96.18.10109; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; MODRICH P, 1975, J BIOL CHEM, V250, P5515; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; TABOR S, 1987, J BIOL CHEM, V262, P16212; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0	19	394	410	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					103	106		10.1038/35003614	http://dx.doi.org/10.1038/35003614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716452				2022-12-28	WOS:000085775100055
J	Cavicchi, M; Beau, P; Crenn, P; Degott, C; Messing, B				Cavicchi, M; Beau, P; Crenn, P; Degott, C; Messing, B			Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure	ANNALS OF INTERNAL MEDICINE			English	Article							P-GLYCOPROTEIN GENE; URSODEOXYCHOLIC ACID; CHRONIC CHOLESTASIS; LIPID EMULSIONS; BOWEL RESECTION; FUNCTION TESTS; CHILDREN; RATS; TRANSPLANTATION; METRONIDAZOLE	Background: Liver cholestasis can be a life-threatening complication during home parenteral nutrition and may lead to combined liver-intestinal transplantation. Objective: To assess the prevalence of home parenteral nutrition-related liver disease and its contributing factors in patients with permanent intestinal failure. Design: Prospective cohort study. Setting: Two approved home parenteral nutrition centers, Patients: 90 patients with permanent intestinal failure who were receiving home parenteral nutrition were enrolled from 1985 to 1996. Intervention: Clinical, biological, endoscopic, and ultrasonographic follow-up. Histologic examination of the liver was done in 57 patients (112 liver biopsies). Measurements: The Kaplan-Meier method was used to determine the actuarial occurrence of chronic cholestasis and complicated home parenteral nutrition-related liver disease (bilirubin level greater than or equal to 60 mu mol/L [3.5 mg/dL], factor V level less than or equal to 50%, portal hypertension, encephalopathy, ascites, gastrointestinal bleeding, or histologically proven extensive fibrosis or cirrhosis). Contributing factors were assessed by using univariate and multivariate (Cox model) analysis. Results: 58 patients (65%) developed chronic cholestasis after a median of 6 months (range, 3 to 132 months), and 37 (41.5%)developed complicated home parenteral nutrition-related liver disease after a median of 17 months (range, 2 to 155 months). Of these patients, 17 showed extensive fibrosis after 26 months (range, 2 to 148 months) and 5 had cirrhosis after 37 months (range, 26 to 77 months). The prevalence of complicated home parenteral nutrition-related liver disease was 26% +/- 9% at 2 years and 50% +/- 13% at 6 years. Six patients died of liver disease (22% of all deaths). In multivariate analysis, chronic cholestasis was significantly associated with a parenteral nutrition-independent risk for liver disease, a bowel remnant shorter than 50 cm in length, and a parenteral lipid intake of 1 g/kg of body weight per day or more (omega-6-rich long-chain triglycerides), whereas complicated home parenteral nutrition-related liver disease was significantly associated with chronic cholestasis and lipid parenteral intake of 1 g/kg per day or more. Conclusion: The prevalence of complicated home parenteral nutrition-related liver disease increased with longer duration of parenteral nutrition. This condition was one of the main causes of death in patients with permanent intestinal failure. Parenteral intake of w-6-rich long-chain triglycerides lipid emulsion consisting of less than 1 g/kg per day is recommended in these patients.	Hop Lariboisiere, Serv Gastroenterol & Assistance Nutr, F-75475 Paris 10, France; Ctr Hosp La Miletrie, Poitiers, France; Hop Beaujon, Clichy, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Poitiers; Universite de Poitiers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Messing, B (corresponding author), Hop Lariboisiere, Serv Gastroenterol & Assistance Nutr, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	bernard.messing@lrb.ap-hop-paris.fr	CRENN, Pascal/B-5850-2008	CRENN, Pascal/0000-0002-8213-2319				ALLARDYCE DB, 1982, SURG GYNECOL OBSTET, V154, P641; BEAU P, 1994, J HEPATOL, V20, P240, DOI 10.1016/S0168-8278(05)80064-9; BEAU P, 1994, GASTROEN CLIN BIOL, V18, P63; BELLI DC, 1987, JPEN-PARENTER ENTER, V11, P67, DOI 10.1177/014860718701100167; BENJAMIN DR, 1981, AM J CLIN PATHOL, V76, P276; BOWYER BA, 1985, JPEN-PARENTER ENTER, V9, P11, DOI 10.1177/014860718500900111; Brousse N, 1996, BRIT MED J, V312, P261; BURNES JU, 1992, JPEN-PARENTER ENTER, V16, P327, DOI 10.1177/0148607192016004327; CANO N, 1994, NUTR CLIN METAB, V8, P149; CAPRON JP, 1983, LANCET, V1, P446; CLARKE PJ, 1991, JPEN-PARENTER ENTER, V15, P54, DOI 10.1177/014860719101500154; CLAYTON PT, 1993, GASTROENTEROLOGY, V105, P1806, DOI 10.1016/0016-5085(93)91079-W; Cox DR., 1989, ANAL BINARY DATA; CRAIG RM, 1980, GASTROENTEROLOGY, V79, P131; Crenn P, 1997, CLIN NUTR, V16, P133, DOI 10.1016/S0261-5614(97)80240-3; DAHMS BB, 1981, GASTROENTEROLOGY, V81, P136; DEGOTT C, 1988, GASTROENTEROLOGY, V95, P183, DOI 10.1016/0016-5085(88)90309-5; DRONGOWSKI RA, 1989, JPEN-PARENTER ENTER, V13, P586, DOI 10.1177/0148607189013006586; FISCHER GW, 1980, LANCET, V2, P819; Forbush B, 1998, GASTROENTEROLOGY, V114, pA1241, DOI 10.1016/S0016-5085(98)85034-8; FOUINFORTUNET H, 1982, GASTROENTEROLOGY, V82, P932; GERARDBONCOMPAIN M, 1992, JPEN-PARENTER ENTER, V16, P78, DOI 10.1177/014860719201600178; GOGOS CA, 1992, NUTRITION, V8, P26; Grant D, 1999, TRANSPLANTATION, V67, P1061, DOI 10.1097/00007890-199904150-00021; GUERTIN F, 1991, JPEN-PARENTER ENTER, V15, P247, DOI 10.1177/0148607191015003247; Harris JA., 1919, BIOMETRIC STUDY BASA; INNES GK, 1988, TRANSPLANTATION, V45, P749, DOI 10.1097/00007890-198804000-00017; ITO Y, 1991, JPEN-PARENTER ENTER, V15, P271, DOI 10.1177/0148607191015003271; KAMINSKI DL, 1980, SURGERY, V88, P93; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KONO K, 1988, GASTROENTEROLOGY, V94, P787, DOI 10.1016/0016-5085(88)90255-7; LAMBERT JR, 1985, JPEN-PARENTER ENTER, V9, P501, DOI 10.1177/0148607185009004501; LEVECQ H, 1988, GASTROEN CLIN BIOL, V12, P691; MARTINEZ M, 1987, LIPIDS, V22, P133, DOI 10.1007/BF02537290; MESSING B, 1992, NUTRITION, V8, P30; Messing B, 1999, GASTROENTEROLOGY, V117, P1043, DOI 10.1016/S0016-5085(99)70388-4; MESSING B, 1995, GASTROENTEROLOGY, V108, P1005, DOI 10.1016/0016-5085(95)90196-5; MESSING B, 1990, AM J CLIN NUTR, V52, P1094, DOI 10.1093/ajcn/52.6.1094; MESSING B, 1994, TRANSPL P, V26, P1438; MESSING B, 1982, GASTROEN CLIN BIOL, V6, P740; MUGHAL M, 1986, LANCET, V2, P383; NANJI AA, 1985, JPEN-PARENTER ENTER, V9, P307, DOI 10.1177/0148607185009003307; PEDEN VH, 1971, J PEDIATR-US, V78, P180, DOI 10.1016/S0022-3476(71)80289-5; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Piquette-Miller M, 1998, PHARMACEUT RES, V15, P706, DOI 10.1023/A:1011962818051; QUIGLEY EMM, 1993, GASTROENTEROLOGY, V104, P286, DOI 10.1016/0016-5085(93)90864-9; Quigley EMM, 1996, GASTROENTEROLOGY, V110, P2009, DOI 10.1053/gast.1996.v110.agast962009; Roth B, 1996, INTENS CARE MED, V22, P1224, DOI 10.1007/s001340050242; SCOTTCONNER CEH, 1994, J SURG RES, V57, P316, DOI 10.1006/jsre.1994.1151; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Spagnuolo MI, 1996, GASTROENTEROLOGY, V111, P716, DOI 10.1053/gast.1996.v111.pm8780577; Stanko RT, 1987, GASTROENTEROLOGY, V92, P197, DOI 10.1016/0016-5085(87)90859-6; Tabachnik B.G., 1983, USING MULTIVARIATE S; TKOUB M, 1997, CLIN NUTR S1, V16, P32; Trauner M, 1997, GASTROENTEROLOGY, V113, P255, DOI 10.1016/S0016-5085(97)70103-3; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDEVENTER SJH, 1988, GASTROENTEROLOGY, V94, P825, DOI 10.1016/0016-5085(88)90261-2; vanNieuwkerk CMJ, 1996, GASTROENTEROLOGY, V111, P165, DOI 10.1053/gast.1996.v111.pm8698195; WOLFE BM, 1988, ARCH SURG-CHICAGO, V123, P1084	59	434	450	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					525	532		10.7326/0003-4819-132-7-200004040-00003	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744588				2022-12-28	WOS:000086129300002
J	Seidenfeld, J; Samson, DJ; Hasselblad, V; Aronson, N; Albertsen, PC; Bennett, CL; Wilt, TJ				Seidenfeld, J; Samson, DJ; Hasselblad, V; Aronson, N; Albertsen, PC; Bennett, CL; Wilt, TJ			Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							PHASE-III TRIAL; CYPROTERONE-ACETATE; RANDOMIZED TRIAL; CLINICAL-TRIALS; PHARMACOKINETIC PROPERTIES; MG MONOTHERAPY; FINAL ANALYSIS; FOLLOW-UP; ORCHIECTOMY; CARCINOMA	Purpose: To compare luteinizing hormone-releasing hormone (LHRH) agonists with orchiectomy or diethylstilbestrol, and to compare antiandrogens with any of these three alternatives. Data Sources: A search of the MEDLINE, Cancerlit, EMBASE, and Cochrane Library databases from 1966 to March 1998 and Current Contents to 24 August 1998 for articles comparing the outcomes of the specified treatments. The search was limited to studies on prostatic neoplasms in humans. Total yield was 1477 studies. Study Selection: Reports of efficacy outcomes were limited to randomized, controlled trials. Twenty-four trials involving more than 6600 patients, phase II studies that reported on withdrawals from therapy (the most reliable indicator of adverse effects), and all studies reporting on quality of life were abstracted. Data Extraction: Two independent reviewers abstracted each article by following a prospectively designed protocol. The meta-analysis combined data on 2-year overall survival by using a random-effects model and reported results as a hazard ratio relative to orchiectomy. Data Synthesis: Ten trials of LHRH agonists involving 1908 patients reported no significant difference in overall survival. The hazard ratio showed LHRH agonists to be essentially equivalent to orchiectomy (hazard ratio, 1.262 [95% CI, 0.915 to 1.386]). There was no evidence of difference in overall survival among the LHRH agonists, although Cls were wider for leuprolide (hazard ratio, 1.0994 [CI, 0.207 to 5.835]) and buserelin (hazard ratio, 1.1315 [CI, 0.533 to 2.404]) than for goserelin (hazard ratio, 1.1172 [CI, 0.898 to 1.390]). Evidence from 8 trials involving 2717 patients suggests that nonsteroidal antiandrogens were associated with lower overall survival. The CI for the hazard ratio approached statistical significance (hazard ratio, 1.2158 [CI, 0.988 to 1.496]). Treatment withdrawals were less frequent with LHRH agonists (0% to 4%) than with nonsteroidal antiandrogens (4% to 10%). Conclusions: Survival after therapy with an LHRH agonist was equivalent to that after orchiectomy. No evidence shows a difference in effectiveness among the LHRH agonists. Survival rates may be somewhat lower if a nonsteroidal antiandrogen is used as monotherapy.	Blue Cross & Blue Shield Assoc, Technol Evaluat Ctr, Chicago, IL 60601 USA; Duke Univ, Durham, NC USA; Univ Connecticut, Ctr Hlth, Farmington, CT USA; Vet Affairs Med Ctr, Chicago, IL USA; Northwestern Univ, Chicago, IL 60611 USA; Vet Affairs Med Ctr, VISN 13, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA	Duke University; University of Connecticut; US Department of Veterans Affairs; Veterans Health Administration (VHA); Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Seidenfeld, J (corresponding author), Blue Cross & Blue Shield Assoc, Technol Evaluat Ctr, 225 N Michigan Ave, Chicago, IL 60601 USA.	Jerome.Seidenfeld@bebsa.com	Bennett, Charles L/C-2050-2008					Andersson L, 1997, UROLOGY, V49, P1, DOI 10.1016/S0090-4295(97)00159-3; [Anonymous], 1995, Lancet, V346, P265; ARONSON N, 1999, AHCPR PUBLICATION; Bales GT, 1996, UROLOGY, V47, P38, DOI 10.1016/S0090-4295(96)80007-0; Bennett CL, 1999, PROSTATE CANCER P D, V2, P4, DOI 10.1038/sj.pcan.4500265; Blackard C E, 1973, Urology, V1, P553, DOI 10.1016/0090-4295(73)90515-3; BocconGibod L, 1997, EUR UROL, V32, P391, DOI 10.1159/000480795; BROGDEN RN, 1989, DRUGS, V38, P185, DOI 10.2165/00003495-198938020-00003; Bruun E, 1996, SCAND J UROL NEPHROL, V30, P291, DOI 10.3109/00365599609182309; Byar D P, 1988, NCI Monogr, P165; Cassileth B R, 1992, Qual Life Res, V1, P323, DOI 10.1007/BF00434946; Caubet JF, 1997, UROLOGY, V49, P71, DOI 10.1016/S0090-4295(96)00325-1; Chang A, 1996, J CLIN ONCOL, V14, P2250, DOI 10.1200/JCO.1996.14.8.2250; CHODAK G, 1995, UROLOGY, V46, P849, DOI 10.1016/S0090-4295(99)80356-2; CHRISP P, 1991, DRUGS, V41, P254, DOI 10.2165/00003495-199141020-00008; CITRIN DL, 1991, PROSTATE, V18, P139, DOI 10.1002/pros.2990180206; CLEARY PD, 1995, QUAL LIFE RES, V4, P207, DOI 10.1007/BF02260860; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEVOOGT HJ, 1990, J STEROID BIOCHEM, V37, P965, DOI 10.1016/0960-0760(90)90451-P; DEVOOGT HJ, 1990, PROG CLIN BIOL RES, V359, P85; *EGRET, 1993, EGRET REF MAN REV 4; GARNICK MB, 1984, NEW ENGL J MED, V311, P1281; GARNICK MB, 1986, UROLOGY, V27, P21; Goldenberg S. Larry, 1997, P583; Hasselblad V, 1998, MED DECIS MAKING, V18, P37, DOI 10.1177/0272989X9801800110; Herbst WP, 1942, J AMER MED ASSOC, V120, P1116, DOI 10.1001/jama.1942.02830490036009; Herbst WP, 1941, T AM ASS GENITOURINA, V34, P195; Herr HW, 1997, CA-CANCER J CLIN, V47, P207, DOI 10.3322/canjclin.47.4.207; HUBEN RP, 1988, CANCER, V62, P1881, DOI 10.1002/1097-0142(19881101)62:9<1881::AID-CNCR2820620902>3.0.CO;2-9; Huggins C, 1941, CANCER RES, V1, P293; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; Iversen P, 1998, UROLOGY, V51, P389, DOI 10.1016/S0090-4295(98)00004-1; Iversen P, 1996, SCAND J UROL NEPHROL, V30, P93, DOI 10.3109/00365599609180896; IVERSEN P, 1994, EUR UROL, V26, P5; JORDAN WP, 1977, SOUTH MED J, V70, P1411; KAISARY AV, 1991, BRIT J UROL, V67, P502, DOI 10.1111/j.1464-410X.1991.tb15195.x; KAISARY AV, 1995, EUR UROL, V28, P215; KLIJN JGM, 1993, CANCER-AM CANCER SOC, V72, P3858, DOI 10.1002/1097-0142(19931215)72:12+<3858::AID-CNCR2820721719>3.0.CO;2-6; KLIOZE SS, 1988, AM J CLIN ONCOL-CANC, V11, pS176, DOI 10.1097/00000421-198801102-00041; Kolvenbag GJCM, 1998, PROSTATE, V34, P61, DOI 10.1002/(SICI)1097-0045(19980101)34:1<61::AID-PROS8>3.0.CO;2-N; KOUTSILIERIS M, 1985, PROSTATE, V7, P31, DOI 10.1002/pros.2990070105; LUND F, 1988, BRIT J UROL, V61, P140, DOI 10.1111/j.1464-410X.1988.tb05062.x; MOFFAT LEF, 1990, EUR UROL, V18, P26; Moher D., 1999, HEALTH TECHNOL ASSES, V3, pi, DOI [DOI 10.3310/HTA3120, 10.3310/hta3120]; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; MULROW CD, 1996, COCHRANE COLLABORATI; Nicholson S, 1997, ENDOCR-RELAT CANCER, V4, P141, DOI 10.1677/erc.0.0040141; OSTRI P, 1991, UROL INT, V46, P167, DOI 10.1159/000282125; PAVONEMACALUSO M, 1986, J UROLOGY, V136, P624, DOI 10.1016/S0022-5347(17)44996-2; PEELING WB, 1984, MONOGRAPH SERIES EUR, V13, P171; PLOSKER GL, 1994, DRUGS, V48, P930, DOI 10.2165/00003495-199448060-00008; ROBINSON MRG, 1995, EUR UROL, V28, P273; ROILA F, 1989, BIOMED PHARMACOTHER, V43, P279, DOI 10.1016/0753-3322(89)90009-7; SCHRODER FH, 1993, CANCER, V72, P3810, DOI 10.1002/1097-0142(19931215)72:12+<3810::AID-CNCR2820721710>3.0.CO;2-O; SEELY JH, 1987, J ANDROL, V8, pS23; SOLOWAY MS, 1991, UROLOGY, V37, P46, DOI 10.1016/0090-4295(91)80077-K; SOLOWAY MS, 1993, CANCER, V71, P1083, DOI 10.1002/1097-0142(19930201)71:3+<1083::AID-CNCR2820711430>3.0.CO;2-1; STANFORD JL, 1999, NIH PUBLICATION; Thorpe SC, 1996, EUR UROL, V29, P47; Tyrrell CJ, 1998, EUR UROL, V33, P447, DOI 10.1159/000019634; *VET ADM COOP UR R, 1967, SURG GYNECOL OBSTET, V124, P1011; VOGELZANG NJ, 1995, UROLOGY, V46, P220, DOI 10.1016/S0090-4295(99)80197-6; WAYMONT B, 1992, BRIT J UROL, V69, P614, DOI 10.1111/j.1464-410X.1992.tb15633.x; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105	64	304	323	1	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					566	577		10.7326/0003-4819-132-7-200004040-00009	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00009			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744594				2022-12-28	WOS:000086129300008
J	Horton, R				Horton, R			From star signs to trial guidelines	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; QUALITY; CONSORT		The Lancet, London WC1X 8RR, England		Horton, R (corresponding author), The Lancet, London WC1X 8RR, England.							[Anonymous], 1988, LANCET, V2, P349; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Deeks JJ, 1998, LANCET, V352, P1908, DOI 10.1016/S0140-6736(05)60399-6; Moher D, 1998, JAMA-J AM MED ASSOC, V279, P1489, DOI 10.1001/jama.279.18.1489; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	6	22	22	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	2000	355	9209					1033	1034		10.1016/S0140-6736(00)02031-6	http://dx.doi.org/10.1016/S0140-6736(00)02031-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744086				2022-12-28	WOS:000086380800007
J	Li, K; McKay, G				Li, K; McKay, G			Ischemic retinopathy caused by severe megaloblastic anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Glasgow Royal Infirm, Glasgow G4 OSF, Lanark, Scotland		Li, K (corresponding author), Glasgow Royal Infirm, Glasgow G4 OSF, Lanark, Scotland.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	2000	342	12					860	860		10.1056/NEJM200003233421205	http://dx.doi.org/10.1056/NEJM200003233421205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296FU	10727590				2022-12-28	WOS:000086014100005
J	Reichhardt, T				Reichhardt, T			Space researchers protest at 'disruptive' export controls	NATURE			English	News Item																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					321	321		10.1038/35006225	http://dx.doi.org/10.1038/35006225			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746691	Bronze			2022-12-28	WOS:000086119000007
J	Badesch, DB; Tapson, VF; McGoon, MD; Brundage, BH; Rubin, LJ; Wigley, FM; Rich, S; Barst, RJ; Barrett, PS; Kral, KM; Jobsis, MM; Loyd, JE; Murali, S; Frost, A; Girgis, R; Bourge, RC; Ralph, DD; Elliott, CG; Hill, NS; Langleben, D; Schilz, RJ; McLaughlin, VV; Robbins, IM; Groves, BM; Shapiro, S; Medsger, TA; Gaine, SP; Horn, E; Decker, JC; Knobil, K				Badesch, DB; Tapson, VF; McGoon, MD; Brundage, BH; Rubin, LJ; Wigley, FM; Rich, S; Barst, RJ; Barrett, PS; Kral, KM; Jobsis, MM; Loyd, JE; Murali, S; Frost, A; Girgis, R; Bourge, RC; Ralph, DD; Elliott, CG; Hill, NS; Langleben, D; Schilz, RJ; McLaughlin, VV; Robbins, IM; Groves, BM; Shapiro, S; Medsger, TA; Gaine, SP; Horn, E; Decker, JC; Knobil, K			Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							PROGRESSIVE SYSTEMIC-SCLEROSIS; RAYNAUD PHENOMENON SECONDARY; CONNECTIVE-TISSUE DISEASE; CONTROLLED DOUBLE-BLIND; CREST SYNDROME VARIANT; ILOPROST INFUSION; PROSTACYCLIN PGI2; PLATELET-AGGREGATION; VASCULAR-RESISTANCE; PLEXIFORM LESIONS	Background: Pulmonary hypertension is a progressive and often fatal complication of the scleroderma spectrum of disease for which no treatment has been proven effective in a randomized trial. Objective: To determine the effect of epoprostenol on pulmonary hypertension secondary to the scleroderma spectrum of disease. Design: Randomized, open-label, controlled trial. Setting: 17 pulmonary hypertension referral centers. Patients: 111 patients with moderate to severe pulmonary hypertension. Intervention: Epoprostenol plus conventional therapy or conventional therapy alone. Measurements: The primary outcome measure was exercise capacity. Other measures were cardiopulmonary hemodynamics, signs and symptoms of pulmonary hypertension and scleroderma, and survival. Results: Exercise capacity improved with epoprostenol (median distance walked in 6 minutes, 316 m at 12 weeks compared with 270 m at baseline) but decreased with conventional therapy (192 m at 12 weeks compared with 240 m at baseline). The difference between treatment groups in the median distance walked at week 12 was 108 m (95% CI, 55.2 m to 180.0 m) (P < 0.001). Hemodynamics improved at 12 weeks with epoprostenol. The changes in mean pulmonary artery pressure for the epoprostenol and conventional therapy groups were-5.0 and 0.9 mm Hg, respectively (difference, -6.0 mm Hg [CI, -9.0 to -3.0 mm Hg), and the mean changes in pulmonary vascular resistance were -4.6 and 0.9 mm Hg/L per minute, respectively (difference, -5.5 mm Hg/L per minute [CI, -7.3 to -3.7 mm Hg/L per minute). Twenty-one patients treated with epoprostenol and no patients receiving conventional therapy showed improved New York Heart Association functional class. Borg Dyspnea Scores and Dyspnea-Fatigue Ratings improved in the epoprostenol group. Trends toward greater improvement in severity of the Raynaud phenomenon and fewer new digital ulcers were seen in the epoprostenol group. Four patients in the epoprostenol group and five in the conventional therapy group died (P value not significant). Side effects of epoprostenol therapy included jaw pain, nausea, and anorexia. Adverse events related to the epoprostenol delivery system included sepsis, cellulitis, hemorrhage, and pneumothorax (4% incidence for each condition). Conclusions: Continuous epoprostenol therapy improves exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary hypertension due to the scleroderma spectrum of disease.	Univ Colorado, Hlth Sci Ctr, Div Pulm, Denver, CO 80262 USA; Duke Univ, Med Ctr, Div Pulm Med, Durham, NC 27710 USA; Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Maryland, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21201 USA; Johns Hopkins Univ, Div Rheumatol, Baltimore, MD 21205 USA; Rush Presbyterian St Lukes Med Ctr, Med Ctr, Cardiol Sect, Chicago, IL 60612 USA; Columbia Presbyterian Med Ctr, Dept Med, Div Cardiol, New York, NY 10032 USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; Baylor Coll Med, Lung Transplant Program, Pulm Sect, Houston, TX 77030 USA; Wayne State Univ, Harper Hosp, Sch Med, Div Pulm & Crit Care Med, Detroit, MI 48201 USA; Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA; Univ Washington, Med Ctr, Seattle, WA 98195 USA; LDS Hosp, Div Pulm, Salt Lake City, UT 84143 USA; Brown Univ, Providence, RI USA; McGill Univ, Montreal, PQ, Canada; Cleveland Clin, Cleveland, OH USA; Harbor UCLA Med Ctr, Div Cardiol, Torrance, CA 90509 USA; Bend Mem Clin, Bend, OR 97701 USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Babies Hosp, Columbia Presbyterian Med Ctr, Pediat Cardiol Ctr, New York, NY 10032 USA; Baylor Coll Med, Pulm Sect, Lung Transpland Program, Houston, TX 77030 USA; Rhode Isl Hosp, Div Pulm, Providence, RI 02903 USA; Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Duke University; Mayo Clinic; University of California System; University of California Los Angeles; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Rush University; Columbia University; NewYork-Presbyterian Hospital; GlaxoSmithKline; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine; Wayne State University; University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; Brown University; McGill University; Cleveland Clinic Foundation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California San Diego; Columbia University; NewYork-Presbyterian Hospital; Baylor College of Medicine; Lifespan Health Rhode Island; Rhode Island Hospital; McGill University; Cleveland Clinic Foundation; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Badesch, DB (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm, C272,4200 E 9th Ave, Denver, CO 80262 USA.	David.Badesch@UCHS.edu	Langleben, David/AAJ-9152-2020	Gaine, Sean/0000-0002-5941-684X; Loyd, James/0000-0002-5042-7390				ALPERT MA, 1991, AM J CARDIOL, V68, P1687, DOI 10.1016/0002-9149(91)90330-N; ALPERT MA, 1992, CHEST, V102, P1407, DOI 10.1378/chest.102.5.1407; ALSABBAGH MR, 1989, J RHEUMATOL, V16, P1038; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; BADESCH DB, 1989, AM J RESP CELL MOL, V1, P489, DOI 10.1165/ajrcmb/1.6.489; BALINT GA, 1983, ACTA PHYSIOL HUNG, V61, P115; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BARST RJ, 1994, ANN INTERN MED, V121, P409, DOI 10.7326/0003-4819-121-6-199409150-00003; BEICH JJ, 1981, THROMB HAEMOSTASIS, V45, P255; BELCH JJF, 1983, LANCET, V1, P313; BELCH JJF, 1995, ANN RHEUM DIS, V54, P197, DOI 10.1136/ard.54.3.197; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; Cool CD, 1997, HUM PATHOL, V28, P434, DOI 10.1016/S0046-8177(97)90032-0; CORBIN DOC, 1986, EUR HEART J, V7, P165, DOI 10.1093/oxfordjournals.eurheartj.a062040; Cox D. R., 1984, ANAL SURVIVAL DATA; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; DATA JL, 1981, CIRCULATION, V64, P4, DOI 10.1161/01.CIR.64.1.4; DEFEYTER PJ, 1983, AM HEART J, V105, P333, DOI 10.1016/0002-8703(83)90539-2; DELAMATA J, 1994, ARTHRITIS RHEUM-US, V37, P1528; DOWD PM, 1982, BRIT J DERMATOL, V106, P81, DOI 10.1111/j.1365-2133.1982.tb00905.x; FEINSTEIN AR, 1989, AM J CARDIOL, V64, P50, DOI 10.1016/0002-9149(89)90652-8; Friedman R, 1997, CIRCULATION, V96, P2782, DOI 10.1161/01.CIR.96.9.2782; FUDMAN EJ, 1985, J RHEUMATOL, V12, P1191; GERBER JG, 1980, J APPL PHYSIOL, V49, P107, DOI 10.1152/jappl.1980.49.1.107; GLIKSON M, 1990, CHEST, V98, P759, DOI 10.1378/chest.98.3.759; GRAHAM DR, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90351-W; GROVES BM, 1993, FLUX PULMONARY VASCU, P317; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HERFINDAL ET, 1992, CLIN PHARMACY, V11, P543; HOLANDER M, 1973, NONPARAMETRIC STAT M, P67; Humbert M, 1998, CHEST, V114, p80S, DOI 10.1378/chest.114.1_Supplement.80S; HYMAN AL, 1979, CIRC RES, V45, P404, DOI 10.1161/01.RES.45.3.404; JANINI SD, 1988, J CLIN PHARM THER, V13, P145, DOI 10.1111/j.1365-2710.1988.tb00171.x; KAHALEH B, 1995, ARTHRITIS RHEUM, V38, P1, DOI 10.1002/art.1780380102; KAHAN A, 1985, ANN RHEUM DIS, V44, P30, DOI 10.1136/ard.44.1.30; KAHAN A, 1985, INT ANGIOL, V4, P221; KALLENBERG CGM, 1987, J RHEUMATOL, V14, P284; KONTUREK SJ, 1981, GUT, V22, P927, DOI 10.1136/gut.22.11.927; KOSSMAN CE, 1964, DIS HEART BLOOD VESS; KYLE MV, 1992, J RHEUMATOL, V19, P1403; LAU CS, 1993, CLIN EXP RHEUMATOL, V11, P35; Lee SD, 1998, J CLIN INVEST, V101, P927, DOI 10.1172/JCI1910; LEFER AM, 1978, SCIENCE, V200, P52, DOI 10.1126/science.345441; LUNDE P, 1984, AM HEART J, V108, P415, DOI 10.1016/0002-8703(84)90637-9; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; Menon N, 1998, ARTHRITIS RHEUM-US, V41, P466; MEYRICK TRH, 1987, BRIT J DERMATOL, V117, P237; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MONCADA S, 1977, THROMB RES, V11, P323, DOI 10.1016/0049-3848(77)90185-2; OCKEN S, 1983, ARTHRITIS RHEUM, V26, P794, DOI 10.1002/art.1780260615; OLIVARI MT, 1984, CHEST, V86, P14, DOI 10.1378/chest.86.1.14; Palmer SM, 1998, CHEST, V113, P237, DOI 10.1378/chest.113.1.237; RADEMAKER M, 1987, POSTGRAD MED J, V63, P617, DOI 10.1136/pgmj.63.742.617; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; RODEHEFFER RJ, 1983, NEW ENGL J MED, V308, P880, DOI 10.1056/NEJM198304143081507; RUBIN LJ, 1983, ANN INTERN MED, V99, P433, DOI 10.7326/0003-4819-99-4-433; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; SAITO D, 1983, AM HEART J, V105, P1041, DOI 10.1016/0002-8703(83)90414-3; SALERNI R, 1977, ANN INTERN MED, V86, P394, DOI 10.7326/0003-4819-86-4-394; SFIKAKIS PP, 1991, AM J MED, V90, P541; Shapiro SM, 1997, J AM COLL CARDIOL, V30, P343, DOI 10.1016/S0735-1097(97)00187-3; SMITH CD, 1982, LANCET, V2, P1299; STARLING MB, 1979, PROSTAG LEUKOTR ESS, V3, P105, DOI 10.1016/0161-4630(79)90078-8; STOKES ME, 1995, CATEGORICAL DATA ANA, P155; STUPI AM, 1986, ARTHRITIS RHEUM, V29, P515, DOI 10.1002/art.1780290409; THURM CA, 1991, AM J MED, V90, P547; TUDER RM, 1994, AM J PATHOL, V144, P275; UNGERER RG, 1983, AM J MED, V75, P65, DOI 10.1016/0002-9343(83)91169-5; Wigley FM, 1998, ARTHRITIS RHEUM-US, V41, P670, DOI 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I; WIGLEY FM, 1994, ANN INTERN MED, V120, P199, DOI 10.7326/0003-4819-120-3-199402010-00004; Wigley Fredrick M., 1996, Current Opinion in Rheumatology, V8, P561; YARDUMIAN DA, 1988, BRIT J RHEUMATOL, V27, P220; YOUNG RH, 1978, AM J MED, V64, P998, DOI 10.1016/0002-9343(78)90455-2; Zachariae H, 1996, ACTA DERM-VENEREOL, V76, P236	79	790	839	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					425	+		10.7326/0003-4819-132-6-200003210-00002	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293CV	10733441				2022-12-28	WOS:000085834700001
J	Rein, M				Rein, M			Stress and genital herpes recurrences in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Background: Results of several studies suggest that psychological stress and negative mood can trigger genital herpes recurrences, but results are inconsistent. Objective: To determine whether short-term or persistent psychological stress or specific negative moods are predictive of genital herpes recurrences in women. Methods: A prospective cohort study followed up participants for 6 months using weekly assessments of stress and mood, monthly assessment of life chang events, and diary reports of genital herpes recurrences confirmed medical examination when feasible. The. community sample consisted of 58 women, aged 20 to 44 years; with a 1- to 10-year history of visible genital herpes recurrence and at least 1 recurrence in the previous 6 months. Results: Persistent stress predicted recurrence in the subsequent week (odds ratio, 1.08 per unit increase in stress; 95%, confidence interval, 1.01-1.15; P = .03). After adjusting for recurrence in the previous week, the more weekly persistent stress reported, the greater the likelihood of recurrence the following week. Also, an increased recurrence rate occurred after the month during which participants experienced their highest levels of anxiety (P = .03). There were no significant associations between recurrence and short-term stress, life events, depressive mood, anger, or phase of menstrual cycle. Conclusions: Persistent stressors and highest level of anxiety predicted genital herpes recurrence, whereas transient mood states, short-term stressors, and life change events did not. Women with herpes can be reassured that short-term stressful life experiences and dysphoric mood states do not put them at risk for increased outbreaks of recurrent genital herpes.	Univ Virginia, Hlth Sci Ctr, Div Infect Dis, Charlottesville, VA 22908 USA	University of Virginia	Rein, M (corresponding author), Univ Virginia, Hlth Sci Ctr, Div Infect Dis, Charlottesville, VA 22908 USA.	mfr6t@virginia.edu							0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2000	283	11					1394	1394		10.1001/jama.283.11.1394	http://dx.doi.org/10.1001/jama.283.11.1394			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290UR	10732915				2022-12-28	WOS:000085696700001
J	Bosch, X				Bosch, X			Newspaper apportions blame in Spanish hepatitis C scandal	LANCET			English	News Item																		MAESO, 1998, LANCET, V351, P1415	1	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					818	818		10.1016/S0140-6736(05)72446-6	http://dx.doi.org/10.1016/S0140-6736(05)72446-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711938				2022-12-28	WOS:000085766900034
J	Mehigan, BJ; Monson, JRT; Hartley, JE				Mehigan, BJ; Monson, JRT; Hartley, JE			Stapling procedure for haemorrhoids versus Milligan-Morgan haemorrhoidectomy: randomised controlled trial	LANCET			English	Article							ANAL-SPHINCTER; HEMORRHOIDECTOMY; PAIN; DIATHERMY	Background Surgical haemorrhoidectomy has a reputation for being a painful procedure for a fairly-benign disorder. The circular transanal stapled technique for the treatment of haemorrhoids has the potential to offer a less painful rectal procedure in place of ablative perianal surgery. We compared the short-term outcome of the circular stapled procedure for haemorrhoids with current standard surgery in a randomised controlled trial. Methods 40 patients admitted for surgical treatment of prolapsing haemorrhoids were randomly assigned to Milligan-Morgan haemorrhoidectomy (n=20) or the circular stapled procedure. Under general anaesthesia patients underwent standardised diathermy excision haemorrhoidectomy or had a circumferential doughnut of rectal mucosa and submucosa above the dentate line excised and closed with a standard circular end-to-end stapling device. All patients received standardised preoperative and postoperative analgesic and laxative regimens. Patients completed linear analogue pain charts each day and were interviewed at 1, 3, and 6-10 weeks postoperatively. Summary measures of average pain experience were calculated from 10 cm linear analogue pain scores and were used as the primary outcome measure. Findings The stapled group had shorter anaesthesia time (median 18 [range 9-25] vs 22 [15-35] mins). Average pain in the stapled group was significantly lower than it was in the Milligan-Morgan group (2.1[0.2-7.6] vs 6.5 [3.1-8.5], 95.1% CI difference medians 1.9-4.7, p<0.0001. Mann-Whitney U test). Average pain relative to what the patient expected was also significantly less in the stapled group (-2.8 [-4.4 to 1.3] vs 0.7 [-1.8 to 3.4]. Hospital stay and time to first bowel motion were not significantly different between groups. Return to normal activity was significantly shorter in the stapled group (1.7 [3-60] vs 34 [14-90]. Early and late complications, patient-assessed symptom control, and functional outcome appear similar after short-term follow-up Interpretation The circular stapled technique offers a significantly less painful alternative to Milligan-Morgan haemorrhoidectomy and is associated with an earlier return to normal activity. Early symptom control and functional outcome appear similar. However, long-term symptomatic and functional outcome need further study.	Univ Hull, Castle Hill Hosp, Acad Surg Unit, Cottingham HU16 5JQ, England	University of Hull	Monson, JRT (corresponding author), Univ Hull, Castle Hill Hosp, Acad Surg Unit, Cottingham HU16 5JQ, England.	J.R.Monson@medschool.hull.ac.uk		Mehigan, Brian J/0000-0001-5602-4325				ANDREWS BT, 1993, DIS COLON RECTUM, V36, P580, DOI 10.1007/BF02049865; BENNETT RC, 1962, BMJ-BRIT MED J, V2, P216; Carapeti EA, 1998, LANCET, V351, P169, DOI 10.1016/S0140-6736(97)09003-X; Farouk R, 1998, DIS COLON RECTUM, V41, P888, DOI 10.1007/BF02235373; Goligher JC, 1984, SURG ANUS RECTUM COL, P96; Ho YH, 1997, BRIT J SURG, V84, P377, DOI 10.1002/bjs.1800840332; HO YH, 1995, BRIT J SURG, V82, P1034, DOI 10.1002/bjs.1800820809; Hunt L, 1999, BRIT J SURG, V86, P255, DOI 10.1046/j.1365-2168.1999.01024.x; Ibrahim S, 1998, DIS COLON RECTUM, V41, P1418, DOI 10.1007/BF02237059; Justin T, 1999, BRIT J SURG, V86, P60; KAUFMAN HD, 1976, BRIT J SURG, V63, P462, DOI 10.1002/bjs.1800630616; Law WL, 1999, DIS COLON RECTUM, V42, P363, DOI 10.1007/BF02236354; LEHMAN EL, 1978, NONPARAMETRICS STAT; Longo A., 1998, P 6 WORLD C END SURG; MACRAE HM, 1995, DIS COLON RECTUM, V38, P687, DOI 10.1007/BF02048023; Mathai V, 1996, BRIT J SURG, V83, P380, DOI 10.1002/bjs.1800830327; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MILITO G, 1998, P 6 WORLD C END SURG; Milligan ETC, 1937, LANCET, V2, P1119; MURIE JA, 1982, BRIT J SURG, V69, P536, DOI 10.1002/bjs.1800690913; Pescatori M, 1997, TECH COLOPROCTOL, V1, P96	21	302	323	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2000	355	9206					782	785		10.1016/S0140-6736(99)08362-2	http://dx.doi.org/10.1016/S0140-6736(99)08362-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711925				2022-12-28	WOS:000085766900009
J	Geijtenbeek, TBH; Kwon, DS; Torensma, R; van Vliet, SJ; van Duijnhoven, GCF; Middel, J; Cornelissen, ILMHA; Nottet, HSLM; KewalRamani, VN; Littman, DR; Figdor, CG; van Kooyk, Y				Geijtenbeek, TBH; Kwon, DS; Torensma, R; van Vliet, SJ; van Duijnhoven, GCF; Middel, J; Cornelissen, ILMHA; Nottet, HSLM; KewalRamani, VN; Littman, DR; Figdor, CG; van Kooyk, Y			DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; C-TYPE LECTIN; CHEMOKINE-CORECEPTORS; HIV ENTRY; IN-VITRO; PATHOGENESIS; RECEPTORS; INHIBITION; BLOOD; USAGE	Dendritic cells (DC) capture microorganisms that enter peripheral mucosal tissues and then migrate to secondary lymphoid organs, where they present these in antigenic form to resting T cells and thus initiate adaptive immune responses. Here, we describe the properties of a DC-specific C-type lectin, DC-SIGN, that is highly expressed on DC present in mucosal tissues and binds to the HIV-1 envelope glycoprotein gp120. DC-SIGN does not function as a receptor for viral entry into DC but instead promotes efficient infection in trans of cells that express CD4 and chemokine receptors. We propose that DC-SIGN efficiently captures HIV-1 in the periphery and facilitates its transport to secondary lymphoid organs rich in T cells, to enhance infection in trans of these target cells.	Univ Med Ctr St Radboud, Dept Tumor Immunol, NL-6525 EX Nijmegen, Netherlands; Univ Med Ctr St Radboud, Dept Pathol, NL-6525 EX Nijmegen, Netherlands; Univ Utrecht Hosp, Eykman Winkler Inst Microbiol, NL-3584 CX Utrecht, Netherlands; NYU, Med Ctr, Howard Hughes Med Inst, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA	Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Howard Hughes Medical Institute; New York University; New York University	van Kooyk, Y (corresponding author), Univ Med Ctr St Radboud, Dept Tumor Immunol, Philips van Leydenlaan 25, NL-6525 EX Nijmegen, Netherlands.		Figdor, Carl G/A-4232-2010; KewalRamani, Vineet/V-5084-2019; Torensma, Ruurd/C-2853-2009; Geijtenbeek, Teunis/C-2229-2009	Figdor, Carl G/0000-0002-2366-9212; Torensma, Ruurd/0000-0002-0555-7903; Van Kooyk, Yvette/0000-0001-5997-3665; van Vliet, Sandra/0000-0003-1811-2687	NIAID NIH HHS [AI33856] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033856] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Ayehunie S, 1997, BLOOD, V90, P1379, DOI 10.1182/blood.V90.4.1379.1379_1379_1386; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BarrattBoyes SM, 1997, J IMMUNOL, V158, P4543; Bjorndal A, 1997, J VIROL, V71, P7478; Blauvelt A, 1997, J CLIN INVEST, V100, P2043, DOI 10.1172/JCI119737; Cameron P, 1996, J LEUKOCYTE BIOL, V59, P158, DOI 10.1002/jlb.59.2.158; CAMERON PU, 1994, J LEUKOCYTE BIOL, V56, P257, DOI 10.1002/jlb.56.3.257; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Canque B, 1999, BLOOD, V93, P3866, DOI 10.1182/blood.V93.11.3866.411k43_3866_3875; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Geijtenbeek TBH, 1999, BLOOD, V94, P754, DOI 10.1182/blood.V94.2.754.414k11_754_764; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Grouard G, 1997, CURR OPIN IMMUNOL, V9, P563, DOI 10.1016/S0952-7915(97)80111-2; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; Hladik F, 1999, J VIROL, V73, P5833, DOI 10.1128/JVI.73.7.5833-5842.1999; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lee S, 1997, J VIROL, V71, P6037, DOI 10.1128/JVI.71.8.6037-6043.1997; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; Rowland-Jones SL, 1999, CURR BIOL, V9, pR248, DOI 10.1016/S0960-9822(99)80155-9; Rubbert A, 1998, J IMMUNOL, V160, P3933; Speck RF, 1999, CURR BIOL, V9, P547, DOI 10.1016/S0960-9822(99)80241-3; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; Steinman RM, 1999, J LEUKOCYTE BIOL, V66, P205, DOI 10.1002/jlb.66.2.205; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WEISSMAN D, 1995, P NATL ACAD SCI USA, V92, P826, DOI 10.1073/pnas.92.3.826	37	1875	1977	2	125	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 3	2000	100	5					587	597		10.1016/S0092-8674(00)80694-7	http://dx.doi.org/10.1016/S0092-8674(00)80694-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721995	Bronze			2022-12-28	WOS:000085700000011
J	Farquhar, J; Savarino, J; Jackson, TL; Thiemens, MH				Farquhar, J; Savarino, J; Jackson, TL; Thiemens, MH			Evidence of atmospheric sulphur in the martian regolith from sulphur isotopes in meteorites	NATURE			English	Article							CHEMICAL-COMPOSITION; EARLY EARTH; MARS; SULFUR; CARBONATES; ALH84001; TEMPERATURE; CHONDRITES; SULFATES; SOIL	Sulphur is abundant at the martian surface, yet its origin and evolution over time remain poorly constrained(1,2). This sulphur is likely to have originated in atmospheric chemical reactions, and so should provide records of the evolution of the martian atmosphere, the cycling of sulphur between the atmosphere and crust, and the mobility of sulphur in the martian regolith(3-6). Moreover, the atmospheric deposition of oxidized sulphur species could establish chemical potential gradients in the martian near-surface environment, and so provide a potential energy source for chemolithoautotrophic organisms', Here we present measurements of sulphur isotopes in oxidized and reduced phases from the SNC meteorites-the group of related achondrite meteorites believed to have originated on Mars-together with the results of laboratory photolysis studies of two important martian atmospheric sulphur species (SO2 and H2S). The photolysis experiments can account for the observed sulphur-isotope compositions in the SNC meteorites, and so identify a mechanism for producing large abiogenic S-34 fractionations in the surface sulphur reservoirs. We conclude that the sulphur data from the SNC meteorites reflects deposition of oxidized sulphur species produced by atmospheric chemical reactions, followed by incorporation, reaction and mobilization of the sulphur within the regolith.	Univ Calif San Diego, Dept Chem 0356, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Farquhar, J (corresponding author), Univ Calif San Diego, Dept Chem 0356, La Jolla, CA 92093 USA.	jfarquha@ucsd.edu	Savarino, Joel/H-9730-2012	Savarino, Joel/0000-0002-6708-9623				Banin A, 1997, J GEOPHYS RES-PLANET, V102, P13341, DOI 10.1029/97JE01160; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; CLARK BC, 1982, J GEOPHYS RES, V87, P59, DOI 10.1029/JB087iB12p10059; Colman JJ, 1996, SCIENCE, V273, P774, DOI 10.1126/science.273.5276.774; Cooper GW, 1997, SCIENCE, V277, P1072, DOI 10.1126/science.277.5329.1072; Farquhar J, 1998, SCIENCE, V280, P1580, DOI 10.1126/science.280.5369.1580; FARQUHAR J, 1999, 30 LUN PLAN SCI C, V30, P1675; GAO X, 1993, GEOCHIM COSMOCHIM AC, V57, P3159, DOI 10.1016/0016-7037(93)90300-L; GAO X, 1993, GEOCHIM COSMOCHIM AC, V57, P3171, DOI 10.1016/0016-7037(93)90301-C; Gao X., 1991, GEOCHIM COSMOCHIM AC, V55, P2671, DOI DOI 10.1016/0016-7037(91)90381-E; Greenwood JP, 1997, GEOCHIM COSMOCHIM AC, V61, P4449, DOI 10.1016/S0016-7037(97)00246-9; GREENWOOD JP, IN PRESS GEOCHIM COS; HARVEY RP, 1992, GEOCHIM COSMOCHIM AC, V56, P1655, DOI 10.1016/0016-7037(92)90232-8; Jakosky BM, 1998, J GEOPHYS RES-PLANET, V103, P19359, DOI 10.1029/98JE01892; KARLSSON KR, 1992, SCIENCE, V255, P1409, DOI 10.1126/science.11537889; KASTING JF, 1984, J ATMOS CHEM, V1, P403, DOI 10.1007/BF00053803; McSween HY, 1998, INT GEOL REV, V40, P774, DOI 10.1080/00206819809465238; Mukhin LM, 1996, NATURE, V379, P141, DOI 10.1038/379141a0; Newsom HE, 1999, J GEOPHYS RES-PLANET, V104, P8717, DOI 10.1029/1998JE900043; Okabe H., 1978, PHOTOCHEMISTRY SMALL; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P14595, DOI 10.1029/JB095iB09p14595; Rieder R, 1997, SCIENCE, V278, P1771, DOI 10.1126/science.278.5344.1771; SETTLE M, 1979, J GEOPHYS RES, V84, P8343, DOI 10.1029/JB084iB14p08343; Shearer CK, 1996, GEOCHIM COSMOCHIM AC, V60, P2921, DOI 10.1016/0016-7037(96)00165-2; Thiemens MH, 1999, SCIENCE, V283, P341, DOI 10.1126/science.283.5400.341; Toulmin P.  III, 1977, Journal of Geophysical Research, V82, P4625, DOI 10.1029/JS082i028p04625; WANKE H, 1994, PHILOS T R SOC A, V349, P285, DOI 10.1098/rsta.1994.0132; Warren PH, 1998, J GEOPHYS RES-PLANET, V103, P16759, DOI 10.1029/98JE01544; Yung YL, 1997, ICARUS, V130, P222, DOI 10.1006/icar.1997.5808	29	221	229	5	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2000	404	6773					50	52		10.1038/35003517	http://dx.doi.org/10.1038/35003517			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716436				2022-12-28	WOS:000085775100039
J	Jayaraman, KS				Jayaraman, KS			Funding crisis for Indian biotech centre	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					694	694		10.1038/35001745	http://dx.doi.org/10.1038/35001745			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10733382	Bronze			2022-12-28	WOS:000085423100014
J	Watine, J				Watine, J			Managing patients with lung cancer - Biomedical literature does not support routine use of laboratory variables as prognostic factors	BRITISH MEDICAL JOURNAL			English	Letter									Ctr Hosp Gen, Lab Biol Polyvalente, F-12027 Rodez 9, France		Watine, J (corresponding author), Ctr Hosp Gen, Lab Biol Polyvalente, F-12027 Rodez 9, France.		Watine, Joseph/I-3047-2019	Watine, Joseph/0000-0002-7881-0594				*IFCC COMM SYST RE, 1997, JIFCC, V9, P154; IHDE DC, 1993, CANCER PRINCIPLES PR, P723; Simmonds P, 1999, BMJ-BRIT MED J, V319, P527, DOI 10.1136/bmj.319.7209.527; Watine J, 1998, HEMATOL CELL THER, V40, P99; Watine J, 1999, ACTA MED OKAYAMA, V53, P99	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	2000	320	7231					379	380						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HC	10712029				2022-12-28	WOS:000085211400047
J	Subhedar, NV; Bennett, AJ; Wardle, SP; Shaw, NJ				Subhedar, NV; Bennett, AJ; Wardle, SP; Shaw, NJ			More trials on early treatment with corticosteroids are needed	BRITISH MEDICAL JOURNAL			English	Letter									Liverpool Womens Hosp, Neonatal Intens Care Unit, Liverpool L8 7SS, Merseyside, England	University of Liverpool	Subhedar, NV (corresponding author), Liverpool Womens Hosp, Neonatal Intens Care Unit, Liverpool L8 7SS, Merseyside, England.			Wardle, Stephen/0000-0001-5727-3315				HALLIDAY HL, 1999, COCHRANE LIB; Subhedar NV, 1997, ARCH DIS CHILD-FETAL, V77, pF185, DOI 10.1136/fn.77.3.F185; Tarnow-Mordi W, 1999, BRIT MED J, V319, P1385, DOI 10.1136/bmj.319.7222.1385; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7	4	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					941	941		10.1136/bmj.320.7239.941	http://dx.doi.org/10.1136/bmj.320.7239.941			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10742018	Green Published			2022-12-28	WOS:000086337100053
J	Gould, DC; Petty, R; Jacobs, HS				Gould, DC; Petty, R; Jacobs, HS			For and against - The male menopause - does it exist?	BRITISH MEDICAL JOURNAL			English	Editorial Material							HYPOGONADAL MEN; BIOAVAILABLE TESTOSTERONE; ANDROGEN LEVELS; AGING MALE; LONG-TERM; OLDER MEN; ADULT MEN; PLASMA; REPLACEMENT; AGE		WellMan Clin, London W1N 3FA, England		Gould, DC (corresponding author), Goldcross Med Serv, 20 Harley St, London W1N 1AL, England.							Barrett-Connor E, 1999, J CLIN ENDOCR METAB, V84, P573, DOI 10.1210/jc.84.2.573; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P407, DOI 10.1210/jc.82.2.407; BROWN WA, 1978, ARCH SEX BEHAV, V7, P97, DOI 10.1007/BF01542059; BURRIS AS, 1992, J ANDROL, V13, P297; DAVIDSON JM, 1983, J CLIN ENDOCR METAB, V57, P71, DOI 10.1210/jcem-57-1-71; DESLYPERE JP, 1984, J CLIN ENDOCR METAB, V59, P955, DOI 10.1210/jcem-59-5-955; FELDMAN JM, 1976, ARCH INTERN MED, V136, P606, DOI 10.1001/archinte.136.5.606; FINKELSTEIN JS, 1998, TESTOSTERONE ACTION, P187; GIAGULLI VA, 1994, J CLIN ENDOCR METAB, V79, P997, DOI 10.1210/jc.79.4.997; GOUCHIE C, 1991, PSYCHONEUROENDOCRINO, V16, P323, DOI 10.1016/0306-4530(91)90018-O; GRAY A, 1991, J CLIN EPIDEMIOL, V44, P671, DOI 10.1016/0895-4356(91)90028-8; Greendale GA, 1997, J BONE MINER RES, V12, P1833, DOI 10.1359/jbmr.1997.12.11.1833; Heller CG, 1944, J AMER MED ASSOC, V126, P472, DOI 10.1001/jama.1944.02850430006003; IDA Y, 1992, DRUG ALCOHOL DEPEN, V31, P57, DOI 10.1016/0376-8716(92)90009-2; JACKSON JA, 1992, AM J MED SCI, V304, P4, DOI 10.1097/00000441-199207000-00003; JANOWSKY JS, 1994, BEHAV NEUROSCI, V108, P325, DOI 10.1037/0735-7044.108.2.325; Katznelson L, 1996, J CLIN ENDOCR METAB, V81, P4358, DOI 10.1210/jc.81.12.4358; KAUFMAN JM, 1998, TESTOSTERONE ACTION, P437; KLEY HK, 1974, HORM METAB RES, V6, P213, DOI 10.1055/s-0028-1093855; KORENMAN SG, 1990, J CLIN ENDOCR METAB, V71, P963, DOI 10.1210/jcem-71-4-963; MANTZOROS CS, 1995, BRIT MED J, V310, P1289, DOI 10.1136/bmj.310.6990.1289; MEIKLE AW, 1988, J CLIN ENDOCR METAB, V67, P104, DOI 10.1210/jcem-67-1-104; MORLEY JE, 1986, AM J MED, V80, P897, DOI 10.1016/0002-9343(86)90635-2; NAHOUL K, 1990, J STEROID BIOCHEM, V35, P293, DOI 10.1016/0022-4731(90)90287-3; NANKIN HR, 1986, J CLIN ENDOCR METAB, V63, P1418, DOI 10.1210/jcem-63-6-1418; NIESCHLAG E, 1978, CIBA F SYMP, V62, P182; NILSSON PM, 1995, J INTERN MED, V237, P479, DOI 10.1111/j.1365-2796.1995.tb00873.x; PHILLIPS GB, 1994, ARTERIOSCLER THROMB, V14, P701, DOI 10.1161/01.ATV.14.5.701; SIMON D, 1992, AM J EPIDEMIOL, V135, P783, DOI 10.1093/oxfordjournals.aje.a116365; STEPAN JJ, 1989, J CLIN ENDOCR METAB, V69, P523; Tenover JL, 1997, J ANDROL, V18, P103; THEORELL T, 1990, J INTERN MED, V227, P31, DOI 10.1111/j.1365-2796.1990.tb00115.x; VERMEULEN A, 1985, MATURITAS, V7, P273, DOI 10.1016/0378-5122(85)90050-7; Vermeulen A, 1996, J CLIN ENDOCR METAB, V81, P1821, DOI 10.1210/jc.81.5.1821; VERMEULEN A, 1992, J CLIN ENDOCR METAB, V74, P939, DOI 10.1210/jc.74.4.939; Wang C, 1996, J CLIN ENDOCR METAB, V81, P3578, DOI 10.1210/jc.81.10.3578; Werner AA, 1939, J AMER MED ASSOC, V112, P1441, DOI 10.1001/jama.1939.02800150013004; *WORLD HLTH ORG, 1992, GUID US ANDR MEN	38	31	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					858	860		10.1136/bmj.320.7238.858	http://dx.doi.org/10.1136/bmj.320.7238.858			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731186	Green Published			2022-12-28	WOS:000086180300031
J	Tucker, GT				Tucker, GT			Chiral switches	LANCET			English	Article							REGIONAL ANESTHESIA; TERFENADINE; DRUG	Developments in synthetic and analytical chemistry have provided the tools to differentiate between two enantiomers (mirror images) of drugs or between the parent compound and metabolite(s) with respect to desired and undesired pharmacological effects. Several drugs are now marketed or being developed as single enantiomers in place of a previous racemic mixture, a process known as "chiral switching". It is easier to understand "pure" as opposed to "mixture" pharmacology but whether the promise of chiral (and metabolite) switches will translate into real clinical advances remains to be seen.	Univ Sheffield, Royal Hallamshire Hosp, Div Clin Sci, Sect Mol Pharmacol & Pharmacogenet, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield	Tucker, GT (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Clin Sci, Sect Mol Pharmacol & Pharmacogenet, Sheffield S10 2JF, S Yorkshire, England.	g.t.tucker@sheffield.ac.uk						Agranat I, 1999, DRUG DISCOV TODAY, V4, P313, DOI 10.1016/S1359-6446(99)01363-X; ALBRIGHT GA, 1979, ANESTHESIOLOGY, V51, P285, DOI 10.1097/00000542-197910000-00001; Committee for Proprietary Medicinal Products, 1993, WORK PART QUAL SAF E; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Evans AM, 1996, J CLIN PHARMACOL, V36, pS7; Fawcett JP, 1999, EUR RESPIR J, V13, P1223; Food and Drug Administration, 1992, FED REGISTER, V57; Hey JA, 1996, ARZNEIMITTEL-FORSCH, V46, P159; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; Lane RM, 1999, CELL MOL NEUROBIOL, V19, P355, DOI 10.1023/A:1006997731966; Markham A, 1996, DRUGS, V52, P429, DOI 10.2165/00003495-199652030-00012; McClellan KJ, 1998, DRUGS, V56, P355, DOI 10.2165/00003495-199856030-00005; Neupert W, 1997, BRIT J PHARMACOL, V122, P487, DOI 10.1038/sj.bjp.0701415; Tucker GT, 1991, PRESCRIBERS J, V31, P189; WALLIN JD, 1989, J CLIN PHARMACOL, V29, P1057, DOI 10.1002/j.1552-4604.1989.tb03280.x; WESCHE DL, 1997, ACTIVE DRUG METABOLI; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532	17	128	129	2	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	2000	355	9209					1085	1087		10.1016/S0140-6736(00)02047-X	http://dx.doi.org/10.1016/S0140-6736(00)02047-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744105				2022-12-28	WOS:000086380800040
J	Delworth, TL; Knutson, TR				Delworth, TL; Knutson, TR			Simulation of early 20th century global warming	SCIENCE			English	Article							OCEAN-ATMOSPHERE MODEL; SURFACE-TEMPERATURE; GREENHOUSE GASES; NORTH-ATLANTIC; COUPLED MODEL; CLIMATE; VARIABILITY; OSCILLATION; AEROSOLS; SEA	The observed global warming of the past century occurred primarily in two distinct 20-year periods, from 1925 to 1944 and from 1978 to the present. Although the Latter warming is often attributed to a human-induced increase of greenhouse gases, causes of the earlier warming are less clear because this period precedes the time of strongest increases in human-induced greenhouse gas (radiative) forcing. Results from a set of six integrations of a coupled ocean-atmosphere climate model suggest that the warming of the early 20th century could have resulted from a combination of human-induced radiative forcing and an unusually Large realization of internal multidecadal variability of the coupled ocean-atmosphere system. This conclusion is dependent on the model's climate sensitivity, internal variability, and the specification of the time-varying human-induced radiative forcing.	NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA	National Oceanic Atmospheric Admin (NOAA) - USA	Delworth, TL (corresponding author), NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA.	td@gfdl.gov	Knutson, Thomas/G-7457-2019; Delworth, Thomas L/C-5191-2014; Knutson, Thomas/P-7225-2019	Knutson, Thomas/0000-0003-4541-519X; Delworth, Thomas L/0000-0003-4865-5391; Knutson, Thomas/0000-0003-4541-519X				ALLEN MR, 1999, RALTR1999084; Barnett TP, 1999, B AM METEOROL SOC, V80, P2631, DOI 10.1175/1520-0477(1999)080<2631:DAAORC>2.0.CO;2; Battisti DS, 1997, J CLIMATE, V10, P1909, DOI 10.1175/1520-0442(1997)010<1909:DGCMUT>2.0.CO;2; Crowley TJ, 1999, GEOPHYS RES LETT, V26, P1901, DOI 10.1029/1999GL900347; Delworth TL, 1997, GEOPHYS RES LETT, V24, P257, DOI 10.1029/96GL03927; DELWORTH TL, IN PRESS CLIM DYN; Free M, 1999, J GEOPHYS RES-ATMOS, V104, P19057, DOI 10.1029/1999JD900233; Fu CB, 1999, INT J CLIMATOL, V19, P581, DOI 10.1002/(SICI)1097-0088(199905)19:6<581::AID-JOC396>3.0.CO;2-P; Haywood JM, 1997, GEOPHYS RES LETT, V24, P1335, DOI 10.1029/97GL01163; Hegerl GC, 1997, CLIM DYNAM, V13, P613, DOI 10.1007/s003820050186; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; Kattenberg A., 1996, CLIMATE CHANGE 1995, P285; Knutson TR, 1999, J GEOPHYS RES-ATMOS, V104, P30981, DOI 10.1029/1999JD900965; MANABE S, 1991, J CLIMATE, V4, P785, DOI 10.1175/1520-0442(1991)004<0785:TROACO>2.0.CO;2; MANABE S, 1994, J CLIMATE, V7, P5, DOI 10.1175/1520-0442(1994)007<0005:MCROAC>2.0.CO;2; MANN ME, 1995, NATURE, V378, P266, DOI 10.1038/378266a0; Mann ME, 1996, J CLIMATE, V9, P2137, DOI 10.1175/1520-0442(1996)009<2137:JSMOST>2.0.CO;2; MITCHELL JFB, 1995, J CLIMATE, V8, P2364, DOI 10.1175/1520-0442(1995)008<2364:OSTGGA>2.0.CO;2; MITCHELL JFB, 1995, NATURE, V376, P501, DOI 10.1038/376501a0; PARKER DE, 1994, J GEOPHYS RES-ATMOS, V99, P14373, DOI 10.1029/94JD00548; ROGERS JC, 1985, J CLIM APPL METEOROL, V24, P1303, DOI 10.1175/1520-0450(1985)024<1303:ACCAWT>2.0.CO;2; Santer BD, 1996, NATURE, V382, P39, DOI 10.1038/382039a0; SCHLESINGER ME, 1994, NATURE, V367, P723, DOI 10.1038/367723a0; STOTT P, IN PRESS CLIM DYN; Tett SFB, 1999, NATURE, V399, P569, DOI 10.1038/21164	26	203	214	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2246	2250		10.1126/science.287.5461.2246	http://dx.doi.org/10.1126/science.287.5461.2246			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731143				2022-12-28	WOS:000086049100046
J	Baveye, P				Baveye, P			To create generalists, teach students how to learn by themselves	NATURE			English	Letter									Cornell Univ, Lab Environm Geophys, Ithaca, NY 14853 USA; Univ Paris 10, Sch Educ, F-92001 Nanterre, France	Cornell University; Universite Paris Nanterre	Baveye, P (corresponding author), Cornell Univ, Lab Environm Geophys, Bradfield Hall, Ithaca, NY 14853 USA.			Baveye, Philippe/0000-0002-8432-6141				BAVEYE P, 1996, CURRENT DEV SELF DIR, P157; Candy P., 1994, DEV LIFELONG LEARNER; Kett J., 1994, PURSUIT KNOWLEDGE DI; Ludmerer Kenneth M., 1985, LEARNING HEAL DEV AM; Seitz F, 2000, NATURE, V403, P483, DOI 10.1038/35000668	5	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					329	329		10.1038/35006249	http://dx.doi.org/10.1038/35006249			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746696	Bronze			2022-12-28	WOS:000086119000016
J	Helmreich, RL				Helmreich, RL			On error management: lessons from aviation	BRITISH MEDICAL JOURNAL			English	Article									Univ Texas, Dept Psychol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Helmreich, RL (corresponding author), Univ Texas, Dept Psychol, Austin, TX 78712 USA.							AMALBERTI R, 1996, CONDUITE SYSTEMES RI; *FED AV ADM, 1999, 12066A FAA; HELMREICH R, 1998, CULTURE WORK NATL OR; Helmreich R L, 1991, Int J Aviat Psychol, V1, P287, DOI 10.1207/s15327108ijap0104_3; Helmreich R.L., 1996, BAILLIERE CLIN ANAES, V10, P277, DOI https://doi.org/10.1016/S0950-3501(96)80017-1; Helmreich RL, 1999, INT J AVIAT PSYCHOL, V9, P19, DOI 10.1207/s15327108ijap0901_2; Helmreich RL, SAFETY AVIATION MANA; HELMREICH RL, 1999, P 10 INT S AV PSYCH, P677; Helmreich RL., 1994, HUMAN ERROR MED, P225; Helmreich RL, 1993, COCKPIT RESOURCE MAN, P3; Klinect JR, 1999, P 10 INT S AV PSYCH, P683; RASON J, 1997, MANAGING RISKS ORG A; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745	13	747	774	2	88	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					781	785		10.1136/bmj.320.7237.781	http://dx.doi.org/10.1136/bmj.320.7237.781			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720367	Green Published			2022-12-28	WOS:000086054700032
J	Castner, SA; Williams, GV; Goldman-Rakic, PS				Castner, SA; Williams, GV; Goldman-Rakic, PS			Reversal of antipsychotic-induced working memory deficits by short-term doper D1 receptor stimulation	SCIENCE			English	Article							VENTRAL TEGMENTAL AREA; POSITRON EMISSION TOMOGRAPHY; PRIMATE CEREBRAL-CORTEX; AGE-RELATED-CHANGES; DOPAMINE-RECEPTORS; PREFRONTAL CORTEX; BEHAVIORAL SUPERSENSITIVITY; HALOPERIDOL TREATMENT; AMPHETAMINE; SENSITIZATION	Chronic blockade of dopamine D2 receptors, a common mechanism of action for antipsychotic drugs, down-regulates D1 receptors in the prefrontal cortex and, as shown here, produces severe impairments in working memory. These deficits were reversed in monkeys by short-term coadministration of a D1 agonist, ABT 431, and this improvement was sustained for more than a year after cessation of D1 treatment. These findings indicate that pharmacological modulation of the D1 signaling pathway can produce long-lasting changes in functional circuits underlying working memory. Resetting this pathway by brief exposure to the agonist may provide a valuable strategy for therapeutic intervention in schizophrenia and other dopamine dysfunctional states.	Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA	Yale University	Goldman-Rakic, PS (corresponding author), Yale Univ, Sch Med, Neurobiol Sect, 333 Cedar St, New Haven, CT 06510 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH044866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010160] Funding Source: NIH RePORTER; NIDA NIH HHS [P01DA10160] Funding Source: Medline; NIMH NIH HHS [P50MH44866] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arnsten AFT, 1998, ARCH GEN PSYCHIAT, V55, P362, DOI 10.1001/archpsyc.55.4.362; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; BACHEVALIER J, 1984, BEHAV NEUROSCI, V98, P770, DOI 10.1037/0735-7044.98.5.770; Bjijou Y, 1996, J PHARMACOL EXP THER, V277, P1177; BUCKLAND PR, 1993, NEUROSCI LETT, V150, P25, DOI 10.1016/0304-3940(93)90099-7; CAI JX, 1997, J PHARMACOL EXP THER, V282, P1; CASTNER SA, UNPUB; CIVELLI O, 1993, ANN REV PHARM TOXICO, V32, P281; Crawford CA, 1997, NEUROREPORT, V8, P2523, DOI 10.1097/00001756-199707280-00021; CRISWELL H, 1989, J NEUROSCI, V9, P125; DAVIDSON M, 1990, ARCH GEN PSYCHIAT, V47, P190; DEKEYSER J, 1990, BRAIN RES, V528, P308, DOI 10.1016/0006-8993(90)91672-4; Florijn WJ, 1997, J PHARMACOL EXP THER, V280, P561; GOLDMANRAKIC PS, 1992, J NEURAL TRANSM-GEN, P163; GOSS JR, 1991, LIFE SCI, V48, P1015, DOI 10.1016/0024-3205(91)90367-K; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; Kelley JJ, 1997, EXP NEUROL, V146, P471, DOI 10.1006/exnr.1997.6552; LEZCANO, 2000, SCIENCE, V287, P1660; LIDOW MS, 1991, NEUROSCIENCE, V40, P657, DOI 10.1016/0306-4522(91)90003-7; Lidow MS, 1997, J PHARMACOL EXP THER, V281, P597; LIDOW MS, 1994, P NATL ACAD SCI USA, V91, P4353, DOI 10.1073/pnas.91.10.4353; Lidow MS, 1998, TRENDS PHARMACOL SCI, V19, P136, DOI 10.1016/S0165-6147(98)01186-9; MARIN C, 1993, EUR J PHARMACOL, V231, P191, DOI 10.1016/0014-2999(93)90448-Q; Meltzer HY, 1999, SCHIZOPHRENIA BULL, V25, P233, DOI 10.1093/oxfordjournals.schbul.a033376; Okubo Y, 1997, MOL PSYCHIATR, V2, P291, DOI 10.1038/sj.mp.4000281; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; RINNE JO, 1990, BRAIN RES, V508, P349, DOI 10.1016/0006-8993(90)90423-9; Robinson TE, 1997, J NEUROSCI, V17, P8491; ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SCHNEIDER JS, 1994, BRAIN RES, V663, P140, DOI 10.1016/0006-8993(94)90471-5; SEDVALL G, 1995, LANCET, V346, P743, DOI 10.1016/S0140-6736(95)91508-7; SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203; STEWART J, 1989, BRAIN RES, V495, P401, DOI 10.1016/0006-8993(89)90236-9; SUHARA T, 1992, PSYCHOPHARMACOLOGY, V106, P14, DOI 10.1007/BF02253582; SUHARA T, 1991, PSYCHOPHARMACOLOGY, V103, P41, DOI 10.1007/BF02244071; Vezina P, 1996, J NEUROSCI, V16, P2411; VINCENT SL, 1991, NEUROPSYCHOPHARMACOL, V5, P147; WENK GL, 1989, NEUROBIOL AGING, V10, P11, DOI 10.1016/S0197-4580(89)80005-3; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0	40	295	310	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2020	2022		10.1126/science.287.5460.2020	http://dx.doi.org/10.1126/science.287.5460.2020			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720329				2022-12-28	WOS:000085902800063
J	Fliss, MS; Usadel, H; Cabellero, OL; Wu, L; Buta, MR; Eleff, SM; Jen, J; Sidransky, D				Fliss, MS; Usadel, H; Cabellero, OL; Wu, L; Buta, MR; Eleff, SM; Jen, J; Sidransky, D			Facile detection of mitochondrial DNA mutations in tumors and bodily fluids	SCIENCE			English	Article							OXIDATIVE DAMAGE; NUCLEAR	Examination of human bladder, head and neck, and lung primary tumors revealed a high frequency of mitochondrial DNA (mtDNA) mutations. The majority of these somatic mutations were homoplasmic in nature, indicating that the mutant mtDNA became dominant in tumor cells. The mutated mtDNA was readily detectable in paired bodily fluids from each type of cancer and was 19 to 220 times as abundant as mutated nuclear p53 DNA. By virtue of their clonal nature and high copy number, mitochondrial mutations may provide a powerful molecular marker for noninvasive detection of cancer.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [P50CA058184, P01CA077664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012488] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 58184, R01 CA77664] Funding Source: Medline; NIDCR NIH HHS [R01 DE 012488] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; JEN J, 1994, CANCER RES, V54, P5523; Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8746; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309	17	649	710	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2017	2019		10.1126/science.287.5460.2017	http://dx.doi.org/10.1126/science.287.5460.2017			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720328				2022-12-28	WOS:000085902800062
J	Berridge, MJ; Lipp, P; Bootman, MD				Berridge, MJ; Lipp, P; Bootman, MD			Signal transduction - The calcium entry Pas de Deux	SCIENCE			English	Editorial Material							STORE		Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Berridge, MJ (corresponding author), Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England.	michael.berridge@bbsrc.ac.uk	Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6	11	156	165	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2000	287	5458					1604	1605		10.1126/science.287.5458.1604	http://dx.doi.org/10.1126/science.287.5458.1604			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	289NE	10733429				2022-12-28	WOS:000085628200026
J	Henderson, GM; Slowey, NC				Henderson, GM; Slowey, NC			Evidence from U-Th dating against Northern Hemisphere forcing of the penultimate deglaciation	NATURE			English	Article							VOSTOK ICE-CORE; WESTERN-AUSTRALIA; TH-230 AGES; SEA LEVELS; DURATION; CORALS; EVENTS; RECORD; PERIOD	Millankovitch proposed that summer insolation at mid-latitudes in the:Northern Hemisphere directly causes the ice-age climate cycles'. This would imply that times of ice-sheet collapse should correspond to peaks in Northern Hemisphere June insolation. But the penultimate deglaciation has proved controversial because June insolation peaks 127 kyr ago whereas several records of past climate suggest that change may have occurred up to 15 kyr earlier(2-8). There is a dear signature of the penultimate deglaciation in marine oxygen-isotope records. But dating this event, which is significantly before the C-14 age range, has not been possible. Here we date the penultimate deglaciation in a record from the Bahamas using a new U-Th isochron technique. After the necessary corrections for or-recoil mobility of U-234 and Th-230 and a small age correction for sediment mixing, the midpoint age for the penultimate deglaciation is determined to be 135 +/- 2.5 kyr ago, This age is consistent with some coral-based sea-level estimates, but it is difficult to reconcile with Tune Northern Hemisphere insolation as the trigger for the ice-age cycles. Potential alternative driving mechanisms for the ice-age cycles that are consistent with such an early date for the penultimate deglaciation are either the variability of the tropical ocean-atmosphere system or changes in atmospheric CO2 concentration controlled by a process in the Southern Hemisphere.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Texas A&M Univ, Dept Oceanog, College Stn, TX 77843 USA	Columbia University; Texas A&M University System; Texas A&M University College Station	Henderson, GM (corresponding author), Univ Oxford, Dept Earth Sci, Parks Rd, Oxford OX1 3PR, England.	gideonh@earth.ox.ac.uk		Henderson, Gideon/0000-0002-6279-7137				BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; Bard E, 1996, GEOPHYS RES LETT, V23, P1473, DOI 10.1029/96GL01279; BARNOLA JM, 1991, TELLUS B, V43, P83, DOI 10.1034/j.1600-0889.1991.t01-1-00002.x; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P352, DOI 10.1029/98PA00920; Burnett W.C., 1992, URANIUM SERIES DISEQ, P486; BURNS SJ, 1987, MAR GEOL, V77, P277, DOI 10.1016/0025-3227(87)90117-4; Clement AC, 1999, PALEOCEANOGRAPHY, V14, P441, DOI 10.1029/1999PA900013; Esat TM, 1999, SCIENCE, V283, P197, DOI 10.1126/science.283.5399.197; GALLUP CD, 1994, SCIENCE, V263, P796, DOI 10.1126/science.263.5148.796; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; Henderson GM, 1999, MAR GEOL, V160, P105, DOI 10.1016/S0025-3227(99)00018-3; HENDERSON GM, 1993, EARTH PLANET SC LETT, V115, P65, DOI 10.1016/0012-821X(93)90213-S; Henderson GM, 1999, EARTH PLANET SC LETT, V169, P99, DOI 10.1016/S0012-821X(99)00065-5; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; JOUZEL J, 1993, NATURE, V364, P407, DOI 10.1038/364407a0; Kim SJ, 1998, SCIENCE, V280, P728, DOI 10.1126/science.280.5364.728; LAMBECK K, 1992, NATURE, V357, P125, DOI 10.1038/357125a0; LORIUS C, 1985, NATURE, V316, P591, DOI 10.1038/316591a0; LUDWIG KR, 1992, SCIENCE, V258, P284, DOI 10.1126/science.258.5080.284; MILANKOVITCH M, 1930, HDB KLIMATOLOGIE, V1, P1; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Redfern SAT, 1998, MINERAL MAG, V62, P607, DOI 10.1180/002646198548007; Slowey NC, 1996, NATURE, V383, P242, DOI 10.1038/383242a0; SOWERS T, 1993, PALEOCEANOGRAPHY, V8, P737, DOI 10.1029/93PA02328; STEIN M, 1993, GEOCHIM COSMOCHIM AC, V57, P2541, DOI 10.1016/0016-7037(93)90416-T; Stirling CH, 1998, EARTH PLANET SC LETT, V160, P745, DOI 10.1016/S0012-821X(98)00125-3; STIRLING CH, 1995, EARTH PLANET SC LETT, V135, P115, DOI 10.1016/0012-821X(95)00152-3; SZABO BJ, 1994, SCIENCE, V266, P93, DOI 10.1126/science.266.5182.93; Winograd IJ, 1997, QUATERNARY RES, V48, P141, DOI 10.1006/qres.1997.1918; ZHU ZR, 1993, EARTH PLANET SC LETT, V118, P281, DOI 10.1016/0012-821X(93)90173-7	30	167	175	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2000	404	6773					61	66		10.1038/35003541	http://dx.doi.org/10.1038/35003541			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716440				2022-12-28	WOS:000085775100043
J	Wadman, M				Wadman, M			Republican candidates clash on fetal tissue in research	NATURE			English	News Item																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 17	2000	403	6771					694	694		10.1038/35001743	http://dx.doi.org/10.1038/35001743			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286BE	10733383	Bronze			2022-12-28	WOS:000085423100013
J	Paris, G; De Leo, G; Menozzi, P; Gatto, M				Paris, G; De Leo, G; Menozzi, P; Gatto, M			Region-based citation bias in science	NATURE			English	Letter									Politecn Milan, Dipartimento Elettron & Informat, I-20133 Milan, Italy; Univ Parma, Dipartimento Sci Ambientali, I-43100 Parma, Italy; Fdn Lombardia Ambiente, I-20121 Milan, Italy	Polytechnic University of Milan; University of Parma	Paris, G (corresponding author), Politecn Milan, Dipartimento Elettron & Informat, Piazza Leonardo da Vinci 32, I-20133 Milan, Italy.		De Leo, Giulio/AAC-5098-2019; MENOZZI, PAOLO/A-6234-2012; Gatto, Marino/D-9531-2012	De Leo, Giulio/0000-0002-4186-3369; MENOZZI, PAOLO/0000-0001-8638-7370; Gatto, Marino/0000-0001-8063-9178				Barreto GR, 1997, SCIENCE, V276, P882; May RM, 1997, SCIENCE, V275, P793, DOI 10.1126/science.275.5301.793; May RM, 1997, SCIENCE, V276, P885	3	38	38	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1998	396	6708					210	210		10.1038/24249	http://dx.doi.org/10.1038/24249			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	10744503	Bronze			2022-12-28	WOS:000077110400017
J	McLeary, EH				McLeary, EH			The Mutter Museum: Education, preservation, and commemoration	ANNALS OF INTERNAL MEDICINE			English	Article									Univ Penn, Dept Hist & Sociol Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	McLeary, EH (corresponding author), Univ Penn, Dept Hist & Sociol Sci, 303 Logan Hall,249 S 36th St, Philadelphia, PA 19104 USA.							BILLINGS JS, 1888, MED NEWS, V53, P309; Daukes S. H., 1929, MED MUSEUM MODERN DE; Flexner A., 1910, FLEXNER REPORT; KRUMBHAAR EB, 1922, ANN MED HIST, V4, P272; Stevens Rosemary, 1971, AM MED PUBLIC INTERE; WORDEN G, 1995, T STUD COLL PHYSICIA, V17, P95	6	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					599	603		10.7326/0003-4819-132-7-200004040-00033	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00033			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744614				2022-12-28	WOS:000086129300030
J	Fears, R; Roberts, D; Poste, G				Fears, R; Roberts, D; Poste, G			Rational or rationed medicine? The promise of genetics for improved clinical practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERVICES; NHS; CHALLENGE		SmithKline Beecham, Harlow CM19 5AW, Essex, England; UCL, Sch Publ Policy, London WC1H 9EZ, England	GlaxoSmithKline; University of London; University College London	Fears, R (corresponding author), SmithKline Beecham, Harlow CM19 5AW, Essex, England.	robon_b_fears@sbphrd.com						Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; Bell J, 1998, BMJ-BRIT MED J, V316, P618, DOI 10.1136/bmj.316.7131.618; Bell J., 1998, CLIN FUTURES, P20; Blair Tony, 1998, 3 WAY NEW POLITICS N, V588; Buxton M, 1998, J ROY SOC MED, V91, P2, DOI 10.1177/014107689809135S02; *CLIN GEN COMM ROY, 1998, CLIN GEN SERV; *CLIN GEN COMM ROY, 1996, CLIN GEN SERV 21 CEN; *DEP HLTH, 1998, MEM HLTH COMM FUT ST; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Fears R, 1999, BRIT MED BULL, V55, P460, DOI 10.1258/0007142991902376; Fears R, 1999, SCIENCE, V284, P267, DOI 10.1126/science.284.5412.267; *GEN INT GROUP, 1998, GUID GEN SERV; Gill M, 1998, BMJ-BRIT MED J, V316, P570, DOI 10.1136/bmj.316.7131.570; Harris R, 1997, EUR J HUM GENET, V5, P3; Iredale R, 1998, BRIT J SOC WORK, V28, P961; Kinmonth AL, 1998, BMJ-BRIT MED J, V316, P767, DOI 10.1136/bmj.316.7133.767; KIRK M, 1999, NURS EDUC TODAY, V19, P1; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LENAGHAN J, 1998, BRAVE NEW NHS; MARINKER M, 1998, CLIN FUTURES, P1; MIHILL C, 1999, HARD RATIONS GETTING; Modell M, 1998, BMJ-BRIT MED J, V317, P788, DOI 10.1136/bmj.317.7161.788; PECKHAM M, 1998, CLIN FUTURES, P184; Poste G, 1998, Nat Biotechnol, V16 Suppl, P19, DOI 10.1038/5403; Richard T, 1999, BMJ-BRIT MED J, V318, P341, DOI 10.1136/bmj.318.7180.341; RICHMOND MH, 1999, IMPLICATIONS GENET G; Rosen R, 1998, J ROY SOC MED, V91, P3, DOI 10.1177/014107689809100102; Shekelle PG, 1998, LANCET, V352, P163, DOI 10.1016/S0140-6736(05)77801-6; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; Skirton H, 1998, J MED GENET, V35, P410, DOI 10.1136/jmg.35.5.410; Smith R, 1998, BRIT MED J, V317, P3, DOI 10.1136/bmj.317.7150.3	31	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2000	320	7239					933	935		10.1136/bmj.320.7239.933	http://dx.doi.org/10.1136/bmj.320.7239.933			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10742009	Green Published			2022-12-28	WOS:000086337100036
J	Ross, NA; Wolfson, MC; Dunn, JR; Berthelot, JM; Kaplan, GA; Lynch, JM				Ross, NA; Wolfson, MC; Dunn, JR; Berthelot, JM; Kaplan, GA; Lynch, JM			Relation between income inequality and mortality in Canada and in the United States: cross sectional assessment using census data and vital statistics	BRITISH MEDICAL JOURNAL			English	Article							INFANT-MORTALITY; LIFE EXPECTANCY; HEALTH; COUNTRIES; DETERMINANTS; POPULATION; CHICAGO	Objective To compare the relation between mortality and income inequality in Canada with that in the United States. Design The degree of income inequality, defined as the percentage of total household income received by the less well of 50% of households, was calculated and these measures were examined in relation to all cause mortality,grouped by and adjusted for age. Setting The 10 Canadian provinces, the 50 US states, and 53 Canadian and 282 US metropolitan areas. Results Canadian provinces and metropolitan areas generally and both lower income inequality and lower mortality than US states and metropolitan areas. In age grouped regression models that combined Canadian and US metropolitan areas, income inequality was a significant explanatory variable for all age groupings except for elderly people. the effect was largest for working age populations, in which a hypothetical 1% increase in the share of income to the poorer half of households would reduce mortality by 21 deaths per 100 000, Within Canada, however, income inequality was not significantly associated with mortality. Conclusions Canada seems to counter the increasingly noted association at the societal level between income inequality and mortality. The lack of a significant association between income inequality and mortality in Canada may indicate that the effects of income inequality on health are not automatic and may be blunted by the different ways in which social and economic resources are distributed in Canada and in the United States.	Stat Canada, Hlth Anal & Modelling Grp, Ottawa, ON K1A 0T6, Canada; Univ British Columbia, Ctr Hlth Serv & Policy Res, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1Z3, Canada; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; Stat Canada, Anal & Dev Branch, Ottawa, ON K1A 0T6, Canada	Statistics Canada; University of British Columbia; University of Michigan System; University of Michigan; Statistics Canada	Ross, NA (corresponding author), Stat Canada, Hlth Anal & Modelling Grp, Ottawa, ON K1A 0T6, Canada.		Lynch, John W/A-4797-2008; Kaplan, George/AAJ-2398-2020; Dunn, James R/G-1543-2016	Lynch, John W/0000-0003-2781-7902; Dunn, James/0000-0003-1054-9956				Badcock B., 1984, UNFAIRLY STRUCTURED; BenShlomo Y, 1996, BRIT MED J, V312, P1013; BOURNE LS, 1997, DEV SMALL AREA INDIC; Daly MC, 1998, MILBANK Q, V76, P315, DOI 10.1111/1468-0009.00094; Fiscella K, 1997, BRIT MED J, V314, P1724, DOI 10.1136/bmj.314.7096.1724; FLEGG AT, 1982, POP STUD-J DEMOG, V36, P441, DOI 10.2307/2174055; GOLDBERG M, 1986, MYTH N AM CITY; Gravelle H, 1998, BMJ-BRIT MED J, V316, P382, DOI 10.1136/bmj.316.7128.382; Guest AM, 1998, DEMOGRAPHY, V35, P23, DOI 10.2307/3004024; Holzer Harry J., 1996, WHAT EMPLOYERS WANT; Kaplan GA, 1996, BRIT MED J, V312, P999; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Kennedy BP, 1998, BRIT MED J, V317, P917; LEGRAND J, 1987, EUR ECON REV, V31, P182, DOI 10.1016/0014-2921(87)90030-4; Lynch J W, 1997, J Health Psychol, V2, P297, DOI 10.1177/135910539700200303; Lynch JW, 1998, AM J PUBLIC HEALTH, V88, P1074, DOI 10.2105/AJPH.88.7.1074; LYNCH JW, IN PRESS BMJ; Marmot MG, 1998, MILBANK Q, V76, P403, DOI 10.1111/1468-0009.00097; MURDIE RA, 1998, URBAN SEGREGATION WE, P64; MURPHY K, 1998, 6638 NBER; Neter J, 1990, APPL LINEAR STAT MOD; OConnell JM, 1996, HEALTH ECON, V5, P573, DOI 10.1002/(SICI)1099-1050(199611)5:6<573::AID-HEC231>3.0.CO;2-L; Orfield Myron, 1997, METROPOLITICS REGION; RODGERS GB, 1979, POP STUD-J DEMOG, V33, P343, DOI 10.2307/2173539; Smith GD, 1996, BRIT MED J, V313, P1584, DOI 10.1136/bmj.313.7072.1584; Soobader MJ, 1999, SOC SCI MED, V48, P733, DOI 10.1016/S0277-9536(98)00401-8; Statistics Canada, 1998, REP DEM SIT CAN 1997; Waitzman NJ, 1998, MILBANK Q, V76, P341, DOI 10.1111/1468-0009.00095; WALDMANN RJ, 1992, Q J ECON, V107, P1283, DOI 10.2307/2118389; WENNEMO I, 1993, SOCIOL HEALTH ILL, V15, P429, DOI 10.1111/1467-9566.ep11372773; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wilkinson RG, 1986, CLASS HLTH RES LONGI; Wilson M, 1997, BRIT MED J, V314, P1271, DOI 10.1136/bmj.314.7089.1271; Wolfson M, 1999, BRIT MED J, V319, P953, DOI 10.1136/bmj.319.7215.953; WOLFSON M, 1993, J GERONTOL, V48, pS167, DOI 10.1093/geronj/48.4.S167; WOLFSON Michael C., 1998, MONTHLY LABOR RE APR, P3; Yeates M., 1990, N AM CITY	38	308	310	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					898	902		10.1136/bmj.320.7239.898	http://dx.doi.org/10.1136/bmj.320.7239.898			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	301YA	10741994	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086337100021
J	Weber, MF; Stover, CA; Gilbert, LR; Nevitt, TJ; Ouderkirk, AJ				Weber, MF; Stover, CA; Gilbert, LR; Nevitt, TJ; Ouderkirk, AJ			Giant birefringent optics in multilayer polymer mirrors	SCIENCE			English	Article							FILMS; ANGLES; MEDIA	Multilayer mirrors that maintain or increase their reflectivity with increasing incidence angle can be constructed using polymers that exhibit Large birefringence in their indices of refraction. The most important feature of these multilayer interference stacks is the index difference in the thickness direction (z axis) relative to the in-plane directions of the film. This z-axis refractive index difference provides a variable that determines the existence and value of the Brewster's angle at layer interfaces, and it controls both the interfacial Fresnel reflection coefficient and the phase relations that determine the optics of multilayer stacks. These films can yield optical results that are difficult or impossible to achieve with conventional multilayer optical designs. The materials and processes necessary to fabricate such films are amenable to Large-scale manufacturing.	3M Ctr, 3M Film Light Management Technol Ctr, St Paul, MN 55144 USA	3M	Ouderkirk, AJ (corresponding author), 3M Ctr, 3M Film Light Management Technol Ctr, St Paul, MN 55144 USA.							ALFREY T, 1969, POLYM ENG SCI, V9, P400, DOI 10.1002/pen.760090605; AZZAM RMA, 1987, ELLIPSOMETRY POLARIZ, P119; AZZAM RMA, 1987, ELLIPSOMETRY POLARIZ, P357; BANNING M, 1947, J OPT SOC AM, V37, P792, DOI 10.1364/JOSA.37.000792; BAUMEISTER P, 1970, SCI AM, V223, P58, DOI 10.1038/scientificamerican1270-58; BERREMAN DW, 1972, J OPT SOC AM, V62, P502, DOI 10.1364/JOSA.62.000502; BORN M, 1975, PRINCIPLES OPTICS, P40; BORN M, 1975, PRINCIPLES OPTICS, P66; BREWSTER D, 1839, TREATISE OPTICS; CAKMAK M, 1989, POLYM ENG SCI, V29, P1534, DOI 10.1002/pen.760292108; COSTICH VR, 1970, APPL OPTICS, V9, P866, DOI 10.1364/AO.9.000866; Drude P., 1891, WIED ANN, V43, P146; DRUDE P, 1891, ANN PHYS CHEM, V38, P865; Fink Y, 1998, SCIENCE, V282, P1679, DOI 10.1126/science.282.5394.1679; HEAVENS OS, 1966, APPL OPTICS, V5, P373, DOI 10.1364/AO.5.000373; HEFFELFINGER CJ, 1971, SCI TECHNOLOGY POLYM, P587; HODGKINSON I, 1993, J OPT SOC AM A, V10, P2065, DOI 10.1364/JOSAA.10.002065; HOLMES DA, 1966, J OPT SOC AM, V56, P1763, DOI 10.1364/JOSA.56.001763; ITO T, 1996, Patent No. 5579159; Jones RL, 1999, NATURE, V400, P146, DOI 10.1038/22017; Kim JC, 1998, POLYMER, V39, P4225, DOI 10.1016/S0032-3861(98)00004-4; LEKNER J, 1993, J OPT SOC AM A, V10, P2059, DOI 10.1364/JOSAA.10.002059; LISSBERG.PH, 1970, REP PROG PHYS, V33, P197, DOI 10.1088/0034-4885/33/1/305; MACLEOD HA, 1986, THIN FILM OPTICAL FI, P334; SEFERIS JC, 1989, POLYM HDB, P45; THELEN A, 1980, J OPT SOC AM, V70, P118, DOI 10.1364/JOSA.70.000118; THELEN A, 1976, APPL OPTICS, V15, P2983, DOI 10.1364/AO.15.002983; THELEN A, 1963, J OPT SOC AM, V53, P1266, DOI 10.1364/JOSA.53.001266; YEH P, 1979, J OPT SOC AM, V69, P742, DOI 10.1364/JOSA.69.000742	29	400	517	5	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2451	2456		10.1126/science.287.5462.2451	http://dx.doi.org/10.1126/science.287.5462.2451			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741958				2022-12-28	WOS:000086202200035
J	Smith, GD; Harding, S; Rosato, M				Smith, GD; Harding, S; Rosato, M			Relation between infants' birth weight and mothers' mortality: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Off Natl Stat, London SW1V 2QQ, England	University of Bristol	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				Barker D. J. P., 1994, MOTHERS BABIES DIS L; Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7; Goldblatt P, 1990, LONGITUDINAL STUDY M; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Smith GD, 1997, BRIT MED J, V315, P1189, DOI 10.1136/bmj.315.7117.1189	5	108	108	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					839	840		10.1136/bmj.320.7238.839	http://dx.doi.org/10.1136/bmj.320.7238.839			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731177	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000086180300025
J	Stevens, B; Fields, RD				Stevens, B; Fields, RD			Response of Schwann cells to action potentials in development	SCIENCE			English	Article							INCREASES INTRACELLULAR CALCIUM; PERIPHERAL NERVOUS-SYSTEM; DIFFERENTIAL REGULATION; NEUROMUSCULAR-JUNCTION; DEPENDENT REGULATION; MYELINATION; PATTERNS; L1; MECHANISMS; ACTIVATION	Sensory axons become functional late in development when Schwann cells (SC) stop proliferating and differentiate into distinct phenotypes, We report that impulse activity in premyelinated axons can inhibit proliferation and differentiation of SCs. This neuron-glial signaling is mediated by adenosine triphosphate acting through PZ receptors on SCs and intracellular signaling pathways involving Ca(2+), Ca(2+)/calmodulin kinase, mitogen-activated protein kinase, cyclic adenosine 3',5'-monophosphate response element binding protein, and expression of c-fos and Krox-24. Adenosine triphosphate arrests maturation of SCs in an immature morphological stage and prevents expression of O4, myelin basic protein, and the formation of myelin. Through;this mechanism, functional activity in the developing nervous system could delay terminal differentiation of SCs until exposure to appropriate axon-derived signals.	NICHHD, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Fields, RD (corresponding author), NICHHD, Dev Neurobiol Lab, NIH, Bldg 49,Room 5A38,49 Convent Dr, Bethesda, MD 20892 USA.	fields@helix.nih.gov	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				Ansselin AD, 1997, NEUROSCIENCE, V76, P947, DOI 10.1016/S0306-4522(96)00370-3; COLELLO RJ, 1995, J NEUROSCI, V15, P7665; Demerens C, 1996, P NATL ACAD SCI USA, V93, P9887, DOI 10.1073/pnas.93.18.9887; Fields RD, 1997, J NEUROSCI, V17, P7252; FITZGERALD M, 1987, NATURE, V326, P603, DOI 10.1038/326603a0; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Green AC, 1997, NEUROSCIENCE, V80, P635, DOI 10.1016/S0306-4522(97)00117-6; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Itoh K, 1997, J NEUROBIOL, V33, P735, DOI 10.1002/(SICI)1097-4695(19971120)33:6<735::AID-NEU3>3.0.CO;2-A; ITOH K, 1995, SCIENCE, V270, P1369, DOI 10.1126/science.270.5240.1369; JAHROMI BS, 1992, NEURON, V8, P1069, DOI 10.1016/0896-6273(92)90128-Z; JESSEN KR, 1991, GLIA, V4, P185, DOI 10.1002/glia.440040210; LEVRAM V, 1995, J NEUROSCI, V15, P2628; LYONS SA, 1995, GLIA, V13, P27, DOI 10.1002/glia.440130104; Mayer C, 1998, GLIA, V23, P374, DOI 10.1002/(SICI)1098-1136(199808)23:4<374::AID-GLIA9>3.0.CO;2-2; MINXU I, 1996, J NEUROPHYSIOL, V76, P2595; Mirsky R, 1999, BRAIN PATHOL, V9, P293; REIST NE, 1992, P NATL ACAD SCI USA, V89, P7625, DOI 10.1073/pnas.89.16.7625; ROBITAILLE R, 1995, J NEUROSCI, V15, P7121; Scherer SS, 1997, CURR OPIN NEUROL, V10, P386, DOI 10.1097/00019052-199710000-00006; SEILHEIMER B, 1988, J CELL BIOL, V107, P341, DOI 10.1083/jcb.107.1.341; SHENG HZ, 1993, J NEUROSCI RES, V35, P459, DOI 10.1002/jnr.490350502; SHENG HZ, 1994, ANAL BIOCHEM, V222, P123, DOI 10.1006/abio.1994.1463; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Stevens B, 1998, J NEUROSCI, V18, P9303; STEVENS B, UNPUB; STEWART HJS, 1993, EUR J NEUROSCI, V5, P1136, DOI 10.1111/j.1460-9568.1993.tb00968.x; Topilko P, 1997, J NEUROSCI RES, V50, P702, DOI 10.1002/(SICI)1097-4547(19971201)50:5<702::AID-JNR7>3.0.CO;2-L; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; WOOD P, 1990, ANN NY ACAD SCI, V605, P1, DOI 10.1111/j.1749-6632.1990.tb42376.x; WOOD PM, 1990, J NEUROSCI, V10, P3635; Zorick TS, 1999, DEVELOPMENT, V126, P1397	32	202	206	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2267	2271		10.1126/science.287.5461.2267	http://dx.doi.org/10.1126/science.287.5461.2267			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731149				2022-12-28	WOS:000086049100052
J	Liss, KD; Hock, R; Gomm, M; Waibel, B; Magerl, A; Krisch, M; Tucoulou, R				Liss, KD; Hock, R; Gomm, M; Waibel, B; Magerl, A; Krisch, M; Tucoulou, R			Storage of X-ray photons in a crystal resonator	NATURE			English	Article								The temporal structure and high brilliance of the X-ray beams produced by third-generation synchrotrons open up new possibilities in time-dependent diffraction and spectroscopy, where timescales down to the sub-nanosecond regime can now be accessed. These beam properties are such that one can envisage the development of the X-ray equivalent of optical components, such as photon delay lines and resonators, that have proved indispensable in a wide range of experiments-for example, pump-probe and multiple-interaction experiments-and (through shaping the temporal structure and repetition rate of the beams) time-dependent measurements in crystallography, physics, biology and chemistry(1-3). Optical resonators, such as those used in lasers, are available at wavelengths from the visible to soft X-rays(4,5). Equivalent components for hard X-rays have been discussed for more than thirty years(4,6,7), but have yet to be realized. Here we report the storage of hard X-ray photons (energy 15.817 keV) in a crystal resonator formed by two plates of crystalline silicon. The photons are stored for as many as 14 back-and-forth cycles within the resonator, each cycle separated by one nanosecond.	European Synchrotron Radiat Facil, F-38043 Grenoble, France; Lehrstuhl Kristallog & Strukturphys, D-91054 Erlangen, Germany; MTU GmbH, D-80991 Munich, Germany	European Synchrotron Radiation Facility (ESRF); MTU Aero Engines	Liss, KD (corresponding author), European Synchrotron Radiat Facil, BP 220, F-38043 Grenoble, France.		Hock, Rainer/E-1397-2013; Liss, Klaus-Dieter/E-8548-2011; Magerl, Andreas/E-1797-2013; Liss, Klaus Dieter/E-8624-2014; Krisch, Michael H/U-5662-2018	Liss, Klaus-Dieter/0000-0003-4323-0343; Liss, Klaus Dieter/0000-0003-4323-0343; Krisch, Michael H/0000-0001-7423-1715				BOND WL, 1967, APPL PHYS LETT, V10, P216, DOI 10.1063/1.1754919; CATICHA A, 1990, PHYS STATUS SOLIDI A, V119, P643, DOI 10.1002/pssa.2211190228; CEGLIO NM, 1988, APPL OPTICS, V27, P5022, DOI 10.1364/AO.27.005022; DESLATTES R, 1968, APPL PHYS LETT, V12, P135; HART M, 1971, REP PROG PHYS, V34, P435, DOI 10.1088/0034-4885/34/2/302; KISHIMOTO S, 1991, NUCL INSTRUM METH A, V309, P603, DOI 10.1016/0168-9002(91)90272-R; LISS KD, 1998, P SOC PHOTO-OPT INS, V3451, P177; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Rose-Petruck C, 1999, NATURE, V398, P310, DOI 10.1038/18631; STEYERL A, 1979, Z PHYS B CON MAT, V34, P221, DOI 10.1007/BF01322144; Zachariasen W. H., 1945, THEORY XRAY DIFFRACT	11	30	30	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					371	373		10.1038/35006017	http://dx.doi.org/10.1038/35006017			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746719				2022-12-28	WOS:000086119000044
J	Tollestrup, AV				Tollestrup, AV			Robert Rathbun Wilson (1914-2000) - Obituary	NATURE			English	Biographical-Item									Fermi Natl Accelerator Lab, Batavia, IL 60510 USA	United States Department of Energy (DOE); University of Chicago; Fermi National Accelerator Laboratory	Tollestrup, AV (corresponding author), Fermi Natl Accelerator Lab, POB 500, Batavia, IL 60510 USA.	alvin@fnal.gov							0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					350	350		10.1038/35006208	http://dx.doi.org/10.1038/35006208			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746710	Bronze			2022-12-28	WOS:000086119000035
J	Gaba, DM				Gaba, DM			Anaesthesiology as a model for patient safety in health care	BRITISH MEDICAL JOURNAL			English	Article							ANESTHESIA; ERRORS; ENVIRONMENT; INCIDENTS; MORTALITY; MISHAPS; SYSTEM		VA Palo Alto Hlth Care Syst, Patient Safety Ctr Inquiry, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Gaba, DM (corresponding author), VA Palo Alto Hlth Care Syst, Patient Safety Ctr Inquiry, 112PSCI,3801 Miranda Ave, Palo Alto, CA 94304 USA.		Gaba, David M/D-5229-2009	Gaba, David M/0000-0002-0657-5396				ARENS J, 1999, ASA NEWSLETTER, V63, P26; Beckmann U, 1996, ANAESTH INTENS CARE, V24, P314, DOI 10.1177/0310057X9602400303; Bhasale AL, 1998, MED J AUSTRALIA, V169, P73, DOI 10.5694/j.1326-5377.1998.tb140186.x; Cheney FW, 1999, ANESTHESIOLOGY, V91, P552, DOI 10.1097/00000542-199908000-00030; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; COOPER JB, 1978, ANESTHESIOLOGY, V49, P399, DOI 10.1097/00000542-197812000-00004; DEANDA A, 1991, ANESTH ANALG, V72, P308; DERRINGTON MC, 1987, BRIT J ANAESTH, V59, P815, DOI 10.1093/bja/59.7.815; DRUI AB, 1973, ANESTH ANALG, V52, P584; EAGLE CJ, 1992, CAN J ANAESTH, V39, P118, DOI 10.1007/BF03008640; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; GABA D, 1999, ANESTHESIA; GABA DM, 1987, ANESTHESIOLOGY, V66, P670, DOI 10.1097/00000542-198705000-00013; GABA DM, 1988, ANESTHESIOLOGY, V69, P387, DOI 10.1097/00000542-198809000-00017; GABA DM, 1991, PROBLEMS ANESTHESIA, V5, P329; GALLETLY DC, 1991, ANAESTH INTENS CARE, V19, P66, DOI 10.1177/0310057X9101900112; GOOD ML, 1989, INT ANESTHESIOL CLIN, V27, P161, DOI 10.1097/00004311-198902730-00005; KURREK M, 1998 M SOC TECHN AN; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LUNN JN, 1986, EPIDEMIOLOGY ANAESTH; MACKENZIE CF, 1994, ANESTHESIOLOGY, V81, P763, DOI 10.1097/00000542-199409000-00030; MARSCH S, 1998, SIMULATORS ANESTHESI; *NAT PAT SAF FDN, 1997, PROSP NPSF IMP LEAD; ORKIN FK, 1993, ANESTHESIOLOGY, V78, P417; PETTY C, 1987, ANESTHESIA MACH; RAEMER D, 1998 M SOC TECHN AN; RUNCIMAN WB, 1993, ANAESTH INTENS CARE, V21, P506, DOI 10.1177/0310057X9302100506; SCHWID HA, 1987, COMPUT BIOMED RES, V20, P64, DOI 10.1016/0010-4809(87)90019-X; Small SD, 1999, ACAD EMERG MED, V6, P312, DOI 10.1111/j.1553-2712.1999.tb00395.x; WARDEN JC, 1994, MED J AUSTRALIA, V161, P585, DOI 10.5694/j.1326-5377.1994.tb127636.x; WEBB RK, 1993, ANAESTH INTENS CARE, V21, P520, DOI 10.1177/0310057X9302100507; Weinger MB, 1997, ANESTHESIOLOGY, V87, P144, DOI 10.1097/00000542-199707000-00019; XIAO Y, 1992, PROCEEDINGS OF THE HUMAN FACTORS SOCIETY, 36TH ANNUAL MEETING, VOLS 1 AND 2, P1279	33	306	316	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					785	788		10.1136/bmj.320.7237.785	http://dx.doi.org/10.1136/bmj.320.7237.785			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720368	Green Published			2022-12-28	WOS:000086054700033
J	Schimel, D; Melillo, J; Tian, HQ; McGuire, AD; Kicklighter, D; Kittel, T; Rosenbloom, N; Running, S; Thornton, P; Ojima, D; Parton, W; Kelly, R; Sykes, M; Neilson, R; Rizzo, B				Schimel, D; Melillo, J; Tian, HQ; McGuire, AD; Kicklighter, D; Kittel, T; Rosenbloom, N; Running, S; Thornton, P; Ojima, D; Parton, W; Kelly, R; Sykes, M; Neilson, R; Rizzo, B			Contribution of increasing CO2 and climate to carbon storage by ecosystems in the United States	SCIENCE			English	Article							TERRESTRIAL ECOSYSTEMS; VARIABILITY; DATABASE; PRECIPITATION; DIOXIDE; CYCLE; SINK	The effects of increasing carbon dioxide (CO2) and climate on net carbon storage in terrestrial ecosystems of the conterminous United States for the period 1895-1993 were modeled with new, detailed historical climate information. For the period 1980-1993, results from an ensemble of three models agree within 25%, simulating a land carbon sink from CO2 and climate effects of 0.08 gigaton of carbon per year. The best estimates of the total sink from inventory data are about three times larger, suggesting that processes such as regrowth on abandoned agricultural land or in forests harvested before 1980 have effects as large as or larger than the direct effects of CO2 and climate. The modeled sink varies by about 100% from year to year as a result of climate variability.	Max Planck Inst Biogeochem, D-07701 Jena, Germany; Marine Biol Lab, Ctr Ecosyst, Woods Hole, MA 02543 USA; Univ Alaska, US Geol Survey, Alaska Cooperat Fish & Wildlife Res Unit, Fairbanks, AK 99775 USA; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; Univ Montana, Missoula, MT 59812 USA; Colorado State Univ, NREL, Ft Collins, CO 80523 USA; Univ Lund, Ekol Huset, S-22362 Lund, Sweden; Oregon State Univ, Forest Sci Lab, USDA, US Forest Serv, Corvallis, OR 97333 USA; Univ Virginia, Dept Environm Sci, Charlottesville, VA 22903 USA	Max Planck Society; Marine Biological Laboratory - Woods Hole; United States Department of the Interior; United States Geological Survey; University of Alaska System; University of Alaska Fairbanks; National Center Atmospheric Research (NCAR) - USA; University of Montana System; University of Montana; Colorado State University; Lund University; Oregon State University; United States Department of Agriculture (USDA); United States Forest Service; University of Virginia	Schimel, D (corresponding author), Max Planck Inst Biogeochem, Postfach 10 01 64, D-07701 Jena, Germany.		Ojima, Dennis/C-5272-2016; Tian, Hanqin/A-6484-2012; Thornton, Peter E/B-9145-2012; Kittel, Timothy G. F./F-2792-2011; Gutierrez, Emilia/O-7568-2014; Noojipady, Praveen/B-2511-2010	Tian, Hanqin/0000-0002-1806-4091; Thornton, Peter E/0000-0002-4759-5158; Kittel, Timothy G. F./0000-0002-4153-1006; Gutierrez, Emilia/0000-0002-6085-5700; 				BIRDSEY RA, 1995, PRODUCTIVITY AM FORE, P56; Braswell BH, 1997, SCIENCE, V278, P870, DOI 10.1126/science.278.5339.870; Brown SL, 1999, ECOL APPL, V9, P968, DOI 10.1890/1051-0761(1999)009[0968:SPOAPA]2.0.CO;2; Cao MK, 1998, NATURE, V393, P249, DOI 10.1038/30460; CIAS P, 1995, SCIENCE, V269, P1098; DAI A, 1993, GLOBAL BIOGEOCHEM CY, V7, P599, DOI 10.1029/93GB01165; DALY C, 1994, J APPL METEOROL, V33, P140, DOI 10.1175/1520-0450(1994)033&lt;0140:ASTMFM&gt;2.0.CO;2; ENTING IG, 1994, CSIRO DIV ATMOS RES, V31, P1; Fan S, 1998, SCIENCE, V282, P442, DOI 10.1126/science.282.5388.442; Goulden ML, 1996, SCIENCE, V271, P1576, DOI 10.1126/science.271.5255.1576; Holland EA, 1997, J GEOPHYS RES-ATMOS, V102, P15849, DOI 10.1029/96JD03164; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; Karl TR, 1998, B AM METEOROL SOC, V79, P231, DOI 10.1175/1520-0477(1998)079<0231:STOPAF>2.0.CO;2; Kittel TGF, 1995, J BIOGEOGR, V22, P857, DOI 10.2307/2845986; KITTEL TGF, 1997, P 10 C APPL CLIM BOS, P222; LOVELAND TR, 1991, PHOTOGRAMM ENG REM S, V57, P1453; MELILLO JM, 1995, GLOBAL BIOGEOCHEM CY, V9, P407; Parton W.J., 1994, SSSA SPECIAL PUBLICA, V39, P147, DOI DOI 10.2136/SSSASPECPUB39.C9; Peterson TC, 1997, B AM METEOROL SOC, V78, P2837, DOI 10.1175/1520-0477(1997)078<2837:AOOTGH>2.0.CO;2; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; Running S.W., 1993, SCALING PHYSL PROCES, P141, DOI DOI 10.1016/B978-0-12-233440-5.50014-2; SAMIENTO JL, 1999, US CARBON CYCLE SCI; SCHIMEL DS, 1995, GLOBAL CHANGE BIOL, V1, P77, DOI 10.1111/j.1365-2486.1995.tb00008.x; Stallard RF, 1998, GLOBAL BIOGEOCHEM CY, V12, P231, DOI 10.1029/98GB00741; Steffen W, 1998, SCIENCE, V280, P1393; Tian H, 1999, TELLUS B, V51, P414, DOI 10.1034/j.1600-0889.1999.00021.x	26	434	534	7	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2004	2006		10.1126/science.287.5460.2004	http://dx.doi.org/10.1126/science.287.5460.2004			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720324				2022-12-28	WOS:000085902800058
J	Capes, SE; Hunt, D; Malmberg, K; Gerstein, HC				Capes, SE; Hunt, D; Malmberg, K; Gerstein, HC			Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview	LANCET			English	Article							FREE FATTY ACIDS; PROGNOSTIC IMPORTANCE; INSULIN-TREATMENT; BLOOD-GLUCOSE; MORTALITY; MELLITUS; ADMISSION; THERAPY; DETERMINANTS; PREVALENCE	Background High blood glucose concentration may increase risk of death and poor outcome after acute myocardial infarction. We did a systematic review and metaanalysis to assess the risk of in-hospital mortality or congestive heart failure after myocardial infarction in patients with and without diabetes who had stress hyperglycaemia on admission. Methods We did two searches of MEDLINE for English-language articles published from 1966 to October, 1998, a computerised search of Science Citation Index from 1980 to September, 1998, and manual searches of bibliographies. Two searchers identified all cohort studies or clinical trials reporting in-hospital mortality or rates of congestive heart failure after myocardial infarction in relation to glucose concentration on admission. We compared the relative risks of in-hospital mortality and congestive heart failure in hyperglycaemic and normoglycaemic patients with and without diabetes. Findings 14 articles describing 15 studies were identified. Patients without diabetes who had glucose concentrations more than or equal to range 6.1-8.0 mmol/L had a 3.9-fold (95% CI 2.9-5.4) higher risk of death than patients without diabetes who had lower glucose concentrations. Glucose concentrations higher than values in the range of 8.0-10.0 mmol/L on admission were associated with increased risk of congestive heart failure or cardiogenic shock in patients without diabetes. In patients with diabetes who had glucose concentrations more than or equal to range 10.0-11.0 mmol/L the risk of death was moderately increased (relative risk 1.7 [1.2-2.4]). Interpretation Stress hyperglycaemia with myocardial infarction is associated with an increased risk of in-hospital mortality in patients with and without diabetes; the risk of congestive heart failure or cardiogenic shock is also increased in patients without diabetes.	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; Karolinska Hosp, Dept Cardiol, S-10401 Stockholm, Sweden	McMaster University; Karolinska Institutet; Karolinska University Hospital	Capes, SE (corresponding author), McMaster Univ, Dept Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	scapes@fhs.osu.mcmaster.ca	Gerstein, Hertzel/ABB-8781-2020; Gerstein, Hertzel C/B-1235-2013	Gerstein, Hertzel/0000-0001-8072-2836; Gerstein, Hertzel C/0000-0001-8072-2836				ALLISON SP, 1969, BRIT J ANAESTH, V41, P588, DOI 10.1093/bja/41.7.588; Aronson D, 1997, ANN INTERN MED, V126, P296, DOI 10.7326/0003-4819-126-4-199702150-00006; BANERJEE AK, 1986, BRIT J CLIN PRACT, V40, P516; BELLODI G, 1989, AM J CARDIOL, V64, P885, DOI 10.1016/0002-9149(89)90836-9; CLARKE RSJ, 1970, BRIT J ANAESTH, V42, P295, DOI 10.1093/bja/42.4.295; Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233; Cruickshank N, 1931, BRIT MED J, V1931, P618, DOI 10.1136/bmj.1.3666.618; DATEY KK, 1967, NEW ENGL J MED, V276, P262, DOI 10.1056/NEJM196702022760504; DAVI G, 1990, NEW ENGL J MED, V322, P1769, DOI 10.1056/NEJM199006213222503; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EBERLI FR, 1991, CIRC RES, V68, P466, DOI 10.1161/01.RES.68.2.466; EPSTEIN M, 1992, HYPERTENSION, V19, P403, DOI 10.1161/01.HYP.19.5.403; FathOrdoubadi F, 1997, CIRCULATION, V96, P1152, DOI 10.1161/01.CIR.96.4.1152; Fava S, 1996, DIABETIC MED, V13, P80, DOI 10.1002/(SICI)1096-9136(199601)13:1<80::AID-DIA10>3.3.CO;2-N; GWILT DJ, 1984, BRIT HEART J, V51, P626; Holubarsch C, 1996, CIRCULATION, V94, P683, DOI 10.1161/01.CIR.94.4.683; JAIN SK, 1993, DIABETIC MED, V10, P27, DOI 10.1111/j.1464-5491.1993.tb01992.x; JONES DB, 1987, DIABETES METAB, V13, P463; LAKHDAR A, 1984, BRIT MED J, V288, P288, DOI 10.1136/bmj.288.6413.288; LEOR J, 1993, AM J MED, V94, P265, DOI 10.1016/0002-9343(93)90058-W; LEWANDOWICZ J, 1979, COR VASA, V21, P305; LYNCH M, 1994, DIABETIC MED, V11, P162, DOI 10.1111/j.1464-5491.1994.tb02013.x; Malmberg K, 1997, CARDIOVASC RES, V34, P248, DOI 10.1016/S0008-6363(96)00263-5; MALMBERG K, 1989, EUR HEART J, V10, P423, DOI 10.1093/oxfordjournals.eurheartj.a059505; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; Marcus JT, 1997, MAGNET RESON MED, V38, P803, DOI 10.1002/mrm.1910380517; McKibbon K A, 1995, ACP J Club, V123, pA12; MJOS OD, 1971, J CLIN INVEST, V50, P1386, DOI 10.1172/JCI106621; MODAN B, 1975, JAMA-J AM MED ASSOC, V233, P266, DOI 10.1001/jama.233.3.266; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; OSULLIVAN JJ, 1991, DIABETES CARE, V14, P758, DOI 10.2337/diacare.14.8.758; OSWALD GA, 1986, BMJ-BRIT MED J, V293, P917, DOI 10.1136/bmj.293.6552.917; OSWALD GA, 1984, LANCET, V1, P1264; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; RAVID M, 1975, JAMA-J AM MED ASSOC, V233, P807, DOI 10.1001/jama.233.7.807; RYTTER L, 1985, DIABETES CARE, V8, P230, DOI 10.2337/diacare.8.3.230; SEWDARSEN M, 1987, DIABETES RES CLIN EX, V6, P47; SEWDARSEN M, 1989, Q J MED, V71, P461; SOLER NG, 1975, Q J MED, V44, P125; SOLER NG, 1981, JAMA-J AM MED ASSOC, V246, P1690, DOI 10.1001/jama.246.15.1690; TANSEY M J B, 1986, Canadian Journal of Cardiology, V2, P326; THOMASSEN AR, 1986, EUR HEART J, V7, P773, DOI 10.1093/oxfordjournals.eurheartj.a062139; YUDKIN JS, 1988, DIABETES CARE, V11, P351, DOI 10.2337/diacare.11.4.351; YUDKIN JS, 1987, DIABETIC MED, V4, P13, DOI 10.1111/j.1464-5491.1987.tb00821.x	46	1455	1566	0	48	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2000	355	9206					773	778		10.1016/S0140-6736(99)08415-9	http://dx.doi.org/10.1016/S0140-6736(99)08415-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711923				2022-12-28	WOS:000085766900007
J	Hall, AC; Lucas, FR; Salinas, PC				Hall, AC; Lucas, FR; Salinas, PC			Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling	CELL			English	Article							SYNAPSIN-I; GRANULE CELLS; NEURONS; LOCALIZATION; EXPRESSION; TARGET; MOUSE; CLONING; MOSSY; MECHANISMS	Synapse formation requires changes in cell morphology and the upregulation and localization of synaptic proteins. In the cerebellum, mossy fibers undergo extensive remodeling as they contact several granule cells and form complex, multisynaptic glomerular rosettes. Here we show that granule cells secrete factors that induce axon and growth cone remodeling in mossy fibers. This effect is blocked by the WNT antagonist, sFRP-1, and mimicked by WNT-7a, which is expressed by granule cells. WNT-7a also induces synapsin I clustering at remodeled areas of mossy fibers, a: preliminary step in synaptogenesis. Wnt-7a mutant mice show a delay in the morphological maturation of glomerular rosettes and in the accumulation of synapsin I. We propose that WNT-7a can function as a synaptogenic factor.	Kings Coll London, Randall Inst, Dev Biol Res Ctr, London WC2B 5RL, England	University of London; King's College London	Salinas, PC (corresponding author), Kings Coll London, Randall Inst, Dev Biol Res Ctr, 26-29 Drury Lane, London WC2B 5RL, England.	patricia.salinas@kcl.ac.uk						ALTMAN J, 1997, DEV CEREBELLAR SYSTE, P470; ATACK JR, 1995, TRENDS NEUROSCI, V18, P343, DOI 10.1016/0166-2236(95)93926-O; BAIRD DH, 1992, J NEUROSCI, V12, P619; BOWIE JE, 1977, ACTA CYTOL, V21, P455; BRAY D, 1978, P NATL ACAD SCI USA, V75, P5226, DOI 10.1073/pnas.75.10.5226; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHIN LS, 1995, P NATL ACAD SCI USA, V92, P9230, DOI 10.1073/pnas.92.20.9230; EISENMAN LM, 1991, BRAIN RES, V558, P149, DOI 10.1016/0006-8993(91)90733-C; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; FRADKIN LG, 1995, DEV BIOL, V168, P202, DOI 10.1006/dbio.1995.1072; HAMORI J, 1983, J COMP NEUROL, V220, P365, DOI 10.1002/cne.902200402; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Katoh M, 1996, ONCOGENE, V13, P873; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; Lucas FR, 1997, DEV BIOL, V192, P31, DOI 10.1006/dbio.1997.8734; Lucas FR, 1998, J CELL SCI, V111, P1351; Martin CS, 1998, NEUROSCIENCE, V87, P861, DOI 10.1016/S0306-4522(98)00195-X; MASON CA, 1984, J NEUROSCI, V4, P1715; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; SALINAS PC, 1994, DEVELOPMENT, V120, P1277; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schlesinger A, 1999, GENE DEV, V13, P2028, DOI 10.1101/gad.13.15.2028; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; SOTELO C, 1975, BRAIN RES, V94, P19, DOI 10.1016/0006-8993(75)90874-4; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; TAKAHASHI M, 1994, J NEUROCHEM, V63, P245; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Wang JW, 1996, ONCOGENE, V13, P1537; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Zhang Q, 1998, DEV BIOL, V195, P75, DOI 10.1006/dbio.1997.8837	41	559	578	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 3	2000	100	5					525	535		10.1016/S0092-8674(00)80689-3	http://dx.doi.org/10.1016/S0092-8674(00)80689-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721990	Bronze			2022-12-28	WOS:000085700000006
J	Oudejans, RRD; Verheijen, R; Bakker, FC; Gerrits, JC; Steinbruckner, M; Beek, PJ				Oudejans, RRD; Verheijen, R; Bakker, FC; Gerrits, JC; Steinbruckner, M; Beek, PJ			Errors in judging 'offside' in football - Optical trickery can undermine the assistant referee's view of this ruling.	NATURE			English	Article									Free Univ Amsterdam, Fac Human Movement Sci, Inst Fundamental & Clin Human Movement Sci, NL-1081 BT Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Oudejans, RRD (corresponding author), Free Univ Amsterdam, Fac Human Movement Sci, Inst Fundamental & Clin Human Movement Sci, Van der Boechorststr 9, NL-1081 BT Amsterdam, Netherlands.			Oudejans, Raoul/0000-0002-1643-0107				Sanabria J, 1998, LANCET, V351, P268, DOI 10.1016/S0140-6736(05)78269-6	1	85	85	2	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					33	33		10.1038/35003639	http://dx.doi.org/10.1038/35003639			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716430	Green Published, Bronze			2022-12-28	WOS:000085775100031
J	Christin-Maitre, S; Bouchard, P; Spitz, IM				Christin-Maitre, S; Bouchard, P; Spitz, IM			Drug therapy - Medical termination of pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROGESTERONE ANTAGONIST RU-486; EARLY ABORTION; VAGINAL MISOPROSTOL; MIFEPRISTONE RU-486; VACUUM ASPIRATION; UNITED-STATES; ORAL METHOTREXATE; CLINICAL-PHARMACOLOGY; UTERINE CONTRACTILITY; PROSTAGLANDIN PESSARY		Univ Paris 06, Assistance Publ Hop Paris, Hop St Antoine, Serv Endocrinol, F-75571 Paris 12, France; Populat Council, Ctr Biomed Res, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Endocrinol, New York, NY 10021 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Population Council; Cornell University	Bouchard, P (corresponding author), Univ Paris 06, Assistance Publ Hop Paris, Hop St Antoine, Serv Endocrinol, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.							*A GUTTM I, 1999, SHAR RESP WOM SOC AB, P25; [Anonymous], 1993, BMJ, V307, P532; Ashok PW, 1998, HUM REPROD, V13, P2962, DOI 10.1093/humrep/13.10.2962; Aubeny E, 1996, INT J FERTIL MENOP S, V41, P56; BAIRD DT, 1995, HUM REPROD, V10, P1521, DOI 10.1093/HUMREP/10.6.1521; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BIRGERSON L, 1987, CONTRACEPTION, V35, P111, DOI 10.1016/S0010-7824(87)80002-1; BLEYER WA, 1978, CANCER-AM CANCER SOC, V41, P36, DOI 10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I; Blinder V, 1998, AM J OBSTET GYNECOL, V179, P1376, DOI 10.1016/S0002-9378(98)70161-9; BROOME M, 1994, BR J FAM PLANN, V20, P11; Bugalho A, 1996, CONTRACEPTION, V53, P243, DOI 10.1016/0010-7824(96)00044-3; BYGDEMAN M, 1985, CONTRACEPTION, V32, P45, DOI 10.1016/0010-7824(85)90115-5; Cabezas E, 1998, INT J GYNECOL OBSTET, V63, pS141, DOI 10.1016/S0020-7292(98)00196-9; CAMERON IT, 1988, BRIT J OBSTET GYNAEC, V95, P271, DOI 10.1111/j.1471-0528.1988.tb06868.x; Cameron ST, 1996, BRIT J OBSTET GYNAEC, V103, P1222, DOI 10.1111/j.1471-0528.1996.tb09633.x; Carbonell J L, 1997, Eur J Contracept Reprod Health Care, V2, P181; Carbonell JLL, 1998, CONTRACEPTION, V57, P83, DOI 10.1016/S0010-7824(98)00004-3; Carbonell JLL, 1997, CONTRACEPTION, V55, P165, DOI 10.1016/S0010-7824(97)00020-6; CASTADOT RG, 1986, FERTIL STERIL, V45, P5; CHAN YF, 1993, CONTRACEPTION, V47, P85, DOI 10.1016/0010-7824(93)90111-J; Chwalisz K, 1997, ANN NY ACAD SCI, V828, P238, DOI 10.1111/j.1749-6632.1997.tb48545.x; COELHO HLL, 1993, LANCET, V341, P1261, DOI 10.1016/0140-6736(93)91157-H; COELHO HLL, 1993, LANCET, V341, P1486; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; COUZINET B, 1986, NEW ENGL J MED, V315, P1565, DOI 10.1056/NEJM198612183152501; CREANGE JE, 1981, CONTRACEPTION, V24, P289, DOI 10.1016/0010-7824(81)90042-1; CREININ MD, 1993, CONTRACEPTION, V48, P339, DOI 10.1016/0010-7824(93)90079-M; Creinin MD, 1997, OBSTET GYNECOL, V89, P768, DOI 10.1016/S0029-7844(97)81438-X; CREININ MD, 1994, JAMA-J AM MED ASSOC, V272, P1190, DOI 10.1001/jama.272.15.1190; Creinin MD, 1997, OBSTET GYNECOL, V90, P611, DOI 10.1016/S0029-7844(97)00266-4; Creinin MD, 1999, CONTRACEPTION, V59, P11, DOI 10.1016/S0010-7824(98)00142-5; Creinin MD, 1997, CONTRACEPTION, V56, P367, DOI 10.1016/S0010-7824(97)00173-X; Creinin MD, 1996, CONTRACEPTION, V54, P15, DOI 10.1016/0010-7824(96)00113-8; Creinin MD, 1996, CONTRACEPTION, V53, P321, DOI 10.1016/0010-7824(96)00080-7; CREININ MD, 1994, CONTRACEPTION, V49, P99; CROOIJ MJ, 1988, NEW ENGL J MED, V319, P813, DOI 10.1056/NEJM198809293191301; Danielsson KG, 1999, OBSTET GYNECOL, V93, P275, DOI 10.1016/S0029-7844(98)00436-0; DONNENFELD AE, 1994, TERATOLOGY, V49, P79, DOI 10.1002/tera.1420490202; ELREFAEY H, 1994, BRIT J OBSTET GYNAEC, V101, P792, DOI 10.1111/j.1471-0528.1994.tb11948.x; ELREFAEY H, 1995, NEW ENGL J MED, V332, P983, DOI 10.1056/NEJM199504133321502; Elul B, 1999, CONTRACEPTION, V59, P107, DOI 10.1016/S0010-7824(99)00003-7; Esteve JLC, 1999, GYNECOL OBSTET INVES, V47, P182, DOI 10.1159/000010090; Fernandez H, 1998, HUM REPROD, V13, P3239, DOI 10.1093/humrep/13.11.3239; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; GARFIELD RE, 1988, OXFORD REV REPROD B, V10, P436; GIUDICE LC, 1999, MOL BIOL REPROD MED, P333; Gonzalez CH, 1998, LANCET, V351, P1624, DOI 10.1016/S0140-6736(97)12363-7; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; HALPRIN KM, 1971, ARCH DERMATOL, V103, P243, DOI 10.1001/archderm.103.3.243; Harper C, 1998, INT J GYNECOL OBSTET, V63, P39, DOI 10.1016/S0020-7292(98)00102-7; HAUSKNECHT RU, 1995, NEW ENGL J MED, V333, P537, DOI 10.1056/NEJM199508313330901; HENSHAW RC, 1994, HUM REPROD, V9, P2167, DOI 10.1093/oxfordjournals.humrep.a138412; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P263, DOI 10.2307/2991501; HENSHAW SK, 1998, FAMILY PLANNING PERS, V30, P287; HERRMANN W, 1982, CR ACAD SCI III-VIE, V294, P933; IZUMI H, 1994, EUR J OBSTET GYN R B, V56, P55, DOI 10.1016/0028-2243(94)90154-6; Jensen JT, 1999, CONTRACEPTION, V59, P153, DOI 10.1016/S0010-7824(99)00016-5; JOHANNISSON E, 1989, CONTRACEPTION, V39, P103, DOI 10.1016/0010-7824(89)90019-X; JOST A, 1986, CR ACAD SCI III-VIE, V303, P281; KARIM SMM, 1970, LANCET, V1, P157; Koopersmith TB, 1996, CONTRACEPTION, V53, P237, DOI 10.1016/0010-7824(96)00043-1; Martin CW, 1998, CONTRACEPTION, V58, P99, DOI 10.1016/S0010-7824(98)00072-9; MCKINLEY C, 1993, HUM REPROD, V8, P1502, DOI 10.1093/oxfordjournals.humrep.a138287; Mishell DR, 1998, CONTRACEPTION, V58, P1, DOI 10.1016/S0010-7824(98)00061-4; NORMAN J, 1995, HUM REPROD, V10, P308; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; NORMAN JE, 1992, BRIT J OBSTET GYNAEC, V99, P601, DOI 10.1111/j.1471-0528.1992.tb13830.x; Pastuszak AL, 1998, NEW ENGL J MED, V338, P1881, DOI 10.1056/NEJM199806253382604; PENNEY GC, 1995, BRIT J FAM PLAN, V21, P5; PEYRON R, 1993, NEW ENGL J MED, V328, P1509, DOI 10.1056/NEJM199305273282101; PHILIBERT D, 1982, CNS PHARM NEUROPEPTI; Piaggio G, 1999, LANCET, V353, P697; Prasad RNV, 1996, AUST NZ J OBSTET GYN, V36, P20, DOI 10.1111/j.1479-828X.1996.tb02915.x; RODGER MW, 1989, CONTRACEPTION, V39, P497, DOI 10.1016/0010-7824(89)90104-2; ROSENFIELD A, 1993, NEW ENGL J MED, V328, P1560, DOI 10.1056/NEJM199305273282110; SANG GW, 1994, CONTRACEPTION, V50, P501, DOI 10.1016/0010-7824(94)90009-4; Schaff E A, 1996, Fam Med, V28, P198; Schaff EA, 1999, CONTRACEPTION, V59, P1, DOI 10.1016/S0010-7824(98)00150-4; Schaff EA, 1996, OBSTET GYNECOL, V87, P450, DOI 10.1016/0029-7844(95)00406-8; Schaff EA, 1997, J FAM PRACTICE, V44, P353; SILVESTRE L, 1990, NEW ENGL J MED, V322, P645, DOI 10.1056/NEJM199003083221001; Sitruk-Ware R, 1998, LANCET, V352, P323, DOI 10.1016/S0140-6736(05)60300-5; SPITZ IM, 1993, CONTRACEPTION, V48, P403, DOI 10.1016/0010-7824(93)90133-R; Spitz IM, 1998, NEW ENGL J MED, V338, P1241, DOI 10.1056/NEJM199804303381801; SPITZ IM, 1993, NEW ENGL J MED, V329, P404; SWAHN ML, 1994, HUM REPROD, V9, P57, DOI 10.1093/oxfordjournals.humrep.a138320; TANAKA T, 1982, FERTIL STERIL, V37, P851; Tang OS, 1999, HUM REPROD, V14, P722, DOI 10.1093/humrep/14.3.722; THONG KJ, 1992, BRIT J OBSTET GYNAEC, V99, P1004, DOI 10.1111/j.1471-0528.1992.tb13707.x; THONNEAU P, 1994, FERTIL STERIL, V61, P627; THONNEAU P, 1995, HUM REPROD, V10, P1512, DOI 10.1093/HUMREP/10.6.1512; ULMANN A, 1992, ACTA OBSTET GYN SCAN, V71, P278, DOI 10.3109/00016349209021052; Urquhart DR, 1997, CONTRACEPTION, V55, P1, DOI 10.1016/S0010-7824(96)00252-1; VANLOOK PFA, 1991, FERTIL STERIL, V56, P32; WEBSTER MA, 1985, BRIT J OBSTET GYNAEC, V92, P963, DOI 10.1111/j.1471-0528.1985.tb03078.x; Wiebe ER, 1997, CONTRACEPTION, V55, P159, DOI 10.1016/S0010-7824(97)00021-8; Wiebe ER, 1999, CONTRACEPTION, V59, P7, DOI 10.1016/S0010-7824(98)00146-2; Wiebe ER, 1996, CAN MED ASSOC J, V154, P165; Winikoff B, 1998, ARCH FAM MED, V7, P360, DOI 10.1001/archfami.7.4.360; Winikoff B, 1997, AM J OBSTET GYNECOL, V176, P431, DOI 10.1016/S0002-9378(97)70511-8; WU SC, 1992, CONTRACEPTION, V46, P203; Zieman M, 1997, OBSTET GYNECOL, V90, P88, DOI 10.1016/S0029-7844(97)00111-7	103	84	87	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	2000	342	13					946	956		10.1056/NEJM200003303421307	http://dx.doi.org/10.1056/NEJM200003303421307			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DC	10738054				2022-12-28	WOS:000086179700007
J	Aggarwal, S; Monga, AP; Perusse, SR; Ramesh, R; Ballarotto, V; Williams, ED; Chalamala, BR; Wei, Y; Reuss, RH				Aggarwal, S; Monga, AP; Perusse, SR; Ramesh, R; Ballarotto, V; Williams, ED; Chalamala, BR; Wei, Y; Reuss, RH			Spontaneous ordering of oxide nanostructures	SCIENCE			English	Article							DEVICE	We report the spontaneous formation of uniformly distributed arrays of "tips" (tall conical hillocks) upon oxidation of palladium (Pd) thin films. The formation of the palladium oxide tips depended on the thickness and granularity of the Pd film and on annealing and oxidation conditions. As the Pd film thickness increased from 40 to 200 nanometers, the average height of the tips increased from 0.5 to 1.2 micrometers, their height distribution became broader, and their density decreased from 55 X 10(6) to 12 X 10(6) per square centimeter. Enhanced photoelectron emission from locations corresponding to the tips suggests their possible use in field emission applications.	Univ Maryland, Dept Mat & Nucl Engn, College Pk, MD 20742 USA; Univ Maryland, Dept Phys, College Pk, MD 20742 USA; Motorola Inc, Flat Panel Display Div, Tempe, AZ 85284 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Aggarwal, S (corresponding author), Univ Maryland, Dept Mat & Nucl Engn, College Pk, MD 20742 USA.	aggarwal@eng.umd.edu	Chalamala, Babu R./AAF-1454-2019; Way, James Douglas/A-9408-2010	Chalamala, Babu R./0000-0003-0469-636X; Way, James Douglas/0000-0001-9612-8508				BERNHARD JH, UNPUB; Chakoumakos BC, 1998, J APPL PHYS, V83, P1979, DOI 10.1063/1.366925; Chalamala BR, 1998, IEEE SPECTRUM, V35, P42, DOI 10.1109/6.666960; COBLE RL, 1963, J APPL PHYS, V34, P1679, DOI 10.1063/1.1702656; DHEURLE FM, 1989, INT MATER REV, V34, P53, DOI 10.1179/imr.1989.34.1.53; HELLWEGE KH, 1975, LANDOLTBORNSTEIN, V7, P26; HERRING C, 1950, J APPL PHYS, V21, P437, DOI 10.1063/1.1699681; Holborn L, 1901, ANN PHYS-BERLIN, V4, P104; LIFSHITZ IM, 1961, J PHYS CHEM SOLIDS, V19, P35, DOI 10.1016/0022-3697(61)90054-3; NABARRO FRN, 1948, C STRENGTH SOL PHYS, P75; Rakhshandehroo MR, 1998, J VAC SCI TECHNOL B, V16, P2849, DOI 10.1116/1.590283; SCHHUKIN VA, 1999, REV MOD PHYS, V71, P4; SPINDT CA, 1968, J APPL PHYS, V39, P3504, DOI 10.1063/1.1656810; Temple D, 1999, MAT SCI ENG R, V24, P185, DOI 10.1016/S0927-796X(98)00014-X; XIE QH, 1995, PHYS REV LETT, V75, P2542, DOI 10.1103/PhysRevLett.75.2542	15	125	134	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2235	2237		10.1126/science.287.5461.2235	http://dx.doi.org/10.1126/science.287.5461.2235			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731139				2022-12-28	WOS:000086049100042
J	Lee, L; Tirnauer, JS; Li, JJ; Schuyler, SC; Liu, JY; Pellman, D				Lee, L; Tirnauer, JS; Li, JJ; Schuyler, SC; Liu, JY; Pellman, D			Positioning of the mitotic spindle by a cortical-microtubule capture mechanism	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; NUCLEAR MIGRATION; BINDING PROTEIN; YEAST; ORIENTATION; DYNEIN; SITES; BNI1P; EB1	Correct positioning of the mitotic spindle is critical for cell division and development. Spindle positioning involves a search-and-capture mechanism whereby dynamic microtubules find and then interact with specific sites on the submembrane cortex. Genetic, biochemical, and imaging experiments suggest a mechanism for cortical-microtubule capture. Bim1p, Located at microtubule distal ends, bound Kar9p, a protein associated with the daughter cell cortex. Bim1p is the yeast ortholog of human EB1, a binding partner for the adenomatous polyposis coli tumor suppressor. EB1 family proteins may have a general role in linking the microtubule cytoskeleton to cortical polarity determinants.	Harvard Univ, Childrens Hosp, Sch Med, Dana Farber Canc Inst,Dept Pediat Oncol, Boston, MA 02115 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Harvard Univ, Childrens Hosp, Sch Med, Dana Farber Canc Inst,Dept Pediat Hematol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Princeton University; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Pellman, D (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dana Farber Canc Inst,Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	daivd_pellman@dfci.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002578] Funding Source: NIH RePORTER; NIDDK NIH HHS [KO8 DK02578] Funding Source: Medline; NIGMS NIH HHS [GM55772] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; Cottingham FR, 1997, J CELL BIOL, V138, P1041, DOI 10.1083/jcb.138.5.1041; DeZwaan TM, 1997, J CELL BIOL, V138, P1023, DOI 10.1083/jcb.138.5.1023; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fuchs E, 1999, CELL, V98, P547, DOI 10.1016/S0092-8674(00)80041-0; Gavin RH, 1997, INT REV CYTOL, V173, P207; Gonczy P, 1999, J CELL BIOL, V147, P135, DOI 10.1083/jcb.147.1.135; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Heil-Chapdelaine RA, 1999, J CELL BIOL, V144, P809, DOI 10.1083/jcb.144.5.809; Hunt AJ, 1998, MOL BIOL CELL, V9, P2857, DOI 10.1091/mbc.9.10.2857; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; LEE L, UNPUB; Miller R, UNPUB; Miller RK, 1998, J CELL BIOL, V140, P377, DOI 10.1083/jcb.140.2.377; Miller RK, 1998, MOL BIOL CELL, V9, P2051, DOI 10.1091/mbc.9.8.2051; Miller RK, 1999, J CELL BIOL, V144, P963, DOI 10.1083/jcb.144.5.963; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; Shaw SL, 1998, MOL BIOL CELL, V9, P1627, DOI 10.1091/mbc.9.7.1627; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SNYDER M, 1991, J CELL BIOL, V114, P515, DOI 10.1083/jcb.114.3.515; SU LK, 1995, CANCER RES, V55, P2972; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; XIANG X, 1995, P NATL ACAD SCI USA, V92, P9890, DOI 10.1073/pnas.92.21.9890	34	237	239	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2260	2262		10.1126/science.287.5461.2260	http://dx.doi.org/10.1126/science.287.5461.2260			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731147				2022-12-28	WOS:000086049100050
J	Nishida, K; Kobayashi, N; Fukao, Y				Nishida, K; Kobayashi, N; Fukao, Y			Resonant oscillations between the solid Earth and the atmosphere	SCIENCE			English	Article							MOUNT PINATUBO; EXCITATION; RAYLEIGH; MODEL; WAVES	Continuously excited free oscillations of the whole Earth have been found in the ground noise in a frequency band of Long-period surface waves. Here we report evidence of an annual variation of this phenomenon, indicating that the excitation source is not within the solid Earth. There is evidence that these seismic free oscillations resonate with acoustic free oscillations of the atmosphere. The observed amplitudes suggest that the excitation source is at or just above Earth's surface.	Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, Tokyo 1130032, Japan; Tokyo Inst Technol, Meguro Ku, Tokyo 1528550, Japan	University of Tokyo; Tokyo Institute of Technology	Nishida, K (corresponding author), Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Nishida, Kiwamu/B-5416-2012	Nishida, Kiwamu/0000-0001-6778-8080				AGNEW DC, 1978, J GEOPHYS RES, V83, P5420, DOI 10.1029/JB083iB11p05420; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Fleming E. L., 1990, Advances in Space Research, V10, P11, DOI 10.1016/0273-1177(90)90386-E; JACOBOWITZ H, 1984, J GEOPHYS RES-ATMOS, V89, P4997, DOI 10.1029/JD089iD04p04997; KANAMORI H, 1992, GEOPHYS RES LETT, V19, P721, DOI 10.1029/92GL00258; Kandel R, 1998, B AM METEOROL SOC, V79, P765, DOI 10.1175/1520-0477(1998)079<0765:TSERBD>2.0.CO;2; Kobayashi N, 1998, NATURE, V395, P357, DOI 10.1038/26427; Kobayashi N, 1998, J PHYS-CONDENS MAT, V10, P11557, DOI 10.1088/0953-8984/10/49/044; Lognonne P, 1998, GEOPHYS J INT, V135, P388, DOI 10.1046/j.1365-246X.1998.00665.x; LOGNONNE P, 1994, ICARUS, V110, P180, DOI 10.1006/icar.1994.1115; Nawa K, 1998, EARTH PLANETS SPACE, V50, P3, DOI 10.1186/BF03352080; Nishida K, 1999, J GEOPHYS RES-SOL EA, V104, P28741, DOI 10.1029/1999JB900286; Roult G., 1994, ANN GEOFIS, V37, P1054; Smith S. W., 1986, EOS Transactions of the American Geophysical Union, V67, P213, DOI 10.1029/EO067i016p00213; Suda N, 1998, SCIENCE, V279, P2089, DOI 10.1126/science.279.5359.2089; Tanimoto T, 1998, GEOPHYS RES LETT, V25, P1553, DOI 10.1029/98GL01223; WATADA S, 1995, THESIS CALTECH PASAD; WIDMER R, 1992, GEOPHYS RES LETT, V19, P765, DOI 10.1029/92GL00685	18	87	92	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2244	2246		10.1126/science.287.5461.2244	http://dx.doi.org/10.1126/science.287.5461.2244			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731142				2022-12-28	WOS:000086049100045
J	Rubin, GM; Yandell, MD; Wortman, JR; Miklos, GLG; Nelson, CR; Hariharan, IK; Fortini, ME; Li, PW; Apweiler, R; Fleischmann, W; Cherry, JM; Henikoff, S; Skupski, MP; Misra, S; Ashburner, M; Birney, E; Boguski, MS; Brody, T; Brokstein, P; Celniker, SE; Chervitz, SA; Coates, D; Cravchik, A; Gabrielian, A; Galle, RF; Gelbart, WM; George, RA; Goldstein, LSB; Gong, FC; Guan, P; Harris, NL; Hay, BA; Hoskins, RA; Li, JY; Li, ZY; Hynes, RO; Jones, SJM; Kuehl, PM; Lemaitre, B; Littleton, JT; Morrison, DK; Mungall, C; O'Farrell, PH; Pickeral, OK; Shue, C; Vosshall, LB; Zhang, J; Zhao, Q; Zheng, XQH; Zhong, F; Zhong, WY; Gibbs, R; Venter, JC; Adams, MD; Lewis, S				Rubin, GM; Yandell, MD; Wortman, JR; Miklos, GLG; Nelson, CR; Hariharan, IK; Fortini, ME; Li, PW; Apweiler, R; Fleischmann, W; Cherry, JM; Henikoff, S; Skupski, MP; Misra, S; Ashburner, M; Birney, E; Boguski, MS; Brody, T; Brokstein, P; Celniker, SE; Chervitz, SA; Coates, D; Cravchik, A; Gabrielian, A; Galle, RF; Gelbart, WM; George, RA; Goldstein, LSB; Gong, FC; Guan, P; Harris, NL; Hay, BA; Hoskins, RA; Li, JY; Li, ZY; Hynes, RO; Jones, SJM; Kuehl, PM; Lemaitre, B; Littleton, JT; Morrison, DK; Mungall, C; O'Farrell, PH; Pickeral, OK; Shue, C; Vosshall, LB; Zhang, J; Zhao, Q; Zheng, XQH; Zhong, F; Zhong, WY; Gibbs, R; Venter, JC; Adams, MD; Lewis, S			Comparative genomics of the eukaryotes	SCIENCE			English	Review							DROSOPHILA-MELANOGASTER; INNATE IMMUNITY; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; RECEPTOR FAMILY; CYTOCHROME-C; PROTEIN; GENE; BINDING; GASTRULATION	A comparative analysis of the genomes of Drosophila melanogaster, Caenorhabditis elegans, and Saccharomyces cerevisiae-and the proteins they are predicted to encode-was undertaken in the context of cellular, developmental, and evolutionary processes. The nonredundant protein sets of flies and worms are similar in size and are only twice that of yeast, but different gene families are expanded in each genome, and the multidomain proteins and signaling pathways of the fly and worm are far more complex than those of yeast. The fly has orthologs to 177 of the 289 human disease genes examined and provides the foundation for rapid analysis of some of the basic processes involved in human disease.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA; Celera Genom, Rockville, MD 20850 USA; Genetixxpress, Sydney, NSW 2108, Australia; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; EMBL, EBI, Cambridge CB10 1SD, England; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; NINDS, Neurogenet Unit, Neurochem Lab, NIH, Bethesda, MD 20892 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA; Neomorphic, Berkeley, CA 94710 USA; Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Calif San Diego, Howard Hughes Med Inst, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Dept Pharmacol, La Jolla, CA 92093 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; BC Canc Res Ctr, Genome Sequence Ctr, Vancouver, BC V52 4E6, Canada; Univ Maryland, Cell & Mol Biol Program, Baltimore, MD 21201 USA; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; MIT, Ctr Learning & Memory, Cambridge, MA 02139 USA; NCI, Regulat Cell Growth Lab, Div Basic Sci, Frederick Canc Res & Dev Ctr,NIH, Ft Detrick, MD 21702 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Baylor Coll Med, Human Genome Sequencing Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Harvard University; Massachusetts General Hospital; University of Pennsylvania; European Molecular Biology Laboratory (EMBL); Stanford University; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Leeds; Harvard University; Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; California Institute of Technology; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); British Columbia Cancer Agency; University System of Maryland; University of Maryland Baltimore; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California San Francisco; Columbia University; Baylor College of Medicine	Rubin, GM (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.		Lemaitre, Bruno/T-8146-2019; Mungall, Chris/I-6006-2019; Jones, Steven J/C-3621-2009	Lemaitre, Bruno/0000-0001-7970-1667; Mungall, Chris/0000-0002-6601-2165; Jones, Steven J/0000-0003-3394-2208; O'Farrell, Patrick/0000-0003-0011-2734; Birney, Ewan/0000-0001-8314-8497; Rubin, Gerald/0000-0001-8762-8703; Littleton, J. Troy/0000-0001-5576-2887; Cherry, J. Michael/0000-0001-9163-5180; Vosshall, Leslie/0000-0002-6060-8099; Henikoff, Steven/0000-0002-7621-8685; Wortman, Jennifer/0000-0002-8713-1227; Lewis, Suzanna/0000-0002-8343-612X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000750, P41HG000739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060988, R01GM037193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040296] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ADAMS MD, 1998, SCIENCE, V282, P2012; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Aparicio S, 2000, TRENDS GENET, V16, P54, DOI 10.1016/S0168-9525(99)01934-4; Attwood TK, 1999, NUCLEIC ACIDS RES, V27, P220, DOI 10.1093/nar/27.1.220; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARRETT J, 1998, HDB PROTEOLYTIC ENZY; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Blaumueller CM, 1997, PERSPECT DEV NEUROBI, V4, P325; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Capdevila J, 1999, CURR OPIN GENET DEV, V9, P427, DOI 10.1016/S0959-437X(99)80065-3; Chang P, 2000, NAT CELL BIOL, V2, P30, DOI 10.1038/71350; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Colas JF, 1999, MECH DEVELOP, V87, P77, DOI 10.1016/S0925-4773(99)00141-0; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Engstrom L, 1997, CURR TOP DEV BIOL, V35, P229, DOI 10.1016/S0070-2153(08)60261-6; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hauser F, 1997, J BIOL CHEM, V272, P1002, DOI 10.1074/jbc.272.2.1002; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Henikoff JG, 2000, NUCLEIC ACIDS RES, V28, P228, DOI 10.1093/nar/28.1.228; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLLAND PWH, 1994, DEVELOPMENT, P125; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Konrad KD, 1998, P NATL ACAD SCI USA, V95, P6819, DOI 10.1073/pnas.95.12.6819; Kreis T., 1999, GUIDEBOOK CYTOSKELET, V2nd; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; Laissue PP, 1999, J COMP NEUROL, V405, P543; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; LeMosy EK, 1999, TRENDS CELL BIOL, V9, P102, DOI 10.1016/S0962-8924(98)01494-9; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Miklos GLG, 1998, DAEDALUS, V127, P197; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; PARK AG, 2000, TRENDS CELL BIOL, V10, P394; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; Schmid KJ, 1997, P NATL ACAD SCI USA, V94, P9746, DOI 10.1073/pnas.94.18.9746; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; VERNIER P, 1995, TRENDS PHARMACOL SCI, V16, P375, DOI 10.1016/S0165-6147(00)89078-1; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; WEBER K, 1999, GUIDEBOOK CYTOSKELET, P291; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	84	1283	1326	3	166	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2204	2215		10.1126/science.287.5461.2204	http://dx.doi.org/10.1126/science.287.5461.2204			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731134	Green Accepted, Green Submitted			2022-12-28	WOS:000086049100035
J	Hill, EW; Jobling, MA; Bradley, DG				Hill, EW; Jobling, MA; Bradley, DG			Y-chromosome variation and Irish origins	NATURE			English	Article									Trinity Coll, Dept Genet, Dublin 2, Ireland; Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England	Trinity College Dublin; University of Leicester	Hill, EW (corresponding author), Trinity Coll, Dept Genet, Dublin 2, Ireland.		Bradley, Daniel G/A-3240-2012	Jobling, Mark/0000-0002-8061-1308; Hill, Emmeline/0000-0002-1805-2250; Bradley, Daniel G/0000-0001-7335-7092	Wellcome Trust [057559] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Hurles ME, 1999, AM J HUM GENET, V65, P1437, DOI 10.1086/302617; Hurles ME, 1998, AM J HUM GENET, V63, P1793, DOI 10.1086/302147; JOBLING MA, 1995, TRENDS GENET, V11, P449, DOI 10.1016/S0168-9525(00)89144-1; MacLYSAGHT EDWARD, 1997, SURNAMES IRELAND; SEIELSTAD MT, 1994, HUM MOL GENET, V3, P2159; WHITFIELD LS, 1995, NATURE, V378, P379, DOI 10.1038/378379a0	6	96	97	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					351	352		10.1038/35006158	http://dx.doi.org/10.1038/35006158			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746711				2022-12-28	WOS:000086119000036
J	Nielsen, LK; Bjornholm, T; Mouritsen, OG				Nielsen, LK; Bjornholm, T; Mouritsen, OG			Critical phenomena - Fluctuations caught in the act	NATURE			English	Article							MEMBRANES		Tech Univ Denmark, Dept Chem, DK-2800 Lyngby, Denmark; Univ Copenhagen, Dept Chem, DK-2100 Copenhagen, Denmark	Technical University of Denmark; University of Copenhagen	Nielsen, LK (corresponding author), Tech Univ Denmark, Dept Chem, DK-2800 Lyngby, Denmark.	ogm@kemi.dtu.dk		Bjornholm, Thomas/0000-0002-2981-8290; Mouritsen, Ole G./0000-0002-4258-8960				ALBRECHT O, 1978, J PHYS-PARIS, V39, P301, DOI 10.1051/jphys:01978003903030100; Andrews T, 1869, PHILOS T R SOC LOND, V159, P575, DOI [10.1098/rstl.1869.0021, DOI 10.1098/RSTL.1869.0021]; Edidin M, 1997, CURR OPIN STRUC BIOL, V7, P528, DOI 10.1016/S0959-440X(97)80117-0; Honger T, 1996, BIOCHEMISTRY-US, V35, P9003, DOI 10.1021/bi960866a; Knobler CM, 1999, CURR OPIN COLLOID IN, V4, P46, DOI 10.1016/S1359-0294(99)00002-3; Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461; MONRITSEN OG, 1997, CURR OPIN STRUC BIOL, V7, P518; Mouritsen O. G., 1998, BIOL SKR DAN VID SEL, V49, P1; MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006; Nielsen LK, 2000, J PHYS-CONDENS MAT, V12, pA309, DOI 10.1088/0953-8984/12/8A/340; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stanley HE, 1999, REV MOD PHYS, V71, pS358, DOI 10.1103/RevModPhys.71.S358	12	79	80	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					352	352		10.1038/35006162	http://dx.doi.org/10.1038/35006162			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746712				2022-12-28	WOS:000086119000037
J	Caplan, AL; Snyder, L; Faber-Langendoen, K				Caplan, AL; Snyder, L; Faber-Langendoen, K		Univ Pennsylvania	The role of guidelines in the practice of physician-assisted suicide	ANNALS OF INTERNAL MEDICINE			English	Article							DEATH; NETHERLANDS; EUTHANASIA; MODEL; CARE	Oregon has legalized and implemented physician-assisted suicide, while observers argue about the moral import of attempting to formulate guidelines; the utility any set of guidelines can have for physician practice, health care providers, patients, or families; and whether guidelines can really protect against harm or abuse. What were once theoretical questions have taken on new urgency. The debate over the value and power of guidelines includes the following questions: What has been the experience of efforts to implement physician-assisted suicide using consensus guidelines? What goals are guidelines intended to serve? Who should formulate guidelines? What features should be reflected in any proposed guidelines to make them practical and to permit achievement of their goals? Are there any fundamental obstacles to the creation or implementation of guidelines', Is dying a process that is amenable to direction under guidelines, be they issued by physicians, departments of health, blue ribbon panels, or other regulatory bodies? This paper explores these questions as physician-assisted suicide becomes legal.	Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA	University of Pennsylvania; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Snyder, L (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.	lsnyder@mail.acponline.org						Albom M., 1997, TUESDAYS MORRIE OLD; Anderson P, 1996, ALL US AM TALK MEANI; Baron CH, 1996, HARVARD J LEGIS, V33, P1; Battin Margaret, 1994, LEAST WORST DEATH ES; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Byock I., 1997, DYING WELL; Callahan Daniel, 1996, Univ Richmond Law Rev, V30, P1; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Coleman CH, 1996, J LAW MED ETHICS, V24, P217, DOI 10.1111/j.1748-720X.1996.tb01855.x; *COMM STUD MED PRA, 1991, MED DEC END LIF; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; *DUTCH SOC ADV PHA, 1994, ADM PREP EUTH; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Faber-Langendoen K, 2000, ANN INTERN MED, V132, P482, DOI 10.7326/0003-4819-132-6-200003210-00010; Field MJ, 1997, APPROACHING DEATH IM; Fins, 1996, Cancer Control, V3, P272; Gomez Carlos F., 1991, REGULATING DEATH EUT; Heilig S, 1997, WESTERN J MED, V166, P370; Hendin H., 1998, SEDUCED DEATH DOCTOR; Humphrey D., 1991, FINAL EXIT PRACTICAL; HUMPHREY D, 1993, LAWFUL EXIT LIMITS F; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Kubler-Ross Elisabeth, 1997, WHEEL LIFE MEMOIR LI; LARUE GA, 1996, PLAYING GOD 50 RELIG; MCNEES P, 1998, DYING BOOK COMFORT; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; Miller FG, 1997, CAMB Q HEALTHC ETHIC, V6, P78, DOI 10.1017/S0963180100007635; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT ASS; Nuland S.B., 1994, HOW WE DIE; PECK MS, 1997, DENIAL SOUL; PIJNENBORG P, 1995, END LIFE DECISIONS D; Quill T, 1996, MIDWIFE DYING PROCES; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Rabe David, 1998, QUESTION MERCY; ROLLIN B, 1985, LAST WISH; SHAVELSON L, 1995, CHOSEN DEATH DYING C; SIMONS M, 1995, NY TIMES        0909; Smith W.J., 1997, FORCED EXIT SLIPPERY; SNEIDERMAN B, 1992, HUM MED, V8, P104; Snyder L, 1996, Pa Med, V99, P10; TILDEN VP, 1997, J FAMILY NURSING, V3, P120; Tolle SW, 1998, ANN INTERN MED, V128, P567, DOI 10.7326/0003-4819-128-7-199804010-00009; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VITEZ M, 1998, FINAL CHOICES SEEKIN; Webb M, 1997, GOOD DEATH NEW AM SE; Young EWD, 1997, WESTERN J MED, V166, P381	47	24	24	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					476	481		10.7326/0003-4819-132-6-200003210-00009	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293CV	10733448				2022-12-28	WOS:000085834700008
J	Quill, TE; Lee, BC; Nunn, S				Quill, TE; Lee, BC; Nunn, S		Univ Pennslyvania	Palliative treatments of last resort: Choosing the least harmful alternative	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN-ASSISTED SUICIDE; VOLUNTARY ACTIVE EUTHANASIA; LIFE-SUSTAINING TREATMENT; CRITICALLY ILL PATIENTS; TERMINAL DEHYDRATION; DECISION-MAKING; HOPELESSLY ILL; UNITED-STATES; CARE; DEATH	Comprehensive palliative care, as exemplified by many state-of-the-art hospice programs, is the standard of care for the dying. Although palliative care is very effective, physicians, nurses, patients, families, and loved ones regularly face clinically, ethically, legally, and morally challenging decisions throughout the dying process. This is especially true when terminally ill patients are ready to die in the face of complex, difficult-to-treat suffering and request assistance from their health care providers. Although physician-assisted suicide has received the most attention as a potential last-resort response, this practice remains illegal in the United States except in Oregon, and even there it is relatively infrequent. More commonly, decisions are made about accelerating opioid therapy for pain, forgoing life-sustaining therapy, voluntarily stopping eating and drinking, and administering terminal sedation in response to unacceptable suffering. The moral distinctions between these practices are critical to some but relatively inconsequential to others. This paper illustrates, through summaries of real clinical cases, how each of these practices might be used in response to patients in particular clinical circumstances, keeping in focus the patient's values as well as those of families, other loved ones, and health care providers. The challenge is to find the least harmful solution to the patient's problem without abandoning patients and their loved ones to unacceptable suffering or to acting in a more deleterious way on their own.	Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Rochester, Sch Med, Genesee Hosp, Rochester, NY USA; Compass Dying Federat, Portland, OR USA	University of Pennsylvania; Pennsylvania Medicine; University of Rochester	Quill, TE (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.							ACKERMAN F, 1991, HASTINGS CENT REP, V21, P27, DOI 10.2307/3562998; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; Byock I R, 1993, J Palliat Care, V9, P25; Cherny N I, 1994, J Palliat Care, V10, P31; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; Field MJ, 1997, APPROACHING DEATH IM; FOLEY KM, 1995, PAIN FORUM, V4, P163; Glantz L H, 1987, Law Med Health Care, V15, P231; Lynn J, 1997, J AM GERIATR SOC, V45, P489, DOI 10.1111/j.1532-5415.1997.tb05176.x; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MEISEL A, 1991, ARCH INTERN MED, V151, P1497, DOI 10.1001/archinte.151.8.1497; MILLER DK, 1992, J GEN INTERN MED, V7, P475, DOI 10.1007/BF02599446; Miller FG, 1998, ANN INTERN MED, V128, P559, DOI 10.7326/0003-4819-128-7-199804010-00007; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; Quill T E, 1998, J Palliat Med, V1, P333, DOI 10.1089/jpm.1998.1.333; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; Quill TE, 1993, DEATH DIGNITY MAKING; RIE MA, 1991, HASTINGS CENT REP, V21, P24, DOI 10.2307/3562997; TROUG RD, 1991, NEW ENGL J MED, V327, P1678; Ventafridda V, 1990, J Palliat Care, V6, P7; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	38	89	90	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					488	493		10.7326/0003-4819-132-6-200003210-00011	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293CV	10733450				2022-12-28	WOS:000085834700010
J	Russell, CT; Kivelson, MG				Russell, CT; Kivelson, MG			Detection of SO in lo's exosphere	SCIENCE			English	Article							ION-CYCLOTRON WAVES; PLASMA TORUS; GALILEO; ENCOUNTER	The Galileo orbiter's close pass by Io in 1995 produced evidence for extensive mass Loading of the plasma torus through the ionization of SO2. On 11 October 1999, Galileo passed even closer to Io, this time across the upstream side relative to the flow of magnetospheric plasma that corotates with Jupiter. On the first flyby, ion cyclotron waves gave direct evidence for the production of SO2+ ions. On the second flyby, ion cyclotron waves associated with SO+ were stronger and more persistent. Moreover, SO+ emissions were seen closer to lo than SO2+ emissions, suggesting that the exosphere was spatially inhomogeneous. The location of the waves suggests a fan-shaped region of ion pickup extending in the anti-Jupiter direction. Because the wave spectra were different even where the 1995 and 1999 trajectories crossed, we infer that lo's exosphere is temporally variable.	Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Russell, CT (corresponding author), Univ Calif Los Angeles, Inst Geophys & Planetary Phys, 3845 Slichter Hall, Los Angeles, CA 90095 USA.		Russell, Christopher T/E-7745-2012; Kivelson, Margaret G/I-9019-2012	Russell, Christopher T/0000-0003-1639-8298; Kivelson, Margaret G/0000-0003-3859-8581				BALCHER JW, 1983, PHYSICS JOVIAN MAGNE, P68; Frank LA, 1996, SCIENCE, V274, P394, DOI 10.1126/science.274.5286.394; Gurnett DA, 1996, SCIENCE, V274, P391, DOI 10.1126/science.274.5286.391; Huddleston DE, 1997, GEOPHYS RES LETT, V24, P2143, DOI 10.1029/97GL01203; Kivelson MG, 1996, SCIENCE, V274, P396, DOI 10.1126/science.274.5286.396; Lellouch E, 1996, ICARUS, V124, P1, DOI 10.1006/icar.1996.0186; Lopes-Gautier R, 1999, ICARUS, V140, P243, DOI 10.1006/icar.1999.6129; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; Russell CT, 1999, J GEOPHYS RES-SPACE, V104, P17471, DOI 10.1029/1999JA900202; Warnecke J, 1997, GEOPHYS RES LETT, V24, P2139, DOI 10.1029/97GL01129; Williams DJ, 1996, SCIENCE, V274, P401, DOI 10.1126/science.274.5286.401; Zolotov MY, 1998, ICARUS, V132, P431, DOI 10.1006/icar.1998.5906	12	46	46	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1998	1999		10.1126/science.287.5460.1998	http://dx.doi.org/10.1126/science.287.5460.1998			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720321				2022-12-28	WOS:000085902800055
J	McAlindon, TE; LaValley, MP; Gulin, JP; Felson, DT				McAlindon, TE; LaValley, MP; Gulin, JP; Felson, DT			Glucosamine and chondroitin for treatment of osteoarthritis - A systematic quality assessment and meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED TRIALS; KNEE OSTEOARTHRITIS; ARTICULAR-CARTILAGE; CLINICAL-TRIALS; SULFATE; EFFICACY; DRUGS; HIP; TOLERABILITY; METAANALYSES	Context Glucosamine and chondroitin preparations are widely touted in the lay press as remedies for osteoarthritis (OA), but uncertainty about their efficacy exists among the medical community. Objective To evaluate benefit of glucosamine and chondroitin preparations for OA symptoms using meta-analysis combined with systematic quality assessment of clinical trials of these preparations in knee and/or hip OA. Data Sources We searched for human clinical trials in MEDLINE (1966 to June 1999) and the Cochrane Controlled Trials Register using the terms osteoarthritis, osteoarthrosis, degenerative arthritis, glucosamine, chondroitin, and glycosaminoglycans. We also manually searched review articles, manuscripts, and supplements from rheumatology and OA journals and sought unpublished data by contacting content experts, study authors, and manufacturers of glucosamine or chondroitin. Study Selection Studies were included if they were published or unpublished double-blind, randomized, placebo-controlled trials of 4 or more weeks' duration that tested glucosamine or chondroitin for knee or hip OA and reported extractable data on the effect of treatment on symptoms. Fifteen of 37 studies were included in the analysis. Data Extraction Reviewers performed data extraction and scored each trial using a quality assessment instrument. We computed an effect size from the intergroup difference in mean outcome values at trial end, divided by the SD of the outcome value in the placebo group (0.2, small effect; 0.5, moderate; 0.8, large), and applied a correction factor to reduce bias. We tested for trial heterogeneity and publication bias and stratified for trial quality and size. We pooled effect sizes using a random effects model. Data Synthesis Quality scores ranged from 12.3% to 55.4% of the maximum, with a mean (SD) of 35.5% (12%). Only 1 study described adequate allocation concealment and 2 reported an intent-to-treat analysis. Most were supported or performed by a manufacturer. Funnel plots showed significant asymmetry (P less than or equal to.01) compatible with publication bias. Tests for heterogeneity were nonsignificant after removing 1 outlier trial. The aggregated effect sizes were 0.44 (95% confidence interval [CI], 0.24-0.64) for glucosamine and 0.78 (95% CI, 0.60-0.95) for chondroitin, but they were diminished when only high-quality or large trials were considered. The effect sizes were relatively consistent for pain and functional outcomes. Conclusions Trials of glucosamine and chondroitin preparations for OA symptoms demonstrate moderate to large effects, but quality issues and likely publication bias suggest that these effects are exaggerated. Nevertheless, some degree of efficacy appears probable for these preparations.	Boston Univ, Sch Med, Arthrit Ctr, Boston, MA 02118 USA	Boston University	McAlindon, TE (corresponding author), Boston Univ, Sch Med, Arthrit Ctr, 715 Albany St,A203, Boston, MA 02118 USA.	tmcalind@bu.edu	LaValley, Michael/AAA-2030-2020	Felson, David/0000-0002-2668-2447; LaValley, Michael/0000-0002-8488-5170	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; Bassleer C, 1998, OSTEOARTHR CARTILAGE, V6, P427, DOI 10.1053/joca.1998.0146; BLOTMAN F, 1993, OSTEOARTHR CARTILAGE, V1, P68; Bourgeois P, 1998, OSTEOARTHR CARTILAGE, V6, P25, DOI 10.1016/S1063-4584(98)80008-3; Bucsi L, 1998, OSTEOARTHR CARTILAGE, V6, P31, DOI 10.1016/S1063-4584(98)80009-5; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; *COCHR LIBR, 1998, COCHR CONTR TRIALS R; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Conrozier T, 1998, PRESSE MED, V27, P1862; CONROZIER T, 1992, LITERA RHEUMATOIOGIC, V14, P69; CONSTANZ RB, 1998, TXB RHEUMATOLOGY; CROLLE G, 1980, CURR MED RES OPIN, V7, P104, DOI 10.1185/03007998009112035; DAMBROSIO E, 1981, PHARMATHERAPEUTICA, V2, P504; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1343, DOI 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; Giordano N, 1996, Clin Ter, V147, P99; Hedges L.V., 1985, STAT METHODS METAANA, DOI [10.1016/C2009-0-03396-0, DOI 10.1016/C2009-0-03396-0]; Hedges LV, 1981, J EDUC STAT, V6, P107, DOI [10.2307/1164588, DOI 10.2307/1164588, 10.3102/10769986006002107]; HOUPT JB, 1998, J RHEUMATOL S52, V25, P8; KERZBERG EM, 1987, SCAND J RHEUMATOL, V16, P377, DOI 10.3109/03009748709102512; Lequesne MG, 1997, J RHEUMATOL, V24, P779; LHIRONDEL JL, 1992, LITERA RHEUMATOLOGIC, V14, P77; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; MAZIERES B, 1992, REV RHUM, V59, P466; MCCARTY MF, 1994, MED HYPOTHESES, V42, P323, DOI 10.1016/0306-9877(94)90007-8; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Noack W, 1994, Osteoarthritis Cartilage, V2, P51, DOI 10.1016/S1063-4584(05)80006-8; PAVELKA K, 1995, OSTEOARTHR CARTILAGE, V3, P15, DOI 10.1016/S1063-4584(05)80034-2; PAVELKA K, 1998, EULAR RHEUMATOL L S2, V27, P63; PUJALTE JM, 1980, CURR MED RES OPIN, V7, P110, DOI 10.1185/03007998009112036; Qiu GX, 1998, ARZNEIMITTEL-FORSCH, V48, P469; REICHELT A, 1994, ARZNEIMITTELFORSCH, V44-1, P75; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; Ronca F, 1998, OSTEOARTHR CARTILAGE, V6, P14, DOI 10.1016/S1063-4584(98)80006-X; ROVATI LC, 1992, INT J TISSUE REACT, V14, P243; ROVATI LC, 1997, OSTEOARTHR CARTILAGE, V5, P72; ROVETTA G, 1991, DRUG EXP CLIN RES, V17, P53; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SETNIKAR I, 1986, ARZNEIMITTELFORSCH, V36-1, P729; SETNIKAR I, 1992, INT J TISSUE REACT, V14, P253; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; Tamblyn R, 1997, ANN INTERN MED, V127, P429, DOI 10.7326/0003-4819-127-6-199709150-00003; THEODOSAKIS J, 1997, ARTHRITIS CURE; Towheed TE, 1997, J RHEUMATOL, V24, P349; Uebelhart D, 1998, OSTEOARTHR CARTILAGE, V6, P6, DOI 10.1016/S1063-4584(98)80005-8; Uebelhart D, 1998, OSTEOARTHR CARTILAGE, V6, P39, DOI 10.1016/S1063-4584(98)80011-3; VAJARADUL Y, 1981, CLIN THER, V3, P336; VAZ AL, 1982, CURR MED RES OPIN, V8, P145, DOI 10.1185/03007998209112375; Verbruggen G, 1998, OSTEOARTHR CARTILAGE, V6, P37, DOI 10.1016/S1063-4584(98)80010-1	54	573	630	1	88	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2000	283	11					1469	1475		10.1001/jama.283.11.1469	http://dx.doi.org/10.1001/jama.283.11.1469			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290UR	10732937				2022-12-28	WOS:000085696700032
J	Molloy, DW; Guyatt, GH; Russo, R; Goeree, R; O'Brien, BJ; Bedard, M; Willan, A; Watson, J; Patterson, C; Harison, C; Standish, T; Strang, D; Darzins, PJ; Smith, S; Dubois, S				Molloy, DW; Guyatt, GH; Russo, R; Goeree, R; O'Brien, BJ; Bedard, M; Willan, A; Watson, J; Patterson, C; Harison, C; Standish, T; Strang, D; Darzins, PJ; Smith, S; Dubois, S			Systematic implementation of an advance directive program in nursing homes - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-DETERMINATION ACT; HEALTH-CARE PROXIES; DURABLE POWER; LIVING WILLS; PATIENT; COMPLETION; LIFE; OUTPATIENTS; ATTITUDES; END	Context Although advance directives are commonly used in the community, little is known about the effects of their systematic implementation. Objectives To examine the effect of systematically implementing an advance directive in nursing homes on patient and family satisfaction with involvement in decision making and on health care costs. Design Randomized controlled trial conducted June 1, 1994, to August 31, 1998. Setting and Participants A total of 1292 residents in 6 Ontario nursing homes with more than 100 residents each. Intervention The Let Me Decide advance directive program included educating staff in local hospitals and nursing homes, residents, and families about advance directives and offering competent residents or next-of-kin of mentally incompetent residents an advance directive that provided a range of health care choices for life-threatening illness, cardiac arrest, and nutrition. The 6 nursing homes were pair-matched on key characteristics, and 1 home per pair was randomized to take part in the program. Control nursing homes continued with prior policies concerning advance directives. Main Outcome Measures Residents' and families' satisfaction with health care and health care services utilization over 18 months, compared between intervention and control nursing homes. Results Of 527 participating residents in intervention nursing homes, 49% of competent residents and 78% of families of incompetent residents completed advance directives. Satisfaction was not significantly different in intervention and control nursing homes. The mean difference (scale, 1-7) between intervention and control homes was -0.16 (95% confidence interval [CI], -0.41 to 0.10) for competent residents and 0.07 (95% CI, -0.08 to 0.23) for families of incompetent residents. intervention nursing homes reported fewer hospitalizations per resident (mean, 0.27 vs 0.48; P =.001) and less resource use (average total cost per patient, Can $3490 vs Can $5239; P =.01) than control nursing homes. Proportion of deaths in intervention (24%) and control (28%) nursing homes were similar (P =.20). Conclusion Our data suggest that systematic implementation of a program to increase use of advance directives reduces health care services utilization without affecting satisfaction or mortality.	McMaster Univ, Hamilton Hlth Sci Corp, Geriatr Res Grp, Dept Med, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Sch Nursing, Hamilton, ON L8V 1C3, Canada; St Josephs Hosp, Father Sean OSullivan Res Ctr, Hamilton, ON, Canada; St Josephs Hosp, Ctr Evaluat Med, Hamilton, ON, Canada; Univ Manitoba, Dept Med, Winnipeg, MB, Canada; Univ Melbourne, Natl Ageing Res Inst, Parkville, Vic 3052, Australia	McMaster University; McMaster University; McMaster University; McGill University; McMaster University; McGill University; McMaster University; University of Manitoba; National Ageing Research Institute; University of Melbourne	Molloy, DW (corresponding author), McMaster Univ, Hamilton Hlth Sci Corp, Geriatr Res Grp, Dept Med, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	molloy@mcmaster.ca	Smith, Stephen K/F-6938-2012	Dubois, Sacha/0000-0003-3579-6072	AHRQ HHS [R01 HS07878-02S1] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007878] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALEMAYEHU E, 1991, CAN MED ASSOC J, V144, P1133; Bradley EH, 1997, J LAW MED ETHICS, V25, P150, DOI 10.1111/j.1748-720X.1997.tb01890.x; BROADWELL AW, 1993, SOUTH MED J, V86, P165, DOI 10.1097/00007611-199302000-00003; Dexter PR, 1998, ANN INTERN MED, V128, P102, DOI 10.7326/0003-4819-128-2-199801150-00005; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; ELSEMANN M, 1999, INT PSYCHOGERIATR, V11, P313; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Fried TR, 1997, J AM GERIATR SOC, V45, P265, DOI 10.1111/j.1532-5415.1997.tb00938.x; Ghusn HF, 1997, J AM GERIATR SOC, V45, P465, DOI 10.1111/j.1532-5415.1997.tb05172.x; GUYATT GH, 1995, J CLIN EPIDEMIOL, V48, P1215, DOI 10.1016/0895-4356(95)00024-X; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; HARRISON C, 1995, J CLIN ETHIC, V6, P14; HIGH DM, 1993, GERONTOLOGIST, V33, P342, DOI 10.1093/geront/33.3.342; HOLLEY JL, 1993, J AM SOC NEPHROL, V3, P1405; JACOBSON JA, 1994, WESTERN J MED, V160, P232; JAMES J, 1996, CAN HLTH CARE MANAGE, P78; Johns J L, 1996, Image J Nurs Sch, V28, P149, DOI 10.1111/j.1547-5069.1996.tb01208.x; JOOS SK, 1993, J GEN INTERN MED, V8, P259, DOI 10.1007/BF02600093; KELNER M, 1993, CAN MED ASSOC J, V148, P1331; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Konings J W, 1994, Ned Tijdschr Geneeskd, V138, P2655; Landry FJ, 1997, J GEN INTERN MED, V12, P412, DOI 10.1046/j.1525-1497.1997.00072.x; LUPTAK MK, 1994, GERONTOLOGIST, V34, P409; MEHRAN S, 1993, CANADIAN MED ASS J, V148, P1497; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; MOLLOY D, 1996, LET ME DECIDE; Molloy D, 1997, ANN RCPSC, V30, P339; MOLLOY DW, 1993, HUM MED, V9, P70; Molloy DW, 1996, J AM GERIATR SOC, V44, P660, DOI 10.1111/j.1532-5415.1996.tb01828.x; MOLLOY DW, 1991, AM J PSYCHIAT, V148, P102; MOLLOY DW, IN PRESS GERONTOLOGI; MOLLOY DW, 1992, ANN R COLL PHYSICIAN, V7, P433; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; Moss AH, 1996, CHEST, V110, P249, DOI 10.1378/chest.110.1.249; *ONT CAS COST PROJ, 1995, ONT GUID CAS COST; *ONT MIN HLTH, 1992, SCHED BEN PHYS SERV; *ONT MIN HLTH, 1997, DRUG BEN FORM COMP D, V35; *ONT MIN HLTH, 1997, ONT GOV PHARM MED SU; Patterson C, 1997, Can J Nurs Adm, V10, P96; Patterson C, 1997, J PALLIATIVE CARE, V13, P13, DOI 10.1177/082585979701300303; REILLY BM, 1995, ARCH INTERN MED, V155, P2202, DOI 10.1001/archinte.155.20.2202; Richter K P, 1995, Arch Fam Med, V4, P609, DOI 10.1001/archfami.4.7.609; ROBINSON MK, 1993, J FAM PRACTICE, V37, P363; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; Shore Andrew D., 1993, Journal of Psychosocial Oncology, V11, P39; SPEARS R, 1993, J FAM PRACTICE, V36, P409; Sugarman J, 1994, J Law Med Ethics, V22, P29; Sulmasy DP, 1996, J GEN INTERN MED, V11, P657, DOI 10.1007/BF02600156; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; Teno J, 1997, J AM GERIATR SOC, V45, P513, DOI 10.1111/j.1532-5415.1997.tb05180.x; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; Terry M, 1994, Arch Fam Med, V3, P141, DOI 10.1001/archfami.3.2.141	57	365	368	0	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2000	283	11					1437	1444		10.1001/jama.283.11.1437	http://dx.doi.org/10.1001/jama.283.11.1437			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	290UR	10732933	Bronze			2022-12-28	WOS:000085696700028
J	Vilan, A; Shanzer, A; Cahen, D				Vilan, A; Shanzer, A; Cahen, D			Molecular control over Au/GaAs diodes	NATURE			English	Article							ACID DERIVATIVES; ADSORPTION; DEVICES; GAAS	The use of molecules to control electron transport is an interesting possibility, not least because of the anticipated role of molecules in future electronic devices(1). But physical implementations using discrete molecules are neither conceptually(2,3) simple nor technically straightforward (difficulties arise in connecting the molecules to the macroscopic environment). But the use of molecules in electronic devices is not limited to single molecules, molecular wires or bulk material. Here we demonstrate that molecules can control the electrical characteristics of conventional metal-semiconductor junctions, apparently without the need for electrons to be transferred onto and through the molecules. We modify diodes by adsorbing small molecules onto single crystals of n-type GaAs semiconductor. Gold contacts were deposited onto the modified surface, using a 'soft' method to avoid damaging the molecules(4). By using a series of multifunctional molecules whose dipole is varied systematically, we produce diodes with an effective barrier height that is tuned by the molecule's dipole moment. These barrier heights correlate well with the change in work function of the GaAs surface after molecular modification. This behaviour is consistent with that of unmodified metal-semiconductor diodes, in which the barrier height can depend on the metal's work function.	Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Cahen, D (corresponding author), Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel.	david.cahen@weizmann.ac.il	CAHEN, DAVID/K-1501-2012	CAHEN, DAVID/0000-0001-8118-5446				AVIRAM A, 1998, ANN NY ACAD SCI, V852; Bastide S, 1997, J PHYS CHEM B, V101, P2678, DOI 10.1021/jp9626935; Boer K W, 1992, SURVEY SEMICONDUCTOR; Bruening M, 1997, J AM CHEM SOC, V119, P5720, DOI 10.1021/ja964434z; Bumm LA, 1999, J PHYS CHEM B, V103, P8122, DOI 10.1021/jp9921699; Campbell IH, 1997, APPL PHYS LETT, V71, P3528, DOI 10.1063/1.120381; CAPASSO F, 1985, APPL PHYS LETT, V46, P664, DOI 10.1063/1.95521; Cohen R, 1997, CHEM PHYS LETT, V279, P270, DOI 10.1016/S0009-2614(97)01070-1; Cohen R, 1999, J AM CHEM SOC, V121, P10545, DOI 10.1021/ja9906150; Cohen R, 1997, ADV MATER, V9, P746, DOI 10.1002/adma.19970090915; Gal D, 1997, P INDIAN AS-CHEM SCI, V109, P487; Haag R, 1999, J AM CHEM SOC, V121, P7895, DOI 10.1021/ja990230h; Heath JR, 1998, SCIENCE, V280, P1716, DOI 10.1126/science.280.5370.1716; Kronik L, 1999, SURF SCI REP, V37, P1, DOI 10.1016/S0167-5729(99)00002-3; Kruger J, 2000, ADV MATER, V12, P447, DOI 10.1002/(SICI)1521-4095(200003)12:6<447::AID-ADMA447>3.0.CO;2-8; KURTIN S, 1969, PHYS REV LETT, V22, P1433, DOI 10.1103/PhysRevLett.22.1433; LIDE DR, 1992, HDB CHEM PHYSICS, P9; MARTIN AS, 1993, PHYS REV LETT, V70, P218, DOI 10.1103/PhysRevLett.70.218; Moons E, 1996, SYNTHETIC MET, V76, P245, DOI 10.1016/0379-6779(95)03463-T; MOONS E, 1995, THESIS WEIZMANN I SC; Ratner MA, 1998, ANN NY ACAD SCI, V852, P22, DOI 10.1111/j.1749-6632.1998.tb09862.x; Rhoderick E.H., 1988, METAL SEMICONDUCTOR; Slowinski K, 1999, J AM CHEM SOC, V121, P7257, DOI 10.1021/ja991613i; SZE SM, 1981, PHYSICS SEMICONDUCTO; Tour JM, 1998, J AM CHEM SOC, V120, P8486, DOI 10.1021/ja9808090; Tung R. T., 1993, CONTACTS SEMICONDUCT, P219; VANRUYVEN LJ, 1964, PHYS STATUS SOLIDI, V5, pK109, DOI 10.1002/pssb.19640050326; Vilan A, 1998, J PHYS CHEM B, V102, P3307, DOI 10.1021/jp9804749; Wilson EK, 1999, CHEM ENG NEWS, V77, P43, DOI 10.1021/cen-v077n034.p043; YABLONOVITCH E, 1990, APPL PHYS LETT, V56, P2419, DOI 10.1063/1.102896; Yaliraki SN, 1999, J CHEM PHYS, V111, P6997, DOI 10.1063/1.480096; Zuppiroli L, 1999, EUR PHYS J B, V11, P505, DOI 10.1007/s100510050962	32	307	338	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2000	404	6774					166	168		10.1038/35004539	http://dx.doi.org/10.1038/35004539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724164				2022-12-28	WOS:000085870900045
J	Williams, RJ; Martinez, ND				Williams, RJ; Martinez, ND			Simple rules yield complex food webs	NATURE			English	Article							TROPHIC INTERACTIONS; PATTERNS; SCALE; ECOSYSTEM; PREY	Several of the most ambitious theories in ecology(1-14) describe food webs that document the structure of strong and weak trophic links(9) that is responsible for ecological dynamics among diverse assemblages of species(4,11-13). Early mechanism-based theory asserted that food webs have little omnivory and several properties that are independent of species richness(1-4,6). This theory was overturned by empirical studies that found food webs to be much more complex(5,7-9,14-18), but these studies did not provide mechanistic explanations for the complexity(9). Here we show that a remarkably simple model. fills this scientific void by successfully predicting key structural properties of the most complex and comprehensive food webs in the primary literature. These properties include the fractions of species at top, intermediate and basal trophic levels, the means and variabilities of generality, vulnerability and food-chain length, and the degrees of cannibalism, omnivory, looping and trophic similarity. Using only two empirical parameters, species number and connectance, our 'niche model' extends the existing 'cascade model'(3,19) and improves its fit ten-fold by constraining species to consume a contiguous sequence of prey in a one-dimensional trophic niche(20).	San Francisco State Univ, Dept Biol, Romberg Tiburon Ctr, Tiburon, CA 94920 USA	California State University System; San Francisco State University	Martinez, ND (corresponding author), San Francisco State Univ, Dept Biol, Romberg Tiburon Ctr, POB 855, Tiburon, CA 94920 USA.		Williams, Richard J/B-8344-2011; Martinez, Neo/A-5312-2008	Williams, Richard J/0000-0001-8847-3213; Martinez, Neo/0000-0002-1130-5550				BAIRD D, 1989, ECOL MONOGR, V59, P329, DOI 10.2307/1943071; Begon M, 1996, ECOLOGY INDIVIDUALS; Berlow EL, 1999, NATURE, V398, P330, DOI 10.1038/18672; Cohen J. E., 1990, BIOMATHEMATICS, V20; COHEN JE, 1993, J ANIM ECOL, V62, P67, DOI 10.2307/5483; COHEN JE, 1978, FOOD WEBS NICHE SPAC; DERUITER PC, 1995, SCIENCE, V269, P1257, DOI 10.1126/science.269.5228.1257; GOLDWASSER L, 1993, ECOLOGY, V74, P1216, DOI 10.2307/1940492; HALL SJ, 1991, J ANIM ECOL, V60, P823, DOI 10.2307/5416; HAVENS K, 1992, SCIENCE, V257, P1107, DOI 10.1126/science.257.5073.1107; HUTCHINSON GE, 1957, COLD SPRING HARB SYM, V22, P415, DOI 10.1101/SQB.1957.022.01.039; HUXMAN M, 1995, J ANIM ECOL, V64, P168; Lawton J.H., 1989, P43; LAWTON JH, 1995, OIKOS, V72, P305, DOI 10.2307/3546114; Marcogliese DJ, 1997, TRENDS ECOL EVOL, V12, P320, DOI 10.1016/S0169-5347(97)01080-X; MARTINEZ ND, 1991, ECOL MONOGR, V61, P367, DOI 10.2307/2937047; MARTINEZ ND, 1994, AM NAT, V144, P935, DOI 10.1086/285719; MARTINEZ ND, 1993, SCIENCE, V260, P242, DOI 10.1126/science.260.5105.242; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; McCann K, 1998, NATURE, V395, P794, DOI 10.1038/27427; Murtaugh PA, 1997, ECOLOGY, V78, P1382; PIMM SL, 1991, NATURE, V350, P669, DOI 10.1038/350669a0; Polis G.A., 1996, FOOD WEBS INTEGRATIO; POLIS GA, 1991, AM NAT, V138, P123, DOI 10.1086/285208; SCHOENER TW, 1989, ECOLOGY, V70, P1559, DOI 10.2307/1938088; Solow AR, 1998, ECOLOGY, V79, P2013, DOI 10.1890/0012-9658(1998)079[2013:OLSIFW]2.0.CO;2; Symstad AJ, 1998, OIKOS, V81, P389, DOI 10.2307/3547058; WARREN PH, 1989, OIKOS, V55, P299, DOI 10.2307/3565588; WARREN PH, 1987, OECOLOGIA, V74, P231, DOI 10.1007/BF00379364; Warren Philip H., 1996, P142	30	949	988	10	333	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					180	183		10.1038/35004572	http://dx.doi.org/10.1038/35004572			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724169				2022-12-28	WOS:000085870900050
J	Spechler, SJ; Fischbach, L; Feldman, M				Spechler, SJ; Fischbach, L; Feldman, M			Clinical aspects of genetic variability in Helicobacter pylori	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DUODENAL-ULCER DISEASE; GASTRIC-CANCER; REFLUX ESOPHAGITIS; INCREASED RISK; CAGA GENE; CYTOTOXIN ACTIVITY; INFECTION; STRAINS; ANTIGENS; STOMACH		Dept Vet Affairs Med Ctr, Dallas, TX USA; Univ Texas, SW Med Ctr, Houston, TX USA; Univ Texas, Sch Publ Hlth, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston	Spechler, SJ (corresponding author), Dallas VA Med Ctr, Div Gastroenterol 111B1, 4500 S Lancaster Rd, Dallas, TX 75216 USA.							Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Atherton JC, 1998, BRIT MED BULL, V54, P105; Atherton JC, 1999, GUT, V44, P307, DOI 10.1136/gut.44.3.307; Blaser MJ, 1998, GUT, V43, P721, DOI 10.1136/gut.43.5.721; Blaser MJ, 1997, LANCET, V349, P1020, DOI 10.1016/S0140-6736(96)09133-7; Blaser MJ, 1996, ALIMENT PHARM THER, V10, P73, DOI 10.1046/j.1365-2036.1996.22164008.x; BLASER MJ, 1995, CANCER RES, V55, P2111; Ching CK, 1996, AM J GASTROENTEROL, V91, P949; Cover TL, 1999, GASTROENTEROLOGY, V117, P257, DOI 10.1016/S0016-5085(99)70575-5; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; FORMAN D, 1993, GUT, V34, P1672, DOI 10.1136/gut.34.12.1672; Go M F, 1996, Helicobacter, V1, P107, DOI 10.1111/j.1523-5378.1996.tb00019.x; Graham DY, 1998, HELICOBACTER, V3, P145, DOI 10.1046/j.1523-5378.1998.08031.x; Hamlet A, 1999, GASTROENTEROLOGY, V116, P259, DOI 10.1016/S0016-5085(99)70121-6; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; Holtmann G, 1998, AM J GASTROENTEROL, V93, P1222, DOI 10.1111/j.1572-0241.1998.00399.x; Kidd M, 1999, GUT, V45, P499, DOI 10.1136/gut.45.4.499; Kikuchi S, 1999, AM J GASTROENTEROL, V94, P3455, DOI 10.1111/j.1572-0241.1999.01607.x; Klaamas K, 1996, INT J CANCER, V67, P1, DOI 10.1002/(SICI)1097-0215(19960703)67:1<1::AID-IJC1>3.0.CO;2-0; Labenz J, 1997, GASTROENTEROLOGY, V112, P1442, DOI 10.1016/S0016-5085(97)70024-6; Miehlke S, 1996, AM J GASTROENTEROL, V91, P1322; Mitchell HM, 1996, AM J GASTROENTEROL, V91, P1785; Park SM, 1998, SCAND J GASTROENTERO, V33, P923, DOI 10.1080/003655298750026921; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; PEEK RM, 1995, LAB INVEST, V71, P760; Rudi J, 1997, DIGEST DIS SCI, V42, P1652, DOI 10.1023/A:1018849112533; Scheiman JM, 1999, AM J MED, V106, P222, DOI 10.1016/S0002-9343(98)00393-3; Shyu RY, 1998, J CLIN GASTROENTEROL, V27, P54, DOI 10.1097/00004836-199807000-00011; TUMMURU MKR, 1994, INFECT IMMUN, V62, P2609, DOI 10.1128/IAI.62.6.2609-2613.1994; van Doorn LJ, 1998, GASTROENTEROLOGY, V115, P58, DOI 10.1016/S0016-5085(98)70365-8; Vicari JJ, 1998, GASTROENTEROLOGY, V115, P50, DOI 10.1016/S0016-5085(98)70364-6; Vorobjova T, 1998, EUR J GASTROEN HEPAT, V10, P41, DOI 10.1097/00042737-199801000-00008; Werdmuller BFM, 1997, DIGEST DIS SCI, V42, P103, DOI 10.1023/A:1018841222856; Wong BCY, 1999, ALIMENT PHARM THER, V13, P1295; Yamaoka Y, 1999, J CLIN PATHOL, V52, P215, DOI 10.1136/jcp.52.3.215	36	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2000	283	10					1264	1266		10.1001/jama.283.10.1264	http://dx.doi.org/10.1001/jama.283.10.1264			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289ND	10714712				2022-12-28	WOS:000085628100001
J	Fazio, VW				Fazio, VW			Early promise of stapling technique for haemorrhoidectomy	LANCET			English	Editorial Material									Cleveland Clin Fdn, Dept Colorectal Surg, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Fazio, VW (corresponding author), Cleveland Clin Fdn, Dept Colorectal Surg, Cleveland, OH 44195 USA.							Ho YH, 1999, DIS COLON RECTUM, V42, P89, DOI 10.1007/BF02235189; TUCKSON W, 1991, AM J SURG, V6, P90	2	65	70	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					768	769		10.1016/S0140-6736(00)00086-6	http://dx.doi.org/10.1016/S0140-6736(00)00086-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711919				2022-12-28	WOS:000085766900003
J	Yamamoto, A				Yamamoto, A			Crowded universities cramp more than just students' style	NATURE			English	Letter									Waseda Univ, Dept Appl Chem, Sinjuku Ku, Tokyo 1698555, Japan	Waseda University	Yamamoto, A (corresponding author), Waseda Univ, Dept Appl Chem, Sinjuku Ku, 3-4-1 Ohkubo, Tokyo 1698555, Japan.							Swinbanks D, 2000, NATURE, V403, P7, DOI 10.1038/47330; YAMAMOTO A, 1989, NATURE, V339, P575, DOI 10.1038/339575a0	2	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					13	13		10.1038/35003739	http://dx.doi.org/10.1038/35003739			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716420	Bronze			2022-12-28	WOS:000085775100017
J	Bull, J; Levin, B				Bull, J; Levin, B			Microbiology - Mice are not furry petri dishes	SCIENCE			English	Editorial Material							ANTIBIOTIC-RESISTANCE; VIRULENCE; DRUG		Univ Texas, Sect Integrat Biol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Emory University	Bull, J (corresponding author), Univ Texas, Sect Integrat Biol, Austin, TX 78712 USA.							Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152; Bjorkman J, 2000, SCIENCE, V287, P1479, DOI 10.1126/science.287.5457.1479; Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; Borman AM, 1996, J GEN VIROL, V77, P419, DOI 10.1099/0022-1317-77-3-419; Levin BR, 1997, CLIN INFECT DIS, V24, pS9, DOI 10.1093/clinids/24.Supplement_1.S9; Levin Bruce R., 1994, Trends in Microbiology, V2, P76, DOI 10.1016/0966-842X(94)90538-X; Levy S B, 1994, Trends Microbiol, V2, P341, DOI 10.1016/0966-842X(94)90607-6; Nijhuis M, 1999, AIDS, V13, P2349, DOI 10.1097/00002030-199912030-00006; Schrag SJ, 1996, NATURE, V381, P120, DOI 10.1038/381120b0; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	10	15	15	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1409	1410		10.1126/science.287.5457.1409	http://dx.doi.org/10.1126/science.287.5457.1409			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10722389				2022-12-28	WOS:000085531600026
J	Willis, KJ; Whittaker, RJ				Willis, KJ; Whittaker, RJ			Paleoecology - The refugial debate	SCIENCE			English	Editorial Material							PHYLOGEOGRAPHY; SPECIATION; FOREST; EUROPE		Univ Oxford, Sch Geog, Oxford OX1 3TB, England	University of Oxford	Willis, KJ (corresponding author), Univ Oxford, Sch Geog, Mansfield Rd, Oxford OX1 3TB, England.		Whittaker, Robert J/H-1548-2015	Whittaker, Robert J/0000-0001-7775-3383; Willis, Katherine/0000-0002-6763-2489				Aide TM, 1998, J BIOGEOGR, V25, P695, DOI 10.1046/j.1365-2699.1998.2540695.x; Avise JC, 1998, P ROY SOC B-BIOL SCI, V265, P457, DOI 10.1098/rspb.1998.0317; BENNETT KD, 1991, J BIOGEOGR, V18, P103, DOI 10.2307/2845248; Colinvaux PA, 2000, QUATERNARY SCI REV, V19, P141, DOI 10.1016/S0277-3791(99)00059-1; Colinvaux PA, 1996, SCIENCE, V274, P85, DOI 10.1126/science.274.5284.85; Demesure B, 1996, EVOLUTION, V50, P2515, DOI 10.1111/j.1558-5646.1996.tb03638.x; Haberle SG, 1999, QUATERNARY RES, V51, P27, DOI 10.1006/qres.1998.2020; HAFFER J, 1969, SCIENCE, V165, P131, DOI 10.1126/science.165.3889.131; Hewitt GM, 1999, BIOL J LINN SOC, V68, P87, DOI 10.1111/j.1095-8312.1999.tb01160.x; Klicka J, 1997, SCIENCE, V277, P1666, DOI 10.1126/science.277.5332.1666; Nores M, 1999, J BIOGEOGR, V26, P475, DOI 10.1046/j.1365-2699.1999.t01-1-00311.x; TABERLET P, 1994, P ROY SOC B-BIOL SCI, V255, P195, DOI 10.1098/rspb.1994.0028	12	180	187	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1406	1407		10.1126/science.287.5457.1406	http://dx.doi.org/10.1126/science.287.5457.1406			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10722388				2022-12-28	WOS:000085531600024
J	Martin, W				Martin, W			Evolutionary biology - A powerhouse divided	SCIENCE			English	Editorial Material							CELL-DIVISION; PROTEINS; TUBULIN; FTSZ; HYDROGENOSOME; HOMOLOG		Univ Dusseldorf, Inst Bot 3, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Martin, W (corresponding author), Univ Dusseldorf, Inst Bot 3, D-40225 Dusseldorf, Germany.	w.martin@uni-duesseldorf.de	Martin, William F./O-5446-2015; Martin, William/C-5680-2008	Martin, William F./0000-0003-1478-6449; 				Beech PL, 2000, SCIENCE, V287, P1276, DOI 10.1126/science.287.5456.1276; Benchimol M, 1996, BIOL CELL, V87, P197, DOI 10.1016/S0248-4900(97)89276-3; Burns R, 1998, NATURE, V391, P121, DOI 10.1038/34286; Desai A, 1998, BIOESSAYS, V20, P523, DOI 10.1002/(SICI)1521-1878(199807)20:7<523::AID-BIES1>3.0.CO;2-L; DOOLITTLE RF, 1995, PHILOS T R SOC B, V349, P235, DOI 10.1098/rstb.1995.0107; Doolittle RF, 1998, NATURE, V392, P339, DOI 10.1038/32789; Doolittle WF, 1997, P NATL ACAD SCI USA, V94, P12751, DOI 10.1073/pnas.94.24.12751; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; Faguy DM, 1998, CURR BIOL, V8, pR338, DOI 10.1016/S0960-9822(98)70216-7; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Hackstein JHP, 1999, TRENDS MICROBIOL, V7, P441, DOI 10.1016/S0966-842X(99)01613-3; Lu CL, 2000, J BACTERIOL, V182, P164, DOI 10.1128/JB.182.1.164-170.2000; Lutkenhaus J, 1998, CURR BIOL, V8, pR619, DOI 10.1016/S0960-9822(98)70391-4; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; MULLER M, 1988, EVOLUTIONARY RELATIO, P109; Roger AJ, 1999, AM NAT, V154, pS146, DOI 10.1086/303290; Strepp R, 1998, P NATL ACAD SCI USA, V95, P4368, DOI 10.1073/pnas.95.8.4368; Zauner S, 2000, P NATL ACAD SCI USA, V97, P200, DOI 10.1073/pnas.97.1.200	19	10	11	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	2000	287	5456					1219	1219		10.1126/science.287.5456.1219	http://dx.doi.org/10.1126/science.287.5456.1219			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10712157				2022-12-28	WOS:000085444700037
J	Pelosi, AJ; Jackson, GA				Pelosi, AJ; Jackson, GA			Home treatment - enigmas and fantasies	BRITISH MEDICAL JOURNAL			English	Article									Lanarkshire Primary Care NHS Trust, E Kilbride G75 8RG, Lanark, Scotland; Greater Glasgow Primary Care NHS Trust, Leverndale Hosp, Glasgow G52 7TU, Lanark, Scotland		Pelosi, AJ (corresponding author), Lanarkshire Primary Care NHS Trust, E Kilbride G75 8RG, Lanark, Scotland.			jackson, graham/0000-0002-0526-7084; Pelosi, Anthony/0000-0002-5501-2661				Caplan G., 1964, PRINCIPLES PREVENTIV; CATHERALL S, 1996, HOSP DOCTOR, V7, P43; Dale J, 1996, BRIT MED J, V312, P1340, DOI 10.1136/bmj.312.7042.1340; HOULT J, 1990, RECENT ADV CRISIS IN, V1, P45; MINGHELLA E, 1999, OPEN ALL HOURS 24 HO	5	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 29	2000	320	7230					308	309						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280ZB	10722288				2022-12-28	WOS:000085132700035
J	Brinsden, PR; Appleton, TC; Murray, E; Hussein, M; Akagbosu, F; Marcus, SF				Brinsden, PR; Appleton, TC; Murray, E; Hussein, M; Akagbosu, F; Marcus, SF			Treatment by in vitro fertilisation with surrogacy: experience of one British centre	BRITISH MEDICAL JOURNAL			English	Article							INVITRO FERTILIZATION		Bourn Hall Clin, Cambridge CB3 7TR, England		Brinsden, PR (corresponding author), Bourn Hall Clin, Cambridge CB3 7TR, England.							*AM COLL OBST GYN, 1990, ETH ISS SURR MOTH; [Anonymous], GENESIS; [Anonymous], GENESIS, V21; [Anonymous], GENESIS; Blyth E., 1994, J REPROD INFANT PSYC, V12, P189, DOI DOI 10.1080/02646839408408885; BRAZIER M, 1998, SURROGACY REV UK HLT; Brinsden PR, 1999, TXB IN VITRO FERTILI, P361; *BRIT MED ASS, 1985, BMJ S, V291; *BRIT MED ASS, 1987, SURR MOTH REP BOARD; *BRIT MED ASS, 1985, BMJ S, V295; British Medical Association, 1996, CHANG CONC MOTH PRAC; British Medical Association, 1990, SURR ETH CONS REP WO; *DEP HLTH, 1997, SURR REV UK HLTH MIN; *ETH COMM AM FERT, 1986, FERTIL STERIL S1, V46, P62; *ETH COMM BOURN HA, GUID TREATM IN VITRO; FISHER S, 1991, PSYCHIATRY, V54, P13; MACNAMEE MC, 1999, TXB IN VITRO FERTILI, P91; MARCUS SF, 1993, HUM REPROD, V8, P238, DOI 10.1093/oxfordjournals.humrep.a138030; MARRS RP, 1993, AM J OBSTET GYNECOL, V168, P1858, DOI 10.1016/0002-9378(93)90702-K; SATHANANDAN M, 1991, HUM REPROD, V5, P1025; UTIAN WH, 1989, FERTIL STERIL, V52, P633	21	16	17	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					924	928		10.1136/bmj.320.7239.924	http://dx.doi.org/10.1136/bmj.320.7239.924			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10742007	Green Published			2022-12-28	WOS:000086337100033
J	Smith, H; Pickering, RM; Struthers, A; Simpson, I; Mant, D				Smith, H; Pickering, RM; Struthers, A; Simpson, I; Mant, D			Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NATRIURETIC PEPTIDE; HEART-FAILURE; CARE	Objective To investigate die usefulness of measuring plasma concentrations of B type natriuretic peptide in the diagnosis of left ventricular systolic dysfunction ill an unselected group of elderly people. Design Observational study. Setting General practice with four centres in Poole, Dorset Participants 155 elderly patients aged 70 to 84 years. Main outcome measures Diagnostic characteristics of plasma B type natriuretic peptide measured by radioimmunoassay as a test for left ventricular systolic dysfunction assessed by echocardiograph): Results The median plasma concentration of B type natriuretic peptide was 39.3 pmol/l in patients with left ventricular systolic dysfunction and 15.8 pmol/l in those with normal function. The proportional area under the receiver operator curve was 0.85. At a cut-off point of 18.7 pmol/l the test sensitivity. was 92% and the predictive value 18%. Conclusions Plasma concentration of B type natriuretic peptide could be used effectively as an initial test in a community screening programme and, possibly, using a low cut-off point, as a means of ruling out left ventricular systolic dysfunction. It is, however, not a good test to "rule in" the diagnosis, and access to echocardiography remains essential for general practitioners to diagnose heart failure early.	Univ Southampton, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England; Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England; Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Dundee DD1 9SY, Scotland; Southampton Gen Hosp, Wessex Cardiothorac Ctr, Dept Cardiol, Southampton, Hants, England; Univ Oxford, Div Publ Hlth & Primary Hlth Care, Inst Hlth Sci, Oxford OX3 7LF, England	University of Southampton; University of Southampton; University of Dundee; University of Southampton; University of Oxford	Smith, H (corresponding author), Univ Southampton, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England.	hes@soton.ac.uk	Mant, David CA/C-7763-2009; Smith, Helen E/M-2449-2016	Smith, Helen E/0000-0003-1883-6124; Struthers, Allan/0000-0002-2926-2528				Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5; DAVIDSON NC, 1995, CIRCULATION, V91, P1276; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; Morgan S, 1999, BRIT MED J, V318, P368, DOI 10.1136/bmj.318.7180.368; Omland T, 1998, LANCET, V351, P1063, DOI 10.1016/S0140-6736(05)79035-8; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; STRUTHERS AD, 1994, BMJ-BRIT MED J, V308, P1615, DOI 10.1136/bmj.308.6944.1615; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0	8	75	82	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2000	320	7239					906	908		10.1136/bmj.320.7239.906	http://dx.doi.org/10.1136/bmj.320.7239.906			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10741999	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086337100024
J	Kouskoff, V; Lacaud, G; Nemazee, D				Kouskoff, V; Lacaud, G; Nemazee, D			T cell-independent rescue of B lymphocytes from peripheral immune tolerance	SCIENCE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; MONOCLONAL-ANTIBODIES; MOLECULAR MIMICRY; TRANSGENIC MICE; SELF ANTIGEN; DISEASE; INFECTION; AUTOANTIGEN; ACTIVATION	Autoimmunity arises when immune tolerance to specific self-antigens is broken. The mechanisms leading to such a failure remain poorly understood. One hypothesis proposes that infectious agents or antigens can break B or T lymphocyte self-tolerance by expressing epitopes that mimic self. Using a transgenic immunoglobulin model, we show that challenge with self-mimicking foreign antigen rescues B cells from peripheral tolerance independent of T cell help, resulting in the accumulation of self-reactive cells in the Lymph nodes and secretion of immunoglobulins that bind to a liver-expressed self-antigen. Therefore, our studies reveal a potentially important mechanism by which B Lymphocytes can escape self-tolerance.	Scripps Res Inst, La Jolla, CA 92037 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	Scripps Research Institute; National Jewish Health; National Jewish Health	Nemazee, D (corresponding author), Scripps Res Inst, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	nemazee@scripps.edu	lacaud, Georges/ABH-5215-2020	Lacaud, Georges/0000-0002-5630-2417	NIAID NIH HHS [R01AI33608, R01 AI033608, P01 AI022295, P01AI22295] Funding Source: Medline; NIGMS NIH HHS [R01 GM044809] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI022295, R01AI033608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044809] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akkaraju S, 1997, J EXP MED, V186, P2005, DOI 10.1084/jem.186.12.2005; Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; Caton AJ, 1996, J EXP MED, V183, P13, DOI 10.1084/jem.183.1.13; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; Cyster JG, 1995, IMMUNITY, V3, P691, DOI 10.1016/1074-7613(95)90059-4; FRITZ RB, 1983, J IMMUNOL, V130, P1024; Fulcher DA, 1996, J EXP MED, V183, P2313, DOI 10.1084/jem.183.5.2313; GOODNOW CC, 1991, NATURE, V352, P532, DOI 10.1038/352532a0; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; GU DL, 1995, J EXP MED, V181, P547, DOI 10.1084/jem.181.2.547; HANG L, 1983, J EXP MED, V157, P874, DOI 10.1084/jem.157.3.874; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; JIN FS, 1991, J IMMUNOL, V146, P1806; Kouskoff V, 1998, J EXP MED, V188, P1453, DOI 10.1084/jem.188.8.1453; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; LECLERC C, 1991, J IMMUNOL, V147, P3545; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Mamula MJ, 1998, IMMUNOL REV, V164, P231, DOI 10.1111/j.1600-065X.1998.tb01223.x; MCHEYZERWILLIAMS MG, 1988, J IMMUNOL, V141, P4118; MCRAE BL, 1995, J EXP MED, V182, P75, DOI 10.1084/jem.182.1.75; Melamed D, 1997, J IMMUNOL, V159, P1233; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OZATO K, 1980, J IMMUNOL, V124, P533; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; ROCKEN M, 1992, NATURE, V359, P79, DOI 10.1038/359079a0; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Szomolanyi-Tsuda E, 1998, CURR OPIN IMMUNOL, V10, P431, DOI 10.1016/S0952-7915(98)80117-9; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	42	53	56	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2000	287	5462					2501	2503		10.1126/science.287.5462.2501	http://dx.doi.org/10.1126/science.287.5462.2501			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741972	Green Accepted			2022-12-28	WOS:000086202200049
J	Benos, PV; Gatt, MK; Ashburner, M; Murphy, L; Harris, D; Barrell, B; Ferraz, C; Vidal, S; Brun, C; Demailles, J; Cadieu, E; Dreano, S; Gloux, S; Lelaure, V; Mottier, S; Galibert, F; Borkova, D; Minana, B; Kafatos, FC; Louis, C; Siden-Kiamos, I; Bolshakov, S; Papagiannakis, G; Spanos, L; Cox, S; Madueno, E; de Pablos, B; Modolell, J; Peter, A; Schottler, P; Werner, M; Mourkioti, F; Beinert, N; Dowe, G; Schafer, U; Jackle, H; Bucheton, A; Callister, DM; Campbell, LA; Darlamitsou, A; Henderson, NS; McMillan, PJ; Salles, C; Tait, EA; Valenti, P; Saunders, RDC; Glover, DM				Benos, PV; Gatt, MK; Ashburner, M; Murphy, L; Harris, D; Barrell, B; Ferraz, C; Vidal, S; Brun, C; Demailles, J; Cadieu, E; Dreano, S; Gloux, S; Lelaure, V; Mottier, S; Galibert, F; Borkova, D; Minana, B; Kafatos, FC; Louis, C; Siden-Kiamos, I; Bolshakov, S; Papagiannakis, G; Spanos, L; Cox, S; Madueno, E; de Pablos, B; Modolell, J; Peter, A; Schottler, P; Werner, M; Mourkioti, F; Beinert, N; Dowe, G; Schafer, U; Jackle, H; Bucheton, A; Callister, DM; Campbell, LA; Darlamitsou, A; Henderson, NS; McMillan, PJ; Salles, C; Tait, EA; Valenti, P; Saunders, RDC; Glover, DM			From sequence to chromosome: The tip of the X chromosome of D. melanogaster	SCIENCE			English	Editorial Material							DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENTS; PHYSICAL MAP; DNA; POPULATION; NUMBER; GENE	One of the rewards of having a Drosophila melanogaster whole-genome sequence will be the potential to understand the molecular bases for structural features of chromosomes that have been a Long-standing puzzle. Analysis of 2.6 megabases of sequence from the tip of the X chromosome of Drosophila identifies 273 genes. Cloned DNAs from the characteristic bulbous structure at the tip of the X chromosome in the region of the broad complex display an unusual pattern of in situ hybridization. Sequence analysis revealed that this region comprises 154 kilobases of DNA flanked by 1.2-kilobases of inverted repeats, each composed of a 350-base pair satellite related element. Thus, some aspects of chromosome structure appear to be revealed directly within the DNA sequence itself.	European Bioinformat Inst, Cambridge CB10 1SD, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; Sanger Ctr, Cambridge CB10 1SA, England; Univ Montpellier, Sch Med, IGH, CNRS, F-34396 Montpellier 5, France; Fac Med, CNRS, Unite Propre Rech 41, F-35043 Rennes, France; European Mol Biol Lab, Heidelberg, Germany; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Heraklion, Greece; Univ Crete, Dept Biol, Heraklion, Greece; Univ Autonoma Madrid, E-28049 Madrid, Spain; CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Max Planck Inst Biophys Chem, Dept Mol Dev Biol, D-37070 Gottingen, Germany; Univ Dundee, Dept Anat & Physiol, Canc Res Campaign, Cell Cycle Genet Grp, Dundee DD1 4HN, Scotland; Open Univ, Dept Biol Sci, Milton Keynes MK7 6AA, Bucks, England	European Molecular Biology Laboratory (EMBL); University of Cambridge; Wellcome Trust Sanger Institute; Centre National de la Recherche Scientifique (CNRS); Universite de Franche-Comte; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL); Foundation for Research & Technology - Hellas (FORTH); University of Crete; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Max Planck Society; University of Dundee; Open University - UK	Benos, PV (corresponding author), European Bioinformat Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SD, England.		Louis, Christos/F-2527-2012; minana, belen/K-5530-2015; McMillan, Paul James/P-6441-2019; McMillan, Paul/B-5081-2008	minana, belen/0000-0001-7676-5788; McMillan, Paul James/0000-0001-5629-1175; Glover, David/0000-0003-0956-0103; Murphy, Lee/0000-0001-6467-7449; Benos, Panayiotis/0000-0003-3172-3132; Mourkioti, Foteini/0000-0002-7119-6640				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ashburner M, 1999, GENETICS, V153, P179; Ashburner M., 1989, DROSOPHILA LAB HDB; BECKER HJ, 1959, CHROMOSOMA, V10, P654, DOI 10.1007/BF00396591; BRIDGES C. B., 1937, Cytologia, P745, DOI 10.1508/cytologia.FujiiJubilaei.745; Bridges CB, 1938, J HERED, V29, P11, DOI 10.1093/oxfordjournals.jhered.a104399; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; Carson Hampton L., 1992, P441; CHARLESWORTH B, 1989, GENET RES, V54, P113, DOI 10.1017/S0016672300028482; DIBARTOLOMEIS SM, 1992, NUCLEIC ACIDS RES, V20, P1113, DOI 10.1093/nar/20.5.1113; GUBB D, 1990, GENETICS, V126, P167; Hoogland C, 1996, GENETICS, V144, P197; Hoskins RA, 2000, SCIENCE, V287, P2271, DOI 10.1126/science.287.5461.2271; KASTRITSIS CD, 1986, CHROMOSOMA, V93, P381, DOI 10.1007/BF00327598; LANGLEY CH, 1988, GENET RES, V52, P223, DOI 10.1017/S0016672300027695; MADUENO E, 1995, GENETICS, V139, P1631; Morgan TH, 1910, SCIENCE, V32, P120, DOI 10.1126/science.32.812.120; OFFERMANN CA, 1936, J GENET, V32, P102; Parsons JD, 1995, COMPUT APPL BIOSCI, V11, P615; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; SAUNDERS RDC, 1989, NUCLEIC ACIDS RES, V17, P9027, DOI 10.1093/nar/17.22.9027; SIDENKIAMOS I, 1990, NUCLEIC ACIDS RES, V18, P6261, DOI 10.1093/nar/18.21.6261; SNIEGOWSKI PD, 1994, GENETICS, V137, P815; Sonnhammer ELL, 1995, GENE, V167, pGC1, DOI 10.1016/0378-1119(95)00714-8; SORSA V, 1988, CHROMOSOME MAPS DROS, V1; STALKER HD, 1972, GENETICS, V70, P457; Sturtevant AH, 1913, J EXP ZOOL, V14, P43, DOI 10.1002/jez.1400140104; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4573; Tzolovsky G, 1999, GENETICS, V153, P1371; WARING GL, 1987, P NATL ACAD SCI USA, V84, P2843, DOI 10.1073/pnas.84.9.2843; ZHIMULEV IF, 1995, EUR J ENTOMOL, V92, P263; [No title captured]	32	22	153	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2220	2222		10.1126/science.287.5461.2220	http://dx.doi.org/10.1126/science.287.5461.2220			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731137				2022-12-28	WOS:000086049100038
J	Miller, FG; Fins, JJ; Snyder, L				Miller, FG; Fins, JJ; Snyder, L			Assisted suicide compared with refusal of treatment: A valid distinction?	ANNALS OF INTERNAL MEDICINE			English	Article							VOLUNTARY ACTIVE EUTHANASIA; TERMINALLY ILL PATIENTS; DEATH; HYDRATION; NUTRITION	The continuing debate over the deeply controversial issue of physician-assisted suicide has been complicated by confusion about how this practice resembles or differs from refusal of life-sustaining treatment. Perspectives on ethics and policy hinge on the contested issue of whether a valid distinction can be made between assisted suicide and withdrawal of treatment. This paper uses three illustrative cases to examine leading arguments for and against the recognition of a fundamental distinction between these practices. The first case involves assisted suicide by ingestion of prescribed barbiturates, the second involves withdrawal of artificial nutrition and hydration, and the third involves a decision to stop eating and drinking. On theoretical and practical grounds, this paper defends the position that there is a valid distinction between assisted suicide and refusal of treatment.	Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Virginia, Charlottesville, VA USA	University of Pennsylvania; Pennsylvania Medicine; University of Virginia	Snyder, L (corresponding author), Univ Penn, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.	lsnyder@mail.acponline.org		Fins, Joseph/0000-0002-7221-0053				Alpers A, 1997, JAMA-J AM MED ASSOC, V277, P1705, DOI 10.1001/jama.277.21.1705; Baron CH, 1996, HARVARD J LEGIS, V33, P1; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P238; BEAUCHAMP TL, 1995, ETHICAL ISSUES DEATH, P112; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BROCK DW, 1993, LIFE DEATH, P208; BROCK DW, 1993, LIFE DEATH, P165; BRODY H, 1993, J CLIN ETHIC, V4, P112; CALLAHAN D, 1993, TROUBLED DREAM LIFE, P76; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; Field MJ, 1997, APPROACHING DEATH IM; FINS JJ, 1995, J AM GERIATR SOC, V43, P563, DOI 10.1111/j.1532-5415.1995.tb06107.x; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Meisel Alan, 1992, Kennedy Institute of Ethics Journal, V2, P309; Miller FG, 1998, ANN INTERN MED, V128, P559, DOI 10.7326/0003-4819-128-7-199804010-00007; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MILLER FG, 1996, BIOLAW LEGAL ETHICAL, pS136; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT ASS, P146; Pellegrino E D, 1992, J Clin Ethics, V3, P95; PENCE GE, 1995, CLASSIC CASES MED ET, P51; Powell T, 1996, J LAW MED ETHICS, V24, P54, DOI 10.1111/j.1748-720X.1996.tb01833.x; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; Snyder L, 1996, Pa Med, V99, P10; Ubel PA, 1997, J CLIN ETHIC, V8, P242; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13	27	27	28	2	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					470	475		10.7326/0003-4819-132-6-200003210-00008	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293CV	10733447				2022-12-28	WOS:000085834700007
J	Gordin, F; Chaisson, RE; Matts, JP; Miller, C; Garcia, MD; Hafner, R; Valdespino, JL; Coberly, J; Schechter, M; Klukowicz, AJ; Barry, MA; O'Brien, RJ				Gordin, F; Chaisson, RE; Matts, JP; Miller, C; Garcia, MD; Hafner, R; Valdespino, JL; Coberly, J; Schechter, M; Klukowicz, AJ; Barry, MA; O'Brien, RJ		Terry Beirn Community Programs Cli; Adult AIDS Clinical Trials Grp; Pan Amer Hlth Org; Ctr Dis Control Prevention Study G	Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons - An international randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT TUBERCULOSIS; ACTIVE TUBERCULOSIS; UNITED-STATES; DRUG-USERS; THERAPY; RISK; PROGRESSION; PROPHYLAXIS; OUTBREAK	Context Because of problems with adherence, toxicity, and increasing resistance associated with 6- to 12-month isoniazid regimens, an alternative short-course tuberculosis preventive regimen is needed. Objective To compare a 2-month regimen of daily rifampin and pyrazinamide with a 12-month regimen of daily isoniazid in preventing tuberculosis in persons with human immunodeficiency virus (HIV) infection. Design Randomized, open-label controlled trial conducted from September 1991 to May 1996, with follow-up through October 1997. Setting Outpatient clinics in the United States, Mexico, Haiti, and Brazil. Participants A total of 1583 HIV-positive persons aged 13 years or older with a positive tuberculin skin test result. Interventions Patients were randomized to isoniazid, 300 mg/d, with pyridoxine hydrochloride for 12 months (n = 792) or rifampin, 600 mg/d, and pyrazinamide, 20 mg/kg per day, for 2 months (n = 791). Main Outcome Measures The primary end point was culture-confirmed tuberculosis; secondary end points were proven or probable tuberculosis, adverse events, and death, compared by treatment group. Results Of patients assigned to rifampin and pyrazinamide, 80% completed the regimen compared with 69% assigned to isoniazid (P<.001). After a mean follow-up of 37 months, 19 patients (2.4%) assigned to rifampin and pyrazinamide and 26 (3.3%) assigned to isoniazid developed confirmed tuberculosis at rates of 0.8 and 1.1 per 100 person-years, respectively (risk ratio, 0.72 [95% confidence interval, 0.40-1.31]; P =.28). In multivariate analysis, there were no significant differences in rates for confirmed or probable tuberculosis (P =.83), HIV progression and/or death (P =.09), or overall adverse events (P =.27), although drug discontinuation was slightly higher in the rifampin and pyrazinamide group (P =.01). Neither regimen appeared to, lead to the development of drug-resistant tuberculosis. Conclusions Our data suggest that for preventing tuberculosis in HIV-infected patients, a daily 2-month regimen of rifampin and pyrazinamide is similar in safety and efficacy to a daily 12-month regimen of isoniazid. This shorter regimen offers practical advantages to both patients and tuberculosis control programs.	Vet Affairs Med Ctr, Washington, DC 20422 USA; Georgetown Univ, Washington, DC USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Univ Minnesota, Sch Publ Hlth, Community Programs Clin Res AIDS, Ctr Stat, Minneapolis, MN USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico; NIAID, Div AIDS, Bethesda, MD 20892 USA; Univ Fed Rio de Janeiro, Dept Prevent Med, Hosp Univ Clementino Fraga Filho, Infect Dis Serv, BR-21941 Rio De Janeiro, Brazil; St Michaels Hosp, Div Pulm, Newark, NJ USA; Boston Publ Hlth Commiss, Boston, MA USA; Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Georgetown University; Johns Hopkins University; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Instituto Nacional de Salud Publica; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universidade Federal do Rio de Janeiro; Centers for Disease Control & Prevention - USA	Gordin, F (corresponding author), Vet Affairs Med Ctr, 50 Irving St NW, Washington, DC 20422 USA.	vawrap@erols.com	Schechter, Mauro/AAG-7445-2020	Garcia-Garcia, Lourdes/0000-0001-5262-1157				[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BYRD RB, 1979, JAMA-J AM MED ASSOC, V241, P1239, DOI 10.1001/jama.241.12.1239; *CDC, 1989, MMWR-MORBID MORTAL W, V38, pS1; *CDCP, 1995, 1995 TUB PROGR MAN R; Centers for Disease Control (CDC), 1987, MMWR Suppl, V36, p1S; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; Goletti D, 1996, J IMMUNOL, V157, P1271; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; ISEMAN MD, 1989, AM REV RESPIR DIS, V140, P1187, DOI 10.1164/ajrccm/140.5.1187; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Moore M, 1997, JAMA-J AM MED ASSOC, V278, P833, DOI 10.1001/jama.278.10.833; Moreno S, 1997, ARCH INTERN MED, V157, P1729, DOI 10.1001/archinte.157.15.1729; Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014; OBRIEN RJ, 1995, AIDS, V9, P665, DOI 10.1097/00002030-199507000-00001; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; Rose DN, 1998, ANN INTERN MED, V129, P779, DOI 10.7326/0003-4819-129-10-199811150-00005; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMIEJA MJ, 1999, ISONIAZID PREVENTING; SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494, DOI 10.1164/ajrccm/145.2_Pt_1.494; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; WHO, 1996, GROUPS RISK WHO REP; WILKINSON D, 1999, DRUGS PREVENTING TUB	34	215	219	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2000	283	11					1445	1450		10.1001/jama.283.11.1445	http://dx.doi.org/10.1001/jama.283.11.1445			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290UR	10732934	Bronze			2022-12-28	WOS:000085696700029
J	Cummings, SR; Palermo, L; Browner, W; Marcus, R; Wallace, R; Pearson, J; Blackwell, T; Eckert, S; Black, D				Cummings, SR; Palermo, L; Browner, W; Marcus, R; Wallace, R; Pearson, J; Blackwell, T; Eckert, S; Black, D		Fracture Intervention Trial Res Gr	Monitoring osteoporosis therapy with bone densitometry - Misleading changes and regression to the man	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VARIABILITY; FRACTURE	Context The principle of "regression to the mean" predicts that patients with unusual responses to treatment might represent outliers who are likely to have more typical responses if treatment is continued without change. Objective To test whether women who lose bone mineral density (BMD) during the first year of treatment for osteoporosis continue to lose BMD if the same treatment is continued beyond 1 year. Design and Setting Two randomized, double-blind, placebo-controlled trials in 11 US clinical research centers for the Fracture Intervention Trial and 180 centers in the United States and other countries for the Multiple Outcomes of Raloxifene Evaluation Trial. Participants and Interventions Postmenopausal women with low BMD assigned to treatment with 5 mg/d of alendronate sodium in the Fracture Intervention Trial who completed 2 years of BMD monitoring and adhered to study medication (n = 2634), and postmenopausal women with osteoporosis assigned to treatment with 60 or 120 mg/d of raloxifene hydrochloride in the Multiple Outcomes of Raloxifene Evaluation trial who similarly completed 2 years of monitoring while adhering to study medication (n = 3954). Main Outcome Measures Baseline, 12-, and 24-month hip and spine BMD. Results Women with the greatest loss of BMD during the first year of treatment were the most likely to gal n BMD during continued treatment. Specifically, among women taking alendronate whose hip BMD decreased by more than 4% during the first year, 83% (95% confidence interval [CI], 82%-84%) had increases in hip BMD during the second year, with an overall mean increase of 4.7%, In contrast, those who seemed to gain at least 8% during the first year lost an average of 1% (95% CI, 0.1%-1.9%) during the next year. Similar results were observed among women taking raloxifene for 2 years. Conclusions Our data suggest that most women who lose BMD during the first year of treatment with alendronate or raloxifene will gain BMD if the same treatment is continued for a second year. These results illustrate the principle of regression to the mean and suggest that effective treatments for osteoporosis should not be changed because of loss of BMD during the first year of use.	Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Palo Alto, CA 94304 USA; Univ Iowa, Dept Prevent Med, Iowa City, IA 52242 USA; Eli Lilly & Co, Indianapolis, IN 46285 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa; Eli Lilly	Cummings, SR (corresponding author), Suite 600,74 New Montgomery St, San Francisco, CA 94105 USA.							Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P2124; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; Grampp S, 1997, J BONE MINER RES, V12, P697, DOI 10.1359/jbmr.1997.12.5.697; LOOKER A, IN PRESS J BONE MINE; Machado ABD, 1999, J BONE MINER RES, V14, P602; Sebastian-Gambaro MA, 1997, EUR J CLIN CHEM CLIN, V35, P845; Yudkin PL, 1996, LANCET, V347, P241, DOI 10.1016/S0140-6736(96)90410-9	10	182	187	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2000	283	10					1318	1321		10.1001/jama.283.10.1318	http://dx.doi.org/10.1001/jama.283.10.1318			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289ND	10714731				2022-12-28	WOS:000085628100028
J	Davenport, RJ; Wuite, GJL; Landick, R; Bustamante, C				Davenport, RJ; Wuite, GJL; Landick, R; Bustamante, C			Single-molecule study of transcriptional pausing and arrest by E-coli RNA polymerase	SCIENCE			English	Article							DNA; FORCE; BACTERIOPHAGE-T7; TERMINATION; MICROSCOPY; REGION	Using an optical-trap/flow-control video microscopy technique, we followed transcription by single molecules of Escherichia coli RNA polymerase in real time over long template distances. These studies reveal that RNA polymerase molecules possess different intrinsic transcription rates and different propensities to pause and stop. The data also show that reversible pausing is a kinetic intermediate between normal elongation and the arrested state. The conformational metastability of RNA polymerase revealed by this single-molecule study of transcription has direct implications for the mechanisms of gene regulation in both bacteria and eukaryotes.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Wisconsin System; University of Wisconsin Madison; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Bustamante, C (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	carlos@alice.berkeley.edu		Bustamante, Carlos/0000-0002-2970-0073; wuite, gijs/0000-0002-5706-043X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R37GM038660, R01GM038660, R01GM032543, R29GM038660] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38660, GM-32543] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; Guthold M, 1999, BIOPHYS J, V77, P2284, DOI 10.1016/S0006-3495(99)77067-0; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; Kasas S, 1997, BIOCHEMISTRY-US, V36, P461, DOI 10.1021/bi9624402; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KORNISSAROVA N, 1997, J BIOL CHEM, V272, P15329; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Landick R, 1999, SCIENCE, V284, P598, DOI 10.1126/science.284.5414.598; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Palangat M, 1998, MOL CELL, V1, P1033, DOI 10.1016/S1097-2765(00)80103-3; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0	22	266	279	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2000	287	5462					2497	2500		10.1126/science.287.5462.2497	http://dx.doi.org/10.1126/science.287.5462.2497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741971				2022-12-28	WOS:000086202200048
J	Goldman, JM				Goldman, JM			Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia	LANCET			English	Editorial Material							ABL-POSITIVE CELLS; LEUKEMIA; GROWTH		Hammersmith Hosp, Imperial Coll, Sch Med, Dept Haematol, London W12 0NN, England	Imperial College London	Goldman, JM (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Dept Haematol, London W12 0NN, England.							Buchdunger E, 1996, CANCER RES, V56, P100; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Melo JV, 1996, LEUKEMIA, V10, P751; NOWELL PC, 1960, SCIENCE, V132, P1497; ROWLEY D, 1973, NATURE, V43, P290	8	42	46	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1031	1032		10.1016/S0140-6736(00)02029-8	http://dx.doi.org/10.1016/S0140-6736(00)02029-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744084				2022-12-28	WOS:000086380800005
J	Myers, EW; Sutton, GG; Delcher, AL; Dew, IM; Fasulo, DP; Flanigan, MJ; Kravitz, SA; Mobarry, CM; Reinert, KHJ; Remington, KA; Anson, EL; Bolanos, RA; Chou, HH; Jordan, CM; Halpern, AL; Lonardi, S; Beasley, EM; Brandon, RC; Chen, L; Dunn, PJ; Lai, ZW; Liang, Y; Nusskern, DR; Zhan, M; Zhang, Q; Zheng, XQ; Rubin, GM; Adams, MD; Venter, JC				Myers, EW; Sutton, GG; Delcher, AL; Dew, IM; Fasulo, DP; Flanigan, MJ; Kravitz, SA; Mobarry, CM; Reinert, KHJ; Remington, KA; Anson, EL; Bolanos, RA; Chou, HH; Jordan, CM; Halpern, AL; Lonardi, S; Beasley, EM; Brandon, RC; Chen, L; Dunn, PJ; Lai, ZW; Liang, Y; Nusskern, DR; Zhan, M; Zhang, Q; Zheng, XQ; Rubin, GM; Adams, MD; Venter, JC			A whole-genome assembly of Drosophila	SCIENCE			English	Review							SHOTGUN	We report on the quality of a whole-genome assembly of Drosophila melanogaster and the nature of the computer algorithms that accomplished it. Three independent external data sources essentially agree with and support the assembly's sequence and ordering of contigs across the euchromatic portion of the genome. In addition, there are isolated contigs that we believe represent nonrepetitive pockets within the heterochromatin of the centromeres. Comparison with a previously sequenced 2.9-megabase region indicates that sequencing accuracy within nonrepetitive segments is greater than 99.99% without manual curation. As such, this initial reconstruction of the Drosophila sequence should be of substantial value to the scientific community.	Celera Genom Inc, Rockville, MD 20850 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Myers, EW (corresponding author), Celera Genom Inc, 45 W Gude Dr, Rockville, MD 20850 USA.	Myers@celera.com	Lonardi, Stefano/AAO-8070-2020; Reinert, Knut/V-3327-2019	Lonardi, Stefano/0000-0002-2696-7274; Reinert, Knut/0000-0003-3078-8129; Rubin, Gerald/0000-0001-8762-8703				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ashburner M, 1999, GENETICS, V153, P179; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHURCHILL G, 1982, GENOMICS, V14, P89; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Green P, 1997, GENOME RES, V7, P410, DOI 10.1101/gr.7.5.410; Hoskins RA, 2000, SCIENCE, V287, P2271, DOI 10.1126/science.287.5461.2271; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; MYERS EW, 1995, J COMP BIOL, V2, P2; MYERS EW, 1999, P 7 INT C INT SYST M; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; SANGER F, 1982, J MOL BIOL, V162, P4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P12; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401	20	1083	1146	5	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2196	2204		10.1126/science.287.5461.2196	http://dx.doi.org/10.1126/science.287.5461.2196			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731133				2022-12-28	WOS:000086049100034
J	Rubin, GM; Lewis, EB				Rubin, GM; Lewis, EB			A brief history of Drosophila's contributions to genome research	SCIENCE			English	Editorial Material							EUKARYOTIC DNA; P-ELEMENTS; MELANOGASTER; CHROMOSOMES; SEQUENCES; GENES	The sequence of the Drosophila melanogaster genome presented in this issue of Science is the latest milestone in nine decades of research on this organism. Genetic and physical mapping, whole-genome mutational screens, and functional alteration of the genome by gene transfer were pioneered in metazoans with the use of this small fruit fly. Here we Look at some of the instances in which work on Drosophila has Led to major conceptual or technical breakthroughs in our understanding of animal genomes.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; California Institute of Technology	Rubin, GM (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703	NICHD NIH HHS [HD06331] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006331, R37HD006331] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Allen G., 1978, HIST GENETICS, p[1, 1]; Ashburner M, 1999, GENETICS, V153, P179; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BENDER W, 1979, Journal of Supramolecular Structure, V8, P32; BENDER W, COMMUNICATION; BENDER W, 1980, ANN REP BIOL CALIF I, P165; BINGHAM PM, 1981, CELL, V25, P693, DOI 10.1016/0092-8674(81)90176-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRIDGES C. B., 1937, Cytologia, P745, DOI 10.1508/cytologia.FujiiJubilaei.745; Bridges C. B., 1914, Science New York N S, V40, DOI 10.1126/science.40.1020.107; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DUBOVSKY NV, 1938, B BIOL MED EXP, V6, P733; FINNEGAN DJ, UNPUB; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; Heitz E., 1933, Zeitschrift fuer Zellforschung, V17, P67, DOI 10.1007/BF00403356; HOGNESS DS, 1972, GB257691; HOGNESS DS, 1981, J SUPRAMOL STRUCT CE, V5, P385; LINDSLEY DL, 1972, GENETICS, V71, P157; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MORROW JF, 1974, P NATL ACAD SCI USA, V71, P1743, DOI 10.1073/pnas.71.5.1743; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; Muller HJ, 1930, J GENET, V22, P299, DOI 10.1007/BF02984195; MULLER HJ, 1918, GENETICS, V3, P442; MULLER HJ, 1930, ANAT REC, V47, P393; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PAINTER TS, 1934, J HERED, V25, P464; PARDUE ML, 1973, CHROMOSOMA, V42, P191, DOI 10.1007/BF00320940; PETTERSON JT, 1940, U TEXAS PUBL, V4032, P167; Rubin G. M., 2000, SCIENCE, V287; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUBIN GM, UNPUB; SPIERER P, 1983, J MOL BIOL, V168, P35, DOI 10.1016/S0022-2836(83)80321-0; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Sturtevant AH, 1913, J EXP ZOOL, V14, P43, DOI 10.1002/jez.1400140104; STURTEVANT AH, 1965, AM SCI, V53, P303; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; WENSINK PC, 1974, CELL, V3, P315, DOI 10.1016/0092-8674(74)90045-2; WHITEHOUSE HLK, 1969, UNDERSTANDING MECH H, P1	45	159	175	1	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2216	2218		10.1126/science.287.5461.2216	http://dx.doi.org/10.1126/science.287.5461.2216			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731135				2022-12-28	WOS:000086049100036
J	Adams, MM; Elam-Evans, LD; Wilson, HG; Gilbertz, DA				Adams, MM; Elam-Evans, LD; Wilson, HG; Gilbertz, DA			Rates of and factors associated with recurrence of preterm delivery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKING VITAL RECORDS; GESTATIONAL-AGE; REPRODUCTIVE HISTORIES; BIRTH; OUTCOMES; RISK; PREGNANCIES; PREDICTION; COHORT	Context Information about risk of recurrent preterm delivery is useful to clinicians, researchers, and policy makers for counseling, generating etiologic leads, and measuring the related public health burden. Objectives To identify the rate of recurrence of preterm delivery in second pregnancies, factors associated with recurrence, and the percentage of preterm deliveries in women with a history of preterm delivery. Design and Setting Population-based cohort study of data from birth and fetal death certificates from the state of Georgia between 1980 and 1995. Subjects A total of 122 722 white and 56 174 black women with first and second singleton deliveries at 20 to 44 weeks' gestation. Main Outcome Measure Length of gestation (categorized as 20-31, 32-36, or greater than or equal to 37 weeks) at second delivery compared with length of gestation at first delivery, by age and race. Results Most women whose first delivery was preterm subsequently had term deliveries. Of 1023 white women whose first delivery occurred at 20 to 31 weeks, 8.2% (95% confidence interval [CI], 6.6%-10.1%) delivered their second birth at 20 to 31 weeks and 20.1% (95 % CI, 17.7%-22.8%) at 32 to 36 weeks. Of 1084 comparable black women, 13.4% (95% CI, 11.4%-15.6%) delivered at 20 to 31 weeks and 23.4% (95% CI, 20.9%-26.1%) delivered at 32 to 36 weeks. Among women whose first delivery occurred at 32 to 36 weeks, all corresponding rates were lower than those whose first birth was at 20 to 31 weeks; the rates of second birth at 20 to 31 weeks were substantially lower (for white women, 1.9% [95% CI, 1.7%-2.2%]; for black women, 3.8% [95% CI, 3.4%-4.2%]). Compared with women aged 20 to 49 years at their second delivery, women younger than 18 years had twice the risk of recurrence of delivery at 20 to 31 weeks. Of all second deliveries at 20 to 31 weeks, 29.4% for white women and 37.8% for black women were preceded by a preterm delivery. Conclusions Our data suggest that recurrence of preterm delivery contributes a notable portion of all preterm deliveries, especially at the shortest gestations.	Ctr Dis Control & Prevent, Div Reprod Hlth, WHO, Collaborating Ctr Perinatal Care & Hlth Serv Res, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; World Health Organization	Adams, MM (corresponding author), Ctr Dis Control & Prevent, Div Reprod Hlth, WHO, Collaborating Ctr Perinatal Care & Hlth Serv Res, MS E 52,1600 Clifton Rd, Atlanta, GA 30333 USA.	mma1@cdc.gov		Elam-Evans, Laurie/0000-0003-1313-5484				Adams MM, 1997, AM J EPIDEMIOL, V145, P339; ADAMS MM, 1991, INT J EPIDEMIOL, V20, P950, DOI 10.1093/ije/20.4.950; Adams MM, 1997, PAEDIATR PERINAT EP, V11, P78, DOI 10.1111/j.1365-3016.1997.tb00799.x; Adams MM, 1997, PAEDIATR PERINAT EP, V11, P1; ALEXANDER GR, 1995, PUBLIC HEALTH REP, V110, P395; Baker RK, 1997, MEDIA STUD J, V11, P1; BAKKETEIG LS, 1979, AM J OBSTET GYNECOL, V135, P1086, DOI 10.1016/0002-9378(79)90742-7; BLANKSON ML, 1993, JAMA-J AM MED ASSOC, V269, P1401, DOI 10.1001/jama.269.11.1401; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P185; Cnattingius S, 1999, NEW ENGL J MED, V341, P943, DOI 10.1056/NEJM199909233411303; Emery ES, 1997, PAEDIATR PERINAT EP, V11, P313; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; Goldenberg RL, 1998, AM J PUBLIC HEALTH, V88, P233, DOI 10.2105/AJPH.88.2.233; IAMS JD, 1995, AM J OBSTET GYNECOL, V172, P1097, DOI 10.1016/0002-9378(95)91469-2; Iams JD, 1998, AM J OBSTET GYNECOL, V178, P1035, DOI 10.1016/S0002-9378(98)70544-7; Kramer MS, 1998, JAMA-J AM MED ASSOC, V280, P1849, DOI 10.1001/jama.280.21.1849; KRISTENSEN J, 1995, OBSTET GYNECOL, V86, P800, DOI 10.1016/0029-7844(95)00275-V; Mercer B., 1995, American Journal of Obstetrics and Gynecology, V172, P404; Schieve LA, 1996, OBSTET GYNECOL, V88, P356, DOI 10.1016/0029-7844(96)00203-7; Ventura S J, 1999, Natl Vital Stat Rep, V47, P1; Winkvist A, 1998, INT J EPIDEMIOL, V27, P248, DOI 10.1093/ije/27.2.248; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	22	210	212	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2000	283	12					1591	1596		10.1001/jama.283.12.1591	http://dx.doi.org/10.1001/jama.283.12.1591			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MV	10735396	Bronze			2022-12-28	WOS:000085857300036
J	Josefson, D				Josefson, D			Adding fatty acids to baby milk improves development	BRITISH MEDICAL JOURNAL			English	News Item																		Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					735	735						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720351				2022-12-28	WOS:000086054700016
J	Schreiber, SL				Schreiber, SL			Target-oriented and diversity-oriented organic synthesis in drug discovery	SCIENCE			English	Review							SOLID-PHASE SYNTHESIS; STEREOSELECTIVE SYNTHESIS; COMBINATORIAL CHEMISTRY; GENERAL-METHOD; LARGE NUMBERS; AMINO-ACIDS; LIBRARIES; SUPPORTS; METATHESIS; TANDEM	Modern drug discovery often involves screening small molecules for their ability to bind to a preselected protein target. Target-oriented syntheses of these small molecules, individually or as collections (focused Libraries), can be planned effectively with retrosynthetic analysis. Drug discovery can also involve screening small molecules for their ability to modulate a biological pathway in cells or organisms, without regard for any particular protein target. This process is Likely to benefit in the future from an evolving forward analysis of synthetic pathways, used in diversity-oriented synthesis, that Leads to structurally complex and diverse small molecules. One goal of diversity-oriented syntheses is to synthesize efficiently a collection of small molecules capable of perturbing any disease-related biological pathway, Leading eventually to the identification of therapeutic protein targets capable of being modulated by small molecules. Several synthetic planning principles for diversity-oriented synthesis and their role in the drug discovery process are presented in this review.	Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Harvard Inst Chem & Cell Biol, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University	Schreiber, SL (corresponding author), Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.							BERTZ SH, 1982, J AM CHEM SOC, V104, P5801, DOI 10.1021/ja00385a049; Blaney JM, 1997, CURR OPIN CHEM BIOL, V1, P54, DOI 10.1016/S1367-5931(97)80108-1; Brooking P, 1999, SYNTHESIS-STUTTGART, P1986; BUNIN BA, 1992, J AM CHEM SOC, V114, P10997, DOI 10.1021/ja00053a067; CAMPS F, 1974, AN QUIM, V70, P848; CAMPS F, 1971, TETRAHEDRON LETT, V12, P1713; Corey E. J., 1989, LOGIC CHEM SYNTHESIS; CROWLEY JI, 1970, J AM CHEM SOC, V92, P6363; de Meijere A, 1999, ANGEW CHEM INT EDIT, V38, P3669, DOI 10.1002/(SICI)1521-3773(19991216)38:24<3669::AID-ANIE3669>3.0.CO;2-X; DEWITT SH, 1993, P NATL ACAD SCI USA, V90, P6909, DOI 10.1073/pnas.90.15.6909; Dolle RE, 1999, J COMB CHEM, V1, P235, DOI 10.1021/cc9900192; EVANS DA, 1980, J AM CHEM SOC, V102, P774, DOI 10.1021/ja00522a056; FRANK R, 1983, NUCLEIC ACIDS RES, V11, P4365, DOI 10.1093/nar/11.13.4365; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; FURKA A, 1988, 10 INT S MED CHEM BU; Furka A, 1988, HIGHLIGHTS MODERN BI, P47; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; Heerding DA, 1998, TETRAHEDRON LETT, V39, P6815, DOI 10.1016/S0040-4039(98)01473-7; Hermkens PHH, 1996, TETRAHEDRON, V52, P4527, DOI 10.1016/0040-4020(96)00216-5; Hermkens PHH, 1997, TETRAHEDRON, V53, P5643, DOI 10.1016/S0040-4020(97)00279-2; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KERR JM, 1993, J AM CHEM SOC, V115, P2529, DOI 10.1021/ja00059a070; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; Lee D, 1999, J AM CHEM SOC, V121, P10648, DOI 10.1021/ja992658m; Lee DS, 2000, ORG LETT, V2, P709, DOI 10.1021/ol005574n; LEZNOFF CC, 1972, CAN J CHEMISTRY, V50, P2892, DOI 10.1139/v72-463; Martinez EJ, 1999, P NATL ACAD SCI USA, V96, P3496, DOI 10.1073/pnas.96.7.3496; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Myers AG, 1998, J AM CHEM SOC, V120, P5319, DOI 10.1021/ja980588y; NIKOLAIEV V, 1993, PEPTIDE RES, V6, P161; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; PATCHORNIK A, 1970, J AM CHEM SOC, V92, P7857; Paulvannan K, 1999, TETRAHEDRON LETT, V40, P1851, DOI 10.1016/S0040-4039(99)00072-6; Powers DG, 1998, TETRAHEDRON, V54, P4085, DOI 10.1016/S0040-4020(98)00137-9; Schurer SC, 1999, SYNLETT, P1879; SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367; Spaller MR, 1997, CURR OPIN CHEM BIOL, V1, P47, DOI 10.1016/S1367-5931(97)80107-X; Tan DS, 1998, J AM CHEM SOC, V120, P8565, DOI 10.1021/ja981746o; YEDIDA V, 1980, CAN J CHEM, V58, P1140; Zuercher WJ, 1996, J AM CHEM SOC, V118, P6634, DOI 10.1021/ja9606743	43	2160	2220	6	436	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1964	1969		10.1126/science.287.5460.1964	http://dx.doi.org/10.1126/science.287.5460.1964			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720315				2022-12-28	WOS:000085902800047
J	Sun, SH; Murray, CB; Weller, D; Folks, L; Moser, A				Sun, SH; Murray, CB; Weller, D; Folks, L; Moser, A			Monodisperse FePt nanoparticles and ferromagnetic FePt nanocrystal superlattices	SCIENCE			English	Article							CLUSTERS; COLLOIDS; FILMS	Synthesis of monodisperse iron-platinum (FePt) nanoparticles by reduction of platinum acetylacetonate and decomposition of iron pentacarbonyl in the presence of oleic acid and oleyl amine stabilizers is reported. The FePt particle composition is readily controlled, and the size is tunable from 3- to 10-nanometer diameter with a standard deviation of Less than 5%. These nanoparticles self-assemble into three-dimensional superlattices. Thermal annealing converts the internal particle structure from a chemically disordered face-centered cubic phase to the chemically ordered face-centered tetragonal phase and transforms the nanoparticle superlattices into ferromagnetic nanocrystal assemblies. These assemblies are chemically and mechanically robust and can support high-density magnetization reversal transitions.	IBM Corp, Thomas J Watson Res Ctr, Yorktown Heights, NY 10598 USA; IBM Corp, Almaden Res Ctr, San Jose, CA 95120 USA	International Business Machines (IBM); International Business Machines (IBM)	Sun, SH (corresponding author), IBM Corp, Thomas J Watson Res Ctr, Yorktown Heights, NY 10598 USA.		Folks, Liesl/C-7611-2016; bee, betty/G-1104-2011	Folks, Liesl/0000-0003-0161-957X; 				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Andres RP, 1996, SCIENCE, V272, P1323, DOI 10.1126/science.272.5266.1323; Back CH, 1999, SCIENCE, V285, P864, DOI 10.1126/science.285.5429.864; BRADLEY JS, 1994, CLUSTERS COLLOIDS, pCH6; COFFEY KR, 1995, IEEE T MAGN, V31, P2737, DOI 10.1109/20.490108; Collier CP, 1997, SCIENCE, V277, P1978, DOI 10.1126/science.277.5334.1978; Davidovic D, 1998, APPL PHYS LETT, V73, P3959, DOI 10.1063/1.122949; Fievet F., 1989, MRS BULL, V14, P29, DOI [DOI 10.1557/S0883769400060930, 10.1557/S0883769400060930]; HANSON M, 1995, J PHYS-CONDENS MAT, V7, P9269, DOI 10.1088/0953-8984/7/48/016; Hong MH, 1998, J APPL PHYS, V84, P4403, DOI 10.1063/1.368662; INOMATA K, 1988, J APPL PHYS, V64, P2537, DOI 10.1063/1.341638; *INT CTR DIFFR DAT, 1994, 431359 INT CTR DIFFR; Li JS, 1999, J APPL PHYS, V85, P4286, DOI 10.1063/1.370345; Li N, 1999, IEEE T MAGN, V35, P1077, DOI 10.1109/20.748856; Majetich SA, 1999, SCIENCE, V284, P470, DOI 10.1126/science.284.5413.470; Moser A, 1999, J APPL PHYS, V85, P5018, DOI 10.1063/1.370077; Moser A, 1999, APPL PHYS LETT, V75, P1604, DOI 10.1063/1.124768; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; Ristau RA, 1999, J APPL PHYS, V86, P4527, DOI 10.1063/1.371397; SCHMID G, 1992, CHEM REV, V92, P1709, DOI 10.1021/cr00016a002; Sun S, 1999, MATER RES SOC SYMP P, V577, P385, DOI 10.1557/PROC-577-385; Sun SH, 1999, J APPL PHYS, V85, P4325, DOI 10.1063/1.370357; Suslick KS, 1996, J AM CHEM SOC, V118, P11960, DOI 10.1021/ja961807n; Weller D, 1999, IEEE T MAGN, V35, P4423, DOI 10.1109/20.809134; YOGI T, 1990, IEEE T MAGN, V26, P2271, DOI 10.1109/20.104695	25	5444	5638	30	2023	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					1989	1992		10.1126/science.287.5460.1989	http://dx.doi.org/10.1126/science.287.5460.1989			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720318				2022-12-28	WOS:000085902800052
J	Thomas, PC; Malin, MC; Edgett, KS; Carr, MH; Hartmann, WK; Ingersoll, AP; James, PB; Soderblom, LA; Veverka, J; Sullivan, R				Thomas, PC; Malin, MC; Edgett, KS; Carr, MH; Hartmann, WK; Ingersoll, AP; James, PB; Soderblom, LA; Veverka, J; Sullivan, R			North-south geological differences between the residual polar caps on Mars	NATURE			English	Article							VIKING; REGION; DEPOSITS	Polar processes can be sensitive indicators of global climate, and the geological features associated with polar ice caps can therefore indicate evolution of climate with time. The polar regions on Mars have distinctive morphologic and climatologic features: thick layered deposits, seasonal CO2 frost caps extending to mid latitudes, and near-polar residual frost deposits that survive the summer(1,2). The relationship of the seasonal and residual frost caps to the layered deposits has been poorly constrained(3,4), mainly by the limited spatial resolution of the available data. In particular, it has not been known if the residual caps represent simple thin frost cover or substantial geologic features. Here we show that the residual cap on the south pole is a distinct geologic unit with striking collapse and erosional topography; this is very different from the residual cap on the north pole, which grades into the underlying layered materials. These findings indicate that the differences between the caps are substantial (rather than reflecting short-lived differences in frost cover), and so support the idea of long-term asymmetry in the polar climates of Mars.	Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA; Malin Space Sci Syst, San Diego, CA 92191 USA; US Geol Survey, Menlo Park, CA 94025 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Planetary Sci Inst, Tucson, AZ 85719 USA; Univ Toledo, Dept Phys & Astron, Toledo, OH 43606 USA; US Geol Survey, Flagstaff, AZ 86001 USA	Cornell University; United States Department of the Interior; United States Geological Survey; California Institute of Technology; University System of Ohio; University of Toledo; United States Department of the Interior; United States Geological Survey	Thomas, PC (corresponding author), Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA.			Edgett, Kenneth/0000-0001-7197-5751				CUTTS JA, 1982, ICARUS, V50, P216, DOI 10.1016/0019-1035(82)90124-5; FARMER CB, 1976, SCIENCE, V194, P1339, DOI 10.1126/science.194.4271.1339; HERKENHOFF KE, IN PRESS ICARUS; HOWARD AD, 1982, ICARUS, V50, P161, DOI 10.1016/0019-1035(82)90123-3; Jakosky B. M., 1992, MARS, P969; JAMES PB, 1979, J GEOPHYS RES, V84, P2889, DOI 10.1029/JB084iB06p02889; JAMES PB, 1992, MARS, P934; Kieffer H. H., 1992, MARS, P1180; KIEFFER HH, 1979, J GEOPHYS RES, V84, P8263, DOI 10.1029/JB084iB14p08263; KIEFFER HH, UNPUB J GEOPHYS RES; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; MALIN MC, 2000, LUNAR PLANET SCI, V34; Mellon MT, 1997, J GEOPHYS RES-PLANET, V102, P25617, DOI 10.1029/97JE02582; Mellon MT, 1996, ICARUS, V124, P268, DOI 10.1006/icar.1996.0203; MUHLEMAN DO, 1995, ANNU REV EARTH PL SC, V23, P337, DOI 10.1146/annurev.earth.23.1.337; PAIGE DA, 1994, J GEOPHYS RES-PLANET, V99, P25993, DOI 10.1029/93JE03429; PLAUT JJ, 1988, ICARUS, V76, P357, DOI 10.1016/0019-1035(88)90076-0; POLLACK JB, 1979, J GEOPHYS RES, V84, P2929, DOI 10.1029/JB084iB06p02929; SCHENK PM, INPRESS J GEOPHYS RE; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Thomas P., 1992, MARS, P767; TOON OB, 1980, ICARUS, V44, P552, DOI 10.1016/0019-1035(80)90130-X; Ward W. R., 1992, MARS, P298; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053	24	88	88	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					161	164		10.1038/35004528	http://dx.doi.org/10.1038/35004528			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724162				2022-12-28	WOS:000085870900043
J	Burden, SJ				Burden, SJ			Wnts as retrograde signals for axon and growth cone differentiation	CELL			English	Review							RECEPTOR TYROSINE KINASES; GRANULE CELLS; CRD DOMAIN; NEURONS; MOUSE; EXPRESSION; CEREBELLUM		NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program, New York, NY 10016 USA	New York University	Burden, SJ (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program, New York, NY 10016 USA.	burden@saturn.med.nyu.edu		Burden, Steven/0000-0002-3550-6891	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027963] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS027963-10, R01 NS027963] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAIRD DH, 1992, J NEUROSCI, V12, P619; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; DAHM LM, 1988, DEV BIOL, V130, P621, DOI 10.1016/0012-1606(88)90357-0; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lucas FR, 1997, DEV BIOL, V192, P31, DOI 10.1006/dbio.1997.8734; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Murase S, 1999, CURR OPIN CELL BIOL, V11, P549, DOI 10.1016/S0955-0674(99)00019-8; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; SALINAS PC, 1994, DEVELOPMENT, V120, P1277; Serafini T, 1999, CELL, V98, P133, DOI 10.1016/S0092-8674(00)81008-9; SOTELO C, 1975, BRAIN RES, V94, P19, DOI 10.1016/0006-8993(75)90874-4; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3; Zhang Q, 1998, DEV BIOL, V195, P75, DOI 10.1006/dbio.1997.8837	19	31	32	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 3	2000	100	5					495	497		10.1016/S0092-8674(00)80685-6	http://dx.doi.org/10.1016/S0092-8674(00)80685-6			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	290WC	10721986	Bronze			2022-12-28	WOS:000085700000002
J	Kulmala, M; Pirjola, U; Makela, JM				Kulmala, M; Pirjola, U; Makela, JM			Stable sulphate clusters as a source of new atmospheric particles	NATURE			English	Article							MARINE BOUNDARY-LAYER; CONDENSATION NUCLEUS COUNTER; FREE-TROPOSPHERE; AEROSOL-PARTICLES; NUCLEATION; NM; GROWTH; ATLANTIC; ACE-1	The formation of new atmospheric particles with diameters of 3-10 nn has been observed at a variety of altitudes and locations. Such aerosol particles have the potential to grow into cloud condensation nuclei, thus affecting cloud formation as well as the global radiation budget. In some cases, the observed formation rates of new particles have been adequately explained by binary nucleation, involving water and sulphuric acid(1), but in certain locations-particularly those within the marine boundary layer(1,2) and at continental sites(1,3)-observed ambient nucleation rates exceed those predicted by the binary scheme. In these locations, ambient sulphuric acid (H2SO4) levels are typically lower than required for binary nucleation(1), but ape sufficient for ternary nucleation(4) (sulphuric acid-ammonia-water). Here we present results from an aerosol dynamics model with a ternary nucleation scheme which indicate that nucleation in the troposphere should be ubiquitous, and yield a reservoir of thermodynamically stable clusters 1-3 nn in size. We suggest that the growth of these clusters to a delectable size (> 3 nm particle diameter) is restricted by the availability of condensable vapour. Observations of atmospheric particle formation and growth from a continental and a coastal sire support this hypothesis, indicating that a growth process including ternary nucleation is likely to be responsible for the formation of cloud condensation nuclei.	Univ Helsinki, Dept Phys, FIN-00014 Helsinki, Finland	University of Helsinki	Kulmala, M (corresponding author), Univ Helsinki, Dept Phys, POB 9, FIN-00014 Helsinki, Finland.	markku.kulmala@helsinki.fi	Kulmala, Markku T/I-7671-2016; Mäkelä, Jyrki/G-4223-2014	Kulmala, Markku T/0000-0003-3464-7825; 				CLARKE AD, 1992, J ATMOS CHEM, V14, P479, DOI 10.1007/BF00115252; Clarke AD, 1998, J GEOPHYS RES-ATMOS, V103, P16397, DOI 10.1029/97JD02987; COFFMAN DJ, 1995, J GEOPHYS RES-ATMOS, V100, P7147, DOI 10.1029/94JD03253; COVERT DS, 1992, J GEOPHYS RES-ATMOS, V97, P20581, DOI 10.1029/92JD02074; DOYLE GJ, 1961, J CHEM PHYS, V35, P795, DOI 10.1063/1.1701218; EASTER RC, 1994, J APPL METEOROL, V33, P775, DOI 10.1175/1520-0450(1994)033<0775:BHNTAR>2.0.CO;2; HEGG DA, 1991, J GEOPHYS RES-ATMOS, V96, P18727, DOI 10.1029/91JD01870; HOPPEL WA, 1994, J GEOPHYS RES-ATMOS, V99, P14443, DOI 10.1029/94JD00797; Horrak U, 1998, J GEOPHYS RES-ATMOS, V103, P13909, DOI 10.1029/97JD01570; Kerminen VM, 1996, TELLUS B, V48, P65, DOI 10.1034/j.1600-0889.1996.00007.x; KERMINEN VM, 1994, ATMOS ENVIRON, V28, P2399, DOI 10.1016/1352-2310(94)90391-3; Korhonen P, 1999, J GEOPHYS RES-ATMOS, V104, P26349, DOI 10.1029/1999JD900784; Kulmala M, 1998, TELLUS B, V50, P449, DOI 10.1034/j.1600-0889.1998.t01-4-00004.x; Kulmala M, 1998, J GEOPHYS RES-ATMOS, V103, P8301, DOI 10.1029/97JD03718; Makela JM, 1997, GEOPHYS RES LETT, V24, P1219, DOI 10.1029/97GL00920; Nilsson ED, 1998, J GEOPHYS RES-ATMOS, V103, P1381, DOI 10.1029/97JD02629; O'Dowd C, 1999, GEOPHYS RES LETT, V26, P1707, DOI 10.1029/1999GL900335; Pirjola L, 1999, J AEROSOL SCI, V30, P355, DOI 10.1016/S0021-8502(98)00065-2; Pirjola L, 1998, J GEOPHYS RES-ATMOS, V103, P8309, DOI 10.1029/97JD03079; RAES F, 1985, J AEROSOL SCI, V16, P217, DOI 10.1016/0021-8502(85)90028-X; RAES F, 1992, J AEROSOL SCI, V23, P759, DOI 10.1016/0021-8502(92)90042-T; Raes F, 1997, J GEOPHYS RES-ATMOS, V102, P21315, DOI 10.1029/97JD01122; Reischl GP, 1996, J AEROSOL SCI, V27, P931, DOI 10.1016/0021-8502(96)00026-2; Schroder F, 1997, ATMOS RES, V44, P333, DOI 10.1016/S0169-8095(96)00034-8; STOLZENBURG MR, 1991, AEROSOL SCI TECH, V14, P48, DOI 10.1080/02786829108959470; VANDINGENEN R, 1995, J GEOPHYS RES-ATMOS, V100, P21057, DOI 10.1029/95JD02141; Weber RJ, 1998, J GEOPHYS RES-ATMOS, V103, P16385, DOI 10.1029/97JD02465; Weber RJ, 1999, GEOPHYS RES LETT, V26, P307, DOI 10.1029/1998GL900308; Weber RJ, 1998, J AEROSOL SCI, V29, P601, DOI 10.1016/S0021-8502(97)10026-X; Wiedensohler A, 1996, TELLUS B, V48, P213, DOI 10.1034/j.1600-0889.1996.t01-1-00006.x	30	478	493	3	241	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2000	404	6773					66	69		10.1038/35003550	http://dx.doi.org/10.1038/35003550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716441				2022-12-28	WOS:000085775100044
J	Winker, K				Winker, K			Evolution - Migration and speciation	NATURE			English	Article									Univ Alaska Museum, Fairbanks, AK 99775 USA	University of Alaska System; University of Alaska Fairbanks	Winker, K (corresponding author), Univ Alaska Museum, 907 Yukon Dr, Fairbanks, AK 99775 USA.		Winker, Kevin/M-2042-2014	Winker, Kevin/0000-0002-8985-8104				Bohning-Gaese K, 1998, EVOL ECOL, V12, P767, DOI 10.1023/A:1006538414645; COX GW, 1985, AM NAT, V126, P451, DOI 10.1086/284432; Darwin C., 1877, ORIGIN SPECIES; Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521; DILGER W. C., 1956, AUK, V73, P313; Grinnell J., 1922, Auk Lancaster Pa, V39, P373; Groth JG, 1993, U CALIFORNIA PUBLICA, V127, P1; Helbig AJ, 1996, IBIS, V138, P650, DOI 10.1111/j.1474-919X.1996.tb04767.x; Kondrashov AS, 1999, NATURE, V400, P351, DOI 10.1038/22514; Mayr E., 1963, ANIMAL SPECIES EVOLU; Mengel R. M., 1964, LIVING BIRD, V3, P9; Montgomery Jr T. H, 1896, AM NAT, P458; RICHMAN AD, 1996, EVOLUTION, V50, P767	13	51	52	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					36	36		10.1038/35003651	http://dx.doi.org/10.1038/35003651			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716433	Bronze			2022-12-28	WOS:000085775100035
J	Zambon, D; Sabate, J; Munoz, S; Campero, B; Casals, E; Merlos, M; Laguna, JC; Ros, E				Zambon, D; Sabate, J; Munoz, S; Campero, B; Casals, E; Merlos, M; Laguna, JC; Ros, E			Substituting walnuts for monounsaturated fat improves the serum lipid profile of hypercholesterolemic men and women - A randomized crossover trial	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; ARTERY DISEASE; NUT CONSUMPTION; DIET RICH; ACIDS; RISK; OXIDATION; CHOLESTEROL; METAANALYSIS	Background: It has been reported that walnuts reduce serum cholesterol levels in normal young men. Objective: To assess the acceptability of walnuts and their effects on serum lipid levels and low-density lipoprotein (LDL) oxidizability in free-living hypercholesterolemic persons. Design: Randomized, crossover feeding trial. Setting: Lipid clinic at a university hospital. Patients: 55 men and women (mean age, 56 years) with polygenic hypercholesterolemia. Intervention: A cholesterol-lowering Mediterranean diet and a diet of similar energy and fat content in which walnuts replaced approximately 35% of the energy obtained from monounsaturated fat. Patients followed each diet for 6 weeks. Measurements: Low-density lipoprotein fatty acids (to assess compliance), serum lipid levels, lipoprotein(a) levels, and LDL resistance to in vitro oxidative stress. Results: 49 persons completed the trial. The walnut diet was well tolerated. Planned and observed diets were closely matched. Compared with the Mediterranean diet, the walnut diet produced mean changes of -4.1% in total cholesterol level, -5.9% in LDL cholesterol level, and -6.2% in lipoprotein(a) level. The mean differences in the changes in serum lipid levels were -0.28 mmol/L (95% CI, -0.43 to -0.12 mmol/L) (-10.8 mg/dL [-16.8 to -4.8 mg/dL]) (P < 0.001) for total cholesterol level, -0.29 mmol/L (CI, -0.41 to -0.15 mmol/L) (-11.2 mg/dL [-16.3 to -6.1 mg/dL]) (P < 0.001) for LDL cholesterol level, and -0.021 g/L (CI, -0.042 to -0.001 g/L) (P = 0.042) for lipoprotein(a) level. Lipid changes were similar in men and women except for lipoprotein(a) levels, which decreased only in men. Low-density lipoprotein particles were enriched with polyunsaturated fatty acids from walnuts, but their resistance to oxidation was preserved. Conclusion: Substituting walnuts for part of the monounsaturated fat in a cholesterol-lowering Mediterranean diet further reduced total and LDL cholesterol levels in men and women with hypercholesterolemia.	Univ Barcelona, Hosp Clin, Barcelona, Spain; Univ Barcelona, Sch Pharm, Barcelona, Spain; Loma Linda Univ, Loma Linda, CA 92350 USA	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Loma Linda University	Ros, E (corresponding author), Hosp Clin Barcelona, Lipid Clin, Nutr & Dietet Serv, Villarroel 170, E-08036 Barcelona, Spain.		Merlos, Manuel/AAC-3064-2021; Laguna, JCLaguna - Juan C./C-5481-2017	Merlos, Manuel/0000-0002-8423-3033; Laguna, JCLaguna - Juan C./0000-0002-7082-0704; Sabate, Joan/0000-0002-9063-9785; Ros, Emilio/0000-0002-2573-1294				Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; BEIL FU, 1991, ATHEROSCLEROSIS, V90, P95, DOI 10.1016/0021-9150(91)90248-2; BUZZARD J, 1998, NUTR EPIDEMIOLOGY, P50; Chisholm A, 1998, EUR J CLIN NUTR, V52, P12, DOI 10.1038/sj.ejcn.1600507; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; COMINACINI L, 1993, ATHEROSCLEROSIS, V99, P63, DOI 10.1016/0021-9150(93)90051-U; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; ERITSLAND J, 1995, SCAND J CLIN LAB INV, V55, P295, DOI 10.3109/00365519509104966; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; EXLER J, 1986, USDA PUBLICATION; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; Halevy D, 1997, ARTERIOSCL THROM VAS, V17, P1432, DOI 10.1161/01.ATV.17.7.1432; HERRMANN W, 1995, AM J CARDIOL, V76, P459, DOI 10.1016/S0002-9149(99)80130-1; HOPKINS PN, 1992, AM J CLIN NUTR, V55, P1060, DOI 10.1093/ajcn/55.6.1060; Hu FB, 1999, AM J CLIN NUTR, V69, P890; Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; KARK JD, 1993, ATHEROSCLEROSIS, V98, P139, DOI 10.1016/0021-9150(93)90124-D; KLEINVELD HA, 1992, CLIN CHEM, V38, P2066; KrisEtherton PM, 1997, AM J CLIN NUTR, V65, P1590; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Prasad K, 1997, ATHEROSCLEROSIS, V132, P69, DOI 10.1016/S0021-9150(97)06110-8; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SABATE J, 1993, NEW ENGL J MED, V328, P603, DOI 10.1056/NEJM199303043280902; Sabate Joan, 1994, Current Opinion in Lipidology, V5, P11, DOI 10.1097/00041433-199402000-00003; *SAS I INC, 1990, GLM PROCEDURE, P891; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; Simopoulos AP, 1999, AM J CLIN NUTR, V70, p560S, DOI 10.1093/ajcn/70.3.560s; Stein JH, 1997, ARCH INTERN MED, V157, P1170, DOI 10.1001/archinte.157.11.1170; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Tsimikas S, 1998, CURR OPIN LIPIDOL, V9, P301, DOI 10.1097/00041433-199808000-00003; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; VAZQUEZ M, 1993, BIOCHEM PHARMACOL, V46, P1515; YU SM, 1995, AM J CLIN NUTR, V61, P1129, DOI 10.1093/ajcn/61.5.1129; ZAMBON D, 1995, AM J CLIN NUTR, V61, P141, DOI 10.1093/ajcn/61.1.141	40	218	227	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					538	546		10.7326/0003-4819-132-7-200004040-00039	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00039			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744590				2022-12-28	WOS:000086129300004
J	Lancaster, T				Lancaster, T			PDQ evidence-based principles and practice - (Book with CD-Rom for Windows and Macintosh)	BRITISH MEDICAL JOURNAL			English	Software Review									Inst Hlth Sci, Div Publ Hlth & Primary Care, Oxford, England	University of Oxford	Lancaster, T (corresponding author), Inst Hlth Sci, Div Publ Hlth & Primary Care, Oxford, England.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					947	947						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10742027				2022-12-28	WOS:000086337100071
J	Scott, NA				Scott, NA			Treating colorectal cancer: chances in front of goal	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					949	949		10.1136/bmj.320.7239.949	http://dx.doi.org/10.1136/bmj.320.7239.949			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10742030	Green Published			2022-12-28	WOS:000086337100072
J	Tay, JI; Moore, J; Walker, JJ				Tay, JI; Moore, J; Walker, JJ			Regular review - Ectopic pregnancy	BRITISH MEDICAL JOURNAL			English	Review							PELVIC INFLAMMATORY DISEASE; CHORIONIC-GONADOTROPIN LEVELS; TUBAL PREGNANCY; EXPECTANT MANAGEMENT; RADICAL SURGERY; CHLAMYDIAL INFECTIONS; CONSERVATIVE SURGERY; MEDICAL-TREATMENT; RISK-FACTORS; FERTILITY		St James Univ Hosp, Div Obstet & Gynaecol, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Walker, JJ (corresponding author), St James Univ Hosp, Div Obstet & Gynaecol, Leeds LS9 7TF, W Yorkshire, England.			Walker, James/0000-0002-8922-083X				Aboud E., 1997, Clinical and Experimental Obstetrics and Gynecology, V24, P127; Ankum WM, 1996, FERTIL STERIL, V65, P1093, DOI 10.1016/S0015-0282(16)58320-4; Ankum WM, 1996, J REPROD MED, V41, P724; ANKUM WM, 1995, J REPROD MED, V40, P525; Atri M, 1996, RADIOGRAPHICS, V16, P755, DOI 10.1148/radiographics.16.4.8835969; Bouyer J, 1996, CONTRACEPT FERTIL S, V24, P475; BRAUNSTEIN GD, 1976, AM J OBSTET GYNECOL, V126, P678, DOI 10.1016/0002-9378(76)90518-4; BUCHAN H, 1993, BRIT J OBSTET GYNAEC, V100, P558, DOI 10.1111/j.1471-0528.1993.tb15308.x; CACCIATORE B, 1990, BRIT J OBSTET GYNAEC, V97, P899, DOI 10.1111/j.1471-0528.1990.tb02444.x; CARTWRIGHT PS, 1984, OBSTET GYNECOL, V63, P76; Castles A, 1999, AM J PREV MED, V16, P208, DOI 10.1016/S0749-3797(98)00089-0; *CHIEF MED OFF EXP, 1998, CHLAM TRACH REP CHIE; Clasen K, 1997, HUM REPROD, V12, P596; Clausen I, 1996, ACTA OBSTET GYN SCAN, V75, P8, DOI 10.3109/00016349609033276; delaCruz A, 1997, FERTIL STERIL, V68, P871, DOI 10.1016/S0015-0282(97)00322-1; DEMOUZON J, 1988, INT J EPIDEMIOL, V17, P378, DOI 10.1093/ije/17.2.378; *DEP HLTH, 1998, WHY WOM DIE REP CONF; Dubuisson JB, 1996, HUM REPROD, V11, P1199; Dwarakanath LS, 1996, BRIT J OBSTET GYNAEC, V103, P1021, DOI 10.1111/j.1471-0528.1996.tb09554.x; Egger M, 1998, BRIT MED J, V316, P1776, DOI 10.1136/bmj.316.7147.1776; Fernandez H, 1998, FERTIL STERIL, V70, P680, DOI 10.1016/S0015-0282(98)00251-9; Gazvani MR, 1998, HUM REPROD, V13, P1987, DOI 10.1093/humrep/13.7.1987; HAJENIUS PJ, 1995, EARLY PREGNANCY, V1, P1258; HARJENIUS PJ, 1997, LANCET, V350, P774; Hendrix NW, 1998, J REPROD MED, V43, P515; Hidlebaugh D, 1997, J AM ASSOC GYN LAP, V4, P207, DOI 10.1016/S1074-3804(97)80011-4; HILLIS SD, 1995, FAM PLANN PERSPECT, V27, P108, DOI 10.2307/2136107; Hillis SD, 1997, AM J OBSTET GYNECOL, V176, P103, DOI 10.1016/S0002-9378(97)80020-8; Jimenez-Caraballo A, 1998, EUR J OBSTET GYN R B, V79, P167, DOI 10.1016/S0301-2115(98)00036-0; Job-Spira N, 1999, AM J OBSTET GYNECOL, V180, P938, DOI 10.1016/S0002-9378(99)70665-4; JobSpira N, 1996, HUM REPROD, V11, P99; KADAR N, 1993, FERTIL STERIL, V60, P409; Kaplan BC, 1996, ANN EMERG MED, V28, P10, DOI 10.1016/S0196-0644(96)70131-2; Korell M, 1997, FERTIL STERIL, V68, P220, DOI 10.1016/S0015-0282(97)81505-1; LARIMORE WL, 2000, HERITAGE FAMILY PHYS; Lecuru F, 1999, J REPROD MED, V44, P46; Lipscomb GH, 1999, OBSTET GYNECOL, V93, P590, DOI 10.1016/S0029-7844(98)00523-7; Lipscomb GH, 1998, AM J OBSTET GYNECOL, V178, P1354, DOI 10.1016/S0002-9378(98)70343-6; Lundorff P, 1997, ACTA OBSTET GYN SCAN, V76, P81; MARCHBANKS PA, 1988, JAMA-J AM MED ASSOC, V259, P1823, DOI 10.1001/jama.259.12.1823; Mehta TS, 1997, RADIOLOGY, V205, P569, DOI 10.1148/radiology.205.2.9356647; Mol BWJ, 1997, BRIT J OBSTET GYNAEC, V104, P834, DOI 10.1111/j.1471-0528.1997.tb12029.x; Mol BWJ, 1998, HUM REPROD, V13, P1804, DOI 10.1093/humrep/13.7.1804; Mol BWJ, 1998, FERTIL STERIL, V70, P972, DOI 10.1016/S0015-0282(98)00278-7; NYBERG DA, 1988, RADIOLOGY, V167, P620; Parker J, 1998, AUST NZ J OBSTET GYN, V38, P145, DOI 10.1111/j.1479-828X.1998.tb02988.x; Peterson HB, 1997, NEW ENGL J MED, V336, P762, DOI 10.1056/NEJM199703133361104; Pisarska MD, 1998, LANCET, V351, P1115, DOI 10.1016/S0140-6736(97)11476-3; PITTAWAY DE, 1985, AM J OBSTET GYNECOL, V152, P299, DOI 10.1016/S0002-9378(85)80215-5; Rantala M, 1997, FERTIL STERIL, V68, P1043, DOI 10.1016/S0015-0282(97)00414-7; *ROYAL COLL OBST G, 1996, REC AR 31 STUD GROUP; Serour GI, 1998, FERTIL STERIL, V70, P638, DOI 10.1016/S0015-0282(98)00250-7; SHALEV E, 1995, FERTIL STERIL, V63, P15, DOI 10.1016/S0015-0282(16)57289-6; Simms I, 1997, EPIDEMIOL INFECT, V119, P49, DOI 10.1017/S0950268897007711; Skjeldestad FE, 1997, ACTA OBSTET GYN SCAN, V76, P684, DOI 10.3109/00016349709024611; Skjeldestad FE, 1997, ACTA OBSTET GYN SCAN, V76, P159, DOI 10.3109/00016349709050073; Spandorfer SD, 1997, FERTIL STERIL, V68, P430, DOI 10.1016/S0015-0282(97)00253-7; Storeide O, 1997, ACTA OBSTET GYN SCAN, V76, P345, DOI 10.1111/j.1600-0412.1997.tb07990.x; Strandell A, 1999, FERTIL STERIL, V71, P282, DOI 10.1016/S0015-0282(98)00441-5; Tal J, 1996, FERTIL STERIL, V66, P1; Thoen LD, 1997, FERTIL STERIL, V68, P727, DOI 10.1016/S0015-0282(97)00284-7; TRIO D, 1995, FERTIL STERIL, V63, P469, DOI 10.1016/S0015-0282(16)57410-X; VARMA R, 2000, OBSTET GYNAECOLOGY C; VELEBIL P, 1995, OBSTET GYNECOL, V86, P764, DOI 10.1016/0029-7844(95)00252-M; WESTROM L, 1981, BRIT MED J, V282, P15, DOI 10.1136/bmj.282.6257.15; XIONG X, 1995, CONTRACEPTION, V52, P23, DOI 10.1016/0010-7824(95)00120-Y; Yao ML, 1997, FERTIL STERIL, V67, P421, DOI 10.1016/S0015-0282(97)80064-7; Zohav E, 1996, EUR J OBSTET GYN R B, V66, P1, DOI 10.1016/0301-2115(95)02370-4; 1995, MMWR, V44, P46; 1998, WHY WOMEN DIE REPORT	70	103	119	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					916	919		10.1136/bmj.320.7239.916	http://dx.doi.org/10.1136/bmj.320.7239.916			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10742003	Green Published			2022-12-28	WOS:000086337100031
J	Keck, JL; Roche, DD; Lynch, AS; Berger, JM				Keck, JL; Roche, DD; Lynch, AS; Berger, JM			Structure of the RNA polymerase domain of E-coli primase	SCIENCE			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; REPLICATION FORK; PROTEIN MODELS; HELICASE; BACTERIOPHAGE-T7; TOPOISOMERASES; RECOGNITION; REFINEMENT; EVOLUTION	All cellular organisms use specialized RNA polymerases called "primases" to synthesize RNA primers for the initiation of DNA replication. The high-resolution crystal structure of a primase, comprising the catalytic core of the Escherichia coli DnaG protein, was determined. The core structure contains an active-site architecture that is unrelated to other DNA or RNA polymerase palm folds, but is instead related to the "toprim" fold. On the basis of the structure, it is Likely that DnaG binds nucleic acid in a groove clustered with invariant residues and that DnaG is positioned within the replisome to accept single-stranded DNA directly from the replicative helicase.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Tularik, S San Francisco, CA 94080 USA	University of California System; University of California Berkeley	Lynch, AS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall,No 3206, Berkeley, CA 94720 USA.			Keck, James/0000-0002-5961-0220				Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; BENNER SA, 1994, PROTEIN ENG, V7, P1323, DOI 10.1093/protein/7.11.1323; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; BRUTLAG D, 1971, P NATL ACAD SCI USA, V68, P2826, DOI 10.1073/pnas.68.11.2826; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLTON J, UNPUB; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABASCH W, 1988, J APPL CRYSTALLOGR, V21, P916; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KECK J, UNPUB; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; Kornberg A., 1992, DNA REPLICATION; Kusakabe T, 1998, EMBO J, V17, P1542, DOI 10.1093/emboj/17.5.1542; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Leslie A, 1992, NEWSLETTER PROTEIN C; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR D, V50, P1507; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nichols MD, 1999, EMBO J, V18, P6177, DOI 10.1093/emboj/18.21.6177; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Sun WL, 1999, J BACTERIOL, V181, P3761, DOI 10.1128/JB.181.12.3761-3767.1999; SUN WL, 1994, P NATL ACAD SCI USA, V91, P11462, DOI 10.1073/pnas.91.24.11462; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; TOUGU K, 1994, J BIOL CHEM, V269, P4675; VERSALOVIC J, 1993, GENE, V136, P281, DOI 10.1016/0378-1119(93)90480-Q; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZIEGELIN G, 1995, J BACTERIOL, V177, P4333, DOI 10.1128/jb.177.15.4333-4341.1995	40	124	126	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2482	2486		10.1126/science.287.5462.2482	http://dx.doi.org/10.1126/science.287.5462.2482			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741967				2022-12-28	WOS:000086202200044
J	Ly, DH; Lockhart, DJ; Lerner, RA; Schultz, PG				Ly, DH; Lockhart, DJ; Lerner, RA; Schultz, PG			Mitotic misregulation and human aging	SCIENCE			English	Article							CELL-CYCLE; BINDING-DOMAIN; PROTEINS; IDENTIFICATION; SUPPRESSION; ARTHRITIS; KINESIN; FAMILY; KINASE; BARD1	Messenger RNA Levels were measured in actively dividing fibroblasts isolated from young, middle-age, and old-ago humans and humans with progeria, a rare genetic disorder characterized by accelerated aging. Genes whose expression is associated with age-related phenotypes and diseases were identified. The data also suggest that an underlying mechanism of the aging process involves increasing errors in the mitotic machinery of dividing cells in the postreproductive stage of Life. We propose that this dysfunction leads to chromosomal pathologies that result in misregulation of genes involved in the aging process.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; Novartis	Lerner, RA (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; BROWN WT, 1992, AM J CLIN NUTR, V55, P1222; Carlsen S, 1998, CLIN EXP IMMUNOL, V114, P477; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Ichikawa Y, 1998, CLIN EXP RHEUMATOL, V16, P533; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JACOBS PA, 1963, NATURE, V197, P1080, DOI 10.1038/1971080a0; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kawasaki K, 1999, J CELL PHYSIOL, V179, P142, DOI 10.1002/(SICI)1097-4652(199905)179:2<142::AID-JCP4>3.0.CO;2-Q; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; LY DH, UNPUB; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; NATH J, 1995, CHROMOSOMA, V103, P725, DOI 10.1007/s004120050085; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Toomes C, 1999, NAT GENET, V23, P421, DOI 10.1038/70525; Truscott RJW, 1998, INT J BIOL MACROMOL, V22, P321, DOI 10.1016/S0141-8130(98)00030-0; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; Watabe Y, 1996, J BIOL CHEM, V271, P25126, DOI 10.1074/jbc.271.41.25126; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	46	453	471	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2000	287	5462					2486	2492		10.1126/science.287.5462.2486	http://dx.doi.org/10.1126/science.287.5462.2486			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741968				2022-12-28	WOS:000086202200045
J	Spurgeon, D				Spurgeon, D			Canada turns to France for staff to treat cancer patients	BRITISH MEDICAL JOURNAL			English	News Item																		1999, BRIT MED J, V318, P1507	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					826	826						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731171				2022-12-28	WOS:000086180300019
J	Marean, CW				Marean, CW			Anthropology - Age, sex, and old goats	SCIENCE			English	Editorial Material									SUNY Stony Brook, Dept Anthropol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Marean, CW (corresponding author), SUNY Stony Brook, Dept Anthropol, Stony Brook, NY 11794 USA.	curtis.marean@sunysb.edu						Evins M.A., 1982, PALEORIENT, V8, P37; INGOLD T, 1974, MAN, V9, P523, DOI 10.2307/2801122; Marean CW, 1998, CURR ANTHROPOL, V39, pS79, DOI 10.1086/204691; Saxon E.C., 1974, LIBYCA, V22, P49; Zeder MA, 2000, SCIENCE, V287, P2254, DOI 10.1126/science.287.5461.2254	5	1	2	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2174	2175		10.1126/science.287.5461.2174	http://dx.doi.org/10.1126/science.287.5461.2174			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	296WE	10744540				2022-12-28	WOS:000086049100029
J	Emanuel, EJ; Fairclough, DL; Slutsman, J; Emanuel, LL				Emanuel, EJ; Fairclough, DL; Slutsman, J; Emanuel, LL			Understanding economic and other burdens of terminal illness: The experience of patients and their caregivers	ANNALS OF INTERNAL MEDICINE			English	Article						terminally ill; terminal care; cost of illness; caregivers; physician role	PHYSICIAN-ASSISTED SUICIDE; MENTAL-HEALTH; UNITED-STATES; CARE; EUTHANASIA; CANCER; ATTITUDES; FAMILIES; ADULTS; NEEDS	Background: Terminal illness imposes substantial burdens-economic and otherwise-on patients and caregivers. The cause of these burdens is not understood. Objective: To determine the mechanism for economic and noneconomic burdens of terminal illness and to identify potential ameliorating interventions. Design: In-person interviews of terminally ill patients and their caregivers. Setting: Six randomly selected U.S. sites: Worcester, Massachusetts; St. Louis, Missouri; Tucson, Arizona; Birmingham, Alabama; Brooklyn, New York; and Mesa County, Colorado. Participants: 988 terminally ill patients and 893 caregivers. Measurements: Needs for transportation, nursing care, homemaking, and personal care; subjective perception of economic burden; expenditure of more than 10% of household income on health care costs; caregiver depression and sense of interference with his or her life; and patient consideration of euthanasia or physician-assisted suicide. Results: Of all patients, 34.7% had substantial care needs. Patients who had substantial care needs were more likely to report that they had a subjective sense of economic burden (44.9% compared with 35.3%; difference, 9.6 percentage points [95% CI, 3.1 to 16.1]; P = 0.005); that 10% of their household income was spent on health care (28.0% compared with 17.0%; difference, 11.0 percentage points [CI, 4.8 to 17.1]; P less than or equal to 0.001); and that they or their families had to take out a loan or mortgage, spend their savings, or obtain an additional job (16.3% compared with 10.2%; difference, 6.1 percentage points [CI, 1.4 to 10.6]; P = 0.004). Patients with substantial care needs were more likely to consider euthanasia or physician-assisted suicide (P = 0.001). Caregivers of these patients were more likely to have depressive symptoms (31.4% compared with 24.8%; difference, 6.6 percentage points [CI, 0.4 to 12.8]; P = 0.01) and to report that caring for the patients interfered with their lives (35.6% compared with 24.3%; difference, 11.3 percentage points [CI, 5.0 to 17.7]; P = 0.001). Caregivers of patients whose physicians listened to patients' and caregivers' needs had fewer burdens. Conclusions: Substantial care needs are an important cause of the economic and other burdens imposed by terminal illness. Through empathy, physicians may be able to ameliorate some of these burdens.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; AMC Canc Res Ctr, Denver, CO USA; Johns Hopkins Univ, Baltimore, MD USA; Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA	National Institutes of Health (NIH) - USA; AMC Cancer Research Center; Johns Hopkins University; American Medical Association	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.							BERKMAN BJ, 1993, CANCER-AM CANCER SOC, V72, P2846, DOI 10.1002/1097-0142(19931101)72:9+<2846::AID-CNCR2820721515>3.0.CO;2-3; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; *BUR CENS, 1998, STAT ABSTR US 1998; CANTOR MH, 1983, GERONTOLOGIST, V23, P597, DOI 10.1093/geront/23.6.597; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EPSTEIN AM, 1995, INQUIRY-J HEALTH CAR, V32, P211; Field MJ, 1997, APPROACHING DEATH IM; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; *GROUP HLTH ASS AM, 1992, NAT DIR HMOS; HOUTS PS, 1988, CANCER, V62, P627, DOI 10.1002/1097-0142(19880801)62:3<627::AID-CNCR2820620331>3.0.CO;2-1; KISSANE DW, 1994, PSYCHO-ONCOLOGY, V3, P47, DOI DOI 10.1002/P0N.2960030109; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MOR V, 1987, Journal of Psychosocial Oncology, V5, P1, DOI 10.1300/J077v05n01_01; *OFF PROT RES RISK, 1993, PROT HUM RES SUBJ I; PATRICK C, 1992, GEN HOSP PSYCHIAT, V14, P219, DOI 10.1016/0163-8343(92)90091-N; PRUCHNO RA, 1989, J AM GERIATR SOC, V37, P697, DOI 10.1111/j.1532-5415.1989.tb02230.x; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; Ware JE, 1993, SF36 HLTH SURVEY MAN; Zubrod C.G., 1960, J CHRON DIS, V11, P7	30	294	299	0	46	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					451	+		10.7326/0003-4819-132-6-200003210-00005	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	293CV	10733444				2022-12-28	WOS:000085834700004
J	Ling, LH; Oh, JK; Breen, JF; Schaff, HV; Danielson, GK; Mahoney, DW; Seward, JB; Tajik, AJ				Ling, LH; Oh, JK; Breen, JF; Schaff, HV; Danielson, GK; Mahoney, DW; Seward, JB; Tajik, AJ			Calcific constrictive pericarditis: Is it still with us?	ANNALS OF INTERNAL MEDICINE			English	Article						pericarditis, constrictive; calcinosis; heart failure, congestive; dyspnea	TUBERCULOUS PERICARDITIS; ETIOLOGY	Background: The presence of pericardial calcification on a plain radiograph strongly suggests constrictive pericarditis in patients with heart failure. However, calcific constrictive pericarditis is considered rare in the United States since tuberculosis incidence has decreased, and doubt has therefore been raised about the importance of this radiologic finding in modern cardiovascular practice. Objective: To determine the clinical and prognostic significance of pericardial calcification on radiography in patients with constrictive pericarditis. Design: Retrospective cohort study. Setting: Tertiary referral center. Patients: A consecutive series of 135 patients (mean age +/- SD, 56 +/- 16 years) who from 1985 through 1995 had constrictive pericarditis confirmed surgically (n = 133) or by autopsy (n = 2). Patients were divided into two groups: those with pericardial calcification on chest radiography (group I) and those without (group II). Measurements: Clinical and diagnostic findings were compared in both groups, and outcome was compared in 132 patients who had pericardiectomy. Results: Pericardial calcification was seen in 36 patients (27%). The cause of constrictive pericardial disease was indeterminate in 67% of patients in group I and in 21% of patients in group II(P < 0.001). Patients in group I had had symptoms for a longer period and were more likely to have pericardial knock, larger atrial size, and atrial arrhythmia. Significantly more perioperative deaths were seen in group I, but incidence of late survival and incidence of noncalcific disease were similar in both groups. Conclusions: Pericardial calcification is a common finding in patients with constrictive pericarditis. It is often associated with idiopathic disease and other markers of disease chronicity and is an independent predictor of increased perioperative mortality rates.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Oh, JK (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.			Ling, Lieng H./0000-0001-6063-8530; Schaff, Hartzell/0000-0003-0994-027X				AAGAARD MT, 1984, THORAC CARDIOV SURG, V32, P311, DOI 10.1055/s-2007-1023411; BASHI VV, 1988, THORAX, V43, P637, DOI 10.1136/thx.43.8.637; BLAKE S, 1983, BRIT HEART J, V50, P273; CAMERON J, 1987, AM HEART J, V113, P354, DOI 10.1016/0002-8703(87)90278-X; CHAMBLISS JR, 1951, CIRCULATION, V4, P816, DOI 10.1161/01.CIR.4.6.816; CIMINO JJ, 1989, AM HEART J, V118, P1292, DOI 10.1016/0002-8703(89)90021-5; DALTON JC, 1956, ANN INTERN MED, V45, P445, DOI 10.7326/0003-4819-45-3-445; DCRUZ IA, 1978, RADIOLOGY, V127, P755, DOI 10.1148/127.3.755; DINES DE, 1958, P STAFF M MAYO CLIN, V33, P93; FEIRING AJ, 1985, CIRCULATION, V72, P1355, DOI 10.1161/01.CIR.72.6.1355; FOWLER NO, 1991, JAMA-J AM MED ASSOC, V266, P99, DOI 10.1001/jama.266.1.99; GIMLETTE TMD, 1959, BRIT HEART J, V21, P9; HAGEMAN JH, 1964, NEW ENGL J MED, V270, P327, DOI 10.1056/NEJM196402132700702; HARVEY RM, 1953, CIRCULATION, V8, P695, DOI 10.1161/01.CIR.8.5.695; HEINZ R, 1957, RADIOLOGY, V69, P54, DOI 10.1148/69.1.54; HOLMAN E, 1955, JAMA-J AM MED ASSOC, V157, P789, DOI 10.1001/jama.1955.02950270007003; LEVINE HD, 1973, CIRCULATION, V48, P1268, DOI 10.1161/01.CIR.48.6.1268; Ling LH, 1999, CIRCULATION, V100, P1380, DOI 10.1161/01.CIR.100.13.1380; MACGREGOR JH, 1987, AM J ROENTGENOL, V148, P675, DOI 10.2214/ajr.148.4.675; Matsubara H, 1995, J Cardiol, V25, P89; MCCAUGHAN BC, 1985, J THORAC CARDIOV SUR, V89, P340; NI Y, 1990, ANN THORAC SURG, V49, P445, DOI 10.1016/0003-4975(90)90252-2; PAUL O, 1948, AM J MED SCI, V216, P361, DOI 10.1097/00000441-194810000-00001; Potwar S A, 1989, Indian Heart J, V41, P30; RIENMULLER R, 1993, J THORAC IMAG, V8, P108; SANFILIPPO AJ, 1990, CIRCULATION, V82, P792, DOI 10.1161/01.CIR.82.3.792; SCHIAVONE WA, 1989, AM J CARDIOL, V63, P145, DOI 10.1016/0002-9149(89)91106-5; SCHIAVONE WA, 1986, AM J CARDIOL, V58, P373, DOI 10.1016/0002-9149(86)90087-1; SCHOENFELD MH, 1987, CIRCULATION, V75, P1012, DOI 10.1161/01.CIR.75.5.1012; STEINBERG I, 1961, AM J CARDIOL, V7, P33, DOI 10.1016/0002-9149(61)90421-0; SUWAN PK, 1995, BRIT HEART J, V73, P187; TIRILOMIS T, 1994, EUR J CARDIO-THORAC, V8, P487, DOI 10.1016/1010-7940(94)90020-5; Wise D E, 1976, Cardiovasc Clin, V7, P197; WOOD P, 1961, AM J CARDIOL, V7, P48, DOI 10.1016/0002-9149(61)90422-2; WYCHULIS AR, 1971, J THORAC CARDIOV SUR, V62, P608, DOI 10.1016/S0022-5223(19)42030-8	35	102	112	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					444	+		10.7326/0003-4819-132-6-200003210-00004	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293CV	10733443				2022-12-28	WOS:000085834700003
J	Russ, AP; Wattler, S; Colledge, WH; Aparicio, SAJR; Carlton, MBL; Pearce, JJ; Barton, SC; Surani, MA; Ryan, K; Nehls, MC; Wilson, V; Evans, MJ				Russ, AP; Wattler, S; Colledge, WH; Aparicio, SAJR; Carlton, MBL; Pearce, JJ; Barton, SC; Surani, MA; Ryan, K; Nehls, MC; Wilson, V; Evans, MJ			Eomesodermin is required for mouse trophoblast development and mesoderm formation	NATURE			English	Article							CHIMERIC ANALYSIS; T-GENE; EMBRYO; GASTRULATION; EXPRESSION; FAMILY	The earliest cell fate decision in the mammalian embryo separates the extra-embryonic trophoblast lineage, which forms the fetal portion of the placenta, from the embryonic cell lineages. The body plan of the embryo proper is established only later at gastrulation, when the pluripotent epiblast gives rise to the germ layers ectoderm, mesoderm and endoderm. Here we show that the T-box gene Eomesodermin(1) performs essential functions in both trophoblast development and gastrulation, Mouse embryos lacking Eomesodermin arrest at the blastocyst stage. Mutant trophoectoderm does not differentiate into trophoblast, indicating that Eomesodermin may be required for the development of trophoblast stem cells(2), In the embryo proper, Eomesodermin is essential for mesoderm formation. Although the specification of the anterior-posterior axis and the initial response to mesoderm-inducing signals is intact in mutant epiblasts, the prospective mesodermal cells are not recruited into the primitive streak. Our results indicate that Eomesodermin defines a conserved molecular pathway controlling the morphogenetic movements of germ layer formation and has acquired a new function in mammals in the differentiation of trophoblast.	Univ Cambridge, Wellcome CRC Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England; Paradigm Therapeut Ltd, Cambridge CB2 3EG, England; Niedersachs Inst Peptidforsch, D-30625 Hannover, Germany; Addenbrookes Hosp, Cambridge Inst Med Res, Dept Oncol, Cambridge CB2 2XY, England; Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland	University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh	Russ, AP (corresponding author), Univ Cambridge, Wellcome CRC Inst Canc & Dev Biol, Tennis Court Rd, Cambridge CB2 1QR, England.		Colledge, William/X-4976-2019; Wilson, Valerie A/H-5427-2011	Colledge, William/0000-0002-9603-4429; Aparicio, Samuel/0000-0002-0487-9599				Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Bulfone A, 1999, MECH DEVELOP, V84, P133, DOI 10.1016/S0925-4773(99)00053-2; Casey ES, 1999, DEVELOPMENT, V126, P4193; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; Ciruna BG, 1999, MECH DEVELOP, V81, P199, DOI 10.1016/S0925-4773(98)00243-3; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Hancock SN, 1999, MECH DEVELOP, V81, P205, DOI 10.1016/S0925-4773(98)00244-5; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Hogan B, 1994, MANIPULATING MOUSE E; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Pearce JJH, 1999, MECH DEVELOP, V87, P189, DOI 10.1016/S0925-4773(99)00135-5; Rossant J, 1998, TRENDS GENET, V14, P358, DOI 10.1016/S0168-9525(98)01552-2; ROSSANT J, 1981, J EMBRYOL EXP MORPH, V62, P217; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; Sun X, 1999, GENE DEV, V13, P1834, DOI 10.1101/gad.13.14.1834; SUTHERLAND AE, 1988, J CELL BIOL, V106, P1331, DOI 10.1083/jcb.106.4.1331; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; Tada M, 1998, DEVELOPMENT, V125, P3997; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Wattler S, 1998, GENOMICS, V48, P24, DOI 10.1006/geno.1997.5150; WILSON V, 1993, DEVELOPMENT, V117, P1321; WILSON V, 1995, DEVELOPMENT, V121, P877	29	466	474	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					95	99		10.1038/35003601	http://dx.doi.org/10.1038/35003601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716450				2022-12-28	WOS:000085775100053
J	Kafatos, FC				Kafatos, FC			European policy - Interesting times - Biology, European science, and EMBL	SCIENCE			English	Article									European Mol Biol Lab, Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Kafatos, FC (corresponding author), European Mol Biol Lab, Heidelberg, Germany.							Ashburner M, 1999, NATURE, V402, P12, DOI 10.1038/46888; 1999, NATURE, V402, P1	2	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 25	2000	287	5457					1401	+		10.1126/science.287.5457.1401	http://dx.doi.org/10.1126/science.287.5457.1401			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	287WZ	10722387				2022-12-28	WOS:000085531600021
J	Weber, JM; Kelley, JA; Nielsen, SB; Ayotte, P; Johnson, MA				Weber, JM; Kelley, JA; Nielsen, SB; Ayotte, P; Johnson, MA			Isolating the spectroscopic signature of a hydration shell with the use of clusters: Superoxide tetrahydrate	SCIENCE			English	Article							WATER; SOLVATION; SPECTRUM; ION; CO2	Cluster spectroscopy, aided by ab initio theory, was used to determine the detailed structure of a complete hydration shell around an anion. Infrared spectra of size-selected O-2(-.) (H2O)(n) (n = 1 to 4) cluster ions were obtained by photoevaporation of an argon nanomatrix. Four water molecules are required to complete the coordination shell. The simple spectrum of the tetrahydrate reveals a structure in which each water molecule is engaged in a single hydrogen bond to one of the four Lobes of the pi* orbital of the superoxide, whereas the water molecules bind together in pairs. This illustrates how water networks deform upon accommodating a solute ion to create a distinct supramolecular species.	Yale Univ, Sterling Chem Lab, New Haven, CT 06520 USA	Yale University	Johnson, MA (corresponding author), Yale Univ, Sterling Chem Lab, POB 208107, New Haven, CT 06520 USA.	mark.johnson@yale.edu	Nielsen, Steen Brondsted/G-5844-2016; /B-1618-2009	/0000-0002-5493-5886				Ayotte P, 1999, J PHYS CHEM A, V103, P10665, DOI 10.1021/jp991963r; Ayotte P, 1998, J AM CHEM SOC, V120, P12361, DOI 10.1021/ja981979f; Ayotte P, 1998, CHEM PHYS, V239, P485, DOI 10.1016/S0301-0104(98)00287-0; Ayotte P, 2000, CHEM PHYS LETT, V316, P455, DOI 10.1016/S0009-2614(99)01257-9; Ayotte P, 1999, J CHEM PHYS, V110, P7129, DOI 10.1063/1.478616; AYOTTE P, 1999, THESIS YALE U NEW HA; Choi JH, 1998, J PHYS CHEM A, V102, P503, DOI 10.1021/jp9729425; CURTISS LA, 1986, J COMPUT CHEM, V7, P294, DOI 10.1002/jcc.540070307; FAHEY DW, 1982, J CHEM PHYS, V76, P1799, DOI 10.1063/1.443220; FRISCH MJ, 1995, GAUSSIAN 94; Gruenloh CJ, 1997, SCIENCE, V276, P1678, DOI 10.1126/science.276.5319.1678; Johnson M. A., 1988, TECHNIQUES STUDY ION, P591; Keese R.G., 1979, J GEOPHYS RES, V84, P3791; Mallard W.G., 69 NIST, P20899; NARAYANA PA, 1982, J AM CHEM SOC, V104, P3552, DOI 10.1021/ja00377a002; Sadlej J, 1999, J PHYS CHEM A, V103, P4933, DOI 10.1021/jp990546b; Salvemini D, 1999, SCIENCE, V286, P304, DOI 10.1126/science.286.5438.304; Schoneich C, 1999, EXP GERONTOL, V34, P19, DOI 10.1016/S0531-5565(98)00066-7; SYMONS MCR, 1980, J CHEM SOC FARAD T 1, V76, P1868, DOI 10.1039/f19807601868; Xantheas SS, 1996, J PHYS CHEM-US, V100, P9703, DOI 10.1021/jp960779s; YANG X, 1991, J AM CHEM SOC, V113, P6766, DOI 10.1021/ja00018a008	21	168	168	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2461	2463		10.1126/science.287.5462.2461	http://dx.doi.org/10.1126/science.287.5462.2461			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741960				2022-12-28	WOS:000086202200037
J	Douillard, JY; Cunningham, D; Roth, AD; Navarro, M; James, RD; Karasek, P; Jandik, P; Iveson, T; Carmichael, J; Alakl, M; Gruia, G; Awad, L; Rougier, P				Douillard, JY; Cunningham, D; Roth, AD; Navarro, M; James, RD; Karasek, P; Jandik, P; Iveson, T; Carmichael, J; Alakl, M; Gruia, G; Awad, L; Rougier, P			Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial	LANCET			English	Article							QUALITY-OF-LIFE; 24-HOUR INFUSION; CLINICAL-TRIALS; TOPOISOMERASE-I; 5-FLUOROURACIL; ONCOLOGY; FAILURE	Background Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer. Methods 387 patients previously untreated with chemotherapy (other than adjuvant) for advanced colorectal cancer were randomly assigned open-label irinotecan plus fluorouracil and calcium folinate (irinotecan group, n=199) or fluorouracil and calcium folinate alone (no-irinotecan group, n=188). Infusion schedules were once weekly or every 2 weeks, and were chosen by each centre. We assessed response rates and time to progression, and also response duration, survival, and quality of life. Analyses were done on the intention-to-treat population and on evaluable patients. Findings The response rate was significantly higher in patients in the irinotecan group than in those in the no-irinotecan group (49 vs 31%, p<0.001 for evaluable patients, 35 vs 22%, p<0.005 by intention to treat). Time to progression was significantly longer in the irinotecan group than in the no-irinotecan group (median 6.7 vs 4.4 months, p<0. 001), and overall survival was higher (median 17.4 vs 14.1 months, p=0.031). Some grade 3 and 4 toxic effects were significantly more frequent in the irinotecan group than in the no-irinotecan group, but effects were predictible, reversible, non-cumulative, and manageable. Interpretation Irinotecan combined with fluorouracil and calcium folinate was well-tolerated and increased response rate, time to progression, and survival, with a later deterioration in quality of life. This combination should be considered as a reference first-line treatment for metastatic colorectal cancer.	Ctr Rene Gauducheau, F-44805 St Herblain, France; Royal Marsden Hosp, London SW3 6JJ, England; Hosp Cantonal, Geneva, Switzerland; Hosp Duran & Reynals, Barcelona, Spain; Masaryk Mem Canc Inst, Brno, Czech Republic; Univ Hosp, Hradec Kralove, Czech Republic; Royal S Hants Hosp, Southampton SO9 4PE, Hants, England; City Hosp, Nottingham NG5 1PB, England; Rhone Poulenc, Rorer, France; Hosp A Pare, Boulogne, France	UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Royal Marsden NHS Foundation Trust; University of Geneva; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Masaryk Memorial Cancer Institute; University Hospital Hradec Kralove; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Nottingham; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Douillard, JY (corresponding author), Ctr Rene Gauducheau, F-44805 St Herblain, France.			Cunningham, David/0000-0001-5158-1069				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; CREEMERS GJ, 1994, CANCER TREAT REV, V20, P73, DOI 10.1016/0305-7372(94)90011-6; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; De Gramont A, 1998, P AN M AM SOC CLIN, V17, P985; Ducreux M, 1999, J CLIN ONCOL, V17, P2901, DOI 10.1200/JCO.1999.17.9.2901; FAGES B, 1997, P ASCO, V16; FINDLAY M, 1994, ANN ONCOL, V5, P239, DOI 10.1093/oxfordjournals.annonc.a058800; GIACCHETTI S, 1997, P AN M AM SOC CLIN, V16, P229; GLIMELIUS B, 1994, CANCER, V73, P556, DOI 10.1002/1097-0142(19940201)73:3<556::AID-CNCR2820730310>3.0.CO;2-8; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; IZZO J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P217; JAGER E, 1995, EUR J CANC A, V31; JAXEL C, 1989, CANCER RES, V49, P1465; Kohne CH, 1998, J CLIN ONCOL, V16, P418; MARSONI S, 1987, CANC TREAT REP, V71, P7180; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2; SALTZ LB, 1999, P AN M AM SOC CLIN, V18, P233; SCHMOLL HJ, 1996, IS THERE 2 LINE THER; SCHOENFELD DA, 1982, BIOMETRICS, V38, P163, DOI 10.2307/2530299; Vanhoefer U, 1999, J CLIN ONCOL, V17, P907, DOI 10.1200/JCO.1999.17.3.907; WEH HJ, 1994, ANN ONCOL, V5, P233, DOI 10.1093/oxfordjournals.annonc.a058799	24	2611	2727	1	99	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1041	1047		10.1016/S0140-6736(00)02034-1	http://dx.doi.org/10.1016/S0140-6736(00)02034-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744089				2022-12-28	WOS:000086380800010
J	Lloyd, BW; Brodie, K				Lloyd, BW; Brodie, K			Recognition of television images as a developmental milestone in young children: observational study	BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine the age at which children with apparently normal development can recognise the television image of a cat, dog, or baby. Design Observational study. Setting District general hospital in north London. Subjects 797 children with apparently normal development aged between 8 and 23 months and 26 children with Down's syndrome aged 18 months. Outcome measures Whether or not the child recognised the television image of a cat, dog, or baby by naming, imitating, or pointing at the image. Results by 18 months of age 96% (95% confidence interval 94% to 98%) of normal children recognised the television image of a cat, dog, or baby compared with 5 of 26 (19%) children with Down's syndrome. Conclusion Recognition of the television image of a cat, dog, or baby is a simple milestone, which may help in the developmental assessment of young children.	N Middlesex Hosp, Childrens Dept, London N18 1QX, England		Lloyd, BW (corresponding author), Royal Free Hosp, Pond St, London NW3 2QG, England.							Baron-Cohen Simon, 1996, British Journal of Psychiatry, V168, P158, DOI 10.1192/bjp.168.2.158; Bayley N, 1993, BAYLEY SCALES INFANT; FRANKENBURG WK, 1992, PEDIATRICS, V89, P91; HUNTLEY M, 1996, GRIFFITHMS MENTAL DE; REYNELL J, 1980, LANGUAGE DEV ASSESSM; Sheridan M., 1997, BIRTH 5 YEARS CHILDR	6	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					836	838		10.1136/bmj.320.7238.836	http://dx.doi.org/10.1136/bmj.320.7238.836			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	299DJ	10731175	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000086180300023
J	Mayor, S				Mayor, S			Genetics commission consults UK population	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					823	823						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731163				2022-12-28	WOS:000086180300011
J	Power, C; Li, L				Power, C; Li, L			Cohort study of birthweight, mortality, and disability	BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; INFANTS		Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; University College London	Power, C (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.							FERRI E, 1993, LIFE 33 5 FOLLOW UP; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; PHAROAH POD, 1994, ARCH DIS CHILD, V70, P264, DOI 10.1136/adc.70.4.264; STEWART AL, 1981, LANCET, V1, P1038; WEIR W, 1992, ARCH DIS CHILD, V67, P675	5	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					840	841		10.1136/bmj.320.7238.840	http://dx.doi.org/10.1136/bmj.320.7238.840			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731178	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000086180300026
J	Rubin, GM; Hong, L; Brokstein, P; Evans-Holm, M; Frise, E; Stapleton, M; Harvey, DA				Rubin, GM; Hong, L; Brokstein, P; Evans-Holm, M; Frise, E; Stapleton, M; Harvey, DA			A Drosophila complementary DNA resource	SCIENCE			English	Editorial Material							EXPRESSED SEQUENCE TAGS	Collections of nonredundant, full-length complementary DNA (cDNA) clones for each of the model organisms and humans will be important resources for studies of gene structure and function. We describe a general strategy for producing such collections and its implementation, which so far has generated a set of cDNAs corresponding to over 40% of the genes in the fruit fly Drosophila melanogaster.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Rubin, GM (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; MUNROE DJ, 1995, P NATL ACAD SCI USA, V92, P2209, DOI 10.1073/pnas.92.6.2209; Strausberg RL, 1999, SCIENCE, V286, P455, DOI 10.1126/science.286.5439.455	7	289	361	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2222	2224		10.1126/science.287.5461.2222	http://dx.doi.org/10.1126/science.287.5461.2222			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731138				2022-12-28	WOS:000086049100039
J	Smith, R				Smith, R			X-ray optics - Making hard light sharper	NATURE			English	Editorial Material							LASER		Univ London Imperial Coll Sci Technol & Med, Dept Phys, London SW7 1BQ, England	Imperial College London	Smith, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Phys, Prince Consort Rd, London SW7 1BQ, England.							CEGLIO NM, 1988, OPT LETT, V13, P108, DOI 10.1364/OL.13.000108; COHENTANNOUDJI CN, 1990, PHYS TODAY, V43, P33, DOI 10.1063/1.881239; Liss KD, 2000, NATURE, V404, P371, DOI 10.1038/35006017; Remington BA, 1999, SCIENCE, V284, P1488, DOI 10.1126/science.284.5419.1488; Saleh B., 1994, FUNDAMENTALS PHOTONI	5	1	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					345	+		10.1038/35006194	http://dx.doi.org/10.1038/35006194			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746708				2022-12-28	WOS:000086119000032
J	Nolan, TW				Nolan, TW			System changes to improve patient safety	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG EVENTS; TASK COMPLEXITY; MEDICINE		Associates Proc Improvement, Silver Spring, MD 20910 USA		Nolan, TW (corresponding author), Associates Proc Improvement, 1110 Bonifant St, Silver Spring, MD 20910 USA.	TNolan@apiweb.org						BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Cook RI, 1994, HUMAN ERROR MED, P255; Fraass BA, 1998, INT J RADIAT ONCOL, V42, P651, DOI 10.1016/S0360-3016(98)00244-2; HINCKLEY CM, 1995, J QUAL TECHNOL, V27, P242, DOI 10.1080/00224065.1995.11979596; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEVENSON MD, 1993, SOLID STATE TECHNOL, V36, P18; LEVESON NG, 1993, SAFEWARE SYSTEMS SAF; MAYLOR EA, 1992, Q J EXP PSYCHOL-A, V44, P119, DOI 10.1080/14640749208401286; Murray SA, 1996, HUM FACTORS, V38, P323, DOI 10.1518/001872096779048011; Norman D., 1988, PSYCHOL EVERYDAY THI; Norman D. A., 1993, THINGS MAKE US SMART; Park K, 1997, HDB HUMAN FACTORS ER, P150; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; Salvendy G., 2021, HDB HUMAN FACTORS ER, DOI [10.1002/9781119636113, DOI 10.1002/9781119636113]; SARTER NB, 1992, INT J AVIAT PSYCHOL, V4, P1; Strong MJ, 1999, NEUROLOGY, V53, pS31; Ushakov IA, 1994, HDB RELIABILITY ENG; Vincent C, 1998, BRIT MED J, V316, P1154, DOI 10.1136/bmj.316.7138.1154; WICHMAN H, 1983, HUM FACTORS, V25, P583, DOI 10.1177/001872088302500512	22	202	217	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2000	320	7237					771	773		10.1136/bmj.320.7237.771	http://dx.doi.org/10.1136/bmj.320.7237.771			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296YQ	10720364	Green Published			2022-12-28	WOS:000086054700029
J	Abdurashidova, G; Deganuto, M; Klima, R; Riva, S; Biamonti, G; Giacca, M; Falaschi, A				Abdurashidova, G; Deganuto, M; Klima, R; Riva, S; Biamonti, G; Giacca, M; Falaschi, A			Start sites of bidirectional DNA synthesis at the human lamin B2 origin	SCIENCE			English	Article							REPLICATION ORIGIN; RECOGNITION COMPLEX; IN-VIVO; IDENTIFICATION; PROTEINS; MEMBER	The initiation sites of bidirectional synthesis at the DNA replication origin located at the 3' end of the human lamin B2 gene were investigated. RNA-primed nascent DNA molecules were subjected to second-strand synthesis with appropriate primers, amplified by ligation-mediated polymerase chain reaction, and size fractionated. Evidence for precise start sites was obtained. Exploration of close to 1 kilobase, coupled to inhibition of Okazaki fragment synthesis, demonstrates that the leading strands initiate at precise nucleotides on either helix, overlapping by three base pairs, within the area bound to a protein complex possibly analogous to the prereplicative complex of yeast.	Int Ctr Genet Engn & Biotechnol, Mol Biol Unit, I-34012 Trieste, Italy; Int Ctr Genet Engn & Biotechnol, Mol Med Unit, I-34012 Trieste, Italy; CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB); Consiglio Nazionale delle Ricerche (CNR)	Falaschi, A (corresponding author), Int Ctr Genet Engn & Biotechnol, Mol Biol Unit, Padriciano 99, I-34012 Trieste, Italy.		Giacca, Mauro/J-9287-2016	Giacca, Mauro/0000-0003-2927-7225; BIAMONTI, GIUSEPPE/0000-0001-6804-4315				Abdurashidova G, 1998, EMBO J, V17, P2961, DOI 10.1093/emboj/17.10.2961; BIAMONTI G, 1992, CHROMOSOMA, V102, pS24, DOI 10.1007/BF02451782; Bielinsky AK, 1999, MOL CELL, V3, P477, DOI 10.1016/S1097-2765(00)80475-X; Bielinsky AK, 1998, SCIENCE, V279, P95, DOI 10.1126/science.279.5347.95; BURHANS WC, 1991, EMBO J, V10, P4351, DOI 10.1002/j.1460-2075.1991.tb05013.x; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Dimitrova DS, 1996, P NATL ACAD SCI USA, V93, P1498, DOI 10.1073/pnas.93.4.1498; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Giacca M, 1997, METHODS, V13, P301, DOI 10.1006/meth.1997.0529; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; HAY RT, 1982, CELL, V28, P767, DOI 10.1016/0092-8674(82)90056-3; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kumar S, 1996, NUCLEIC ACIDS RES, V24, P3289, DOI 10.1093/nar/24.17.3289; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; QUIVY JP, 1993, NUCLEIC ACIDS RES, V21, P2779, DOI 10.1093/nar/21.11.2779; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421	19	148	152	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2023	2026		10.1126/science.287.5460.2023	http://dx.doi.org/10.1126/science.287.5460.2023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720330				2022-12-28	WOS:000085902800064
J	Akashi, K; Traver, D; Miyamoto, T; Weissman, IL				Akashi, K; Traver, D; Miyamoto, T; Weissman, IL			A clonogenic common myeloid progenitor that gives rise to all myeloid lineages	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; TRANSCRIPTION FACTOR GATA-1; MICE; GENE; DIFFERENTIATION; LEUKEMIA; SYSTEM; LYMPHOPOIESIS; COMMITMENT; LACKING	Haematopoietic stem cells give rise to progeny that progressively lose self-renewal capacity and become restricted to one lineage(1,2). The points at which haematopoietic stem cell-derived progenitors commit to each of the various lineages remain mostly unknown. We have identified a clonogenic common lymphoid progenitor that can differentiate into T, B and natural killer cells but not myeloid cells(3). Here we report the prospective identification, purification and characterization, using cell-surface markers and flow cytometry, of a complementary clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Common myeloid progenitors give rise to either megakaryocyte/erythrocyte or granulocyte/macrophage progenitors. Purified progenitors were used to provide a first-pass expression profile of various haematopoiesis-related genes. We propose that the common lymphoid progenitor and common myeloid progenitor populations reflect the earliest branch points between the lymphoid and myeloid lineages, and that the commitment of common myeloid progenitors to either the megakaryocyte/erythrocyte or the granulocyte/macrophage lineages are mutually exclusive events.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University; Stanford University	Akashi, K (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.	akashi@leland.stanford.edu						Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; DEXTER TM, 1990, CANCER SURV, V9, P1; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; METCALF D, 1979, J CELL PHYSIOL, V98, P401, DOI 10.1002/jcp.1040980216; Metcalf D, 1999, ANN NY ACAD SCI, V872, P289, DOI 10.1111/j.1749-6632.1999.tb08473.x; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; OGAWA M, 1993, BLOOD, V81, P2844; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; UCHIDA N, 1994, BLOOD, V83, P3758; WEISS TG, 1994, ETHICS INT AFF, V8, P1	30	1836	1896	5	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2000	404	6774					193	197		10.1038/35004599	http://dx.doi.org/10.1038/35004599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724173				2022-12-28	WOS:000085870900054
J	Mooser, V; Helbecque, N; Miklossy, J; Marcovina, SM; Nicod, P; Amouyel, P				Mooser, V; Helbecque, N; Miklossy, J; Marcovina, SM; Nicod, P; Amouyel, P			Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease	ANNALS OF INTERNAL MEDICINE			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; APO(A) ISOFORMS; LP(A); GENE; PLASMA; ASSOCIATION; GENOTYPE; APOE	Background: Apolipoprotein(a) [apo(a)], the distinctive, highly polymorphic glycoprotein of lipoprotein(a), shares a series of common features with apolipoprotein E (apoE), which is implicated in the development of Alzheimer disease. Objective: To determine whether apo(a) is associated with Alzheimer disease. Design: Case-control study. Setting: University hospitals in Europe. Participants: 285 patients with Alzheimer disease and 296 controls. Measurements: Plasma lipoprotein(a) levels, size of the apo(a) isoforms, and apoE and apo(a) genotyping. Results: Among carriers of the apoE epsilon 4 allele, lipoprotein(a) was associated with a progressive, age-dependent increased risk for late-onset Alzheimer disease (odds ratio for patients >80 years of age, 6.0 [95% CI, 1.2 to 30.8]; P < 0.01). Among noncarriers older than 80 years of age, lipoprotein(a) was associated with a reduced risk for Alzheimer disease (odds ratio, 0.4 [CI, 0.2 to 0.9]; P < 0.05). Conclusions: In this convenience sample, lipoprotein(a) was an additional risk factor for late-onset Alzheimer disease in carriers of the apoE epsilon 4 allele. However, lipoprotein(a) may protect against late-onset Alzheimer disease in noncarriers.	Univ Lausanne Hosp, CHU Vaudois, Dept Med, CH-1011 Lausanne, Switzerland; Inst Pasteur, Lille, France; Univ Washington, Seattle, WA 98195 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Washington; University of Washington Seattle	Mooser, V (corresponding author), Univ Lausanne Hosp, CHU Vaudois, Dept Med, BH 19-135, CH-1011 Lausanne, Switzerland.	vincent.mooser@hola.hospvd.ch		Amouyel, Philippe/0000-0001-9088-234X; Miklossy, Judith/0000-0003-4948-8708				Argraves KM, 1997, J CLIN INVEST, V100, P2170, DOI 10.1172/JCI119753; BARD JM, 1992, BIOCHIM BIOPHYS ACTA, V1127, P124, DOI 10.1016/0005-2760(92)90267-Y; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Fontana P, 1999, ARTERIOSCL THROM VAS, V19, P1075, DOI 10.1161/01.ATV.19.4.1075; Helbecque N, 1998, ALZ DIS ASSOC DIS, V12, P368, DOI 10.1097/00002093-199812000-00019; HIXSON JE, 1990, J LIPID RES, V31, P545; Hobbs HH, 1999, CURR OPIN LIPIDOL, V10, P225, DOI 10.1097/00041433-199906000-00005; Lin H, 1996, J HEART LUNG TRANSPL, V15, P1223; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; MARZ W, 1993, FEBS LETT, V325, P271, DOI 10.1016/0014-5793(93)81087-G; Meyer MR, 1998, NAT GENET, V19, P321, DOI 10.1038/1206; Mooser V, 1997, AM J HUM GENET, V61, P402, DOI 10.1086/514851; MOOSER V, 1995, HUM MOL GENET, V4, P173, DOI 10.1093/hmg/4.2.173; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Ramharack R, 1996, J LIPID RES, V37, P2029; SANDHOLZER C, 1992, ARTERIOSCLER THROMB, V12, P1214, DOI 10.1161/01.ATV.12.10.1214; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; Thillet J, 1998, ATHEROSCLEROSIS, V136, P389, DOI 10.1016/S0021-9150(97)00217-7; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; vanBarlingen HHJJ, 1997, METABOLISM, V46, P650, DOI 10.1016/S0026-0495(97)90008-1; WavrantDeVrieze F, 1997, NEUROSCI LETT, V227, P68, DOI 10.1016/S0304-3940(97)00304-2; Williams KR, 1998, NEUROBIOL DIS, V5, P271, DOI 10.1006/nbdi.1998.0198	24	31	32	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					533	537		10.7326/0003-4819-132-7-200004040-00004	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744589				2022-12-28	WOS:000086129300003
J	Hippisley-Cox, J; Allen, J; Pringle, M; Ebdon, D; McPhearson, M; Churchill, D; Bradley, S				Hippisley-Cox, J; Allen, J; Pringle, M; Ebdon, D; McPhearson, M; Churchill, D; Bradley, S			Association between teenage pregnancy rates and the age and sex of general practitioners: cross sectional survey in Trent 1994-7	BRITISH MEDICAL JOURNAL			English	Article							FAMILY-PLANNING-SERVICES; WOMENS HEALTH; PHYSICIANS; PREFERENCE; CARE; CONSULTATION; PREVENTION; PATTERNS; MEN	Objective To examine variations in teenage pregnancy rates in Trent region and to determine possible associations with local general practice characteristics such as the age and sex of the doctors. Design Cross sectional survey. Setting All 526 general practices in Trent region in existence between 1994 and 1997. Subjects All pregnancies of teenagers aged 13 to 19 between 1994 and 1997 that resulted in an admission to an NHS hospital. Main outcome measures Pregnancy rates for teenagers aged 13 to 19 and general practice characteristics: presence of a female or young doctor (under 36 years old), number of whole time equivalent practice nurses, Townsend score, vocational training status, list size per whole time equivalent doctor, fundholding status, and partnership size. Results On multivariate analysis, lower teenage pregnancy rates were associated with the presence of a female or young doctor and more nurse time. Practices in deprived areas had higher teenage pregnancy rates. Conclusion General practices with female doctors, young doctors, or more nurse time had lower teenage pregnancy rates. The findings may have implications for the mix of health professionals within primary care.	Queens Med Ctr, Sch Med, Div Gen Practice, Nottingham NG7 2UH, England; Queens Med Ctr, Dept Obstet & Gynaecol, Nottingham NG7 2UH, England; Queens Med Ctr, Sch Nursing, Nottingham NG7 2UH, England; Univ Nottingham, Dept Geog, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham	Hippisley-Cox, J (corresponding author), Queens Med Ctr, Sch Med, Div Gen Practice, Nottingham NG7 2UH, England.		Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Churchill, Richard/0000-0003-0049-8200; Bethea, Jane/0000-0003-0297-0468				Adler MW, 1997, BRIT MED J, V314, P1743, DOI 10.1136/bmj.314.7096.1743; BABB P, 1993, POPULATION TRENDS, V74, P12; BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; Britt H, 1996, MED CARE, V34, P403, DOI 10.1097/00005650-199605000-00003; Carstairs V, 1991, DEPRIVATION HLTH; Craft N, 1997, BRIT MED J, V315, P1301, DOI 10.1136/bmj.315.7118.1301; CURTIS HA, 1988, ARCH DIS CHILD, V63, P373, DOI 10.1136/adc.63.4.373; Frank E, 1996, ARCH FAM MED, V5, P215, DOI 10.1001/archfami.5.4.215; GARLICK R, 1993, PUBLIC HEALTH, V107, P135, DOI 10.1016/S0033-3506(05)80411-1; Glatstein IZ, 1997, FERTIL STERIL, V67, P443, DOI 10.1016/S0015-0282(97)80067-2; JACOBSON LD, 1995, FAM PRACT, V12, P232, DOI 10.1093/fampra/12.2.232; JEFFREYS LA, 1995, BRIT J GEN PRACT, V45, P415; Kerssens JJ, 1997, SOC SCI MED, V44, P1531, DOI 10.1016/S0277-9536(96)00272-9; Langille DB, 1997, CAN FAM PHYSICIAN, V43, P1563; LAW SAT, 1995, BRIT J GEN PRACT, V45, P520; Maheux B, 1997, CAN FAM PHYSICIAN, V43, P1089; McKee M, 1993, Qual Health Care, V2, P104, DOI 10.1136/qshc.2.2.104; MELLANBY AR, 1995, BRIT MED J, V311, P414, DOI 10.1136/bmj.311.7002.414; MOORE AT, 1989, BRIT MED J, V298, P500, DOI 10.1136/bmj.298.6672.500; NHS Centre for Reviews and Dissemination University of York, 1997, EFFECTIVE HLTH CARE, V3, P1; *OFF NAT STAT, 1996, MONITOR POPUL HLTH, V96, P1; PEARSON VAH, 1995, BRIT J FAM PLAN, V21, P45; PHILLIPS DR, 1995, ATTITUDES FAMILY PLA, P403; Reid I, 1998, BRIT MED J, V317, P1051; ROWLANDS S, 1991, BRIT J GEN PRACT, V41, P138; Seamark CJ, 1997, BRIT J GEN PRACT, V47, P175; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; SMITH R, 1997, BRIT MED J, V314, P695; SMITH T, 1993, BRIT MED J, V306, P1232, DOI 10.1136/bmj.306.6887.1232; van den Brink-Muinen A, 1998, MED CARE, V36, P100, DOI 10.1097/00005650-199801000-00012; WEYRAUCH KF, 1990, J FAM PRACTICE, V30, P559; WILSON SH, 1992, J PUBLIC HEALTH MED, V14, P17	32	33	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					842	845		10.1136/bmj.320.7238.842	http://dx.doi.org/10.1136/bmj.320.7238.842			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	299DJ	10731180	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000086180300027
J	Jasny, BR				Jasny, BR			The universe of Drosophila genes	SCIENCE			English	Editorial Material																			0	13	13	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2181	2181		10.1126/science.287.5461.2181	http://dx.doi.org/10.1126/science.287.5461.2181			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10744541				2022-12-28	WOS:000086049100030
J	Ritchie, KB; Nagelkerken, I; James, S; Smith, GW				Ritchie, KB; Nagelkerken, I; James, S; Smith, GW			Environmental microbiology - A tetrodotoxin-producing marine pathogen	NATURE			English	Article							MASS		Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Carmabi Fdn, Curacao, Neth Antilles; Clemson Univ, Dept Microbiol & Mol Med, Clemson, SC 29634 USA; Univ S Carolina, Dept Biol, Aiken, SC 29801 USA	University of North Carolina; University of North Carolina Chapel Hill; Clemson University; University of South Carolina	Ritchie, KB (corresponding author), Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA.	Smithres@aiken.ac.edu	Nagelkerken, Ivan/E-1093-2011	Nagelkerken, Ivan/0000-0003-4499-3940				BOCHNER BR, 1989, NATURE, V339, P157, DOI 10.1038/339157a0; Brigmon RL, 1998, APPL ENVIRON MICROB, V64, P3491; HUGHES TP, 1994, SCIENCE, V265, P1547, DOI 10.1126/science.265.5178.1547; LESSIOS HA, 1984, SCIENCE, V226, P335, DOI 10.1126/science.226.4672.335; LESSIOS HA, 1988, ANNU REV ECOL SYST, V19, P371, DOI 10.1146/annurev.es.19.110188.002103; MARTINEZMURCIA AJ, 1992, INT J SYST BACTERIOL, V42, P412, DOI 10.1099/00207713-42-3-412; Nagelkerken I, 1999, DIS AQUAT ORGAN, V38, P71, DOI 10.3354/dao038071; NOGUCHI T, 1987, MAR BIOL, V94, P625, DOI 10.1007/BF00431409; PETERS EC, 1993, ADV FISH SC, P393; Ritchie KB, 1995, MOL MAR BIOL BIOTECH, V4, P345; SIMIDU U, 1987, APPL ENVIRON MICROB, V53, P1714, DOI 10.1128/AEM.53.7.1714-1715.1987; YOTSU M, 1987, TOXICON, V25, P225, DOI 10.1016/0041-0101(87)90245-5	12	40	42	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					354	354		10.1038/35006168	http://dx.doi.org/10.1038/35006168			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746714	Bronze			2022-12-28	WOS:000086119000039
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 43-year-old woman coping with cancer, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Spiegel D, 1999, JAMA-J AM MED ASSOC, V282, P371, DOI 10.1001/jama.282.4.371	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2000	283	12					1614	1614		10.1001/jama.283.12.1614	http://dx.doi.org/10.1001/jama.283.12.1614			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MV	10735400				2022-12-28	WOS:000085857300040
J	Cook, RI; Render, M; Woods, DD				Cook, RI; Render, M; Woods, DD			Gaps in the continuity of care and progress on patient safety	BRITISH MEDICAL JOURNAL			English	Article									Univ Chicago, VA Patient Safety Ctr Inquiry GAPS, Chicago, IL 60637 USA; Cincinnati VAMC, VA Patient Safety Ctr Inquiry GAPS, Cincinnati, OH 45220 USA; Ohio State Univ, VA Patient Safety Ctr Inquiry GAPS, Columbus, OH 43210 USA	University of Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; Ohio State University	Cook, RI (corresponding author), Univ Chicago, VA Patient Safety Ctr Inquiry GAPS, 5841 S Maryland Ave,MC 4028, Chicago, IL 60637 USA.							BARLEY SR, 1997, CRAFT SCI TECHNICAL, P16; Cook R., 1998, TALE 2 STORIES CONTR; Cook RI, 1994, HUMAN ERROR MED, P255; COOK RI, 1999, ENHANCING PATIENT SA, P61; Klein G.A., 2017, SOURCES POWER PEOPLE; Kohn LTCJ., BUILDING SAFER HLTH; *NAT PAT SAF FDN, 1999, AG RES DEV PAT SAF; RASMUSSEN J, 1994, COGNITIVE SYSTEMS EN, P135; SENDERS JW, 1999, ENHANCING PATIENT SA, P65; Woods D.D., 1988, TASKS ERRORS MENTAL, P128; WOODS DD, 1999, HDB APPL COGNITION, P141	11	323	327	0	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					791	794		10.1136/bmj.320.7237.791	http://dx.doi.org/10.1136/bmj.320.7237.791			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720370	Green Published			2022-12-28	WOS:000086054700035
J	van Haastregt, JCM; Diederiks, JPM; van Rossum, E; de Witte, LP; Crebolder, HFJM				van Haastregt, JCM; Diederiks, JPM; van Rossum, E; de Witte, LP; Crebolder, HFJM			Effects of preventive home visits to elderly people living in the community: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED TRIAL; HEALTH PROMOTION PROGRAM; COMPREHENSIVE GERIATRIC ASSESSMENT; NURSE INTERVENTION; OLDER ADULTS; FALLS; METAANALYSIS; CARE; SURVEILLANCE; GUIDELINES	Objective To assess the effects of preventive home visits to elderly people living in the community. Design Systematic review. Setting 15 trials retrieved from Medline, Embase, and the Cochrane controlled trial register. Main outcome measures Physical function, psychosocial function, falls, admissions to institutions, and mortality. Results Considerable differences in the methodological quality of the 15 trials were found, but in general the quality was considered adequate. Favourable effects of the home visits were observed in 5 out of 12 trials measuring physical functioning, 1 out of 8 measuring psychosocial function, 2 out of 6 measuring falls, 2 out of 7 measuring admissions to institutions, and 3 of 13 measuring mortality. None of the trials reported negative effects. Conclusions No clear evidence was found in favour Of the effectiveness of preventive home visits to elderly people living in the community. It seems essential that the effectiveness of such visits is improved, but if this cannot be achieved consideration should be given to discontinuing these visits.	Inst Rehabil Res, Div Res, NL-6430 AD Hoensbroek, Netherlands; Maastricht Univ, Dept Med Sociol, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Epidemiol, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Gen Practice, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University	van Haastregt, JCM (corresponding author), Inst Rehabil Res, Div Res, POB 192, NL-6430 AD Hoensbroek, Netherlands.	jolanda.vanhaastregt@irv.nl	De+Witte, Luc/AAI-3518-2020	De+Witte, Luc/0000-0002-3013-2640				Alessi CA, 1997, J AM GERIATR SOC, V45, P1044, DOI 10.1111/j.1532-5415.1997.tb05964.x; BALABAN DJ, 1988, J FAM PRACTICE, V26, P307; BLACK ME, 1993, AM J PUBLIC HEALTH, V83, P1751, DOI 10.2105/AJPH.83.12.1751; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; CLARKE M, 1992, AM J EPIDEMIOL, V136, P1517, DOI 10.1093/oxfordjournals.aje.a116473; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; FABACHER D, 1994, J AM GERIATR SOC, V42, P630, DOI 10.1111/j.1532-5415.1994.tb06862.x; Gallagher EM, 1996, CAN J AGING, V15, P84, DOI 10.1017/S0714980800013301; HALL N, 1992, CAN J AGING, V11, P72, DOI 10.1017/S0714980800014537; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; HENDRIKSEN C, 1989, J AM GERIATR SOC, V37, P117, DOI 10.1111/j.1532-5415.1989.tb05869.x; HORNBROOK MC, 1994, GERONTOLOGIST, V34, P16, DOI 10.1093/geront/34.1.16; Luker KA, 1981, NURS TIMES, V77, P137; MCEWAN RT, 1990, BRIT J GEN PRACT, V40, P94; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; PATHY MSJ, 1992, LANCET, V340, P890, DOI 10.1016/0140-6736(92)93294-W; PLOEG J, 1994, CAN J PUBLIC HEALTH, V85, P188; REUBEN DB, 1993, GERONTOLOGIST, V33, P557; Rizzo JA, 1996, MED CARE, V34, P954, DOI 10.1097/00005650-199609000-00007; RUBENSTEIN LZ, 1994, AGING-CLIN EXP RES, V6, P105, DOI 10.1007/BF03324224; Sorensen K H, 1988, Compr Gerontol B, V2, P85; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; STUCK AE, 1995, AGING-CLIN EXP RES, V7, P237, DOI 10.1007/BF03324342; TINETTI ME, 1993, J AM GERIATR SOC, V41, P315, DOI 10.1111/j.1532-5415.1993.tb06710.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Tulloch A J, 1979, J R Coll Gen Pract, V29, P733; VANROSSUM E, 1993, BMJ-BRIT MED J, V307, P27, DOI 10.1136/bmj.307.6895.27; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800	33	208	209	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2000	320	7237					754	758		10.1136/bmj.320.7237.754	http://dx.doi.org/10.1136/bmj.320.7237.754			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296YQ	10720360	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086054700025
J	Landor, M; Petrozzo, P				Landor, M; Petrozzo, P			Hepatic hemangioma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Catholic Med Ctr Brooklyn & Queens, Elmhurst, NY 11373 USA		Landor, M (corresponding author), Catholic Med Ctr Brooklyn & Queens, Elmhurst, NY 11373 USA.								0	3	3	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2000	342	11					791	791		10.1056/NEJM200003163421106	http://dx.doi.org/10.1056/NEJM200003163421106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293HW	10717014				2022-12-28	WOS:000085846900006
J	Battle, M; Bender, ML; Tans, PP; White, JWC; Ellis, JT; Conway, T; Francey, RJ				Battle, M; Bender, ML; Tans, PP; White, JWC; Ellis, JT; Conway, T; Francey, RJ			Global carbon sinks and their variability inferred from atmospheric O-2 and delta C-13	SCIENCE			English	Article							CO2; CYCLE; AIR; DIOXIDE; OXYGEN; RATIO	Recent time-series measurements of atmospheric O-2 show that the land biosphere and world oceans annually sequestered 1.4 +/- 0.8 and 2.0 +/- 0.6 gigatons of carbon, respectively between mid-1991 and mid-1997. The rapid storage of carbon by the Land biosphere from 1991 to 1997 contrasts with the 1980s, when the land biosphere was approximately neutral. Comparison with measurements of delta(13)CO(2) implies an isotopic flux of 89 +/- 21 gigatons of carbon per mil per year, in agreement with model- and inventory-based estimates of this flux. Both the delta(13)C and the O-2 data show significant interannual variability in carbon storage over the period of record. The general agreement of the independent estimates from O-2 and delta(13)C is a robust signal of variable carbon uptake by both the Land biosphere and the oceans.	Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; NOAA, Climate Monitoring & Diagnost Lab, Boulder, CO 80303 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA; CSIRO, Div Atmospher Res, Mordialloc, Vic 3195, Australia	Princeton University; National Oceanic Atmospheric Admin (NOAA) - USA; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Rhode Island; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Battle, M (corresponding author), Bowdoin Coll, Dept Phys & Astron, 8800 Coll Stn, Brunswick, ME 04011 USA.		White, James W.C./A-7845-2009; Tans, Pieter/AAG-8273-2019; Francey, Roger J/A-2345-2012	White, James W.C./0000-0001-6041-4684; Tans, Pieter/0000-0002-9883-0787; 				ANDRES R, COMMUNICATION; Battle M, 1996, NATURE, V383, P231, DOI 10.1038/383231a0; Bender M, 1996, GLOBAL BIOGEOCHEM CY, V10, P9, DOI 10.1029/95GB03295; BENDER ML, 1994, GEOCHIM COSMOCHIM AC, V58, P4751, DOI 10.1016/0016-7037(94)90205-4; CIAIS P, 1995, J GEOPHYS RES-ATMOS, V100, P5051, DOI 10.1029/94JD02847; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; CONWAY TJ, 1994, J GEOPHYS RES-ATMOS, V99, P22831, DOI 10.1029/94JD01951; FRANCEY R, 1994, 22 NOAA; FRANCEY RJ, 1995, NATURE, V373, P326, DOI 10.1038/373326a0; Heimann M, 1996, GLOBAL BIOGEOCHEM CY, V10, P89, DOI 10.1029/95GB03191; KEELING CD, 1995, NATURE, V375, P666, DOI 10.1038/375666a0; KEELING CD, 1989, GEOPHYS MONOGR SER, V55, P305, DOI DOI 10.1029/GM055P0305; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; KEELING RF, 1992, NATURE, V358, P723, DOI 10.1038/358723a0; KEELING RF, 1993, GLOBAL BIOGEOCHEM CY, V7, P37, DOI 10.1029/92GB02733; KEELING RF, 1988, THESIS HARVARD U; Langenfelds RL, 1999, GEOPHYS RES LETT, V26, P1897, DOI 10.1029/1999GL900446; MACHTA L, 1970, SCIENCE, V168, P199; MARLAND G, 1997, 5 INT CARB DIOX C CA, P4; MASARIE K, UNPUB; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; SARMIENTO JL, 1992, NATURE, V356, P589, DOI 10.1038/356589a0; SCHIMEL DS, 1995, GLOBAL CHANGE BIOL, V1, P77, DOI 10.1111/j.1365-2486.1995.tb00008.x; Severinghaus J.P., 1995, THESIS COLUMBIA U; Siegenthaler U., 1981, CARBON CYCLE MODEL, P249; TANS PP, 1993, GLOBAL BIOGEOCHEM CY, V7, P353, DOI 10.1029/93GB00053; THONING KW, 1989, J GEOPHYS RES-ATMOS, V94, P8549, DOI 10.1029/JD094iD06p08549; Trolier M, 1996, J GEOPHYS RES-ATMOS, V101, P25897, DOI 10.1029/96JD02363; WANNINKHOF R, 1985, TELLUS B, V37, P128, DOI 10.1111/j.1600-0889.1985.tb00061.x	29	373	421	5	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2467	2470		10.1126/science.287.5462.2467	http://dx.doi.org/10.1126/science.287.5462.2467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741962				2022-12-28	WOS:000086202200039
J	Hoffman, RE; Boutros, NN; Hu, S; Berman, RM; Krystal, JH; Charney, DS				Hoffman, RE; Boutros, NN; Hu, S; Berman, RM; Krystal, JH; Charney, DS			Transcranial magnetic stimulation and auditory hallucinations in schizophrenia	LANCET			English	Article								12 patients with schizophrenia and auditory hallucinations received 1 Hz transcranial magnetic stimulation of left temporoparietlal cortex. In a double-blind crossover trial, active stimulation significantly reduced hallucinations relative to sham stimulation.	Yale Univ, Sch Med, Yale Psychiat Inst, Dept Psychiat, New Haven, CT 06520 USA	Yale University	Hoffman, RE (corresponding author), Yale Univ, Sch Med, Yale Psychiat Inst, Dept Psychiat, POB 208038, New Haven, CT 06520 USA.				NCRR NIH HHS [RR00125] Funding Source: Medline; NIMH NIH HHS [MH-50557] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050557] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Fiez JA, 1996, CEREB CORTEX, V6, P1, DOI 10.1093/cercor/6.1.1; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; Siebner HR, 1999, NEUROLOGY, V52, P529, DOI 10.1212/WNL.52.3.529; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0; Wassermann EM, 1998, NEUROSCI LETT, V250, P141, DOI 10.1016/S0304-3940(98)00437-6	5	220	232	1	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1073	1075		10.1016/S0140-6736(00)02043-2	http://dx.doi.org/10.1016/S0140-6736(00)02043-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744097				2022-12-28	WOS:000086380800018
J	Neal, KR; Nguyen-Van-Tam, JS; Jeffrey, N; Slack, RCB; Madeley, RJ; Ait-Tahar, K; Job, K; Wale, MCJ; Ala'Aldeen, DAA				Neal, KR; Nguyen-Van-Tam, JS; Jeffrey, N; Slack, RCB; Madeley, RJ; Ait-Tahar, K; Job, K; Wale, MCJ; Ala'Aldeen, DAA			Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							C MENINGOCOCCAL DISEASE; COAGGLUTINATION; OUTBREAK; ELISA	Objective To determine the rates of, and risk factors for, meningococcal carriage and acquisition among university students. Design Repeated cross sectional study. Participants 2507 students in their first year at university. Main outcome measures Prevalence of carriage of meningococci and risk factors for carriage and acquisition of meningococci. Results Carriage rates for meningoccoci increased rapidly in the first week of term from 6.9% on day 1, to 11.2% on day 2, to 19.0% on day 3, and to 23.1% on day 4. The average carriage rate during the first week of term in October among students living in catered halls was 13.9%. By November this had risen to 31.0% and in December it had reached 34.2%. Independent associations for acquisition of meningococci in the autumn term were frequency of visits to a hall bar (5-7 visits: odds ratio 2.7, 95% confidence interval 1.5 to 4.8), active smoking (1.6, 1.0 to 2.6), being male (1.6, 1.2 to 2.2), visits to night clubs (1.3, 1.0 to 1.6), and intimate kissing (1.4, 1.0 to 1.8). Lower rates of acquisition were found in female only halls (0.5, 0.3 to 0.9). The most commonly acquired meningococcal strain was C2a P1.5 (P1.2), which has been implicated in clusters of invasive meningococcal disease at other UK universities. Conclusions Carriage rates of meningococci among university students increase rapidly in the first week of term, with further increases during the term. The rapid rate of acquisition may explain the increased risk of invasive meningococcal disease and the timing of cases and outbreaks in university students.	Univ Nottingham, Queens Med Ctr, Dept Epidemiol & Publ Hlth Med, Nottingham NG7 2UH, England; Queens Med Ctr, Div Microbiol, Meningococcal Res Grp, Nottingham, England; Queens Med Ctr, Ctr Communicable Dis Surveillance, Nottingham, England	University of Nottingham; University of Nottingham; University of Nottingham	Neal, KR (corresponding author), Univ Nottingham, Queens Med Ctr, Dept Epidemiol & Publ Hlth Med, Nottingham NG7 2UH, England.		Nguyen-Van-Tam, Jonathan/I-2162-2019	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655				ABDILLAHI H, 1988, MICROB PATHOGENESIS, V4, P27, DOI 10.1016/0882-4010(88)90045-9; Andersen J, 1998, EPIDEMIOL INFECT, V121, P85, DOI 10.1017/S0950268898008930; DEVINE LF, 1970, AM J EPIDEMIOL, V92, P25, DOI 10.1093/oxfordjournals.aje.a121176; ELDRIDGE J, 1978, MED LAB SCI, V35, P63; FRASCH CE, 1985, REV INFECT DIS, V7, P504; Hubert B, 1997, Euro Surveill, V2, P69; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; JACKSON LA, 1995, AM J PUBLIC HEALTH, V85, P843, DOI 10.2105/AJPH.85.6.843; Jelfs J, 1998, EPIDEMIOL INFECT, V120, P263, DOI 10.1017/S0950268898008681; Le Saux N, 1992, Can J Infect Dis, V3, P60; MELTON LJ, 1977, AM J EPIDEMIOL, V106, P215, DOI 10.1093/oxfordjournals.aje.a112456; Neal KR, 1999, EPIDEMIOL INFECT, V122, P351, DOI 10.1017/S0950268899002368; Neal KR, 1998, EPIDEMIOL INFECT, V121, P487, DOI 10.1017/S0950268898001502; RONNE T, 1993, SCAND J INFECT DIS, V25, P331, DOI 10.3109/00365549309008507; STUART JM, 1989, LANCET, V2, P723, DOI 10.1016/S0140-6736(89)90781-2; WEDEGE E, 1990, J MED MICROBIOL, V31, P195, DOI 10.1099/00222615-31-3-195; WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390; 1999, FORMIC INTEGRATED QU; 1997, COMMUN DIS REP, V7, P393; 1996, COMMUN DIS REP, V6, P425	21	94	101	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					846	849		10.1136/bmj.320.7238.846	http://dx.doi.org/10.1136/bmj.320.7238.846			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731181	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000086180300028
J	Scully, RE				Scully, RE			Influence of origin of ovarian cancer on efficacy of screening	LANCET			English	Editorial Material									Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Scully, RE (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA 02114 USA.							BELL DA, 1994, CANCER, V73, P1859, DOI 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L; BELL DA, IN PRESS PATHOLOGY I; BHAN V, 1989, BRIT J OBSTET GYNAEC, V96, P1384, DOI 10.1111/j.1471-0528.1989.tb06299.x; Caduff RF, 1999, AM J SURG PATHOL, V23, P323, DOI 10.1097/00000478-199903000-00012; Deligdisch L, 1997, INT J GYNECOL CANCER, V7, P89, DOI 10.1046/j.1525-1438.1997.00379.x; PECORELLI S, 1998, J EPIDEMIOL BIOSTAT, V3, P1; PULS LE, 1992, GYNECOL ONCOL, V47, P53, DOI 10.1016/0090-8258(92)90075-T; Rosenthal A, 1998, SEMIN ONCOL, V25, P315; RUSSELL P, 1997, SURG PATHOLOGY OVARI; SCULLY R, 1995, OVARIAN CANC, V3, P139; Scully RE, 1998, ATLAS TUMOUR PATHOL	11	29	29	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	2000	355	9209					1028	1029		10.1016/S0140-6736(00)02026-2	http://dx.doi.org/10.1016/S0140-6736(00)02026-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744081				2022-12-28	WOS:000086380800002
J	Wald, A; Zeh, J; Selke, S; Warren, T; Ryncarz, AJ; Ashley, R; Krieger, JN; Corey, L				Wald, A; Zeh, J; Selke, S; Warren, T; Ryncarz, AJ; Ashley, R; Krieger, JN; Corey, L			Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-18, 1996	NEW ORLEANS, LOUISIANA	Amer Soc Microbiol			ACYCLOVIR TREATMENT; PREGNANT-WOMEN; LARGE-SCALE; ANTIBODIES; SUPPRESSION; FREQUENCY; ASSAY; EPIDEMIOLOGY; VALACICLOVIR; POPULATION	Background: Most persons who have serologic evidence of infection with herpes simplex virus (HSV) type 2 (HSV-2) are asymptomatic. Historically, it has been assumed that these persons have less frequent viral reactivation than those with symptomatic infection. Methods: We conducted a prospective study to investigate genital shedding of HSV among 53 subjects who had antibodies to HSV-2 but who reported having no history of genital herpes, and we compared their patterns of viral shedding with those in a similar cohort of 90 subjects with symptomatic HSV-2 infection. Genital secretions of the subjects in both groups were sampled daily and cultured for HSV for a median of 94 days. Results: HSV was isolated from the genital mucosa in 38 of the 53 HSV-2-seropositive subjects (72 percent) who reported no history of genital herpes, and HSV DNA was detected by the polymerase-chain-reaction assay in cultures prepared from genital mucosal swabs in 6 additional subjects. The rate of subclinical shedding of HSV in the subjects with no reported history of genital herpes was similar to that in the subjects with such a history (3.0 percent vs. 2.7 percent). Of the 53 subjects who had no reported history of genital herpes, 33 (62 percent) subsequently reported having typical herpetic lesions; the duration of their recurrences in these subjects was shorter (median, three days vs. five days; P<0.001) and the frequency lower (median, 3.0 per year vs. 8.2 per year; P<0.001) than in the 90 subjects with previously diagnosed symptomatic infection. Only 1 of these 53 subjects had no clinical or virologic evidence of HSV infection. Conclusions: Seropositivity for HSV-2 is associated with viral shedding in the genital tract, even in subjects with no reported history of genital herpes. (N Engl J Med 2000;342:844-50.) (C)2000, Massachusetts Medical Society.	Univ Washington, Virol Res Clin, Dept Med, Seattle, WA 98122 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98122 USA; Univ Washington, Dept Stat, Seattle, WA 98122 USA; Univ Washington, Dept Lab Med, Seattle, WA 98122 USA; Univ Washington, Dept Urol, Seattle, WA 98122 USA; Westover Hts Clin, Portland, OR USA; Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Wald, A (corresponding author), Univ Washington, Virol Res Clin, Dept Med, 1001 Broadway,Suite 320, Seattle, WA 98122 USA.		Wald, Anna/B-6272-2012; Warren, Terri/AAJ-1650-2021	Wald, Anna/0000-0003-3486-6438; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashley R, 1998, SEX TRANSM INFECT, V74, P228; ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1993, SEX TRANSM DIS, V20, P230, DOI 10.1097/00007435-199307000-00009; Ashley RL, 1998, J CLIN MICROBIOL, V36, P294, DOI 10.1128/JCM.36.1.294-295.1998; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; Benedetti JK, 1999, ANN INTERN MED, V131, P14, DOI 10.7326/0003-4819-131-1-199907060-00004; Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; FORSGREN M, 1994, INT J STD AIDS, V5, P113, DOI 10.1177/095646249400500207; FRENKEL LM, 1993, ANN INTERN MED, V118, P414, DOI 10.7326/0003-4819-118-6-199303150-00003; Garcia-Corbeira P, 1999, J MED VIROL, V59, P194, DOI 10.1002/(SICI)1096-9071(199910)59:2&lt;194::AID-JMV11&gt;3.0.CO;2-9; KAPLOWITZ LG, 1991, JAMA-J AM MED ASSOC, V265, P747, DOI 10.1001/jama.265.6.747; KOELLE DM, 1992, ANN INTERN MED, V116, P433, DOI 10.7326/0003-4819-116-6-433; Krone MR, 1998, J INFECT DIS, V178, P978, DOI 10.1086/515666; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; LOWHAGEN GB, 1990, ACTA DERM-VENEREOL, V70, P330; MCCULLAGH P, 1983, GEN LINEAR MODELS, P131; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; Oliver L, 1995, Arch Fam Med, V4, P228, DOI 10.1001/archfami.4.3.228; Pliskin KL, 1995, CULT MED PSYCHIAT, V19, P479, DOI 10.1007/BF01379399; Reitano M, 1998, J INFECT DIS, V178, P603, DOI 10.1086/515385; Ryncarz AJ, 1999, J CLIN MICROBIOL, V37, P1941, DOI 10.1128/JCM.37.6.1941-1947.1999; Schacker T, 1998, J INFECT DIS, V178, P1616, DOI 10.1086/314486; Schacker T, 1998, ANN INTERN MED, V128, P21, DOI 10.7326/0003-4819-128-1-199801010-00004; SLOMKA MJ, 1995, J VIROL METHODS, V55, P27, DOI 10.1016/0166-0934(95)00042-S; Spruance SL, 1996, ARCH INTERN MED, V156, P1729, DOI 10.1001/archinte.156.15.1729; Wald A, 1997, SEX TRANSM DIS, V24, P149, DOI 10.1097/00007435-199703000-00005; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109	36	407	422	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	2000	342	12					844	850		10.1056/NEJM200003233421203	http://dx.doi.org/10.1056/NEJM200003233421203			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296FU	10727588				2022-12-28	WOS:000086014100003
J	Pfister, GC; Puffer, JC; Maron, BJ				Pfister, GC; Puffer, JC; Maron, BJ			Preparticipation cardiovascular screening for US collegiate student-athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMERICAN-HEART-ASSOCIATION; SUDDEN CARDIAC DEATH; HYPERTROPHIC CARDIOMYOPATHY; CLINICAL CARDIOLOGY; YOUNG-ADULTS; DISEASE; PROFESSIONALS; STATEMENT	Context Sudden death in young competitive athletes due to unsuspected cardiovascular disease has heightened interest in preparticipation screening. Objective To assess screening practices for detecting potentially lethal cardiovascular diseases in college-aged student-athletes. Design, Setting, and Participants A total of 1110 National Collegiate Athletic Association member colleges and universities were surveyed between 1995 and 1997, with 879 (79%) responding to the questionnaire, Main Outcome Measures Information on the administration and scope of the preparticipation screening process was obtained from the team physician or athletic director; preparticipation screening forms were evaluated for content and compared with 12 items recommended by the 1996 American Heart Association (AHA) consensus panel screening guidelines. Results Preparticipation screening was a requirement at 855 (97%) of 879 schools, was performed on campus at 713 schools (81%), and was required annually by 446 schools (51%), Team physicians were responsible for examinations at 603 (85%) of 713 schools with on-campus screening, although 135 of these schools (19%) also approved nurse practitioners and 244 schools (34%) allowed athletic trainers to perform examinations. Of the history and physical examination screening forms analyzed from 625 institutions, only 163 schools (26%) had forms that contained at least 9 of the recommended 12 AHA screening guidelines and were judged to be adequate, whereas 150 (24%) contained 4 or fewer of these parameters and were considered to be inadequate. Smaller Division III schools were more likely than larger Division I schools to have inadequate screening forms (30% vs 14%, P<.001). Relevant items that were omitted from more than 40% of the screening forms included history of exertional chest pain, dyspnea, or fatigue; familial heart disease or premature sudden death; and physical stigmata or family history of Marfan syndrome. Conclusion The preparticipation screening process used by many US colleges and universities may have limited potential to detect (or raise the suspicion of) cardiovascular abnormalities capable of causing sudden death in competitive student-athletes.	Minneapolis Heart Inst Fdn, Cardiovasc Res Div, Minneapolis, MN 55407 USA; Univ Calif Los Angeles, Sch Med, Dept Family Med, Div Sports Med, Los Angeles, CA USA	Minneapolis Heart Institute Foundation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Maron, BJ (corresponding author), Minneapolis Heart Inst Fdn, Cardiovasc Res Div, 920 E 28th St,Suite 40, Minneapolis, MN 55407 USA.							BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; Corrado D, 1998, NEW ENGL J MED, V339, P364, DOI 10.1056/NEJM199808063390602; Glover DW, 1998, JAMA-J AM MED ASSOC, V279, P1817, DOI 10.1001/jama.279.22.1817; KAPLAN NM, 1994, J AM COLL CARDIOL, V24, P885, DOI 10.1016/0735-1097(94)90845-1; Liberthson RR, 1996, NEW ENGL J MED, V334, P1039, DOI 10.1056/NEJM199604183341607; Maron BJ, 1998, CIRCULATION, V98, P1460, DOI 10.1161/01.CIR.98.14.1460; Maron BJ, 1998, NEW ENGL J MED, V339, P1632, DOI 10.1056/NEJM199811263392211; Maron BJ, 1998, J AM COLL CARDIOL, V32, P1881, DOI 10.1016/S0735-1097(98)00491-4; Maron BJ, 1998, ANN INTERN MED, V129, P379, DOI 10.7326/0003-4819-129-5-199809010-00006; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Maron BJ, 1994, J AM COLL CARDIOL, V24, P845; *NAT COLL ATHL ASS, 1996, 1996 97 NCAA DIR; SMITH DM, 1996, PREPARTICIPATION PHY, P1; Smith J, 1998, MAYO CLIN PROC, V73, P419; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641	19	89	89	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2000	283	12					1597	+		10.1001/jama.283.12.1597	http://dx.doi.org/10.1001/jama.283.12.1597			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MV	10735397	Bronze			2022-12-28	WOS:000085857300037
J	Schiff, ER				Schiff, ER			Update in hepatology	ANNALS OF INTERNAL MEDICINE			English	Review							TRIAL; VIRUS		Ctr Liver Dis, Div Hepatol, Miami, FL 33136 USA		Schiff, ER (corresponding author), Ctr Liver Dis, Div Hepatol, Suite 1101, Miami, FL 33136 USA.	escheff@med.miami.edu						Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Neuschwander-Tetri BA, 1998, ANN INTERN MED, V129, P38, DOI 10.7326/0003-4819-129-1-199807010-00009; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; VENTO S, 1991, LANCET, V337, P1183, DOI 10.1016/0140-6736(91)92858-Y	4	3	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 21	2000	132	6					460	466		10.7326/0003-4819-132-6-200003210-00006	http://dx.doi.org/10.7326/0003-4819-132-6-200003210-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293CV	10733445				2022-12-28	WOS:000085834700005
J	Newby, LK; Eisenstein, EL; Califf, RM; Thompson, TD; Nelson, CL; Peterson, ED; Armstrong, PW; Van de Werf, F; White, HD; Topol, EJ; Mark, DB				Newby, LK; Eisenstein, EL; Califf, RM; Thompson, TD; Nelson, CL; Peterson, ED; Armstrong, PW; Van de Werf, F; White, HD; Topol, EJ; Mark, DB			Cost effectiveness of early discharge after uncomplicated acute myocardial infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; HOSPITAL DISCHARGE; MEDICARE PATIENTS; TRIAL; ANGIOPLASTY; QUALITY; CARE; ERA	Background: Reducing the length of hospitalizations can reduce short-term costs, but there are few data on the long-term clinical and economic consequences of early discharge after uncomplicated myocardial infarction. Methods: Using data from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-1) trial, we identified 22,361 patients with acute myocardial infarction who had an uncomplicated course for 72 hours after thrombolysis. Then, using a decision-analytic model, we examined the cost effectiveness of an additional day of hospitalization in this group. We defined incremental survival attributable to another day of monitored hospitalization, on the basis of the rate of resuscitation after cardiac arrest between 72 and 96 hours. Lifetime survival curves for each group in the decision-analytic model were estimated from one-year survival data from GUSTO-1. Results: Of the patients with an uncomplicated course within 72 hours after thrombolysis, 16 had ventricular arrhythmias during the next 24 hours; 13 of these patients (81 percent) survived for at least 24 hours. On average, another 0.006 year of life per patient could be saved by keeping patients with an uncomplicated course in the hospital another day. At a cost of $624 for hospital and physicians' services, extending the hospital stay by another day would cost $105,629 per year of life saved. In sensitivity analyses, it was found that a fourth day of hospitalization would be economically attractive only if its cost could be reduced by more than 50 percent or if a high-risk subgroup could be identified in which the estimated survival benefit would be doubled. Conclusions: Hospitalization of patients with uncomplicated myocardial infarction beyond three days after thrombolysis is economically unattractive by conventional standards. (N Engl J Med 2000;342:749-55.) (C)2000, Massachusetts Medical Society.	Duke Clin Res Inst, Durham, NC 27715 USA; Univ Ziekenhuizen Leuven, Louvain, Belgium; Univ Alberta, Edmonton, AB, Canada; Green Lane Hosp, Auckland 3, New Zealand; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Duke University; KU Leuven; University Hospital Leuven; University of Alberta; Cleveland Clinic Foundation	Newby, LK (corresponding author), Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.	newby001@mc.duke.edu	Peterson, Eric David/ABF-5033-2021	Armstrong, Paul/0000-0002-0460-3445; Mark, Daniel/0000-0001-6340-8087; Topol, Eric/0000-0002-1478-4729				EISENBERG MS, 1991, AM J EMERG MED, V9, P544, DOI 10.1016/0735-6757(91)90108-V; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Gold MR, 1996, COST EFFECTIVENESS H; Grines CL, 1998, J AM COLL CARDIOL, V31, P967, DOI 10.1016/S0735-1097(98)00031-X; JAIN A, 1993, J AM COLL CARDIOL, V22, P1816, DOI 10.1016/0735-1097(93)90763-Q; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Krumholz HM, 1997, AM J CARDIOL, V79, P581, DOI 10.1016/S0002-9149(96)00819-3; Krumholz HM, 1999, JAMA-J AM MED ASSOC, V281, P37; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; MADSEN EB, 1983, CIRCULATION, V68, P9, DOI 10.1161/01.CIR.68.1.9; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MARK DB, 1991, CIRCULATION, V83, P1186, DOI 10.1161/01.CIR.83.4.1186; Mark DB, 2000, CIRCULATION, V101, P366, DOI 10.1161/01.CIR.101.4.366; Mark DB, 1998, CIRCULATION, V97, P1702, DOI 10.1161/01.CIR.97.17.1702; MARK DB, 1995, NEW ENGL J MED, V333, P267; MARK DB, 1997, TXB CARDIOVASCULAR M, P1033; MCNEER JF, 1978, NEW ENGL J MED, V298, P229, DOI 10.1056/NEJM197802022980501; Newby LK, 1996, J AM COLL CARDIOL, V27, P625; Pierard LA, 1999, AM HEART J, V137, P500, DOI 10.1016/S0002-8703(99)70499-0; SANZ G, 1993, J AM COLL CARDIOL, V22, P1795, DOI 10.1016/0735-1097(93)90759-T; Stratmann HG, 1998, AM HEART J, V136, P87, DOI 10.1016/S0002-8703(98)70186-3; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; TOPOL EJ, 1987, AM J CARDIOL, V60, P958, DOI 10.1016/0002-9149(87)90332-8; *TREEAG SOFTW, 1996, DATA 3 0 US MAN	27	98	99	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2000	342	11					749	755		10.1056/NEJM200003163421101	http://dx.doi.org/10.1056/NEJM200003163421101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293HW	10717009				2022-12-28	WOS:000085846900001
J	Loder, N				Loder, N			Unesco 'worse than I imagined,' says new director	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					113	113		10.1038/35004723	http://dx.doi.org/10.1038/35004723			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724135	Bronze			2022-12-28	WOS:000085870900007
J	Schrag, DP				Schrag, DP			Of ice and elephants	NATURE			English	Editorial Material							CLIMATE-CHANGE		Harvard Univ, Dept Earth & Planetary Sci, Lab Geochem Oceanog, Cambridge, MA 02138 USA	Harvard University	Schrag, DP (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, Lab Geochem Oceanog, 20 Oxford St, Cambridge, MA 02138 USA.							Blunier T, 1998, NATURE, V394, P739, DOI 10.1038/29447; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P119, DOI 10.1029/97PA03707; Cane MA, 1998, SCIENCE, V282, P59, DOI 10.1126/science.282.5386.59; Clement AC, 1999, PALEOCEANOGRAPHY, V14, P441, DOI 10.1029/1999PA900013; Croll J., 1875, CLIMATE TIME; Henderson GM, 2000, NATURE, V404, P61, DOI 10.1038/35003541; Imbrie J, 1992, PALEOCEANOGRAPHY, V7, P701, DOI 10.1029/92PA02253; Kim SJ, 1998, SCIENCE, V280, P728, DOI 10.1126/science.280.5364.728; Milankovitch M., 1930, HDB KLIMATOLOGIE, VA, P1; Steig EJ, 1998, SCIENCE, V282, P92, DOI 10.1126/science.282.5386.92; STEPHENS BB, IN PRESS NATURE; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255	12	6	6	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 2	2000	404	6773					23	24		10.1038/35003667	http://dx.doi.org/10.1038/35003667			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716424				2022-12-28	WOS:000085775100024
J	[Anonymous]				[Anonymous]			Albright's last scientific stand	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2000	404	6773					1	1						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	292BW	10716409				2022-12-28	WOS:000085775100001
J	Murphy, AW; Plunkett, PK; Bury, G; Leonard, C; Walsh, J; Lynam, F; Johnson, Z				Murphy, AW; Plunkett, PK; Bury, G; Leonard, C; Walsh, J; Lynam, F; Johnson, Z			Effect of patients seeing a general practitioner in accident and emergency on their subsequent reattendance: cohort study	BRITISH MEDICAL JOURNAL			English	Article							INAPPROPRIATE ATTENDERS; CARE		Natl Univ Ireland Univ Coll Galway, Dept Gen Practice, Galway, Ireland; St James Hosp, Dept Accid & Emergency Med, Dublin 8, Ireland; Natl Univ Ireland Univ Coll Dublin, Dept Gen Practice, Dublin 4, Ireland; Natl Univ Ireland Univ Coll Galway, Dept Psychol, Galway, Ireland; St Jamess Hosp, Informat & Management Syst Dept, Dublin, Ireland; Eastern Hlth Board, Hlth Informat Unit, Dublin, Ireland	Ollscoil na Gaillimhe-University of Galway; Trinity College Dublin; University College Dublin; Ollscoil na Gaillimhe-University of Galway; Trinity College Dublin	Murphy, AW (corresponding author), Natl Univ Ireland Univ Coll Galway, Dept Gen Practice, Galway, Ireland.		Walsh, Jane/AAP-6870-2021; Bury, Gerard/D-2985-2019; Bury, Gerard/J-8813-2019	Walsh, Jane/0000-0001-5476-1348; Bury, Gerard/0000-0002-4441-6724; Bury, Gerard/0000-0002-4441-6724; Murphy, Andrew/0000-0001-5549-8246; Plunkett, Patrick/0000-0003-0714-2717				DALE J, 1995, BRIT MED J, V311, P427, DOI 10.1136/bmj.311.7002.427; Murphy AW, 1996, BRIT MED J, V312, P1135; Murphy AW, 1998, FAM PRACT, V15, P33, DOI 10.1093/fampra/15.1.33; Murphy AW, 1998, FAM PRACT, V15, P23, DOI 10.1093/fampra/15.1.23; Raw M, 1999, BMJ-BRIT MED J, V318, P182, DOI 10.1136/bmj.318.7177.182	5	11	11	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					903	904		10.1136/bmj.320.7239.903	http://dx.doi.org/10.1136/bmj.320.7239.903			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10741996	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086337100022
J	Thomas, DD; Donnelly, CA; Wood, RJ; Alphey, LS				Thomas, DD; Donnelly, CA; Wood, RJ; Alphey, LS			Insect population control using a dominant, repressible, lethal genetic system	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; EXPRESSION	A major modification to the sterile insect technique is described, in which transgenic insects homozygous for a dominant, repressible, female-specific lethal gene system are used. We demonstrate two methods that give the required genetic characteristics in an otherwise wild-type genetic background. The first system uses a sex-specific promoter or enhancer to drive the expression of a repressible transcription factor, which in turn controls the expression of a toxic gene product. The second system uses non-sex-specific expression of the repressible transcription factor to regulate a selectively Lethal gene product. Both methods work efficiently in Drosophila melanogaster, and we expect these principles to be widely applicable to more economically important organisms.	Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Oxford; University of Manchester	Alphey, LS (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, S Parks Rd, Oxford OX1 3PS, England.			Donnelly, Christl/0000-0002-0195-2463; Alphey, Luke/0000-0002-2916-3802				Bello B, 1998, DEVELOPMENT, V125, P2193; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FOSTER GG, 1988, THEOR APPL GENET, V76, P870, DOI 10.1007/BF00273675; Gebauer F, 1998, RNA, V4, P142; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HENDRICHS J, 1995, J APPL ENTOMOL, V119, P371, DOI 10.1111/j.1439-0418.1995.tb01303.x; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KNIPLING EF, 1955, J ECON ENTOMOL, V48, P459, DOI 10.1093/jee/48.4.459; Krafsur ES, 1998, J AGR ENTOMOL, V15, P303; LIDDELL S, 1991, MOL GEN GENET, V230, P219, DOI 10.1007/BF00290671; Matsuo T, 1997, DEVELOPMENT, V124, P2671; ROBINSON A, IN PRESS TRENDS ENTO; ROGERS DJ, 1984, INSECT SCI APPL, V5, P419, DOI 10.1017/S1742758400008766; RONALDSON E, 1995, GENET RES, V66, P9, DOI 10.1017/S0016672300034340; SEAWRIGHT JA, 1978, SCIENCE, V200, P1303, DOI 10.1126/science.663614; TELFER WH, 1991, ANNU REV ENTOMOL, V36, P205, DOI 10.1146/annurev.en.36.010191.001225; THOMAS D, UNPUB	18	407	449	1	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 31	2000	287	5462					2474	2476		10.1126/science.287.5462.2474	http://dx.doi.org/10.1126/science.287.5462.2474			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741964				2022-12-28	WOS:000086202200041
J	Lemon, MA; Aeling, JL				Lemon, MA; Aeling, JL			Images in clinical medicine - Furuncular myiasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Colorado, Hlth Sci Ctr, Denver, CO 80205 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Lemon, MA (corresponding author), Univ Colorado, Hlth Sci Ctr, 4200 E 9th Ave, Denver, CO 80205 USA.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	2000	342	13					937	937		10.1056/NEJM200003303421305	http://dx.doi.org/10.1056/NEJM200003303421305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DC	10738052				2022-12-28	WOS:000086179700005
J	Sheldon, T				Sheldon, T			Dutch insurers flouting law on genetic disease, researchers say	BRITISH MEDICAL JOURNAL			English	News Item																		2000, MEDISCH CONTACT, V10, P360	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					826	826						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731172				2022-12-28	WOS:000086180300020
J	Spurgeon, P; Barwell, F; Kerr, D				Spurgeon, P; Barwell, F; Kerr, D			Waiting times for cancer patients in England after general practitioners' referrals: retrospective national survey	BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Sch Publ Policy, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England; Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Birmingham B15 2TJ, W Midlands, England	University of Birmingham; University of Birmingham	Spurgeon, P (corresponding author), Univ Birmingham, Sch Publ Policy, Hlth Serv Management Ctr, Pk House, Birmingham B15 2RT, W Midlands, England.							Berrino F, 1999, IARC SCI PUBLICATION, V151; Coleman MP., 1999, CANC SURVIVAL TRENDS; National Cancer Institute, 1998, SEER STAT CANC INC P	3	53	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					838	839		10.1136/bmj.320.7238.838	http://dx.doi.org/10.1136/bmj.320.7238.838			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731176	Green Submitted, Bronze			2022-12-28	WOS:000086180300024
J	Trachtenberg, JT; Trepel, C; Stryker, MP				Trachtenberg, JT; Trepel, C; Stryker, MP			Rapid extragranular plasticity in the absence of thalamocortical plasticity in the developing primary visual cortex	SCIENCE			English	Article							MONOCULAR DEPRIVATION; HORIZONTAL CONNECTIONS; OCULAR DOMINANCE; CORTICAL PLASTICITY; BRIEF PERIODS; KITTENS; MAPS; CATS	Monocular deprivation during early postnatal development remodels the circuitry of the primary visual cortex so that most neurons respond poorly to stimuli presented to the deprived eye. This rapid physiological change is ultimately accompanied by a matching anatomical loss of input from the deprived eye. This remodeling is thought to be initiated at the thalamocortical synapse. Ocular dominance plasticity after brief (24 hours) monocular deprivation was analyzed by intrinsic signal optical imaging and by targeted extracellular unit recordings. Deprived-eye responsiveness was lost in the extragranular Layers, whereas normal binocularity in layer IV was preserved. This finding supports the hypothesis that thalamocortical organization is guided by earlier changes at higher stages.	Univ Calif San Francisco, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Stryker, MP (corresponding author), Univ Calif San Francisco, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA.			Stryker, Michael/0000-0003-1546-5831	NEI NIH HHS [EY06824, R37 EY002874, F32 EY006824, R37-EY02874, R37 EY002874-21] Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY006824, R37EY002874] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; DAW NW, 1992, J NEUROPHYSIOL, V67, P197, DOI 10.1152/jn.1992.67.1.197; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; FREEMAN RD, 1982, J NEUROPHYSIOL, V47, P139, DOI 10.1152/jn.1982.47.2.139; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Hess G, 1996, J NEUROPHYSIOL, V75, P1765, DOI 10.1152/jn.1996.75.5.1765; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; MALONEK D, 1990, 20 ANN M SOC NEUR ST; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MITCHELL DE, 1991, PHILOS T R SOC B, V333, P51, DOI 10.1098/rstb.1991.0060; MOVSHON JA, 1977, J NEUROPHYSIOL, V40, P1255, DOI 10.1152/jn.1977.40.6.1255; OLSON CR, 1975, J NEUROPHYSIOL, V38, P26, DOI 10.1152/jn.1975.38.1.26; REITER H, 1986, P NATL ACAD SCI USA, V85, P3623; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; Stryker Michael P., 1999, Journal of Physiology (Cambridge), V515P, p25S	23	183	194	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2029	2032		10.1126/science.287.5460.2029	http://dx.doi.org/10.1126/science.287.5460.2029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720332	Green Accepted			2022-12-28	WOS:000085902800066
J	Cande, SC; Stock, JM; Muller, RD; Ishihara, T				Cande, SC; Stock, JM; Muller, RD; Ishihara, T			Cenozoic motion between East and West Antarctica	NATURE			English	Article							SOUTHERN VICTORIA-LAND; MARIE-BYRD-LAND; TRANSANTARCTIC MOUNTAINS; AUSTRALIAN PLATES; RELATIVE MOTIONS; ROSS SEA; PACIFIC; CONSTRAINTS; TECTONICS; BOUNDARY	The West Antarctic rift system is the result of late Mesozoic and Cenozoic extension between East and West Antarctica, and represents one of the largest active continental rift systems on Earth. But the timing and magnitude of the plate motions leading to Be development of this rift system remain poorly known, because of a lack of magnetic anomaly and fracture zone constraints on seafloor spreading. Here we report on magnetic data, gravity data and swath bathymetry collected in several areas of the south Tasman Sea and northern Boss Sea. These results enable us to calculate mid-Cenozoic rotation parameters for East and West Antarctica. These rotations show that there was roughly 180 km of separation in the western Ross Sea embayment in Eocene and Oligocene time. This episode of extension provides a tectonic setting for several significant Genozoic tectonic events in the Ross Sea embayment including the uplift of the Transantarctic Mountains and the deposition of large thicknesses of Oligocene sediments. Inclusion of this East-West Antarctic motion in the plate circuit linking the Australia, Antarctic and Pacific plates removes a puzzling gap between the Lord Howe rise and Campbell plateau found in previous early Tertiary reconstructions of the New Zealand region. Determination of this East-West Antarctic motion also resolves a long standing controversy regarding the contribution of deformation in this region to the global plate circuit linking the Pacific to the rest of the world.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; CALTECH, Pasadena, CA 91125 USA; Univ Sydney, Sch Geosci, Sydney, NSW 2006, Australia; Geol Survey Japan, Tsukuba, Ibaraki 3058567, Japan	University of California System; University of California San Diego; Scripps Institution of Oceanography; California Institute of Technology; University of Sydney	Cande, SC (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.		Stock, Joann Miriam/AAN-1526-2021; Müller, Dietmar/L-1200-2019	Stock, Joann Miriam/0000-0003-4816-7865; Müller, Dietmar/0000-0002-3334-5764				ACTON GD, 1994, SCIENCE, V263, P1246, DOI 10.1126/science.263.5151.1246; BEHRENDT JC, 1991, TECTONICS, V10, P1257, DOI 10.1029/91TC00868; CANDE SC, 1995, SCIENCE, V270, P947, DOI 10.1126/science.270.5238.947; CANDE SC, 1995, J GEOPHYS RES-SOL EA, V100, P6093, DOI 10.1029/94JB03098; CHANG T, 1987, J GEOPHYS RES, V87, P6319; Cooper A.K., 1987, ANTARCTIC CONTINENTA, V5B, P27; DALZIEL IWD, 1982, TECTONICS, V1, P3, DOI 10.1029/TC001i001p00003; Davey F. J., 1987, ANTARCT RES SER, V68, P167, DOI DOI 10.1029/AR068P0167; DEMETS C, 1988, J GEOPHYS RES-SOLID, V93, P11877, DOI 10.1029/JB093iB10p11877; DIVENERE VJ, 1994, J GEOPHYS RES-SOL EA, V99, P15115, DOI 10.1029/94JB00807; Fielding C.R., 1999, TERRA ANTARTICA, V6; FITZGERALD PG, 1986, EARTH PLANET SC LETT, V81, P67, DOI 10.1016/0012-821X(86)90101-9; FITZGERALD PG, 1992, TECTONICS, V11, P634, DOI 10.1029/91TC02495; Grindley G. W., 1983, Antarctic Earth Science. Fourth International Symposium, P573; HELLINGER SJ, 1981, J GEOPHYS RES, V86, P9312, DOI 10.1029/JB086iB10p09312; HOUTZ R, 1973, J GEOPHYS RES, V78, P3448, DOI 10.1029/JB078i017p03448; Lawver L.A., 1994, TERRA ANTARCT, V1, P545; Lemasurier W., 1990, VOLCANOES ANTARCT PL, V48, P1, DOI DOI 10.1029/AR048P0001; Luyendyk B, 1996, TECTONICS, V15, P122, DOI 10.1029/95TC02524; McAdoo D, 1997, SCIENCE, V276, P556, DOI 10.1126/science.276.5312.556; MOLNAR P, 1975, GEOPHYS J ROY ASTR S, V40, P383, DOI 10.1111/j.1365-246X.1975.tb04139.x; MOLNAR P, 1987, NATURE, V327, P587, DOI 10.1038/327587a0; Royer JY, 1997, SCIENCE, V277, P1268, DOI 10.1126/science.277.5330.1268; ROYER JY, 1991, J GEOPHYS RES-SOLID, V96, P11779, DOI 10.1029/91JB00897; ROYER JY, 1989, J GEOPHYS RES-SOLID, V94, P13755, DOI 10.1029/JB094iB10p13755; Salvini F, 1997, J GEOPHYS RES-SOL EA, V102, P24669, DOI 10.1029/97JB01643; Sandwell DT, 1997, J GEOPHYS RES-SOL EA, V102, P10039, DOI 10.1029/96JB03223; Sato S., 1984, MEMOIRS NATL I POLAR, V33, P66; STOCK J, 1982, J GEOPHYS RES, V87, P4697, DOI 10.1029/JB087iB06p04697; STOCK J, 1987, NATURE, V325, P495, DOI 10.1038/325495a0; SUTHERLAND R, 1995, TECTONICS, V14, P819, DOI 10.1029/95TC00930; TANAHASHI M., 1997, P NIPR S ANT GEOSC, V10, P36; TIKKU AA, 1999, THESIS U CALIF, P162; Tonarini S., 1997, ANTARCTIC REGION GEO, P511; WEISSEL JK, 1977, MAR GEOL, V25, P231, DOI 10.1016/0025-3227(77)90054-8; WEISSEL JK, 1972, ANTARCTIC RESEARCH S, V19, P165; WILSON TJ, 1995, TECTONICS, V14, P531, DOI 10.1029/94TC02441	37	229	236	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					145	150		10.1038/35004501	http://dx.doi.org/10.1038/35004501			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724159				2022-12-28	WOS:000085870900040
J	Greer, AL				Greer, AL			Condensed matter - Too hot to melt	NATURE			English	Editorial Material							PRESSURE		Univ Cambridge, Dept Mat Sci & Met, Cambridge CB2 3QZ, England	University of Cambridge	Greer, AL (corresponding author), Univ Cambridge, Dept Mat Sci & Met, Pembroke St, Cambridge CB2 3QZ, England.		Greer, Lindsay A.L./E-9433-2017; Greer, Alan Lindsay/G-1977-2011					ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; BAUS M, 1987, J STAT PHYS, V48, P1129, DOI 10.1007/BF01009537; HEMLEY RJ, 1988, NATURE, V334, P52, DOI 10.1038/334052a0; MISHIMA O, 1985, NATURE, V314, P76, DOI 10.1038/314076a0; RASTOGI S, 1993, J POLYM SCI POL PHYS, V31, P125, DOI 10.1002/polb.1993.090310202; Rastogi S, 1999, MACROMOLECULES, V32, P8897, DOI 10.1021/ma9912958; Sinkler W, 1997, J MATER RES, V12, P1872, DOI 10.1557/JMR.1997.0257; Tammann G., 1903, KRISTALLISIEREN SCHM, P26; Tammann G., 1925, STATES AGGREGATION; TAMMANN G, 1925, TXB METALLOGRAPHY; TAMMANN G, 1921, LEHRBUCH METALLOGRAP; Vogel R., 1959, HETEROGENEN GLEICHGE	12	77	78	3	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					134	135		10.1038/35004689	http://dx.doi.org/10.1038/35004689			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724150				2022-12-28	WOS:000085870900029
J	Ostermann, A; Waschipky, R; Parak, FG; Nienhaus, GU				Ostermann, A; Waschipky, R; Parak, FG; Nienhaus, GU			Ligand binding and conformational motions in myoglobin	NATURE			English	Article							SPERM WHALE MYOGLOBIN; CARBONMONOXY-MYOGLOBIN; MOLECULAR-DYNAMICS; HEME-PROTEINS; MONOXIDE; CRYSTALLOGRAPHY; SPECTROSCOPY; TRANSITION; SCATTERING; PHOTOLYSIS	Myoglobin, a small globular haem protein that binds gaseous ligands such as O-2, CO and NO reversibly at the haem iron, serves as a model for studying structural and dynamic aspects of protein reactions. Time-resolved spectroscopic measurements after photodissociation of the ligand revealed a complex ligand-binding reaction with multiple kinetic intermediates, resulting from protein relaxation and movements of the ligand within the protein(1-3). To observe the structural changes induced by ligand dissociation, we have carried out X-ray crystallographic investigations of carbon monoxy-myoglobin (MbCO mutant L29W) crystals illuminated below and above 180 K, complemented by time-resolved infrared spectroscopy of CO rebinding. Here we show that below 180 K photodissociated ligands migrate to specific sites within an internal cavity-the distal haem pocket-of an essentially immobilized, frozen protein, from where they subsequently rebind by thermally activated barrier crossing. Upon photodissociation above 180 K. Ligands escape from the distal pocket, aided by protein fluctuations that transiently open exit channels. We recover most of the ligands in a cavity on the opposite side of the haem group.	Univ Ulm, Dept Biophys, D-89069 Ulm, Germany; Tech Univ Munich, Fak Phys E17, D-85747 Garching, Germany; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	Ulm University; Technical University of Munich; University of Illinois System; University of Illinois Urbana-Champaign	Nienhaus, GU (corresponding author), Univ Ulm, Dept Biophys, D-89069 Ulm, Germany.		Nienhaus, Gerd Ulrich/G-8698-2012	Nienhaus, Gerd Ulrich/0000-0002-5027-3192; Ostermann, Andreas/0000-0002-1477-5590				ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, X PLOR VERSION 3 1; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; Hartmann H, 1996, P NATL ACAD SCI USA, V93, P7013, DOI 10.1073/pnas.93.14.7013; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HUANG XH, 1994, NAT STRUCT BIOL, V1, P226, DOI 10.1038/nsb0494-226; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; Nienhaus G. U., 1996, ENCY APPL PHYSICS, V15, P163; NIENHAUS GU, 1989, NATURE, V338, P665, DOI 10.1038/338665a0; NIENHAUS GU, 1992, P NATL ACAD SCI USA, V89, P2902, DOI 10.1073/pnas.89.7.2902; NIENHAUS GU, 1994, BIOCHEMISTRY-US, V33, P13413, DOI 10.1021/bi00249a030; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PARAK F, 1982, J MOL BIOL, V161, P177, DOI 10.1016/0022-2836(82)90285-6; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; RASMUSSEN BF, 1992, NATURE, V357, P423, DOI 10.1038/357423a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Vitkup D, 1997, NAT STRUCT BIOL, V4, P202, DOI 10.1038/nsb0397-202	31	359	361	1	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					205	208		10.1038/35004622	http://dx.doi.org/10.1038/35004622			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724176				2022-12-28	WOS:000085870900057
J	Walter, P; Keenan, R; Schmitz, U				Walter, P; Keenan, R; Schmitz, U			Structural biology - SRP - Where the RNA and membrane worlds meet	SCIENCE			English	Editorial Material							SIGNAL RECOGNITION PARTICLE; SEQUENCE; SUBUNIT		Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Maxygen, Redwood City, CA 94063 USA; Genelab Technol, Redwood City, CA 94063 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Walter, P (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.			Keenan, Robert/0000-0003-1466-0889				Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BUTLER S, 1904, NOT SAD STYGIAN SHOR; GEWIRTH DT, 1995, NAT STRUCT BIOL, V2, P386, DOI 10.1038/nsb0595-386; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Khvorova A, 1999, P NATL ACAD SCI USA, V96, P10649, DOI 10.1073/pnas.96.19.10649; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; Royer WE, 1996, P NATL ACAD SCI USA, V93, P14526, DOI 10.1073/pnas.93.25.14526; Sauter NK, 1998, NAT STRUCT BIOL, V5, P945, DOI 10.1038/2919; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; Schmitz U, 1999, NAT STRUCT BIOL, V6, P634, DOI 10.1038/10683; Schmitz U, 1999, RNA, V5, P1419, DOI 10.1017/S1355838299991458	12	24	25	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1212	1213		10.1126/science.287.5456.1212	http://dx.doi.org/10.1126/science.287.5456.1212			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10712156				2022-12-28	WOS:000085444700033
J	Goldman, LE; Eisenberg, MJ				Goldman, LE; Eisenberg, MJ			Identification and management of patients with failed thrombolysis after acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Review							TRANSLUMINAL CORONARY ANGIOPLASTY; TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; ARTERY BYPASS-SURGERY; ST SEGMENT ELEVATION; RESCUE ANGIOPLASTY; RANDOMIZED TRIAL; ELECTROCARDIOGRAPHIC EVIDENCE; REPERFUSION THERAPY; ADJUNCTIVE THERAPY	Clinical outcome after thrombolytic therapy for acute myocardial infarction is closely related to restoration of flow in the infarct-related artery. Because thrombolytic therapy does not achieve coronary artery patency in 15% to 50% of patients, the early identification and treatment of patients with failed thrombolysis may lead to improved clinical outcomes. Unfortunately, the noninvasive identification of patients with failed thrombolysis continues to be problematic. Reduction in chest pain, decrease in ST-segment elevation, and presence of arrhythmias, although suggestive of reperfusion, are not diagnostic. Biochemical markers may hold promise for improved early identification of failed thrombolysis. In the setting of failed thrombolysis, clinical outcome may be improved by "rescue" percutaneous transluminal coronary angioplasty (PTCA) of the infarct-related artery. Several studies suggest that successful rescue PTCA is associated with high technical success rates and improved clinical outcomes. However, these same studies also suggest that patients with failed rescue PTCA may have higher mortality rates than patients who are treated conservatively. On the basis of current data, if failed thrombolysis is suspected, rescue PTCA should be considered, particularly in patients with anterior myocardial infarction and early presentation. Further investigations are needed to study the role of adjunctive methods such as stenting, glycoprotein IIb/IIIa inhibition, and intraaortic balloon counterpulsation in the setting of rescue PTCA. Because of the relative lack of prospective data in this area, additional studies are urgently needed to help improve the ability to identify and manage patients with failed thrombolysis after acute myocardial infarction.	McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada	McGill University	Eisenberg, MJ (corresponding author), McGill Univ, Jewish Gen Hosp, Div Cardiol, 3755 Cote St Catherine Rd,Suite A-118, Montreal, PQ H3T 1E2, Canada.	marke@epid.jgh.mcgill.ca						ABBOTTSMITH CW, 1990, J AM COLL CARDIOL, V16, P770, DOI 10.1016/S0735-1097(10)80320-1; ABE S, 1994, J AM COLL CARDIOL, V23, P1382, DOI 10.1016/0735-1097(94)90381-6; ANDERSON JL, 1993, CIRCULATION, V87, P1829, DOI 10.1161/01.CIR.87.6.1829; [Anonymous], 1985, NEW ENGL J MED, V312, P932; Antoniucci D, 1998, J AM COLL CARDIOL, V31, P1234, DOI 10.1016/S0735-1097(98)00097-7; BELENKIE I, 1992, CAN J CARDIOL, V8, P357; BRENER SJ, 1997, AM J CARDIOL 4, P24; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CALIFF RM, 1988, CIRCULATION, V77, P1090, DOI 10.1161/01.CIR.77.5.1090; CANNON CP, 1995, J INTERV CARDIOL, V8, P117, DOI 10.1111/j.1540-8183.1995.tb00526.x; Davies CH, 1998, LANCET, V351, P1191, DOI 10.1016/S0140-6736(97)11198-9; DEWOOD MA, 1983, CIRCULATION, V68, P8; DOEVENDANS PA, 1995, AM J CARDIOL, V75, P1206, DOI 10.1016/S0002-9149(99)80763-2; Drenth JPH, 1998, BRIT MED J, V317, P147, DOI 10.1136/bmj.317.7151.147; ELLIS AK, 1988, CIRCULATION, V78, P1352, DOI 10.1161/01.CIR.78.6.1352; ELLIS SG, 1994, CIRCULATION, V90, P2280, DOI 10.1161/01.CIR.90.5.2280; ELLIS SG, 1992, J AM COLL CARDIOL, V19, P681, DOI 10.1016/S0735-1097(10)80292-X; Garot P, 1998, AM J CARDIOL, V82, P554, DOI 10.1016/S0002-9149(98)00409-3; Gibson CM, 1997, AM J CARDIOL, V80, P21, DOI 10.1016/S0002-9149(97)00277-4; Gruberg L, 1998, CARDIOLOGY, V90, P48, DOI 10.1159/000006816; Himbert D, 1998, CATHETER CARDIO DIAG, V44, P371, DOI 10.1002/(SICI)1097-0304(199808)44:4<371::AID-CCD1>3.0.CO;2-1; HOHNLOSER SH, 1991, J AM COLL CARDIOL, V18, P44, DOI 10.1016/S0735-1097(10)80215-3; HOORNTJE JC, 1996, CIRCULATION S1, V94, P570; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; ISHIHARA M, 1991, AM HEART J, V122, P385, DOI 10.1016/0002-8703(91)90990-Y; ISHIHARA M, 1995, AM J CARDIOL, V76, P73, DOI 10.1016/S0002-9149(99)80805-4; Juliard JM, 1999, AM J CARDIOL, V83, P305, DOI 10.1016/S0002-9149(98)00858-3; KARAGOUNIS L, 1992, J AM COLL CARDIOL, V19, P1, DOI 10.1016/0735-1097(92)90043-M; KEREIAKES DJ, 1988, J AM COLL CARDIOL, V11, P899, DOI 10.1016/S0735-1097(98)90043-2; LANGER A, 1995, J AM COLL CARDIOL, V25, P1552, DOI 10.1016/0735-1097(95)00110-P; LAPERCHE T, 1995, CIRCULATION, V92, P2079, DOI 10.1161/01.CIR.92.8.2079; LEE KF, 1988, J THORAC CARDIOV SUR, V95, P216; Lefkovits J, 1996, AM J CARDIOL, V77, P1045, DOI 10.1016/S0002-9149(96)00128-2; LINCOFF AM, 1995, AM J CARDIOL, V75, P871, DOI 10.1016/S0002-9149(99)80678-X; MCKENDALL GR, 1995, AM J CARDIOL, V76, P1108, DOI 10.1016/S0002-9149(99)80315-4; MIYATA M, 1994, J AM COLL CARDIOL, V23, P1009, DOI 10.1016/0735-1097(94)90583-5; MOUNSEY JP, 1995, BRIT HEART J, V74, P348; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; OHMAN EM, 1994, CIRCULATION, V90, P792, DOI 10.1161/01.CIR.90.2.792; OHMAN EM, 1991, AM HEART J, V121, P895, DOI 10.1016/0002-8703(91)90205-V; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; PIRWITZ MJ, 1994, CORONARY ARTERY DIS, V5, P385, DOI 10.1097/00019501-199405000-00004; Rodriguez A, 1998, AM J CARDIOL, V81, P1286, DOI 10.1016/S0002-9149(98)00154-4; Rodriguez AE, 1996, AM J CARDIOL, V77, P685, DOI 10.1016/S0002-9149(97)89200-4; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; Ross AM, 1998, J AM COLL CARDIOL, V31, P1511, DOI 10.1016/S0735-1097(98)00141-7; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Saito S., 1997, Journal of the American College of Cardiology, V29, p390A; SARAN RK, 1990, BRIT HEART J, V64, P113; SHECHTER M, 1992, J AM COLL CARDIOL, V20, P1460, DOI 10.1016/0735-1097(92)90437-R; SIMOONS ML, 1988, LANCET, V1, P199; STEG PG, 1994, AM J CARDIOL, V74, P172; Steinhubl SR, 1997, LANCET, V350, P532, DOI 10.1016/S0140-6736(05)63135-2; Stewart JT, 1998, J AM COLL CARDIOL, V31, P1499, DOI 10.1016/S0735-1097(98)00139-9; Stone GW, 1997, J AM COLL CARDIOL, V29, P1459, DOI 10.1016/S0735-1097(97)00088-0; Stone GW, 1998, J AM COLL CARDIOL, V31, P23, DOI 10.1016/S0735-1097(97)00439-7; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; VOGT A, 1993, J AM COLL CARDIOL, V21, P1391, DOI 10.1016/0735-1097(93)90314-Q; Wong CK, 1999, AM J CARDIOL, V83, P164, DOI 10.1016/S0002-9149(98)00818-2	60	21	24	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 4	2000	132	7					556	565		10.7326/0003-4819-132-7-200004040-00008	http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298FU	10744593				2022-12-28	WOS:000086129300007
J	Bath, PHW; Lees, KR				Bath, PHW; Lees, KR			ABC of arterial and venous disease - Acute stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Nottingham, Nottingham NG7 2RD, England; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland	University of Nottingham; University of Glasgow	Bath, PHW (corresponding author), Univ Nottingham, Nottingham NG7 2RD, England.							Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Bath PMW, 1997, INT J CLIN PRACT, V51, P504; LEES KR, 1998, LANCET S3, V352, P28; *ROYAL COLL PHYS, 1994, STROK AUD PACK	4	34	38	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	2000	320	7239					920	923		10.1136/bmj.320.7239.920	http://dx.doi.org/10.1136/bmj.320.7239.920			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10742005	Green Published			2022-12-28	WOS:000086337100032
J	Howe, R; Christensen-Dalsgaard, J; Hill, F; Komm, RW; Larsen, RM; Schou, J; Thompson, MJ; Toomre, J				Howe, R; Christensen-Dalsgaard, J; Hill, F; Komm, RW; Larsen, RM; Schou, J; Thompson, MJ; Toomre, J			Dynamic variations at the base of the solar convection zone	SCIENCE			English	Article							DIFFERENTIAL ROTATION; INTERIOR; TACHOCLINE; INTERFACE; MODELS; DEPTH; SUN	We have detected changes in the rotation of the sun near the base of its convective envelope, including a prominent variation with a period of 1.3 years at Low latitudes. Such helioseismic probing of the deep solar interior has been enabled by nearly continuous observation of its oscillation modes with two complementary experiments. Inversion of the global-mode frequency splittings reveals that the Largest temporal changes in the angular velocity Omega are of the order of 6 nanohertz and occur above and below the tachocline that separates the sun's differentially rotating convection zone (outer 30% by radius) from the nearly uniformly rotating deeper radiative interior beneath. Such changes are most pronounced near the equator and at high Latitudes and are a substantial fraction of the average 30-nanohertz difference in Omega with radius across the tachocline at the equator. The results indicate variations of rotation close to the presumed site of the solar dynamo, which may generate the ZZ-year cycles of magnetic activity.	Natl Opt Astron Observ, Natl Solar Observ, Tucson, AZ 85726 USA; Aarhus Univ, Inst Phys & Astron, DK-8000 Aarhus C, Denmark; Danish Natl Res Fdn, Theoret Astrophys Ctr, DK-8000 Aarhus C, Denmark; Stanford Univ, Hansen Expt Phys Lab, Stanford, CA 94305 USA; Queen Mary Univ London, Astron Unit, London E1 4NS, England; Univ Colorado, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; Univ Colorado, Dept Astrophys & Planetary Sci, Boulder, CO 80309 USA	National Optical Astronomy Observatory; Aarhus University; Danmarks Grundforskningsfond; Stanford University; University of London; Queen Mary University London; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Howe, R (corresponding author), Natl Opt Astron Observ, Natl Solar Observ, POB 26732, Tucson, AZ 85726 USA.	rhowe@noao.edu		Christensen-Dalsgaard, Jorgen/0000-0001-5137-0966; Howe, Rachel/0000-0002-3834-8585				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Antia HM, 1998, ASTRON ASTROPHYS, V339, P239; Basu S, 1997, MON NOT R ASTRON SOC, V287, P189, DOI 10.1093/mnras/287.1.189; Brun AS, 1999, ASTROPHYS J, V525, P1032, DOI 10.1086/307932; CALIGARI P, 1995, ASTROPHYS J, V441, P886, DOI 10.1086/175410; Charbonneau P, 1999, ASTROPHYS J, V527, P445, DOI 10.1086/308050; Charbonneau P, 1997, ASTROPHYS J, V486, P502, DOI 10.1086/304485; Christensen-Dalsgaard J, 2000, NATO ADV SCI I C-MAT, V544, P59; CHRISTENSENDALSGAARD J, 1985, SCIENCE, V229, P923, DOI 10.1126/science.229.4717.923; CHRISTENSENDALSGAARD J, 1991, ASTROPHYS J, V378, P413, DOI 10.1086/170441; Corbard T, 1998, ASTRON ASTROPHYS, V330, P1149; Corbard T, 1997, ASTRON ASTROPHYS, V324, P298; Dikpati M, 1999, ASTROPHYS J, V512, P417, DOI 10.1086/306748; Elliott JR, 2000, ASTROPHYS J, V533, P546, DOI 10.1086/308643; Elliott JR, 1997, ASTRON ASTROPHYS, V327, P1222; Elliott JR, 1999, ASTROPHYS J, V516, P475, DOI 10.1086/307092; ELLIOTT JR, 1998, ESA, P765; Gilman PA, 1999, ASTROPHYS J, V510, P1018, DOI 10.1086/306609; GOUGH D, 1991, ANNU REV ASTRON ASTR, V29, P627, DOI 10.1146/annurev.aa.29.090191.003211; Gough DO, 1998, NATURE, V394, P755, DOI 10.1038/29472; Gough DO, 1996, ASTROPHYS J, V459, P779, DOI 10.1086/176942; Harvey JW, 1996, SCIENCE, V272, P1284, DOI 10.1126/science.272.5266.1284; HOWARD R, 1980, ASTROPHYS J, V239, pL33, DOI 10.1086/183286; Howe R, 1996, MON NOT R ASTRON SOC, V281, P1385, DOI 10.1093/mnras/281.4.1385; HOWE R, IN PRESS ASTROPHYS J; Kosovichev AG, 1996, ASTROPHYS J, V469, pL61, DOI 10.1086/310253; Kosovichev AG, 1997, AIP CONF PROC, P159, DOI 10.1063/1.51753; Miesch MS, 2000, ASTROPHYS J, V532, P593, DOI 10.1086/308555; PARKER EN, 1993, ASTROPHYS J, V408, P707, DOI 10.1086/172631; RITZWOLLER MH, 1991, ASTROPHYS J, V369, P557, DOI 10.1086/169785; Scherrer PH, 1995, SOL PHYS, V162, P129, DOI 10.1007/BF00733429; SCHOU J, 1994, ASTROPHYS J, V433, P389, DOI 10.1086/174653; Schou J, 1999, ASTROPHYS J, V523, pL181, DOI 10.1086/312279; Schou J, 1998, ASTROPHYS J, V505, P390, DOI 10.1086/306146; SCHOU J, 1998, P IAU S, V185, P199; SPIEGEL EA, 1992, ASTRON ASTROPHYS, V265, P106; Takata M, 1998, ASTROPHYS J, V504, P1035, DOI 10.1086/306094; Thompson MJ, 1996, SCIENCE, V272, P1300, DOI 10.1126/science.272.5266.1300; Tobias SM, 1997, ASTRON ASTROPHYS, V322, P1007; TOOMRE J, IN PRESS SOL PHYS; ULRICH RK, 1998, ESA, P851; WEISS NO, 1994, LECT SOLAR PLANETARY, P59	42	392	402	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2000	287	5462					2456	2460		10.1126/science.287.5462.2456	http://dx.doi.org/10.1126/science.287.5462.2456			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	299MK	10741959				2022-12-28	WOS:000086202200036
J	Kmietowicz, Z				Kmietowicz, Z			Relatives to be told if organs are to be retained after postmortem	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					821	821						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731158				2022-12-28	WOS:000086180300007
J	Adams, MD; Celniker, SE; Holt, RA; Evans, CA; Gocayne, JD; Amanatides, PG; Scherer, SE; Li, PW; Hoskins, RA; Galle, RF; George, RA; Lewis, SE; Richards, S; Ashburner, M; Henderson, SN; Sutton, GG; Wortman, JR; Yandell, MD; Zhang, Q; Chen, LX; Brandon, RC; Rogers, YHC; Blazej, RG; Champe, M; Pfeiffer, BD; Wan, KH; Doyle, C; Baxter, EG; Helt, G; Nelson, CR; Miklos, GLG; Abril, JF; Agbayani, A; An, HJ; Andrews-Pfannkoch, C; Baldwin, D; Ballew, RM; Basu, A; Baxendale, J; Bayraktaroglu, L; Beasley, EM; Beeson, KY; Benos, PV; Berman, BP; Bhandari, D; Bolshakov, S; Borkova, D; Botchan, MR; Bouck, J; Brokstein, P; Brottier, P; Burtis, KC; Busam, DA; Butler, H; Cadieu, E; Center, A; Chandra, I; Cherry, JM; Cawley, S; Dahlke, C; Davenport, LB; Davies, A; de Pablos, B; Delcher, A; Deng, ZM; Mays, AD; Dew, I; Dietz, SM; Dodson, K; Doup, LE; Downes, M; Dugan-Rocha, S; Dunkov, BC; Dunn, P; Durbin, KJ; Evangelista, CC; Ferraz, C; Ferriera, S; Fleischmann, W; Fosler, C; Gabrielian, AE; Garg, NS; Gelbart, WM; Glasser, K; Glodek, A; Gong, FC; Gorrell, JH; Gu, ZP; Guan, P; Harris, M; Harris, NL; Harvey, D; Heiman, TJ; Hernandez, JR; Houck, J; Hostin, D; Houston, DA; Howland, TJ; Wei, MH; Ibegwam, C; Jalali, M; Kalush, F; Karpen, GH; Ke, ZX; Kennison, JA; Ketchum, KA; Kimmel, BE; Kodira, CD; Kraft, C; Kravitz, S; Kulp, D; Lai, ZW; Lasko, P; Lei, YD; Levitsky, AA; Li, JY; Li, ZY; Liang, Y; Lin, XY; Liu, XJ; Mattei, B; McIntosh, TC; McLeod, MP; McPherson, D; Merkulov, G; Milshina, NV; Mobarry, C; Morris, J; Moshrefi, A; Mount, SM; Moy, M; Murphy, B; Murphy, L; Muzny, DM; Nelson, DL; Nelson, DR; Nelson, KA; Nixon, K; Nusskern, DR; Pacleb, JM; Palazzolo, M; Pittman, GS; Pan, S; Pollard, J; Puri, V; Reese, MG; Reinert, K; Remington, K; Saunders, RDC; Scheeler, F; Shen, H; Shue, BC; Siden-Kiamos, I; Simpson, M; Skupski, MP; Smith, T; Spier, E; Spradling, AC; Stapleton, M; Strong, R; Sun, E; Svirskas, R; Tector, C; Turner, R; Venter, E; Wang, AHH; Wang, X; Wang, ZY; Wassarman, DA; Weinstock, GM; Weissenbach, J; Williams, SM; Woodage, T; Worley, KC; Wu, D; Yang, S; Yao, QA; Ye, J; Yeh, RF; Zaveri, JS; Zhan, M; Zhang, GG; Zhao, Q; Zheng, LS; Zheng, XQH; Zhong, FN; Zhong, WY; Zhou, XJ; Zhu, SP; Zhu, XH; Smith, HO; Gibbs, RA; Myers, EW; Rubin, GM; Venter, JC				Adams, MD; Celniker, SE; Holt, RA; Evans, CA; Gocayne, JD; Amanatides, PG; Scherer, SE; Li, PW; Hoskins, RA; Galle, RF; George, RA; Lewis, SE; Richards, S; Ashburner, M; Henderson, SN; Sutton, GG; Wortman, JR; Yandell, MD; Zhang, Q; Chen, LX; Brandon, RC; Rogers, YHC; Blazej, RG; Champe, M; Pfeiffer, BD; Wan, KH; Doyle, C; Baxter, EG; Helt, G; Nelson, CR; Miklos, GLG; Abril, JF; Agbayani, A; An, HJ; Andrews-Pfannkoch, C; Baldwin, D; Ballew, RM; Basu, A; Baxendale, J; Bayraktaroglu, L; Beasley, EM; Beeson, KY; Benos, PV; Berman, BP; Bhandari, D; Bolshakov, S; Borkova, D; Botchan, MR; Bouck, J; Brokstein, P; Brottier, P; Burtis, KC; Busam, DA; Butler, H; Cadieu, E; Center, A; Chandra, I; Cherry, JM; Cawley, S; Dahlke, C; Davenport, LB; Davies, A; de Pablos, B; Delcher, A; Deng, ZM; Mays, AD; Dew, I; Dietz, SM; Dodson, K; Doup, LE; Downes, M; Dugan-Rocha, S; Dunkov, BC; Dunn, P; Durbin, KJ; Evangelista, CC; Ferraz, C; Ferriera, S; Fleischmann, W; Fosler, C; Gabrielian, AE; Garg, NS; Gelbart, WM; Glasser, K; Glodek, A; Gong, FC; Gorrell, JH; Gu, ZP; Guan, P; Harris, M; Harris, NL; Harvey, D; Heiman, TJ; Hernandez, JR; Houck, J; Hostin, D; Houston, DA; Howland, TJ; Wei, MH; Ibegwam, C; Jalali, M; Kalush, F; Karpen, GH; Ke, ZX; Kennison, JA; Ketchum, KA; Kimmel, BE; Kodira, CD; Kraft, C; Kravitz, S; Kulp, D; Lai, ZW; Lasko, P; Lei, YD; Levitsky, AA; Li, JY; Li, ZY; Liang, Y; Lin, XY; Liu, XJ; Mattei, B; McIntosh, TC; McLeod, MP; McPherson, D; Merkulov, G; Milshina, NV; Mobarry, C; Morris, J; Moshrefi, A; Mount, SM; Moy, M; Murphy, B; Murphy, L; Muzny, DM; Nelson, DL; Nelson, DR; Nelson, KA; Nixon, K; Nusskern, DR; Pacleb, JM; Palazzolo, M; Pittman, GS; Pan, S; Pollard, J; Puri, V; Reese, MG; Reinert, K; Remington, K; Saunders, RDC; Scheeler, F; Shen, H; Shue, BC; Siden-Kiamos, I; Simpson, M; Skupski, MP; Smith, T; Spier, E; Spradling, AC; Stapleton, M; Strong, R; Sun, E; Svirskas, R; Tector, C; Turner, R; Venter, E; Wang, AHH; Wang, X; Wang, ZY; Wassarman, DA; Weinstock, GM; Weissenbach, J; Williams, SM; Woodage, T; Worley, KC; Wu, D; Yang, S; Yao, QA; Ye, J; Yeh, RF; Zaveri, JS; Zhan, M; Zhang, GG; Zhao, Q; Zheng, LS; Zheng, XQH; Zhong, FN; Zhong, WY; Zhou, XJ; Zhu, SP; Zhu, XH; Smith, HO; Gibbs, RA; Myers, EW; Rubin, GM; Venter, JC			The genome sequence of Drosophila melanogaster	SCIENCE			English	Review							DNA-REPLICATION; CHROMOSOME DYNAMICS; GENE-EXPRESSION; HETEROCHROMATIN; PROTEINS; FAMILY; PREDICTION; CHROMATIN	The fly Drosophila melanogaster is one of the most intensively studied organisms in biology and serves as a model system for the investigation of many developmental and cellular processes common to higher eukaryotes, including humans. We have determined the nucleotide sequence of nearly all of the similar to 120-megabase euchromatic portion of the Drosophila genome using a whole-genome shotgun sequencing strategy supported by extensive clone-based sequence and a high-quality bacterial artificial chromosome physical map. Efforts are under way to close the remaining gaps; however, the sequence is of sufficient accuracy and Contiguity to be declared substantially complete and to support an initial analysis of genome structure and preliminary gene annotation and interpretation. The genome encodes similar to 13,600 genes, somewhat fewer than the smaller Caenorhabditis elegans genome, but with comparable functional diversity.	Celera Genom, Rockville, MD 20850 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, BDGP, Berkeley, CA 94720 USA; Baylor Coll Med, Dept Mol & Human Genet, Human Genome Sequencing Ctr, Houston, TX 77030 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, BDGP, Berkeley, CA 94720 USA; European Mol Biol Lab, European Bioinformat Inst, Cambridge CB10 1SD, England; Neomorph Inc, Berkeley, CA 94710 USA; Genetixxpress Pty Ltd, Sydney, NSW 2108, Australia; IMIM UPF, Dept Med Informat, Barcelona 08003, Spain; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece; EMBL, EDGP, Heidelberg, Germany; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94710 USA; Genoscope, F-91000 Evry, France; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95618 USA; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; Univ Rennes 2, Fac Med, Sch Med, EDGP,CNRS,UPR 41, F-35043 Rennes, France; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, EDGP, E-28049 Madrid, Spain; Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA; Univ Arizona, Ctr Insect Sci, Tucson, AZ 85721 USA; Univ Montpellier, Sch Med, EDGP, Inst Genet Humaine,CNRS,CRBM, F-34396 Montpellier 5, France; NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; Inst Genom Res, Rockville, MD 20850 USA; Sanger Ctr, EDGP, Cambridge CB10 1SA, England; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; Univ Dundee, Dept Anat & Physiol, EDGP, Dundee DD1 4HN, Scotland; Open Univ, Dept Biol Sci, Milton Keynes MK7 6AA, Bucks, England; Carnegie Inst Sci, HHM Embryol, Baltimore, MD 21210 USA; Motorola Biochip Syst, Tempe, AZ 85284 USA; NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ Calif Berkeley, Howard Hughes Med Inst, BDGP, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Baylor College of Medicine; University of California System; University of California Berkeley; European Molecular Biology Laboratory (EMBL); Pompeu Fabra University; Harvard University; Washington University (WUSTL); Foundation for Research & Technology - Hellas (FORTH); European Molecular Biology Laboratory (EMBL); University of California System; University of California Berkeley; University of California System; University of California Davis; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); Universite de Franche-Comte; Universite Rennes 2; Stanford University; University of California System; University of California Berkeley; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Salk Institute; University of Arizona; University of Arizona; Centre National de la Recherche Scientifique (CNRS); Universite de Franche-Comte; Universite de Montpellier; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); McGill University; University System of Maryland; University of Maryland College Park; J. Craig Venter Institute; Wellcome Trust Sanger Institute; University of Tennessee System; University of Tennessee Health Science Center; University of Dundee; Open University - UK; Carnegie Institution for Science; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Howard Hughes Medical Institute; University of California System; University of California Berkeley	Adams, MD (corresponding author), Celera Genom, 45 W Gude Dr, Rockville, MD 20850 USA.		Weinstock, George M/C-6314-2013; Reinert, Knut/V-3327-2019; Holt, Robert A/C-3303-2009; Ferrando, Josep F Abril/B-3877-2014; Berman, Benjamin P/D-5942-2014; Lasko, Paul/C-6761-2014; BERMAN, BENJAMIN/AAT-3720-2021	Weinstock, George M/0000-0002-2997-4592; Reinert, Knut/0000-0003-3078-8129; Holt, Robert A/0000-0002-7259-1247; Ferrando, Josep F Abril/0000-0001-7793-589X; Berman, Benjamin P/0000-0002-2099-9005; Lasko, Paul/0000-0002-4037-3501; BERMAN, BENJAMIN/0000-0002-2099-9005; Lewis, Suzanna/0000-0002-8343-612X; Benos, Panayiotis/0000-0003-3172-3132; Cherry, J. Michael/0000-0001-9163-5180; Mount, Steve/0000-0003-2748-8205; Rubin, Gerald/0000-0001-8762-8703; Kulp, David/0000-0001-6540-0222; Burtis, Kenneth/0000-0002-9644-3265; Deslattes Mays, Anne/0000-0001-7951-3439; Svirskas, Robert/0000-0001-8374-6008; Worley, Kim/0000-0002-0282-1000; Harris, Michael/0000-0001-8789-0912; Murphy, Lee/0000-0001-6467-7449; Ballew, Richard M/0000-0003-4866-284X; Wortman, Jennifer/0000-0002-8713-1227	Howard Hughes Medical Institute Funding Source: Medline; NHGRI NIH HHS [P50-HG00750] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001005] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000750] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ABRIL JF, IN PRESS BIOINFORMAT; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson B, 1996, BIOTECHNIQUES, V20, P1022; Andersson B, 1996, ANAL BIOCHEM, V236, P107, DOI 10.1006/abio.1996.0138; Ashburner M, 1999, GENETICS, V153, P179; Belotserkovskaya R, 1999, CRIT REV EUKAR GENE, V9, P221, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.70; Biessmann H, 1997, CHROMOSOMA, V106, P63, DOI 10.1007/s004120050225; BRIZUELA BJ, 1994, GENETICS, V137, P803; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burge C. B., 1999, RNA WORLD; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Craig JM, 1999, EXP CELL RES, V246, P249, DOI 10.1006/excr.1998.4278; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; Dunkov BC, 1999, DNA CELL BIOL, V18, P937, DOI 10.1089/104454999314791; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Feger G, 1999, GENE, V227, P149, DOI 10.1016/S0378-1119(98)00596-4; Feyereisen R, 1999, ANNU REV ENTOMOL, V44, P507, DOI 10.1146/annurev.ento.44.1.507; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; Flores C, 1999, P NATL ACAD SCI USA, V96, P2964, DOI 10.1073/pnas.96.6.2964; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fraser CM, 1997, ELECTROPHORESIS, V18, P1207, DOI 10.1002/elps.1150180803; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hartenstein K, 1997, GENETICS, V147, P1755; HARTL DL, 1992, TRENDS GENET, V8, P70, DOI 10.1016/0168-9525(92)90353-6; Henikoff S., 2000, BIOCHIM BIOPHYS ACTA, V1470, P01; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Hoskins RA, 2000, SCIENCE, V287, P2271, DOI 10.1126/science.287.5461.2271; HUANG X, 1995, GENOMICS, V46, P37; Jankowska-Anyszka M, 1998, J BIOL CHEM, V273, P10538, DOI 10.1074/jbc.273.17.10538; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; Kusano K, 1999, GENETICS, V151, P1027; Lambert A, 1998, REPROD NUTR DEV, V38, P69, DOI 10.1051/rnd:19980106; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; LEVIS RW, 1993, MOL GEN GENET, V236, P440, DOI 10.1007/BF00277145; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LOCKE J, UNPUB; LOHE AR, 1993, GENETICS, V134, P1149; Maleszka R, 1997, MICROBIOL-UK, V143, P1781, DOI 10.1099/00221287-143-6-1781; MIKLOS GLG, 1988, P NATL ACAD SCI USA, V85, P2051, DOI 10.1073/pnas.85.7.2051; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; PETER AHG, UNPUB; PIMPINELLI S, 1995, P NATL ACAD SCI USA, V92, P3804, DOI 10.1073/pnas.92.9.3804; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; Rabenstein MD, 1999, P NATL ACAD SCI USA, V96, P4791, DOI 10.1073/pnas.96.9.4791; Reeder RH, 1999, PROG NUCLEIC ACID RE, V62, P293; REESE MG, IN PRESS GENOME RES; Rohrbough J, 1999, NEURON, V23, P55, DOI 10.1016/S0896-6273(00)80753-9; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Rubin GM, 2000, SCIENCE, V287, P2216, DOI 10.1126/science.287.5461.2216; Saffery R, 1999, CHROMOSOME RES, V7, P261, DOI 10.1023/A:1009222729850; Saffery R, 2000, HUM MOL GENET, V9, P175, DOI 10.1093/hmg/9.2.175; Sekelsky JJ, 1999, NUCLEIC ACIDS RES, V27, P3762, DOI 10.1093/nar/27.18.3762; SHAFFER CD, 1994, METHOD CELL BIOL, V44, P185, DOI 10.1016/S0091-679X(08)60913-9; Spradling AC, 1999, GENETICS, V153, P135; Strunnikov AV, 1998, TRENDS CELL BIOL, V8, P454, DOI 10.1016/S0962-8924(98)01370-1; TEARLE RG, 1989, GENETICS, V122, P595; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang Q, 1999, J BIOL CHEM, V274, P10309, DOI 10.1074/jbc.274.15.10309; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Will CL, 1999, SCIENCE, V284, P2003, DOI 10.1126/science.284.5422.2003; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; YAMAMOTO MT, 1990, GENETICS, V125, P821; Yoshiga T, 1999, EUR J BIOCHEM, V260, P414, DOI 10.1046/j.1432-1327.1999.00173.x	82	4480	8378	14	972	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	2000	287	5461					2185	2195		10.1126/science.287.5461.2185	http://dx.doi.org/10.1126/science.287.5461.2185			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731132				2022-12-28	WOS:000086049100033
J	Tropepe, V; Coles, BLK; Chiasson, BJ; Horsford, DJ; Elia, AJ; McInnes, RR; van der Kooy, D				Tropepe, V; Coles, BLK; Chiasson, BJ; Horsford, DJ; Elia, AJ; McInnes, RR; van der Kooy, D			Retinal stem cells in the adult mammalian eye	SCIENCE			English	Article							PIGMENT EPITHELIUM; HOMEOBOX GENE; IN-VITRO; PHOTORECEPTOR DIFFERENTIATION; PROGENITOR PROLIFERATION; NERVOUS-SYSTEM; NEURAL RETINA; RAT RETINA; GROWTH; FOREBRAIN	The mature mammalian retina is thought to lack regenerative capacity. Here, we report the identification of a stem cell in the adult mouse eye, which represents a possible substrate for retinal regeneration. Single pigmented ciliary margin cells clonally proliferate in vitro to form sphere colonies of cells that can differentiate into retinal-specific cell types, including rod photoreceptors, bipolar neurons, and Muller glia. Adult retinal stem cells are localized to the pigmented ciliary margin and not to the central and peripheral retinal pigmented epithelium, indicating that these cells may be homologous to those found in the eye germinal zone of other nonmammalian vertebrates.	Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Res Inst, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Genet Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5S 1A8, Canada; Univ Toronto, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	van der Kooy, D (corresponding author), Univ Toronto, Dept Anat & Cell Biol, Med Sci Bldg 1105,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.							BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; BEACH DH, 1979, J COMP NEUROL, V183, P603, DOI 10.1002/cne.901830308; BODENSTEIN L, 1987, DEV BIOL, V121, P192, DOI 10.1016/0012-1606(87)90152-7; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; COULOMBRE JL, 1965, DEV BIOL, V12, P79, DOI 10.1016/0012-1606(65)90022-9; Craig CG, 1996, J NEUROSCI, V16, P2649; Doetsch F, 1997, J NEUROSCI, V17, P5046; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; HICKS D, 1987, J HISTOCHEM CYTOCHEM, V35, P1317, DOI 10.1177/35.11.3655327; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HOLLYFIELD JG, 1972, J COMP NEUROL, V144, P373, DOI 10.1002/cne.901440308; Ilia M, 1996, DEV BRAIN RES, V95, P176; JOHNS PR, 1977, J COMP NEUROL, V176, P343, DOI 10.1002/cne.901760304; KELLEY MW, 1994, DEVELOPMENT, V120, P2091; KONYUKHOV BV, 1975, DEV BIOL, V45, P1, DOI 10.1016/0012-1606(75)90235-3; KONYUKHOV BV, 1966, FOLIA BIOL-PRAGUE, V12, P116; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Levine EM, 1997, J NEUROSCI, V17, P6277; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Morshead C. M., 1998, Society for Neuroscience Abstracts, V24, P1528; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; PARK CM, 1989, DEV BIOL, V134, P201, DOI 10.1016/0012-1606(89)90089-4; Pittack C, 1997, DEVELOPMENT, V124, P805; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; REH TA, 1987, DEV BIOL, V122, P471, DOI 10.1016/0012-1606(87)90311-3; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E; STRANZNICKY C, 1971, J EMBRYOL EXP MORPH, V27, P67; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Tropepe V, 1997, J NEUROSCI, V17, P7850; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; TRUSLOVE GM, 1962, J EMBRYOL EXP MORPH, V10, P652; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; WETTS R, 1989, DEV BIOL, V136, P254, DOI 10.1016/0012-1606(89)90146-2; ZHANG DR, 1991, VISUAL NEUROSCI, V6, P429, DOI 10.1017/S0952523800001292; ZHAO SL, 1995, BRAIN RES, V677, P300, DOI 10.1016/0006-8993(95)00163-K	42	822	917	3	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2032	2036		10.1126/science.287.5460.2032	http://dx.doi.org/10.1126/science.287.5460.2032			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720333				2022-12-28	WOS:000085902800067
J	Barnett, HJM; Gunton, RV; Eliasziw, M; Fleming, L; Sharpe, B; Gates, P; Meldrum, H				Barnett, HJM; Gunton, RV; Eliasziw, M; Fleming, L; Sharpe, B; Gates, P; Meldrum, H			Causes and severity of ischemic stroke in patients with internal carotid artery stenosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR THROMBI; NONVALVULAR ATRIAL-FIBRILLATION; DATA-BANK; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; MYOCARDIAL-INFARCTION; CEREBRAL INFARCTION; LACUNAR INFARCTS; NATURAL-HISTORY; CARDIAC SOURCES; CLINICAL RISK	Context Therapeutic trials generally have not distinguished outcomes of stroke according to cause. Objective To determine whether stroke and subsequent disability was of large-artery, lacunar, or cardioembolic origin in patients with different degrees of symptomatic and asymptomatic carotid stenosis. Design Observational study of prospective data collected from the North American Symptomatic Carotid Endarterectomy Trial between 1987 and 1997. Setting and Patients A total of 2885 patients from 106 sites in the United States and abroad (median age, 67 years; 70% male) who had symptomatic internal carotid artery stenosis. Main Outcome Measure Risk of stroke from each of the 3 causes at 5 years by territory and degree of stenosis. Results During an average follow-up of 5 years, 749 patients had 1039 strokes, including 112 of cardioembolic, 211 of lacunar, 698 of large-artery, 17 of primary intracerebral hemorrhage, and 1 of subarachnoid hemorrhage origin. The 5-year risk of first stroke after entry into the trial in any territory was 2.6% of cardioembolic cause, 6.9% of lacunar cause, and 19.7% of large-artery cause. The proportion of cardioembolic strokes in the territory of the symptomatic artery was 12.0% and 6.9% in 60% to 69% and 70% to 99% arterial stenosis, respectively; large-artery strokes predominated (78.4%) at 70% to 99% arterial stenosis. With 70% to 99% arterial stenosis, the proportion of strokes of cardioembolic and lacunar origin was 43.5% and 21.6% in asymptomatic and symptomatic arteries, respectively. A total of 67.6% of cardioembolic, 16.7% of lacunar, and 33.0% of large-artery strokes in the territory of the asymptomatic artery were disabling or fatal. Conclusions Our data suggest that approximately 20% and 45% of strokes in the territory of symptomatic and asymptomatic carotid arteries with 70% to 99% stenosis, respectively, are unrelated to carotid stenosis. The cause of subsequent strokes in similar types of patients should be considered when making treatment decisions involving carotid endarterectomy for patients with asymptomatic carotid stenosis, since lacunar and cardioembolic strokes cannot be prevented by endarterectomy.	John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada; Geelong Hosp, Dept Neurosci, Geelong, Vic, Australia; Univ Melbourne, Dept Med, Melbourne, Vic, Australia	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Geelong Hospital; University of Melbourne	Barnett, HJM (corresponding author), John P Robarts Res Inst, POB 5015,100 Perth Dr, London, ON N6A 5K8, Canada.				NINDS NIH HHS [R01-NS-24456] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024456] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; Arboix A, 1997, ACTA NEUROL SCAND, V96, P407; ARBOIX A, 1990, STROKE, V21, P842, DOI 10.1161/01.STR.21.6.842; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Biller J, 1998, STROKE, V29, P554, DOI 10.1161/01.STR.29.2.554; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; BOGOUSSLAVSKY J, 1991, NEUROLOGY, V41, P855, DOI 10.1212/WNL.41.6.855; Bousser MG, 1997, LANCET, V349, P1564, DOI 10.1016/S0140-6736(97)22022-2; BRICKNER ME, 1994, AM J CARDIOL, V74, P391, DOI 10.1016/0002-9149(94)90409-X; Brickner ME, 1996, AM J MED, V100, P465; CAIRNS JA, 1992, CHEST, V102, pS456, DOI 10.1378/chest.102.4_Supplement.456S; CAPLAN LR, 1988, NEUROLOGY, V38, P791, DOI 10.1212/WNL.38.5.791; CHAN K, 1996, CAN J CARDIOL, V12, pE121; CLAVIER I, 1994, STROKE, V25, P2005, DOI 10.1161/01.STR.25.10.2005; Davis BR, 1998, STROKE, V29, P1333, DOI 10.1161/01.STR.29.7.1333; FOULKES MA, 1988, STROKE, V19, P547, DOI 10.1161/01.STR.19.5.547; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P71; HUMPHREY PRD, 1985, POSTGRAD MED J, V61, P1039, DOI 10.1136/pgmj.61.722.1039; Inzitari D, 2000, NEUROLOGY, V54, P660, DOI 10.1212/WNL.54.3.660; KEREN A, 1990, J AM COLL CARDIOL, V15, P790, DOI 10.1016/0735-1097(90)90275-T; KITTNER SJ, 1992, NEUROLOGY, V42, P299, DOI 10.1212/WNL.42.2.299; KITTNER SJ, 1990, NEUROLOGY, V40, P281, DOI 10.1212/WNL.40.2.281; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; MADDEN KP, 1995, NEUROLOGY, V45, P1975, DOI 10.1212/WNL.45.11.1975; MAST H, 1994, STROKE, V25, P776, DOI 10.1161/01.STR.25.4.776; QI A, 1996, CAN J CARDIOL, V12, pE98; Rauh G, 1996, STROKE, V27, P691, DOI 10.1161/01.STR.27.4.691; ROSENTHAL MS, 1992, INT J CARDIOL, V37, P277, DOI 10.1016/0167-5273(92)90256-3; ROTHROCK JF, 1993, ARCH INTERN MED, V153, P619, DOI 10.1001/archinte.153.5.619; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; STRATTON JR, 1988, CIRCULATION, V78, P1388, DOI 10.1161/01.CIR.78.6.1388; STRATTON JR, 1987, CIRCULATION, V75, P1004, DOI 10.1161/01.CIR.75.5.1004; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; Yamamoto H, 1998, J NEUROL NEUROSUR PS, V64, P771, DOI 10.1136/jnnp.64.6.771; Yip PK, 1997, STROKE, V28, P2507, DOI 10.1161/01.STR.28.12.2507; Zabalgoitia M, 1998, J AM COLL CARDIOL, V31, P1622, DOI 10.1016/S0735-1097(98)00146-6; ZABALGOITIA M, 1990, CIRCULATION, V82, P109	44	172	184	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	2000	283	11					1429	1436		10.1001/jama.283.11.1429	http://dx.doi.org/10.1001/jama.283.11.1429			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	290UR	10732932				2022-12-28	WOS:000085696700027
J	Collacott, EA; Zimmerman, JT; White, DM; Rindone, JP				Collacott, EA; Zimmerman, JT; White, DM; Rindone, JP			Bipolar permanent magnets for the treatment of chronic low back pain - A pilot study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VISUAL ANALOG SCALES; QUESTIONNAIRE; MEDICINE	Context Chronic low back pain is one of the most prevalent and costly medical conditions in the United States. Permanent magnets have become a popular treatment for various musculoskeletal conditions, including low back pain, despite little scientific support for therapeutic benefit. Objective To compare the effectiveness of 1 type of therapeutic magnet, a bipolar permanent magnet, with a matching placebo device for patients with chronic low back pain. Design Randomized, double-blind, placebo-controlled, crossover pilot study conducted from February 1998 to May 1999. Setting An ambulatory care physical medicine and rehabilitation clinic at a Veterans Affairs hospital. Patients Nineteen men and 1 woman with stable low back pain of a mean of 19 years' duration, with no past use of magnet therapy for low back pain. Twenty patients were determined to provide 80% power in the study at P<.05 to detect a difference of 2 points (the difference believed to be clinically significant) on a visual analog scale (VAS). Interventions For each patient, real and sham bipolar permanent magnets were applied, on alternate weeks, for 6 hours per day, 3 days per week for 1 week, with a 1-week washout period between the 2 treatment weeks. Main Outcome Measures Pretreatment and posttreatment pain intensity on a VAS; sensory and affective components of pain on the Pain Rating Index (PRI) of the McGill Pain Questionnaire; and range of motion (ROM) measurements of the lumbosacral spine, compared by real vs sham treatment. Results Mean VAS scores declined by 0.49 (SD, 0.96) points for real magnet treatment and by 0.44 (SD, 1.4) points for sham treatment (P = .90). No statistically significant differences were noted in the effect between real and sham magnets with any of the other outcome measures (ROM, P = .66; PRI, P = .55). Conclusions Application of 1 variety of permanent magnet had no effect on our small group of subjects with chronic low back pain.	Vet Affairs Med Ctr, Prescott, AZ 86313 USA; Bioelectromagnet Inst, Reno, NV USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Collacott, EA (corresponding author), Vet Affairs Med Ctr, 500 N Hwy 89, Prescott, AZ 86313 USA.							*AM MED ASS, 1993, GUID EV PERM IMP, P127; Croft PR, 1998, BRIT MED J, V316, P1356, DOI 10.1136/bmj.316.7141.1356; DUNCAN GH, 1989, PAIN, V37, P295, DOI 10.1016/0304-3959(89)90194-2; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fontanarosa PB, 1997, JAMA-J AM MED ASSOC, V278, P2111, DOI 10.1001/jama.1997.03550230087045; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; HOLROYD KA, 1992, PAIN, V48, P301, DOI 10.1016/0304-3959(92)90077-O; HONG CZ, 1982, ARCH PHYS MED REHAB, V63, P462; Kirkaldy-Willis WH., 1983, MANAGING LOW BACK PA; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MONTREY JS, 1999, VET HLTH SYST J, V4, P21; *NIH, 1997, NIH GUIDE, V26, P1; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; RUIBAL S, 1997, USA TODAY       0820, pC3; TURK DC, 1985, PAIN, V21, P385, DOI 10.1016/0304-3959(85)90167-8; Vallbona C, 1997, ARCH PHYS MED REHAB, V78, P1200, DOI 10.1016/S0003-9993(97)90332-4; WEINTRAUB M, 1998, AM J PAIN MANAGE, V8, P9; Weintraub MI, 1999, AM J PAIN MANAGE, V9, P8; WHITE AH, 1995, SPINE CARE DIAGNOS 1, P27; 1998, NBC TELEVISION  0510	20	70	72	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2000	283	10					1322	1325		10.1001/jama.283.10.1322	http://dx.doi.org/10.1001/jama.283.10.1322			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289ND	10714732				2022-12-28	WOS:000085628100029
J	Hjalmarson, A; Goldstein, S; Fagerberg, B; Wedel, H; Waagstein, F; Kjekshus, J; Wikstrand, J; El Allaf, D; Vitovec, J; Aldershvile, J; Halinen, M; Dietz, R; Neuhaus, KL; Janosi, A; Thorgeirsson, G; Dunselman, PHJM; Gullestad, L; Kuch, J; Herlitz, J; Rickenbacher, P; Ball, S; Gottlieb, S; Deedwania, P				Hjalmarson, A; Goldstein, S; Fagerberg, B; Wedel, H; Waagstein, F; Kjekshus, J; Wikstrand, J; El Allaf, D; Vitovec, J; Aldershvile, J; Halinen, M; Dietz, R; Neuhaus, KL; Janosi, A; Thorgeirsson, G; Dunselman, PHJM; Gullestad, L; Kuch, J; Herlitz, J; Rickenbacher, P; Ball, S; Gottlieb, S; Deedwania, P		MERIT-HF Study Grp	Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure - The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS; DOUBLE-BLIND; CARVEDILOL; QUESTIONNAIRE; MORBIDITY; BLOCKADE	Context Results from recent studies on the effects of beta(1)-blockade in patients with heart failure demonstrated a 34% reduction in total mortality. However, the effect of beta(1)-blockade on the frequency of hospitalizations, symptoms, and quality of life in patients with heart failure has not been fully explored. Objective To examine the effects of the beta(1)-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR/XL) on mortality, hospitalization, symptoms, and quality of life in patients with heart failure. Design Randomized, double-blind controlled trial, preceded by a 2-week single-blind placebo run-in period, conducted from February 14, 1997, to October 31, 1998, with a mean follow-up of 1 year. Setting Three hundred thirteen sites in 14 countries. Participants Patients (n = 3991) with chronic heart failure, New York Heart Association (NYHA) functional class II to IV, and election fraction of 0.40 or less who were stabilized with optimum standard therapy. Interventions Patients were randomized to metoprolol CR/XL, 25 mg once per day (NYHA class II), or 12.5 mg once per day (NYHA class III or IV), titrated for 6 to 8 weeks up to a target dosage of 200 mg once per day (n = 1990); or matching placebo (n = 2001). Main Outcome Measures Total mortality or any hospitalization (time to first event), number of hospitalizations for worsening heart failure, and change in NYHA class, by intervention group; quality of life was assessed in a substudy of 741 patients. Results The incidence of all predefined end points was lower in the metoprolol CR/XL group than in the placebo group, including total mortality or all-cause hospitalizations (the prespecified second primary end point; 641 vs 767 events; risk reduction, 19%; 95% confidence interval [CI], 10%-27%; P<.001); total mortality or hospitalizations due to worsening heart failure (311 vs 439 events; risk reduction, 31%; 95% CI, 20%-40%; P<.001), number of hospitalizations due to worsening heart failure (317 vs 451; P<.001); and number of days in hospital due to worsening heart failure (3401 vs 5303 days; P<.001). NYHA functional class, assessed by physicians, and McMaster Overall Treatment Evaluation score, assessed by patients, both improved in the metoprolol CR/XL group compared with the placebo group (P = .003 and P = .009, respectively). Conclusions In this study of patients with symptomatic heart failure, metoprolol CR/XL improved survival, reduced the need for hospitalizations due to worsening heart failure, improved NYHA functional class, and had beneficial effects on patient well-being.	Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, SE-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Cardiol, SE-41345 Gothenburg, Sweden; Nord Sch Publ Hlth, Gothenburg, Sweden; Henry Ford Hosp, Detroit, MI 48202 USA; Univ Oslo, Rikshosp, Dept Med, N-0027 Oslo, Norway; Baerums Sykehus, Baerum, Norway; Ctr Hosp Hutois, Serv Cardiol & Reanimat Cardiaque, Huy, Belgium; Fak Nemocnice, Interni Klin 2, Brno, Czech Republic; Rigshosp, Dept Med B, DK-2100 Copenhagen, Denmark; Kuopio Univ Hosp, Dept Accid & Emergency, SF-70210 Kuopio, Finland; Franz Volhard Klin, Berlin, Germany; Klinikum Kassel, Med Klin 2, Kassel, Germany; Szent Janos Hosp, Budapest, Hungary; Univ Hosp, Landspitalinn, Dept Med, Reykjavik, Iceland; St Ignatius Ziekenhuis, Dept Cardiol, Breda, Netherlands; Warsaw Sch Med, Dept Cardiol, Warsaw, Poland; Kantonsspital Bruderholz, Bruderholz, Switzerland; Leeds Gen Infirm, Inst Cardiovasc Res, Leeds, W Yorkshire, England; Univ Maryland, Div Cardiol, Baltimore, MD 21201 USA; Dept Vet Affairs Med Ctr, Fresno, CA USA	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Henry Ford Health System; Henry Ford Hospital; University of Oslo; National Hospital Norway; University Hospital Brno; Rigshospitalet; University of Copenhagen; Kuopio University Hospital; University of Eastern Finland; Franz-Volhard Clinical Research Center; Klinikum Kassel; University of Hamburg; University Medical Center Hamburg-Eppendorf; Landspitali National University Hospital; Kantonsspital Baselland; Leeds General Infirmary; University of Leeds; University System of Maryland; University of Maryland Baltimore	Fagerberg, B (corresponding author), Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, SE-41345 Gothenburg, Sweden.		Dietz, Rune/F-9154-2015; Dietz, Rune/L-4640-2013	Dietz, Rune/0000-0001-9652-317X; 				ANDERSSON B, 1991, J AM COLL CARDIOL, V18, P1059, DOI 10.1016/0735-1097(91)90767-4; Andersson Bert, 1999, Journal of the American College of Cardiology, V33, p183A; Cohn J N, 1997, J Card Fail, V3, P173, DOI 10.1016/S1071-9164(97)90013-0; Colucci WS, 1996, CIRCULATION, V94, P2800, DOI 10.1161/01.CIR.94.11.2800; Fischer D, 1999, JAMA-J AM MED ASSOC, V282, P1157, DOI 10.1001/jama.282.12.1157; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; Hjalmarson A, 1999, LANCET, V353, P2001; *INT STEER COMM ME, 1997, AM J CARDIOL, V80, P541; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Krum H, 1999, CIRCULATION, V100, P203; Krumholz HM, 1997, ARCH INTERN MED, V157, P99, DOI 10.1001/archinte.157.1.99; Lauriola P, 1998, LANCET, V351, P1180, DOI 10.1016/S0140-6736(05)79124-8; Lechat P, 1999, LANCET, V353, P9; MacMahon S, 1997, LANCET, V349, P375; Narang R, 1996, EUR HEART J, V17, P1390; Packer M, 1996, CIRCULATION, V94, P2793, DOI 10.1161/01.CIR.94.11.2793; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RECTOR TS, 1992, AM HEART J, V124, P1017, DOI 10.1016/0002-8703(92)90986-6; SANDBERG A, 1988, EUR J CLIN PHARMACOL, V33, pS3, DOI 10.1007/BF00578405; Senni M, 1999, ARCH INTERN MED, V159, P29, DOI 10.1001/archinte.159.1.29; *STEER COMM MEMB A, 1999, AM J CARDIOL, V83, pA2; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; Waagstein F., 1998, European Heart Journal, V19, P307	25	949	993	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	2000	283	10					1295	1302		10.1001/jama.283.10.1295	http://dx.doi.org/10.1001/jama.283.10.1295			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	289ND	10714728	Bronze			2022-12-28	WOS:000085628100025
J	Chosidow, O				Chosidow, O			Scabies and pediculosis	LANCET			English	Article							CRUSTED NORWEGIAN SCABIES; HEAD LICE; PERMETHRIN CREAM; EPIDEMIC TYPHUS; IVERMECTIN; LINDANE; EFFICACY; CAPITIS; SCHOOLCHILDREN; RESISTANT	Scabies and pediculosis are ubiquitous, contagious, and debilitating parasitic dermatoses. They have been known since antiquity and are distributed worldwide. Clusters of infestation occur-for example, scabies affecting immunocompromised individuals or patients and staff in hospitals and nursing homes for the elderly, and pediculosis affecting schoolchildren or homeless people. Associations with other disorders are common: infections with human T-cell leukaemia/lymphoma virus I (HTLV-1) and HIV are associated with scabies, and trench fever and exanthematous typhus with pediculosis. Specific forms of scabies, including bullous scabies or localised crusted scabies, may be misdiagnosed. Moreover, definitive parasitic diagnosis can be difficult to obtain, and the value of new techniques remains to be confirmed. Difficulties in management have returned scabies and pediculosis to the limelight.	Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Dept Internal Med, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite	Chosidow, O (corresponding author), Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Dept Internal Med, 47-83 Blvd Hop, F-75013 Paris, France.	olivier.chosidow@psl.ap-hop-paris.fr						ABRAMOWICZ M, 1999, MED LETT DRUGS THER, V41, P73; ALINOVI A, 1994, J AM ACAD DERMATOL, V31, P492, DOI 10.1016/S0190-9622(09)80007-8; Argenziano G, 1997, ARCH DERMATOL, V133, P751, DOI 10.1001/archderm.133.6.751; AUBIN F, 1995, NEW ENGL J MED, V332, P612, DOI 10.1056/NEJM199503023320917; Barkwell R, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63020-6; BIRTWISTLE S, 1995, LANCET, V345, P732; Brouqui P, 1999, NEW ENGL J MED, V340, P184, DOI 10.1056/NEJM199901213400303; BURGESS IF, 1994, CLIN THER, V16, P57; BURGESS IF, 1995, BRIT MED J, V311, P752, DOI 10.1136/bmj.311.7007.752; Burkhart CN, 1998, ARCH PEDIAT ADOL MED, V152, P711; Burkhart KM, 1997, ARCH DERMATOL, V133, P1314, DOI 10.1001/archderm.133.10.1314; BURNS DA, 1998, TXB DERMATOLOGY, P1438; BURNS DA, 1998, TXB DERMATOLOGY, P1458; Capasso L, 1998, LANCET, V351, P992, DOI 10.1016/S0140-6736(00)80058-6; CHOSIDOW O, 1994, LANCET, V344, P1724, DOI 10.1016/S0140-6736(94)92884-3; Choudhary S, 1999, BURNS, V25, P184, DOI 10.1016/S0305-4179(98)00135-1; Chouela EN, 1999, ARCH DERMATOL, V135, P651, DOI 10.1001/archderm.135.6.651; Clore E R, 1993, J Pediatr Health Care, V7, P55, DOI 10.1016/0891-5245(93)90074-R; CODINGTON HB, 1993, LANCET, V342, P677, DOI 10.1016/0140-6736(93)91783-I; COURTIADE C, 1993, ANN DERMATOL VENER, V120, P363; DAMSCHEN DD, 1990, NEW ENGL J MED, V323, P1776; Dawes M, 1999, BRIT MED J, V318, P385, DOI 10.1136/bmj.318.7180.385; del Giudice P, 1999, ARCH DERMATOL, V135, P351, DOI 10.1001/archderm.135.3.351; del Giudice P, 1999, ARCH DERMATOL, V135, P705, DOI 10.1001/archderm.135.6.705; delGiudice P, 1997, J INFECT DIS, V176, P1090, DOI 10.1086/516518; Dennis GA, 1999, CLIN DRUG INVEST, V18, P105, DOI 10.2165/00044011-199918020-00003; Downs AMR, 1999, BRIT J DERMATOL, V141, P508, DOI 10.1046/j.1365-2133.1999.03046.x; DRANCOURT M, 1995, NEW ENGL J MED, V332, P419, DOI 10.1056/NEJM199502163320702; ESTES SA, 1993, SEMIN DERMATOL, V12, P26; Farrell AM, 1998, BRIT J DERMATOL, V138, P192, DOI 10.1046/j.1365-2133.1998.02052.x; Franz TJ, 1996, ARCH DERMATOL, V132, P901, DOI 10.1001/archderm.132.8.901; GILLIS D, 1990, ARCH DERMATOL, V126, P638, DOI 10.1001/archderm.126.5.638; GLAZIOU P, 1994, TROP MED PARASITOL, V45, P253; GLAZIOU P, 1993, TROP MED PARASITOL, V44, P331; Hegazy AA, 1999, INT J DERMATOL, V38, P291, DOI 10.1046/j.1365-4362.1999.00630.x; Hemingway J, 1999, MED VET ENTOMOL, V13, P89, DOI 10.1046/j.1365-2915.1999.00141.x; HOLNESS DL, 1992, ARCH DERMATOL, V128, P1257, DOI 10.1001/archderm.128.9.1257; JORM LR, 1994, J PAEDIATR CHILD H, V30, P151, DOI 10.1111/j.1440-1754.1994.tb00600.x; JUDGE MR, 1995, BRIT J DERMATOL, V132, P116, DOI 10.1111/j.1365-2133.1995.tb08635.x; Lord WD, 1998, J FORENSIC SCI, V43, P1097; Macotela-Ruiz E, 1993, Gac Med Mex, V129, P201; Mancini AJ, 1998, PEDIATR DERMATOL, V15, P337, DOI 10.1046/j.1525-1470.1998.1998015337.x; Meinking TL, 1996, CURR PROBL DERMATOL, V24, P157; Meinking TL, 1996, ARCH DERMATOL, V132, P959, DOI 10.1001/archderm.132.8.959; MEINKING TL, 1995, NEW ENGL J MED, V333, P26, DOI 10.1056/NEJM199507063330105; MEYERS LN, 1988, J AM ACAD DERMATOL, V18, P396, DOI 10.1016/S0190-9622(88)80170-1; MUMCUOGLU KY, 1991, J AM ACAD DERMATOL, V25, P248, DOI 10.1016/0190-9622(91)70190-D; ORKIN M, 1995, CURR PROBL DERMATOL, V22, P105; Pollack RJ, 1999, ARCH PEDIAT ADOL MED, V153, P969, DOI 10.1001/archpedi.153.9.969; Portu JJ, 1996, J AM ACAD DERMATOL, V34, P915, DOI 10.1016/S0190-9622(96)90079-1; Quaterman MJ, 1994, PEDIAT DERMATOL, V11, P264; Raoult D, 1998, LANCET, V352, P353, DOI 10.1016/S0140-6736(97)12433-3; Roux V, 1999, J CLIN MICROBIOL, V37, P596, DOI 10.1128/JCM.37.3.596-599.1999; Schachner LA, 1997, PEDIATR DERMATOL, V14, P409, DOI 10.1111/j.1525-1470.1997.tb00996.x; SCHULTZ MW, 1990, ARCH DERMATOL, V126, P167, DOI 10.1001/archderm.126.2.167; SON WY, 1995, PEDIATR INFECT DIS J, V14, P625; SUNDNES, 1994, LANCET, V343, P244; SUNDNES KO, 1993, LANCET, V342, P1213, DOI 10.1016/0140-6736(93)92190-5; TAPLIN D, 1991, LANCET, V337, P1016, DOI 10.1016/0140-6736(91)92669-S; TAPLIN D, 1990, PEDIATR DERMATOL, V7, P67, DOI 10.1111/j.1525-1470.1990.tb01078.x; Tarasevich I, 1998, LANCET, V352, P1151, DOI 10.1016/S0140-6736(05)79799-3; VANDERSTICHELE RH, 1995, BMJ-BRIT MED J, V311, P604, DOI 10.1136/bmj.311.7005.604; Walton SF, 1999, CLIN INFECT DIS, V29, P1226, DOI 10.1086/313466; Youssef MYM, 1995, AM J TROP MED HYG, V53, P652, DOI 10.4269/ajtmh.1995.53.652; Zias J., 1991, ATIQOT, V20, P167	65	279	296	1	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2000	355	9206					819	826		10.1016/S0140-6736(99)09458-1	http://dx.doi.org/10.1016/S0140-6736(99)09458-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711939				2022-12-28	WOS:000085766900036
J	Dilraj, A; Cutts, FT; de Castro, JF; Wheeler, JG; Brown, D; Roth, C; Coovadia, HM; Bennett, JV				Dilraj, A; Cutts, FT; de Castro, JF; Wheeler, JG; Brown, D; Roth, C; Coovadia, HM; Bennett, JV			Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial	LANCET			English	Article							SUCCESSFUL IMMUNIZATION; ANTIBODY-RESPONSE; MATERNAL ANTIBODY; CHILDREN; INFANTS; RUBELLA; MUMPS; REVACCINATION; ELIMINATION; ADULTS	Background More than one dose of measles vaccine is necessary for the sustained control of measles. The aerosol route is thought to be more immunogenic for booster doses than traditional subcutaneous injections, so we did a randomised comparative trial of aerosol and subcutaneous measles Vaccines in South African schoolchildren. Methods 4327 schoolchildren (aged 5-14 years), assigned by block randomisation of classrooms, received standard titre doses of either Schwarz or Edmonston-Zagreb measles Vaccines subcutaneously or by aerosol. Blood samples for antibody assay were collected before vaccination, at 1 month, and 1 year after vaccination. The main endpoints (antibody titres at 1 month and 1 year) were compared between groups. Findings 992 children had antibody titre data available for all timepoints. 14 (3.6%) of 385 children who received Edmonston-Zagreb vaccine by aerosol were seronegative 1 year after vaccination, compared with 28 (8.6%) of 326 children who received Edmonston-Zagreb subcutaneous vaccine and 39 (13.9%) of 281 children who received Schwarz subcutaneous vaccine. At 1 month, 326 (84.7%) children who received aerosol Edmonston-Zagreb vaccine bad seroconverted, compared with 257 (78.8%) who received subcutaneous Edmonston-Zagreb vaccine and 176 (62.6%) who received subcutaneous Schwarz vaccine. At 1 month, only 116 (22.7%) of 511 children in the Schwarz aerosol group had seroconverted; this aerosol Vaccine had no detectable potency after 2 min of nebulisation. There were no serious side-effects: about 5% of children in each group had a rash within 2 weeks of vaccination. Interpretation An aerosol vaccination method that uses currently available devices and a suitably stable vaccine is effective and acceptable. This form of delivery is adaptable to mass campaigns, avoids the risks associated with injections, and could help measles eradication.	MRC, Ctr Epidemiol Res S Africa, Durban, South Africa; London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England; Mexican Minist Hlth, Mexico City, DF, Mexico; Publ Hlth Lab Serv, Enter & Resp Virus Lab, London, England; Univ Natal, Dept Pediat & Child Hlth, ZA-4001 Durban, South Africa; Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA	University of London; London School of Hygiene & Tropical Medicine; Public Health England; University of Kwazulu Natal; Emory University; Rollins School Public Health	Dilraj, A (corresponding author), MRC, POB 17120, ZA-4013 Congella, South Africa.							Bennett JV, 1999, PEDIATRICS, V104, P1123, DOI 10.1542/peds.104.5.1123; COHN ML, 1994, PEDIATR INFECT DIS J, V13, P34, DOI 10.1097/00006454-199401000-00008; Cutts FT, 1997, BIOLOGICALS, V25, P323, DOI 10.1006/biol.1997.0103; CUTTS FT, 1995, BIOLOGICALS, V23, P95; DEQUADROS CA, 1996, JAMA-J AM MED ASSOC, V275, P244; DESEDATOUS J, 1978, AM J DIS CHILD, V132, P287, DOI 10.1001/archpedi.1978.02120280071015; *EXP PROGR IMM, 1994, WKLY EPID REC, V69, P229; Fernandez Bracho J G, 1990, Salud Publica Mex, V32, P653; Fernandez de Castro J, 1990, Bol Med Hosp Infant Mex, V47, P449; Fernandez-de Castro J, 1997, Salud Publica Mex, V39, P53; FORSEY T, 1991, BIOLOGICALS, V19, P237, DOI 10.1016/1045-1056(91)90042-I; HALSEY NA, 1993, PEDIATR INFECT DIS J, V12, P462, DOI 10.1097/00006454-199306000-00002; Hamm M. S., 1997, APOCALYPSE OKLAHOMA, P345; Hayney M S, 1998, Int J Infect Dis, V2, P143, DOI 10.1016/S1201-9712(98)90116-3; Jaye A, 1998, J INFECT DIS, V177, P1282, DOI 10.1086/515271; KROBER MS, 1991, JAMA-J AM MED ASSOC, V265, P2095, DOI 10.1001/jama.265.16.2095; LiCalsi C, 1999, VACCINE, V17, P1796, DOI 10.1016/S0264-410X(98)00438-1; MARKOWITZ LE, 1992, J INFECT DIS, V166, P205, DOI 10.1093/infdis/166.1.205; NORRBY E, 1962, P SOC EXP BIOL MED, V111, P814, DOI 10.3181/00379727-111-27930; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101; PERRY KR, 1993, J MED VIROL, V40, P235, DOI 10.1002/jmv.1890400312; SABIN AB, 1986, BRIT MED J, V292, P531, DOI 10.1136/bmj.292.6519.531; SABIN AB, 1983, JAMA-J AM MED ASSOC, V249, P2651, DOI 10.1001/jama.249.19.2651; SABIN AB, 1984, JAMA-J AM MED ASSOC, V251, P2363; SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007; WARD BJ, 1995, J INFECT DIS, V172, P1591, DOI 10.1093/infdis/172.6.1591; World Health Organization, 1996, STAT WORLDS VACC IMM, P1	27	126	135	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					798	803		10.1016/S0140-6736(99)95140-1	http://dx.doi.org/10.1016/S0140-6736(99)95140-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711928				2022-12-28	WOS:000085766900012
J	Faris, PL; Kim, SW; Meller, WH; Goodale, RL; Oakman, SA; Hofbauer, RD; Marshall, AM; Daughters, RS; Banerjee-Stevens, D; Eckert, ED; Hartman, BK				Faris, PL; Kim, SW; Meller, WH; Goodale, RL; Oakman, SA; Hofbauer, RD; Marshall, AM; Daughters, RS; Banerjee-Stevens, D; Eckert, ED; Hartman, BK			Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial	LANCET			English	Article							5-HT3 RECEPTOR ANTAGONIST; EATING DISORDERS; GASTROINTESTINAL-TRACT; PAIN SENSITIVITY; THRESHOLDS; ANOREXIA; FIBERS; FERRET	Background Several lines of evidence have led us to postulate that afferent vagal hyperactivity could be an important factor in the pathophysiology of the eating disorder bulimia nervosa. Ondansetron is a peripherally active antagonist of the serotonin receptor 5-HT3, and is marketed for prevention of vagally-mediated emesis caused by cancer chemotherapeutic agents. We investigated the effects of ondansetron on bulimic behaviours in patients with severe and chronic bulimia nervosa in a randomised, double-blind, placebo-controlled study. Methods We enrolled patients with severe bulimia nervosa (at least seven coupled binge/vomit episodes per week). The patients were otherwise healthy, their weight was normal, and they were not receiving medical or psychiatric treatment. During the first week of the study, patients recorded all eating-behaviour events to establish a baseline. In the second week, ail patients received placebo, but were told that they were receiving either placebo or active drug. At the end of this single-blind phase, patients were randomly assigned placebo or ondansetron (24 mg daily) for a further 4 weeks. The primary outcome measure was the number of binge/vomit episodes per week. Data were analysed by intention to treat. Findings 29 patients met the inclusion criteria, of whom 28 completed the baseline study, and 26 completed the single-blind placebo week. 12 patients were assigned placebo, and 14 ondansetron; one patient in the ondansetron group dropped out owing to accidental injury. During the 4th week of double-blind treatment, mean binge/vomit frequencies were 13.2 per week (SD 11.6) in the placebo group, versus 6.5 per week (3.9) in the ondansetron group (estimated difference 6.8 [95% CI 4.0-9.5]; p<0.0001). The ondansetron group also showed significant improvement, compared with the placebo group, in two secondary indicators of disease severity. The amount of time spent engaging in bulimic behaviours was decreased on average by 7.6 h per week in the ondansetron group, compared with 2.3 h in the placebo group (estimated difference 5.1 [0.6-9.7]). Similarly, the number of normal meals and snacks increased on average by 4.3 normal eating episodes without vomiting per week in the ondansetron group, compared with 0.2 in the placebo group (estimated difference 4.1 [1.0-7.2]). Interpretation The decrease in binge-eating and vomiting under ondansetron treatment was not achieved by compensatory changes in eating behaviour such as by a smaller number of binges of longer duration, or by not eating, or by binge-eating without vomiting. instead, our findings indicate a normalisation of the physiological mechanism(s) controlling meat termination and satiation. Since meat termination and satiety are mainly vagally mediated functions, since binge-eating and vomiting produce intense stimulation of vagal afferent fibres, and since ondansetron and other 5-HT3 antagonists decrease afferent vagal activity, the symptom improvement may result from a pharmacological correction of abnormal vagal neurotransmission.	Univ Minnesota, Dept Psychiat, Div Neurosci Res, Sch Med, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Eating Disorders Program, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Surg, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Faris, PL (corresponding author), Univ Minnesota, Dept Psychiat, Div Neurosci Res, Sch Med, Box 392,Mayo Mem Bldg, Minneapolis, MN 55455 USA.		Zamora, Cristina Cuesta/E-2864-2016	Zamora, Cristina Cuesta/0000-0003-1121-9561	NIDCR NIH HHS [P30-DE09737] Funding Source: Medline; NIDDK NIH HHS [NIDDK 50456, R01DK42291] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P30DE009737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050456] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Beck A. T., 1960, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BLACKSHAW LA, 1993, J AUTONOM NERV SYST, V45, P41, DOI 10.1016/0165-1838(93)90360-7; BLUNDELL J, 1991, TRENDS PHARMACOL SCI, V12, P147, DOI 10.1016/0165-6147(91)90532-W; CHAMPANERIA S, 1992, BRIT J PHARMACOL, V106, P693, DOI 10.1111/j.1476-5381.1992.tb14396.x; COOPER Z, 1987, INT J EAT DISORDER, V6, P1, DOI 10.1002/1098-108X(198701)6:1<1::AID-EAT2260060102>3.0.CO;2-9; deZwaan M, 1996, J PSYCHOSOM RES, V41, P65, DOI 10.1016/0022-3999(96)00088-8; Faris PL, 1998, PAIN, V77, P297, DOI 10.1016/S0304-3959(98)00108-0; FARIS PL, 1992, BIOL PSYCHIAT, V32, P462, DOI 10.1016/0006-3223(92)90134-L; FAWCETT J, 1987, PSYCHOPHARMACOL BULL, V23, P309; FREEMAN AJ, 1992, ANTI-CANCER DRUG, V3, P79, DOI 10.1097/00001813-199204000-00001; FUKUI H, 1992, JPN J PHARMACOL, V59, P221, DOI 10.1254/jjp.59.221; Galligan JJ, 1996, BEHAV BRAIN RES, V73, P199; HADIGAN CM, 1992, APPETITE, V18, P233, DOI 10.1016/0195-6663(92)90200-P; HALMI KA, 1991, APPETITE, V16, P219, DOI 10.1016/0195-6663(91)90060-6; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Hartman BK, 1997, ARCH GEN PSYCHIAT, V54, P969; Hsu LKG, 1996, PSYCHIAT CLIN N AM, V19, P681, DOI 10.1016/S0193-953X(05)70375-0; Keel PK, 1997, AM J PSYCHIAT, V154, P313; LAUTENBACHER S, 1991, BIOL PSYCHIAT, V29, P1073, DOI 10.1016/0006-3223(91)90249-L; Morales M, 1996, MOL BRAIN RES, V36, P251, DOI 10.1016/0169-328X(96)88406-3; OHUOHA DC, 1994, BRAIN RES, V637, P222, DOI 10.1016/0006-8993(94)91236-X; RANDICH A, 1992, BRAIN RES REV, V17, P77, DOI 10.1016/0165-0173(92)90009-B; REYNOLDS DJM, 1991, BRAIN RES, V565, P231, DOI 10.1016/0006-8993(91)91654-J; SIMPSON KH, 1992, PSYCHOPHARMACOLOGY, V109, P497, DOI 10.1007/BF02247730; SPITZER R. L., 1994, STRUCTURED CLIN INTE	28	98	114	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					792	797		10.1016/S0140-6736(99)09062-5	http://dx.doi.org/10.1016/S0140-6736(99)09062-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	291YG	10711927				2022-12-28	WOS:000085766900011
J	Law, M				Law, M			Plant sterol and stanol margarines and health	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SITOSTANOL-ESTER-MARGARINE; CHOLESTEROL-LOWERING AGENTS; ISCHEMIC-HEART-DISEASE; SERUM-CHOLESTEROL; HYPERCHOLESTEROLEMIC SUBJECTS; DIETARY SITOSTANOL; REDUCTION; PHYTOSTEROLS; ABSORPTION; PHENOTYPES		St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Law, M (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England.	M.R.Law@mds.qmw.ac.uk						Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; BEST MM, 1954, CIRCULATION, V10, P201, DOI 10.1161/01.CIR.10.2.201; Chisholm A, 1996, BRIT MED J, V312, P931, DOI 10.1136/bmj.312.7036.931; COLHOUN H, 1996, HLTH SURVEY ENGLAND; DENKE MA, 1995, AM J CLIN NUTR, V61, P392, DOI 10.1093/ajcn/61.2.392; GLUECK CJ, 1991, METABOLISM, V40, P842, DOI 10.1016/0026-0495(91)90013-M; Gould AL, 1998, CIRCULATION, V97, P946; Gylling H, 1997, CIRCULATION, V96, P4226; Gylling H, 1999, METABOLISM, V48, P575, DOI 10.1016/S0026-0495(99)90053-7; GYLLING H, 1994, DIABETOLOGIA, V37, P773, DOI 10.1007/s001250050178; Hallikainen MA, 1999, EUR J CLIN NUTR, V53, P966, DOI 10.1038/sj.ejcn.1600882; Hallikainen MA, 1999, AM J CLIN NUTR, V69, P403; Heinemann T, 1988, Agents Actions Suppl, V26, P117; HEINEMANN T, 1991, EUR J CLIN PHARMACOL, V40, pS59, DOI 10.1007/BF01409411; Hendriks HFJ, 1999, EUR J CLIN NUTR, V53, P319, DOI 10.1038/sj.ejcn.1600728; Hepburn PA, 1999, FOOD CHEM TOXICOL, V37, P521, DOI 10.1016/S0278-6915(99)00030-7; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Jones PJH, 1997, CAN J PHYSIOL PHARM, V75, P217, DOI 10.1139/cjpp-75-3-217; Jones PJH, 1998, METABOLISM, V47, P751, DOI 10.1016/S0026-0495(98)90041-5; Jones PJH, 1999, AM J CLIN NUTR, V69, P1144; LAW MR, 1994, EUR J CLIN NUTR, V48, P305; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEES AM, 1977, ATHEROSCLEROSIS, V28, P325, DOI 10.1016/0021-9150(77)90180-0; MIETTINEN TA, 1994, ATHEROSCLEROSIS, V105, P217, DOI 10.1016/0021-9150(94)90052-3; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; Niinikoski H., 1997, Scandinavian Journal of Nutrition/Naringsforskning, V41, P9; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Plat J, 2000, ATHEROSCLEROSIS, V148, P101, DOI 10.1016/S0021-9150(99)00261-0; SUGANO M, 1977, J NUTR, V107, P2011, DOI 10.1093/jn/107.11.2011; VANHANEN HT, 1994, CLIN SCI, V87, P61, DOI 10.1042/cs0870061; VANHANEN HT, 1993, J LIPID RES, V34, P1535; Weststrate JA, 1998, EUR J CLIN NUTR, V52, P334, DOI 10.1038/sj.ejcn.1600559; WOOD R, 1993, J LIPID RES, V34, P1	33	482	500	0	58	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	2000	320	7238					861	864		10.1136/bmj.320.7238.861	http://dx.doi.org/10.1136/bmj.320.7238.861			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731187	Green Published			2022-12-28	WOS:000086180300033
J	Sharp, D				Sharp, D			Aids to navigation	LANCET			English	Editorial Material									The Lancet, London WC1X 8RR, England		Sharp, D (corresponding author), The Lancet, London WC1X 8RR, England.							Clayton NS, 1998, NEUROPHARMACOLOGY, V37, P441, DOI 10.1016/S0028-3908(98)00037-9; Gron G, 2000, NAT NEUROSCI, V3, P404, DOI 10.1038/73980; MAGUIRE EA, 2000, NAVIGATION RELATED S	3	2	2	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1034	1034		10.1016/S0140-6736(00)02032-8	http://dx.doi.org/10.1016/S0140-6736(00)02032-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744087				2022-12-28	WOS:000086380800008
J	Friedmann, T				Friedmann, T			Medical ethics - Principles for human gene therapy studies	SCIENCE			English	Article									Univ Calif San Diego, Sch Med, Program Human Gene Therapy, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Friedmann, T (corresponding author), Univ Calif San Diego, Sch Med, Program Human Gene Therapy, La Jolla, CA 92093 USA.	tfriedmann@ucsd.edu						PATTERSON A, 1999, COMMUNICATION   1122; *RAC, 1999, MIN RAC M 5 SEP; ZOON K, 1999, COMMUNICATION   1105	3	32	61	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2163	+		10.1126/science.287.5461.2163	http://dx.doi.org/10.1126/science.287.5461.2163			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10744537				2022-12-28	WOS:000086049100022
J	Lai, HC; FitzSimmons, SC; Allen, DB; Kosorok, MR; Rosenstein, BJ; Campbell, PW; Farrell, PM				Lai, HC; FitzSimmons, SC; Allen, DB; Kosorok, MR; Rosenstein, BJ; Campbell, PW; Farrell, PM			Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALED CORTICOSTEROIDS; BECLOMETHASONE DIPROPIONATE; PREPUBERTAL CHILDREN; ASTHMA; SUPPRESSION; ADOLESCENTS; MORTALITY; THERAPY; GENDER; MILD	Background: It is uncertain whether the growth impairment that occurs in children during long-term treatment with glucocorticoids persists after the medication is discontinued and ultimately affects adult height. Methods: We evaluated growth six to seven years after alternate-day treatment with prednisone had been discontinued in 224 children 6 to 14 years of age with cystic fibrosis who had participated in a multicenter trial of this therapy from 1986 through 1991. Of the children, 151 had been randomly assigned to receive prednisone (1 or 2 mg per kilogram of body weight) and 73 to receive placebo. We obtained data on growth up to 1997 from the Cystic Fibrosis Foundation Patient Registry and standardized the data to sex- and age-specific norms from the National Center for Health Statistics. We used z scores to compare growth patterns among treatment groups. Results: In 1997, 68 percent of the patients were 18 years of age or older. The z scores for height declined during prednisone therapy; catch-up growth began two years after treatment with prednisone was discontinued. Among the boys, the z scores for height in those treated with prednisone remained lower than the scores for those who received placebo (P=0.02). The mean heights for boys 18 years of age or older were 4 cm less in the prednisone groups than in the placebo group, an equivalent of 13 percentile points (P=0.03). Among the girls, differences in height between those who were treated with prednisone and those who received placebo were no longer present two to three years after prednisone therapy was discontinued. Conclusions: Among children with cystic fibrosis who have received alternate-day treatment with prednisone, boys, but not girls, have persistent growth impairment after treatment is discontinued. (N Engl J Med 2000;342:851-9.) (C)2000, Massachusetts Medical Society.	Univ Wisconsin, Sch Med, Dept Pediat, Clin Sci Ctr K6419, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Biostat & Med Informat, Madison, WI 53792 USA; Cyst Fibrosis Fdn, Bethesda, MD USA; Johns Hopkins Univ, Sch Med, Eudowood Div Pediat Resp Sci, Baltimore, MD USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Cystic Fibrosis Foundation; Johns Hopkins University	Lai, HC (corresponding author), Univ Wisconsin, Sch Med, Dept Pediat, Clin Sci Ctr K6419, 600 Highland Ave, Madison, WI 53792 USA.		Kosorok, Michael/ABB-7427-2021		NIDDK NIH HHS [2R01 DK34108] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034108] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen DB, 1996, ENDOCRIN METAB CLIN, V25, P699, DOI 10.1016/S0889-8529(05)70348-0; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; Allen DB, 1998, ACTA PAEDIATR, V87, P123, DOI 10.1080/08035259850157516; AUERBACH HS, 1985, LANCET, V2, P686; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; BERGER M, 1991, CLIN REV ALLERG, V9, P119; BRITTON JR, 1989, BRIT MED J, V298, P483, DOI 10.1136/bmj.298.6672.483; BYARD PJ, 1994, ANN HUM BIOL, V21, P229, DOI 10.1080/03014469400003242; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Dean A.G., 1994, EPI INFO VERSION 6 W; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P749, DOI 10.1093/ajcn/46.5.749; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; EIGEN H, 1995, J PEDIATR-US, V126, P515, DOI 10.1016/S0022-3476(95)70343-8; GREENBERGER PA, 1986, ANN ALLERGY, V56, P444; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; Heuck C, 1998, J PEDIATR-US, V133, P608, DOI 10.1016/S0022-3476(98)70098-8; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; LAM CN, 1968, ARCH DIS CHILD, V43, P589, DOI 10.1136/adc.43.231.589; LANDON C, 1984, AM J DIS CHILD, V138, P388, DOI 10.1001/archpedi.1984.02140420054017; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LLOYDSTI.JD, 1974, PEDIATRICS, V53, P678; MARTHA PM, 1992, J CLIN ENDOCR METAB, V74, P336, DOI 10.1210/jc.74.2.336; MERKUS PJFM, 1993, PEDIATRICS, V91, P1121; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; Oermann CM, 1999, CHEST, V115, P1053, DOI 10.1378/chest.115.4.1053; PANTIN CFA, 1986, THORAX, V41, P34, DOI 10.1136/thx.41.1.34; Patel L, 1998, ARCH DIS CHILD, V79, P169, DOI 10.1136/adc.79.2.169; PRICE JF, 1993, ARCH DIS CHILD, V68, P719, DOI 10.1136/adc.68.6.719; Roemmich JN, 1998, J CLIN ENDOCR METAB, V83, P1440, DOI 10.1210/jc.83.5.1440; Rosenfeld M, 1997, AM J EPIDEMIOL, V145, P794; Tanner J. M., 1986, HUMAN GROWTH, P167; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; Todd G, 1996, LANCET, V348, P27, DOI 10.1016/S0140-6736(96)03339-9; Zeger, 1994, ANAL LONGITUDINAL DA, P146	35	131	133	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	2000	342	12					851	859		10.1056/NEJM200003233421204	http://dx.doi.org/10.1056/NEJM200003233421204			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296FU	10727589				2022-12-28	WOS:000086014100004
J	Phillips, BL; Casey, WH; Karlsson, M				Phillips, BL; Casey, WH; Karlsson, M			Bonding and reactivity at oxide mineral surfaces from model aqueous complexes	NATURE			English	Article							PRESSURE NMR KINETICS; MAGNETIC-RESONANCE; BASE HYDROLYSIS; WATER EXCHANGE; DISSOLUTION; ALUMINUM(III); SPECTROSCOPY; SUBSTITUTION; ADSORPTION; MECHANISMS	The kinetic stability of oxide surfaces affects a broad range of physical phenomena, including mineral dissolution(1-3) and sorption reactions(4), stable-isotope fractionation(5), and catalyst support degradation(6). Our knowledge of the rates of these processes derives mostly from the rates of net mass transfer between the bulk solid and fluid phases. But from such data it is difficult to determine rates of elementary steps that are needed to test theoretical models. Here we determine the rates of oxygen exchange between an aqueous fluid and specific sites on the 'Al(13)' polyoxocation-AlO(4)Al(12)(OH)(24)(H(2)O)(12)(7+)- the structure of which closely resembles the surfaces of some Al-(hydr)oxide minerals in soils and catalyst supports. Extrapolation of these data to 298 K (and near pH 5.3) yields half-lives for oxygen on the complex that range from similar to 0.6 milliseconds for bound water to 41 seconds and 13 hours for the two distinct, but structurally similar, bridging hydroxyls. This surprisingly large range of labilities (similar to 10(7)) indicates that reactivity is very sensitive to molecular structure. Moreover, these results indicate that well chosen aqueous complexes provide important information to relate bonding to reactivity at mineral surfaces.	Univ Calif Davis, Dept Land Air & Water Resources, Davis, CA 95616 USA; Univ Calif Davis, Dept Geol, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Casey, WH (corresponding author), Univ Calif Davis, Dept Land Air & Water Resources, Davis, CA 95616 USA.	whcasey@ucdavis.edu						AKITT JW, 1988, J CHEM SOC DALTON, P1347, DOI 10.1039/dt9880001347; BRADLEY SM, 1993, J COLLOID INTERF SCI, V159, P405, DOI 10.1006/jcis.1993.1340; Casey WH, 1996, NATURE, V381, P506, DOI 10.1038/381506a0; CASEY WH, 1992, NATURE, V355, P147; FU G, 1991, CHEM MATER, V3, P602, DOI 10.1021/cm00016a009; FURRER G, 1992, J COLLOID INTERF SCI, V149, P56, DOI 10.1016/0021-9797(92)90391-X; Furrer G, 1999, GEOCHIM COSMOCHIM AC, V63, P3069, DOI 10.1016/S0016-7037(99)00234-3; HACHIYA K, 1984, J PHYS CHEM-US, V88, P27, DOI 10.1021/j150645a008; HELM L, 1985, INORG CHEM, V24, P1719, DOI 10.1021/ic00205a026; Hiemstra T, 1999, LANGMUIR, V15, P8045, DOI 10.1021/la9903604; HUGICLEARY D, 1985, HELV CHIM ACTA, V68, P545, DOI 10.1002/hlca.19850680302; JOHANSSON G, 1963, ARK KEMI, V20, P305; KARLSSON HR, 1990, GEOCHIM COSMOCHIM AC, V54, P1359, DOI 10.1016/0016-7037(90)90161-D; Kubicki JD, 1997, GEOCHIM COSMOCHIM AC, V61, P1031, DOI 10.1016/S0016-7037(96)00399-7; Lambert JF, 1997, STUD SURF SCI CATAL, V109, P91; LEE MA, 1994, J PHYS CHEM-US, V98, P8641, DOI 10.1021/j100086a010; MERBACH AE, 1987, PURE APPL CHEM, V59, P161, DOI 10.1351/pac198759020161; Nordin JP, 1998, INORG CHEM, V37, P4760, DOI 10.1021/ic980333l; Parker WO, 1997, INORG CHEM, V36, P571, DOI 10.1021/ic960635s; Richens DT., 1997, CHEM AQUA IONS; Sigg L., 1992, CHEM SOLID WATER INT, P369; SPRINGBORG J, 1988, ADV INORG CHEM RAD, V32, P55, DOI 10.1016/S0898-8838(08)60231-7; Sullivan DJ, 1999, GEOCHIM COSMOCHIM AC, V63, P1471, DOI 10.1016/S0016-7037(99)00113-1; THOMPSON AR, 1987, J CHEM SOC DALTON, P2317, DOI 10.1039/dt9870002317; WEHRLI B, 1990, AQUAT SCI, V52, P3, DOI 10.1007/BF00878239; XIAO YT, 1994, GEOCHIM COSMOCHIM AC, V58, P379	26	104	111	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					379	382		10.1038/35006036	http://dx.doi.org/10.1038/35006036			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746722				2022-12-28	WOS:000086119000047
J	Sirenko, AA; Bernhard, C; Golnik, A; Clark, AM; Hao, JH; Si, WD; Xi, XX				Sirenko, AA; Bernhard, C; Golnik, A; Clark, AM; Hao, JH; Si, WD; Xi, XX			Soft-mode hardening in SrTiO3 thin films	NATURE			English	Article							TEMPERATURE; DEPENDENCE; THICKNESS	Understanding the behaviour of the dielectric constant in ferroelectric thin films remains a challenging problem, These ferroelectric materials have high static dielectric constants, and so are important for their applications in high-storage-density capacitor structures such as dynamic random access memory (DRAM)(1), But the dielectric constant tends to be significantly reduced in thin films, thereby limiting the potential benefit of ferroelectrics for memory devices(2). Extensive studies have shown that this phenomenon could be caused by a 'dead layer' of very low dielectric constant between the ferroelectric film and the electrode(2,3). And, although very few direct measurements are in fact available, it has been recognized that the lattice dynamical properties in the thin films should also play a key role in the reduction(2) of the dielectric constant. Here we report far-infrared ellipsometry and low-frequency dielectric measurements in SrTiO3 thin films, which demonstrate that the Lyddane-Sachs-Teller relation between the optical-phonon eigenfrequencies and the dielectric constant is fully maintained, as is the case in the bulk material. This indicates that the dramatic reduction of the dielectric constant is a consequence of a profound change of the lattice dynamical properties, in particular of the reduced softening of its lowest optical-phonon mode. Our results therefore provide a better understanding of the fundamental limitations of the dielectric constant values in ferroelectric thin films.	Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Max Planck Society	Sirenko, AA (corresponding author), Penn State Univ, Dept Phys, University Pk, PA 16802 USA.	sirenko@phys.psu.edu	Xi, Xiaoxing/D-8498-2011; Hao, Jianhua/J-2806-2012; Golnik, Andrzej/Q-9736-2018	Hao, Jianhua/0000-0002-6186-5169; Golnik, Andrzej/0000-0003-3509-9509; Bernhard, Christian/0000-0002-9957-3487; Xi, Xiaoxing/0000-0002-3808-1358				AKIMOV IA, UNPUB PHYS REV LETT; Basceri C, 1997, J APPL PHYS, V82, P2497, DOI 10.1063/1.366062; BERREMAN DW, 1963, PHYS REV, V130, P2193, DOI 10.1103/PhysRev.130.2193; Black CT, 1999, IEEE T ELECTRON DEV, V46, P776, DOI 10.1109/16.753713; COCHRAN W, 1960, ADV PHYS, V9, P387, DOI 10.1080/00018736000101229; Fedorov I, 1998, FERROELECTRICS, V208, P413, DOI 10.1080/00150199808014890; Frey MH, 1996, PHYS REV B, V54, P3158, DOI 10.1103/PhysRevB.54.3158; Fuchs D, 1999, J APPL PHYS, V85, P7362, DOI 10.1063/1.369363; Henn R, 1998, THIN SOLID FILMS, V313, P642, DOI 10.1016/S0040-6090(97)00970-X; Kostic P, 1998, PHYS REV LETT, V81, P2498, DOI 10.1103/PhysRevLett.81.2498; Kotecki DE, 1999, IBM J RES DEV, V43, P367, DOI 10.1147/rd.433.0367; Li HC, 1998, APPL PHYS LETT, V73, P464, DOI 10.1063/1.121901; Lippmaa M, 1999, APPL PHYS LETT, V74, P3543, DOI 10.1063/1.124155; MITSUI T, 1981, LANDOLTBORNSTEIN N A, V16, P328; MULLER KA, 1979, PHYS REV B, V19, P3593, DOI 10.1103/PhysRevB.19.3593; SERVOIN JL, 1980, PHYS REV B, V22, P5501, DOI 10.1103/PhysRevB.22.5501; SHIRANE G, 1969, PHYS REV, V177, P858, DOI 10.1103/PhysRev.177.858; Sirenko AA, 1999, PHYS REV LETT, V82, P4500, DOI 10.1103/PhysRevLett.82.4500; Streiffer SK, 1999, J APPL PHYS, V86, P4565, DOI 10.1063/1.371404; Vendik O. G., 1994, Physics of the Solid State, V36, P1778; VOGT H, 1995, PHYS REV B, V51, P8046, DOI 10.1103/PhysRevB.51.8046; Zhou C, 1997, J APPL PHYS, V82, P3081, DOI 10.1063/1.366147	22	228	231	4	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2000	404	6776					373	376		10.1038/35006023	http://dx.doi.org/10.1038/35006023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746720				2022-12-28	WOS:000086119000045
J	Talan, DA; Stamm, WE; Hooton, TM; Moran, GJ; Burke, T; Iravani, A; Reuning-Scherer, J; Church, DA				Talan, DA; Stamm, WE; Hooton, TM; Moran, GJ; Burke, T; Iravani, A; Reuning-Scherer, J; Church, DA			Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTIONS; THERAPY; SUSCEPTIBILITY; AMPICILLIN	Context The optimal antimicrobial regimen and treatment duration for acute uncomplicated pyelonephritis are unknown. Objective To compare the efficacy and safety of a 7-day ciprofloxacin regimen and a 14-day trimethoprim-sulfamethoxazole regimen for the treatment of acute pyelonephritis in women. Design Randomized, double-blind comparative trial conducted from October 1994 through January 1997. Setting Twenty-five outpatient centers in the United States. Patients Of 378 enrolled premenopausal women aged at least 18 years with clinical diagnosis of acute uncomplicated pyelonephritis, 255 were included in the analysis. Other individuals were excluded for no baseline causative organism, inadequate receipt of study drug, loss to follow-up, no appropriate cultures, and other reasons. Interventions Patients were randomized to oral ciprofloxacin, 500 mg twice per day for 7 days (with or without an initial 400-mg intravenous dose) followed by placebo for 7 days (n = 128 included in analysis) vs trimethoprim-sulfamethoxazole, 160/800 mg twice per day for 14 days (with or without intravenous ceftriaxone, 1 g) (n = 127 included in the analysis). Main Outcome Measure Continued bacteriologic and clinical cure, such that alternative antimicrobial drugs were not required, among evaluable patients through the 4- to 11-day posttherapy visit, compared by treatment group. Results At 4 to 11 days posttherapy, bacteriologic cure rates were 99% (112 of 113) for the ciprofloxacin regimen and 89% (90 of 101) for the trimethoprimsulfamethoxazole regimen (95% confidence interval [CI] for difference, 0.04-0.16; P =.004). Clinical cure rates were 96% (109 of 113) for the ciprofloxacin regimen and 83% (92 of 111) for the trimethoprim-sulfamethoxazole regimen (95% CI, 0.06-0.22; P =.002), Escherichia coli, which caused more than 90% of infections, was more frequently resistant to trimethoprim-sulfamethoxazole (18%) than to ciprofloxacin (0%; P<.001). Among trimethoprim-sulfamethoxazole-treated patients, drug resistance was associated with greater bacteriologic and clinical failure rates (P<.001 for both). Drug-related adverse events occurred in 24% of 191 ciprofloxacin-treated patients and in 33% of 187 trimethoprim-sulfamethoxazole-treated patients, respectively (95% CI, -0.001 to 0.2). Conclusions In our study of outpatient treatment of acute uncomplicated pyelonephritis in women, a 7-day ciprofloxacin regimen was associated with greater bacteriologic and clinical cure rates than a 14-day trimethoprim-sulfamethoxazole regimen, especially in patients infected with trimethoprim-sulfamethoxazole-resistant strains.	Univ Calif Los Angeles, Olive View UCLA Med Ctr, Dept Med, Div Emergency Med, Los Angeles, CA USA; Univ Calif Los Angeles, Olive View UCLA Med Ctr, Dept Med, Div Infect Dis, Los Angeles, CA USA; Univ Washington, Harborview Med Ctr, Dept Med, Div Infect Dis, Seattle, WA 98104 USA; Providence St Peters Hosp, Olympia, WA USA; Cent Florida Med Res Ctr, Orlando, FL USA; Bayer Corp, Div Pharmaceut, W Haven, CT USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harborview Medical Center; University of Washington; University of Washington Seattle; Bayer AG	Talan, DA (corresponding author), Olive View UCLA Med Ctr, 14445 Olive View Dr, Sylmar, CA 91342 USA.							ALON U, 1987, ANTIMICROB AGENTS CH, V31, P126, DOI 10.1128/AAC.31.1.126; *AM HOSP ASS, 1995, HOSP STAT; *AM MED ASS, 1997, PHYS CURR PROC TERM; BAILEY RR, 1992, NEW ZEAL MED J, V105, P102; BEUNDERS AJ, 1994, J ANTIMICROB CHEMOTH, V33, P17, DOI 10.1093/jac/33.suppl_A.17; BRAHAM E, 1982, CURR THER RES, V31, P536; *BUR LAB STAT, 1997, CONS PRIC IND MED CA; GLECKMAN R, 1985, J UROLOGY, V133, P176, DOI 10.1016/S0022-5347(17)48870-7; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; HOOTON TM, 1995, JAMA-J AM MED ASSOC, V273, P41; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; JERNELIUS H, 1988, ACTA MED SCAND, V223, P469; JOHNSON JR, 1991, J INFECT DIS, V163, P325, DOI 10.1093/infdis/163.2.325; MCCARTHY E, 1989, DHHS PUBLICATION; *MED EC CO INC, 1997, 1997 DRUG TOP REDB; *NAT COMM CLIN LAB, 1993, APPR STAND METH DIL; *NAT COMM CLIN LAB, 1993, APPR STAND PERF STAN; NORRBY SR, 1990, REV INFECT DIS, V12, P458; ODE B, 1980, ACTA MED SCAND, V207, P305; RUBIN RH, 1992, CLIN INFECT DIS, V15, pS216, DOI 10.1093/clind/15.Supplement_1.S216; SAFRIN S, 1988, AM J MED, V85, P793; SEGAL MJ, 1995, MED RBRVS PHYSICIANS; STAMM WE, 1989, J INFECT DIS, V159, P400, DOI 10.1093/infdis/159.3.400; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; STAMM WE, 1987, ANN INTERN MED, V106, P341, DOI 10.7326/0003-4819-106-3-341; *STAT MAR HLTH SER, 1998, CUR RAT REP; *STAT MAR HLTH SER, 1996, ACC BUDG MAN FISC OP; *US FOOD DRUG ADM, 1992, POINTS CONS, P20; WARD G, 1991, ANN EMERG MED, V20, P258, DOI 10.1016/S0196-0644(05)80935-7; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; Winstanley TG, 1997, J ANTIMICROB CHEMOTH, V40, P591, DOI 10.1093/jac/40.4.591	31	303	319	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2000	283	12					1583	1590		10.1001/jama.283.12.1583	http://dx.doi.org/10.1001/jama.283.12.1583			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MV	10735395	Bronze			2022-12-28	WOS:000085857300035
J	Nightingale, PG; Adu, D; Richards, NT; Peters, M				Nightingale, PG; Adu, D; Richards, NT; Peters, M			Implementation of rules based computerised bedside prescribing and administration: intervention study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG EVENTS; DECISION-SUPPORT; MEDICATION ERRORS; PREVENTION; SYSTEMS	Obectives: To Implement and assess a rules based computerised prescribing system with the aim of improving the safety of prescriptions and the administration of drugs. Design: Analysis of performance of computerised system plus questionnaire survey of users. Setting: 64 bed renal unit in a teaching hospital. Intervention: Introduction of the system into routine clinical use. Main outcome measures: Number of attempted prescriptions cancelled by the system; proportion of warning messages overridden; users' comparisons of the system with conventional procedures. Results: Between October 1998 and August 1999 die system cancelled 58 (0.07%) out of 87 789 prescriptions on the grounds of clinical safety. In addition, 427 (57%) attempted prescriptions generating high level warnings and 1257 (8%) generating low level warnings were not completed. In a user survey 82% (31/38) of doctors and nurses considered the system to be an improvement on conventional procedures. Conclusions: The system has contributed to safety and patient care. All prescriptions are complete and legible, and transcription errors have been eliminated. The system assists clinicians when they are writing a prescription by making available information on patients. The system supports clinical decision making and has been well received by doctors, nurses, and pharmacists.	Univ Birmingham, Queen Elizabeth Med Ctr, Dept Med, Wolfson Comp Lab, Birmingham B15 2TH, W Midlands, England; Univ Hosp Birmingham NHS Trust, Queen Elizabeth Hosp, Dept Nephrol, Renal Serv, Birmingham B15 2TH, W Midlands, England; Univ Hosp Birmingham NHS Trust, Queen Elizabeth Hosp, Dept Nephrol, Urol Serv, Birmingham B15 2TH, W Midlands, England	Birmingham City University; University of Birmingham; University of Birmingham; University of Birmingham	Nightingale, PG (corresponding author), Univ Birmingham, Queen Elizabeth Med Ctr, Dept Med, Wolfson Comp Lab, Birmingham B15 2TH, W Midlands, England.	P.G.Nightingale@bham.ac.uk						Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; FERNER RE, 1992, J MED DEFENCE UNION, V8, P60; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Purves IN, 1998, BRIT J GEN PRACT, V48, P1552; Raschke RA, 1998, JAMA-J AM MED ASSOC, V280, P1317, DOI 10.1001/jama.280.15.1317; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; Shojania KG, 1998, J AM MED INFORM ASSN, V5, P554, DOI 10.1136/jamia.1998.0050554; WYATT J, 1995, BRIT MED J, V311, P1181, DOI 10.1136/bmj.311.7014.1181	18	127	128	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2000	320	7237					750	753		10.1136/bmj.320.7237.750	http://dx.doi.org/10.1136/bmj.320.7237.750			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720357	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000086054700022
J	Maloney, ED; Hartmann, DL				Maloney, ED; Hartmann, DL			Modulation of hurricane activity in the Gulf of Mexico by the Madden-Julian oscillation	SCIENCE			English	Article							EL-NINO	The Madden-Julian oscillation (MJO) is a large-scale episodic modulation of tropical winds and precipitation that travels eastward from Asia to America, with a characteristic repeat time of 30 to 60 days. Here it is shown that when MJO wind anomalies in the lower troposphere of the eastern Pacific are westerly, Gulf of Mexico and western Caribbean hurricane genesis is four times more likely than when the MJO winds are easterly. Accurate predictions of the MJO may lead to improved long-range forecasts of tropical cyclone activity.	Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Maloney, ED (corresponding author), Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA.		Maloney, Eric D/A-9327-2008	Maloney, Eric D/0000-0002-2660-2611				Bove MC, 1998, B AM METEOROL SOC, V79, P2477, DOI 10.1175/1520-0477(1998)079<2477:EOENOO>2.0.CO;2; Ferreira RN, 1997, J ATMOS SCI, V54, P261, DOI 10.1175/1520-0469(1997)054<0261:BAOIB>2.0.CO;2; Gray WM, 1998, METEOROL ATMOS PHYS, V67, P37, DOI 10.1007/BF01277501; GRAY WM, 1984, MON WEATHER REV, V112, P1649, DOI 10.1175/1520-0493(1984)112<1649:ASHFPI>2.0.CO;2; Gray WM., 1979, METEOROLOGY TROPICAL, P155, DOI DOI 10.1175/1520-0450; HARTMANN D, UNPUB; HEBERT PJ, 1993, NOAA TECHNICAL MEMOR; HENDON HH, 1994, J ATMOS SCI, V51, P2225, DOI 10.1175/1520-0469(1994)051<2225:TLCOTM>2.0.CO;2; Jarvinen B. R., 1984, NOAA TECHNICAL MEMOR; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Kutzbach J. E., 1967, J APPL METEOROL, V6, P791, DOI DOI 10.1175/1520-0450(1967)006<0791:EEOSLP>2.0.CO;2; Landsea C. W., 1994, Weather, V49, P273, DOI 10.1002/j.1477-8696.1994.tb06035.x; Lester Paul, 1900, GREAT GALVESTON DISA; MADDEN RA, 1994, MON WEATHER REV, V122, P814, DOI 10.1175/1520-0493(1994)122<0814:OOTDTO>2.0.CO;2; Maloney ED, 1998, J CLIMATE, V11, P2387, DOI 10.1175/1520-0442(1998)011<2387:FMCIAC>2.0.CO;2; MALONEY ED, UNPUB; Molinari J, 1997, MON WEATHER REV, V125, P2699, DOI 10.1175/1520-0493(1997)125<2699:PVEWAE>2.0.CO;2; Simpson R.H., 1981, HURRICANE ITS IMPACT; Waliser DE, 1999, J CLIMATE, V12, P1918, DOI 10.1175/1520-0442(1999)012<1918:ASERTF>2.0.CO;2; ZEHR RM, 1992, 61 NESDIS	20	293	313	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2002	2004		10.1126/science.287.5460.2002	http://dx.doi.org/10.1126/science.287.5460.2002			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720323				2022-12-28	WOS:000085902800057
J	Odom, AR; Stahlberg, A; Wente, SR; York, JD				Odom, AR; Stahlberg, A; Wente, SR; York, JD			A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control	SCIENCE			English	Article							PHOSPHOLIPASE-C GENE; SACCHAROMYCES-CEREVISIAE; ARGININE METABOLISM; CELL-CYCLE; S-PHASE; YEAST; EXPRESSION; DNA; PHOSPHORYLATION; TRISPHOSPHATE	Phospholipase C and two inositol polyphosphate (IP) kinases constitute a signaling pathway that regulates nuclear messenger RNA export through production of inositol hexakisphosphate (IP6). The inositol 1,4,5-trisphosphate kinase of this pathway in Saccharomyces cerevisiae, designated Ipk2, was found to be identical to Arg82, a regulator of the transcriptional complex ArgR-Mcm1. Synthesis of inositol 1,4,5,6-tetrakisphosphate, but not IP6, was required for gene regulation through ArgR-Mcm1. Thus, the phospholipase C pathway produces multiple IP messengers that modulate distinct nuclear processes. The results reveal a direct mechanism by which activation of IP signaling may control gene expression.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Duke University; Duke University; Washington University (WUSTL)	York, JD (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, DUMC 3813, Durham, NC 27710 USA.		John, Audrey Odom/AAF-1300-2019; Pillay, Nischalan/F-9536-2012	John, Audrey Odom/0000-0001-8395-8537; 				BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; BERCY J, 1987, GENE, V55, P277, DOI 10.1016/0378-1119(87)90287-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BORONENKOV I, 1998, MOL BIOL CELL, P9; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; DUBOIS E, 1987, MOL GEN GENET, V207, P142, DOI 10.1007/BF00331501; DUBOIS E, 1991, MOL CELL BIOL, V11, P2162, DOI 10.1128/MCB.11.4.2162; DUBOIS E, 1994, MOL GEN GENET, V243, P315, DOI 10.1007/BF00301067; ESTEVEZ F, 1994, BIOCHEM J, V302, P709, DOI 10.1042/bj3020709; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Hsu AL, 1998, BIOCHEM BIOPH RES CO, V243, P653, DOI 10.1006/bbrc.1998.8161; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MESSENGUY F, 1993, MOL CELL BIOL, V13, P2586, DOI 10.1128/MCB.13.4.2586; Ongusaha PP, 1998, BIOCHEM J, V335, P671, DOI 10.1042/bj3350671; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; RIJCKE MD, 1992, MOL CELL BIOL, V12, P68; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SMITH CD, 1983, J BIOL CHEM, V258, P9368; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; VanderKaay J, 1995, BIOCHEM J, V312, P911, DOI 10.1042/bj3120911; Wolberger C, 1999, ANNU REV BIOPH BIOM, V28, P29, DOI 10.1146/annurev.biophys.28.1.29; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; YORK JD, 1994, J BIOL CHEM, V269, P19992; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YORK JD, 1994, J BIOL CHEM, V269, P7847; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	39	313	329	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 17	2000	287	5460					2026	2029		10.1126/science.287.5460.2026	http://dx.doi.org/10.1126/science.287.5460.2026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	294GE	10720331				2022-12-28	WOS:000085902800065
J	Ryan, DP; Compton, CC; Mayer, RJ				Ryan, DP; Compton, CC; Mayer, RJ			Medical progress: Carcinoma of the anal canal.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS-CELL CARCINOMA; HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMARY RADIATION-THERAPY; COOPERATIVE-ONCOLOGY-GROUP; COMBINED-MODALITY THERAPY; EPIDERMOID CARCINOMA; MITOMYCIN-C; INTRAEPITHELIAL NEOPLASIA; CANCER INCIDENCE		Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Mayer, RJ (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.							ALLAIRE FJ, 1961, CANCER CHEMOTH REP, P59; ALLAL A, 1993, INT J RADIAT ONCOL, V27, P59, DOI 10.1016/0360-3016(93)90421-Q; Allal AS, 1999, CANCER, V86, P405, DOI 10.1002/(SICI)1097-0142(19990801)86:3<405::AID-CNCR7>3.0.CO;2-Q; Allal AS, 1997, INT J RADIAT ONCOL, V39, P1099, DOI 10.1016/S0360-3016(97)00390-8; Arnott SJ, 1996, LANCET, V348, P1049; Bartelink H, 1997, J CLIN ONCOL, V15, P2040, DOI 10.1200/JCO.1997.15.5.2040; BEAHRS OH, 1976, ANN SURG, V184, P422, DOI 10.1097/00000658-197610000-00004; BIGGAR RJ, 1987, AM J EPIDEMIOL, V126, P578, DOI 10.1093/oxfordjournals.aje.a114697; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BOMAN BM, 1984, CANCER-AM CANCER SOC, V54, P114, DOI 10.1002/1097-0142(19840701)54:1<114::AID-CNCR2820540124>3.0.CO;2-P; BUCKWALTER JA, 1957, ARCH SURG-CHICAGO, V75, P352; CANTRIL ST, 1983, INT J RADIAT ONCOL, V9, P1271, DOI 10.1016/0360-3016(83)90257-2; CHADHA M, 1994, DIS COLON RECTUM, V37, P861, DOI 10.1007/BF02052589; CHANG AYC, 1986, CANCER, V57, P2285, DOI 10.1002/1097-0142(19860615)57:12<2285::AID-CNCR2820571209>3.0.CO;2-4; CHILDS DS, 1968, AMER J ROENTGENOL RA, V102, P541, DOI 10.2214/ajr.102.3.541; Constantinou EC, 1997, INT J RADIAT ONCOL, V39, P651, DOI 10.1016/S0360-3016(97)00329-5; CRITCHLOW CW, 1995, AIDS, V9, P1255, DOI 10.1097/00002030-199511000-00007; CUMMINGS B, 1984, CANCER-AM CANCER SOC, V54, P2062, DOI 10.1002/1097-0142(19841115)54:10<2062::AID-CNCR2820541004>3.0.CO;2-T; CUMMINGS BJ, 1982, DIS COLON RECTUM, V25, P778, DOI 10.1007/BF02553310; CUMMINGS BJ, 1991, INT J RADIAT ONCOL, V21, P1115, DOI 10.1016/0360-3016(91)90265-6; DALING JR, 1982, JAMA-J AM MED ASSOC, V247, P1988; DALING JR, 1992, AM J EPIDEMIOL, V135, P180, DOI 10.1093/oxfordjournals.aje.a116270; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; DALY JJ, 1989, DIGEST DIS SCI, V25, P464; DOCI R, 1992, ANN SURG, V215, P150, DOI 10.1097/00000658-199202000-00010; Doci R, 1996, J CLIN ONCOL, V14, P3121, DOI 10.1200/JCO.1996.14.12.3121; DOGGETT SW, 1988, INT J RADIAT ONCOL, V15, P1069, DOI 10.1016/0360-3016(88)90186-1; DOUGHERTY BG, 1985, AM J CLIN PATHOL, V83, P159, DOI 10.1093/ajcp/83.2.159; DUBOIS JB, 1991, INT J RADIAT ONCOL, V20, P575, DOI 10.1016/0360-3016(91)90072-C; DUGGAN MA, 1989, AM J CLIN PATHOL, V92, P16, DOI 10.1093/ajcp/92.1.16; ENKER WE, 1986, ARCH SURG-CHICAGO, V121, P1386; ESCHWEGE F, 1985, RADIOTHER ONCOL, V3, P145, DOI 10.1016/S0167-8140(85)80019-0; FENGER C, 1991, SEMIN DIAGN PATHOL, V8, P190; Flam M, 1996, J CLIN ONCOL, V14, P2527, DOI 10.1200/JCO.1996.14.9.2527; FLAM M, 1999, CLASSIC PAPERS CURR, V3, P539; FLAM MS, 1983, CANCER, V51, P1378, DOI 10.1002/1097-0142(19830415)51:8<1378::AID-CNCR2820510810>3.0.CO;2-F; FOYE LV, 1960, CANCER CHEMOTH REP, P12; FRANK W, 1962, CANCER CHEMOTH REP, P55; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; FRISCH M, 1994, NEW ENGL J MED, V331, P300, DOI 10.1056/NEJM199408043310504; Frisch M, 1997, NEW ENGL J MED, V337, P1350, DOI 10.1056/NEJM199711063371904; FROST DB, 1984, CANCER, V53, P1285, DOI 10.1002/1097-0142(19840315)53:6<1285::AID-CNCR2820530611>3.0.CO;2-N; Fung CY, 1994, RADIAT ONCOL INVEST, V2, P152, DOI DOI 10.1002/R0I.2970020307; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Goldie SJ, 1999, JAMA-J AM MED ASSOC, V281, P1822, DOI 10.1001/jama.281.19.1822; GREENALL MJ, 1985, SURG GYNECOL OBSTET, V161, P509; GREENALL MJ, 1985, AM J SURG, V149, P95, DOI 10.1016/S0002-9610(85)80016-7; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HARNLY ME, 1988, AM J EPIDEMIOL, V128, P261, DOI 10.1093/oxfordjournals.aje.a114966; HENDERSON IW, 1968, AMER J ROENTGENOL RA, V102, P545, DOI 10.2214/ajr.102.3.545; Hoffman R, 1999, INT J RADIAT ONCOL, V44, P127, DOI 10.1016/S0360-3016(98)00528-8; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; HOLMES F, 1988, GASTROENTEROLOGY, V95, P107, DOI 10.1016/0016-5085(88)90297-1; HUGHES LL, 1989, INT J RADIAT ONCOL, V17, P1153, DOI 10.1016/0360-3016(89)90520-8; John M, 1996, INT J RADIAT ONCOL, V34, P65, DOI 10.1016/0360-3016(95)00223-5; John M, 1996, Cancer J Sci Am, V2, P205; JOHN MJ, 1987, INT J RADIAT ONCOL, V13, P299, DOI 10.1016/0360-3016(87)90002-2; JOHNSON D, 1993, SURG GYNECOL OBSTET, V177, P329; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; KIVIAT N, 1990, J INFECT DIS, V162, P358, DOI 10.1093/infdis/162.2.358; Klas JV, 1999, CANCER, V85, P1686, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1686::AID-CNCR7>3.0.CO;2-7; KLINE RJ, 1964, ARCH SURG-CHICAGO, V89, P989; KLOTZ RG, 1967, CANCER-AM CANCER SOC, V20, P1727, DOI 10.1002/1097-0142(196710)20:10<1727::AID-CNCR2820201024>3.0.CO;2-1; LEICHMAN L, 1985, AM J MED, V78, P211, DOI 10.1016/0002-9343(85)90428-0; LESESNE JB, 1989, J CLIN ONCOL, V7, P781, DOI 10.1200/JCO.1989.7.6.781; MARTENSON JA, 1995, CANCER-AM CANCER SOC, V76, P1731, DOI 10.1002/1097-0142(19951115)76:10<1731::AID-CNCR2820761009>3.0.CO;2-H; MARTENSON JA, 1993, CANCER, V71, P1736, DOI 10.1002/1097-0142(19930301)71:5<1736::AID-CNCR2820710506>3.0.CO;2-F; Martenson JA, 1996, INT J RADIAT ONCOL, V35, P745, DOI 10.1016/0360-3016(96)00146-0; MEEKER WR, 1986, CANCER, V57, P525, DOI 10.1002/1097-0142(19860201)57:3<525::AID-CNCR2820570320>3.0.CO;2-V; MELBYE M, 1994, AM J EPIDEMIOL, V139, P772, DOI 10.1093/oxfordjournals.aje.a117073; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MICHAELSON RA, 1983, CANCER, V51, P390, DOI 10.1002/1097-0142(19830201)51:3<390::AID-CNCR2820510306>3.0.CO;2-V; MOERTEL CG, 1969, LANCET, V2, P865; NIGH S S, 1991, International Journal of Radiation Oncology, Biology, Physics, V21, P224, DOI 10.1016/0360-3016(91)90629-I; NIGRO ND, 1983, CANCER, V51, P1826, DOI 10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L; NIGRO ND, 1987, WORLD J SURG, V11, P446, DOI 10.1007/BF01655808; NIGRO ND, 1984, DIS COLON RECTUM, V27, P763, DOI 10.1007/BF02553933; NIGRO ND, 1974, DIS COLON RECTUM, V17, P354, DOI 10.1007/BF02586980; NOFFSINGER AE, 1995, MODERN PATHOL, V8, P509; PALEFSKY J, 1991, HEMATOL ONCOL CLIN N, V5, P357, DOI 10.1016/S0889-8588(18)30447-7; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P314, DOI 10.1097/00042560-199804010-00004; PALEFSKY JM, 1991, CANCER RES, V51, P1014; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P320, DOI 10.1097/00042560-199804010-00005; PAPILLON J, 1983, CANCER, V51, P1830, DOI 10.1002/1097-0142(19830515)51:10<1830::AID-CNCR2820511013>3.0.CO;2-Z; Peddada AV, 1997, INT J RADIAT ONCOL, V37, P1101, DOI 10.1016/S0360-3016(96)00596-2; PEDERSENBJERGAARD J, 1993, LEUKEMIA, V7, P1975; Peiffert D, 1997, ANN ONCOL, V8, P575, DOI 10.1023/A:1008295119573; PENN I, 1986, CANCER-AM CANCER SOC, V58, P611, DOI 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M; PETERS RK, 1983, BRIT J CANCER, V48, P629, DOI 10.1038/bjc.1983.244; PETERS RK, 1984, JNCI-J NATL CANCER I, V72, P609; PINTOR MP, 1989, BRIT J SURG, V76, P806, DOI 10.1002/bjs.1800760814; Pocard M, 1998, DIS COLON RECTUM, V41, P1488, DOI 10.1007/BF02237294; PRESTON DM, 1983, BRIT J SURG, V70, P346, DOI 10.1002/bjs.1800700612; PUTHAWALA AA, 1982, CANCER, V50, P1746, DOI 10.1002/1097-0142(19821101)50:9<1746::AID-CNCR2820500917>3.0.CO;2-F; Rabki C. S., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P251; RABKIN CS, 1992, AM J EPIDEMIOL, V136, P54, DOI 10.1093/oxfordjournals.aje.a116420; RABKIN CS, 1994, J NATL CANCER I, V86, P1711, DOI 10.1093/jnci/86.22.1711; SCHLIENGER M, 1989, INT J RADIAT ONCOL, V17, P1141, DOI 10.1016/0360-3016(89)90519-1; SCHNEIDER TC, 1981, SURGERY, V90, P729; SCHRAUT WH, 1983, CANCER, V51, P1291, DOI 10.1002/1097-0142(19830401)51:7<1291::AID-CNCR2820510719>3.0.CO;2-R; Selik RM, 1998, J NATL CANCER I, V90, P1300, DOI 10.1093/jnci/90.17.1300; SHELDON R, 1986, CANCER, V58, P1428, DOI 10.1002/1097-0142(19861001)58:7<1428::AID-CNCR2820580709>3.0.CO;2-J; SHROYER KR, 1992, ARCH SURG-CHICAGO, V127, P741; SILLMAN F, 1984, AM J OBSTET GYNECOL, V150, P300, DOI 10.1016/S0002-9378(84)90369-7; SINGH R, 1981, CANCER, V48, P411, DOI 10.1002/1097-0142(19810715)48:2<411::AID-CNCR2820480232>3.0.CO;2-Z; SISCHY B, 1982, DIS COLON RECTUM, V25, P685, DOI 10.1007/BF02629541; SISCHY B, 1985, INT J RADIAT ONCOL, V11, P1587, DOI 10.1016/0360-3016(85)90210-X; SISCHY B, 1989, J NATL CANCER I, V81, P850, DOI 10.1093/jnci/81.11.850; SLATER G, 1984, ANN SURG, V199, P348, DOI 10.1097/00000658-198403000-00016; Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903; TANUM G, 1991, CANCER, V67, P2462, DOI 10.1002/1097-0142(19910515)67:10<2462::AID-CNCR2820671012>3.0.CO;2-1; TOUBOUL E, 1994, CANCER, V73, P1569, DOI 10.1002/1097-0142(19940315)73:6<1569::AID-CNCR2820730607>3.0.CO;2-F; VERWEIJ J, 1987, CANCER, V60, P756, DOI 10.1002/1097-0142(19870815)60:4<756::AID-CNCR2820600408>3.0.CO;2-H; VERWEY J, 1987, EUR J CANCER CLIN ON, V23, P195, DOI 10.1016/0277-5379(87)90014-9; VincentSalomon A, 1996, MODERN PATHOL, V9, P614; WAGNER JP, 1994, INT J RADIAT ONCOL, V29, P17, DOI 10.1016/0360-3016(94)90221-6; WILLIAMS AB, 1994, OBSTET GYNECOL, V83, P205; Williams GR, 1996, J PATHOL, V180, P378, DOI 10.1002/(SICI)1096-9896(199612)180:4<378::AID-PATH697>3.0.CO;2-H; ZAKI SR, 1992, AM J PATHOL, V140, P1345	121	294	309	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2000	342	11					792	800		10.1056/NEJM200003163421107	http://dx.doi.org/10.1056/NEJM200003163421107			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293HW	10717015				2022-12-28	WOS:000085846900007
J	Gubareva, LV; Kaiser, L; Hayden, FG				Gubareva, LV; Kaiser, L; Hayden, FG			Influenza virus neuraminidase inhibitors	LANCET			English	Article							ACTIVE-SITE; DECREASED SENSITIVITY; A VIRUS; 4-GUANIDINO-NEU5AC2EN; RESISTANCE; ZANAMIVIR; MUTATIONS; SEQUENCE; EFFICACY; SAFETY	Neuraminidase promotes influenza virus release from infected cells and facilitates virus spread within the respiratory tract. Several potent and specific inhibitors of this enzyme have been developed, and two (zanamivir and oseltamivir) have been approved for human use. Unlike amantadine and rimantadine that target the M2 protein of influenza A viruses, these drugs inhibit replication of both influenza A and B viruses. Zanamivir is delivered by inhalation because of its low oral bioavailability whereas oseltamivir is administered by mouth. Early treatment with either drug reduces the severity and duration of influenza symptoms and associated complications. Both agents are effective for chemoprophylaxis. Because of a broader antiviral spectrum, better tolerance, and less potential for emergence of resistance than is seen with the M2 inhibitors, the neuraminidase inhibitors represent an important advance in the treatment of influenza.	Univ Virginia, Sch Med, Dept Internal Med, Charlottesville, VA 22908 USA	University of Virginia	Gubareva, LV (corresponding author), Univ Virginia, Sch Med, Dept Internal Med, Charlottesville, VA 22908 USA.	lvg9b@virginia.edu		Kaiser, Laurent/0000-0002-0857-2252				AOKI FY, 1998, 38 ICAAC SAN DIEG; BANTIA S, 1999, 39 ICAAC SAN FRANC S; Blick TJ, 1998, VIROLOGY, V246, P95, DOI 10.1006/viro.1998.9194; Blick TJ, 1995, VIROLOGY, V214, P475, DOI 10.1006/viro.1995.0058; BOIVIN G, 1999, 39 ICAAC SAN FRANC S; Calfee DP, 1998, DRUGS, V56, P537, DOI 10.2165/00003495-199856040-00003; Calfee DP, 1999, ANTIMICROB AGENTS CH, V43, P1616, DOI 10.1128/AAC.43.7.1616; Calfee DP, 1999, ANTIVIR THER, V4, P143; CASS L, IN PRESS RESP MED; Cass LMR, 1999, CLIN PHARMACOKINET, V36, P21, DOI 10.2165/00003088-199936001-00003; Cass LMR, 1999, CLIN PHARMACOKINET, V36, P1, DOI 10.2165/00003088-199936001-00001; Colacino JM, 1997, VIROLOGY, V236, P66, DOI 10.1006/viro.1997.8709; COLMAN PM, 1993, J VIROL, V67, P2972, DOI 10.1128/JVI.67.6.2972-2980.1993; COVINGTON E, 1999, 2 INT S INFL OTH RES; Daniel MJ, 1999, CLIN PHARMACOKINET, V36, P41, DOI 10.2165/00003088-199936001-00005; Eisenberg EJ, 1997, ANTIMICROB AGENTS CH, V41, P1949, DOI 10.1128/AAC.41.9.1949; FLEMING D, 1998, IDSA 98 DENV NOV 12; Freund B, 1999, DRUG SAFETY, V21, P267, DOI 10.2165/00002018-199921040-00003; Fritz RS, 1999, J INFECT DIS, V180, P586, DOI 10.1086/314938; GOR D, 1999, 39 ICAAC SAN FRANC S; Goto H, 1998, P NATL ACAD SCI USA, V95, P10224, DOI 10.1073/pnas.95.17.10224; GRAVENSTEIN S, 1999, 39 ICAC SAN FRANC SE; Gubareva LV, 1998, J INFECT DIS, V178, P1592, DOI 10.1086/314515; Gubareva LV, 1998, J INFECT DIS, V178, P1257, DOI 10.1086/314440; Gubareva LV, 1997, J VIROL, V71, P3385, DOI 10.1128/JVI.71.5.3385-3390.1997; Gubareva LV, 1996, J VIROL, V70, P1818, DOI 10.1128/JVI.70.3.1818-1827.1996; GUBAREVA LV, 1999, 2 INT S INFL OTH RES; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; Hayden FG, 1996, JAMA-J AM MED ASSOC, V275, P295, DOI 10.1001/jama.275.4.295; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; Hayden FG, 1996, INT CONGR SER, V1123, P718; Hayden FG, 1996, ANTIVIRAL DRUG RESIS, P59; HAYDEN FG, 1999, 39 ICAAC SEP SAN FRA; HAYDEN FG, 1999, IDSA 98 PHIL NOV 18; IVES J, 1999, 2 INT S INFL OTH RES; KAISER L, IN PRESS CLIN INFECT; KAISER L, 1999, 39 ICAAC SAN FRANC S; Kim CU, 1999, ANTIVIR CHEM CHEMOTH, V10, P141, DOI 10.1177/095632029901000401; Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t; Lalezari Jacob, 1999, Journal of Antimicrobial Chemotherapy, V44, P42; Laver WG, 1999, SCI AM, V280, P78, DOI 10.1038/scientificamerican0199-78; LEE C, 1999, 39 ICAAC SAN FRANC S; LENEVA IA, 1999, 2 INT S INFL OTH RES; Li WX, 1998, ANTIMICROB AGENTS CH, V42, P647, DOI 10.1128/AAC.42.3.647; McKimm-Breschkin JL, 1998, J VIROL, V72, P2456, DOI 10.1128/JVI.72.3.2456-2462.1998; McKimmBreschkin JL, 1996, VIROLOGY, V225, P240, DOI 10.1006/viro.1996.0595; Mendel DB, 1998, DRUG RESIST UPDATE, V1, P184, DOI 10.1016/S1368-7646(98)80038-1; Monto AS, 1999, J ANTIMICROB CHEMOTH, V44, P23, DOI 10.1093/jac/44.suppl_2.23; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; Monto AS, 1999, J INFECT DIS, V180, P254, DOI 10.1086/314904; OSTERHAUS AD, 1999, 39 ICAAC SAN FRANC S; OXFORD J, 1999, 2 INT S INFL OTH RES; OXFORD JS, 1999, EUR RESPIR J, V14, pS254; PENG AW, 1999, 39 ICAAC SAN FRANC S; PETERS PH, 1999, 2 INT S INFL OTH RES; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; Staschke KA, 1995, VIROLOGY, V214, P642, DOI 10.1006/viro.1995.0078; Stephenson I, 1999, J ANTIMICROB CHEMOTH, V44, P6, DOI 10.1093/jac/44.1.6; Tai CY, 1998, ANTIMICROB AGENTS CH, V42, P3234, DOI 10.1128/AAC.42.12.3234; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; *US FDA, 2000, PUBL HLTH AD SAF APP; VARGHESE JN, 1991, J MOL BIOL, V221, P473, DOI 10.1016/0022-2836(91)80068-6; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Walker JB, 1997, J INFECT DIS, V176, P1417, DOI 10.1086/514136; Webster A, 1999, CLIN PHARMACOKINET, V36, P51, DOI 10.2165/00003088-199936001-00006; WOOD ND, 1997, 37 ICAAC TOR	68	516	553	0	80	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	2000	355	9206					827	835		10.1016/S0140-6736(99)11433-8	http://dx.doi.org/10.1016/S0140-6736(99)11433-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711940				2022-12-28	WOS:000085766900037
J	Kiss, A				Kiss, A			Treatment of chronic bulimic symptoms: new answers, more questions	LANCET			English	Editorial Material							NERVOSA; ONDANSETRON		Univ Basel Hosp, Dept Psychosomat, CH-4031 Basel, Switzerland	University of Basel	Kiss, A (corresponding author), Univ Basel Hosp, Dept Psychosomat, CH-4031 Basel, Switzerland.							American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P539; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; FAIRBURN CG, 1995, ARCH GEN PSYCHIAT, V52, P304; HAY PJ, 1999, COCHRANE LIB; Keel PK, 1997, AM J PSYCHIAT, V154, P313; OREN DA, 1995, AM J PSYCHIAT, V152, P1101; RUSSELL G, 1979, PSYCHOL MED, V9, P429, DOI 10.1017/S0033291700031974; Walsh BT, 1997, AM J PSYCHIAT, V154, P523; Wilde MI, 1996, DRUGS, V52, P773, DOI 10.2165/00003495-199652050-00010; ZOLDAN J, 1995, NEUROLOGY, V45, P1305, DOI 10.1212/WNL.45.7.1305	10	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					769	770		10.1016/S0140-6736(99)00447-X	http://dx.doi.org/10.1016/S0140-6736(99)00447-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711920				2022-12-28	WOS:000085766900004
J	Spengler, SJ				Spengler, SJ			Computers and biology - Bioinformatics in the information age	SCIENCE			English	Editorial Material									Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Bioinformat & Computat Genom, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Spengler, SJ (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Bioinformat & Computat Genom, LBNL 84-171,1 Cyclotron Rd, Berkeley, CA 94720 USA.							Domian IJ, 1999, P NATL ACAD SCI USA, V96, P6648, DOI 10.1073/pnas.96.12.6648; LOOTS GG, COMMUNICATION; Malakoff D, 1999, SCIENCE, V284, P1742, DOI 10.1126/science.284.5421.1742; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; SHANNON CE, 1968, MATH THEORY COMMUNIC	6	25	27	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	2000	287	5456					1221	+		10.1126/science.287.5456.1221	http://dx.doi.org/10.1126/science.287.5456.1221			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286KG	10712158				2022-12-28	WOS:000085444700038
J	Krauss, B; Green, SM				Krauss, B; Green, SM			Primary care: Sedation and analgesia for procedures in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRANSMUCOSAL FENTANYL CITRATE; CHLORAL HYDRATE SEDATION; NITROUS-OXIDE ANALGESIA; LACERATION REPAIR; PEDIATRIC SEDATION; ORAL MIDAZOLAM; PRESCHOOL-CHILDREN; KETAMINE SEDATION; INTRAVENOUS KETAMINE; CONSCIOUS SEDATION		Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Loma Linda Univ, Med Ctr, Dept Emergency Med, Loma Linda, CA USA; Loma Linda Univ, Sch Med, Loma Linda, CA USA; Childrens Hosp, Loma Linda, CA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Loma Linda University; Loma Linda University; Children's Hospital Los Angeles	Krauss, B (corresponding author), Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	krauss@al.tch.harvard.edu	Krauss, Baruch/U-6182-2019					*AC PAIN MAN GUID, 1992, AHCPR PUBL; *AM NURS ASS, 1996, COMP ANA POS STAT, P148; [Anonymous], 1985, PEDIATRICS, V76, P317; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Beekman RP, 1996, EUR J PEDIATR, V155, P820; BELL GD, 1991, GUT, V32, P823, DOI 10.1136/gut.32.7.823; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V254, P1073; BILLMIRE DA, 1985, J TRAUMA, V25, P1079; BONADIO WA, 1988, AM J DIS CHILD, V142, P203, DOI 10.1001/archpedi.1988.02150020105040; Burton JH, 1998, ACAD EMERG MED, V5, P112, DOI 10.1111/j.1553-2712.1998.tb02594.x; CONNORS K, 1994, ANN EMERG MED, V24, P1074, DOI 10.1016/S0196-0644(94)70236-5; Dachs RJ, 1997, ANN EMERG MED, V29, P146, DOI 10.1016/S0196-0644(97)70321-4; DANIELS AL, 1992, CAN J ANAESTH, V39, P27, DOI 10.1007/BF03008668; Egelhoff JC, 1997, AM J ROENTGENOL, V168, P1259, DOI 10.2214/ajr.168.5.9129423; *EM NURS ASS, 1992, CONS SED; Epstein RH, 1996, ANESTH ANALG, V83, P1200, DOI 10.1097/00000539-199612000-00012; FELD LH, 1990, ANESTHESIOLOGY, V73, P831, DOI 10.1097/00000542-199011000-00006; GAMIS AS, 1989, ANN EMERG MED, V18, P177, DOI 10.1016/S0196-0644(89)80110-6; GLASIER CM, 1995, AM J NEURORADIOL, V16, P111; Green SM, 1999, ACAD EMERG MED, V6, P975, DOI 10.1111/j.1553-2712.1999.tb01176.x; GREEN SM, 1990, ANN EMERG MED, V19, P1024, DOI 10.1016/S0196-0644(05)82568-5; Green SM, 1998, ACAD EMERG MED, V5, P971, DOI 10.1111/j.1553-2712.1998.tb02773.x; Green SM, 1998, ANN EMERG MED, V31, P688, DOI 10.1016/S0196-0644(98)70226-4; GREEN SM, 1990, ANN EMERG MED, V19, P1033, DOI 10.1016/S0196-0644(05)82569-7; GREENBERG SB, 1993, AM J ROENTGENOL, V161, P639, DOI 10.2214/ajr.161.3.8352124; Gross JB, 1996, ANESTHESIOLOGY, V84, P459; HALLEN B, 1982, ANESTHESIOLOGY, V57, P340, DOI 10.1097/00000542-198210000-00024; HALPERIN DL, 1989, PEDIATRICS, V84, P281; HANDAL KA, 1983, ANN EMERG MED, V12, P438, DOI 10.1016/S0196-0644(83)80343-6; HAWK W, 1990, Pediatric Emergency Care, V6, P84, DOI 10.1097/00006565-199006000-00003; HENNES HM, 1990, ANN EMERG MED, V19, P1006, DOI 10.1016/S0196-0644(05)82564-8; HENNRIKUS WL, 1994, J PEDIATR ORTHOPED, V14, P538, DOI 10.1097/01241398-199407000-00023; HUBBARD AM, 1992, J COMPUT ASSIST TOMO, V16, P3, DOI 10.1097/00004728-199201000-00002; Jagoda AS, 1998, ANN EMERG MED, V31, P663, DOI 10.1016/S0196-0644(98)70216-1; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; Kim MK, 1999, ANN EMERG MED, V33, P395, DOI 10.1016/S0196-0644(99)70302-1; KOREN G, 1993, J PEDIATR-US, V122, pS30, DOI 10.1016/S0022-3476(11)80007-7; Krauss B, 1998, PEDIATR EMERG CARE, V14, P99, DOI 10.1097/00006565-199804000-00003; KRAUSS B, 1998, GUIDELINES PEDIAT PR; KRAUSS B, 1999, PEDIAT PROCEDURAL SE; LIU LMP, 1980, ANESTHESIOLOGY, V53, P343, DOI 10.1097/00000542-198010000-00014; LONGNECKER DE, 1973, ANESTH ANALG, V52, P447, DOI 10.1213/00000539-197352030-00033; MALINOVSKY JM, 1995, ANAESTHESIA, V50, P351, DOI 10.1111/j.1365-2044.1995.tb04616.x; MANULI MA, 1993, AM J ROENTGENOL, V160, P577, DOI 10.2214/ajr.160.3.8430557; OBRIEN JF, 1991, ANN EMERG MED, V20, P644, DOI 10.1016/S0196-0644(05)82384-4; Parker RI, 1997, PEDIATRICS, V99, P427, DOI 10.1542/peds.99.3.427; Pena BMG, 1999, ANN EMERG MED, V34, P483, DOI 10.1016/S0196-0644(99)80050-X; PEREIRA JK, 1993, PEDIATR RADIOL, V23, P341, DOI 10.1007/BF02011952; SACCHETTI A, 1994, ANN EMERG MED, V23, P237, DOI 10.1016/S0196-0644(94)70037-0; SACCHETTI A, 1937, ANN EMERG MED, V24, P540; SCHILLING CG, 1995, ANN EMERG MED, V25, P203, DOI 10.1016/S0196-0644(95)70325-X; SCHUTZMAN SA, 1994, ANN EMERG MED, V24, P1059, DOI 10.1016/S0196-0644(94)70234-9; SHANE SA, 1994, ANN EMERG MED, V24, P1065, DOI 10.1016/S0196-0644(94)70235-7; Shannon M, 1997, J PEDIATR-US, V131, P582, DOI 10.1016/S0022-3476(97)70066-0; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; SIEVERS TD, 1991, PEDIATRICS, V88, P1172; SLOVIS TL, 1993, PEDIATR RADIOL, V23, P345, DOI 10.1007/BF02011953; Smith GA, 1997, PEDIATRICS, V100, P825, DOI 10.1542/peds.100.5.825; STRAIN JD, 1988, AM J ROENTGENOL, V151, P975, DOI 10.2214/ajr.151.5.975; THEROUX MC, 1993, PEDIATRICS, V91, P624; VADE A, 1995, AM J ROENTGENOL, V165, P905, DOI 10.2214/ajr.165.4.7676990; WELDON BC, 1992, ANESTH ANALG, V75, P51; Wilson Stephen, 1996, Pediatric Dentistry, V18, P287; YASTER M, 1990, PEDIATRICS, V86, P463; ZELTZER L, 1991, PAIN, V44, P73, DOI 10.1016/0304-3959(91)90150-V; Zempsky WT, 1998, J PEDIATR-US, V132, P1061, DOI 10.1016/S0022-3476(98)70413-5; 1993, PEDIAT DENT, V15, P297	68	274	277	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	2000	342	13					938	945		10.1056/NEJM200003303421306	http://dx.doi.org/10.1056/NEJM200003303421306			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DC	10738053				2022-12-28	WOS:000086179700006
J	Lembo, T				Lembo, T			Neurotransmitter antagonism in management of irritable bowel syndrome	LANCET			English	Editorial Material							SENSITIVITY		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lembo, T (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.							Camilleri M, 1999, ALIMENT PHARM THERAP, V13, P1149; De Ponti F, 1998, PHARMACOL THERAPEUT, V80, P49, DOI 10.1016/S0163-7258(98)00021-7; Drossman DA, 1997, GASTROENTEROLOGY, V112, P2120, DOI 10.1053/gast.1997.v112.agast972120; Goldberg PA, 1996, DIGESTION, V57, P478, DOI 10.1159/000201377	4	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	2000	355	9209					1030	1031		10.1016/S0140-6736(00)02028-6	http://dx.doi.org/10.1016/S0140-6736(00)02028-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10744083				2022-12-28	WOS:000086380800004
J	Schoenlein, RW; Chattopadhyay, S; Chong, HHW; Glover, TE; Heimann, PA; Shank, CV; Zholents, AA; Zolotorev, MS				Schoenlein, RW; Chattopadhyay, S; Chong, HHW; Glover, TE; Heimann, PA; Shank, CV; Zholents, AA; Zolotorev, MS			Generation of femtosecond pulses of synchrotron radiation	SCIENCE			English	Article							X-RAY PULSES	Femtosecond synchrotron pulses were generated directly from an electron storage ring. An ultrashort Laser pulse was used to modulate the energy of electrons within a 100-femtosecond slice of the stored 30-picosecond electron bunch. The energy-modulated electrons were spatially separated from the long bunch and used to generate similar to 300-femtosecond synchrotron pulses at a bend-magnet beamline, with a spectral range from infrared to x-ray wavelengths. The same technique can be used to generate similar to 100-femtosecond x-ray pulses of substantially higher flux and brightness with an undulator, Such synchrotron-based femtosecond x-ray sources offer the possibility of applying x-ray techniques on an ultrafast time scale to investigate structural dynamics in condensed matter.	Univ Calif Berkeley, Ernest Orlando Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Ernest Orlando Lawrence Berkeley Natl Lab, Div Accelerator & Fus Res, Berkeley, CA 94720 USA; Univ Calif Berkeley, Ernest Orlando Lawrence Berkeley Natl Lab, Adv Light Source, Berkeley, CA 94720 USA; Univ Calif Berkeley, Appl Sci & Technol Grad Grp, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Schoenlein, RW (corresponding author), Univ Calif Berkeley, Ernest Orlando Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA.	rwschoenlein@lbi.gov	Schoenlein, Robert W/D-1301-2014	Schoenlein, Robert W/0000-0002-6066-7566				Alferov D. F., 1979, Particle Accelerators, V9, P223; AMIR A, 1986, NUCL INSTRUM METH A, V250, P404, DOI 10.1016/0168-9002(86)90917-4; Backus S, 1998, REV SCI INSTRUM, V69, P1207, DOI 10.1063/1.1148795; Chin AH, 1999, PHYS REV LETT, V83, P336, DOI 10.1103/PhysRevLett.83.336; ELSAESSER T, 1998, SPRINGER SRIES CHEM, V63; *LBL, 1986, PUB5172 LBL; LIMBORG C, 1998, P SPIE, V3451; Lindenberg AM, 2000, PHYS REV LETT, V84, P111, DOI 10.1103/PhysRevLett.84.111; MINI SM, 1998, MAT RES SOC S P, V524; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; RODWELL MJW, 1989, IEEE J QUANTUM ELECT, V25, P817, DOI 10.1109/3.17346; Schoenlein RW, 1996, SCIENCE, V274, P236, DOI 10.1126/science.274.5285.236; SCHOENLEIN RW, IN PRESS APPL PHYS B; Siders CW, 1999, SCIENCE, V286, P1340, DOI 10.1126/science.286.5443.1340; Tomov IV, 1999, J PHYS CHEM B, V103, P7081, DOI 10.1021/jp9908449; Zholents AA, 1996, PHYS REV LETT, V76, P912, DOI 10.1103/PhysRevLett.76.912	16	518	521	2	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2237	2240		10.1126/science.287.5461.2237	http://dx.doi.org/10.1126/science.287.5461.2237			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731140				2022-12-28	WOS:000086049100043
J	Velev, OD; Lenhoff, AM; Kaler, EW				Velev, OD; Lenhoff, AM; Kaler, EW			A class of microstructured particles through colloidal crystallization	SCIENCE			English	Article							CAPILLARY IMAGE FORCES; MESOPOROUS SILICA; EMULSION DROPLETS; LATEX-PARTICLES; HOLLOW SPHERES; POROUS SILICA; TEMPLATES; CRYSTALS; SUSPENSIONS; INTERFACE	Microstructured particles were synthesized by growing colloidal crystals in aqueous droplets suspended on fluorinated oil. The droplets template highly ordered and smooth particle assemblies, which diffract Light and have remarkable structural stability. The method allows control of particle size and shape from spheres through ellipsoids to toroids by varying the droplet composition, Cocrystallization in colloidal mixtures yields anisotropic particles of organic and inorganic materials that can, for example, be oriented and turned over by magnetic fields. The results open the way to controllable formation of a wide variety of microstructures.	Univ Delaware, Dept Chem Engn, Ctr Mol Engn Thermodynam, Newark, DE 19716 USA	University of Delaware	Velev, OD (corresponding author), Univ Delaware, Dept Chem Engn, Ctr Mol Engn Thermodynam, Newark, DE 19716 USA.	velev@che.udel.edu	Kaler, Eric/AAR-9561-2020; Velev, Orlin D/A-2853-2008	Velev, Orlin D/0000-0003-0473-8056; Lenhoff, Abraham/0000-0002-7831-219X				Arora AK, 1998, ADV COLLOID INTERFAC, V78, P49, DOI 10.1016/S0001-8686(98)00061-X; Aveyard R, 1999, COLLOID SURFACE A, V146, P95, DOI 10.1016/S0927-7757(98)00793-6; Breen TL, 1999, SCIENCE, V284, P948, DOI 10.1126/science.284.5416.948; Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R; Bruinsma PJ, 1997, CHEM MATER, V9, P2507, DOI 10.1021/cm970282a; CASAGRANDE C, 1988, CR ACAD SCI II, V306, P1423; CASAGRANDE C, 1989, EUROPHYS LETT, V9, P251, DOI 10.1209/0295-5075/9/3/011; CLARK NA, 1979, NATURE, V281, P57, DOI 10.1038/281057a0; Comiskey B, 1998, NATURE, V394, P253, DOI 10.1038/28349; CONCUS P, 1987, VARIATIONAL METHODS; DAVIS KE, 1989, SCIENCE, V245, P507, DOI 10.1126/science.245.4917.507; DEGENNES PG, 1992, ANGEW CHEM INT EDIT, V31, P842, DOI 10.1002/anie.199208421; EGERMANN H, 1980, POWDER TECHNOL, V27, P203, DOI 10.1016/0032-5910(80)85023-6; Grun M, 1997, ADV MATER, V9, P254, DOI 10.1002/adma.19970090317; Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538; HONDA H, 1994, COLLOID SURFACE A, V82, P117, DOI 10.1016/0927-7757(93)02620-T; Huck WTS, 1998, J AM CHEM SOC, V120, P8267, DOI 10.1021/ja981390g; Huo QS, 1997, CHEM MATER, V9, P14, DOI 10.1021/cm960464p; ILER RK, 1972, Patent No. 3855172; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS MO; KRALCHEVSKY PA, 1992, J COLLOID INTERF SCI, V151, P79, DOI 10.1016/0021-9797(92)90239-I; KRALCHEVSKY PA, 1994, J COLLOID INTERF SCI, V167, P47, DOI 10.1006/jcis.1994.1332; Lu YF, 1999, NATURE, V398, P223, DOI 10.1038/18410; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; Masters K., 1991, SPRAY DRYING HDB, Vfifth; Matijevic E, 1969, SURFACE COLLOID SCI, V2, P1; MORITA M, 1992, COLLOID SURFACE, V67, P81, DOI 10.1016/0166-6622(92)80288-D; Neser S, 1997, PHYS REV LETT, V79, P2348, DOI 10.1103/PhysRevLett.79.2348; ORR FM, 1975, J FLUID MECH, V67, P723, DOI 10.1017/S0022112075000572; Park SH, 1998, ADV MATER, V10, P1028, DOI 10.1002/(SICI)1521-4095(199809)10:13<1028::AID-ADMA1028>3.0.CO;2-P; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; ROTH C, 1988, J AEROSOL SCI, V19, P939, DOI 10.1016/0021-8502(88)90071-7; Rowlinson J. S., 2013, COURIER; Schacht S, 1996, SCIENCE, V273, P768, DOI 10.1126/science.273.5276.768; SUGIMOTO T, 1987, ADV COLLOID INTERFAC, V28, P65, DOI 10.1016/0001-8686(87)80009-X; SUN LF, 1994, J COLLOID INTERF SCI, V163, P464, DOI 10.1006/jcis.1994.1125; Svec F, 1996, SCIENCE, V273, P205, DOI 10.1126/science.273.5272.205; TAHRAN IJ, 1996, PHYS REV LETT, V76, P315; Tanev PT, 1996, SCIENCE, V271, P1267, DOI 10.1126/science.271.5253.1267; Terfort A, 1997, NATURE, V386, P162, DOI 10.1038/386162a0; Tien J, 1998, J AM CHEM SOC, V120, P12670, DOI 10.1021/ja982246y; van Blaaderen A, 1998, MRS BULL, V23, P39, DOI 10.1557/S0883769400029584; Velev OD, 1997, NATURE, V389, P447, DOI 10.1038/38921; Velev OD, 1996, LANGMUIR, V12, P2385, DOI 10.1021/la950679y; Velev OD, 1996, LANGMUIR, V12, P2374, DOI 10.1021/la9506786; VELEV OD, 1994, J COLLOID INTERF SCI, V167, P66, DOI 10.1006/jcis.1994.1333; Velev OD, 1998, CHEM MATER, V10, P3597, DOI 10.1021/cm980444i; Velev OD, 1997, LANGMUIR, V13, P1856, DOI 10.1021/la960652u; Vos WL, 1996, J PHYS-CONDENS MAT, V8, P9503, DOI 10.1088/0953-8984/8/47/052; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; Yang H, 1997, NATURE, V386, P692, DOI 10.1038/386692a0; Yang PD, 1998, SCIENCE, V282, P2244, DOI 10.1126/science.282.5397.2244; Zakhidov AA, 1998, SCIENCE, V282, P897, DOI 10.1126/science.282.5390.897; Zhao DY, 1998, CURR OPIN SOLID ST M, V3, P111, DOI 10.1016/S1359-0286(98)80073-9; Zhu JX, 1997, NATURE, V387, P883, DOI 10.1038/43141	55	452	468	7	289	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 24	2000	287	5461					2240	2243		10.1126/science.287.5461.2240	http://dx.doi.org/10.1126/science.287.5461.2240			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	296WE	10731141				2022-12-28	WOS:000086049100044
J	Lorenzo, MO; Baddeley, CJ; Muryn, C; Raval, R				Lorenzo, MO; Baddeley, CJ; Muryn, C; Raval, R			Extended surface chirality from supramolecular assemblies of adsorbed chiral molecules	NATURE			English	Article							ASYMMETRIC CATALYST	The increasing demand of the chemical and pharmaceutical industries for enantiomerically pure compounds has spurred the development of a range of so-called 'chiral technologies' (ref. 1), which aim to exert the ultimate control over a chemical reaction by directing its enantioselectivity(2). Heterogeneous enantioselective catalysis(3-5) is particularly attractive because it allows the production and ready separation of large quantities of chiral product while using only small quantities of catalyst. Heterogeneous enantioselectivity is usually induced by adsorbing chiral molecules onto catalytically active surfaces(1,3-7). A mimic of one such catalyst is formed by adsorbing (R,R)-tartaric acid molecules on Cu(110) surfaces: this generates a variety of surface phases, of which only one is potentially catalytically active(8), and leaves the question of how adsorbed chiral molecules give rise to enantioselectivity. Here we show that the active phase consists of extended supramolecular assemblies of adsorbed (R,R)-tartaric acid, which destroy existing symmetry elements of the underlying metal and directly bestow chirality to the modified surface. The adsorbed assemblies create chiral 'channels' exposing bare metal atoms, and it is these chiral spaces that we believe to be responsible for imparting enantioselectivity, by forcing the orientation of reactant molecules docking onto catalytically active metal sites. Our findings demonstrate that it is possible to sustain a single chiral domain across an extended surface-provided that reflection domains of opposite handedness are removed by a rigid and chiral local adsorption geometry, and that inequivalent rotation domains are removed by successful matching of the rotational symmetry of the adsorbed molecule with that of the underlying metal surface.	Univ Liverpool, Leverhulme Ctr Innovat Catalysis, Liverpool L69 7ZD, Merseyside, England; Univ Liverpool, Ctr Surface Sci, Dept Chem, Liverpool L69 7ZD, Merseyside, England	University of Liverpool; University of Liverpool	Raval, R (corresponding author), Univ Liverpool, Leverhulme Ctr Innovat Catalysis, Liverpool L69 7ZD, Merseyside, England.		Baddeley, Chris J/I-5206-2013	Baddeley, Chris J/0000-0001-9750-6494; Muryn, Christopher/0000-0002-1581-9778				Baiker A., 1997, HDB HETEROGENEOUS CA, P2422; BLASER HU, 1991, TETRAHEDRON-ASYMMETR, V2, P843, DOI 10.1016/S0957-4166(00)82195-3; BROWN JM, 1989, NATURE, V342, P631, DOI 10.1038/342631a0; HENRY NFM, 1965, INT TABLES XRAY CRYS, V1; IZUMI Y, 1983, ADV CATAL, V32, P215, DOI 10.1016/S0360-0564(08)60441-1; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Lopinski GP, 1998, NATURE, V392, P909, DOI 10.1038/31913; Lorenzo MO, 1999, J PHYS CHEM B, V103, P10661, DOI 10.1021/jp992188i; MacGillivray LR, 1997, NATURE, V389, P469, DOI 10.1038/38985; Prins LJ, 1999, NATURE, V398, P498, DOI 10.1038/19053; Rivera JM, 1998, SCIENCE, V279, P1021, DOI 10.1126/science.279.5353.1021; Sheldon R. A., 1993, CHIROTECHNOLOGY; TAI A, 1986, TAILORED METAL CATAL, P265, DOI DOI 10.1007/978-94-009-5261-4_5; VISWANATHAN R, 1994, NATURE, V368, P440, DOI 10.1038/368440a0; WAN KT, 1994, NATURE, V370, P449, DOI 10.1038/370449a0; WOODRUFF DP, 1988, SURF SCI, V201, P228, DOI 10.1016/0039-6028(88)90608-5; WOODRUFF DP, 1986, MODERN TECHNIQUES SU; [No title captured]	18	436	440	2	207	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 23	2000	404	6776					376	379						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	298BG	10746721				2022-12-28	WOS:000086119000046
J	Naslund, J; Haroutunian, V; Mohs, R; Davis, KL; Davies, P; Greengard, P; Buxbaum, JD				Naslund, J; Haroutunian, V; Mohs, R; Davis, KL; Davies, P; Greengard, P; Buxbaum, JD			Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; SENILE PLAQUES; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; REGIONAL DISTRIBUTION; DEMENTIA SEVERITY; A-BETA-42(43); MECHANISMS; DEPOSITION; DURATION	Context Alzheimer disease (AD) is characterized neuropathologically by the presence of amyloid beta-peptide (A beta)-containing plaques and neurofibrillary tangles composed of abnormal tau protein. Considerable controversy exists as to whether the extent of accumulation of A beta correlates with dementia and whether A beta alterations precede or follow changes in tau. Objectives To determine whether accumulation of A beta correlates with the earliest signs of cognitive deterioration and to define the relationship between A beta accumulation and early tau changes, Design, Setting, and Patients Postmortem cross-sectional study of 79 nursing home residents with Clinical Dementia Rating (CDR) scale scores of 0.0 to 5.0 who died between 1986 and 1997, comparing the levels of A beta variants in the cortices of the subjects with no (CDR score, 0.0 [n = 16]), questionable (CDR score, 0.5 [n = 11]), mild (CDR score, 1.0 [n = 22]), moderate (CDR score, 2.0 [n = 15]), or severe (CDR score, 4.0 or 5.0 [n = 15]) dementia. Main Outcome Measures Levels of total A beta peptides with intact or truncated amino termini and ending in either amino acid 40 (A beta x-40) or 42 (A beta x-42) in 5 neocortical brain regions as well as levels of tau protein undergoing early conformational changes in frontal cortex, as a function of CDR score. Results The levels of both A beta x-40 and A beta x-42 were elevated even in cases classified as having questionable dementia (CDR score = 0.5), and increases of both peptides correlated with progression of dementia, Levels of the more fibril-prone A beta x-42 peptide were higher than those of A beta x-40 in nondemented cases and remained higher throughout progression of disease in all regions examined. Finally, increases in A beta x-40 and A beta x-42 precede significant tau pathology at least in the frontal cortex, an area chosen for examination because of the absence of neuritic changes in the absence of disease. Conclusions In this study, levels of total A beta x-40 and A beta x-42 were elevated early in dementia and levels of both peptides were strongly correlated with cognitive decline. Of particular interest, in the frontal cortex, A beta was elevated before the occurrence of significant tau pathology, These results support an important role for A beta in mediating initial pathogenic events in AD dementia and suggest that treatment strategies targeting the formation, accumulation, or cytotoxic effects of A beta should be pursued.	CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurobiol, New York, NY 10029 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10467 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Buxbaum, JD (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA.		Buxbaum, Joseph D/G-6001-2010	Buxbaum, Joseph/0000-0001-8898-8313	NATIONAL INSTITUTE ON AGING [P01AG002219, R55AG014996, R01AG014996] Funding Source: NIH RePORTER; NIA NIH HHS [AG05138, AG02219, AG14996] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AISEN PS, 1994, AM J PSYCHIAT, V151, P1105; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; BIERER LM, 1995, J NEUROCHEM, V64, P749; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; Davis JN, 1997, TRENDS NEUROSCI, V20, P558; Davis KL, 1999, JAMA-J AM MED ASSOC, V281, P1401, DOI 10.1001/jama.281.15.1401; Desdouits F, 1996, J BIOL CHEM, V271, P24670, DOI 10.1074/jbc.271.40.24670; GIANNAKOPOULOS P, 1995, ARCH NEUROL-CHICAGO, V52, P1150, DOI 10.1001/archneur.1995.00540360028012; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Haroutunian V, 1998, ARCH NEUROL-CHICAGO, V55, P1185, DOI 10.1001/archneur.55.9.1185; Haroutunian V, 1999, ARCH NEUROL-CHICAGO, V56, P713, DOI 10.1001/archneur.56.6.713; HEYMAN A, 1987, NEUROLOGY, V37, P980, DOI 10.1212/WNL.37.6.980; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Ikonomovic MD, 1997, J NEUROPATH EXP NEUR, V56, P1018, DOI 10.1097/00005072-199709000-00007; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Kanne SM, 1998, NEUROLOGY, V50, P979, DOI 10.1212/WNL.50.4.979; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MYERS JL, 1973, FUNDAMENTS EXPT DESI; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Tamaoka A, 1998, MOL BRAIN RES, V56, P178, DOI 10.1016/S0169-328X(98)00044-8; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	29	1027	1085	1	86	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2000	283	12					1571	1577		10.1001/jama.283.12.1571	http://dx.doi.org/10.1001/jama.283.12.1571			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MV	10735393				2022-12-28	WOS:000085857300033
J	Post, JC; Ehrlich, GD				Post, JC; Ehrlich, GD			The impact of the polymerase chain reaction in clinical medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ENZYMATIC AMPLIFICATION; OTITIS-MEDIA; DNA; PATHOGENS; SEQUENCES; DIAGNOSIS; EFFUSION; DISEASE; BLOOD; CELLS		Allegheny Gen Hosp, Ctr Genom Sci, Allegheny Singer Res Inst, Pittsburgh, PA 15212 USA; Allegheny Gen Hosp, Dept Surg, Pittsburgh, PA 15212 USA; MCP Hahnemann Univ, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; MCP Hahnemann Univ, Sch Med, Dept Human Genet, Pittsburgh, PA USA	Allegheny General Hospital; Allegheny General Hospital; Drexel University; Drexel University	Ehrlich, GD (corresponding author), Allegheny Gen Hosp, Ctr Genom Sci, Allegheny Singer Res Inst, Room 1030,320 E North Ave, Pittsburgh, PA 15212 USA.	gehrlich@pgh.auhs.edu		Ehrlich, Garth/0000-0003-1140-6594	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC002398, R01DC002398] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01248, DC02398] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; Ehrlich GD, 1994, PCR BASED DIAGNOSTIC; FOO I, 1992, BIOTECHNIQUES, V12, P811; Fredricks DN, 1996, CLIN MICROBIOL REV, V9, P18, DOI 10.1128/CMR.9.1.18; Ghossein RA, 1999, CLIN CANCER RES, V5, P1950; HOEFFEL DP, 1999, CLIN ORTHOP RELAT R, V360, P37; KWOK S, 1988, BLOOD, V72, P1117; KWOK S, 1988, J INFECT DIS, V158, P1193, DOI 10.1093/infdis/158.6.1193; KWOK S, 1988, HIV DETECTION GENETI, P243; LUPSKI JR, 1993, JAMA-J AM MED ASSOC, V270, P1363, DOI 10.1001/jama.270.11.1363; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; Post JC, 1996, AM J OTOLARYNG, V17, P106, DOI 10.1016/S0196-0709(96)90005-8; Rayner MG, 1998, JAMA-J AM MED ASSOC, V279, P296, DOI 10.1001/jama.279.4.296; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; ROMERO JR, 1994, PCR BASED DIAGNOSTIC, P341; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; SIMPSON JL, 1993, JAMA-J AM MED ASSOC, V270, P2357, DOI 10.1001/jama.270.19.2357; TRIGGSRAINE BL, 1990, NEW ENGL J MED, V323, P6, DOI 10.1056/NEJM199007053230102; WEGEL JG, 1994, J FORENSIC SCI, V39, P844; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z	25	19	20	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	2000	283	12					1544	1546		10.1001/jama.283.12.1544	http://dx.doi.org/10.1001/jama.283.12.1544			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293MV	10735373				2022-12-28	WOS:000085857300001
J	Appleby, L				Appleby, L			Plane speaking	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					813	813		10.1136/bmj.320.7237.813	http://dx.doi.org/10.1136/bmj.320.7237.813			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720397	Green Published			2022-12-28	WOS:000086054700082
J	Bates, DW				Bates, DW			Using information technology to reduce rates of medication errors in hospitals	BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG EVENTS; SYSTEM; PREVENTION		Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 75 Francis St, Boston, MA 02115 USA.		Bates, David/AAE-7283-2019					Allan E L, 1995, Am Pharm, VNS35, P25; BARKER KN, 1984, AM J HOSP PHARM, V41, P1352, DOI 10.1093/ajhp/41.7.1352; BARKER KN, 1995, AM J HEALTH-SYST PH, V52, P2445, DOI 10.1093/ajhp/52.21.2445; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; BOREL JM, 1995, AM J HEALTH-SYST PH, V52, P1875, DOI 10.1093/ajhp/52.17.1875; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CHESTER MIS, 1989, AM J HOSP PHARM, V46, P1380, DOI 10.1093/ajhp/46.7.1380; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; CULLEN DJ, 1995, JOINT COMM J QUAL IM, V21, P541, DOI 10.1016/S1070-3241(16)30180-8; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Jha AK, 1998, J AM MED INFORM ASSN, V5, P305, DOI 10.1136/jamia.1998.0050305; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; *MA HOSP ASS B, 1999, MASS HOSP ASS B 0303; Raschke RA, 1998, JAMA-J AM MED ASSOC, V280, P1317, DOI 10.1001/jama.280.15.1317; Sheridan T.B., 2018, HUMAN ERROR MED, P141	21	243	255	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	2000	320	7237					788	791		10.1136/bmj.320.7237.788	http://dx.doi.org/10.1136/bmj.320.7237.788			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296YQ	10720369	Green Published			2022-12-28	WOS:000086054700034
J	Lovell, DJ; Giannini, EH; Reiff, A; Cawkwell, GD; Silverman, ED; Nocton, JJ; Stein, LD; Gedalia, A; Ilowite, NT; Wallace, CA; Whitmore, J; Finck, BK				Lovell, DJ; Giannini, EH; Reiff, A; Cawkwell, GD; Silverman, ED; Nocton, JJ; Stein, LD; Gedalia, A; Ilowite, NT; Wallace, CA; Whitmore, J; Finck, BK		Pediat Rheumatology Collaborative	Etanercept in children with polyarticular juvenile rheumatoid arthritis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; PLACEBO-CONTROLLED TRIAL; USSR DOUBLE-BLIND; DOSE METHOTREXATE; RESORPTION; CYTOKINES; AURANOFIN; RECEPTORS; ENDOTOXIN; THERAPY	Background: We evaluated the safety and efficacy of etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion protein, in children with polyarticular juvenile rheumatoid arthritis who did not tolerate or had an inadequate response to methotrexate. Methods: Patients 4 to 17 years old received 0.4 mg of etanercept per kilogram of body weight subcutaneously twice weekly for up to three months in the initial, open-label part of a multicenter trial. Those who responded to treatment then entered a double-blind study and were randomly assigned to receive either placebo or etanercept for four months or until a flare of the disease occurred. A response was defined as an improvement of 30 percent or more in at least three of six indicators of disease activity, with no more than one indicator worsening by more than 30 percent. Results: At the end of the open-label study, 51 of the 69 patients (74 percent) had had responses to etanercept treatment. In the double-blind study, 21 of the 26 patients who received placebo (81 percent) withdrew because of disease flare, as compared with 7 of the 25 patients who received etanercept (28 percent) (P = 0.003). The median time to disease flare with placebo was 28 days, as compared with more than 116 days with etanercept (P<0.001). In the double-blind study, there were no significant differences between the two treatment groups in the frequency of adverse events. Conclusions: Treatment with etanercept leads to significant improvement in patients with active polyarticular juvenile rheumatoid arthritis. Etanercept is well tolerated by pediatric patients. (N Engl J Med 2000;342:763-9.) (C)2000, Massachusetts Medical Society.	Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Univ N Carolina, Chapel Hill, NC USA; Childrens Hosp, New Orleans, LA USA; Schneider Childrens Hosp, New Hyde Park, NY USA; Childrens Hosp & Med Ctr, Seattle, WA 98105 USA; Immunex Corp, Seattle, WA USA	Cincinnati Children's Hospital Medical Center; Children's Hospital Los Angeles; State University System of Florida; University of South Florida; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Medical College of Wisconsin; University of North Carolina; University of North Carolina Chapel Hill; Children's Hospital of New Orleans; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Seattle Children's Hospital; Immunex Corporation	Lovell, DJ (corresponding author), Childrens Hosp, Med Ctr, Pavil Bldg 2-129,3333 Burnet Ave, Cincinnati, OH 45229 USA.			Nocton, James/0000-0003-3560-6099	NIAMS NIH HHS [AR42632, AR44059-P60] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P20AR042632, P60AR044059] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BECKHAM JC, 1992, J CLIN IMMUNOL, V12, P353, DOI 10.1007/BF00920793; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BRENNAN FM, 1989, LANCET, V2, P244; BREWER EJ, 1986, NEW ENGL J MED, V314, P1269, DOI 10.1056/NEJM198605153142001; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; EBERHARD BA, 1994, CLIN EXP IMMUNOL, V96, P260; Giannini Edward H., 1994, Arthritis and Rheumatism, V37, pS428; Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202; GIANNINI EH, 1992, NEW ENGL J MED, V326, P1043, DOI 10.1056/NEJM199204163261602; GIANNINI EH, 1990, ARTHRITIS RHEUM, V33, P466, DOI 10.1002/art.1780330402; GIANNINI EH, 1991, J RHEUMATOL, V18, P1240; GIANNINI EH, 1993, DRUG SAFETY, V9, P325, DOI 10.2165/00002018-199309050-00002; GRAHAM LD, 1992, J PEDIATR-US, V120, P468, DOI 10.1016/S0022-3476(05)80923-0; Grom AA, 1996, ARTHRITIS RHEUM, V39, P1703, DOI 10.1002/art.1780391013; HALLE F, 1991, CLIN EXP RHEUMATOL, V9, P297; MANGGE H, 1995, ARTHRITIS RHEUM, V38, P211, DOI 10.1002/art.1780380209; MEHTA CR, 1992, AM STAT, V46, P146, DOI 10.2307/2684185; MOHLER KM, 1993, J IMMUNOL, V151, P1548; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Peterson LS, 1996, ARTHRITIS RHEUM, V39, P1385, DOI 10.1002/art.1780390817; Petty R, 1987, WORLD PEDIAT CHILD C, V3, P205; Ramey D R, 1992, Arthritis Care Res, V5, P119, DOI 10.1002/art.1790050303; REIFF A, 1995, CLIN EXP RHEUMATOL, V13, P113; SAEZLLORENS X, 1991, J INFECT DIS, V163, P1267, DOI 10.1093/infdis/163.6.1267; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; SILVERMAN ED, 1993, ARTHRITIS RHEUM, V36, pS59; SINGH G, 1994, ARTHRITIS RHEUM, V37, P1761, DOI 10.1002/art.1780371209; STUART A, 1955, BIOMETRIKA, V42, P412, DOI 10.2307/2333387; THORNTON SC, 1991, CLIN EXP IMMUNOL, V86, P79; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; WALLACE CA, 1992, J RHEUMATOL, V19, P1604; Wallace CA, 1998, ARTHRITIS RHEUM-US, V41, P381, DOI 10.1002/1529-0131(199803)41:3<381::AID-ART2>3.0.CO;2-3; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401	35	867	926	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	2000	342	11					763	769		10.1056/NEJM200003163421103	http://dx.doi.org/10.1056/NEJM200003163421103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	293HW	10717011	Bronze			2022-12-28	WOS:000085846900003
J	Zadnik, K; Jones, LA; Irvin, BC; Kleinstein, RN; Manny, RE; Shin, JA; Mutti, DO				Zadnik, K; Jones, LA; Irvin, BC; Kleinstein, RN; Manny, RE; Shin, JA; Mutti, DO		CLEERE Study Grp	Vision - Myopia and ambient night-time lighting	NATURE			English	Article									Ohio State Univ, Coll Optometry, Columbus, OH 43210 USA; Univ Alabama, Sch Optometry, Birmingham, AL 35294 USA; Univ Houston, Coll Optometry, Houston, TX 77204 USA; So Calif Coll Optometry, Fullerton, CA 92831 USA	University System of Ohio; Ohio State University; University of Alabama System; University of Alabama Birmingham; University of Houston System; University of Houston	Zadnik, K (corresponding author), Ohio State Univ, Coll Optometry, 338 W 10th Ave, Columbus, OH 43210 USA.				NEI NIH HHS [U10 EY008893] Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY008893] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Mutti DO, 1996, INVEST OPHTH VIS SCI, V37, P952; Quinn GE, 1999, NATURE, V399, P113, DOI 10.1038/20094; RAVIOLA E, 1985, NEW ENGL J MED, V312, P1609, DOI 10.1056/NEJM198506203122505; SPERDUTO RD, 1983, ARCH OPHTHALMOL-CHIC, V101, P405, DOI 10.1001/archopht.1983.01040010405011; STONE RA, 1995, VISION RES, V35, P1195, DOI 10.1016/0042-6989(94)00232-B	5	58	61	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 9	2000	404	6774					143	144		10.1038/35004661	http://dx.doi.org/10.1038/35004661			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	293UC	10724157				2022-12-28	WOS:000085870900037
J	Danesh, J; Pounder, RE				Danesh, J; Pounder, RE			Eradication of Helicobacter pylori and non-ulcer dyspepsia	LANCET			English	Editorial Material									Univ Oxford, Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Univ Oxford, Radcliffe Infirm, Epidemiol Studies Unit, Nuffield Dept Clin Med, Oxford OX2 6HE, England; UCL Royal Free & Univ Coll Med Sch, Ctr Gastroenterol, London NW3 2PF, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford; University of London; University College London; UCL Medical School	Danesh, J (corresponding author), Univ Oxford, Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.							Blaser MJ, 1997, LANCET, V349, P1020, DOI 10.1016/S0140-6736(96)09133-7; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; Danesh J, 1999, ALIMENT PHARM THERAP, V13, P851; Hammer J, 1999, CURR OPIN GASTROEN, V15, P492, DOI 10.1097/00001574-199911000-00006; Heaney A, 1999, GUT, V45, P186, DOI 10.1136/gut.45.2.186; Jaakkimainen RL, 1999, BMJ-BRIT MED J, V319, P1040, DOI 10.1136/bmj.319.7216.1040; Laheij RJF, 1996, ALIMENT PHARM THER, V10, P843, DOI 10.1046/j.1365-2036.1996.86258000.x; Lam SJ, 1998, J GASTROEN HEPATOL, V13, P1, DOI 10.1111/j.1440-1746.1998.tb00537.x; *MAASTR CONS REP, 1997, EUR J GASTROEN HEPAT, V9, P1; McColl K, 1998, NEW ENGL J MED, V339, P1869, DOI 10.1056/NEJM199812243392601; RYDER SD, 1994, BRIT MED J, V308, P827, DOI 10.1136/bmj.308.6932.827; Talley NJ, 1999, BMJ-BRIT MED J, V318, P833, DOI 10.1136/bmj.318.7187.833; Talley NJ, 1999, NEW ENGL J MED, V341, P1106, DOI 10.1056/NEJM199910073411502; Talley NJ, 1998, GASTROENTEROLOGY, V114, P582, DOI 10.1016/S0016-5085(98)70542-6; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	15	28	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 4	2000	355	9206					766	767		10.1016/S0140-6736(00)90005-9	http://dx.doi.org/10.1016/S0140-6736(00)90005-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291YG	10711918				2022-12-28	WOS:000085766900002
J	Parkes, CM				Parkes, CM			Commentary: Prognoses should be based on proved indices not intuition	BRITISH MEDICAL JOURNAL			English	Editorial Material																		Maltoni M, 1999, J PAIN SYMPTOM MANAG, V17, P240, DOI 10.1016/S0885-3924(98)00146-8; Morita T, 1999, SUPPORT CARE CANCER, V7, P128, DOI 10.1007/s005200050242; Morita T, 1999, JPN J CLIN ONCOL, V29, P156, DOI 10.1093/jjco/29.3.156; MORITA T, 1998, JPN J CANC CHEMOTHER, V25, P1203; PARKES CM, 1972, BRIT MED J, V2, P29, DOI 10.1136/bmj.2.5804.29; Pirovano M, 1999, J PAIN SYMPTOM MANAG, V17, P231, DOI 10.1016/S0885-3924(98)00145-6	6	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	2000	320	7233					473	473						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288KP	10722295				2022-12-28	WOS:000085562200020
J	Dyer, C				Dyer, C			NHS bill for negligence set to soar again	BRITISH MEDICAL JOURNAL			English	News Item																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					891	891						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10787245				2022-12-28	WOS:000086337100012
J	Delamothe, T				Delamothe, T			BMJ set to sign with PubMed Central, JSTOR, and WorldSpace	BRITISH MEDICAL JOURNAL			English	News Item																		Delamothe T, 1999, BRIT MED J, V318, P1637, DOI 10.1136/bmj.318.7199.1637	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	2000	320	7226					8	8		10.1136/bmj.320.7226.8	http://dx.doi.org/10.1136/bmj.320.7226.8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271YB	10720393				2022-12-28	WOS:000084621600008
J	Beecham, L				Beecham, L			Blair demands reform of the NHS	BRITISH MEDICAL JOURNAL			English	News Item																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					889	889						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10787242				2022-12-28	WOS:000086337100008
J	Beecham, L				Beecham, L			Blair throws down challenge to GPs over NHS changes	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					824	824		10.1136/bmj.320.7238.824	http://dx.doi.org/10.1136/bmj.320.7238.824			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731164	Green Published			2022-12-28	WOS:000086180300012
J	Zinn, C				Zinn, C			Australia to consider a class action against tobacco industry	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					894	894						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10787252				2022-12-28	WOS:000086337100019
J	Morant, H				Morant, H			NICE issues guidelines on wisdom teeth	BRITISH MEDICAL JOURNAL			English	News Item																			0	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					890	890						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10787243				2022-12-28	WOS:000086337100010
J	Beecham, L				Beecham, L			NHS board appointments criticised	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					892	892						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10741987				2022-12-28	WOS:000086337100014
J	Beecham, L				Beecham, L			UK junior doctors to vote on pay offer	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	2000	320	7238					824	824		10.1136/bmj.320.7238.824	http://dx.doi.org/10.1136/bmj.320.7238.824			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299DJ	10731164	Green Published			2022-12-28	WOS:000086180300014
J	Charatan, F				Charatan, F			Mrs Clinton aims to reduce psychoactive drugs in young children	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					893	893						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10741989				2022-12-28	WOS:000086337100016
J	Richards, LJ; Wall, SN				Richards, LJ; Wall, SN			Iraqi medical education under the intellectual embargo	LANCET			English	Editorial Material									Univ Chicago, Pritzker Sch Med, Dept Pediat, Chicago, IL 60637 USA	University of Chicago	Richards, LJ (corresponding author), 1 Main St,Apt 7L, Brooklyn, NY 11201 USA.							Hoskins E., 2000, WAR PUBLIC HLTH, P254; RICHARDS L, 1999, LIVING SANCTIONS INT; RICHARDS L, 1999, CHILD MATERNAL HLTH; *UN, 1999, S1999356 UN; *UN COORD HUM ASS, 1999, SPEC TOP SOC COND IR; *UN SEC COUNC, 1999, S1999896 UN SEC COUN; *UNICEF, 1998, SIT AN CHILDR WOM IR; United Nations Development Program, 1990, HUM DEV REP 1990, P10; 2000, US POST OFFICE INT M, P581	9	24	24	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 25	2000	355	9209					1093	1094		10.1016/S0140-6736(00)02049-3	http://dx.doi.org/10.1016/S0140-6736(00)02049-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TB	10752738				2022-12-28	WOS:000086380800042
